Clustering O 0 0.0007991910097189248
of O 0 3.0171153412084095e-05
missense O 0 0.002992951311171055
mutations O 0 0.0003155268495902419
in O 0 7.25210566088208e-06
the O 0 5.5886303016450256e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9997544884681702
telangiectasia I-Disease 1 0.9999964237213135
gene O 0 3.1014067644719034e-05
in O 0 1.087713258129952e-06
a O 0 4.251847258274211e-06
sporadic B-Disease 0 0.0020925921853631735
T I-Disease 1 0.9697731733322144
- I-Disease 0 0.3951602876186371
cell I-Disease 0 0.3930680751800537
leukaemia I-Disease 1 0.9647862315177917
. O 0 4.502951560425572e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999977350234985
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.002656928263604641
A B-Disease 1 0.9999581575393677
- I-Disease 1 0.9999972581863403
T I-Disease 1 0.9999988079071045
) O 0 7.774249297654023e-07
is O 0 1.4594192521144578e-07
a O 0 1.7826671410148265e-06
recessive B-Disease 0 0.004930844064801931
multi I-Disease 0 0.11905986070632935
- I-Disease 1 0.9999570846557617
system I-Disease 1 0.9907957911491394
disorder I-Disease 1 0.9988203644752502
caused O 0 4.9221427616430447e-05
by O 0 2.431796474411385e-06
mutations O 0 8.616547347628511e-06
in O 0 3.4583683827804634e-07
the O 0 6.756575885447091e-07
ATM O 0 2.062232124444563e-05
gene O 0 3.869699412462069e-06
at O 0 8.640018904770841e-07
11q22 O 0 1.666255593590904e-05
- O 0 5.105641685076989e-05
q23 O 0 3.5430035495664924e-05
( O 0 3.7884087760176044e-06
ref O 0 0.00010677744285203516
. O 0 5.572552481680759e-07
3 O 0 3.0045100629649824e-06
) O 0 5.719339696952375e-06
. O 0 1.1088238352385815e-05

The O 0 3.8731661334168166e-05
risk O 0 3.133245263597928e-05
of O 0 2.208166051786975e-06
cancer B-Disease 0 0.0015218764310702682
, O 0 8.288487833851832e-07
especially O 0 1.547467832097027e-06
lymphoid B-Disease 0 0.0006837446708232164
neoplasias I-Disease 0 0.002042060950770974
, O 0 3.9515359162578534e-07
is O 0 2.268239569502839e-07
substantially O 0 9.203594345308375e-06
elevated O 0 0.00026300002355128527
in O 0 8.815051842248067e-06
A B-Disease 1 0.9999983310699463
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00011726178490789607
and O 0 6.802869734201522e-07
has O 0 6.957756113479263e-07
long O 0 2.717682718866854e-06
been O 0 2.018306304307771e-06
associated O 0 5.163296464161249e-06
with O 0 3.9114838727982715e-05
chromosomal O 1 0.9999982118606567
instability O 1 0.9937923550605774
. O 0 0.0001079445137293078

By O 0 0.00014626439951825887
analysing O 0 0.001448021619580686
tumour B-Disease 1 0.9999982118606567
DNA O 0 0.00012884964235126972
from O 0 7.974907020980027e-06
patients O 0 7.245351753226714e-06
with O 0 1.3605335880129132e-06
sporadic B-Disease 0 0.0037916144356131554
T I-Disease 1 0.8659711480140686
- I-Disease 0 0.016242627054452896
cell I-Disease 0 0.008084757253527641
prolymphocytic I-Disease 1 0.8706826567649841
leukaemia I-Disease 1 0.999947190284729
( O 0 4.3472777178976685e-05
T B-Disease 0 0.12702764570713043
- I-Disease 0 0.0005586524493992329
PLL I-Disease 0 0.0004972313181497157
) O 0 5.462372314468666e-07
, O 0 1.5255555751991778e-07
a O 0 4.071193870913703e-07
rare O 0 3.2900036330829607e-06
clonal B-Disease 0 6.545358337461948e-05
malignancy I-Disease 0 0.00015818412066437304
with O 0 3.3460153758824163e-07
similarities O 0 1.6986290347631439e-06
to O 0 6.236606964193925e-07
a O 0 3.230082484151353e-06
mature B-Disease 0 1.0985563676513266e-05
T I-Disease 0 0.3341192901134491
- I-Disease 0 0.025275560095906258
cell I-Disease 0 0.013255289755761623
leukaemia I-Disease 0 0.06539174169301987
seen O 0 1.986511279028491e-06
in O 0 1.158439999926486e-06
A B-Disease 1 0.9989990592002869
- I-Disease 1 0.9999797344207764
T I-Disease 1 0.9999980926513672
, O 0 4.3858850062861165e-07
we O 0 5.8012396664253174e-08
demonstrate O 0 2.851877241027978e-07
a O 0 5.111916721034504e-07
high O 0 8.602945626989822e-07
frequency O 0 1.6725493878766429e-06
of O 0 2.2795639154082892e-07
ATM O 0 0.0004042274667881429
mutations O 0 3.5900960938306525e-05
in O 0 8.304666152980644e-06
T B-Disease 0 0.48707643151283264
- I-Disease 0 0.004220274742692709
PLL I-Disease 0 0.006301210727542639
. O 0 4.175495632807724e-05

In O 0 2.8589716748683713e-05
marked O 0 1.930363396240864e-05
contrast O 0 9.497510291112121e-06
to O 0 8.441540444437123e-07
the O 0 8.037018233153503e-07
ATM O 0 6.307286093942821e-05
mutation O 0 8.414393960265443e-06
pattern O 0 6.368969934555935e-06
in O 0 1.705992872302886e-06
A B-Disease 1 0.9994887113571167
- I-Disease 1 0.9999938011169434
T I-Disease 1 0.9999947547912598
, O 0 2.6880556447395065e-07
the O 0 1.3003017329538125e-07
most O 0 1.0472638223291142e-07
frequent O 0 8.707485221748357e-07
nucleotide O 0 1.7696225995678105e-06
changes O 0 7.213275239337236e-07
in O 0 6.923290811755578e-07
this O 0 2.7889977900485974e-06
leukaemia B-Disease 1 0.843717634677887
were O 0 1.859544681792613e-05
missense O 0 0.0011516956146806479
mutations O 0 0.0003129495307803154
. O 0 2.5338589694001712e-05

These O 0 1.042640178638976e-05
clustered O 0 2.3930719180498272e-05
in O 0 1.1985948731307872e-06
the O 0 4.4714715841109864e-07
region O 0 5.285848487801559e-07
corresponding O 0 4.202181855816889e-07
to O 0 1.301914664963988e-07
the O 0 1.5490327598399745e-07
kinase O 0 1.4590627870347816e-05
domain O 0 4.979764867130143e-07
, O 0 6.402307661801387e-08
which O 0 8.379812044267965e-08
is O 0 5.7309311074504876e-08
highly O 0 1.6041124695220788e-07
conserved O 0 5.326726295606932e-07
in O 0 2.433027361803397e-07
ATM O 0 2.64219670498278e-05
- O 0 1.6080279237939976e-05
related O 0 9.506260312264203e-07
proteins O 0 6.413907271962671e-07
in O 0 4.01026653662484e-07
mouse O 0 8.00220459495904e-06
, O 0 7.517455173911003e-07
yeast O 0 1.996103128476534e-05
and O 0 2.340797664146521e-06
Drosophila O 0 4.2789684812305495e-05
. O 0 1.877207432698924e-05

The O 0 2.2597834686166607e-05
resulting O 0 2.8342712539597414e-05
amino O 0 1.7700343960314058e-05
- O 0 5.261789556243457e-05
acid O 0 9.866874279396143e-06
substitutions O 0 4.482941221795045e-06
are O 0 2.122775981661107e-07
predicted O 0 2.0457191567402333e-06
to O 0 2.542397226079629e-07
interfere O 0 1.3381215921981493e-06
with O 0 3.060670792365272e-07
ATP O 0 1.171517124021193e-05
binding O 0 4.238253040966811e-06
or O 0 1.8313752434551134e-06
substrate O 0 2.1618252503685653e-05
recognition O 0 8.518395588907879e-06
. O 0 1.9923927538911812e-05

Two O 0 8.03310194896767e-06
of O 0 3.174102403136203e-06
seventeen O 0 2.409831176919397e-05
mutated O 0 0.00013246445450931787
T B-Disease 0 0.0035986125003546476
- I-Disease 0 9.136704466072842e-05
PLL I-Disease 0 0.00021528126671910286
samples O 0 2.0178927115921397e-06
had O 0 9.178562550005154e-07
a O 0 8.204879691220412e-07
previously O 0 9.51250422076555e-06
reported O 0 0.0005666760844178498
A B-Disease 1 0.9936382174491882
- I-Disease 1 0.9998447895050049
T I-Disease 1 0.9999921321868896
allele O 0 0.0006561001646332443
. O 0 2.640025741129648e-05

In O 0 2.4785038476693444e-05
contrast O 0 1.5722021998954006e-05
, O 0 1.5384065363832633e-06
no O 0 4.913381985716114e-07
mutations O 0 5.010494533053134e-06
were O 0 3.3068658922275063e-07
detected O 0 1.974979113583686e-06
in O 0 1.521146373306692e-07
the O 0 2.820439988227008e-07
p53 O 0 2.878183067878126e-06
gene O 0 1.4788562339163036e-06
, O 0 1.4479735455097398e-07
suggesting O 0 7.719652330706595e-07
that O 0 1.7749320591065043e-07
this O 0 1.8395726328890305e-06
tumour B-Disease 1 0.999995231628418
suppressor O 0 0.001908484031446278
is O 0 5.323476557350659e-07
not O 0 2.638400360410742e-07
frequently O 0 2.011939614021685e-06
altered O 0 1.3769223187409807e-05
in O 0 1.645584347897966e-06
this O 0 1.0151924470847007e-05
leukaemia B-Disease 1 0.9723020792007446
. O 0 3.211004150216468e-05

Occasional O 0 0.0008456905488856137
missense O 0 0.0066299173049628735
mutations O 0 0.000326552806654945
in O 0 4.296997303754324e-06
ATM O 0 7.948283746372908e-05
were O 0 1.2422475492712692e-06
also O 0 5.384629275795305e-07
found O 0 6.118494866313995e-07
in O 0 3.3733886084519327e-06
tumour B-Disease 1 0.9999992847442627
DNA O 0 2.938553734566085e-05
from O 0 5.505527042259928e-06
patients O 0 5.419887656898936e-06
with O 0 7.85845884365699e-07
B B-Disease 0 2.625821616675239e-05
- I-Disease 0 7.914053276181221e-05
cell I-Disease 0 4.880088090430945e-05
non I-Disease 0 1.4717731573909987e-05
- I-Disease 1 0.9082733392715454
Hodgkins I-Disease 1 0.9998533725738525
lymphomas I-Disease 1 0.8863683938980103
( O 0 3.433410256548086e-06
B B-Disease 0 6.573917744390201e-06
- I-Disease 0 6.198556093295338e-06
NHL I-Disease 0 2.204513521064655e-06
) O 0 2.8814406505262014e-07
and O 0 9.934090883234603e-08
a O 0 1.0259344662699732e-06
B B-Disease 0 1.0238476534141228e-05
- I-Disease 0 1.7969186956179328e-05
NHL I-Disease 0 1.2470140063669533e-05
cell O 0 5.410893209045753e-05
line O 0 5.403921750257723e-05
. O 0 1.3645757462654728e-05

The O 0 9.091877473110799e-06
evidence O 0 2.5590752557036467e-06
of O 0 2.205412386047101e-07
a O 0 5.05203331613302e-07
significant O 0 2.7578411732065433e-07
proportion O 0 1.6785513423656084e-07
of O 0 9.570410952619568e-08
loss O 0 2.703331301745493e-05
- O 0 1.3988054888613988e-05
of O 0 1.8001716739490803e-07
- O 0 0.0001248933549504727
function O 0 7.743978471808077e-07
mutations O 0 1.397408937009459e-06
and O 0 5.5157041600750745e-08
a O 0 2.9366447051870637e-07
complete O 0 1.0506585113034816e-06
absence O 0 5.412343284660892e-07
of O 0 4.1446462262229034e-08
the O 0 1.3186425462663465e-07
normal O 0 3.903507206359791e-07
copy O 0 4.463100253815355e-07
of O 0 5.268605818287142e-08
ATM O 0 3.6846242892352166e-06
in O 0 1.4377414458977e-07
the O 0 1.1830148594071943e-07
majority O 0 4.774578314936662e-07
of O 0 5.323989284988784e-07
mutated O 0 0.0013690810883417726
tumours B-Disease 1 0.9998078942298889
establishes O 0 5.1006289140786976e-05
somatic O 0 5.424905248219147e-05
inactivation O 0 0.00025111783179454505
of O 0 2.4726173819544783e-07
this O 0 1.8627662257131306e-07
gene O 0 1.1608320846789866e-06
in O 0 1.5273185738351458e-07
the O 0 3.2878568845262635e-07
pathogenesis O 0 5.432746547739953e-06
of O 0 2.5558577476658684e-07
sporadic B-Disease 0 0.0005057312082499266
T I-Disease 1 0.585481584072113
- I-Disease 0 0.0002867726143449545
PLL I-Disease 0 0.0001985083508770913
and O 0 4.184461772638315e-07
suggests O 0 5.863501542080485e-07
that O 0 1.426235911594631e-07
ATM O 0 4.290462129574735e-06
acts O 0 8.546733738512557e-07
as O 0 9.776549632078968e-07
a O 0 7.407991506624967e-05
tumour B-Disease 1 0.9999982118606567
suppressor O 0 0.013537866063416004
. O 0 4.128162618144415e-05

As O 0 1.2500801858550403e-05
constitutional O 0 2.2015714421286248e-05
DNA O 0 1.5582872947561555e-05
was O 0 2.193457112298347e-05
not O 0 2.681045998542686e-07
available O 0 2.5208325382664043e-07
, O 0 1.2151936346072034e-07
a O 0 9.034831123244658e-07
putative O 0 0.0002496753877494484
hereditary O 1 0.987274169921875
predisposition O 0 0.005009594839066267
to O 0 1.7931475667865016e-05
T B-Disease 1 0.6655411720275879
- I-Disease 0 0.0008143779123201966
PLL I-Disease 0 0.0003879166906699538
will O 0 5.49841445263155e-07
require O 0 4.812246174878965e-07
further O 0 8.8635141537452e-07
investigation O 0 5.491337105922867e-06
. O 0 3.0455930755124427e-06
. O 0 1.1244498637097422e-05

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.0024648027028888464
kinase O 0 0.07842353731393814
is O 0 2.6168600015807897e-06
involved O 0 1.019984438244137e-06
in O 0 2.1099977232097444e-07
the O 0 2.5379469548170164e-07
modulation O 0 3.867393843393074e-06
of O 0 1.8375685328919644e-07
the O 0 1.3544037074098014e-06
Ca2 O 0 9.548044909024611e-05
+ O 0 3.5475066397339106e-05
homeostasis O 0 0.0008305964875034988
in O 0 6.177446721267188e-06
skeletal O 0 0.229227215051651
muscle O 0 0.4956534504890442
cells O 0 0.00026023382088169456
. O 0 3.425588147365488e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9954947233200073
DM B-Disease 1 1.0
) O 0 1.2829259503632784e-05
, O 0 4.1792375782279123e-07
the O 0 3.171307980665006e-07
most O 0 4.533565345354873e-07
prevalent O 0 0.00242409436032176
muscular B-Disease 1 0.9999958276748657
disorder I-Disease 1 0.9999004602432251
in O 0 3.1282474083127454e-05
adults O 0 7.193489182100166e-06
, O 0 3.331200559841818e-07
is O 0 3.553177236881311e-07
caused O 0 8.03685725259129e-06
by O 0 8.968729048319801e-07
( O 0 2.458169774399721e-06
CTG O 0 0.0001075649488484487
) O 0 6.158284691082372e-07
n O 0 3.129703600279754e-06
- O 0 2.2770311716158176e-06
repeat O 0 1.6577888573010569e-06
expansion O 0 7.697707360421191e-07
in O 0 1.6502757205216767e-07
a O 0 5.300477141645388e-07
gene O 0 2.2971412363403942e-06
encoding O 0 1.7638317331147846e-06
a O 0 1.8553710106061772e-06
protein O 0 7.003403425187571e-06
kinase O 0 0.00021006364841014147
( O 0 7.822553925507236e-06
DM B-Disease 1 0.9998793601989746
protein O 0 8.702763807377778e-06
kinase O 0 0.00010707925684982911
; O 0 1.11421070414508e-06
DMPK O 0 6.647601549047977e-05
) O 0 4.7626858190596977e-07
and O 0 1.8889240038788557e-07
involves O 0 4.5473782961380493e-07
changes O 0 1.3764108643954387e-06
in O 0 1.1652243756543612e-06
cytoarchitecture O 0 0.0001824344217311591
and O 0 7.216609901661286e-06
ion O 0 0.0015641474165022373
homeostasis O 0 0.13517679274082184
. O 0 3.396144165890291e-05

To O 0 1.4766796084586531e-05
obtain O 0 6.656192908849334e-06
clues O 0 4.185705620329827e-06
to O 0 6.200360189723142e-07
the O 0 3.462665176812152e-07
normal O 0 9.908768561217585e-07
biological O 0 6.599732955692161e-07
role O 0 1.4776253465242917e-07
of O 0 8.145806873471884e-08
DMPK O 0 3.1920080800773576e-05
in O 0 8.584227089158958e-07
cellular O 0 2.6716032152762637e-05
ion O 0 0.0014007309218868613
homeostasis O 0 0.21055033802986145
, O 0 3.2515828252144274e-07
we O 0 7.707677696089377e-08
have O 0 8.298898990233283e-08
compared O 0 4.15946061593786e-07
the O 0 4.0192603023569973e-07
resting O 0 2.0717705410788767e-05
[ O 0 6.210424999153474e-06
Ca2 O 0 2.7493575544212945e-05
+ O 0 6.163546913739992e-06
] O 0 2.2911988253326854e-06
i O 0 2.713221078920469e-07
, O 0 4.9729781181895305e-08
the O 0 1.0922562410087266e-07
amplitude O 0 9.802549811865902e-07
and O 0 1.3021927713907644e-07
shape O 0 6.838717467871902e-07
of O 0 2.0433118663731875e-07
depolarization O 0 4.059836646774784e-05
- O 0 0.0005421808455139399
induced O 0 0.00024006559397093952
Ca2 O 0 6.899973232066259e-05
+ O 0 7.983156137925107e-06
transients O 0 6.718519671267131e-06
, O 0 1.2005553173821681e-07
and O 0 6.548299325004336e-08
the O 0 8.273485008203352e-08
content O 0 2.1184541765251197e-07
of O 0 5.5053408942740134e-08
ATP O 0 6.645821940765018e-06
- O 0 9.330476132163312e-06
driven O 0 4.783087206305936e-06
ion O 0 7.60820284995134e-06
pumps O 0 4.660263130062958e-06
in O 0 4.802421358363063e-07
cultured O 0 1.0390350325906184e-05
skeletal O 0 0.001579512027092278
muscle O 0 0.0008958481485024095
cells O 0 3.154981186526129e-06
of O 0 1.4099438772063877e-07
wild O 0 8.921469998313114e-07
- O 0 9.821068670134991e-05
type O 0 9.53246490098536e-06
and O 0 1.4151208915791358e-06
DMPK O 0 0.004152294714003801
[ O 0 2.0825407773372717e-05
- O 0 0.0023638468701392412
/ O 0 0.0007683691219426692
- O 0 0.00019395722483750433
] O 0 2.092067734338343e-05
knockout O 0 0.0002878562663681805
mice O 0 0.0010246572783216834
. O 0 4.452038774616085e-05

In O 0 0.00010623590787872672
vitro O 0 0.0005896394723095
- O 0 0.0004916537436656654
differentiated O 0 0.0001533929316792637
DMPK O 0 0.002816106891259551
[ O 0 5.455919381347485e-05
- O 0 0.0010128456633538008
/ O 0 0.000708943116478622
- O 0 6.799111724831164e-05
] O 0 4.857918156631058e-06
myotubes O 0 1.2219238669786137e-05
exhibit O 0 2.014339315792313e-06
a O 0 1.4652725894848118e-06
higher O 0 2.5163553800666705e-06
resting O 0 1.524357412563404e-05
[ O 0 6.146928626549197e-06
Ca2 O 0 4.7774035920156166e-05
+ O 0 1.3966260667075403e-05
] O 0 2.694104750844417e-06
i O 0 4.2553952539492457e-07
than O 0 5.422842619395851e-08
do O 0 7.523028244804664e-08
wild O 0 4.392816776999098e-07
- O 0 0.00026074665947817266
type O 0 1.739796789479442e-05
myotubes O 0 3.793100768234581e-05
because O 0 8.282611219101454e-08
of O 0 2.7125734547439606e-08
an O 0 1.299882512739714e-07
altered O 0 1.2278778740437701e-05
open O 0 7.521894076489843e-07
probability O 0 2.774987137854623e-07
of O 0 1.8291254377800215e-07
voltage O 0 5.2906496421201155e-05
- O 0 3.935155109502375e-05
dependent O 0 5.461223281599814e-06
l O 0 0.0001695237006060779
- O 0 2.2302239813143387e-05
type O 0 2.3829947167541832e-05
Ca2 O 0 3.5908804420614615e-05
+ O 0 7.505294433940435e-06
and O 0 1.1474348866613582e-06
Na O 0 2.2352851374307647e-05
+ O 0 2.255415529361926e-05
channels O 0 1.9504779629642144e-05
. O 0 1.1893709597643465e-05

The O 0 3.8215766835492104e-05
mutant O 0 0.00018066406482830644
myotubes O 0 0.00017773140280041844
exhibit O 0 1.7602807929506525e-05
smaller O 0 4.984030510968296e-06
and O 0 1.292361389459984e-06
slower O 0 3.6076264223083854e-05
Ca2 O 0 9.388187027070671e-05
+ O 0 9.023473467095755e-06
responses O 0 3.1810998279979685e-06
upon O 0 1.7203917650476797e-06
triggering O 0 2.2360909497365355e-05
by O 0 1.888377710201894e-06
acetylcholine O 0 0.0002069661859422922
or O 0 4.682873168349033e-06
high O 0 1.2467607120925095e-05
external O 0 0.00010088317503686994
K O 0 0.00019201153190806508
+ O 0 0.0001418336178176105
. O 0 2.031880103459116e-05

In O 0 1.7152447981061414e-05
addition O 0 2.4378637135669123e-06
, O 0 4.974719445272058e-07
we O 0 1.2370500712677313e-07
observed O 0 7.175627843025723e-07
that O 0 1.3578745949871518e-07
these O 0 4.104662707504758e-07
Ca2 O 0 5.898936797166243e-05
+ O 0 1.8894957975135185e-05
transients O 0 6.551141268573701e-05
partially O 0 4.2176605347776785e-05
result O 0 5.527952566808381e-07
from O 0 1.2934967230648908e-07
an O 0 9.47304883425204e-08
influx O 0 8.866819030117767e-07
of O 0 1.8084034536514082e-07
extracellular O 0 5.9639369283104315e-06
Ca2 O 0 2.5873056074487977e-05
+ O 0 3.4987920116691384e-06
through O 0 3.704842583829304e-07
the O 0 9.901740440909634e-07
l O 0 0.0007671315688639879
- O 0 0.00012932895333506167
type O 0 7.400973117910326e-05
Ca2 O 0 0.0001968756114365533
+ O 0 4.085322143509984e-05
channel O 0 6.807220779592171e-05
. O 0 1.740274456096813e-05

Neither O 0 4.864819493377581e-05
the O 0 4.585278929880587e-06
content O 0 3.4355753086856566e-06
nor O 0 1.5437062756973319e-06
the O 0 3.781871953378868e-07
activity O 0 2.115160441462649e-06
of O 0 7.385290814454493e-07
Na O 0 5.469901952892542e-05
+ O 0 3.0085360776865855e-05
/ O 0 3.819609628408216e-05
K O 0 2.273162863275502e-05
+ O 0 1.5366822481155396e-05
ATPase O 0 6.606941315112635e-05
and O 0 2.751835154413129e-06
sarcoplasmic O 0 0.0008939317194744945
reticulum O 0 0.0009554310236126184
Ca2 O 0 0.0005559131968766451
+ O 0 7.749161159154028e-05
- O 0 7.796138379490003e-05
ATPase O 0 8.460868411930278e-05
are O 0 6.517310566778178e-07
affected O 0 2.474434040777851e-06
by O 0 3.025589194294298e-06
DMPK O 0 0.00204378180205822
absence O 0 0.00016051963029894978
. O 0 4.360102684586309e-05

In O 0 2.4693781597306952e-05
conclusion O 0 6.408578428818146e-06
, O 0 5.421957780527009e-07
our O 0 2.9045500582469685e-07
data O 0 9.015534487843979e-07
suggest O 0 5.127188842379837e-07
that O 0 1.511120615305117e-07
DMPK O 0 2.4221946659963578e-05
is O 0 1.294511093874462e-07
involved O 0 1.487450305148741e-07
in O 0 2.192540335954618e-07
modulating O 0 1.0360289707023185e-05
the O 0 2.5049820351341623e-07
initial O 0 1.0100271765622892e-06
events O 0 3.719817982528184e-07
of O 0 1.8561112824500015e-07
excitation O 0 2.939103069365956e-05
- O 0 8.234602137235925e-05
contraction O 0 2.926283013948705e-05
coupling O 0 2.2023232304491103e-05
in O 0 5.069928192824591e-06
skeletal O 0 0.1511385291814804
muscle O 0 0.015991609543561935
. O 0 6.685304015263682e-06
. O 0 2.001459324674215e-05

Constitutional O 0 0.0008711207192391157
RB1 O 1 0.7578244805335999
- O 0 0.25006937980651855
gene O 0 0.0003978808526881039
mutations O 0 0.00017089248285628855
in O 0 4.416442607180215e-06
patients O 0 1.2131712537666317e-05
with O 0 2.7578121262195054e-06
isolated O 0 0.00019016274018213153
unilateral B-Disease 0 0.00241474574431777
retinoblastoma I-Disease 1 0.8526438474655151
. O 0 7.798591832397506e-05

In O 0 5.366382174543105e-05
most O 0 5.1270258154545445e-06
patients O 0 1.1717716915882193e-05
with O 0 1.4436951687457622e-06
isolated O 0 3.271190507803112e-05
unilateral B-Disease 0 0.00014207173080649227
retinoblastoma I-Disease 0 0.18109667301177979
, O 0 3.76491152564995e-06
tumor B-Disease 0 5.713521022698842e-05
development O 0 4.781535949405225e-07
is O 0 2.3530019177542272e-07
initiated O 0 1.5812863694009138e-06
by O 0 3.222192219709541e-07
somatic O 0 6.97316727382713e-06
inactivation O 0 3.150214979541488e-05
of O 0 1.2934287951793522e-07
both O 0 3.8032766269679996e-07
alleles O 0 2.707152134462376e-06
of O 0 4.368136217181018e-07
the O 0 7.326795184781076e-06
RB1 O 0 0.004927207715809345
gene O 0 8.054770296439528e-05
. O 0 2.1028128685429692e-05

However O 0 1.683960363152437e-05
, O 0 7.520072813349543e-07
some O 0 1.2682677663633513e-07
of O 0 1.062437817722639e-07
these O 0 5.196975507715251e-07
patients O 0 8.875542334862985e-06
can O 0 1.3911740097682923e-06
transmit O 0 0.0006394567317329347
retinoblastoma B-Disease 0 0.40969398617744446
predisposition O 0 0.00014379897038452327
to O 0 1.0074624015032896e-06
their O 0 3.2257664770440897e-06
offspring O 0 5.719123873859644e-05
. O 0 1.576610520714894e-05

To O 0 1.245730345544871e-05
determine O 0 3.736510961971362e-06
the O 0 6.427035259548575e-07
frequency O 0 4.743579211208271e-06
and O 0 1.5365165495495603e-07
nature O 0 2.8547754027385963e-07
of O 0 1.2457243769858906e-07
constitutional O 0 1.2141064871684648e-05
RB1 O 0 0.030496476218104362
- O 0 0.00229302397929132
gene O 0 2.2390102458302863e-05
mutations O 0 1.3739801943302155e-05
in O 0 1.2192571148261777e-06
patients O 0 2.5857116270344704e-06
with O 0 8.198465479836159e-07
isolated O 0 2.781731018330902e-05
unilateral B-Disease 0 8.542466093786061e-05
retinoblastoma I-Disease 0 0.008534052409231663
, O 0 4.0651721633366833e-07
we O 0 1.0148725237968392e-07
analyzed O 0 8.021366966204369e-07
DNA O 0 1.311735786657664e-06
from O 0 8.659644663566723e-07
peripheral O 0 9.702598617877811e-05
blood O 0 2.703632890188601e-05
and O 0 1.7992996390603366e-06
from O 0 9.265107109968085e-06
tumor B-Disease 0 0.184756800532341
tissue O 0 0.007745708804577589
. O 0 5.478995808516629e-05

The O 0 2.679556200746447e-05
analysis O 0 1.3940657481725793e-05
of O 0 2.8126364668423776e-06
tumors B-Disease 1 0.9901053309440613
from O 0 1.7546126400702633e-06
54 O 0 3.0239248189900536e-06
( O 0 6.855885317236243e-07
71 O 0 1.2928950354762492e-06
% O 0 1.7789872686080344e-07
) O 0 1.3895270001285098e-07
of O 0 8.742576085296605e-08
76 O 0 1.953735772985965e-05
informative O 0 1.7207286873599514e-05
patients O 0 4.5110708015272394e-05
showed O 0 0.00017036568897310644
loss O 0 2.6315849027014337e-05
of O 0 1.1896723890458816e-06
constitutional O 0 0.00014739675680175424
heterozygosity O 0 0.22304485738277435
( O 0 0.0001431584096280858
LOH O 1 0.9458284974098206
) O 0 4.134022674406879e-06
at O 0 6.727579602738842e-06
intragenic O 0 0.0002831554156728089
loci O 0 0.00012810941552743316
. O 0 2.442584082018584e-05

Three O 0 1.4649437616753858e-05
of O 0 3.7962533951940713e-06
13 O 0 2.4665230739628896e-05
uninformative O 0 0.11417291313409805
patients O 0 0.0016717622056603432
had O 0 7.83764262450859e-05
constitutional O 0 0.0001130339369410649
deletions O 0 0.0008696842705830932
. O 0 5.7000404922291636e-05

For O 0 2.012368531723041e-05
39 O 0 2.363221938139759e-05
randomly O 0 1.1654749869194347e-05
selected O 0 5.9636527112161275e-06
tumors B-Disease 1 0.9843369126319885
, O 0 1.2189060498712934e-06
SSCP O 0 0.0003014193498529494
, O 0 1.313241455136449e-06
hetero O 0 0.00010126947745447978
- O 0 5.1269140385556966e-05
duplex O 0 0.00012267120473552495
analysis O 0 5.171488624000631e-07
, O 0 8.77264341170303e-08
sequencing O 0 4.196750751361833e-07
, O 0 5.6377135848606486e-08
and O 0 1.1368352659246739e-07
Southern O 0 1.1069156471421593e-06
blot O 0 0.00029706128407269716
analysis O 0 1.454635366826551e-06
were O 0 3.435004600760294e-07
used O 0 7.239421506710642e-07
to O 0 1.9527019503584597e-06
identify O 0 2.3655218683416024e-05
mutations O 0 0.00010254128574160859
. O 0 1.9167191567248665e-05

Mutations O 0 0.0017663445323705673
were O 0 1.0481931894901209e-05
detected O 0 1.580411299073603e-05
in O 0 1.1078524266849854e-06
21 O 0 1.835818579820625e-06
( O 0 7.905039183242479e-07
91 O 0 1.8278104789715144e-06
% O 0 3.0742239687242545e-07
) O 0 1.921920755876272e-07
of O 0 2.732916186687362e-07
23 O 0 0.00016012844571378082
tumors B-Disease 1 0.9999526739120483
with O 0 0.00010096478217747062
LOH O 1 0.9998606443405151
. O 0 7.227439346024767e-05

In O 0 2.8501466658781283e-05
6 O 0 1.0970100447593722e-05
( O 0 1.8552507299318677e-06
38 O 0 1.2396687907312298e-06
% O 0 1.9344193447068392e-07
) O 0 1.7984231703849218e-07
of O 0 8.437147869244654e-08
16 O 0 1.3760730325884651e-05
tumors B-Disease 1 0.999679684638977
without O 0 3.604385256039677e-06
LOH O 1 0.9220201969146729
, O 0 2.2202351601663395e-07
one O 0 1.708935712940729e-07
mutation O 0 2.8672600365098333e-06
was O 0 7.2142493081628345e-06
detected O 0 2.4141170342772966e-06
, O 0 6.511544370368938e-08
and O 0 5.061881225287834e-08
in O 0 1.1829403945284866e-07
9 O 0 5.465373646984517e-07
( O 0 2.3104722401967592e-07
56 O 0 3.427452099913353e-07
% O 0 7.097801102418089e-08
) O 0 5.4087937684244025e-08
of O 0 5.790185042542362e-08
the O 0 1.2228518244228326e-05
tumors B-Disease 1 0.9999899864196777
without O 0 1.3029773981543258e-05
LOH O 1 0.9910306930541992
, O 0 4.926952215100755e-07
both O 0 4.5939137294226384e-07
mutations O 0 1.059491387422895e-05
were O 0 1.221706042997539e-06
found O 0 7.049600299069425e-06
. O 0 2.4820472390274517e-05

Thus O 0 3.34112519340124e-05
, O 0 1.07828861928283e-06
a O 0 5.358693897505873e-07
total O 0 1.1929780896480224e-07
of O 0 7.349640895881748e-08
45 O 0 4.855454562857631e-07
mutations O 0 2.814847675836063e-06
were O 0 3.6761585420208576e-07
identified O 0 2.347652070966433e-06
in O 0 5.9819371927005704e-06
tumors B-Disease 1 0.9961991906166077
of O 0 1.3435562777885934e-06
36 O 0 5.965099626337178e-05
patients O 0 0.00018574215937405825
. O 0 3.104827555944212e-05

Thirty O 0 9.710817539598793e-05
- O 0 2.70785440079635e-05
nine O 0 7.461237032657664e-07
of O 0 1.3924520203545399e-07
the O 0 5.405178171713487e-07
mutations O 0 5.3637882047041785e-06
- O 0 1.8704473632169538e-06
including O 0 9.448147153534592e-08
34 O 0 3.011090825566498e-07
small O 0 4.364042922588851e-07
mutations O 0 3.676028882182436e-06
, O 0 1.0426757057757641e-07
2 O 0 1.9897315439720842e-07
large O 0 2.454781906635617e-07
structural O 0 1.2929795957461465e-05
alterations O 0 2.0013963876408525e-05
, O 0 1.8809478774528543e-07
and O 0 2.3600901499776228e-07
hypermethylation O 0 0.00018309174629393965
in O 0 2.6434429400978843e-06
3 O 0 0.0006993638235144317
tumors O 1 0.9999994039535522
- O 0 0.06780490279197693
were O 0 8.714479804439179e-07
not O 0 1.3507477092389308e-07
detected O 0 1.6370191815440194e-06
in O 0 1.2866806287092913e-07
the O 0 3.672016930522659e-07
corresponding O 0 3.817917786363978e-06
peripheral O 0 0.0003975379222538322
blood O 0 0.00012738608347717673
DNA O 0 9.419726120540872e-05
. O 0 3.230255242669955e-05

In O 0 3.0330975278047845e-05
6 O 0 1.2521216376626398e-05
( O 0 2.117469421136775e-06
17 O 0 1.3174161495044245e-06
% O 0 1.7822357278873824e-07
) O 0 6.327380930315485e-08
of O 0 2.5823398530633312e-08
the O 0 2.2980586322773888e-07
36 O 0 2.561973815318197e-06
patients O 0 2.0600050447683316e-06
, O 0 1.2232433732606296e-07
a O 0 2.296759930686676e-06
mutation O 0 9.706263881525956e-06
was O 0 2.689712528081145e-05
detected O 0 4.356169029051671e-06
in O 0 3.1668653832639393e-07
constitutional O 0 1.2348393738648156e-06
DNA O 0 8.206374673136452e-07
, O 0 6.721973022649763e-08
and O 0 4.3136651584063657e-08
1 O 0 9.724701754976195e-08
of O 0 4.3201286104022074e-08
these O 0 1.8246009858557954e-07
mutations O 0 2.1689329514629208e-06
is O 0 8.580449417650016e-08
known O 0 2.0202847395012213e-07
to O 0 2.046176490466678e-07
be O 0 1.6885732634364103e-07
associated O 0 8.888501952242223e-07
with O 0 1.2008763405901846e-06
reduced O 0 6.760797987226397e-05
expressivity O 0 0.012612995691597462
. O 0 4.638889367925003e-05

The O 0 6.010122888255864e-06
presence O 0 2.7267612949799513e-06
of O 0 1.771262674310492e-07
a O 0 1.1641891433100682e-06
constitutional O 0 1.1354411981301382e-05
mutation O 0 2.8257942176423967e-05
was O 0 2.240736284875311e-05
not O 0 1.877322546306459e-07
associated O 0 2.323076984112049e-07
with O 0 5.607364528259495e-08
an O 0 1.8895221387538186e-07
early O 0 9.430154932488222e-06
age O 0 2.6019190499937395e-06
at O 0 7.829449714336079e-06
treatment O 0 0.00041935915942303836
. O 0 1.6054365914897062e-05

In O 0 2.983205922646448e-05
1 O 0 9.938789844454732e-06
patient O 0 2.267135823785793e-05
, O 0 1.5706441445217934e-06
somatic O 0 5.075993249192834e-05
mosaicism O 0 0.0014618202112615108
was O 0 5.578598938882351e-05
demonstrated O 0 1.829725533752935e-06
by O 0 2.466249213739502e-07
molecular O 0 1.2104334246032522e-06
analysis O 0 1.5732631197806768e-07
of O 0 5.8970485383724736e-08
DNA O 0 1.0453574077473604e-06
and O 0 3.4603249332576524e-07
RNA O 0 5.791659532405902e-06
from O 0 3.7777986108267214e-06
peripheral O 0 0.00035571472835727036
blood O 0 0.00015487424388993531
. O 0 3.543334605637938e-05

In O 0 6.990003021201119e-05
2 O 0 3.614341403590515e-05
patients O 0 1.619536487851292e-05
without O 0 1.1302124676149106e-06
a O 0 6.9485126914514694e-06
detectable O 0 5.330206113285385e-05
mutation O 0 1.2697851161647122e-05
in O 0 1.5438165519299218e-06
peripheral O 0 0.0005631423555314541
blood O 0 7.114690379239619e-05
, O 0 1.945352551047108e-06
mosaicism O 0 0.000507197342813015
was O 0 0.0001561956451041624
suggested O 0 3.4513218452048022e-06
because O 0 1.73203744679995e-07
1 O 0 1.1925730802886392e-07
of O 0 5.0810527341127454e-08
the O 0 1.410399931955908e-06
patients O 0 2.9810844353050925e-05
showed O 0 0.008948875591158867
multifocal O 1 0.9999940395355225
tumors B-Disease 1 0.9999992847442627
and O 0 7.229031666611263e-07
the O 0 2.79811501968652e-07
other O 0 2.2788684361785272e-07
later O 0 4.022813755000243e-06
developed O 0 1.764940498105716e-05
bilateral B-Disease 0 3.155572994728573e-05
retinoblastoma I-Disease 0 0.040679167956113815
. O 0 3.8574886275455356e-05

In O 0 1.6074543964350596e-05
conclusion O 0 5.748935109295417e-06
, O 0 6.965350394239067e-07
our O 0 4.4293989276411594e-07
results O 0 4.859558657699381e-07
emphasize O 0 4.99407974530186e-07
that O 0 5.975329031571164e-08
the O 0 1.2332394305758498e-07
manifestation O 0 1.0956526921290788e-06
and O 0 1.4679255855298834e-07
transmissibility O 0 3.7567772324109683e-06
of O 0 1.7364848758916196e-07
retinoblastoma B-Disease 0 2.2563857783097774e-05
depend O 0 1.963752396250129e-07
on O 0 3.6732987496179703e-07
the O 0 1.2367009105673787e-07
nature O 0 1.3662334197306336e-07
of O 0 1.6010366366003836e-08
the O 0 6.101811322878348e-08
first O 0 3.4270274795744626e-07
mutation O 0 5.262018021312542e-07
, O 0 2.760450712457896e-08
its O 0 8.265740092383567e-08
time O 0 1.0530845884204609e-07
in O 0 7.55640670035973e-08
development O 0 1.027172444878488e-07
, O 0 2.9619094732424855e-08
and O 0 1.7239273120139842e-08
the O 0 2.3075164889974076e-08
number O 0 1.987948117232463e-08
and O 0 4.6658033880930816e-08
types O 0 7.504655741286115e-08
of O 0 4.5067178433555455e-08
cells O 0 1.1604988685576245e-06
that O 0 1.4221707544948003e-07
are O 0 1.4149344451652723e-07
affected O 0 1.42192277508002e-06
. O 0 1.0823706588780624e-06
. O 0 6.359580311254831e-06

Hereditary B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9998730421066284
of I-Disease 0 4.546235231828177e-06
the I-Disease 0 3.1490892524743685e-06
fifth I-Disease 0 4.473537046578713e-06
component I-Disease 0 1.9237029391661054e-06
of I-Disease 0 2.4225550987466704e-07
complement I-Disease 0 2.5617048322601477e-06
in O 0 1.8497917153581511e-06
man O 0 2.7496669645188376e-05
. O 0 1.4720946637680754e-05

I O 0 0.002038596896454692
. O 0 0.0003519943275023252

Clinical O 0 0.0007010868284851313
, O 0 1.5769428500789218e-05
immunochemical O 0 0.0003445925540290773
, O 0 1.9017406884813681e-06
and O 0 1.3085546015645377e-06
family O 0 1.5806690498720855e-05
studies O 0 1.5292791431420483e-05
. O 0 3.089183155680075e-05

The O 0 1.1684820492519066e-05
first O 0 4.116201125725638e-06
recognized O 0 1.6156175206560874e-06
human O 0 1.5185648862825474e-06
kindred O 0 0.0001443195651518181
with O 0 3.43969622917939e-05
hereditary B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.6990621089935303
of I-Disease 0 1.036805556964282e-07
the I-Disease 0 3.601330149649584e-07
fifth I-Disease 0 2.196310333602014e-06
component I-Disease 0 9.867897006188286e-07
of I-Disease 0 2.3968013351804984e-07
complement I-Disease 0 3.769524937524693e-06
( O 0 3.610460908021196e-06
C5 O 0 0.00014605004980694503
) O 0 1.3576367337009287e-06
is O 0 1.0742579661382479e-06
described O 0 4.12695444538258e-05
. O 0 1.5880259525147267e-05

The O 0 2.633633448567707e-05
proband O 0 0.00033699566847644746
, O 0 1.032404497891548e-06
a O 0 7.214596280391561e-07
20 O 0 4.563313495964394e-07
- O 0 5.677311037288746e-06
year O 0 5.985978077660548e-07
- O 0 7.877263669797685e-06
old O 0 3.3099940992542543e-06
black O 0 3.0468943350570044e-06
female O 0 3.3795618037402164e-06
with O 0 0.2521663010120392
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.025545192882418633
age O 0 1.328787584498059e-05
11 O 0 3.3367948617524235e-06
, O 0 1.1947854545724113e-06
lacked O 0 0.00016518414486199617
serum O 0 0.009482057765126228
hemolytic O 0 0.05508991330862045
complement O 0 4.425600309332367e-06
activity O 0 3.627285650509293e-06
, O 0 5.321933258528588e-07
even O 0 1.1066929346270626e-06
during O 0 3.371403363416903e-05
remission O 0 0.0007156434585340321
. O 0 4.1096616769209504e-05

C5 O 0 0.041041042655706406
was O 0 0.0003295194183010608
undetectable O 0 0.00019430482643656433
in O 0 3.5781915812549414e-06
her O 0 8.920056643546559e-06
serum O 0 2.973322079924401e-05
by O 0 9.950624644261552e-07
both O 0 2.2745657588529866e-06
immunodiffusion O 0 0.007501054089516401
and O 0 9.516748832538724e-05
hemolytic O 1 0.9988352656364441
assays O 0 0.0021735571790486574
. O 0 7.49114915379323e-05

Other O 0 6.1956898207427e-06
complement O 0 9.228159797203261e-06
components O 0 4.962696493748808e-06
were O 0 4.453576423202321e-07
normal O 0 1.5073078429850284e-06
during O 0 6.5062208705057856e-06
remission O 0 3.6619629099732265e-05
of O 0 1.194940296045388e-06
lupus O 1 0.8675388693809509
, O 0 7.167523108364549e-07
but O 0 7.517935500800377e-07
C1 O 0 0.00010435513831907883
, O 0 4.397582813453482e-07
C4 O 0 6.287534779403359e-05
, O 0 6.212814582795545e-07
C2 O 0 4.582543624565005e-05
, O 0 2.4399284370701935e-07
and O 0 4.4149123823444825e-07
C3 O 0 0.00014803314115852118
levels O 0 3.723931968124816e-06
fell O 0 8.681333565618843e-05
during O 0 4.6919572923798114e-05
exacerbations O 0 0.016799990087747574
. O 0 5.5511471146019176e-05

A O 0 0.00011245447240071371
younger O 0 4.257708496879786e-05
half O 0 7.335212103498634e-06
- O 0 0.00036380955134518445
sister O 0 0.00011147915211040527
, O 0 3.2938984872998844e-07
who O 0 4.84923930343939e-07
had O 0 4.4452526708482765e-06
no O 0 1.3500797422238975e-06
underlying O 0 0.009816544130444527
disease O 0 0.0026127942837774754
, O 0 3.3690088230287074e-07
was O 0 1.979380067496095e-05
also O 0 6.40918699446047e-07
found O 0 6.268496690609027e-07
to O 0 7.565087116745417e-07
lack O 0 1.1618007192737423e-05
immunochemically O 0 0.1125282272696495
detectable O 0 0.000983095378614962
C5 O 0 0.0011740565532818437
. O 0 3.0021503334864974e-05

By O 0 0.00025819591246545315
hemolytic O 1 0.9992671608924866
assay O 0 0.0038663228042423725
, O 0 4.311577413318446e-06
she O 0 2.0078912257304182e-06
exhibited O 0 5.5387567954312544e-06
1 O 0 4.490963760872546e-07
- O 0 3.1173058232525364e-06
2 O 0 2.242117460582449e-07
% O 0 3.901772060999065e-08
of O 0 2.4209931837049226e-08
the O 0 3.876263292568183e-07
normal O 0 5.579046501225093e-06
serum O 0 3.423256202950142e-05
C5 O 0 1.6546186088817194e-05
level O 0 3.5454496583042783e-07
and O 0 1.5637121464351367e-07
normal O 0 5.353294909582473e-07
concentrations O 0 5.758399197475228e-07
of O 0 8.709721299737794e-08
other O 0 1.6076317876922985e-07
complement O 0 3.5091309200652177e-06
components O 0 4.5069777115713805e-05
. O 0 1.3714744454773609e-05

C5 O 0 0.001515745185315609
levels O 0 1.20954864542e-05
of O 0 4.3751234102273884e-07
other O 0 1.1479631467636864e-07
family O 0 4.6613158133368415e-07
members O 0 8.915025517808317e-08
were O 0 9.463658301456235e-08
either O 0 1.3864902825844183e-07
normal O 0 4.4326145598461153e-07
or O 0 1.4455645214184187e-07
approximately O 0 1.1498850227553703e-07
half O 0 5.262148761175922e-07
- O 0 2.2979953428148292e-05
normal O 0 9.88735905593785e-07
, O 0 1.2411197758410708e-07
consistent O 0 9.055706868821289e-07
with O 0 1.2128136859246297e-06
autosomal O 0 0.0031161087099462748
codominant O 0 0.000915560987778008
inheritance O 0 6.2630742831970565e-06
of O 0 3.0869625788909616e-07
the O 0 3.462626409600489e-06
gene O 0 0.00012059465370839462
determining O 0 0.00036913572694174945
C5 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
. O 0 6.191195279825479e-05

Normal O 0 0.0043964688666164875
hemolytic O 1 0.9998080134391785
titers O 0 0.06928043812513351
were O 0 3.308092345832847e-05
restored O 0 0.00012662529479712248
to O 0 2.8867846140201436e-06
both O 0 3.879105861415155e-06
homozygous O 0 0.01224909070879221
C5 B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999773502349854
deficient I-Disease 1 0.9999991655349731
( O 0 4.721928416984156e-05
C5D B-Disease 1 0.999985933303833
) O 0 2.614799541333923e-06
sera O 0 1.9418606825638562e-05
by O 0 2.257161213492509e-07
addition O 0 2.2114546993634576e-07
of O 0 1.506948592577828e-07
highly O 0 1.839814558479702e-06
purified O 0 2.265000694023911e-05
human O 0 1.0190316970692948e-05
C5 O 0 0.0007153053302317858
. O 0 3.0279734346549958e-05

In O 0 5.3652969654649496e-05
specific O 0 1.911458639369812e-05
C5 O 0 0.000588579336181283
titrations O 0 0.0003643447707872838
, O 0 1.4213018175723846e-06
however O 0 6.239534400265256e-07
, O 0 1.802654168159279e-07
it O 0 1.0581665321751643e-07
was O 0 1.6057485936471494e-06
noted O 0 1.6760975540819345e-07
that O 0 3.978423990247393e-08
when O 0 9.801310341117642e-08
limited O 0 1.528420057184121e-07
amounts O 0 1.4428277950173651e-07
of O 0 9.84862822406285e-08
C5 O 0 2.8263439162401482e-05
were O 0 3.9272254070965573e-07
assayed O 0 3.4406543818477076e-06
in O 0 1.6420369775005383e-07
the O 0 1.8123243705758796e-07
presence O 0 4.4555986278282944e-07
of O 0 1.4148224636301165e-07
low O 0 3.04468107970024e-06
dilutions O 0 2.5241781258955598e-05
of O 0 6.897029720676073e-07
either O 0 1.1499959327920806e-05
C5D B-Disease 1 0.9999964237213135
serum O 0 0.0013138927752152085
, O 0 5.151238724465657e-07
curving O 0 3.810715497820638e-06
rather O 0 3.371023922227323e-07
than O 0 8.697951159319928e-08
linear O 0 7.098375931491319e-07
dose O 0 5.053429049439728e-06
- O 0 6.599270363949472e-06
response O 0 8.983075758806081e-07
plots O 0 7.974442723934771e-07
were O 0 1.5023553601167805e-07
consistently O 0 7.182878221101419e-07
obtained O 0 5.238704829935159e-07
, O 0 2.1737150746048428e-07
suggesting O 0 1.8330106286157388e-06
some O 0 4.5865419906476745e-07
inhibitory O 0 3.164245936204679e-05
effect O 0 3.192153963027522e-05
. O 0 2.0117160602239892e-05

Further O 0 8.265346696134657e-05
studies O 0 3.3742242521839216e-05
suggested O 0 1.0907715477515012e-05
that O 0 1.4273491615313105e-06
low O 0 6.240686616365565e-06
dilutions O 0 7.585967978229746e-05
of O 0 2.2136121060611913e-06
C5D B-Disease 1 0.9999876022338867
serum O 0 0.00038388618850149214
contain O 0 2.98553845823335e-06
a O 0 2.871392098313663e-06
factor O 0 1.9383689959795447e-06
( O 0 5.091477532914723e-07
or O 0 2.796831495288643e-07
factors O 0 2.1867477073556074e-07
) O 0 1.0724956212015968e-07
interfering O 0 5.54017560716602e-07
at O 0 1.0717636200752167e-07
some O 0 3.5860921343555674e-08
step O 0 1.9056825806273991e-07
in O 0 2.3961453621268447e-07
the O 0 2.4862731606845045e-06
hemolytic O 0 0.33511433005332947
assay O 0 2.937864701380022e-05
of O 0 4.817880494556448e-07
C5 O 0 0.00015066277410369366
, O 0 2.0215665585965326e-07
rather O 0 2.450730391956313e-07
than O 0 1.194418217664861e-07
a O 0 1.985804829018889e-06
true O 0 1.2584794603753835e-05
C5 O 0 0.0016770190559327602
inhibitor O 0 0.0001571282191434875
or O 0 7.253551757457899e-06
inactivator O 0 0.0004464713274501264
. O 0 2.7506925107445568e-05

Of O 0 8.481512850266881e-06
clinical O 0 6.616252358071506e-05
interest O 0 3.31638625539199e-06
are O 0 2.2130392096642026e-07
( O 0 2.781287378184061e-07
a O 0 2.922042483533005e-07
) O 0 1.2706320262623194e-07
the O 0 2.8577005650731735e-07
documentation O 0 2.777253257590928e-06
of O 0 1.097381300496636e-06
membranous O 1 0.9925252199172974
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 0.003950195852667093
vasculitis B-Disease 1 0.9999997615814209
, O 0 0.00030081302975304425
and O 0 0.3742556571960449
arthritis B-Disease 1 1.0
in O 0 2.574886821093969e-06
an O 0 4.5430175532601424e-07
individual O 0 2.861685288735316e-07
lacking O 0 8.647539289086126e-06
C5 O 0 0.00021327275317162275
( O 0 4.788381033904443e-07
and O 0 7.400986135053245e-08
its O 0 3.2553091955378477e-07
biologic O 0 6.366340130625758e-06
functions O 0 3.1107467179936066e-07
) O 0 1.3043990065852995e-07
, O 0 5.813179981828398e-08
and O 0 1.253852985882986e-07
( O 0 4.838563540943142e-07
b O 0 4.781381335305923e-07
) O 0 6.585901246580761e-08
a O 0 2.0558135815917922e-07
remarkable O 0 1.0460005341883516e-06
propensity O 0 0.00010075348109239712
to O 0 9.591491107130423e-05
bacterial B-Disease 1 0.9999933242797852
infections I-Disease 1 0.9998948574066162
in O 0 7.782705893077946e-07
the O 0 9.814514214667724e-07
proband O 0 0.0005170319927856326
, O 0 2.387650397395191e-07
even O 0 1.4831427108674688e-07
during O 0 1.0618497299219598e-06
periods O 0 9.874930810838123e-07
of O 0 8.788938998804952e-08
low O 0 7.347009159275331e-06
- O 0 3.5593464417615905e-05
dose O 0 8.101366802293342e-06
or O 0 7.215222126433218e-07
alternate O 0 2.9006962449784623e-06
- O 0 4.824533243663609e-05
day O 0 2.0716104700113647e-05
corticosteroid O 0 0.4160066246986389
therapy O 0 0.0021216999739408493
. O 0 2.415813651168719e-05

Other O 0 8.177645213436335e-06
observations O 0 2.239975583506748e-05
indicate O 0 6.868503078294452e-06
that O 0 4.6353076754712674e-07
the O 0 7.606742542520806e-07
C5D B-Disease 1 0.9987941980361938
state O 0 6.443414690693317e-07
is O 0 1.3221873018665065e-07
compatible O 0 6.30462466233439e-07
with O 0 1.1882103478910722e-07
normal O 0 1.519129796179186e-06
coagulation O 0 4.220695245749084e-06
function O 0 1.9704684461885336e-07
and O 0 4.245095297505941e-08
the O 0 1.158919076260645e-07
capacity O 0 2.3527258008471108e-07
to O 0 2.439251431951561e-07
mount O 0 4.066664769197814e-05
a O 0 2.7841988412546925e-05
neutrophilic O 1 0.5382869839668274
leukocytosis O 0 0.421218603849411
during O 0 0.009645150974392891
pyogenic B-Disease 1 0.9964459538459778
infection I-Disease 0 0.37623733282089233
. O 0 1.3234580364951398e-05
. O 0 3.1766299798619e-05

Susceptibility O 1 0.9449244141578674
to O 1 0.8522546887397766
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.7158122658729553
twins O 0 0.12623058259487152
: O 0 6.024975505170005e-07
the O 0 1.1897660812110189e-07
role O 0 1.5909492390164814e-07
of O 0 7.932681711508849e-08
genes O 0 7.72341536503518e-07
, O 0 3.2628153689984174e-07
HLA O 0 0.00011802314111264423
, O 0 1.3722048208819615e-07
and O 0 2.0359010477477568e-07
the O 0 1.4870928453092347e-06
environment O 0 3.1616276828572154e-05
. O 0 9.987875273509417e-06

OBJECTIVE O 0 4.777271533384919e-05
To O 0 4.646545676223468e-06
determine O 0 2.11700512409152e-06
the O 0 9.390437867295987e-07
relative O 0 2.337797013751697e-06
effects O 0 3.791929657381843e-06
of O 0 1.8789812372688175e-07
genetic O 0 2.277239673276199e-06
and O 0 6.437537081183109e-07
environmental O 0 2.262944690301083e-06
factors O 0 7.840223474886443e-07
in O 0 4.301322860555956e-06
susceptibility O 0 0.17121689021587372
to O 1 0.9270695447921753
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.015087004750967026
AS B-Disease 0 0.1713145226240158
) O 0 9.357341696158983e-06
. O 0 1.4031222235644236e-05

METHODS O 0 0.00016130952280946076
Twins O 0 0.00013376153947319835
with O 0 1.8867073094952502e-06
AS B-Disease 0 0.0004543035465758294
were O 0 6.041292976988188e-07
identified O 0 4.994689675186237e-07
from O 0 1.8600468365548295e-07
the O 0 5.405482284004393e-07
Royal O 0 0.002219664165750146
National O 0 2.9385144443949685e-05
Hospital O 1 0.9714726209640503
for O 0 0.0025622656103223562
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9975850582122803
database O 0 0.00023018849606160074
. O 0 9.71087283687666e-05

Clinical O 0 0.0008086038869805634
and O 0 1.691318720986601e-05
radiographic O 0 0.0019729656632989645
examinations O 0 6.873979145893827e-05
were O 0 2.3944694476085715e-06
performed O 0 2.070652953989338e-06
to O 0 4.928014050165075e-07
establish O 0 1.311135565629229e-05
diagnoses O 0 0.014279020018875599
, O 0 2.089979716402013e-06
and O 0 0.00031955252052284777
disease O 1 0.7384359240531921
severity O 0 0.26153695583343506
was O 0 0.02973371185362339
assessed O 0 5.505999070010148e-06
using O 0 6.927313052074169e-07
a O 0 1.4116836837274604e-06
combination O 0 2.093834382321802e-06
of O 0 2.8767183835043397e-07
validated O 0 2.2533751689479686e-05
scoring O 0 5.288734882924473e-06
systems O 0 0.0003262633690610528
. O 0 1.6063922885223292e-05

HLA O 0 0.46636754274368286
typing O 0 0.0005395947955548763
for O 0 1.7871738236863166e-05
HLA O 0 0.0017102387500926852
- O 0 4.489586717681959e-05
B27 O 0 4.6366159949684516e-05
, O 0 2.493812871762202e-06
HLA O 0 0.0001289334468310699
- O 0 8.735191840969492e-06
B60 O 0 8.50103697302984e-06
, O 0 4.289805417556636e-07
and O 0 1.0370798690928495e-06
HLA O 0 0.030177582055330276
- O 0 0.03668015077710152
DR1 O 1 0.951965868473053
was O 0 6.386828317772597e-05
performed O 0 2.149455440303427e-06
by O 0 7.073393248901994e-07
polymerase O 0 1.5012730727903545e-05
chain O 0 2.6186418836005032e-05
reaction O 0 1.6646772564854473e-06
with O 0 1.9732252098947356e-07
sequence O 0 6.606899773942132e-07
- O 0 2.4961066174000734e-06
specific O 0 3.302976949726144e-07
primers O 0 6.40141934127314e-06
, O 0 1.9684848950873857e-07
and O 0 2.683529771729809e-07
zygosity O 0 0.00011601996811805293
was O 0 2.1515066691790707e-05
assessed O 0 7.948931852297392e-06
using O 0 1.0199474672845099e-05
microsatellite O 0 0.0007556482451036572
markers O 0 0.00014612972154282033
. O 0 2.713867615966592e-05

Genetic O 0 0.0004440009652171284
and O 0 1.0415836186439265e-05
environmental O 0 7.915451533335727e-06
variance O 0 2.3316652004723437e-06
components O 0 4.7563494263158645e-06
were O 0 3.577245877295354e-07
assessed O 0 8.696239888195123e-07
with O 0 1.0457029020471964e-07
the O 0 2.3667503512569965e-07
program O 0 5.971575660623785e-07
Mx O 0 3.650017788459081e-06
, O 0 5.874640507386175e-08
using O 0 1.073076774105175e-07
data O 0 1.1858139004061741e-07
from O 0 4.383166540833372e-08
this O 0 3.224986144800823e-08
and O 0 9.800189104680612e-08
previous O 0 8.114487854982144e-07
studies O 0 3.783585498240427e-07
of O 0 1.4056489305858122e-07
twins O 0 3.365868906257674e-05
with O 0 1.7644105128056253e-06
AS B-Disease 0 0.05195316672325134
. O 0 2.8400587325450033e-05

RESULTS O 0 0.0001625052245799452
Six O 0 7.370230378000997e-06
of O 0 1.9622320905909874e-06
8 O 0 1.4114403711573686e-05
monozygotic O 0 0.0005989147466607392
( O 0 2.9437931516440585e-05
MZ O 1 0.9905675053596497
) O 0 4.996008556190645e-06
twin O 0 0.0038304217159748077
pairs O 0 3.862417997879675e-06
were O 0 8.576898835599422e-06
disease O 0 7.210992043837905e-05
concordant O 0 4.3150732381036505e-05
, O 0 5.620474894385552e-07
compared O 0 8.138148928082956e-07
with O 0 1.6273702385660727e-07
4 O 0 5.121998469803657e-07
of O 0 1.4667207892671286e-07
15 O 0 1.391591922583757e-06
B27 O 0 4.238917972543277e-05
- O 0 0.0001004256191663444
positive O 0 4.719335720437812e-06
dizygotic O 0 7.208613533293828e-05
( O 0 4.395965333969798e-06
DZ O 0 0.0005617142887786031
) O 0 1.289918373004184e-06
twin O 0 5.790852810605429e-05
pairs O 0 1.494696789450245e-06
( O 0 3.697969646054844e-07
27 O 0 4.6400668907153886e-07
% O 0 9.295282410448635e-08
) O 0 6.048717438034146e-08
and O 0 6.928132734174142e-08
4 O 0 2.3700346218902268e-07
of O 0 1.5542312326033425e-07
32 O 0 2.7627004328678595e-06
DZ O 0 0.11054562777280807
twin O 0 0.006511116866022348
pairs O 0 2.161742486350704e-06
overall O 0 3.7127688301552553e-06
( O 0 1.0299243058398133e-06
12 O 0 5.764927095697203e-07
. O 0 2.846659867827839e-07
5 O 0 1.2543976026790915e-06
% O 0 9.95960590444156e-07
) O 0 1.9911299204977695e-06
. O 0 6.39820291326032e-06

Nonsignificant O 0 0.004604140762239695
increases O 0 6.56532502034679e-05
in O 0 2.377646296736202e-06
similarity O 0 2.253565753562725e-06
with O 0 2.7592670903686667e-07
regard O 0 6.973446602387412e-07
to O 0 1.6958982769210706e-06
age O 0 6.200689767865697e-06
at O 0 0.00010995161574101076
disease O 0 0.0342932865023613
onset O 0 0.005163280759006739
and O 0 3.1097499686438823e-07
all O 0 3.141219551139329e-08
of O 0 7.063093931947151e-08
the O 0 8.305055234814063e-05
disease O 0 0.15919755399227142
severity O 0 0.00029316116706468165
scores O 0 4.005861683253897e-06
assessed O 0 1.2120750398025848e-05
were O 0 1.9980957404186483e-06
noted O 0 4.387015906104352e-06
in O 0 1.4562575415766332e-05
disease O 0 0.16059952974319458
- O 0 0.04914252460002899
concordant O 0 0.14204184710979462
MZ O 1 0.9999909400939941
twins O 0 0.0030053569935262203
compared O 0 7.88981924415566e-06
with O 0 4.78982474305667e-06
concordant O 0 0.006595774088054895
DZ O 1 0.9985746145248413
twins O 0 0.04133180156350136
. O 0 6.184556696098298e-05

HLA O 0 0.4279909133911133
- O 0 0.00039451938937418163
B27 O 0 8.25760216685012e-05
and O 0 2.3625768790225266e-06
B60 O 0 2.179607326979749e-05
were O 0 9.282541100219532e-07
associated O 0 5.725489131691575e-07
with O 0 1.4410662174668687e-07
the O 0 3.7876034184591845e-06
disease O 0 0.00019154012261424214
in O 0 5.160073897059192e-07
probands O 0 0.00013233241043053567
, O 0 1.0399823935358654e-07
and O 0 6.686156694968304e-08
the O 0 1.4524241009894467e-07
rate O 0 3.3276728572673164e-07
of O 0 1.0860283339297894e-07
disease O 0 1.9667655578814447e-05
concordance O 0 1.9357481505721807e-05
was O 0 1.410611548635643e-05
significantly O 0 2.087663233396597e-06
increased O 0 7.187853725554305e-07
among O 0 2.7966606808149663e-07
DZ O 0 0.004494783468544483
twin O 0 0.0006636210600845516
pairs O 0 3.151909027110378e-07
in O 0 1.721073061844436e-07
which O 0 1.5330637381794077e-07
the O 0 5.066933113084815e-07
co O 0 5.7254001148976386e-05
- O 0 0.0006067805225029588
twin O 0 0.01661141775548458
was O 0 2.9291477403603494e-06
positive O 0 2.3601710097409523e-07
for O 0 1.1072771854969687e-07
both O 0 3.561733592505334e-07
B27 O 0 3.8217956898733974e-05
and O 0 1.195095683215186e-05
DR1 O 1 0.8861849308013916
. O 0 5.411687743617222e-05

Additive O 0 0.0006670372094959021
genetic O 0 7.307295163627714e-05
effects O 0 2.8633541660383344e-05
were O 0 7.958002470331849e-07
estimated O 0 3.5333991377228813e-07
to O 0 1.8204347895789397e-07
contribute O 0 3.348173436279467e-07
97 O 0 9.789677051230683e-07
% O 0 1.6599672392203502e-07
of O 0 9.187094462959067e-08
the O 0 8.024182420740544e-07
population O 0 2.359501195314806e-06
variance O 0 1.3998237591295037e-05
. O 0 2.0002818928333e-05

CONCLUSION O 0 0.00012175938172731549
Susceptibility O 0 0.0004473075096029788
to O 0 4.428441570780706e-06
AS B-Disease 0 0.0002023320848820731
is O 0 2.6702625177676964e-07
largely O 0 4.204217987080483e-07
genetically O 0 6.330290034384234e-07
determined O 0 2.273823156428989e-07
, O 0 3.709190110612326e-08
and O 0 3.232289813581701e-08
the O 0 1.508468443489619e-07
environmental O 0 8.39630558857607e-07
trigger O 0 7.357462891377509e-06
for O 0 1.727876650647886e-07
the O 0 1.771788993210066e-05
disease O 0 0.01927797868847847
is O 0 1.193361981677299e-06
probably O 0 8.838841495162342e-06
ubiquitous O 0 5.360121576813981e-05
. O 0 1.8564347556093708e-05

HLA O 1 0.6055012941360474
- O 0 0.00038416279130615294
B27 O 0 8.731280104257166e-05
accounts O 0 2.1343660137063125e-06
for O 0 1.568792242778727e-07
a O 0 2.664190787982079e-07
minority O 0 6.377858312589524e-07
of O 0 1.0131589078810066e-07
the O 0 6.827125389463617e-07
overall O 0 1.3480607776727993e-05
genetic O 0 3.3418775274185464e-05
susceptibility O 0 9.335115464637056e-05
to O 0 4.557504325930495e-06
AS B-Disease 0 0.015364800579845905
. O 0 2.8348658815957606e-05

Cell O 0 0.004891055636107922
cycle O 0 0.0009062029421329498
- O 0 0.0001691884535830468
dependent O 0 1.4326365089800674e-05
colocalization O 0 4.00018434447702e-05
of O 0 1.1573832807698636e-06
BARD1 O 0 0.00032253548852168024
and O 0 2.759482640612987e-06
BRCA1 O 0 4.072897354490124e-05
proteins O 0 2.119613100148854e-06
in O 0 1.328228677266452e-06
discrete O 0 1.573355621076189e-05
nuclear O 0 6.308002048172057e-05
domains O 0 5.526522727450356e-05
. O 0 2.326620051462669e-05

Germ O 0 0.2572229206562042
- O 0 0.010878211818635464
line O 0 9.383023279951885e-05
mutations O 0 2.2743728550267406e-05
of O 0 4.83479482227267e-07
the O 0 1.282065682062239e-06
BRCA1 O 0 7.5522817496676e-05
gene O 0 1.1581645594560541e-05
predispose O 0 8.526514648110606e-06
women O 0 4.7679029080427426e-07
to O 0 4.6799257802376815e-07
early O 0 4.101346348761581e-05
- O 1 0.9004870653152466
onset O 1 0.9999339580535889
breast B-Disease 1 0.9999294281005859
and I-Disease 1 0.99953293800354
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
by O 0 8.880208952177782e-06
compromising O 0 0.00010671513882698491
the O 0 3.2516650207981e-06
genes O 0 1.306725425820332e-05
presumptive O 0 0.0011700084432959557
function O 0 2.1024682155257324e-06
as O 0 9.88741589935671e-07
a O 0 1.8925436961581e-05
tumor B-Disease 0 0.008687912486493587
suppressor O 0 0.0011904428247362375
. O 0 2.9891261874581687e-05

Although O 0 2.130543543898966e-05
the O 0 5.5639138736296445e-06
biochemical O 0 2.772921470750589e-05
properties O 0 2.660105792529066e-06
of O 0 4.78660979297274e-07
BRCA1 O 0 4.6428154746536165e-05
polypeptides O 0 1.5298306607292034e-05
are O 0 1.684728943018854e-07
not O 0 1.5704418387940677e-07
understood O 0 4.2049879311889526e-07
, O 0 6.218125747636805e-08
their O 0 8.171358700792553e-08
expression O 0 5.262585318632773e-07
pattern O 0 2.202848918386735e-06
and O 0 2.4630244865875284e-07
subcellular O 0 4.178243671049131e-06
localization O 0 2.2605547655984992e-06
suggest O 0 5.501572104549268e-07
a O 0 3.4962326367349306e-07
role O 0 7.099113759068132e-07
in O 0 7.497193337258068e-07
cell O 0 0.00016628690354991704
- O 0 0.0003318150120321661
cycle O 0 8.36354010971263e-05
regulation O 0 6.308302545221522e-05
. O 0 1.9742767108255066e-05

When O 0 5.730403063353151e-05
resting O 0 0.00012670598516706377
cells O 0 2.5250255930586718e-05
are O 0 3.758533466680092e-07
induced O 0 1.1655894013529178e-05
to O 0 5.950399781795568e-07
proliferate O 0 6.275809482758632e-06
, O 0 7.715237160255128e-08
the O 0 1.6270271885332477e-07
steady O 0 2.383608261879999e-06
- O 0 2.346548626519507e-06
state O 0 1.8892464481723437e-07
levels O 0 1.4686453653212084e-07
of O 0 8.091856074088355e-08
BRCA1 O 0 4.136727966397302e-06
increase O 0 3.7921253692729806e-07
in O 0 3.6691568539026775e-07
late O 0 3.561488847481087e-05
G1 O 0 0.00012012317893095315
and O 0 2.9957155334159324e-07
reach O 0 6.120823741184722e-07
a O 0 7.851903660593962e-07
maximum O 0 3.0464034352917224e-06
during O 0 1.5742953110020608e-05
S O 0 0.0008006879943422973
phase O 0 5.909814717597328e-05
. O 0 2.4838347599143162e-05

Moreover O 0 6.601103086723015e-05
, O 0 4.946051376464311e-06
in O 0 2.179420107495389e-06
S O 0 0.00012554708519019186
phase O 0 1.3408552149485331e-05
cells O 0 9.247663911082782e-06
, O 0 8.621811957709724e-07
BRCA1 O 0 2.453652814438101e-05
polypeptides O 0 7.517794983868953e-06
are O 0 3.0018870234016504e-07
hyperphosphorylated O 0 2.6723524570115842e-05
and O 0 1.096645746656577e-06
accumulate O 0 6.712954473186983e-06
into O 0 8.411436738242628e-07
discrete O 0 1.060067461366998e-05
subnuclear O 0 0.00017609952192287892
foci O 0 0.0002751925203483552
termed O 0 0.0001840097102103755
" O 0 1.3119248251314275e-05
BRCA1 O 0 0.00029082802939228714
nuclear O 0 0.00012128266098443419
dots O 0 0.00030295434407889843
. O 0 3.362082861713134e-05

" O 0 0.00020736777514684945
BRCA1 O 0 0.0023659460712224245
associates O 0 0.0007599341333843768
in O 0 4.295374765206361e-06
vivo O 0 5.811786468257196e-05
with O 0 1.169972279058129e-06
a O 0 1.705770773696713e-05
structurally O 0 0.023715302348136902
related O 0 3.7338159017963335e-05
protein O 0 3.701648529386148e-05
termed O 0 0.00026802424690686166
BARD1 O 0 0.0069601694121956825
. O 0 6.282656249823049e-05

Here O 0 1.4261097021517344e-05
we O 0 9.680634320829995e-07
show O 0 6.092677153901604e-07
that O 0 5.892921706163179e-08
the O 0 8.111263838372906e-08
steady O 0 1.113831331167603e-06
- O 0 1.0597940445222775e-06
state O 0 1.1388677734203156e-07
levels O 0 1.3764775985691813e-07
of O 0 5.263884972350752e-08
BARD1 O 0 4.811906546819955e-05
, O 0 1.416819515043244e-07
unlike O 0 3.5623961025521567e-07
those O 0 7.867437545883149e-08
of O 0 1.9474244083994563e-07
BRCA1 O 0 4.514737520366907e-05
, O 0 4.097704788819101e-07
remain O 0 7.812085982550343e-07
relatively O 0 7.382811872957973e-07
constant O 0 2.1846683466719696e-06
during O 0 6.014405698806513e-06
cell O 0 0.00035092703183181584
cycle O 0 0.00023078866070136428
progression O 0 0.0001540858793305233
. O 0 2.5068891773116775e-05

However O 0 4.498038106248714e-05
, O 0 5.120624336996116e-06
immunostaining O 0 0.00010668197501217946
revealed O 0 1.3314105672179721e-05
that O 0 8.533197615179233e-07
BARD1 O 0 0.00012021645670756698
resides O 0 9.865001629805192e-06
within O 0 2.0725831291201757e-06
BRCA1 O 0 4.6261884563136846e-05
nuclear O 0 1.1508822353789583e-05
dots O 0 1.610950130270794e-05
during O 0 9.068515282706358e-06
S O 0 4.0744824218563735e-05
phase O 0 1.0174429689868703e-06
of O 0 6.35076489174935e-08
the O 0 2.4046704538704944e-07
cell O 0 1.7784554074751213e-05
cycle O 0 4.588581759890076e-06
, O 0 1.0904660996402527e-07
but O 0 6.354544979103594e-08
not O 0 5.753372178673999e-08
during O 0 5.372145324145094e-07
the O 0 1.7858950513982563e-06
G1 O 0 0.00022583971440326422
phase O 0 4.702909791376442e-05
. O 0 2.3122864149627276e-05

Nevertheless O 0 0.00013724964810535312
, O 0 1.142450037150411e-05
BARD1 O 0 0.00016547706036362797
polypeptides O 0 2.1896325051784515e-05
are O 0 2.0481093088164926e-07
found O 0 2.3640863844320847e-07
exclusively O 0 1.9475136525670678e-07
in O 0 1.1715963665892559e-07
the O 0 1.1003106692442088e-07
nuclear O 0 6.295563821367978e-07
fractions O 0 3.1897803864922025e-07
of O 0 4.305765344270185e-08
both O 0 1.8882934682551422e-07
G1 O 0 7.044983067316934e-05
- O 0 1.1871634342242032e-05
and O 0 6.960185032767185e-07
S O 0 9.556979784974828e-05
- O 0 3.321957774460316e-05
phase O 0 1.774516567820683e-05
cells O 0 3.8452948501799256e-05
. O 0 9.906973900797311e-06

Therefore O 0 4.2900326661765575e-05
, O 0 4.353025360614993e-06
progression O 0 1.458486894989619e-05
to O 0 1.7949275843420764e-06
S O 0 6.348482565954328e-05
phase O 0 2.700102641028934e-06
is O 0 2.0190675797948643e-07
accompanied O 0 1.3894848507334245e-06
by O 0 1.8653759070730302e-07
the O 0 2.2319518677704764e-07
aggregation O 0 2.023307388299145e-06
of O 0 3.0527476724273583e-07
nuclear O 0 1.6546453480259515e-05
BARD1 O 0 0.00013584474800154567
polypeptides O 0 2.6557978344499134e-05
into O 0 7.544779236923205e-06
BRCA1 O 0 0.00018549156084191054
nuclear O 0 0.00010022099013440311
dots O 0 0.00029998389072716236
. O 0 4.576045466819778e-05

This O 0 3.358247340656817e-05
cell O 0 0.00024697231128811836
cycle O 0 7.032639405224472e-05
- O 0 2.085295091092121e-05
dependent O 0 2.8154277060821187e-06
colocalization O 0 1.1957546121266205e-05
of O 0 3.1797938504496415e-07
BARD1 O 0 6.835771637270227e-05
and O 0 1.5158880160015542e-06
BRCA1 O 0 2.3841561414883472e-05
indicates O 0 1.3080118606012547e-06
a O 0 5.459757517201069e-07
role O 0 8.398716317969956e-07
for O 0 3.527850083173689e-07
BARD1 O 0 9.899251017486677e-05
in O 0 3.7632246403518366e-06
BRCA1 O 0 0.0005362311494536698
- O 0 0.003582313656806946
mediated O 0 0.005007028579711914
tumor B-Disease 0 0.014441268518567085
suppression O 0 0.00038533227052539587
. O 0 4.575242564897053e-05

Ethnic O 0 7.731328514637426e-05
differences O 0 5.000147211831063e-05
in O 0 1.0157822543988004e-05
the O 0 1.4591435501642991e-05
HFE O 0 0.0037568712141364813
codon O 0 0.000285218091448769
282 O 0 0.0001475158496759832
( O 0 6.313315680017695e-05
Cys O 1 0.9861895442008972
/ O 0 0.11569348722696304
Tyr O 0 0.0028381594456732273
) O 0 2.2778871425543912e-05
polymorphism O 0 0.00038433203008025885
. O 0 3.6375364288687706e-05

Recent O 0 9.888032218441367e-05
studies O 0 2.047894122370053e-05
have O 0 2.2230794911592966e-06
shown O 0 1.1498533240228426e-05
that O 0 0.00030922828591428697
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.6243743300437927
HH B-Disease 1 0.9999933242797852
) O 0 1.8338605514145456e-06
is O 0 2.5687722882139497e-07
likely O 0 5.775834210908215e-07
to O 0 1.4927023528343852e-07
be O 0 1.2139230420871172e-07
caused O 0 1.5451068975380622e-06
by O 0 4.6941264031374885e-07
homozygosity O 0 3.620965435402468e-05
for O 0 3.330107745114219e-07
a O 0 3.2625960102450335e-06
Cys282Tyr O 0 0.00029199800337664783
mutation O 0 8.574118510296103e-06
in O 0 6.719998850712727e-07
the O 0 2.3173249701358145e-06
HFE O 0 0.0011955529917031527
gene O 0 2.6996294764103368e-05
located O 0 8.678653102833778e-06
4 O 0 1.3948810192232486e-05
. O 0 1.6509337001480162e-05

5 O 0 0.0004444712249096483
Mb O 0 0.023102281615138054
telomeric O 0 0.002810647478327155
to O 0 8.783707016846165e-05
HLA O 0 0.05704284459352493
- O 0 0.00021842002752237022
A O 0 5.883621997782029e-05
. O 0 3.9654689317103475e-05

Population O 0 1.5457861081813462e-05
studies O 0 2.889563575081411e-06
of O 0 3.3915551966856583e-07
this O 0 3.045263099465956e-07
polymorphism O 0 4.350552444520872e-06
are O 0 5.3908426167481593e-08
facilitated O 0 5.249202104096184e-07
by O 0 9.012820356701923e-08
the O 0 9.423311553291569e-08
fact O 0 1.0116392701320365e-07
that O 0 6.926362772219363e-08
the O 0 3.761057598694606e-07
Cys282Tyr O 0 6.643812957918271e-05
mutation O 0 8.01246005721623e-06
creates O 0 1.441183258066303e-06
a O 0 1.8077137156069512e-06
Rsal O 0 9.093192784348503e-05
restriction O 0 2.4324446712853387e-05
site O 0 3.456934427958913e-05
. O 0 1.7340373233309947e-05

We O 0 1.6399131709476933e-05
have O 0 2.192449528592988e-06
studied O 0 3.5005839436053066e-06
the O 0 3.2589327929599676e-06
codon O 0 6.197125185281038e-05
282 O 0 5.3810585086466745e-05
( O 0 2.974949893541634e-05
Cys O 1 0.9200974702835083
/ O 0 0.04387670010328293
Tyr O 0 0.0008078769315034151
) O 0 2.44231523538474e-06
polymorphism O 0 1.3396408576227259e-05
in O 0 5.02197224250267e-07
different O 0 3.0782902626924624e-07
ethnic O 0 1.0535140972933732e-06
groups O 0 2.0248478449502727e-06
. O 0 8.824270480545238e-06

In O 0 1.141296888818033e-05
agreement O 0 2.483938715158729e-06
with O 0 5.205189381740638e-07
previous O 0 1.3087955039736698e-06
observations O 0 2.014224037338863e-06
the O 0 8.192986342692166e-07
Tyr O 0 9.684942779131234e-05
allele O 0 1.0452075912326109e-05
appeared O 0 4.065194389113458e-06
to O 0 2.6956314513881807e-07
be O 0 8.350343705387786e-08
rare O 0 4.974705234417343e-07
or O 0 5.030044007980905e-07
absent O 0 3.25047744809126e-06
in O 0 7.992487667252135e-07
Asiatic O 0 3.6973797250539064e-05
( O 0 6.486733923338761e-07
Indian O 0 4.557815884709271e-07
, O 0 2.574304858171672e-07
Chinese O 0 3.448580514486821e-07
) O 0 1.5839412981222267e-06
populations O 0 6.433501312130829e-06
. O 0 6.841021331638331e-06

The O 0 2.5155679395538755e-05
highest O 0 2.19821922655683e-05
allele O 0 5.240561222308315e-05
frequency O 0 1.82645017048344e-05
( O 0 8.27365624900267e-07
7 O 0 4.04236743634101e-07
. O 0 4.77441872703821e-08
5 O 0 1.3786333852294774e-07
% O 0 8.037297050123016e-08
) O 0 1.3527522924050572e-07
was O 0 2.730539790718467e-06
found O 0 6.60262912788312e-07
in O 0 1.760918962645519e-06
Swedes O 0 0.00010991135786753148
. O 0 2.1965259293210693e-05

Saamis O 0 0.003955204505473375
( O 0 3.0319088182295673e-05
2 O 0 6.9278289629437495e-06
% O 0 1.0771262850539642e-06
) O 0 5.099353757032077e-07
and O 0 4.328971101585921e-07
Mordvinians O 0 4.7514698962913826e-05
( O 0 6.400134680006886e-07
1 O 0 2.3784372160662315e-07
. O 0 9.304257986286757e-08
8 O 0 3.9348881841760885e-07
% O 0 8.118647798482925e-08
) O 0 1.6670395552864647e-07
had O 0 8.100640229713463e-07
significantly O 0 2.4275213945657015e-06
lower O 0 2.515587766538374e-06
frequencies O 0 1.897403762995964e-06
of O 0 3.9383795069625194e-07
the O 0 5.455138307297602e-06
Tyr O 0 0.0022104261443018913
allele O 0 0.00034687769948504865
. O 0 4.498604539548978e-05

Comparisons O 0 0.00011477544467197731
with O 0 1.1471786820038687e-05
allele O 0 6.228988786460832e-05
frequencies O 0 1.4910215213603806e-05
based O 0 1.8104516357198008e-06
on O 0 1.7118453570219572e-06
prevalence O 0 8.311797500937246e-06
estimates O 0 9.679425829745014e-07
of O 0 5.117379373587028e-07
HH B-Disease 1 0.9981119632720947
showed O 0 6.712275535392109e-06
some O 0 6.639960759002861e-08
disagreements O 0 5.820984938509355e-07
with O 0 9.778771214996596e-08
the O 0 4.015513468402787e-07
RFLP O 0 3.735479185706936e-05
data O 0 1.1751307056329097e-06
, O 0 1.9063951128828194e-07
particularly O 0 6.71979364597064e-07
in O 0 1.775429154804442e-06
Finns O 0 7.790303789079189e-05
. O 0 2.104801023961045e-05

The O 0 3.7259866076055914e-05
newly O 0 0.0001455230376450345
described O 0 0.00013045755622442812
HFE O 0 0.01191374659538269
marker O 0 2.936080636573024e-05
provides O 0 1.177486524284177e-06
a O 0 4.350753499693383e-07
new O 0 5.032159720030904e-07
approach O 0 2.469475930411136e-07
to O 0 1.1832268853595451e-07
the O 0 1.0192333377290197e-07
screening O 0 4.6104250372991373e-07
of O 0 1.2515377534327854e-07
HH B-Disease 1 0.6295074224472046
as O 0 1.124677808661545e-07
well O 0 4.769676209548379e-08
as O 0 5.4183040276711836e-08
studies O 0 7.380658217925884e-08
of O 0 2.5662151514893594e-08
the O 0 2.0515106768925762e-07
relationship O 0 1.0971018582495162e-06
between O 0 7.385882554444834e-07
the O 0 3.29265276377555e-06
HFE O 0 0.010150518268346786
Tyr O 0 0.0003643497475422919
allele O 0 3.964886855101213e-05
and O 0 1.9240826532040955e-06
different O 0 5.514759322977625e-06
disorders O 1 0.9924236536026001
including O 0 0.00018963910406455398
cancer B-Disease 1 0.995941698551178

Autosomal B-Disease 1 0.9997003078460693
dominant I-Disease 1 0.9967261552810669
neurohypophyseal I-Disease 1 0.9999985694885254
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9998853206634521
associated O 0 0.00012586652883328497
with O 0 3.4552801935205935e-06
a O 0 2.1733329049311578e-05
missense O 0 0.0005618133582174778
mutation O 0 0.00010001496411859989
encoding O 0 4.808328958461061e-05
Gly23 O 0 0.0009050691733136773
- O 0 0.003088952274993062
- O 0 0.0005151984514668584
> O 0 6.127525557531044e-05
Val O 0 0.00023934204364195466
in O 0 9.795544428925496e-06
neurophysin O 0 0.026199597865343094
II O 0 0.3737758994102478
. O 0 5.026038707001135e-05

Autosomal B-Disease 1 0.9995740056037903
dominant I-Disease 1 0.9766010046005249
neurohypophyseal I-Disease 1 0.9999942779541016
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9998732805252075
( O 0 0.00010865563672268763
ADNDI B-Disease 0 0.0887107402086258
) O 0 2.761989208011073e-06
is O 0 9.218265404342674e-07
an O 0 0.000988481449894607
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
caused O 0 0.01032885443419218
by O 0 2.2220719984034076e-05
progressive O 1 0.880001962184906
degeneration O 0 0.1632561981678009
of O 0 2.400701646365633e-07
the O 0 1.1192737474630121e-06
magnocellular O 0 8.162728772731498e-05
neurons O 0 5.789583156001754e-06
of O 0 1.3734707238199917e-07
the O 0 3.5860415437127813e-07
hypothalamus O 0 7.090303824952571e-06
leading O 0 5.506658453668933e-07
to O 0 2.3094808909718267e-07
decreased O 0 1.4703734905197052e-06
ability O 0 3.4121040926038404e-07
to O 0 2.2032406832295237e-07
produce O 0 4.2185806137240434e-07
the O 0 1.0862328281291411e-06
hormone O 0 3.627061960287392e-05
arginine O 0 4.761367381433956e-05
vasopressin O 0 0.00011073317000409588
( O 0 1.2760940990119707e-05
AVP O 0 0.00018984480993822217
) O 0 9.785768270376138e-06
. O 0 1.6077488908194937e-05

Affected O 0 0.00019942618382629007
individuals O 0 7.703437404416036e-06
are O 0 8.222763199228211e-07
not O 0 1.0443728797326912e-06
symptomatic O 0 6.131261034170166e-05
at O 0 6.216042038431624e-06
birth O 0 6.0792288422817364e-05
, O 0 4.357701186563645e-07
but O 0 4.4284905698077637e-07
usually O 0 5.865364528290229e-06
develop O 0 0.0034296722151339054
diabetes B-Disease 1 0.9992861151695251
insipidus I-Disease 0 0.3694835305213928
at O 0 5.882707228010986e-06
1 O 0 4.0722211451793555e-06
- O 0 0.00015656348841730505
6 O 0 1.0395264325779863e-05
yr O 0 0.00017633977404329926
of O 0 1.2302035656830412e-06
age O 0 1.001823056867579e-05
. O 0 1.2450570466171484e-05

The O 0 2.878077248169575e-05
genetic O 0 4.39043651567772e-05
locus O 0 3.621427822508849e-05
of O 0 5.406091077020392e-07
the O 0 5.365072411223082e-06
disease O 0 0.0001311993255512789
is O 0 2.788897006666957e-07
the O 0 1.3152093742974102e-06
AVP O 0 0.0010284000309184194
- O 0 0.002655808813869953
neurophysin O 0 0.006189416628330946
II O 0 0.14230889081954956
( O 0 1.8701905446505407e-06
NPII O 0 4.644887303584255e-05
) O 0 3.311704119823844e-07
gene O 0 8.231605761466199e-07
, O 0 6.568989618926935e-08
and O 0 2.5629361743995105e-07
mutations O 0 1.7331060462311143e-06
that O 0 1.6763901555805205e-07
cause O 0 4.839311259274837e-06
ADNDI B-Disease 0 0.002065113512799144
have O 0 4.5454575570147426e-07
been O 0 3.56297675807582e-07
found O 0 1.3664224240983458e-07
in O 0 7.916327859902594e-08
both O 0 5.962396443237594e-08
the O 0 9.18921543302531e-08
signal O 0 1.0500635880816844e-06
peptide O 0 6.457680683524814e-07
of O 0 6.298915167235464e-08
the O 0 3.5604224990493094e-07
prepro O 0 4.9929614760912955e-05
- O 0 3.8667742046527565e-05
AVP O 0 8.529335900675505e-05
- O 0 1.737281672831159e-05
NPII O 0 4.897005419479683e-05
precursor O 0 6.211266281752614e-06
and O 0 6.624603088312142e-07
within O 0 2.174226210627239e-06
NPII O 0 0.0007049451814964414
itself O 0 4.928173802909441e-05
. O 0 1.927809717017226e-05

An O 0 2.7470881832414307e-05
affected O 0 1.949206125573255e-05
girl O 0 3.154859950882383e-05
who O 0 9.866475920716766e-07
presented O 0 1.0364215086156037e-06
at O 0 4.2839999991883815e-07
9 O 0 6.643437586717482e-07
months O 0 2.605817712719727e-07
of O 0 4.5406874704667644e-08
age O 0 2.9188367989263497e-07
and O 0 2.38459222146048e-07
her O 0 5.825816970173037e-06
similarly O 0 1.9774668544414453e-05
affected O 0 1.3097594546707114e-06
younger O 0 1.0710029982874403e-06
brother O 0 1.4029829799255822e-05
and O 0 6.94953257607267e-07
father O 0 7.891174027463421e-05
were O 0 3.837100166492746e-07
all O 0 2.9523663513941756e-08
found O 0 2.084805288404823e-07
to O 0 1.4680375670650392e-07
have O 0 7.792124989691729e-08
a O 0 6.264218086471374e-07
novel O 0 5.992854767100653e-06
missense O 0 0.00010447799286339432
mutation O 0 1.9186358258593827e-05
( O 0 2.6249883831042098e-06
G1758 O 0 5.424087794381194e-05
- O 0 0.007664336357265711
- O 0 0.0008103364380076528
> O 0 2.0103352653677575e-05
T O 0 5.9147878346266225e-05
) O 0 3.6590617469300923e-07
encoding O 0 1.1338116792103392e-06
the O 0 3.5592651670413034e-07
amino O 0 1.8001887838181574e-06
acid O 0 3.0258315746323206e-06
substitution O 0 6.439092885557329e-06
Gly23 O 0 9.975150896934792e-05
- O 0 0.00021464587189257145
- O 0 0.00012884644092991948
> O 0 3.97193398384843e-05
Val O 0 0.00016030504775699228
within O 0 1.180074832518585e-05
NPII O 0 0.0016813947586342692
. O 0 6.059318911866285e-05

The O 0 6.007622869219631e-05
mutation O 0 0.00033974589314311743
was O 0 3.50848313246388e-05
confirmed O 0 1.9529665223672055e-05
by O 0 4.881012500845827e-06
restriction O 0 4.1595863876864314e-05
endonuclease O 0 0.0011495628859847784
analysis O 0 5.726809104089625e-05
. O 0 2.673101880645845e-05

A O 0 0.0011601323494687676
T1 O 1 0.8784081339836121
- O 0 0.00025757186813279986
weighted O 0 1.744270593917463e-05
magnetic O 0 2.9009814170422032e-05
resonance O 0 4.613702913047746e-05
imaging O 0 6.209821003722027e-05
of O 0 6.210018455021782e-07
the O 0 3.7828094718861394e-06
fathers O 0 5.3617524827132e-05
pituitary O 0 0.0001863353536464274
gland O 0 6.133102579042315e-05
demonstrates O 0 8.36703839013353e-06
an O 0 3.183609578627511e-06
attenuated O 0 0.00036978203570470214
posterior O 0 0.0004441835917532444
pituitary O 0 0.0015851251082494855
bright O 0 0.000258814514381811
spot O 0 7.763873145449907e-05
. O 0 3.145400478388183e-05

This O 0 4.4599677494261414e-05
mutation O 0 0.0004896004102192819
may O 0 8.985321983345784e-06
be O 0 1.758253063144366e-07
valuable O 0 2.1035101838151604e-07
for O 0 1.1391643539582219e-07
developing O 0 3.393790848349454e-07
models O 0 1.1218995723538683e-06
of O 0 4.1561096963960154e-07
dominantly B-Disease 1 0.890235960483551
inherited I-Disease 1 0.9999722242355347
neurodegeneration I-Disease 1 1.0
, O 0 1.0077122851726017e-06
as O 0 1.8258019451877772e-07
the O 0 1.9786354243933602e-07
early O 0 3.1346892228611978e-06
age O 0 3.4209017485409277e-07
of O 0 1.731259686721387e-07
onset O 0 0.004110485780984163
of O 0 2.0960558231308823e-06
symptoms O 0 0.37448447942733765
suggests O 0 2.439358922856627e-06
that O 0 2.0935935651777982e-07
this O 0 6.407823889276187e-07
mutation O 0 3.863512029056437e-05
may O 0 1.1602439371927176e-05
be O 0 2.648613133260369e-07
particularly O 0 6.674688961538777e-07
deleterious O 0 1.9235292711528018e-05
to O 0 1.1067224932048703e-06
the O 0 3.79757875634823e-06
magnocellular O 0 0.0007543379906564951
neuron O 0 0.0016125529073178768
. O 0 6.106589808041463e-06
. O 0 1.7893740732688457e-05

Frequent O 0 0.0017292421543970704
inactivation O 0 0.00752997025847435
of O 0 5.901964323129505e-05
PTEN O 1 0.6722211837768555
/ O 0 0.005721185356378555
MMAC1 O 0 0.007522326894104481
in O 0 0.00013940644566901028
primary O 1 0.9748987555503845
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0002217064320575446

Sporadic B-Disease 1 0.9999412298202515
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 3.377689608896617e-06
the O 0 4.104995525722188e-07
most O 0 2.0261272482002823e-07
common O 0 8.992033144750167e-07
male B-Disease 0 3.1568893064104486e-06
cancer I-Disease 0 4.007271127193235e-05
in O 0 1.0036134057145318e-07
the O 0 1.1107610475846741e-07
Western O 0 2.978600548431132e-07
world O 0 3.237235262076865e-07
, O 0 6.348729897354133e-08
yet O 0 4.538756570582336e-08
many O 0 7.434797666405757e-09
of O 0 9.452975291424082e-09
the O 0 9.446868176610224e-08
major O 0 2.8013243991154013e-07
genetic O 0 6.583439358109899e-07
events O 0 2.30784706900522e-07
involved O 0 1.6154868376361264e-07
in O 0 1.1050449444383048e-07
the O 0 2.0152873503320734e-07
progression O 0 1.3629010027216282e-06
of O 0 9.008471835159071e-08
this O 0 9.945388228516094e-07
often O 0 0.00017635054246056825
fatal O 1 0.9999642372131348
cancer B-Disease 1 0.9828948974609375
remain O 0 1.010582855087705e-05
to O 0 2.5558751985954586e-06
be O 0 4.217400146444561e-06
elucidated O 0 0.0005586521583609283
. O 0 2.8596698030014522e-05

Numerous O 0 0.00012136145232943818
cytogenetic O 0 0.0027469114866107702
and O 0 1.454630728403572e-05
allelotype O 0 0.002821308560669422
studies O 0 1.2483884347602725e-05
have O 0 1.616466761333868e-06
reported O 0 4.896646714769304e-05
frequent O 0 1.3964543541078456e-05
loss O 0 3.6171069950796664e-05
of O 0 1.2006472616121755e-06
heterozygosity O 0 0.00025765193277038634
on O 0 2.5288140022894368e-05
chromosomal O 0 0.0018908367492258549
arm O 0 0.0017918864032253623
10q O 0 0.00013039026816841215
in O 0 3.709815428010188e-05
sporadic B-Disease 1 0.9999135732650757
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00016482638602610677

Deletion O 0 0.0018152307020500302
mapping O 0 0.0002100913116009906
studies O 0 2.1766307327197865e-05
have O 0 2.4206437956308946e-06
unambiguously O 0 2.9807546525262296e-05
identified O 0 1.8034742197414744e-06
a O 0 5.502926114786533e-07
region O 0 5.79323341298732e-07
of O 0 2.116870803092752e-07
chromosome O 0 8.92994739842834e-06
10q23 O 0 8.357133992831223e-06
to O 0 3.843564115868503e-07
be O 0 8.131339512829072e-08
the O 0 1.293242632982583e-07
minimal O 0 1.0663768534868723e-06
area O 0 9.282337032345822e-07
of O 0 1.011550125440408e-06
loss O 0 0.00029960062238387764
. O 0 3.3722040825523436e-05

A O 0 0.00017011049203574657
new O 0 8.697524026501924e-05
tumor B-Disease 0 0.001022661104798317
suppressor O 0 0.0006336895166896284
gene O 0 5.762527143815532e-05
, O 0 4.749323579744669e-06
PTEN O 0 0.0014584393939003348
/ O 0 0.0003174394660163671
MMAC1 O 0 0.0008137247059494257
, O 0 8.181696102838032e-07
was O 0 6.339863375615096e-06
isolated O 0 3.495003284115228e-06
recently O 0 4.148849257035181e-06
at O 0 1.9040422216676234e-07
this O 0 5.4108372893324486e-08
region O 0 2.033293071690423e-07
of O 0 8.215930336064048e-08
chromosome O 0 3.0378510018636007e-06
10q23 O 0 4.333773176767863e-06
and O 0 3.112185709142068e-07
found O 0 4.16043263840038e-07
to O 0 2.802951541980292e-07
be O 0 2.0047060900196811e-07
inactivated O 0 1.2804509424313437e-05
by O 0 3.674735182812583e-07
mutation O 0 4.102696493646363e-06
in O 0 1.555071889924875e-06
three O 0 0.0022356309927999973
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.5029354691505432
lines O 0 0.0005036975489929318
. O 0 3.8595790101680905e-05

We O 0 3.856007242575288e-05
screened O 0 0.00017852320161182433
80 O 0 0.00011740421177819371
prostate B-Disease 1 0.999987006187439
tumors I-Disease 1 0.9999692440032959
by O 0 5.615038844553055e-06
microsatellite O 0 0.0001362812181469053
analysis O 0 2.4990526981127914e-06
and O 0 4.618359525920823e-07
found O 0 1.3304536423675017e-06
chromosome O 0 7.924295459815767e-06
10q23 O 0 8.10748042567866e-06
to O 0 3.792685845382948e-07
be O 0 2.337192341883565e-07
deleted O 0 3.388300910955877e-06
in O 0 3.863346478283347e-07
23 O 0 3.023071485586115e-06
cases O 0 3.553197984729195e-06
. O 0 1.1089507097494788e-05

We O 0 1.3027611203142442e-05
then O 0 3.4721733754849993e-06
proceeded O 0 2.7086757654615212e-06
with O 0 2.4290397959703114e-07
sequence O 0 5.960923772363458e-07
analysis O 0 2.315298388566589e-07
of O 0 5.8885511577955185e-08
the O 0 3.506156076582556e-07
entire O 0 4.706768322648713e-06
PTEN O 0 0.01695915125310421
/ O 0 0.00012170889385743067
MMAC1 O 0 8.538842666894197e-05
coding O 0 9.310484529123642e-06
region O 0 1.1699767128448002e-06
and O 0 8.068197416832845e-07
tested O 0 3.519674692142871e-06
for O 0 2.148402700186125e-07
homozygous O 0 1.1188233656866942e-05
deletion O 0 4.7627904677938204e-06
with O 0 3.167644706536521e-07
new O 0 2.9069492484268267e-06
intragenic O 0 0.0008607866475358605
markers O 0 2.833939106494654e-06
in O 0 1.582731812277416e-07
these O 0 7.141174052094357e-08
23 O 0 4.279557401787315e-07
cases O 0 1.6806465907848178e-07
with O 0 3.777870745125256e-07
10q23 O 0 0.00021574011771008372
loss O 0 5.775224053650163e-05
of O 0 4.030547643196769e-06
heterozygosity O 0 0.0019184492994099855
. O 0 4.61909148725681e-05

The O 0 1.4565519450115971e-05
identification O 0 6.260004738578573e-06
of O 0 3.618067410116055e-07
the O 0 4.960984938406909e-07
second O 0 1.954209210452973e-06
mutational O 0 4.762265962199308e-05
event O 0 1.4841559732303722e-06
in O 0 4.6322892899297585e-07
10 O 0 4.3928045556640427e-07
( O 0 5.775190174972522e-07
43 O 0 1.9128651729261037e-06
% O 0 1.3310234407981625e-06
) O 0 8.99401493370533e-06
tumors B-Disease 1 0.9989922642707825
establishes O 0 0.0004931385046802461
PTEN O 0 0.322941392660141
/ O 0 0.000188722406164743
MMAC1 O 0 6.339105311781168e-05
as O 0 2.9752050068054814e-07
a O 0 4.151696941789851e-07
main O 0 1.2139291811763542e-06
inactivation O 0 2.276566556247417e-05
target O 0 9.173539297080424e-07
of O 0 2.629483333294047e-07
10q O 0 4.4059714127797633e-05
loss O 0 5.1818275096593425e-05
in O 0 2.800886068143882e-05
sporadic B-Disease 1 0.9999768733978271
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.5999619538197294e-05
. O 0 3.849661516142078e-05

Risk O 0 0.0010837833397090435
reversals O 0 0.0008852049941197038
in O 0 4.642071507987566e-05
predictive O 0 0.0005604222533293068
testing O 0 0.0004994955961592495
for O 0 0.0007527360576204956
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 0.0001826037623686716

The O 0 2.0997067622374743e-05
first O 0 1.1281855222478043e-05
predictive O 0 3.7332960346248e-05
testing O 0 2.71344597422285e-05
for O 0 5.613414032268338e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
( O 0 1.1783451554947533e-05
HD B-Disease 0 0.016743149608373642
) O 0 8.589353797106014e-07
was O 0 2.0173097254883032e-06
based O 0 3.161032680054632e-07
on O 0 3.3766642104637867e-07
analysis O 0 3.5073099979854305e-07
of O 0 1.8632282205999218e-07
linked O 0 3.4857286664191633e-05
polymorphic O 0 2.259139364468865e-05
DNA O 0 4.5457541091309395e-06
markers O 0 2.236998625448905e-06
to O 0 1.7102236427035677e-07
estimate O 0 2.5255246782762697e-07
the O 0 1.1949843781167147e-07
likelihood O 0 4.286599448732886e-07
of O 0 1.2311912200857478e-07
inheriting O 0 1.341034203505842e-05
the O 0 1.7228973092642264e-06
mutation O 0 1.5494286344619468e-05
for O 0 3.4179770409537014e-06
HD B-Disease 0 0.0012760605895891786
. O 0 3.468333670753054e-05

Limits O 0 2.93913089990383e-05
to O 0 3.6121346056461334e-06
accuracy O 0 2.620333589220536e-06
included O 0 6.413106348190922e-07
recombination O 0 3.1725953704153653e-06
between O 0 3.1688503554505587e-07
the O 0 4.389140428884275e-07
DNA O 0 2.1338044007279677e-06
markers O 0 1.4848156979496707e-06
and O 0 1.3870418058559153e-07
the O 0 3.151929774958262e-07
mutation O 0 2.151461103494512e-06
, O 0 1.2280777639261942e-07
pedigree O 0 2.1870573618798517e-06
structure O 0 1.021597540784569e-06
, O 0 9.593603067514778e-08
and O 0 7.197621698651346e-08
whether O 0 1.1236871699793483e-07
DNA O 0 3.8260210999396804e-07
samples O 0 1.9061224065808346e-07
were O 0 9.316546112358992e-08
available O 0 1.568168670473824e-07
from O 0 2.2509229324896296e-07
family O 0 2.261029067085474e-06
members O 0 2.2512974737765035e-06
. O 0 9.71551526163239e-06

With O 0 9.743137525219936e-06
direct O 0 6.879175089125056e-06
tests O 0 4.169777184870327e-06
for O 0 2.506344003450067e-07
the O 0 7.071113259371486e-07
HD B-Disease 0 0.0033328181598335505
mutation O 0 6.896549621160375e-06
, O 0 1.4209398102593696e-07
we O 0 4.0175887505711216e-08
have O 0 4.721252722106328e-08
assessed O 0 3.17518782821935e-07
the O 0 1.3431612444492202e-07
accuracy O 0 5.125849042997288e-07
of O 0 8.14907039625723e-08
results O 0 1.0912311836364097e-06
obtained O 0 6.658285656158114e-07
by O 0 3.423544967517955e-07
linkage O 0 3.605306574172573e-06
approaches O 0 7.635778729309095e-07
when O 0 3.1333212291428936e-07
requested O 0 5.449411446534214e-07
to O 0 1.713544293124869e-07
do O 0 5.954986903589088e-08
so O 0 3.11049106471728e-08
by O 0 7.879691565904068e-08
the O 0 4.078491997461242e-07
test O 0 6.164146270748461e-06
individuals O 0 1.4095379583523027e-06
. O 0 7.190553333202843e-06

For O 0 4.391536549519515e-06
six O 0 1.3429605587589322e-06
such O 0 1.984739554927728e-07
individuals O 0 1.0412010453819676e-07
, O 0 9.617878760082021e-08
there O 0 1.1228559060327825e-07
was O 0 3.5401758395892102e-06
significant O 0 5.157535838407057e-07
disparity O 0 1.3404819583229255e-06
between O 0 4.835182494389301e-07
the O 0 2.816523192450404e-06
tests O 0 6.362712883856148e-05
. O 0 2.0946006770827807e-05

Three O 0 1.4849989383947104e-05
went O 0 6.556399057444651e-06
from O 0 5.789395345345838e-07
a O 0 1.3420860796031775e-06
decreased O 0 1.6154825061676092e-05
risk O 0 9.399666396348039e-07
to O 0 1.1658184462248755e-07
an O 0 8.043660670864483e-08
increased O 0 2.174317387471092e-06
risk O 0 5.041425765739405e-07
, O 0 3.545807203408913e-08
while O 0 3.594048791910609e-08
in O 0 4.1813780882193896e-08
another O 0 5.741006958714934e-08
three O 0 6.457791812408686e-08
the O 0 6.613487357753911e-07
risk O 0 4.115282990824198e-06
was O 0 2.5008694137795828e-05
decreased O 0 3.290783570264466e-05
. O 0 1.466226876800647e-05

Knowledge O 0 9.457390660827514e-06
of O 0 8.768851671447919e-07
the O 0 4.999827183382877e-07
potential O 0 7.718474535067799e-07
reasons O 0 3.0735145628568716e-07
for O 0 6.949890973828587e-08
these O 0 8.050107425106034e-08
changes O 0 4.6857627467034035e-07
in O 0 3.563303039300081e-07
results O 0 1.068155029315676e-06
and O 0 1.708350652052104e-07
impact O 0 2.642532876961923e-07
of O 0 6.542693142819189e-08
these O 0 1.8499225973300781e-07
risk O 0 7.925495992822107e-07
reversals O 0 3.264158294769004e-06
on O 0 1.40964687034284e-06
both O 0 4.823093036065984e-07
patients O 0 1.477150703976804e-06
and O 0 1.0916896542312315e-07
the O 0 5.965911782368494e-07
counseling O 0 2.854385456885211e-06
team O 0 4.3771726154773205e-07
can O 0 1.2236377244789765e-07
assist O 0 1.4153825134144427e-07
in O 0 8.202464130135922e-08
the O 0 1.1114752140883866e-07
development O 0 1.1463789917343092e-07
of O 0 6.31379393212228e-08
strategies O 0 4.991741775484115e-07
for O 0 3.6703145411820515e-08
the O 0 2.667648573151382e-07
prevention O 0 4.326636826590402e-06
and O 0 1.8606482399263768e-07
, O 0 8.587964117623414e-08
where O 0 7.819370040351714e-08
necessary O 0 1.8069621887661924e-07
, O 0 9.919833843241577e-08
management O 0 5.660696160703083e-07
of O 0 6.036062671910258e-08
a O 0 4.215136414131848e-06
risk O 0 2.0579432202794123e-06
reversal O 0 4.055908448208356e-06
in O 0 2.9544742119469447e-07
any O 0 5.705767875952006e-07
predictive O 0 1.4704389286634978e-05
testing O 0 6.1165796978457365e-06
program O 0 3.818813638645224e-06
. O 0 1.5036209788377164e-06
. O 0 8.75001660460839e-06

A O 0 0.00023935618810355663
novel O 0 0.00010831590770976618
common O 0 3.8002512155799195e-05
missense O 0 0.0010047168470919132
mutation O 0 0.000107351086626295
G301C O 0 8.639873703941703e-05
in O 0 3.2182751965592615e-06
the O 0 1.7286937463723007e-06
N O 0 5.6706983741605654e-05
- O 0 5.579524804488756e-05
acetylgalactosamine O 0 0.00016039371257647872
- O 0 5.784467430203222e-05
6 O 0 7.835657015675679e-06
- O 0 0.000352798611856997
sulfate O 0 0.0002620074083097279
sulfatase O 0 0.00026675191475078464
gene O 0 3.435369944781996e-05
in O 0 8.95317589311162e-06
mucopolysaccharidosis B-Disease 0 0.0009750869940035045
IVA I-Disease 0 0.006941001396626234
. O 0 8.188753417925909e-05

Mucopolysaccharidosis B-Disease 0 0.1205381229519844
IVA I-Disease 1 0.985270082950592
( O 0 0.001800485304556787
MPS B-Disease 1 0.9999734163284302
IVA I-Disease 1 0.9999853372573853
) O 0 1.0122863386641257e-05
is O 0 1.345615487480245e-06
an O 0 1.3151542589184828e-05
autosomal B-Disease 1 0.998646080493927
recessive I-Disease 1 0.9999668598175049
lysosomal I-Disease 1 0.9999984502792358
storage I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999904632568359
caused O 0 0.00011436794011387974
by O 0 2.5248555175494403e-06
a O 0 0.023569580167531967
genetic B-Disease 1 0.9999328851699829
defect I-Disease 1 0.9999434947967529
in O 0 5.329568921297323e-06
N O 0 0.00020562316058203578
- O 0 0.0001358875015284866
acetylgalactosamine O 0 0.000301476800814271
- O 0 0.00013207194569986314
6 O 0 2.0909865270368755e-05
- O 0 0.005149496719241142
sulfate O 0 0.0025707895401865244
sulfatase O 0 0.0009082329925149679
( O 0 1.8144659406971186e-05
GALNS O 0 0.0006110102403908968
) O 0 1.1213016477995552e-05
. O 0 1.186849840451032e-05

In O 0 2.1120376914041117e-05
previous O 0 1.802400583983399e-05
studies O 0 3.100105004705256e-06
, O 0 2.7409868152972194e-07
we O 0 7.934346513138735e-08
have O 0 5.832849936382445e-08
found O 0 6.569966615188605e-08
two O 0 5.8267229263719855e-08
common O 0 5.657668111780367e-07
mutations O 0 3.4108850286429515e-06
in O 0 4.783652229889412e-07
Caucasians O 0 2.0970835521438858e-06
and O 0 2.966804402149137e-07
Japanese O 0 2.2493102278531296e-06
, O 0 1.250290324605885e-06
respectively O 0 1.4592716070183087e-05
. O 0 1.3540843610826414e-05

To O 0 6.413996015908197e-05
characterize O 0 0.0001576965005369857
the O 0 8.881486792233773e-06
mutational O 0 0.00035395094892010093
spectrum O 0 1.9344915926922113e-05
in O 0 4.007746952083835e-07
various O 0 1.4135116543911863e-07
ethnic O 0 1.6854970397162106e-07
groups O 0 2.074232838822354e-07
, O 0 1.8356840314481815e-07
mutations O 0 1.1195320439583156e-06
in O 0 1.2897496048935864e-07
the O 0 2.9165801151975757e-07
GALNS O 0 5.095465894555673e-05
gene O 0 2.356289996896521e-06
in O 0 4.1120836158370366e-07
Colombian O 0 7.0656801653967705e-06
MPS B-Disease 1 0.9999637603759766
IVA I-Disease 1 0.9999991655349731
patients O 0 0.0012256340123713017
were O 0 2.236864247606718e-06
investigated O 0 1.3776302694168407e-05
, O 0 2.51684241447947e-07
and O 0 4.334399363870034e-07
genetic O 0 1.539635036351683e-06
backgrounds O 0 1.4369385326062911e-06
were O 0 7.200333129731007e-07
extensively O 0 1.4160958016873337e-05
analyzed O 0 5.039622465119464e-06
to O 0 3.7987493328728306e-07
identify O 0 5.903811484131438e-07
racial O 0 5.401828957474208e-07
origin O 0 2.9434778525683214e-07
, O 0 8.544388663267455e-08
based O 0 2.133628242972918e-07
on O 0 4.4725337033924006e-07
mitochondrial O 0 1.1495989383547567e-05
DNA O 0 6.635828867729288e-06
( O 0 2.266649062221404e-06
mtDNA O 0 1.4500434190267697e-05
) O 0 2.133704583684448e-06
lineages O 0 1.6647640222799964e-05
. O 0 1.1906738109246362e-05

Three O 0 4.663258005166426e-05
novel O 0 9.999675239669159e-05
missense O 0 0.0016683381982147694
mutations O 0 0.00022978390916250646
never O 0 8.169390639523044e-06
identified O 0 2.4094410946418066e-06
previously O 0 7.758606557217718e-07
in O 0 1.202730430804877e-07
other O 0 4.593764657556676e-08
populations O 0 1.7880921632240643e-07
and O 0 8.331633694069751e-08
found O 0 2.0561292046750168e-07
in O 0 8.247111082937408e-08
16 O 0 2.029817522952726e-07
out O 0 8.64985736370727e-08
of O 0 1.0370072800469643e-07
19 O 0 1.262086811948393e-06
Colombian O 0 6.706901331199333e-06
MPS B-Disease 1 0.9940524697303772
IVA I-Disease 1 0.9995214939117432
unrelated O 0 6.234629108803347e-05
alleles O 0 2.0840148863499053e-05
account O 0 2.185743824156816e-06
for O 0 8.243051752288011e-07
84 O 0 3.1742802093504e-05
. O 0 2.3313685233006254e-05

2 O 0 3.276738789281808e-05
% O 0 1.3684806390301674e-06
of O 0 1.8529701151237532e-07
the O 0 6.502410201392195e-07
alleles O 0 7.280920726771001e-06
in O 0 6.406619945664715e-07
this O 0 7.434913413817412e-07
study O 0 8.35947685118299e-06
. O 0 1.4859056136629079e-05

The O 0 3.511907561914995e-05
G301C O 0 0.0003118784516118467
and O 0 9.277388016926125e-06
S162F O 0 0.00018942820315714926
mutations O 0 3.707042560563423e-05
account O 0 5.439511824079091e-06
for O 0 2.0233421764714876e-06
68 O 0 4.655752127291635e-05
. O 0 3.247998756705783e-05

4 O 0 8.937404345488176e-05
% O 0 7.90424928709399e-06
and O 0 4.30980981036555e-06
10 O 0 1.1337412615830544e-05
. O 0 1.739946128509473e-05

5 O 0 2.8681746698566712e-05
% O 0 1.660340785747394e-06
of O 0 6.401673431355448e-07
mutations O 0 1.1658750736387447e-05
, O 0 3.139087709769228e-07
respectively O 0 6.120286570876488e-07
, O 0 1.0396372829291067e-07
whereas O 0 1.877854316489902e-07
the O 0 9.940478662429086e-08
remaining O 0 2.994310079884599e-07
F69V O 0 8.001456444617361e-05
is O 0 2.0617096652131295e-07
limited O 0 5.205194497648336e-07
to O 0 1.9986433130725345e-07
a O 0 1.0303821227353183e-06
single O 0 7.73833835410187e-06
allele O 0 0.00013164195115678012
. O 0 1.8030641513178125e-05

The O 0 9.147105447482318e-05
skewed O 0 0.00028804675093851984
prevalence O 0 6.639429921051487e-05
of O 0 1.139000687544467e-06
G301C O 0 3.0543855245923623e-05
in O 0 1.0323512924514944e-06
only O 0 3.4177907082266756e-07
Colombian O 0 4.779958999279188e-06
patients O 0 8.111966053547803e-06
and O 0 1.1010912430720055e-06
haplotype O 0 0.00012130603136029094
analysis O 0 1.043978500092635e-06
by O 0 5.27948543549428e-07
restriction O 0 1.919736860145349e-06
fragment O 0 4.3336240196367726e-06
length O 0 1.3578944617620436e-06
polymorphisms O 0 5.0656803978199605e-06
in O 0 2.7014502279598673e-07
the O 0 6.806880037402152e-07
GALNS O 0 0.0001449664414394647
gene O 0 3.729892796400236e-06
suggest O 0 5.025862606089504e-07
that O 0 1.504006661434687e-07
G301C O 0 5.413559392764e-06
originated O 0 1.0791559361678082e-06
from O 0 3.4410243188176537e-07
a O 0 1.0941157597699203e-06
common O 0 5.187059741729172e-06
ancestor O 0 6.209329148987308e-05
. O 0 2.876513281080406e-05

Investigation O 0 5.2834555390290916e-05
of O 0 1.877474346656527e-06
the O 0 2.3694294668530347e-06
genetic O 0 2.9263303531479323e-06
background O 0 2.2044441720936447e-06
by O 0 2.480496448242775e-07
means O 0 1.5223785965190473e-07
of O 0 7.995630824098043e-08
mtDNA O 0 2.3413267626892775e-06
lineages O 0 1.651016987125331e-06
indicate O 0 3.4124556691494945e-07
that O 0 7.124358347709858e-08
all O 0 4.03820870076288e-08
our O 0 2.3409957350395416e-07
patients O 0 7.752453257126035e-07
are O 0 4.6412353071900725e-08
probably O 0 2.807036594276724e-07
of O 0 9.710096549042646e-08
native O 0 1.7307426105617196e-06
American O 0 1.5378933312604204e-05
descent O 0 0.0009937253780663013

Low O 0 0.00022004818310961127
frequency O 0 0.0001402798661729321
of O 0 5.086811597720953e-06
BRCA1 O 0 0.0005446834256872535
germline O 0 0.0005606295308098197
mutations O 0 5.033214620198123e-05
in O 0 2.406347903161077e-06
45 O 0 8.727356544113718e-06
German O 1 0.999953031539917
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.504635580815375e-05
. O 0 3.2266958442050964e-05

In O 0 1.9453138520475477e-05
this O 0 2.7413291263655992e-06
study O 0 1.6831003222250729e-06
we O 0 3.0677571771775547e-07
investigated O 0 3.7936295029794564e-06
45 O 0 3.322920747450553e-06
German O 1 0.9998117089271545
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 2.709114824028802e-06
for O 0 1.5623052149749128e-06
germline O 0 0.003052979940548539
mutations O 0 5.2792951464653015e-05
in O 0 2.5049916985153686e-06
the O 0 1.1843376341857947e-05
BRCA1 O 0 0.0009442344307899475
gene O 0 0.00017413623572792858
. O 0 3.570388435036875e-05

We O 0 1.8780954633257352e-05
identified O 0 1.1790994904004037e-05
four O 0 1.8687302372200065e-06
germline O 0 0.00014457012002822012
mutations O 0 1.2721753591904417e-05
in O 0 9.156599958259903e-07
three O 0 5.509654783963924e-06
breast B-Disease 1 0.9960576295852661
cancer I-Disease 0 0.03322310000658035
families O 0 3.6092586697122897e-07
and O 0 3.1368881536764093e-07
in O 0 9.60870011113002e-07
one O 0 2.624800254125148e-05
breast B-Disease 1 0.9999967813491821
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0009271181770600379
. O 0 1.8663476453184558e-07
among O 0 5.8787204437749097e-08
these O 0 4.358440364171656e-08
were O 0 2.1293189433890802e-07
one O 0 4.15871113546018e-07
frameshift O 0 0.00037630999577231705
mutation O 0 5.414736733655445e-06
, O 0 1.5760036831125035e-07
one O 0 1.7278124175845733e-07
nonsense O 0 8.05180116003612e-06
mutation O 0 3.980477231380064e-06
, O 0 1.6447435768895957e-07
one O 0 2.3400113491334196e-07
novel O 0 1.6999497347569559e-06
splice O 0 5.668583980877884e-05
site O 0 1.593969136592932e-05
mutation O 0 6.830819074821193e-06
, O 0 2.6855065016206936e-07
and O 0 4.7040083472893457e-07
one O 0 2.9836314752174076e-06
missense O 0 0.0006846115575172007
mutation O 0 0.00017672406102064997
. O 0 3.134745929855853e-05

The O 0 7.060034840833396e-05
missense O 0 0.002119903452694416
mutation O 0 0.0002669653913471848
was O 0 6.933935947017744e-05
also O 0 2.6889504169957945e-06
found O 0 1.297985136261559e-06
in O 0 1.4873141935822787e-06
2 O 0 7.804969754943158e-06
. O 0 1.3263111213746015e-05

8 O 0 2.0251052774256095e-05
% O 0 9.626455721445382e-07
of O 0 1.3222705774751375e-07
the O 0 1.841761729792779e-07
general O 0 4.2946317080350127e-07
population O 0 1.3361535877720598e-07
, O 0 8.33875617445301e-08
suggesting O 0 6.156646463750803e-07
that O 0 8.491911529517893e-08
it O 0 1.4701419104312663e-07
is O 0 3.082632247242145e-07
not O 0 3.4992456221516477e-06
disease O 0 0.00034797569969668984
associated O 0 2.8358692361507565e-05
. O 0 2.1751473468611948e-05

The O 0 2.7881951609742828e-05
average O 0 1.8926952179754153e-05
age O 0 4.6361619752133265e-06
of O 0 1.574059979247977e-06
disease O 0 0.009460965171456337
onset O 0 0.05477449670433998
in O 0 2.8048739295627456e-06
those O 0 5.095367896501557e-07
families O 0 1.5128783843465499e-06
harbouring O 0 0.0036166366189718246
causative O 0 0.00016216743097174913
mutations O 0 3.8988211599644274e-05
was O 0 6.947850124561228e-06
between O 0 2.65348762695794e-06
32 O 0 1.5717419955763035e-05
. O 0 1.3690334526472725e-05

3 O 0 9.450297511648387e-05
and O 0 1.9579270883696154e-05
37 O 0 5.513757059816271e-05
. O 0 2.2541831640410237e-05

4 O 0 4.346718196757138e-05
years O 0 5.116889497003285e-06
, O 0 5.634004196508613e-07
whereas O 0 4.848041612603993e-07
the O 0 3.2906334013205196e-07
family O 0 3.799690830419422e-06
harbouring O 0 5.2868970669806004e-05
the O 0 1.9442268239799887e-06
missense O 0 0.00016208829765673727
mutation O 0 1.0232082786387764e-05
had O 0 1.5537807485088706e-06
an O 0 3.453625652127812e-07
average O 0 1.160089482254989e-06
age O 0 4.18498046883542e-07
of O 0 1.9689976227255102e-07
onset O 0 0.00019700310076586902
of O 0 1.826979200814094e-06
51 O 0 4.876877574133687e-05
. O 0 2.594552279333584e-05

2 O 0 0.00030246892129071057
years O 0 0.00012829450133722275
. O 0 8.265914220828563e-05

These O 0 1.147713828686392e-05
findings O 0 1.468618393118959e-05
show O 0 3.768201850107289e-06
that O 0 8.30901001336315e-07
BRCA1 O 0 3.470848241704516e-05
is O 0 5.639745381813555e-07
implicated O 0 3.581223154469626e-06
in O 0 2.0973065772977861e-07
a O 0 4.4121304654254345e-07
small O 0 2.9611933882733865e-07
fraction O 0 1.0458650194777874e-06
of O 0 3.8207954276003875e-06
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.9288261228211923e-06
suggesting O 0 3.244543677283218e-06
the O 0 3.1467158123632544e-07
involvement O 0 1.1440879461588338e-06
of O 0 3.086108790739672e-07
another O 0 5.998572305543348e-06
susceptibility O 0 0.000394477101508528
gene O 0 8.946417074184865e-05
( O 0 2.5077382815652527e-05
s O 0 0.001849869266152382
) O 0 8.522393909515813e-05

Paternal O 1 0.881990373134613
transmission O 1 0.9974042773246765
of O 0 0.004062301479279995
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.01627073623239994

We O 0 2.2839014491182752e-05
report O 0 1.086990687326761e-05
a O 0 3.251178213758976e-06
rare O 0 5.371015959099168e-06
case O 0 5.676271484844619e-06
of O 0 1.899722519738134e-05
paternally O 1 0.9999990463256836
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9978845715522766
DM B-Disease 1 1.0
) O 0 0.00012742934632115066
. O 0 4.430260742083192e-05

The O 0 2.0992963982280344e-05
proband O 0 0.0003162029024679214
is O 0 1.463473950025218e-06
a O 0 1.5370455912488978e-06
23 O 0 3.1266786209016573e-06
year O 0 1.008146682579536e-06
old O 0 5.6094002502504736e-05
, O 0 1.2401486856106203e-05
mentally B-Disease 1 0.9999914169311523
retarded I-Disease 1 0.9982696771621704
male O 0 2.89183826680528e-05
who O 0 0.005203102249652147
suffers O 1 0.9999982118606567
severe O 1 0.9999995231628418
muscular B-Disease 1 0.9999997615814209
weakness I-Disease 1 0.9999850988388062
. O 0 0.0003615593886934221

He O 0 3.915701017831452e-05
presented O 0 2.6731451725936495e-05
with O 0 1.0766963896458037e-05
respiratory O 1 0.992174506187439
and O 0 8.033439371502027e-06
feeding O 0 4.0685030398890376e-05
difficulties O 0 2.7302086891722865e-05
at O 0 1.7443104297854006e-05
birth O 0 0.0006526389042846859
. O 0 4.057007754454389e-05

His O 0 0.00017156483954750001
two O 0 5.2874922403134406e-05
sibs O 1 0.9693983197212219
suffer O 0 0.08068204671144485
from O 0 9.149398829322308e-05
childhood O 1 0.924657940864563
onset O 1 0.9999971389770508
DM B-Disease 1 1.0
. O 0 0.00048619008157402277

Their O 0 9.550745744490996e-06
late O 0 0.00013860585750080645
father O 0 6.651648436672986e-05
had O 0 2.1075452423247043e-06
the O 0 4.0455640260006476e-07
adult O 0 1.8912072619059472e-06
type O 0 4.984172846889123e-06
of O 0 1.0189995691689546e-06
DM B-Disease 1 1.0
, O 0 6.780052217436605e-07
with O 0 4.928202201881504e-07
onset O 0 0.0003488551010377705
around O 0 1.8858636394725181e-06
30 O 0 3.1775914521858795e-06
years O 0 5.24441611560178e-06
. O 0 1.005673038889654e-05

Only O 0 5.386126758821774e-06
six O 0 1.6153294382093009e-06
other O 0 1.7587292688858724e-07
cases O 0 2.4506766749254894e-07
of O 0 2.7216356102144346e-07
paternal O 0 0.10127882659435272
transmission O 1 0.9931354522705078
of O 0 0.0005562569131143391
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0001121586756198667
been O 0 1.5443538359249942e-05
reported O 0 0.00015145800716709346
recently O 0 0.00011947913299081847
. O 0 1.5624062143615447e-05

We O 0 1.4108455616224092e-05
review O 0 1.3476674212142825e-05
the O 0 1.5410863625220372e-06
sex O 0 4.857779003941687e-06
related O 0 4.653583346225787e-06
effects O 0 1.8848633771995082e-05
on O 0 4.2010899051092565e-05
transmission O 1 0.8704270124435425
of O 0 0.00017605199536774307
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0004910459974780679

Decreased O 0 0.000761858478654176
fertility O 0 0.00012699290527962148
of O 0 1.607686954230303e-06
males O 0 4.067777354066493e-06
with O 0 1.222994114868925e-06
adult O 0 5.5224714742507786e-05
onset O 1 0.9997450709342957
DM B-Disease 1 1.0
and O 0 1.1245613677601796e-05
contraction O 0 1.3677740753337275e-05
of O 0 1.2117935455080442e-07
the O 0 3.780126860419841e-07
repeat O 0 1.4313158089862554e-06
upon O 0 3.620666291226371e-07
male O 0 7.009665523582953e-07
transmission O 0 3.414974344195798e-05
contribute O 0 2.1869354327463952e-07
to O 0 1.0360503921447162e-07
the O 0 1.6595241447703302e-07
almost O 0 3.2010129302761925e-07
absent O 0 1.4713862128701294e-06
occurrence O 0 2.2401948172046104e-06
of O 0 6.169859716464998e-07
paternal O 0 0.0764622688293457
transmission O 1 0.9649878144264221
of O 0 0.00031062320340424776
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.000693535665050149

Also O 0 1.5741165043436922e-05
the O 0 1.5484480400118628e-06
fathers O 0 1.6867847989487927e-06
of O 0 9.329990291462309e-08
the O 0 5.478169100570085e-07
reported O 0 0.0007781082531437278
congenitally O 0 0.0801762044429779
affected O 0 3.4204488201794447e-06
children O 0 6.665859473287128e-07
showed O 0 1.8828499150913558e-06
, O 0 1.1129559851497106e-07
on O 0 5.489030741046008e-07
average O 0 1.1024320656360942e-06
, O 0 3.9275172980524076e-07
shorter O 0 2.1666382963303477e-05
CTG O 0 0.00024637847673147917
repeat O 0 1.3160288290237077e-05
lengths O 0 5.30356919625774e-06
and O 0 5.228168902249308e-07
hence O 0 3.5535367715056054e-06
less O 0 1.0369116353103891e-05
severe O 1 0.9997678399085999
clinical O 1 0.9646007418632507
symptoms O 1 0.9800817370414734
than O 0 4.19650689309492e-07
the O 0 3.1429267437488306e-06
mothers O 0 2.922821749962168e-06
of O 0 4.014571288735169e-07
children O 0 7.495165846194141e-06
with O 0 0.02337532490491867
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0009299509692937136

We O 0 1.3288396075950004e-05
conclude O 0 1.4878311048960313e-05
that O 0 2.58869954450347e-06
paternal O 0 0.0011737847235053778
transmission O 1 0.5782243609428406
of O 0 6.135195872047916e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.1271918992861174e-05
rare O 0 5.262567810859764e-06
and O 0 1.2398129456414608e-06
preferentially O 0 1.0057583494926803e-05
occurs O 0 9.770286624188884e-07
with O 0 6.491146677944926e-07
onset O 0 0.0003029760264325887
of O 0 2.0018417217215756e-06
DM B-Disease 1 0.9999995231628418
past O 0 2.5810034003370674e-06
30 O 0 6.939770855751703e-07
years O 0 2.4274396537293796e-07
in O 0 1.6007489023195376e-07
the O 0 5.227655037742807e-07
father O 0 3.167766044498421e-05
. O 0 2.47894786298275e-06
. O 0 1.0203930287389085e-05

The O 0 0.00010786035272758454
RB1 O 0 0.007818548008799553
gene O 0 0.00011895777424797416
mutation O 0 5.4620519222225994e-05
in O 0 1.6160690847755177e-06
a O 0 5.92720607528463e-06
child O 0 3.072445542784408e-05
with O 0 5.2634350140579045e-05
ectopic B-Disease 1 0.9999809265136719
intracranial I-Disease 1 0.9999926090240479
retinoblastoma I-Disease 1 0.9936291575431824
. O 0 0.00018039243877865374

The O 0 9.893154492601752e-05
RB1 O 0 0.008938963524997234
gene O 0 0.00022818747675046325
mutation O 0 0.00011816187179647386
was O 0 3.85102721338626e-05
investigated O 0 1.2935084669152275e-05
in O 0 5.253994572740339e-07
a O 0 3.957879016525112e-06
child O 0 1.6745918401284143e-05
with O 0 7.534289125032956e-06
ectopic B-Disease 1 0.9996700286865234
intracranial I-Disease 1 0.9988246560096741
retinoblastoma I-Disease 0 0.0010216482914984226
using O 0 2.5677486519271042e-06
DNA O 0 1.9428571249591187e-06
obtained O 0 7.571120477223303e-07
from O 0 1.6718112760827353e-07
both O 0 1.2908668622912955e-07
the O 0 4.3370704361223034e-07
pineal B-Disease 0 0.00033228416577912867
and I-Disease 0 2.361922088311985e-05
retinal I-Disease 1 0.9522916078567505
tumours I-Disease 1 0.9999653100967407
of O 0 1.3277486914375913e-06
the O 0 3.442804154474288e-05
patient O 0 0.002336780773475766
. O 0 2.8542865038616583e-05

A O 0 0.00026032564346678555
nonsense O 0 0.00041204836452379823
mutation O 0 0.00010759355791378766
in O 0 4.4780317693948746e-06
exon O 0 6.874949758639559e-05
17 O 0 5.544887244468555e-06
( O 0 1.5115631413209485e-06
codon O 0 6.72270516588469e-06
556 O 0 3.138697366011911e-06
) O 0 1.600380983290961e-07
of O 0 6.037006983206084e-08
the O 0 4.979556251782924e-07
RB1 O 0 0.00029965833527967334
gene O 0 3.8093346574896714e-06
was O 0 3.4625441003299784e-06
found O 0 1.8025372128249728e-07
to O 0 1.1566996960254983e-07
be O 0 8.907597504048681e-08
present O 0 2.716587061968312e-07
homozygously O 0 1.4441699931921903e-05
in O 0 2.0424839419774798e-07
both O 0 1.654704107068028e-07
the O 0 6.042479867574002e-07
retinal B-Disease 0 8.207726932596415e-05
and I-Disease 0 1.5366352954515605e-06
the I-Disease 0 2.3327427697950043e-05
pineal I-Disease 1 0.9890410304069519
tumours I-Disease 1 0.9999960660934448
. O 0 7.482695218641311e-05

The O 0 1.234391766047338e-05
same O 0 4.651844392355997e-06
mutation O 0 1.5763158444315195e-05
was O 0 2.6112857085536234e-06
present O 0 4.3295574414514704e-07
heterozygously O 0 9.467968084209133e-06
in O 0 1.5654207174975454e-07
the O 0 1.1082681083962598e-07
DNA O 0 2.958037725875329e-07
from O 0 9.415118995548255e-08
the O 0 1.4465146591646771e-07
constitutional O 0 5.383566303862608e-07
cells O 0 4.719569233202492e-07
of O 0 4.5569120032951105e-08
the O 0 4.502263379890792e-07
patient O 0 1.174710996565409e-05
, O 0 2.3907287527435983e-07
proving O 0 1.607673084436101e-06
it O 0 1.015918300595331e-07
to O 0 1.1786713827177664e-07
be O 0 7.317441230725308e-08
of O 0 2.4132023668244074e-07
germline O 0 5.408045035437681e-05
origin O 0 6.777855560358148e-06
. O 0 1.8927783457911573e-05

The O 0 2.1335956262191758e-05
initial O 0 4.322845416027121e-05
mutation O 0 4.378306766739115e-05
was O 0 1.0781791388581041e-05
shown O 0 1.4398959820027812e-06
to O 0 3.0825410135548736e-07
have O 0 2.618272958443413e-07
occurred O 0 1.6750362874518032e-06
in O 0 6.369482434820384e-07
the O 0 3.6434967114473693e-06
paternally O 0 0.001033472828567028
derived O 0 8.649039955344051e-05
RB1 O 0 0.0025850131642073393
allele O 0 0.000398836302338168
. O 0 3.22727755701635e-05

The O 0 3.255893898312934e-05
mutation O 0 8.218512812163681e-05
is O 0 7.279520559677621e-07
in O 0 2.2778340280638076e-07
an O 0 9.443193249580872e-08
area O 0 1.6677600456205255e-07
of O 0 2.7111873635021766e-08
the O 0 1.338558917041155e-07
gene O 0 4.922640641780163e-07
that O 0 6.565495169752467e-08
encodes O 0 5.111048722028499e-07
the O 0 1.3752821814705385e-07
protein O 0 4.0905436549110163e-07
- O 0 8.851426400724449e-07
binding O 0 1.939114611104742e-07
region O 0 1.2881343991466565e-07
known O 0 9.685569324346943e-08
as O 0 3.114355706657079e-08
the O 0 6.787447404121849e-08
pocket O 0 2.03669915208593e-05
region O 0 4.917789055980393e-07
and O 0 3.2078642675514857e-07
has O 0 4.939994369124179e-07
been O 0 5.747864975091943e-07
detected O 0 2.2097037799539976e-06
in O 0 1.0629283053731342e-07
other O 0 7.531211565492413e-08
cases O 0 2.739152193953487e-07
of O 0 5.787998702544428e-07
retinoblastoma B-Disease 0 0.0018438472179695964
. O 0 4.47058573627146e-06
. O 0 1.5476283806492575e-05

Low O 0 0.0001370985701214522
levels O 0 1.2969003364560194e-05
of O 0 9.649222647567512e-07
beta O 0 1.1924465070478618e-05
hexosaminidase O 0 5.984197196085006e-05
A O 0 4.699068085756153e-06
in O 0 1.7835275230027037e-06
healthy O 0 2.981299076054711e-06
individuals O 0 2.144898019196262e-07
with O 0 2.1312966964615043e-06
apparent O 1 0.9937934875488281
deficiency O 1 0.795326292514801
of O 0 3.7507595607166877e-07
this O 0 2.4591006422269857e-06
enzyme O 0 4.51481064374093e-05
. O 0 1.2165775842731819e-05

Appreciable O 0 0.001620951690711081
beta O 0 0.0003307746083009988
hexosaminidase O 0 0.0007974959444254637
A O 0 2.1958934667054564e-05
( O 0 2.5682431896711932e-06
hex O 0 1.5380517652374692e-05
A O 0 1.0910782748396741e-06
) O 0 2.702916503949382e-07
activity O 0 4.6591247837568517e-07
has O 0 1.6363841837119253e-07
been O 0 2.389058124663279e-07
detected O 0 1.6470131640744512e-06
in O 0 3.7252851825542166e-07
cultured O 0 2.226350079581607e-05
skin O 1 0.5312517881393433
fibroblasts O 0 0.00045105107710696757
and O 0 0.00037538312608376145
melanoma B-Disease 1 0.9994230270385742
tissue O 0 0.025229569524526596
from O 0 5.122582933836384e-06
healthy O 0 7.396592991426587e-06
individuals O 0 2.2540461941389367e-07
previously O 0 9.058479918166995e-06
reported O 0 0.0007106713601388037
as O 0 2.6541456463746727e-06
having O 0 0.00039696841849945486
deficiency B-Disease 0 0.0005343917291611433
of I-Disease 0 1.0109004477953931e-07
hex I-Disease 0 1.2335597602941561e-05
A I-Disease 0 1.0178359843848739e-06
activity O 0 7.300363904505502e-07
indistinguishable O 0 5.589877218881156e-07
from O 0 1.1828693402549106e-07
that O 0 7.09044059021835e-08
of O 0 1.6002955760541226e-07
patients O 0 1.022382184601156e-05
with O 0 0.00022011574765201658
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9940083026885986
( O 0 6.351116462610662e-05
TSD B-Disease 0 0.2140120267868042
) O 0 2.393254362687003e-05
. O 0 2.3895874619483948e-05

Identification O 0 7.841156184440479e-05
and O 0 6.147421117930207e-06
quantitation O 0 9.138316818280146e-05
of O 0 1.509839989921602e-06
hex O 0 7.870898116379976e-05
A O 0 5.635586148855509e-06
, O 0 8.124314945234801e-07
amounting O 0 3.6380456549522933e-06
to O 0 1.6192409475479508e-06
3 O 0 1.0136175660591107e-05
. O 0 1.139363394031534e-05

5 O 0 0.00015208595141302794
% O 0 2.625753950269427e-05
- O 0 0.00011980585986748338
6 O 0 4.281633664504625e-05
. O 0 2.277346357004717e-05

9 O 0 5.65378213650547e-05
% O 0 1.6927925798881915e-06
of O 0 1.5225425897824607e-07
total O 0 2.620415955334465e-07
beta O 0 1.8014836768998066e-06
hexosaminidase O 0 1.05745739347185e-05
activity O 0 1.2338234682829352e-06
, O 0 1.346470099861108e-07
has O 0 1.116151082669603e-07
been O 0 1.401570131065455e-07
obtained O 0 3.708653366629733e-07
by O 0 6.627263360314828e-07
cellulose O 0 0.0035654078237712383
acetate O 0 0.019544437527656555
gel O 0 0.0005011055036447942
electrophoresis O 0 5.255109863355756e-05
, O 0 1.7754749706000439e-06
DEAE O 0 0.00013240636326372623
- O 0 3.717514482559636e-05
cellulose O 0 0.00010787885548779741
ion O 0 4.6981542254798114e-05
- O 0 1.128783969761571e-05
exchange O 0 4.122117388760671e-06
chromatography O 0 1.3589576155936811e-05
, O 0 4.2577863723636256e-07
radial O 0 1.4112762073636986e-05
immunodiffusion O 0 7.074651512084529e-05
, O 0 1.0696800245568738e-06
and O 0 1.8522206346460734e-06
radioimmunoassay O 0 0.0005862083635292947
. O 0 2.9194870876381174e-05

Previous O 0 0.000125629230751656
family O 0 3.587303217500448e-05
studies O 0 3.790443543039146e-06
suggested O 0 3.3357448501192266e-06
that O 0 2.2680859501633677e-07
these O 0 1.4383586233179813e-07
individuals O 0 9.338428696992196e-08
may O 0 7.803441235409991e-07
be O 0 1.3706679169445124e-07
compound O 0 4.022506800538395e-06
heterozygotes O 0 6.658376605628291e-06
for O 0 1.1481536432711437e-07
the O 0 1.9165963749401271e-07
common O 0 1.0517774171603378e-06
mutant O 0 2.107777982018888e-05
TSD B-Disease 0 0.00038498747744597495
gene O 0 6.8041167651244905e-06
and O 0 3.5229146533310995e-07
a O 0 1.7429584886485827e-06
rare O 0 9.315991519542877e-06
( O 0 3.6259057196730282e-06
allelic O 0 7.856282900320366e-05
) O 0 5.082975803816225e-06
mutant O 0 6.855271203676239e-05
gene O 0 5.107726246933453e-05
. O 0 1.9796141714323312e-05

Thus O 0 4.59123111795634e-05
, O 0 3.0661797154607484e-06
the O 0 1.8356610098635429e-06
postulated O 0 2.613320975797251e-05
rate O 0 3.6388125863595633e-06
mutant O 0 9.48076012718957e-06
gene O 0 4.190223080513533e-06
appears O 0 1.3427978728941525e-06
to O 0 1.8492470132969174e-07
code O 0 3.198571789653215e-07
for O 0 5.251960644159226e-08
the O 0 7.937767065868684e-08
expression O 0 1.9481191770864825e-07
of O 0 5.483072484935292e-08
low O 0 1.113597704716085e-06
amounts O 0 3.9343890989584906e-07
of O 0 3.3065381899177737e-07
hex O 0 5.018242518417537e-05
A O 0 1.7125479644164443e-05
. O 0 1.3637066331284586e-05

Heterozygotes O 0 0.0009694467298686504
for O 0 3.0906555821275106e-06
the O 0 1.187942302749434e-06
rare O 0 4.044663910462987e-06
mutant O 0 8.750951383262873e-05
may O 0 5.694738774764119e-06
be O 0 1.5868474179114855e-07
indistinguishable O 0 1.090618525267928e-06
from O 0 3.4353649880358716e-07
heterozygotes O 0 5.584955488302512e-06
for O 0 2.0457160587739054e-07
the O 0 1.1229677738811006e-06
common O 0 1.3798917279927991e-05
TSD B-Disease 0 0.01908489689230919
mutant O 0 0.0003059451119042933
. O 0 3.16291261697188e-05

However O 0 2.2737849576515146e-05
, O 0 1.6913886611291673e-06
direct O 0 1.2889764775536605e-06
visualization O 0 8.405346306972206e-06
and O 0 5.547947807826858e-07
quantitation O 0 1.4519863725581672e-05
of O 0 1.9146598617680866e-07
hex O 0 1.1777833606174681e-05
A O 0 8.683014129928779e-07
by O 0 1.5621144200395065e-07
the O 0 1.7089178072637878e-07
methods O 0 1.5673850839448278e-06
described O 0 9.349244646728039e-05
may O 0 4.1162638808600605e-06
prevent O 0 1.8921489299827954e-06
false O 0 4.7578555495420005e-06
- O 0 0.00021318349172361195
positive O 0 4.632127001968911e-06
prenatal O 0 0.00022789592912886292
diagnosis O 0 0.00017373172158841044
of O 0 7.008950433373684e-07
TSD B-Disease 0 0.12074510008096695
in O 0 1.666613206907641e-05
fetuses O 0 6.863394082756713e-05
having O 0 7.209279146991321e-07
the O 0 7.299994422282907e-07
incomplete O 0 7.885380910011008e-06
hex B-Disease 0 0.00026555496151559055
A I-Disease 0 0.0021301768720149994
deficiency I-Disease 0 0.0009515006677247584
of O 0 9.039556658763104e-08
the O 0 7.106335147000209e-07
type O 0 4.6018296416150406e-05
described O 0 4.873732450505486e-06
in O 0 2.4161454348359257e-07
the O 0 4.8803701702127e-07
four O 0 1.8937304275823408e-06
healthy O 0 2.4233037038356997e-05
individuals O 0 9.949193554348312e-06

The O 0 0.00019168171274941415
tumor B-Disease 0 0.0022379839792847633
suppressor O 0 0.0013074296293780208
gene O 0 0.00021245541574899107
Smad4 O 0 0.0011204659240320325
/ O 0 0.0005245053325779736
Dpc4 O 0 7.288643973879516e-05
is O 0 4.412933947151032e-07
required O 0 1.981792934202531e-07
for O 0 1.4808897219609207e-07
gastrulation O 0 5.907404101890279e-06
and O 0 2.582483489277365e-07
later O 0 9.567442020852468e-07
for O 0 1.372700779711522e-07
anterior O 0 5.292352852848126e-06
development O 0 3.514431625717407e-07
of O 0 1.4297617667580198e-07
the O 0 1.1330895404171315e-06
mouse O 0 9.502910688752308e-05
embryo O 0 8.616555714979768e-05
. O 0 2.0937797671649605e-05

Mutations O 0 0.002125356113538146
in O 0 2.161114025511779e-05
the O 0 1.4633030332333874e-05
SMAD4 O 0 0.13618625700473785
/ O 0 0.04042637348175049
DPC4 O 0 0.05738501995801926
tumor B-Disease 0 0.0018690580036491156
suppressor O 0 0.00038160281837917864
gene O 0 1.1686046491377056e-05
, O 0 2.995903969349456e-07
a O 0 5.556706241804932e-07
key O 0 1.0946772590614273e-06
signal O 0 8.260858521680348e-06
transducer O 0 2.0809346096939407e-05
in O 0 3.4320052577641036e-07
most O 0 2.0830822222706047e-07
TGFbeta O 0 2.579732063168194e-05
- O 0 3.4251374017912894e-05
related O 0 1.1811383728854707e-06
pathways O 0 1.1442025424912572e-06
, O 0 6.589381484900514e-08
are O 0 1.7784232753115248e-08
involved O 0 7.581034822123911e-08
in O 0 1.683394259544002e-07
50 O 0 3.536527515279886e-07
% O 0 6.819641953370592e-07
of O 0 3.394300392756122e-06
pancreatic B-Disease 1 0.9999780654907227
cancers I-Disease 1 0.6447874903678894
. O 0 6.095855133025907e-05

Homozygous O 0 0.011939045041799545
Smad4 O 0 0.018406087532639503
mutant O 0 0.007399433758109808
mice O 0 0.049731675535440445
die O 0 0.0003730251337401569
before O 0 9.686503290140536e-06
day O 0 1.2470556612242945e-05
7 O 0 2.7106632842333056e-05
. O 0 2.090994530590251e-05

5 O 0 0.00013809978554490954
of O 0 2.3498279915656894e-05
embryogenesis O 0 0.002635818673297763
. O 0 0.0001794047566363588

Mutant O 0 0.0006747828447259963
embryos O 0 4.916288526146673e-05
have O 0 1.7949035964193172e-06
reduced O 0 3.815443051280454e-06
size O 0 2.9863529107387876e-06
, O 0 5.178032438379887e-07
fail O 0 4.115003775950754e-06
to O 0 5.501466944224376e-07
gastrulate O 0 9.058030263986439e-05
or O 0 8.143707646013354e-07
express O 0 3.1679091989644803e-06
a O 0 1.5154688526308746e-06
mesodermal O 0 5.158678686711937e-05
marker O 0 9.394886546942871e-06
, O 0 3.231778578083322e-07
and O 0 4.6260558406174823e-07
show O 0 6.952761395950802e-06
abnormal O 0 7.961164374137297e-05
visceral O 0 0.00010313397797290236
endoderm O 0 0.000629507761914283
development O 0 3.7776073440909386e-05
. O 0 3.23623426083941e-05

Growth B-Disease 1 0.9992432594299316
retardation I-Disease 1 0.9994877576828003
of O 0 1.822944796003867e-06
the O 0 3.568738065951038e-06
Smad4 O 0 0.018925976008176804
- O 0 0.12421783804893494
deficient O 0 0.0006622421205975115
embryos O 0 4.807544428331312e-06
results O 0 1.1627544154180214e-06
from O 0 4.880253641204035e-07
reduced O 0 2.30579325943836e-06
cell O 0 3.50391237589065e-05
proliferation O 0 6.563956958416384e-06
rather O 0 4.443869272563461e-07
than O 0 3.71547855593235e-07
increased O 0 8.96116307558259e-06
apoptosis O 0 0.00024362115073017776
. O 0 3.0131815947243012e-05

Aggregation O 0 0.0002879652311094105
of O 0 6.314315669442294e-06
mutant O 0 0.00015034172974992543
Smad4 O 0 0.0005846627755090594
ES O 0 0.00019453415006864816
cells O 0 1.5781477486598305e-05
with O 0 9.742689144331962e-07
wild O 0 6.514565484394552e-06
- O 0 8.968284964794293e-05
type O 0 1.7612968804314733e-05
tetraploid O 0 8.011626778170466e-05
morulae O 0 0.00025734875816851854
rescues O 0 0.00011204375914530829
the O 0 1.9409850210649893e-05
gastrulation B-Disease 0 0.014864138327538967
defect I-Disease 0 0.013826161623001099
. O 0 7.191435724962503e-05

These O 0 1.287530903937295e-05
results O 0 8.875407729647122e-06
indicate O 0 3.862922312691808e-06
that O 0 3.339187344408856e-07
Smad4 O 0 1.5937852367642336e-05
is O 0 1.4889219812630472e-07
initially O 0 5.381482424127171e-07
required O 0 8.49596091256899e-08
for O 0 2.8323448475475743e-08
the O 0 5.7498724004290125e-08
differentiation O 0 1.952127064441811e-07
of O 0 2.620690153776195e-08
the O 0 1.878990190107288e-07
visceral O 0 3.185097739333287e-06
endoderm O 0 2.740917625487782e-05
and O 0 2.2497340523841558e-07
that O 0 9.777185994153115e-08
the O 0 5.065194272901863e-07
gastrulation B-Disease 0 0.00010643282439559698
defect I-Disease 0 4.393296694615856e-05
in O 0 3.116878701803216e-07
the O 0 6.184327503433451e-07
epiblast O 0 0.00017407728591933846
is O 0 2.288032021624531e-07
secondary O 0 8.213420983338438e-07
and O 0 2.3591944398049236e-07
non O 0 1.2557549098346499e-06
- O 0 2.8371998268994503e-05
cell O 0 3.1537980248685926e-05
autonomous O 0 2.6114497813978232e-05
. O 0 2.16966109292116e-05

Rescued O 0 0.0011425245320424438
embryos O 0 0.0002488379250280559
show O 0 0.00018190170521847904
severe O 0 0.3326267898082733
anterior O 0 0.002717281924560666
truncations O 0 0.0008942661806941032
, O 0 2.95219160761917e-06
indicating O 0 5.683605650119716e-06
a O 0 8.185239153135626e-07
second O 0 5.086759529149276e-07
important O 0 9.686401369890518e-08
role O 0 3.483259831682517e-07
for O 0 2.5254476554437133e-07
Smad4 O 0 1.906341094581876e-05
in O 0 1.240237565980351e-06
anterior O 0 0.0001665800082264468
patterning O 0 0.0009085671044886112
during O 0 7.083989476086572e-05
embryogenesis O 0 0.0009530376992188394
. O 0 7.848809764254838e-05

Prevalence O 0 0.0007390920072793961
of O 0 1.0784320693346672e-05
p16 O 0 0.00026048850850202143
and O 0 7.896804163465276e-06
CDK4 O 0 0.0035793480928987265
germline O 0 0.0023145468439906836
mutations O 0 8.588500350015238e-05
in O 0 3.5156426747562364e-06
48 O 0 0.0001174628923763521
melanoma B-Disease 1 0.9991746544837952
- O 0 0.3889992833137512
prone O 0 0.00020635656255763024
families O 0 2.462221800669795e-06
in O 0 4.510511644184589e-06
France O 0 0.00029421705403365195
. O 0 3.7073717976454645e-05

The O 0 5.917348971706815e-05
French O 0 0.0008343286463059485
Familial B-Disease 1 0.9774904251098633
Melanoma I-Disease 1 0.999603807926178
Study O 0 8.232560503529385e-05
Group O 0 5.646905628964305e-05
. O 0 3.4204887924715877e-05

Germline O 1 0.6287624835968018
mutations O 0 0.0033910495694726706
in O 0 1.6849500752869062e-05
the O 0 3.293406507509644e-06
p16 O 0 4.838258246309124e-05
and O 0 1.7854181351140141e-06
CDK4 O 0 0.000127122038975358
genes O 0 2.482690661054221e-06
have O 0 2.0652500154483278e-07
been O 0 3.9062851442395186e-07
reported O 0 3.787924924836261e-06
in O 0 2.3694039441579662e-07
a O 0 4.06549816034385e-07
subset O 0 1.2360529808574938e-06
of O 0 6.729836741214967e-07
melanoma B-Disease 0 0.49325788021087646
pedigrees O 0 4.510877624852583e-05
, O 0 3.1345524575954187e-07
but O 0 1.15786846777155e-07
their O 0 5.247655394668982e-07
prevalence O 0 1.6417989172623493e-05
is O 0 2.4664751663294737e-07
not O 0 2.0628445440706855e-07
well O 0 7.620305950695183e-07
known O 0 9.183218026009854e-06
. O 0 1.2708669601124711e-05

We O 0 1.4298356290964875e-05
searched O 0 1.718918065307662e-05
for O 0 8.165716280927882e-07
such O 0 5.199354973228765e-07
germline O 0 6.93959227646701e-05
mutations O 0 8.311939382110722e-06
in O 0 5.920998091824003e-07
48 O 0 3.298423507658299e-06
French O 0 0.009408206678926945
melanoma B-Disease 1 0.9999861717224121
- O 1 0.926935613155365
prone O 0 5.8343986893305555e-05
families O 0 3.6187540786158934e-07
selected O 0 2.991353369452554e-07
according O 0 1.2656384740239446e-07
to O 0 6.9117533030294e-08
two O 0 5.803009983651464e-08
major O 0 2.3173947738541756e-07
criteria O 0 2.5453226726313005e-07
families O 0 8.130160722430446e-08
with O 0 7.075283292579115e-08
at O 0 3.383859450423188e-07
least O 0 1.1402566713059059e-07
three O 0 1.16937719951693e-07
affected O 0 4.676793707858451e-07
members O 0 2.9999753792253614e-07
( O 0 6.420345926017035e-07
n O 0 3.6071878639631905e-06
= O 0 1.4583648635380086e-06
20 O 0 1.2447387121028441e-07
) O 0 1.0233044633878308e-07
or O 0 5.9405792285360803e-08
families O 0 3.313311580654954e-08
with O 0 2.3483607947127894e-08
two O 0 3.4127740633493886e-08
affected O 0 1.2811682381652645e-07
members O 0 3.589493147160283e-08
, O 0 2.6041675482701976e-08
one O 0 1.188245057903714e-08
of O 0 1.339840771663603e-08
them O 0 4.094844285873478e-08
affected O 0 1.6533932978290977e-07
before O 0 1.27103817249008e-07
the O 0 1.2505378776950238e-07
age O 0 7.354604747433768e-08
of O 0 2.794002362804804e-08
50 O 0 2.011579454119783e-07
( O 0 4.880732831225032e-07
n O 0 2.435384203636204e-06
= O 0 2.0103686892980477e-06
28 O 0 3.994414896624221e-07
) O 0 1.0508313152968185e-07
, O 0 3.220179678464774e-08
and O 0 3.8651293721159163e-08
one O 0 6.577678846042545e-08
additional O 0 6.661360316684295e-07
minor O 0 2.0375422536744736e-05
criterion O 0 4.106539927306585e-05
. O 0 2.6522799089434557e-05

Sixteen O 0 0.00012102250184398144
different O 0 1.3780007066088729e-05
p16 O 0 0.0003103322524111718
germline O 0 0.0022238967940211296
mutations O 0 0.0002625853521749377
were O 0 1.9633346255432116e-06
found O 0 8.388733476749621e-07
in O 0 3.681951170619868e-07
21 O 0 8.483604574394121e-07
families O 0 1.9325460698382813e-07
, O 0 6.994800827442305e-08
while O 0 1.0082161594482386e-07
one O 0 2.153559961470819e-07
germline O 0 3.1415031116921455e-05
mutation O 0 5.938244612480048e-06
, O 0 3.3285394351878494e-07
Arg24His O 0 2.2303283913061023e-05
, O 0 3.7177113654252025e-07
was O 0 4.950736638420494e-06
detected O 0 3.277777750554378e-06
in O 0 4.94852884003194e-07
the O 0 1.8670184545044322e-06
CDK4 O 0 0.0014605778269469738
gene O 0 9.992546256398782e-05
. O 0 2.8933887733728625e-05

The O 0 3.75491836166475e-05
frequency O 0 5.118165063322522e-05
of O 0 3.734512347364216e-06
p16 O 0 0.0001323127216892317
gene O 0 4.407946835272014e-05
mutation O 0 1.0041023415396921e-05
in O 0 6.692051215395622e-07
our O 0 3.9689203390480543e-07
sample O 0 8.969473128672689e-07
( O 0 3.557449588242889e-07
44 O 0 3.185360242241586e-07
% O 0 1.1353617423992546e-07
) O 0 6.15936457393218e-08
is O 0 3.240580070951182e-08
among O 0 2.7831253746057882e-08
the O 0 7.633588694488935e-08
highest O 0 3.3739090099516034e-07
rates O 0 2.2408785298466682e-06
yet O 0 3.8170301763784664e-07
reported O 0 3.8104249142634217e-06
and O 0 1.1339788130726447e-07
the O 0 2.425509535441961e-07
CDK4 O 0 0.0005424690316431224
mutation O 0 2.178482873205212e-06
is O 0 6.458542856080385e-08
the O 0 1.5470295977593196e-07
second O 0 1.4206336800270947e-06
mutation O 0 8.257731678895652e-06
detected O 0 4.966952928953106e-06
in O 0 6.598461936846434e-07
this O 0 1.6592787233093986e-06
gene O 0 2.7326494091539644e-05
worldwide O 0 1.6888316167751327e-05
. O 0 2.2281979909166694e-05

In O 0 2.2786432964494452e-05
summary O 0 1.4568243386747781e-05
, O 0 7.813061984052183e-07
our O 0 3.168871103298443e-07
results O 0 6.937838179510436e-07
show O 0 4.829490762858768e-07
frequent O 0 8.434209917140834e-07
involvement O 0 9.949011428034282e-07
of O 0 1.1833916602199679e-07
the O 0 6.299455890257377e-07
p16 O 0 1.9082019207417034e-05
gene O 0 7.218082828330807e-06
in O 0 2.3804618649592157e-06
familial B-Disease 0 0.1854904741048813
melanoma I-Disease 1 0.95201176404953
and O 0 1.4241512644730392e-06
confirm O 0 2.5205779365933267e-06
the O 0 1.2868537169197225e-07
role O 0 2.419835141154181e-07
of O 0 7.51764943629496e-08
the O 0 4.941082920595363e-07
CDK4 O 0 0.00011151667422382161
gene O 0 3.2024345273384824e-06
as O 0 5.165741754353803e-07
a O 0 1.3760612091573421e-05
melanoma B-Disease 1 0.9673174619674683
- O 0 0.00441825482994318
predisposing O 0 8.859357330948114e-05
gene O 0 3.8356556615326554e-05
. O 0 5.1426422942313366e-06
. O 0 1.4909418496245053e-05

Progression O 0 0.0003967909433413297
of O 0 9.312260772276204e-06
somatic O 0 0.0002653067058417946
CTG O 0 0.0010999970836564898
repeat O 0 3.609567284001969e-05
length O 0 5.026072813052451e-06
heterogeneity O 0 1.684031121840235e-05
in O 0 5.978715762466891e-07
the O 0 1.121594664255099e-06
blood O 0 4.0274149796459824e-05
cells O 0 3.077401561313309e-05
of O 0 8.347287075594068e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9699205160140991
. O 0 0.00012599454203154892

The O 0 3.05572320939973e-05
genetic O 0 3.716337596415542e-05
basis O 0 5.108098775963299e-06
of O 0 2.6858422643272206e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9587051868438721
DM B-Disease 1 1.0
) O 0 4.0190866457123775e-06
is O 0 1.3206411608734925e-07
the O 0 8.744228097157247e-08
expansion O 0 4.865262894782063e-07
of O 0 8.848398636018828e-08
an O 0 7.719799555161444e-07
unstable O 0 0.00011089305189670995
CTG O 0 8.265434007626027e-05
repeat O 0 3.910238774551544e-06
in O 0 2.2649216191439336e-07
the O 0 3.097094349868712e-07
34 O 0 1.340436028840486e-06
UTR O 0 6.600843335036188e-06
of O 0 3.0681522389386373e-07
the O 0 4.093688403372653e-06
DM B-Disease 1 0.9999983310699463
protein O 0 2.4651475541759282e-05
kinase O 0 0.00012026393233099952
gene O 0 1.380958201480098e-05
on O 0 3.5997613849758636e-06
chromosome O 0 5.9527112171053886e-05
19 O 0 1.78502104972722e-05
. O 0 1.4764951629331335e-05

One O 0 3.7439053812704515e-06
of O 0 4.1662534044917265e-07
the O 0 2.934925760200713e-07
principal O 0 3.6379691437105066e-07
features O 0 4.0726928318690625e-07
of O 0 1.3378162577737385e-07
the O 0 1.0143853614863474e-05
DM B-Disease 1 1.0
mutation O 0 2.54009628406493e-05
is O 0 1.716234692139551e-07
an O 0 1.3066774329217878e-07
extraordinarily O 0 1.965972614925704e-06
high O 0 5.035275307818665e-07
level O 0 1.741041586456049e-07
of O 0 1.3808927690206474e-07
somatic O 0 1.9479724869597703e-05
mosaicism O 0 0.00020232978567946702
, O 0 4.637359154457954e-07
due O 0 1.7539534837851534e-06
to O 0 1.3727060377277667e-07
an O 0 1.2450865938262723e-07
extremely O 0 1.0058475936602917e-06
high O 0 5.089045203021669e-07
degree O 0 4.008993244042358e-07
of O 0 1.6746307096582314e-07
somatic O 0 2.052649506367743e-05
instability O 0 4.2758633753692266e-06
both O 0 1.0119769200400697e-07
within O 0 1.1383226450334405e-07
and O 0 1.7006343000502966e-07
between O 0 5.956969175713311e-07
different O 0 1.9338453967066016e-06
tissues O 0 0.00015325039566960186
. O 0 2.493011561455205e-05

This O 0 2.4781777028692886e-05
instability O 0 0.00013251295604277402
appears O 0 1.07687401396106e-05
to O 0 4.6758884764130926e-07
be O 0 1.5320625834647217e-07
biased O 0 7.55525206841412e-07
towards O 0 1.5331002600760257e-07
further O 0 2.4788198516034754e-07
expansion O 0 4.810268592336797e-07
and O 0 7.49597219851239e-08
continuous O 0 3.2383189818574465e-07
throughout O 0 7.08231766566314e-08
the O 0 5.316758588946868e-08
life O 0 7.711427230105983e-08
of O 0 1.1035406366488587e-08
an O 0 3.707676654585157e-08
individual O 0 2.1759586132930053e-08
, O 0 4.510604867391521e-08
features O 0 5.004559966437228e-07
that O 0 9.152866198292031e-08
could O 0 2.8556794973155775e-07
be O 0 4.866264546876664e-08
associated O 0 9.989896909701201e-08
with O 0 4.215941729057704e-08
the O 0 4.3470831201375404e-07
progressive O 0 3.193962766090408e-05
nature O 0 5.850877755619877e-07
of O 0 2.3158283113389189e-07
the O 0 3.7724410503869876e-05
disease O 0 0.08072590082883835
. O 0 2.662731276359409e-05

Although O 0 3.994744474766776e-05
increasing O 0 1.358977078780299e-05
measured O 0 1.701528708508704e-05
allele O 0 3.1868494261289015e-05
size O 0 4.681145128415665e-06
between O 0 2.086303766191122e-06
patients O 0 6.9845605139562394e-06
clearly O 0 1.2289815458643716e-06
correlates O 0 1.2047420341332327e-06
with O 0 1.1470635996602141e-07
an O 0 2.1613743683701614e-07
increased O 0 3.6153398923488567e-06
severity O 0 8.864721894497052e-05
of O 0 1.5793528973517823e-06
symptoms O 0 0.4912461042404175
and O 0 3.2985761322379403e-07
an O 0 2.4263979980787553e-07
earlier O 0 2.2136178813525476e-05
age O 0 5.658288841914327e-07
of O 0 1.2404333915583265e-07
onset O 0 0.03523020073771477
, O 0 3.749686925402784e-07
this O 0 1.0694438401515072e-07
correlation O 0 6.939419563423144e-07
is O 0 9.519562382820368e-08
not O 0 4.675870357573331e-08
precise O 0 3.6941628422937356e-07
and O 0 2.644252106165368e-07
measured O 0 1.8388709577266127e-06
allele O 0 4.202187938062707e-06
length O 0 1.3025708085478982e-06
cannot O 0 1.005183094093809e-06
be O 0 8.875426260601671e-08
used O 0 1.6232735333687742e-07
as O 0 1.1060676996521579e-07
an O 0 1.4701335260269843e-07
accurate O 0 1.3949895674159052e-06
predictor O 0 5.814089035993675e-06
of O 0 1.7702291188470554e-07
age O 0 9.608488653611857e-07
of O 0 1.181163156616094e-06
onset O 0 0.08308860659599304
. O 0 4.060150240547955e-05

In O 0 2.0866758859483525e-05
order O 0 2.9713391995755956e-06
to O 0 8.376406412935467e-07
further O 0 9.16383385174413e-07
characterize O 0 4.3547524910536595e-06
the O 0 9.160058880297584e-07
dynamics O 0 5.3863408538745716e-05
of O 0 3.25614587382006e-06
DM B-Disease 1 0.9999998807907104
CTG O 0 0.0028148526325821877
repeat O 0 2.8169260986032896e-05
somatic O 0 3.6655092117143795e-05
instability O 0 1.692609475867357e-05
, O 0 2.544065864640288e-07
we O 0 7.428493375982725e-08
have O 0 6.778662253736911e-08
studied O 0 3.5754010241362266e-07
repeat O 0 1.5263181012414861e-06
length O 0 4.773280579684069e-07
changes O 0 3.6578475715032255e-07
over O 0 1.5978768885815953e-07
time O 0 3.3109586183854844e-07
in O 0 2.4682803996256553e-06
111 O 1 0.5031569600105286
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.005716006271541119
with O 0 2.6452810288901674e-06
varying O 0 3.520364407449961e-05
clinical O 0 0.0013306653127074242
severity O 0 0.021963659673929214
and O 0 2.3316064471146092e-05
CTG O 0 0.0052824560552835464
repeat O 0 1.2948550647706725e-05
size O 0 1.547845613458776e-06
over O 0 3.7924868934169353e-07
time O 0 2.9294810133251303e-07
intervals O 0 1.1405354598537087e-06
of O 0 1.4594553476854344e-07
1 O 0 1.2054902072122786e-06
- O 0 1.732546297716908e-05
7 O 0 4.7961143536667805e-06
years O 0 4.454036570677999e-06
. O 0 9.913997018884402e-06

We O 0 9.583081009623129e-06
have O 0 8.923545919969911e-07
found O 0 5.57614612262114e-07
a O 0 2.2079672135078e-07
direct O 0 4.621183506969828e-07
progression O 0 1.080351353266451e-06
of O 0 5.679698489302609e-08
the O 0 1.2473256560951995e-07
size O 0 5.266144853521837e-07
heterogeneity O 0 1.317011651735811e-06
over O 0 2.0727023297695268e-07
time O 0 1.4824652794231952e-07
related O 0 2.990107077494031e-07
to O 0 1.8980520621880714e-07
initial O 0 1.7486039496361627e-06
CTG O 0 2.7532538297236897e-05
repeat O 0 1.7053373539965833e-06
size O 0 3.490569042696734e-07
and O 0 6.266117935638249e-08
the O 0 9.84684334071062e-08
time O 0 1.994646652292431e-07
interval O 0 1.1261745385127142e-06
and O 0 2.5239765477635956e-07
always O 0 3.6489350918600394e-07
biased O 0 1.6809732414913015e-06
towards O 0 7.291957899724366e-07
further O 0 2.213825382568757e-06
expansion O 0 3.300138996564783e-05
. O 0 2.0593195586116053e-05

Attempts O 0 0.00011027627624571323
to O 0 1.0372825272497721e-05
mathematically O 0 1.7929869500221685e-05
model O 0 5.158429303264711e-06
the O 0 8.867707492754562e-07
dynamics O 0 0.00014512990310322493
have O 0 3.1683788392911083e-07
proved O 0 1.0547546480665915e-06
only O 0 9.028288161516684e-08
partially O 0 3.49553010892123e-06
successful O 0 4.3654625869749e-07
suggesting O 0 5.721881279896479e-07
that O 0 4.3328284959898156e-08
individual O 0 5.715680373441501e-08
specific O 0 1.555067399294785e-07
genetic O 0 1.5468068568225135e-06
and O 0 1.7674452692517661e-06
/ O 0 0.006220022216439247
or O 0 9.757194447956863e-07
environmental O 0 1.5704284805906354e-06
factors O 0 1.7212617819950538e-07
also O 0 9.096460473756451e-08
play O 0 1.2031112817112444e-07
a O 0 2.706636053062539e-07
role O 0 5.915015321988903e-07
in O 0 1.8536447896622121e-06
somatic O 0 0.00014681575703434646
mosaicism O 0 0.0004852231068070978
. O 0 6.76160516377422e-06
. O 0 2.685688559722621e-05

Aspartylglucosaminuria B-Disease 0 0.47871339321136475
among O 0 7.039301272016019e-05
Palestinian O 0 0.00019278147374279797
Arabs O 0 0.00021757010836154222
. O 0 0.00011870395246660337

Aspartylglucosaminuria B-Disease 1 0.9999972581863403
( O 0 0.17478489875793457
AGU B-Disease 1 0.9999984502792358
) O 0 1.7669715816737153e-05
is O 0 1.3204878541728249e-06
a O 0 3.3355761388520477e-06
rare O 0 5.386320481193252e-05
disorder B-Disease 0 0.13352839648723602
of I-Disease 0 1.4577516367353383e-06
glycoprotein I-Disease 0 0.0041254060342907906
metabolism I-Disease 0 0.009529432281851768
caused O 0 5.062375566922128e-05
by O 0 1.7089321318053408e-06
the O 0 6.615350866923109e-05
deficiency B-Disease 0 0.04620799422264099
of I-Disease 0 2.3707987395482633e-07
the I-Disease 0 4.316132162784925e-06
lysosomal I-Disease 0 0.2765250504016876
enzyme I-Disease 0 6.319393287412822e-05
aspartylglucosaminidase I-Disease 0 0.0003716241044458002
( O 0 1.2551307918329258e-05
AGA O 0 0.0008802366792224348
) O 0 1.407614672643831e-05
. O 0 1.5779191016918048e-05

AGU B-Disease 1 0.9999995231628418
is O 0 0.0013289256021380424
inherited O 1 0.7024128437042236
as O 0 6.936244517419254e-06
an O 0 2.5003735572681762e-05
autosomal O 1 0.9989232420921326
recessive O 1 0.9992628693580627
trait O 0 0.0006733059417456388
and O 0 1.8101080740962061e-06
occurs O 0 5.692951390301459e-07
with O 0 1.0870893873970999e-07
a O 0 1.0186944336965098e-06
high O 0 2.2867282041261205e-06
frequency O 0 6.029756150383037e-06
in O 0 8.365310577573837e-07
Finland O 0 1.4800929420744069e-05
because O 0 1.9758294911298435e-07
of O 0 1.1927153309443383e-07
a O 0 4.010862085124245e-06
founder O 0 0.00013398083683568984
effect O 0 2.7395297365728766e-05
. O 0 1.5310697563108988e-05

While O 0 1.727016751829069e-05
very O 0 4.246182470524218e-06
few O 0 2.217051587649621e-06
patients O 0 5.445678652904462e-06
with O 0 5.918140686844708e-06
AGU B-Disease 1 0.9999997615814209
have O 0 1.5617778217347222e-06
been O 0 9.091965011975844e-07
reported O 0 2.044667780864984e-06
from O 0 1.333158650140831e-07
non O 0 3.101563663676643e-07
- O 0 3.5218704397266265e-06
Finnish O 0 3.046699703190825e-06
origin O 0 5.717370186175685e-07
, O 0 4.851237349612347e-07
we O 0 1.1816543974418892e-06
diagnosed O 0 0.3491474986076355
the O 0 3.558749085641466e-05
disorder O 1 0.8654216527938843
in O 0 3.339819159009494e-06
8 O 0 2.3941745894262567e-05
patients O 0 3.6025705867359648e-06
originating O 0 9.745643865244347e-07
from O 0 3.336405143272714e-07
3 O 0 3.583986654120963e-07
unrelated O 0 1.1705392353178468e-06
families O 0 1.3670036480561976e-07
, O 0 5.12620097481431e-08
all O 0 3.260301184582204e-08
Palestinian O 0 7.232251846289728e-07
Arabs O 0 6.088558848205139e-07
from O 0 1.3249693608941016e-07
the O 0 2.0179395221475716e-07
region O 0 6.218078283382056e-07
of O 0 4.5775445300932915e-07
Jerusalem O 0 0.0001656532404012978
. O 0 2.3296573999687098e-05

The O 0 8.455158967990428e-05
clinical O 0 0.01894226297736168
diagnosis O 1 0.8736163973808289
of O 0 3.848685082630254e-05
AGU B-Disease 1 1.0
is O 0 1.1135904060211033e-05
often O 0 1.4020570233697072e-06
difficult O 0 6.257721452129772e-07
, O 0 1.0584572152083638e-07
in O 0 1.3230753381776594e-07
particular O 0 1.7788599393497861e-07
early O 0 7.324227340177458e-07
in O 0 1.2054920262016822e-07
the O 0 1.4985032237291307e-07
course O 0 2.994858618876606e-07
of O 0 4.379297635637158e-08
the O 0 7.759577783872373e-06
disease O 0 0.0007064543897286057
, O 0 8.375322124720697e-08
and O 0 4.8363308025045626e-08
most O 0 2.5568102302031548e-08
of O 0 5.089598431595732e-08
the O 0 6.215283519850345e-06
patients O 0 0.00014940880646463484
are O 0 1.0884956509471522e-06
diagnosed O 0 0.06315980851650238
after O 0 2.657960521901259e-06
the O 0 6.198451387717796e-07
age O 0 4.863072717853356e-07
of O 0 1.5257636221122084e-07
5 O 0 2.171254891436547e-06
years O 0 4.47585443907883e-06
. O 0 1.3267235772218555e-05

However O 0 2.2933018044568598e-05
, O 0 2.046687086476595e-06
since O 0 1.7579440054760198e-06
these O 0 3.591014205994725e-07
patients O 0 2.089704821628402e-06
excrete O 0 4.998176336812321e-06
early O 0 6.417969871108653e-07
large O 0 2.050552296850583e-07
amounts O 0 1.6592646545632306e-07
of O 0 1.184109734708727e-07
aspartylglucosamine O 0 3.0473936931230128e-05
in O 0 1.0892764521486242e-06
urine O 0 7.769574949634261e-06
, O 0 3.74647669332262e-07
biochemical O 0 5.154593054612633e-06
screening O 0 2.315082838322269e-06
is O 0 1.6283078707601817e-07
easy O 0 7.200676463980926e-07
by O 0 1.2444032790881465e-06
urine O 0 8.289776451420039e-05
chromatography O 0 0.00015473179519176483
. O 0 3.973490947828395e-06
. O 0 1.1747524695238099e-05

Detection O 0 0.0003409633063711226
of O 0 9.17066790862009e-06
heterozygous O 0 0.00013774365652352571
carriers O 0 2.0940633476129733e-05
of O 0 1.2626429679585272e-06
the O 0 0.00010502769146114588
ataxia B-Disease 1 1.0
- I-Disease 1 0.999990701675415
telangiectasia I-Disease 1 0.9999991655349731
( O 0 1.1367054867150728e-05
ATM O 0 6.0542472056113183e-05
) O 0 1.2281966519367415e-06
gene O 0 2.8771951292583253e-06
by O 0 1.082666926777165e-06
G2 O 0 0.00032493050093762577
phase O 0 2.2926808014744893e-05
chromosomal O 0 0.00017908036534208804
radiosensitivity O 0 0.00012992622214369476
of O 0 4.454104782780632e-06
peripheral O 0 0.06742186099290848
blood O 0 0.015278815291821957
lymphocytes O 0 0.004019191954284906
. O 0 8.224894554587081e-05

In O 0 0.007901839911937714
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999974966049194
telangiectasia I-Disease 1 1.0
( O 0 0.003003651974722743
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 2.257420783280395e-05
patients O 0 1.3133519132679794e-05
, O 0 5.85160307764454e-07
mutations O 0 3.310158035674249e-06
in O 0 1.9542972040653694e-07
a O 0 5.854807341165724e-07
single O 0 9.517290209259954e-07
gene O 0 1.5672596873628208e-06
, O 0 1.1779341946294153e-07
ATM O 0 4.208769951219438e-06
, O 0 1.613199032135526e-07
result O 0 3.1628178476239555e-07
in O 0 1.9705635168065783e-06
an O 1 0.5576128363609314
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.2711106996430317e-06
embraces O 0 3.885151727445191e-06
a O 0 7.012433798081474e-07
variety O 0 1.8486440467313514e-07
of O 0 1.3119080222168122e-07
clinical O 0 3.5011917134397663e-06
features O 0 4.16743932873942e-06
and O 0 3.2168850339076016e-06
manifests O 0 0.00039000684046186507
extreme O 0 4.579896267387085e-05
radiosensitivity O 0 0.00038410769775509834
and O 0 6.039967956894543e-07
a O 0 8.382688179153774e-07
strong O 0 2.7275207230559317e-06
pre O 0 0.0001630814076634124
- O 0 0.0007570516318082809
disposition O 0 4.330516094341874e-05
to O 0 7.69282087276224e-06
malignancy B-Disease 0 0.003287757746875286
. O 0 2.2601587261306122e-05

Heterozygotes O 0 0.0008651805110275745
for O 0 5.98091082792962e-06
the O 0 3.858051513816463e-06
ATM O 0 7.927876140456647e-05
gene O 0 9.096925168705638e-06
have O 0 3.5058488379036135e-07
no O 0 2.758414723302849e-07
clinical O 0 1.0230151019641198e-06
expression O 0 3.108599742063234e-07
of O 0 1.8790170486226998e-07
A B-Disease 1 0.9999634027481079
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
but O 0 4.308231655159034e-05
may O 0 0.011605027131736279
be O 0 4.158059527981095e-05
cancer B-Disease 0 0.02262716367840767
prone O 0 4.678176992456429e-06
with O 0 1.8738596452294587e-07
a O 0 1.7873859405881376e-06
moderate O 0 5.858137592440471e-05
increase O 0 1.8862646129491623e-06
in O 0 1.1664795920296456e-06
in O 0 4.114219336770475e-06
vitro O 0 0.00022510426060762256
radiosensitivity O 0 0.0012600624468177557
. O 0 3.1579213100485504e-05

We O 0 2.6800187697517686e-05
performed O 0 1.7174890672322363e-05
a O 0 9.260080332751386e-06
blind O 0 7.920576899778098e-05
chromosomal O 0 0.00012394126679282635
analysis O 0 4.294506197766168e-06
on O 0 7.327473213081248e-06
G2 O 0 0.08334913849830627
- O 0 0.00019626533321570605
phase O 0 1.0092577213072218e-05
lymphocytes O 0 2.1502040908671916e-05
from O 0 4.918567242384597e-07
7 O 0 1.4092476021687617e-06
unrelated O 0 1.1405798431951553e-05
A B-Disease 1 0.9998787641525269
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.00011239045852562413
, O 0 3.608862755299924e-07
13 O 0 7.265025487868115e-07
obligate O 0 7.1392378231394105e-06
A B-Disease 1 0.9983918070793152
- I-Disease 1 0.999996542930603
T I-Disease 1 0.9999997615814209
heterozygotes O 0 0.0011116649257019162
( O 0 1.0580499747447902e-06
parents O 0 2.473890958754055e-07
of O 0 6.006455777196607e-08
the O 0 1.3004321317566792e-06
patients O 0 3.997435214841971e-06
) O 0 1.8561307513209613e-07
, O 0 1.019861386453158e-07
and O 0 1.135614056124723e-07
14 O 0 3.184066486028314e-07
normal O 0 9.171195074486604e-07
controls O 0 9.386495548824314e-06
following O 0 2.49993695433659e-06
X O 0 0.00011114151129731908
- O 0 1.4821212971583009e-05
irradiation O 0 3.762517508221208e-06
with O 0 1.5299336553198373e-07
1 O 0 4.822168762075307e-07
Gy O 0 9.60538636718411e-06
in O 0 1.4305324214092252e-07
order O 0 1.7536078189550608e-07
to O 0 1.7182702549689566e-07
evaluate O 0 9.347032801088062e-07
this O 0 1.2880212807431235e-07
cytogenetic O 0 7.46113391869585e-06
method O 0 2.9299448556230345e-07
as O 0 9.525047772740436e-08
a O 0 3.8620794384769397e-07
tool O 0 8.698895044290111e-07
for O 0 1.1319031756329423e-07
detection O 0 2.3019790660328e-06
of O 0 6.398865934897913e-07
ATM O 0 0.0003576846211217344
carriers O 0 5.346022226149216e-05
. O 0 2.187259633501526e-05

Both O 0 9.686198609415442e-05
A B-Disease 1 0.929423987865448
- I-Disease 1 0.9984098672866821
T I-Disease 1 0.9999526739120483
homozygotes O 0 0.0002887506561819464
and O 0 3.697010697578662e-06
heterozygotes O 0 4.670240014092997e-05
showed O 0 5.397403128881706e-06
significantly O 0 4.736473329103319e-06
increased O 0 1.6879498616617639e-06
levels O 0 1.0936065564237651e-06
of O 0 4.489704679144779e-07
radiation O 0 0.27594783902168274
- O 0 0.27050232887268066
induced O 0 0.028675012290477753
chromatid O 0 0.010359085164964199
damage O 0 9.402244177181274e-05
relative O 0 2.2642182102572406e-06
to O 0 2.637449654230295e-07
that O 0 1.4640640699781216e-07
of O 0 3.0189377753231383e-07
normal O 0 1.1186953088326845e-05
controls O 0 0.00031510836561210454
. O 0 1.5425128367496654e-05

These O 0 1.675265775702428e-05
results O 0 7.522377472923836e-06
show O 0 2.254681476188125e-06
that O 0 3.465665088242531e-07
the O 0 1.247982936547487e-06
G2 O 0 0.0020253402180969715
- O 0 5.445721035357565e-05
phase O 0 1.1822048691101372e-05
chromosomal O 0 0.00013831278192810714
radiosensitivity O 0 0.00023793363652657717
assay O 0 0.00022354077373165637
can O 0 4.2449497072993836e-07
be O 0 7.101091625827394e-08
used O 0 1.3005423227241408e-07
for O 0 4.3038852481913636e-08
the O 0 1.3476197580075677e-07
detection O 0 2.4501605366822332e-06
of O 0 6.438138484554656e-07
A B-Disease 1 0.9995393753051758
- I-Disease 1 0.9999933242797852
T I-Disease 1 0.9999964237213135
heterozygotes O 0 0.00224031088873744
. O 0 3.36594894179143e-05

In O 0 2.5393746909685433e-05
combination O 0 1.889214945549611e-05
with O 0 1.6192965404115967e-06
molecular O 0 1.9091648937319405e-05
genetic O 0 5.307054379954934e-06
analyses O 0 3.3937469652300933e-06
, O 0 2.654168440585636e-07
this O 0 3.765554765777779e-07
test O 0 1.2167817658337299e-05
may O 0 2.718999667195021e-06
be O 0 3.0898071656793036e-08
of O 0 1.705283203534691e-08
value O 0 3.032820217185872e-08
in O 0 7.851007666204168e-08
studies O 0 1.2881221778116014e-07
of O 0 7.744621655092487e-08
familial B-Disease 0 2.3889539079391398e-05
and I-Disease 0 1.4658414784207707e-06
sporadic I-Disease 0 0.0006153258145786822
cancers I-Disease 0 0.00011353494483046234
aimed O 0 1.487705731051392e-06
at O 0 4.4628276896219177e-07
determination O 0 5.92199171478569e-07
of O 0 4.741657377849151e-08
the O 0 1.553814854560187e-07
potential O 0 1.820639710103933e-07
involvement O 0 7.084992148520541e-07
of O 0 2.5194287900376366e-07
ATM O 0 0.00036999056464992464
mutations O 0 4.3170370190637186e-05
in O 0 6.649638180533657e-06
tumor B-Disease 0 0.030051378533244133
risk O 0 5.636128662445117e-06
or O 0 1.1592147757255589e-06
development O 0 1.8307814571016934e-06
. O 0 2.0419047359609976e-06
. O 0 1.1194551916560158e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999960660934448
telangiectasia I-Disease 1 0.9999984502792358
: O 0 1.1162909686390776e-05
identification O 0 3.4757911180349765e-06
and O 0 5.440490440378198e-07
detection O 0 2.1812875274918042e-06
of O 0 2.051694565352591e-07
founder O 0 9.796768426895142e-05
- O 0 0.00014255168207455426
effect O 0 2.5438259854126954e-06
mutations O 0 2.3581558252772084e-06
in O 0 1.7202229685153725e-07
the O 0 3.8224249010454514e-07
ATM O 0 1.773060103005264e-05
gene O 0 5.729570602852618e-06
in O 0 8.226480758821708e-07
ethnic O 0 2.274058033435722e-06
populations O 0 1.257371150131803e-05
. O 0 1.797281947801821e-05

To O 0 1.3867650523025077e-05
facilitate O 0 9.32486273086397e-06
the O 0 1.0699473023123574e-06
evaluation O 0 1.8529680119172554e-06
of O 0 3.9420581288140966e-07
ATM O 0 4.812319821212441e-05
heterozygotes O 0 2.9849134079995565e-05
for O 0 4.442136116722395e-07
susceptibility O 0 1.6803829566924833e-05
to O 0 8.193361509256647e-07
other O 0 1.326617166341748e-06
diseases O 0 0.0005897740484215319
, O 0 1.9830140729482082e-07
such O 0 1.589076532582112e-07
as O 0 0.0007749181822873652
breast B-Disease 1 0.9999232292175293
cancer I-Disease 1 0.910590648651123
, O 0 3.477749999092339e-07
we O 0 8.115627991855945e-08
have O 0 5.8975548000717026e-08
attempted O 0 1.7022420024659368e-06
to O 0 1.5293153410311788e-07
define O 0 3.899607463608845e-07
the O 0 1.3290646450059285e-07
most O 0 1.4772604117752053e-07
common O 0 1.2578259429574246e-06
mutations O 0 2.6800644263857976e-06
and O 0 1.0343365630660628e-07
their O 0 2.77084325261967e-07
frequencies O 0 1.4150145034363959e-05
in O 0 6.958697485970333e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999738931655884
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00011853044998133555
A B-Disease 1 0.9991694688796997
- I-Disease 1 0.9999381303787231
T I-Disease 1 0.9999818801879883
) O 0 1.298768893320812e-06
homozygotes O 0 1.0206947990809567e-05
from O 0 4.394899519866158e-07
10 O 0 5.070452857580676e-07
ethnic O 0 1.6530116226931568e-06
populations O 0 9.236004189006053e-06
. O 0 1.3480762390827294e-05

Both O 0 3.275145354564302e-05
genomic O 0 0.00022973131854087114
mutations O 0 9.781692642718554e-05
and O 0 1.0002506769524189e-06
their O 0 9.827140274865087e-07
effects O 0 8.009465091163293e-06
on O 0 1.9672493181133177e-06
cDNA O 0 2.9935479687992483e-05
were O 0 4.111497673875419e-06
characterized O 0 0.0001392512785969302
. O 0 2.4222779757110402e-05

Protein O 0 0.00024242507060989738
- O 0 0.0001091843078029342
truncation O 0 8.296602027257904e-05
testing O 0 4.249204721418209e-06
of O 0 2.325881354181547e-07
the O 0 4.6172098677743634e-07
entire O 0 1.8926145912701031e-06
ATM O 0 1.5701614756835625e-05
cDNA O 0 1.4738559002580587e-05
detected O 0 9.78901607595617e-06
92 O 0 3.0471123864117544e-06
( O 0 6.904169822519179e-07
66 O 0 2.1660266611434054e-06
% O 0 4.5291571382222173e-07
) O 0 6.821638294240984e-07
truncating O 0 4.011541386716999e-05
mutations O 0 1.1953840839851182e-05
in O 0 9.682315749159898e-07
140 O 0 6.486940492322901e-06
mutant O 0 9.13319454411976e-05
alleles O 0 8.447663276456296e-05
screened O 0 0.0001142172040999867
. O 0 4.2746854887809604e-05

The O 0 2.1530233425437473e-05
haplotyping O 0 0.00020657051936723292
of O 0 1.2473236665755394e-06
patients O 0 3.8091386613814393e-06
with O 0 5.173960175852699e-07
identical O 0 0.00023117271484807134
mutations O 0 1.589013663760852e-05
indicates O 0 5.180136781746114e-07
that O 0 3.3453929404458904e-08
almost O 0 4.414680532249804e-08
all O 0 9.166507553004521e-09
of O 0 1.0832804875349211e-08
these O 0 2.291879397375851e-08
represent O 0 5.966662541823098e-08
common O 0 1.9546568807982112e-07
ancestry O 0 7.886560524639208e-07
and O 0 3.94486022514684e-07
that O 0 2.9048715077806264e-07
very O 0 7.4437110697545e-07
few O 0 1.3801267186863697e-06
spontaneously O 0 3.1239367672242224e-05
recurring O 0 9.103812044486403e-05
ATM O 0 0.0012087811483070254
mutations O 0 0.0002671889087650925
exist O 0 2.0513107301667333e-05
. O 0 2.3041002350510098e-05

Assays O 0 0.0008884489652700722
requiring O 0 4.1248924389947206e-05
minimal O 0 1.4730971997778397e-05
amounts O 0 2.507666522433283e-06
of O 0 4.0922293464973336e-07
genomic O 0 4.757769602292683e-06
DNA O 0 4.474301022128202e-06
were O 0 5.113710699333751e-07
designed O 0 4.8708657232054975e-06
to O 0 2.3052471931350738e-07
allow O 0 4.1783289361774223e-07
rapid O 0 7.049956366245169e-06
screening O 0 2.0039619812450837e-06
for O 0 2.243126999701417e-07
common O 0 2.092137492581969e-06
ethnic O 0 4.743896170111839e-06
mutations O 0 0.00012492015957832336
. O 0 2.1376547010731883e-05

These O 0 4.0424369217362255e-05
rapid O 0 0.00021083983301650733
assays O 0 0.0005251091788522899
detected O 0 0.00028327395557425916
mutations O 0 1.657225948292762e-05
in O 0 7.183850811998127e-07
76 O 0 2.6065235942951404e-06
% O 0 2.9562892223111703e-07
of O 0 1.5609438719366153e-07
Costa O 0 2.1535897758440115e-06
Rican O 0 7.485286459996132e-06
patients O 0 2.1988314983900636e-05
( O 0 6.079136483094771e-07
3 O 0 3.274860773672117e-07
) O 0 8.797677253369329e-08
, O 0 3.136292292538201e-08
50 O 0 5.181929907394078e-08
% O 0 3.368840850725974e-08
of O 0 4.310539480911757e-08
Norwegian O 0 0.00654632830992341
patients O 0 1.7477155779488385e-05
( O 0 3.2557809959143924e-07
1 O 0 1.744525377489481e-07
) O 0 8.620671820835923e-08
, O 0 3.051899710726502e-08
25 O 0 5.8701939309457885e-08
% O 0 3.2496540569582066e-08
of O 0 3.927576841533664e-08
Polish O 0 0.08657173067331314
patients O 0 5.328838597051799e-05
( O 0 4.6143927079356217e-07
4 O 0 3.5361600225769507e-07
) O 0 9.105573184342575e-08
, O 0 2.3732162901524134e-08
and O 0 2.8009015551333505e-08
14 O 0 8.227910797131699e-08
% O 0 3.0339890599861974e-08
of O 0 3.007187743264694e-08
Italian O 0 0.00010759213182609528
patients O 0 0.00017042222316376865
( O 0 5.13571876581409e-07
1 O 0 2.5664360236987704e-07
) O 0 9.68396278722139e-08
, O 0 2.432667045582093e-08
as O 0 2.9510715648939367e-08
well O 0 4.517509921697638e-08
as O 0 9.628175945408657e-08
in O 0 3.3897316598086036e-07
patients O 0 9.176872595162422e-07
of O 0 2.2382121755981643e-07
Amish O 0 0.0007649091421626508
/ O 0 0.0008896508952602744
Mennonite O 0 0.0005311349523253739
and O 0 1.9885681012965506e-06
Irish O 0 1.8343540432397276e-05
English O 0 1.1624778380792122e-05
backgrounds O 0 3.014877438545227e-05
. O 0 2.3230037186294794e-05

Additional O 0 6.603526708204299e-05
mutations O 0 0.00021408565226010978
were O 0 3.587533456084202e-06
observed O 0 2.3823376977816224e-06
in O 0 3.7428520727189607e-07
Japanese O 0 8.202931098821864e-07
, O 0 1.340687418860398e-07
Utah O 0 1.0619196473271586e-06
Mormon O 0 1.3294719565237756e-06
, O 0 1.5489028726278775e-07
and O 0 2.054183170230317e-07
African O 0 1.2034169003527495e-06
American O 0 6.711674359394237e-06
patients O 0 6.251930608414114e-05
. O 0 1.8007614926318638e-05

These O 0 1.8615655790199526e-05
assays O 0 5.83337496209424e-05
should O 0 1.6469109596073395e-06
facilitate O 0 1.0122797675649053e-06
screening O 0 2.386308096902212e-06
for O 0 3.345418804201472e-07
A B-Disease 1 0.9920691251754761
- I-Disease 1 0.9999420642852783
T I-Disease 1 0.9999889135360718
heterozygotes O 0 2.50328412221279e-05
in O 0 3.925892144707177e-07
the O 0 3.7331699331843993e-07
populations O 0 1.0090594741996028e-06
studied O 0 3.180074600095395e-06
. O 0 1.685921347416297e-06
. O 0 9.232235242961906e-06

The O 0 0.00021900120191276073
von B-Disease 1 0.9305688142776489
Hippel I-Disease 1 0.9950559139251709
- I-Disease 1 0.9837067127227783
Lindau I-Disease 1 0.9973288774490356
tumor I-Disease 0 0.29874321818351746
suppressor O 0 0.0017772491555660963
gene O 0 2.3280936147784814e-05
is O 0 4.2808795797100174e-07
required O 0 3.2149145567927917e-07
for O 0 3.5573714285419555e-07
cell O 0 3.1654166377848014e-05
cycle O 0 1.3183739611122292e-05
exit O 0 1.3006756489630789e-05
upon O 0 6.8673766691063065e-06
serum O 0 0.00015858795086387545
withdrawal O 0 0.00013147585559636354
. O 0 3.488135916995816e-05

The O 0 3.5681965528056026e-05
inactivation O 0 0.0002318660990567878
of O 0 2.277982503073872e-06
the O 0 7.287797416211106e-06
von B-Disease 1 0.909069299697876
Hippel I-Disease 1 0.9965470433235168
- I-Disease 1 0.9756762981414795
Lindau I-Disease 1 0.761425793170929
( I-Disease 0 2.094283263431862e-05
VHL I-Disease 0 0.001238495227880776
) I-Disease 0 1.0738281162048224e-05
tumor I-Disease 0 0.0001640937407501042
suppressor O 0 0.00020688216318376362
gene O 0 1.6559240975766443e-05
predisposes O 0 3.7813915696460754e-05
affected O 0 1.5451820445377962e-06
individuals O 0 1.0554493456993441e-07
to O 0 1.6256313983831205e-07
the O 0 2.6990778678737115e-06
human O 0 0.0009419916314072907
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 3.092356791967177e-06
is O 0 8.076688686742273e-07
associated O 0 2.264963313791668e-06
with O 0 2.878309260267997e-06
sporadic B-Disease 1 0.9903361797332764
renal I-Disease 1 1.0
cell I-Disease 1 0.9999979734420776
carcinomas I-Disease 1 1.0
( O 0 0.0028735699597746134
RCC B-Disease 1 0.9973384737968445
) O 0 4.005070877610706e-06
and O 0 6.363979082379956e-06
brain B-Disease 0 0.00836360827088356
hemangioblastomas I-Disease 0 0.0060087027959525585
. O 0 4.9409452913096175e-05

VHL O 0 0.383762925863266
- O 0 0.0032858268823474646
negative O 0 0.00018818907847162336
786 O 0 0.00037261616671457887
- O 0 0.00023865159892011434
0 O 0 1.707616502244491e-05
RCC B-Disease 0 0.2961388826370239
cells O 0 6.112125447543804e-06
are O 0 2.3138393601129792e-07
tumorigenic O 0 1.4658073268947192e-05
in O 0 2.178638851546566e-06
nude O 0 0.00022793980315327644
mice O 0 6.76757626933977e-05
which O 0 6.232742180145578e-07
is O 0 2.3741586119285785e-07
suppressed O 0 3.2665311664459296e-06
by O 0 2.644743801738514e-07
the O 0 5.453877633954107e-07
reintroduction O 0 2.3020007574814372e-05
of O 0 4.695040843216702e-06
VHL B-Disease 0 0.005379337817430496
. O 0 6.05296554567758e-05

Remarkably O 0 0.0016144311521202326
, O 0 6.4948703766276594e-06
this O 0 9.735973662827746e-07
occurs O 0 8.319286166624806e-07
without O 0 2.941799550626456e-07
affecting O 0 4.3149364614691876e-07
the O 0 2.458429548823915e-07
growth O 0 1.0816359008458676e-06
rate O 0 5.291113893690635e-07
and O 0 1.7678924280062347e-07
cell O 0 5.072288331575692e-06
cycle O 0 2.9898924367444124e-06
profile O 0 1.1521576652739896e-06
of O 0 8.862518541263853e-08
these O 0 2.1013647710788064e-07
cells O 0 2.875063955798396e-06
in O 0 1.2987924264962203e-06
culture O 0 1.8954044207930565e-05
. O 0 1.9551544028217904e-05

The O 0 2.7741909434553236e-05
786 O 0 0.0003756721562240273
- O 0 0.00015259029169101268
0 O 0 5.143804628460202e-06
cell O 0 3.284165359218605e-05
line O 0 7.361330062849447e-06
, O 0 1.8827803671683796e-07
like O 0 1.3650235075601813e-07
many O 0 1.7344144964681618e-07
cancer B-Disease 0 0.0003075424174312502
cells O 0 3.0993983273219783e-06
, O 0 2.3280871630504407e-07
fails O 0 2.1248085886327317e-06
to O 0 1.5779903606016887e-07
exit O 0 8.508218911629228e-07
the O 0 4.748839046442299e-07
cell O 0 1.1760167581087444e-05
cycle O 0 8.90677074494306e-06
upon O 0 4.726406586996745e-06
serum O 0 0.0001896329631563276
withdrawal O 0 0.00011895073112100363
. O 0 3.807488610618748e-05

Here O 0 2.1611820557154715e-05
, O 0 1.975024360945099e-06
it O 0 3.2594221011095215e-07
is O 0 1.0743915623834255e-07
shown O 0 2.3369159407593543e-07
that O 0 7.677964930508097e-08
reintroduction O 0 1.7051665963663254e-06
of O 0 6.921673900706082e-08
the O 0 4.2915567632917373e-07
wild O 0 3.129193146378384e-06
- O 0 0.0010564563563093543
type O 0 7.455502054654062e-05
VHL B-Disease 0 0.00040425790939480066
gene O 0 1.2117606274841819e-05
restores O 0 1.8511771486373618e-05
the O 0 4.896318159808288e-07
ability O 0 1.2269532589925802e-06
of O 0 8.749580615585728e-07
VHL O 0 0.03167618438601494
- O 1 0.6938186883926392
negative O 0 0.0034525683149695396
RCC B-Disease 1 0.9999465942382812
cancer I-Disease 0 0.05616747587919235
cells O 0 3.643701802502619e-06
to O 0 3.0476888923658407e-07
exit O 0 1.8146122329198988e-06
the O 0 5.93070694776543e-07
cell O 0 1.3512412806448992e-05
cycle O 0 5.401821454142919e-06
and O 0 8.337307235706248e-07
enter O 0 6.902201675984543e-06
G0 O 0 0.0014218647265806794
/ O 0 0.00017262998153455555
quiescence O 0 0.00020112073980271816
in O 0 6.039522759238025e-06
low O 0 9.893003152683377e-05
serum O 0 0.0004932766896672547
. O 0 2.3408369088429026e-05

Both O 0 0.0001328487414866686
VHL O 0 0.016672980040311813
- O 0 0.0008376616169698536
positive O 0 1.0928070878435392e-05
and O 0 4.369121143099619e-06
VHL O 0 0.003713349811732769
- O 0 0.004099713172763586
negative O 0 3.7427635106723756e-05
RCC B-Disease 0 0.03998824581503868
cells O 0 5.657152087223949e-06
exit O 0 3.5105501865473343e-06
the O 0 9.765255981619703e-07
cell O 0 2.0223649698891677e-05
cycle O 0 6.808452326367842e-06
by O 0 1.4772675740459817e-06
contact O 0 3.780464976443909e-05
inhibition O 0 8.996018732432276e-05
. O 0 1.853802132245619e-05

The O 0 6.452713569160551e-05
cyclin O 0 0.00508908461779356
- O 0 0.0001396882871631533
dependent O 0 2.4856093659764156e-05
kinase O 0 0.00019318130216561258
inhibitor O 0 2.71316384896636e-05
, O 0 6.776696750421252e-07
p27 O 0 1.5873220036155544e-05
, O 0 4.5615817612087994e-07
accumulates O 0 2.8906993065902498e-06
upon O 0 6.886920687065867e-07
serum O 0 8.721757694729604e-06
withdrawal O 0 2.0605591544153867e-06
, O 0 7.740707985703921e-08
only O 0 2.9588379746314786e-08
in O 0 4.4551136113568646e-08
the O 0 6.194332513587142e-08
presence O 0 2.038315756180964e-07
of O 0 7.773050469950249e-08
VHL B-Disease 0 4.8424131819047034e-05
, O 0 8.44450553927345e-08
as O 0 3.163960826668699e-08
a O 0 1.1615802009146137e-07
result O 0 5.8522953594319915e-08
of O 0 2.200827253773241e-08
the O 0 1.2870451371327363e-07
stabilization O 0 1.8590585568745155e-06
of O 0 9.466564421245494e-08
the O 0 9.209838935930748e-07
protein O 0 1.0564202057139482e-05
. O 0 1.0391043360868935e-05

We O 0 1.5783811250003055e-05
propose O 0 2.9702950996579602e-05
that O 0 5.096043764751812e-07
the O 0 3.8801948676336906e-07
loss O 0 1.6229821540036937e-06
of O 0 1.2650146175019472e-07
wild O 0 2.0008280898764497e-06
- O 0 0.008519120514392853
type O 0 4.370538954390213e-05
VHL B-Disease 0 0.00021496455883607268
gene O 0 4.584942416840931e-06
results O 0 7.112904540917953e-07
in O 0 1.1899782492719169e-07
a O 0 4.2405514477650286e-07
specific O 0 6.788644100197416e-07
cellular O 0 8.053786586970091e-05
defect O 0 5.266568041406572e-05
in O 0 1.3570606824941933e-06
serum O 0 5.055352085037157e-05
- O 0 2.1202551579335704e-05
dependent O 0 1.8482115820006584e-06
growth O 0 1.111334881898074e-06
control O 0 4.5600086195918266e-06
, O 0 2.7139870439896185e-07
which O 0 6.793618467781926e-07
may O 0 3.809647296293406e-06
initiate O 0 4.511226143222302e-05
tumor B-Disease 0 0.0009785100119188428
formation O 0 5.917135058552958e-05
. O 0 2.4576082068961114e-05

This O 0 1.8538783479016274e-05
is O 0 3.6940643894922687e-06
corrected O 0 2.235353531432338e-05
by O 0 4.0268491829920094e-07
the O 0 3.909191832462966e-07
reintroduction O 0 4.271600118954666e-06
of O 0 2.5111722834481043e-07
wild O 0 2.059413873212179e-06
- O 0 0.0007873353897593915
type O 0 9.371121268486604e-05
VHL B-Disease 0 0.00042656331788748503
, O 0 9.338158974969701e-07
implicating O 0 3.128038588329218e-05
VHL B-Disease 0 7.95912928879261e-05
as O 0 1.995023239942384e-07
the O 0 1.7942825536465534e-07
first O 0 1.101610109799367e-06
tumor B-Disease 0 5.1101909775752574e-05
suppressor O 0 2.054451033473015e-05
involved O 0 3.0482937063425197e-07
in O 0 1.0330983002404537e-07
the O 0 1.6223866339259985e-07
regulation O 0 5.604824195870606e-07
of O 0 1.166860741363962e-07
cell O 0 2.0391284124343656e-05
cycle O 0 8.480590622639284e-06
exit O 0 4.607173195836367e-06
, O 0 1.5853724733005947e-07
which O 0 1.3199081649872824e-07
is O 0 3.7876681346915575e-08
consistent O 0 1.49401842008956e-07
with O 0 5.469097530408362e-08
its O 0 3.415770208903268e-07
gatekeeper O 0 6.043694156687707e-06
function O 0 3.833844743894588e-07
in O 0 3.242234356548579e-07
the O 0 4.960869773640297e-06
kidney O 0 0.0013157090870663524
. O 0 3.5811719953926513e-06
. O 0 1.3240375665191095e-05

Piebaldism B-Disease 1 0.9999728202819824
with O 0 0.0604717954993248
deafness B-Disease 1 1.0
: O 0 1.3622988262795843e-05
molecular O 0 1.5211610843834933e-05
evidence O 0 1.6657872947689611e-06
for O 0 3.521342932799598e-07
an O 0 4.050106781505747e-06
expanded O 0 0.28400927782058716
syndrome O 1 0.9999954700469971
. O 0 3.761659900192171e-05

In O 0 1.3404792298388202e-05
a O 0 4.6243981159932446e-06
South O 0 2.7142352791997837e-06
African O 0 1.3367211977310944e-06
girl O 0 5.671693543263245e-06
of O 0 5.060153398517286e-07
Xhosa O 0 0.0010641154367476702
stock O 0 2.9766866646241397e-05
with O 0 3.9931760511535686e-06
severe O 1 0.6864758133888245
piebaldism B-Disease 1 0.737938642501831
and O 0 0.007298690266907215
profound O 1 0.9998987913131714
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0002101137361023575
identified O 0 1.4715500583406538e-05
a O 0 4.410255314724054e-06
novel O 0 4.922255357087124e-06
missense O 0 2.3763659555697814e-05
substitution O 0 2.161882548534777e-06
at O 0 5.700383098883322e-07
a O 0 4.880783990302007e-07
highly O 0 6.222948059075861e-07
conserved O 0 1.5084107189977658e-06
residue O 0 2.212078015872976e-06
in O 0 1.3146734545443906e-07
the O 0 1.5609811043759692e-07
intracellular O 0 5.287206931825494e-06
kinase O 0 1.1214427104278002e-05
domain O 0 8.532636002200888e-07
of O 0 1.358342274215829e-07
the O 0 1.5225338074742467e-06
KIT O 0 0.015422885306179523
proto O 0 0.12716256082057953
- O 0 0.0005166158662177622
oncogene O 0 0.00027971985400654376
, O 0 4.858408829022665e-06
R796G O 0 0.00016757681441958994
. O 0 3.451446536928415e-05

Though O 0 8.869652810972184e-05
auditory B-Disease 0 0.0013608786975964904
anomalies I-Disease 0 0.4683070182800293
have O 0 2.366974513279274e-06
been O 0 1.0816462463481002e-06
observed O 0 1.366991000395501e-06
in O 0 8.31960335290205e-07
mice O 0 1.433207762602251e-05
with O 0 4.737164260859572e-07
dominant O 0 1.6202564438572153e-05
white O 0 2.57374849752523e-05
spotting O 0 0.0001500665966887027
( O 0 8.491313565173186e-06
W O 1 0.7377385497093201
) O 0 4.0765434050626936e-07
due O 0 1.99042733584065e-06
to O 0 3.420396524234093e-06
KIT O 1 0.9958786964416504
mutations O 0 0.009992869570851326
, O 0 2.048847272817511e-05
deafness B-Disease 1 0.9999998807907104
is O 0 1.7696074792183936e-06
not O 0 2.959702669613762e-07
typical O 0 2.4188530005631037e-06
in O 0 1.760981035658915e-06
human O 0 7.756219019938726e-06
piebaldism B-Disease 0 0.0021832254715263844
. O 0 4.5797740312991664e-05

Thus O 0 3.437824489083141e-05
, O 0 2.3689301542617613e-06
the O 0 6.085064114813576e-07
occurrence O 0 7.056292815832421e-06
of O 0 3.2285179258906282e-06
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 7.1413152909372e-05
this O 0 2.817092536133714e-06
patient O 0 1.72808940988034e-05
extends O 0 3.697575039041112e-06
considerably O 0 5.472078100865474e-06
the O 0 4.459866431716364e-07
phenotypic O 0 3.019976475115982e-06
range O 0 5.778721288152155e-07
of O 0 1.773258588855242e-07
piebaldism B-Disease 0 0.00014722651394549757
due O 0 1.666983553150203e-05
to O 0 2.0766290163010126e-06
KIT O 0 0.0033065651077777147
gene O 0 1.2522733413788956e-05
mutation O 0 4.755106601805892e-06
in O 0 3.947901063838799e-07
humans O 0 6.815870392529177e-07
and O 0 3.9522183215012774e-07
tightens O 0 0.0043593780137598515
the O 0 1.0172169595534797e-06
clinical O 0 2.5127008029812714e-06
similarity O 0 4.6398099584621377e-07
between O 0 3.9882027635940176e-07
piebaldism B-Disease 0 9.103526099352166e-05
and O 0 1.069698924993645e-07
the O 0 1.0298364827576734e-07
various O 0 2.0764021257946297e-07
forms O 0 1.0544247288635233e-06
of O 0 2.612822390801739e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
. O 0 8.930561307352036e-06
. O 0 3.349863982293755e-05

Cycloheximide O 0 0.0023022801615297794
facilitates O 0 0.00014392159937415272
the O 0 6.458915777329821e-06
identification O 0 3.786017941820319e-06
of O 0 5.763113222201355e-07
aberrant O 0 3.490791277727112e-05
transcripts O 0 1.9693725334946066e-05
resulting O 0 5.739578682550928e-06
from O 0 6.873155484754534e-07
a O 0 1.3011318742428557e-06
novel O 0 5.687981229129946e-06
splice O 0 0.00014185810869093984
- O 0 0.00016919765039347112
site O 0 8.44813166622771e-06
mutation O 0 5.094482276035706e-06
in O 0 6.786773383282707e-07
COL17A1 O 0 0.0001883750519482419
in O 0 1.5714742858108366e-06
a O 0 1.6234364011324942e-05
patient O 0 0.00018538035510573536
with O 0 3.196778561687097e-05
generalized O 1 0.9689644575119019
atrophic B-Disease 1 0.9999978542327881
benign I-Disease 1 0.99997878074646
epidermolysis I-Disease 1 0.9999645948410034
bullosa I-Disease 1 0.9996635913848877
. O 0 0.0005400465452112257

Patients O 0 0.0063303555361926556
with O 0 0.00026348690153099597
generalized O 1 0.9910433292388916
atrophic B-Disease 1 0.9999980926513672
benign I-Disease 1 0.999988317489624
epidermolysis I-Disease 1 0.9999779462814331
bullosa I-Disease 1 0.9996566772460938
often O 0 5.1047845772700384e-05
show O 0 1.4137087418930605e-05
decreased O 0 1.3120224139129277e-05
expression O 0 2.0670777303166687e-06
of O 0 7.532740937676863e-07
type O 0 0.016219882294535637
XVII O 1 0.993866503238678
collagen O 0 0.0066749826073646545
, O 0 1.044962687046791e-06
a O 0 3.1675435820943676e-06
transmembrane O 0 2.609261719044298e-05
hemidesmosomal O 0 5.521534330910072e-05
protein O 0 3.971550995629514e-06
encoded O 0 3.99089913116768e-06
by O 0 3.79817652174097e-06
COL17A1 O 0 0.0012596299638971686
. O 0 4.3710435420507565e-05

This O 0 1.361482009087922e-05
report O 0 1.324705681327032e-05
documents O 0 3.034798965018126e-06
a O 0 1.4301424471341306e-06
novel O 0 3.87077716368367e-06
splice O 0 8.555795648135245e-05
- O 0 0.00011730260303011164
site O 0 6.259431756916456e-06
mutation O 0 5.743208930653054e-06
in O 0 5.190328238313668e-07
COL17A1 O 0 9.533468983136117e-05
in O 0 9.643316616347875e-07
a O 0 9.307394975621719e-06
patient O 0 7.101675873855129e-05
with O 0 1.4218592696124688e-05
generalized O 1 0.9448259472846985
atrophic B-Disease 1 0.9999991655349731
benign I-Disease 1 0.9999861717224121
epidermolysis I-Disease 1 0.999845027923584
bullosa I-Disease 1 0.9960058331489563
, O 0 5.104470801597927e-06
and O 0 6.22407583250606e-07
applies O 0 6.248787940421607e-07
a O 0 1.0685574807212106e-06
new O 0 4.186416390439263e-06
methodology O 0 4.200244802632369e-06
to O 0 7.740323439975327e-07
define O 0 2.0046652480232297e-06
and O 0 4.16325036667331e-07
characterize O 0 5.806735771329841e-06
the O 0 8.675995104567846e-07
resulting O 0 8.508676728524733e-06
mRNA O 0 2.8405518605723046e-05
splice O 0 0.00029630467179231346
variants O 0 0.00014448328875005245
. O 0 3.090179234277457e-05

Mutational O 0 0.007366306148469448
analysis O 0 8.773025911068544e-05
of O 0 9.572658200340811e-06
COL17A1 O 0 0.0018847299506887794
identified O 0 3.245125481043942e-05
a O 0 4.006422750535421e-05
maternally O 1 0.8239647746086121
inherited O 1 0.9436624646186829
G O 0 0.02820911444723606
- O 0 0.0006042170571163297
to O 0 2.4736696104810107e-06
- O 0 0.0032292427495121956
T O 0 0.0015395692316815257
transversion O 0 3.538296732585877e-05
at O 0 4.190188462871447e-07
the O 0 3.040666172182682e-07
- O 0 2.7155765565112233e-06
1 O 0 2.6985273393620446e-07
position O 0 6.206465741342981e-07
of O 0 4.5968675976837403e-07
exon O 0 4.7503279347438365e-05
32 O 0 1.5746662029414438e-05
. O 0 1.801589496608358e-05

This O 0 4.321468441048637e-05
acceptor O 0 0.00019509960839059204
splice O 0 0.0006340574473142624
- O 0 0.0003729566524270922
site O 0 1.449888623028528e-05
mutation O 0 7.742663910903502e-06
led O 0 9.480665426053747e-07
to O 0 1.6250314160970447e-07
the O 0 1.7324140344499028e-07
formation O 0 9.328118721896317e-07
of O 0 1.649380436674619e-07
aberrant O 0 8.710137080925051e-06
transcripts O 0 5.410277026385302e-06
present O 0 1.3372974763115053e-06
at O 0 1.4965809214118053e-06
extremely O 0 1.0136774108104873e-05
low O 0 1.9631490431493148e-05
levels O 0 1.6294543456751853e-05
. O 0 1.5733901818748564e-05

Based O 0 2.8236281650606543e-05
on O 0 3.1723050142318243e-06
our O 0 6.200224333952065e-07
recent O 0 7.832197752577486e-07
finding O 0 6.038136461938848e-07
that O 0 3.5036859458159597e-07
cycloheximide O 0 4.1717386920936406e-05
stabilized O 0 0.0001833532878663391
mutant O 0 2.4187713279388845e-05
COL17A1 O 0 6.147840758785605e-05
transcripts O 0 1.3492504876921885e-05
in O 0 2.057417304968112e-06
keratinocytes O 0 5.765604873886332e-05
homozygous O 0 1.8211869246442802e-05
for O 0 4.706130596332514e-07
a O 0 7.749298674752936e-06
frameshift O 0 0.0730939731001854
mutation O 0 8.856155545799993e-06
, O 0 1.7217476511177665e-07
the O 0 1.5287159271792916e-07
effects O 0 7.678945053157804e-07
of O 0 5.799424940278186e-08
the O 0 3.266666510626237e-07
splice O 0 9.760895045474172e-05
- O 0 0.00022558770433533937
site O 0 3.3661101497273194e-06
mutation O 0 1.7391229221175308e-06
on O 0 3.236546888274461e-07
splicing O 0 2.989225322380662e-06
of O 0 2.7373999955671025e-07
COL17A1 O 0 0.0001377494481857866
transcripts O 0 7.442806236213073e-06
were O 0 8.534963740203239e-07
determined O 0 1.5338183629864943e-06
using O 0 2.2091855953476625e-06
reverse O 0 4.257676118868403e-05
transcriptase O 0 0.00014007696881890297
polymerase O 0 4.933948002872057e-05
chain O 0 3.178817860316485e-05
reaction O 0 3.4341635455348296e-06
of O 0 2.3582542496569658e-07
total O 0 4.0519122990190226e-07
RNA O 0 2.341786739634699e-06
from O 0 9.042278747983801e-07
keratinocytes O 0 3.123480928479694e-05
incubated O 0 1.1430909580667503e-05
for O 0 1.0524476010687067e-06
2 O 0 8.325521775987e-06
. O 0 1.3864900211046916e-05

5 O 0 5.3854317229706794e-05
h O 0 5.718420652556233e-05
in O 0 1.2000612059637206e-06
the O 0 5.150865263203741e-07
presence O 0 9.418195645594096e-07
or O 0 3.701858304339112e-07
absence O 0 8.583531325712102e-07
of O 0 2.1591760912542668e-07
10 O 0 1.552409230498597e-06
microg O 0 0.00020265337661840022
cycloheximide O 0 0.0004751950327772647
per O 0 1.7070888134185225e-05
ml O 0 0.001496017910540104
. O 0 3.531150650815107e-05

Using O 0 1.8293143511982635e-05
this O 0 1.940394440680393e-06
approach O 0 2.127383368133451e-06
, O 0 3.3253030551350093e-07
an O 0 4.854296662415436e-07
abnormally O 0 0.00010670455958461389
spliced O 0 0.00014436431229114532
transcript O 0 0.005390206817537546
was O 0 7.409771205857396e-05
identified O 0 7.089803943927109e-07
that O 0 4.5629217737541694e-08
contains O 0 8.442975740763359e-08
an O 0 6.977571587185594e-08
extra O 0 2.037971711388309e-07
264 O 0 9.863570085144602e-07
bases O 0 4.2415993561917276e-07
upstream O 0 1.0559492693573702e-06
from O 0 2.8891014380860724e-07
exon O 0 5.178801529837074e-06
32 O 0 7.547511131633655e-07
, O 0 1.683174417621558e-07
resulting O 0 1.3074169373794575e-06
in O 0 8.192213272195659e-07
a O 0 1.9821700334432535e-05
premature O 0 0.0006096488214097917
termination O 0 6.059567385818809e-05
codon O 0 2.506647797417827e-05
27 O 0 7.940649993543047e-06
bp O 0 2.0369710910017602e-05
downstream O 0 5.246151431492763e-06
from O 0 5.657371389133914e-07
the O 0 2.0187242171232356e-06
cryptic O 0 9.172287536785007e-05
splice O 0 0.00045434755156747997
site O 0 9.555721771903336e-05
. O 0 3.680138979689218e-05

Three O 0 4.477771199162817e-06
other O 0 8.107101052701182e-07
splice O 0 2.3448987121810205e-05
variants O 0 5.787435384263517e-06
, O 0 1.4932933822819905e-07
including O 0 6.675733033034703e-08
one O 0 5.12075786218702e-08
derived O 0 1.6675531355758721e-07
from O 0 7.567598458990688e-08
the O 0 8.648735416727504e-08
skipping O 0 7.859335937610012e-07
of O 0 1.6286355730699142e-07
exon O 0 5.5317991609626915e-06
32 O 0 6.704059956064157e-07
, O 0 1.869900074780162e-07
were O 0 3.439088800405443e-07
also O 0 8.806983942122315e-07
identified O 0 9.934724403137807e-06
. O 0 1.0705182830861304e-05

These O 0 1.3178861991036683e-05
results O 0 1.1605836334638298e-05
indicate O 0 2.9785794595227344e-06
the O 0 6.430094572351663e-07
usefulness O 0 1.8912505765911192e-06
of O 0 1.9804967621439573e-07
cycloheximide O 0 0.010678090155124664
treatment O 0 2.1876225218875334e-05
in O 0 3.711986380494636e-07
evaluating O 0 8.950955816544592e-07
the O 0 2.470948459176725e-07
abnormal O 0 2.2449835341831204e-06
processing O 0 2.1127482341398718e-07
of O 0 3.972532525153838e-08
mRNA O 0 4.5617818500431895e-07
due O 0 4.885394560005807e-07
to O 0 3.0837111353321234e-07
splice O 0 9.93975336314179e-05
- O 0 0.0037821377627551556
site O 0 3.095942520303652e-05
mutations O 0 1.4061066394788213e-05
, O 0 3.1686175816503237e-07
because O 0 6.96047720794013e-07
( O 0 1.3677525885213981e-06
i O 0 9.030816841004707e-07
) O 0 3.8406292901527195e-07
aberrant O 0 4.5566002881969325e-06
splicing O 0 5.01635622640606e-06
often O 0 6.147517410681758e-07
generates O 0 2.6889915716310497e-06
a O 0 3.7235627132758964e-06
premature O 0 6.890669465065002e-05
termination O 0 2.5762899895198643e-05
codon O 0 1.649654223001562e-05
, O 0 8.765949814915075e-07
( O 0 1.1764797136493144e-06
ii O 0 7.857699529267848e-05
) O 0 6.620927024414414e-07
transcripts O 0 2.8131514682172565e-06
with O 0 1.8484338397684041e-06
premature O 0 0.0002443008415866643
termination O 0 1.7396258044755086e-05
codons O 0 6.497787580883596e-06
can O 0 3.8689361758770247e-07
occur O 0 3.592743951230659e-07
at O 0 4.5524421921072644e-07
low O 0 4.252309736330062e-06
or O 0 8.006776397451176e-07
undetectable O 0 6.109269179432886e-06
levels O 0 5.560665954362776e-07
due O 0 8.28712870770687e-07
to O 0 2.9573129722848535e-07
nonsense O 0 2.546114728829707e-06
- O 0 3.385261379662552e-06
mediated O 0 4.98471490573138e-06
mRNA O 0 1.4422447520701098e-06
decay O 0 1.5001834299255279e-06
, O 0 7.781905964066027e-08
and O 0 1.0039235576186911e-07
( O 0 3.290206507244875e-07
iii O 0 4.1816081647994e-05
) O 0 8.495555903209606e-08
the O 0 5.1168132841894476e-08
levels O 0 9.181348303854975e-08
of O 0 1.836042251568415e-08
these O 0 3.842013640564801e-08
transcripts O 0 8.547939955860784e-07
can O 0 8.908752846537027e-08
be O 0 8.097877213231186e-08
increased O 0 6.814005359956354e-07
by O 0 1.659831127653888e-06
cycloheximide O 0 0.0003894471738021821
. O 0 2.315961137355771e-05

A O 0 0.00015988036466296762
deletion O 0 0.0008811501320451498
mutation O 0 0.00013722058793064207
in O 0 5.185557256481843e-06
COL17A1 O 0 0.00022932601859793067
in O 0 1.557954647068982e-06
five O 0 9.300546253143693e-07
Austrian O 0 0.00016620811948087066
families O 0 3.976728294219356e-06
with O 0 2.093309012707323e-05
generalized O 1 0.9847400784492493
atrophic B-Disease 1 0.9999990463256836
benign I-Disease 1 0.9999680519104004
epidermolysis I-Disease 1 0.9998453855514526
bullosa I-Disease 1 0.8776697516441345
represents O 0 1.0708982699725311e-05
propagation O 0 1.4168009329296183e-05
of O 0 5.119254069541057e-07
an O 0 1.12845259536698e-06
ancestral O 0 8.539990813005716e-05
allele O 0 0.0001918098860187456
. O 0 2.273225436510984e-05

Patients O 0 0.00591623829677701
with O 0 0.000222704722546041
generalized O 1 0.9889118671417236
atrophic B-Disease 1 0.9999983310699463
benign I-Disease 1 0.9999938011169434
epidermolysis I-Disease 1 0.99997878074646
bullosa I-Disease 1 0.9996774196624756
, O 0 1.3677258721145336e-05
a O 0 6.989631401665974e-06
usually O 0 2.9100028768880293e-06
nonlethal O 0 1.3659192518389318e-05
form O 0 4.216531579004368e-06
of O 0 3.4160805171268294e-06
junctional B-Disease 1 0.8223737478256226
epidermolysis I-Disease 1 0.9970496892929077
bullosa I-Disease 1 0.959473192691803
, O 0 6.614353878831025e-06
have O 0 1.7146752497865236e-06
generalized O 0 3.080590249737725e-05
blistering B-Disease 0 0.16736626625061035
, O 0 4.677991819335148e-05
nail B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999946355819702
, O 0 7.66010707593523e-05
patchy B-Disease 1 0.999903678894043
alopecia I-Disease 1 0.9999998807907104
, O 0 4.704071761807427e-05
and O 0 0.0010393576230853796
dental B-Disease 1 0.9999980926513672
abnormalities I-Disease 1 0.999995231628418
. O 0 7.569088484160602e-05

Skin B-Disease 1 0.9999728202819824
fragility I-Disease 1 0.9703922271728516
in O 0 1.9571523807826452e-05
most O 0 8.186004265553493e-07
cases O 0 7.020516363809293e-07
is O 0 1.8682956692828157e-07
due O 0 1.6148674149008002e-06
to O 0 8.323078759531199e-07
mutations O 0 4.184907538729021e-06
in O 0 2.1184359866310842e-07
the O 0 7.143264042497321e-07
gene O 0 8.489369974995498e-06
encoding O 0 1.948630051629152e-05
type O 0 0.0007629155879840255
XVII O 1 0.9083128571510315
collagen O 0 0.02257472462952137
( O 0 1.7067470253095962e-05
COL17A1 O 0 0.0014343670336529613
) O 0 1.1580287718970794e-05
. O 0 1.430778229405405e-05

Recently O 0 0.0005349827115423977
, O 0 4.4823300413554534e-06
we O 0 7.408273177134106e-07
reported O 0 3.1860697617958067e-06
five O 0 7.179550038927118e-07
Austrian O 0 7.250088674481958e-05
families O 0 3.800462764047552e-06
with O 0 1.5434148735948838e-05
generalized O 1 0.9210418462753296
atrophic B-Disease 1 0.9999969005584717
benign I-Disease 1 0.9999755620956421
epidermolysis I-Disease 1 0.999906063079834
bullosa I-Disease 1 0.998630702495575
who O 0 3.51812232111115e-05
share O 0 6.126854714239016e-06
the O 0 2.037809736066265e-06
same O 0 9.706329365144484e-06
COL17A1 O 0 0.08241494745016098
mutation O 0 0.0003451942466199398
. O 0 3.293106783530675e-05

Affected O 0 6.47060078335926e-05
individuals O 0 2.0041300103912363e-06
in O 0 4.2194577076770656e-07
three O 0 2.06566156180088e-07
families O 0 1.6405655856033263e-07
are O 0 5.491465771001458e-08
homozygous O 0 1.8013444105235976e-06
for O 0 1.3217271543908282e-07
4003delTC O 0 9.149475772574078e-06
, O 0 1.505955822267424e-07
whereas O 0 2.2896514906278753e-07
those O 0 4.059941360878838e-08
in O 0 5.574296224608588e-08
two O 0 9.266923939321714e-08
others O 0 2.89404596287568e-07
are O 0 2.1575232267423416e-07
compound O 0 2.8410177037585527e-05
heterozygotes O 0 0.0002565821341704577
. O 0 1.5424246157635935e-05

To O 0 2.278141437273007e-05
determine O 0 6.024175036145607e-06
if O 0 7.134413522180694e-07
the O 0 4.317966499911563e-07
occurrence O 0 1.6951690895439242e-06
of O 0 2.310359832335962e-07
4003delTC O 0 1.300385338254273e-05
in O 0 5.155405915502342e-07
these O 0 1.0955653806377086e-07
unrelated O 0 1.1527213246154133e-06
families O 0 2.2246203457143565e-07
signifies O 0 9.021073310577776e-07
propagation O 0 1.3758033219346544e-06
of O 0 7.06096585645355e-08
an O 0 1.7107424810092198e-07
ancestral O 0 4.949065896653337e-06
allele O 0 8.346412869286723e-06
or O 0 4.2540844447103154e-07
a O 0 1.0790345186251216e-06
mutational O 0 7.191230542957783e-05
hot O 0 1.4280054529081099e-05
spot O 0 4.13782481700764e-06
, O 0 2.768545357412222e-07
haplotypes O 0 4.016005732410122e-06
were O 0 2.43655449594371e-07
determined O 0 4.610689074979746e-07
for O 0 2.1041260822585173e-07
polymorphisms O 0 4.803758656635182e-06
both O 0 4.060809146722022e-07
within O 0 1.0028707038145512e-06
and O 0 2.777576355583733e-06
flanking O 0 0.0014020062517374754
COL17A1 O 0 0.13406617939472198
. O 0 6.48364657536149e-05

Five O 0 9.027298801811412e-05
intragenic O 0 0.0011076206574216485
polymorphisms O 0 0.00022497979807667434
were O 0 2.169710796806612e-06
chosen O 0 1.0936994385701837e-06
based O 0 7.999647664291842e-07
on O 0 6.670088055216183e-07
their O 0 1.7368737417200464e-06
informativeness O 0 0.0007544114487245679
. O 0 2.294686419190839e-05

One O 0 3.6833139347436372e-06
of O 0 3.1807277878215245e-07
these O 0 1.1378755004898267e-07
, O 0 7.416303304808025e-08
not O 0 6.441393196610079e-08
previously O 0 6.415883717636461e-07
reported O 0 6.138283424661495e-06
, O 0 2.3530310500063933e-07
was O 0 4.285882369003957e-06
2988 O 0 7.851823283999693e-06
A O 0 5.563902959693223e-06
or O 0 1.7406678125553299e-06
C O 0 7.3608039201644715e-06
that O 0 1.183544142691062e-07
introduces O 0 9.582088296156144e-07
a O 0 3.426298746944667e-07
new O 0 5.734834189752291e-07
restriction O 0 1.7768995803635335e-06
site O 0 1.7096689362006146e-06
for O 0 6.186445489220205e-07
Eco0109 O 0 6.738784577464685e-05
I O 0 2.9078226361889392e-05
. O 0 1.5138991329877172e-05

All O 0 7.700514288444538e-06
the O 0 6.025508355378406e-06
4003delTC O 0 0.00010804729390656576
alleles O 0 2.867105467885267e-05
showed O 0 4.010165412182687e-06
the O 0 6.188262773321185e-07
same O 0 9.91951878859254e-07
haplotype O 0 4.436315066413954e-05
for O 0 3.3818659517237393e-07
these O 0 3.452417161042831e-07
five O 0 1.695840182946995e-06
polymorphic O 0 0.0001459677587263286
markers O 0 0.0001671274658292532
. O 0 4.3535383156267926e-05

Fourteen O 0 0.0001342924078926444
microsatellite O 0 0.0010004214709624648
polymorphisms O 0 0.0001763275358825922
were O 0 1.5322744957302348e-06
selected O 0 6.667117986580706e-07
based O 0 5.515098564501386e-07
on O 0 2.759603887625417e-07
their O 0 2.536860392865492e-07
high O 0 2.5031577024492435e-06
heterozygosity O 0 1.2696083103946876e-05
and O 0 2.0576300130414893e-07
their O 0 2.530604490402766e-07
location O 0 1.6692811186658219e-06
within O 0 1.1177760370628675e-06
10q23 O 0 3.2875181204872206e-05
- O 0 4.704134335042909e-05
q25 O 0 6.481914897449315e-05
near O 0 5.328869156073779e-05
COL17A1 O 0 0.0012747413711622357
. O 0 4.426962914294563e-05

Three O 0 1.816865915316157e-05
families O 0 1.2970512216270436e-05
shared O 0 1.8890383216785267e-05
microsatellite O 0 0.0005229627713561058
polymorphisms O 0 9.231841977452859e-05
covering O 0 9.489252988714725e-06
at O 0 1.3969957990411785e-06
most O 0 2.1068046862637857e-07
19 O 0 7.662097800675838e-07
cM O 0 2.5301148980361177e-06
, O 0 1.5215162818549288e-07
whereas O 0 2.9520856514864136e-07
the O 0 1.4813926441092917e-07
others O 0 2.544376229707268e-07
shared O 0 2.632524171986006e-07
smaller O 0 4.008901441920898e-07
regions O 0 1.8662336742636398e-07
consistent O 0 3.236015970742301e-07
with O 0 1.0631796953930461e-07
cross O 0 1.1559425274754176e-06
- O 0 7.3035080276895314e-06
over O 0 1.594795548953698e-07
events O 0 1.1714992353972775e-07
during O 0 3.2665386129338003e-07
passage O 0 3.7551799891843984e-07
of O 0 7.207018626331774e-08
this O 0 1.6551838655232132e-07
mutation O 0 1.7750940060068388e-06
through O 0 2.9233135023787327e-07
several O 0 8.731358889235707e-07
generations O 0 1.258420707017649e-05
. O 0 1.4610830476158299e-05

These O 0 8.96129131433554e-06
results O 0 4.300366981624393e-06
indicate O 0 2.4704115730855847e-06
that O 0 3.725544672761316e-07
4003delTC O 0 1.3835920071869623e-05
occurs O 0 6.722011676174589e-07
on O 0 4.427502631187963e-07
a O 0 1.1740216905309353e-06
single O 0 3.057469484701869e-06
ancestral O 0 4.937045378028415e-05
allele O 0 7.438848115270957e-05
. O 0 2.933931227744324e-06
. O 0 7.607005954923807e-06

The O 0 0.0001655482337810099
haptoglobin O 0 0.004241158254444599
- O 0 0.0008463833946734667
gene O 0 0.00012707841233350337
deletion O 0 9.143651550402865e-05
responsible O 0 1.3988214050186798e-05
for O 0 5.4160377658263315e-06
anhaptoglobinemia B-Disease 0 0.002280508168041706
. O 0 4.241845817887224e-05

We O 0 1.3135536391928326e-05
have O 0 1.3258508033686667e-06
found O 0 7.983262548805214e-07
an O 0 4.783100848726463e-07
allelic O 0 1.7712669432512484e-05
deletion O 0 8.612488272774499e-06
of O 0 3.055511683669465e-07
the O 0 1.15087925678381e-06
haptoglobin O 0 0.00016826418868731707
( O 0 2.395343926764326e-06
Hp O 0 1.9533576050889678e-05
) O 0 3.722287829077686e-07
gene O 0 8.314297019751393e-07
from O 0 1.3203475646150764e-07
an O 0 1.2224712975239527e-07
individual O 0 3.15713123200112e-07
with O 0 2.566455805208534e-06
anhaptoglobinemia B-Disease 0 0.0014547995524480939
. O 0 3.6687652027467266e-05

The O 0 3.3034961234079674e-05
Hp O 0 0.0002102670696331188
gene O 0 2.086238055198919e-05
cluster O 0 6.524986474687466e-06
consists O 0 5.918220722378464e-07
of O 0 1.7077903180506837e-07
coding O 0 3.7053125652164454e-06
regions O 0 3.788561286910408e-07
of O 0 6.709484523526044e-08
the O 0 2.3086793987658893e-07
alpha O 0 2.577080749688321e-06
chain O 0 8.133795745379757e-06
and O 0 4.5186089892013115e-07
beta O 0 1.3966349570182501e-06
chain O 0 2.2463004825112876e-06
of O 0 9.064090278343429e-08
the O 0 5.902213047193072e-07
haptoglobin O 0 5.789980059489608e-05
gene O 0 6.575949100806611e-06
( O 0 9.424944096281251e-07
Hp O 0 9.546539331495296e-06
) O 0 1.4811158166594396e-07
and O 0 3.62574894552381e-08
of O 0 3.557750716254304e-08
the O 0 1.7534489415993448e-07
alpha O 0 1.4555872667187941e-06
chain O 0 2.9512934816011693e-06
and O 0 1.6157039794961747e-07
beta O 0 9.424314839634462e-07
chain O 0 1.346989279227273e-06
of O 0 9.671318679238539e-08
the O 0 5.909118385716283e-07
haptoglobin O 0 7.713772356510162e-05
- O 0 6.85751365381293e-05
related O 0 4.475427431316348e-06
gene O 0 1.0557030691416003e-05
( O 0 1.4154758218865027e-06
Hpr O 0 2.6883533791988157e-05
) O 0 4.129890953663562e-07
, O 0 1.1875555827600692e-07
in O 0 1.7394847873219987e-07
tandem O 0 3.956584350817138e-06
from O 0 2.5286720983785926e-07
the O 0 4.603632532962365e-07
5 O 0 1.575078044879774e-06
side O 0 1.0660957741492894e-05
. O 0 1.1173753591720015e-05

Southern O 0 0.0002729299885686487
blot O 0 0.0028593007009476423
and O 0 1.3669799045601394e-05
PCR O 0 0.0003281537792645395
analyses O 0 1.3578719517681748e-05
have O 0 5.617190481643775e-07
indicated O 0 1.8697480754781282e-06
that O 0 7.64425465149543e-08
the O 0 7.701799376036433e-08
individual O 0 4.3259991144850574e-08
with O 0 9.56975370058899e-08
anhaptoglobinemia B-Disease 0 7.426267984556034e-05
was O 0 6.201529686222784e-06
homozygous O 0 1.3006194876652444e-06
for O 0 2.8150244801850022e-08
the O 0 1.3815079569212685e-07
gene O 0 9.633150739318808e-07
deletion O 0 1.4584775271941908e-06
and O 0 6.70151649728723e-08
that O 0 3.664942482828337e-08
the O 0 1.2954645001173049e-07
gene O 0 1.2985991588720935e-06
deletion O 0 2.2268500288191717e-06
was O 0 1.037324295793951e-06
included O 0 8.43238581182959e-08
at O 0 1.1025627344452005e-07
least O 0 5.8822312354323e-08
from O 0 8.558350828025141e-08
the O 0 2.27822511078557e-07
promoter O 0 5.192776370677166e-06
region O 0 6.907456508997711e-07
of O 0 1.6412478487382032e-07
Hp O 0 2.3581564164487645e-05
to O 0 7.230120786516636e-07
Hpr O 0 2.0921552277286537e-05
alpha O 0 2.373959887336241e-06
but O 0 2.0460164762425848e-07
not O 0 1.9308106402604608e-07
to O 0 6.474829774560931e-07
Hpr O 0 0.0001218762481585145
beta O 0 2.0602563381544314e-05
( O 0 5.865437287866371e-06
Hpdel O 0 8.118325786199421e-05
) O 0 6.541141829075059e-06
. O 0 1.1360477401467506e-05

In O 0 1.0599026609270368e-05
addition O 0 2.2496942619909532e-06
, O 0 3.992248025497247e-07
we O 0 8.967158038331036e-08
found O 0 7.442007898816883e-08
seven O 0 7.025500536883555e-08
individuals O 0 2.2632519858234446e-08
with O 0 6.895636062154153e-08
hypohaptoglobinemia B-Disease 0 1.8300834199180827e-05
in O 0 1.5196718550214428e-07
three O 0 1.1708312541713894e-07
families O 0 1.3332896742213052e-07
, O 0 5.945884495872633e-08
and O 0 3.365283163248023e-08
the O 0 1.3612327620649012e-07
genotypes O 0 1.1344411632308038e-06
of O 0 1.990744458169047e-08
six O 0 3.234954348840802e-08
of O 0 1.4046018570468277e-08
the O 0 5.124421775803967e-08
seven O 0 9.240307718982876e-08
individuals O 0 3.350258381829008e-08
were O 0 1.1916375086684639e-07
found O 0 2.0319826887771342e-07
to O 0 3.711926410687738e-07
be O 0 1.3873795978724957e-06
Hp2 O 0 0.0006487734499387443
/ O 0 0.0014090267941355705
Hpdel O 0 0.0008351348224096
. O 0 3.473212564131245e-05

The O 0 4.076892219018191e-05
phenotypes O 0 0.0005376288900151849
and O 0 6.733979262207868e-06
genotypes O 0 5.495783261721954e-05
in O 0 5.394718982643099e-07
one O 0 8.191863543061118e-08
of O 0 2.797025544509779e-08
these O 0 3.6538445158385e-08
three O 0 4.183108970323701e-08
families O 0 7.738050555872178e-08
showed O 0 3.4987277786058257e-07
the O 0 2.135757597443444e-07
father O 0 7.260479378601303e-06
to O 0 2.657785387327749e-07
be O 0 2.766236093521002e-07
hypohaptoglobinemic B-Disease 0 1.920422255352605e-05
( O 0 7.534127917097067e-07
Hp2 O 0 7.00958435118082e-06
) O 0 1.834674066003572e-07
and O 0 2.0277028056625568e-07
Hp2 O 0 6.583475624211133e-05
/ O 0 5.9281312132952735e-05
Hpdel O 0 1.4356920473801438e-05
, O 0 1.0288056984109062e-07
the O 0 2.1893309565257368e-07
mother O 0 4.397055818117224e-06
to O 0 1.6177777695247642e-07
be O 0 1.5969459354892024e-07
Hp2 O 0 7.940688192320522e-06
- O 0 3.0197347768989857e-06
1 O 0 2.6216108039989194e-07
and O 0 3.5324222835697583e-07
Hp1 O 0 8.638126746518537e-05
/ O 0 0.00013648798631038517
Hp2 O 0 1.0741006008174736e-05
, O 0 4.0641019438680814e-08
one O 0 9.496599062686073e-09
of O 0 7.191142348261792e-09
the O 0 3.533472536787485e-08
two O 0 5.714852235882972e-08
children O 0 1.203779191882859e-07
to O 0 1.2825618966871843e-07
be O 0 3.4578178542687965e-07
hypohaptoglobinemic B-Disease 0 5.1042639825027436e-05
( O 0 7.039771503514203e-07
Hp2 O 0 1.3586803106591105e-05
) O 0 3.7079811932017037e-07
and O 0 3.472573268936685e-07
Hp2 O 0 7.000122423050925e-05
/ O 0 6.796797242714092e-05
Hpdel O 0 1.8346428987570107e-05
, O 0 8.377799076697556e-08
and O 0 4.257688601683185e-08
the O 0 7.271888335935728e-08
other O 0 6.929308682401825e-08
child O 0 4.280994403416116e-07
to O 0 1.3897536632612173e-07
be O 0 1.6488048970586533e-07
Hp1 O 0 7.088248821673915e-06
and O 0 8.287665878015105e-07
Hp1 O 0 0.0001609606115380302
/ O 0 0.00011448860459495336
Hpdel O 0 2.6741930923890322e-05
, O 0 1.355196701524619e-07
showing O 0 5.730541943194112e-07
an O 0 1.987200022313118e-07
anomalous O 0 1.4419914805330336e-05
inheritance O 0 5.4119177548273e-06
of O 0 4.146019136896939e-07
Hp O 0 0.00046521020703949034
phenotypes O 0 2.6650075596990064e-05
in O 0 6.612093557123444e-07
the O 0 1.2718422794932849e-06
child O 0 7.928625564090908e-06
with O 0 4.0833360799297225e-06
Hp1 O 0 0.001124083180911839
. O 0 3.016565642610658e-05

The O 0 4.608812741935253e-05
Hp2 O 0 0.0013318685814738274
/ O 0 0.00036532903322950006
Hpdel O 0 0.00013743560703005642
individuals O 0 6.651761736975459e-07
had O 0 1.6212620721489657e-06
an O 0 3.213982893157663e-07
extremely O 0 3.3031355997081846e-06
low O 0 2.4114940515573835e-06
level O 0 5.903225996917172e-07
of O 0 3.797314604980784e-07
Hp O 0 6.238310743356124e-05
( O 0 1.5836000102353864e-06
mean O 0 1.5224889011733467e-06
+ O 0 1.036384765029652e-05
/ O 0 5.7822111557470635e-05
- O 0 4.151447137701325e-05
SD O 0 0.0005169498035684228
= O 0 1.3982987184135709e-05
0 O 0 3.123575879726559e-06
. O 0 9.980790309782606e-07
049 O 0 0.0001265375321963802
+ O 0 2.3763635908835568e-05
/ O 0 3.86395440727938e-05
- O 0 1.329783844994381e-05
0 O 0 2.6685645480029052e-06
. O 0 1.5097866707947105e-06
043 O 0 0.00014854443725198507
mg O 0 0.4055555462837219
/ O 0 0.003274157177656889
ml O 0 0.00032469298457726836
; O 0 1.2566750910991686e-06
n O 0 4.181859367236029e-06
= O 0 1.2116333891754039e-06
6 O 0 3.26274687267869e-07
) O 0 1.0572788511353792e-07
, O 0 2.970577384076023e-08
compared O 0 7.100645404989336e-08
with O 0 2.4683805222025512e-08
the O 0 1.2555329931274173e-07
level O 0 2.751483521024056e-07
( O 0 1.642115279310019e-07
1 O 0 1.1578111269727742e-07
. O 0 8.188708022771607e-08
64 O 0 1.024620360112749e-06
+ O 0 6.784354809497017e-06
/ O 0 2.4496759579051286e-05
- O 0 3.7524878280237317e-06
1 O 0 4.816056389245205e-07
. O 0 3.6494847677204234e-07
07 O 0 2.373269853706006e-05
mg O 0 0.0758935883641243
/ O 0 0.0005195023841224611
ml O 0 7.990660378709435e-05
) O 0 2.919719293004164e-07
obtained O 0 3.6427945815376006e-07
from O 0 2.2936379195925838e-07
52 O 0 1.1986714980594115e-06
healthy O 0 1.2063343319823616e-06
volunteers O 0 1.1116698033220018e-06
having O 0 1.8125592760043219e-06
phenotype O 0 6.318718078546226e-05
Hp2 O 0 3.675572952488437e-05
, O 0 2.2662806031803484e-07
whereas O 0 4.451015911399736e-07
the O 0 3.1565534186484e-07
serum O 0 1.3311490874912124e-05
Hp O 0 6.172434950713068e-06
level O 0 1.9369743142760854e-07
of O 0 3.588220209849169e-08
an O 0 6.938751795360076e-08
individual O 0 8.831317899193891e-08
with O 0 6.20952107510675e-07
Hp1 O 0 0.00423480523750186
/ O 0 0.0033388216979801655
Hpdel O 0 0.00039667560486122966
was O 0 4.803315096069127e-05
0 O 0 1.7430167645215988e-05
. O 0 1.2412278010742739e-05

50 O 0 0.0001475891622249037
mg O 1 0.9430114030838013
/ O 0 0.24977771937847137
ml O 0 0.008626396767795086
, O 0 5.471141548696323e-07
which O 0 2.6954023724101717e-07
was O 0 3.62866899195069e-07
approximately O 0 1.1375824726655992e-07
half O 0 9.831904890234e-08
the O 0 6.141088704225695e-08
level O 0 1.0514367687619597e-07
of O 0 6.217556602905461e-08
Hp O 0 1.1021461432392243e-05
in O 0 5.67747747481917e-07
control O 0 2.7383986889617518e-05
sera O 0 3.2241125154541805e-05
from O 0 3.101386027992703e-07
the O 0 5.794703952233249e-07
Hp1 O 0 0.00017492668121121824
phenotype O 0 0.0002992118534166366
( O 0 9.56426788434328e-07
1 O 0 4.698023019500397e-07
. O 0 2.657243101111817e-07
26 O 0 1.9020671970793046e-06
+ O 0 1.0613532140268944e-05
/ O 0 2.8909838874824345e-05
- O 0 5.269176199362846e-06
0 O 0 6.057371138012968e-07
. O 0 2.0611159357031283e-07
33 O 0 2.4947764813987305e-06
mg O 0 0.2928431034088135
/ O 0 0.038019560277462006
ml O 0 0.0010381810134276748
; O 0 1.6738307522246032e-06
n O 0 5.923386197537184e-06
= O 0 2.9993454973009648e-06
9 O 0 7.981511203070113e-07
) O 0 2.1900764579640963e-07
, O 0 7.236965160473119e-08
showing O 0 6.081026526771893e-07
a O 0 1.9495387277856935e-06
gene O 0 2.3460708689526655e-05
- O 0 0.00021244894014671445
dosage O 0 0.00033773784525692463
effect O 0 4.1805276850936934e-05
. O 0 1.668706136115361e-05

The O 0 1.5608125977450982e-05
other O 0 2.5218473638233263e-06
allele O 0 3.8059090002207085e-05
( O 0 2.0621769181161653e-06
Hp2 O 0 1.720715590636246e-05
) O 0 3.233961649584671e-07
of O 0 5.0215312796808576e-08
individuals O 0 5.246824130722416e-08
with O 0 2.2593815174332121e-07
Hp2 O 0 0.002260666573420167
/ O 0 0.009082585573196411
Hpdel O 0 0.00026292676921002567
was O 0 4.382358747534454e-05
found O 0 2.2503112973026873e-07
to O 0 7.41061967346468e-08
have O 0 5.0205446910922547e-08
, O 0 3.032901219057749e-08
in O 0 4.021821098376677e-08
all O 0 3.3040599589639896e-08
exons O 0 1.383378958053072e-06
, O 0 1.125117705669254e-07
no O 0 1.7247289463284687e-07
mutation O 0 1.167763002740685e-06
, O 0 1.2342654542862874e-07
by O 0 3.876958203363756e-07
DNA O 0 8.371731382794678e-06
sequencing O 0 2.364831743761897e-05
. O 0 1.3304053936735727e-05

On O 0 1.0029300028691068e-05
the O 0 6.350679768729606e-07
basis O 0 2.0292367253205157e-07
of O 0 5.121705370925156e-08
the O 0 1.3992570302434615e-07
present O 0 2.5238969669771905e-07
study O 0 1.1530134713666484e-07
, O 0 3.106767465510529e-08
the O 0 5.8290126503379724e-08
mechanism O 0 2.0106301690248074e-07
of O 0 5.4313929354066204e-08
anhaptoglobinemia B-Disease 0 1.014068129734369e-05
and O 0 9.35390289669158e-08
the O 0 9.852422522271809e-08
mechanism O 0 4.6876800752215786e-07
of O 0 1.242982961002781e-07
anomalous O 0 1.3477791981131304e-05
inheritance O 0 3.6902968076901743e-06
of O 0 3.7690253407163254e-07
Hp O 0 0.007029792293906212
phenotypes O 0 9.741944813868031e-05
were O 0 1.9999984033347573e-06
well O 0 2.463001692376565e-06
explained O 0 1.8771572285913862e-05
. O 0 1.0135498996532988e-05

However O 0 2.9616261599585414e-05
, O 0 1.266868139282451e-06
the O 0 5.719873001908127e-07
mechanism O 0 2.59680996350653e-06
of O 0 1.1671227184706368e-06
hypohaptoglobinemia B-Disease 0 0.00046361624845303595
remains O 0 4.3465523049235344e-05
unknown O 0 0.00010004683281295002

ATM O 0 0.014661524444818497
mutations O 0 0.0028332138899713755
and O 0 4.12610788771417e-05
phenotypes O 0 0.002202856121584773
in O 0 0.00040868931682780385
ataxia B-Disease 1 1.0
- I-Disease 1 0.999987006187439
telangiectasia I-Disease 1 0.999998927116394
families O 0 3.311680075057666e-06
in O 0 4.430632429830439e-07
the O 0 5.542966050597897e-07
British O 0 2.7956821213592775e-05
Isles O 0 3.903918695868924e-05
: O 0 2.55320458109054e-07
expression O 0 2.5708260409373906e-07
of O 0 8.104057513946827e-08
mutant O 0 3.1989363833417883e-06
ATM O 0 4.102442289877217e-06
and O 0 1.5097377570327808e-07
the O 0 2.8137799290561816e-07
risk O 0 9.303171850660874e-07
of O 0 9.198795964948658e-07
leukemia B-Disease 1 0.9999220371246338
, O 0 0.008578588254749775
lymphoma B-Disease 1 1.0
, O 0 4.286789408070035e-05
and O 0 0.06760299950838089
breast B-Disease 1 0.9999951124191284
cancer I-Disease 1 0.994575023651123
. O 0 4.3626150727504864e-05

We O 0 1.1774330232583452e-05
report O 0 7.012058631516993e-06
the O 0 7.627802460774546e-07
spectrum O 0 3.927748821297428e-06
of O 0 4.2594024307618383e-07
59 O 0 5.508168214873876e-06
ATM O 0 0.000657280907034874
mutations O 0 8.312217687489465e-05
observed O 0 1.2151328519394156e-05
in O 0 5.785884786746465e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999967813491821
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00010184520942857489
A B-Disease 1 0.9999260902404785
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
) O 0 5.096776021673577e-06
patients O 0 1.7824086171458475e-06
in O 0 2.6538242536844336e-07
the O 0 1.486925725657784e-06
British O 0 0.00015837336832191795
Isles O 0 0.001083520008251071
. O 0 2.7932839657296427e-05

Of O 0 1.3384469639277086e-05
51 O 0 3.371017737663351e-05
ATM O 0 0.00022612347675021738
mutations O 0 3.166271199006587e-05
identified O 0 1.7398263025825145e-06
in O 0 4.087287663878669e-07
families O 0 2.543359869378037e-07
native O 0 1.933943423182427e-07
to O 0 1.1884539929951643e-07
the O 0 3.018502923168853e-07
British O 0 2.38446536968695e-05
Isles O 0 3.046577148779761e-05
, O 0 1.6811129910365707e-07
11 O 0 3.553068950168381e-07
were O 0 2.8249328920537664e-07
founder O 0 2.3281558242160827e-05
mutations O 0 2.6584850729705067e-06
, O 0 5.261917479515432e-08
and O 0 5.34915578498385e-08
2 O 0 7.217941089265878e-08
of O 0 1.921977066388081e-08
these O 0 4.591942470710819e-08
11 O 0 2.7143545366925537e-07
conferred O 0 2.1313189790816978e-06
a O 0 1.0110899893334135e-05
milder O 1 0.6448344588279724
clinical O 0 0.0010138804791495204
phenotype O 0 0.0012115210993215442
with O 0 4.811213329958264e-07
respect O 0 3.2901311897148844e-07
to O 0 8.438610166194849e-07
both O 0 4.816226464754436e-06
cerebellar B-Disease 1 0.9813269972801208
degeneration I-Disease 1 0.9631218314170837
and O 0 6.8828894654870965e-06
cellular O 0 0.00015620053454767913
features O 0 6.642526568612084e-05
. O 0 3.853209636872634e-05

We O 0 2.4536177079426125e-05
report O 0 1.5353829439845867e-05
, O 0 4.3243991854069463e-07
in O 0 1.7621172787585238e-07
two O 0 2.127731448808845e-07
A B-Disease 1 0.9875603318214417
- I-Disease 1 0.9999511241912842
T I-Disease 1 0.9999886751174927
families O 0 2.855339005236601e-07
, O 0 8.754757629958476e-08
an O 0 2.6078737391799223e-07
ATM O 0 0.00010170361201744527
mutation O 0 1.125376729760319e-05
( O 0 1.1008077080987277e-06
7271T O 0 1.906273973872885e-05
- O 0 0.0002916716621257365
- O 0 0.00015858764527365565
> O 0 1.5384301150334068e-05
G O 0 0.00010831446707015857
) O 0 2.666600664724683e-07
that O 0 1.6339545538812672e-07
may O 0 1.4137368680167128e-06
be O 0 4.714962642538012e-08
associated O 0 1.1852892356500888e-07
with O 0 4.069694981012617e-08
an O 0 1.0852269838323991e-07
increased O 0 1.4191658692652709e-06
risk O 0 1.0389439921709709e-06
of O 0 8.927955263970944e-07
breast B-Disease 1 0.997623860836029
cancer I-Disease 0 0.04497084021568298
in O 0 7.372954087259131e-07
both O 0 1.3787612260784954e-06
homozygotes O 0 7.875297160353512e-05
and O 0 2.525235913708457e-06
heterozygotes O 0 7.70468614064157e-05
( O 0 1.7252173165616114e-06
relative O 0 2.862252131308196e-06
risk O 0 1.3069694659861852e-06
12 O 0 3.6589710816770094e-07
. O 0 1.7947155583897256e-07
7 O 0 2.3239444999489933e-06
; O 0 2.9398745482467348e-06
P O 0 0.002827119082212448
= O 0 6.511863375635585e-06
. O 0 3.766725455989217e-07
0025 O 0 4.70420163765084e-05
) O 0 2.995944043959753e-07
, O 0 6.238249028456266e-08
although O 0 7.15231109893466e-08
there O 0 4.200690995048717e-08
is O 0 4.3695106199947986e-08
a O 0 5.956241579951893e-07
less O 0 1.8665359675651416e-06
severe O 1 0.9098881483078003
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.021304704248905182
in O 0 3.118894653653115e-07
terms O 0 1.3457062664201658e-07
of O 0 3.288511862820087e-08
the O 0 2.4461328962388507e-07
degree O 0 2.739449882938061e-06
of O 0 8.187361345335376e-06
cerebellar B-Disease 1 0.9998840093612671
degeneration I-Disease 1 0.9999635219573975
. O 0 0.00013723027950618416

This O 0 5.7313871366204694e-05
mutation O 0 0.00016682877321727574
( O 0 1.3343723367142957e-05
7271T O 0 0.00016174941265489906
- O 0 0.0009765750728547573
- O 0 0.00022081825591158122
> O 0 1.3575599950854667e-05
G O 0 7.550072041340172e-05
) O 0 4.6752060711696686e-07
also O 0 1.8671950385851233e-07
allows O 0 1.6959324966592249e-07
expression O 0 1.80313563191703e-07
of O 0 3.2722439868848596e-08
full O 0 3.68175449239061e-07
- O 0 1.9392286958463956e-06
length O 0 4.7360262556139787e-07
ATM O 0 5.326052814780269e-06
protein O 0 6.302412316472328e-07
at O 0 1.3992610092827817e-07
a O 0 1.754271750087355e-07
level O 0 1.9264477657543466e-07
comparable O 0 3.9439649412997824e-07
with O 0 1.347606968238324e-07
that O 0 2.315682507969541e-07
in O 0 1.1108051012342912e-06
unaffected O 0 5.00576279591769e-05
individuals O 0 1.806123123060388e-06
. O 0 1.0624803508108016e-05

In O 0 1.6022035197238438e-05
addition O 0 2.379299985477701e-06
, O 0 2.76084620054462e-07
we O 0 7.532979395818984e-08
have O 0 7.684587188805381e-08
studied O 0 3.735103746294044e-07
18 O 0 1.2839292367061717e-06
A B-Disease 1 0.9999027252197266
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.8463977287174203e-05
, O 0 1.0065676292470016e-07
in O 0 1.3062425807675027e-07
15 O 0 2.464290957959747e-07
families O 0 1.8189874140261963e-07
, O 0 2.469191144882643e-07
who O 0 5.370872713683639e-06
developed O 1 0.7809043526649475
leukemia B-Disease 1 0.9999961853027344
, O 0 0.017688777297735214
lymphoma B-Disease 1 1.0
, O 0 1.0986516826960724e-05
preleukemic O 0 0.11714258044958115
T O 0 0.18482500314712524
- O 0 0.00026794150471687317
cell O 0 0.00010559739894233644
proliferation O 0 2.283731555507984e-05
, O 0 1.8380135315965163e-06
or O 0 0.0034023411571979523
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.3699287819690653e-06
mostly O 0 7.051315265016456e-07
in O 0 5.25459381606197e-06
childhood O 0 0.000798988388851285
. O 0 3.8004651287337765e-05

A O 0 7.620712858624756e-05
wide O 0 1.4224993719835766e-05
variety O 0 2.5806073153944453e-06
of O 0 5.534857336897403e-07
ATM O 0 0.00010483048390597105
mutation O 0 1.0417266821605153e-05
types O 0 5.788015187135898e-07
, O 0 2.161250591825592e-07
including O 0 3.597300235469447e-07
missense O 0 0.00010981360537698492
mutations O 0 1.0886496056627948e-05
and O 0 3.105885184595536e-07
in O 0 7.708925409133371e-07
- O 0 5.4134379752213135e-05
frame O 0 0.00031928421230986714
deletions O 0 1.0405412467662245e-05
, O 0 2.7187536488781916e-07
were O 0 2.5126431069111277e-07
seen O 0 7.22937613772956e-07
in O 0 5.931261171099322e-07
these O 0 9.354996564070461e-07
patients O 0 2.8140317226643674e-05
. O 0 1.3019252946833149e-05

We O 0 1.2462995073292404e-05
also O 0 1.7822217159846332e-06
show O 0 6.797908440603351e-07
that O 0 1.0030642272340629e-07
25 O 0 2.1299585739598115e-07
% O 0 5.363213162468128e-08
of O 0 3.070092091661536e-08
all O 0 1.1758734785871638e-07
A B-Disease 1 0.9998972415924072
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.4927372831152752e-05
carried O 0 2.2840974907012424e-06
in O 0 4.917920364277961e-07
- O 0 2.3862194211687893e-05
frame O 0 5.765077003161423e-05
deletions O 0 1.069698828359833e-05
or O 0 1.1162665032316e-06
missense O 0 3.342422496643849e-05
mutations O 0 4.984158294973895e-06
, O 0 6.515321615552239e-08
many O 0 1.1391399823423853e-08
of O 0 1.351676282013159e-08
which O 0 2.014895272850481e-07
were O 0 2.4519997054994747e-07
also O 0 3.1739344308334694e-07
associated O 0 2.656343838225439e-07
with O 0 9.254753052800879e-08
expression O 0 3.3428801771151484e-07
of O 0 3.428714308029157e-07
mutant O 0 3.38374957209453e-05
ATM O 0 8.736825839150697e-05
protein O 0 2.9406926842057146e-05
. O 0 1.6895903172553517e-05

The O 0 6.638157356064767e-05
DMPK O 0 0.001241161022335291
gene O 0 9.838616824708879e-05
of O 0 1.2390303709253203e-05
severely O 1 0.9994719624519348
affected O 1 0.8995769619941711
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9114990830421448
is O 0 1.2458122910175007e-05
hypermethylated O 0 0.007484273985028267
proximal O 0 0.0011172184022143483
to O 0 1.68435440173198e-06
the O 0 1.332346755589242e-06
largely O 0 5.885389782633865e-06
expanded O 0 3.9671638660365716e-05
CTG O 0 0.0007547590648755431
repeat O 0 0.00012511087697930634
. O 0 3.3530504879308864e-05

Using O 0 9.4425784482155e-05
methylation O 0 0.00015004513261374086
- O 0 0.00011149360216222703
sensitive O 0 1.1501999324536882e-05
restriction O 0 4.725009603134822e-06
enzymes O 0 2.9210552838776493e-06
, O 0 1.5363407612767332e-07
we O 0 6.990985923494009e-08
characterized O 0 6.083143944124458e-07
the O 0 1.382522754056481e-07
methylation O 0 1.3604259265775909e-06
pattern O 0 2.1396219835878583e-06
on O 0 2.301929811210357e-07
the O 0 1.0407383399524406e-07
5 O 0 1.041961965597693e-07
side O 0 1.4460457009590755e-07
of O 0 2.6237511718818496e-08
the O 0 3.4773850643432525e-07
CTG O 0 6.110445247031748e-05
repeat O 0 1.750976934999926e-06
in O 0 1.784441536756276e-07
the O 0 2.7572048111323966e-07
DMPK O 0 1.7019876395352185e-05
gene O 0 9.145063017967914e-07
of O 0 6.439870503527345e-08
normal O 0 5.516945407180174e-07
individuals O 0 5.2196249100688874e-08
and O 0 7.27934050814838e-08
of O 0 1.944460734648601e-07
patients O 0 1.5239170352288056e-05
affected O 0 5.820219030283624e-06
with O 0 0.011134832166135311
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.3174776490341173e-06
showing O 0 5.95783149037743e-06
expansions O 0 6.14997179582133e-06
of O 0 2.798990124119882e-07
the O 0 1.4456267081186525e-06
repetitive O 0 0.00012320809764787555
sequence O 0 2.5139874196611345e-05
. O 0 2.0569248590618372e-05

The O 0 3.3142561733257025e-05
gene O 0 8.122369035845622e-05
segment O 0 2.7307451091473922e-05
analyzed O 0 1.295429410674842e-05
corresponds O 0 3.471305717539508e-06
to O 0 1.013953010442492e-06
the O 0 1.919868736877106e-06
genomic O 0 2.601802407298237e-05
SacI O 0 0.0001908247941173613
- O 0 2.916810080932919e-05
HindIII O 0 2.5822326279012486e-05
fragment O 0 6.621699412789894e-06
carrying O 0 2.4901789856812684e-06
exons O 0 1.3912635040469468e-05
11 O 0 4.696984433394391e-06
- O 0 2.5501787604298443e-05
15 O 0 9.978144589695148e-06
. O 0 1.4102563909546006e-05

There O 0 1.671856989560183e-05
is O 0 2.7283351755613694e-06
constitutive O 0 2.5198971343343146e-05
methylation O 0 2.3888080249889754e-05
in O 0 2.109403112626751e-06
intron O 0 7.097235356923193e-05
12 O 0 1.5293766182367108e-06
at O 0 4.893106506642653e-07
restriction O 0 1.158609052254178e-06
sites O 0 2.878485645396722e-07
of O 0 9.001944789588379e-08
SacII O 0 6.746506642230088e-06
and O 0 2.564268584137608e-07
HhaI O 0 1.5746361896162853e-05
, O 0 2.049244471891143e-07
localized O 0 1.7068342685888638e-06
1 O 0 2.1979708719754854e-07
, O 0 8.328630940468429e-08
159 O 0 9.951669426300214e-07
- O 0 4.501203875406645e-06
1 O 0 3.0647657922600047e-07
, O 0 1.1048363290910856e-07
232 O 0 1.078022364708886e-06
bp O 0 2.8494107482401887e-06
upstream O 0 5.732504746447376e-07
of O 0 6.24878779831306e-08
the O 0 3.550775886651536e-07
CTG O 0 4.272733713150956e-05
repeat O 0 2.07572998078831e-06
, O 0 9.474006645859845e-08
whereas O 0 1.4628722055931576e-07
most O 0 3.8226357190751514e-08
, O 0 3.14776862353483e-08
if O 0 2.4770349327241092e-08
not O 0 1.6807611302738223e-08
all O 0 1.033196461719399e-08
, O 0 1.3505887963560781e-08
of O 0 8.763374026443671e-09
the O 0 2.6766382887899454e-08
other O 0 1.8638248278080027e-08
sites O 0 7.010842040244825e-08
of O 0 3.38013670386772e-08
SacII O 0 4.305352831579512e-06
, O 0 1.2352828093753487e-07
HhaI O 0 5.511836207006127e-06
, O 0 9.999180861086643e-08
and O 0 9.200632433703504e-08
HpaII O 0 4.8930269258562475e-06
in O 0 1.3546062405112025e-07
this O 0 6.847430711331981e-08
region O 0 3.058975153180654e-07
are O 0 4.962423005849814e-08
unmethylated O 0 2.848117674147943e-06
, O 0 6.669890950661284e-08
in O 0 7.949616076530219e-08
normal O 0 4.4989110392634757e-07
individuals O 0 4.260117236754013e-08
and O 0 3.3296945645133746e-08
most O 0 3.148441507505595e-08
of O 0 9.784611165741808e-08
the O 0 1.0738055607362185e-05
patients O 0 0.00014126164023764431
. O 0 2.1334430130082183e-05

In O 0 9.982913979911245e-06
a O 0 2.0712850528070703e-06
number O 0 2.29180784572236e-07
of O 0 1.3619872163417313e-07
young O 0 5.904025783820543e-07
and O 0 7.346014172071591e-06
severely O 1 0.9976154565811157
affected O 0 8.582246664445847e-05
patients O 0 1.919221358548384e-05
, O 0 3.513355864015466e-07
however O 0 5.311822519615816e-07
, O 0 9.783267529428485e-08
complete O 0 2.466326805006247e-07
methylation O 0 9.722027698444435e-07
of O 0 6.165841170968633e-08
these O 0 8.086178127086896e-08
restriction O 0 6.475639224845509e-07
sites O 0 4.1127697159026866e-07
was O 0 1.5879493275861023e-06
found O 0 3.518267988056323e-07
in O 0 4.1791696503423736e-07
the O 0 2.0935688098688843e-06
mutated O 0 0.00016798317665234208
allele O 0 0.00023581382993143052
. O 0 2.8215716156410053e-05

In O 0 1.7703701814753003e-05
most O 0 9.220648848895507e-07
of O 0 3.83532210435078e-07
these O 0 4.677868616909109e-07
patients O 0 2.1196312900428893e-06
, O 0 1.4111355994828045e-07
the O 0 3.6696607708108786e-07
onset O 0 8.584603347117081e-05
of O 0 4.004652112143958e-07
the O 0 0.0008560430142097175
disease O 1 0.9995546936988831
was O 1 0.9995577931404114
congenital O 1 0.9999998807907104
. O 0 0.00017600985302124172

Preliminary O 0 0.00011984437151113525
in O 0 4.0380749851465225e-05
vivo O 0 0.0006535925203934312
footprinting O 0 0.0010333891259506345
data O 0 4.195121164229931e-06
gave O 0 8.5792601112189e-07
evidence O 0 2.9178821137065825e-07
for O 0 1.3270584986457834e-07
protein O 0 9.557201110510505e-07
- O 0 5.922493528487394e-06
DNA O 0 1.0780830734802294e-06
contact O 0 1.064672801476263e-06
in O 0 2.4251556851595524e-07
normal O 0 8.024419457797194e-07
genes O 0 6.342145866256033e-07
at O 0 2.4716788971090864e-07
an O 0 2.434640578030667e-07
Sp1 O 0 8.69277664605761e-06
consensus O 0 5.511870426744281e-07
binding O 0 6.043401867827924e-07
site O 0 4.908291657557129e-07
upstream O 0 3.682758631384786e-07
of O 0 3.247900437486351e-08
the O 0 2.703689858662983e-07
CTG O 0 4.361391984275542e-05
repeat O 0 1.804280941541947e-06
and O 0 7.59658007609687e-08
for O 0 3.986506413866664e-08
a O 0 1.774327813564014e-07
significant O 0 1.4791170599437464e-07
reduction O 0 2.2377938080353488e-07
of O 0 2.239215035615416e-08
this O 0 5.03073458446579e-08
interaction O 0 1.417474919662709e-07
in O 0 1.6455217632938002e-07
cells O 0 7.050306862765865e-07
with O 0 2.2093678353485302e-07
a O 0 2.7993130515824305e-06
hypermethylated O 0 0.0006042891182005405
DMPK O 0 0.0017003508983179927
gene O 0 3.751135591301136e-05
. O 0 3.652970917755738e-06
. O 0 1.1338061085552908e-05

The O 0 0.0002677622251212597
hemochromatosis B-Disease 1 0.9999966621398926
gene O 0 0.00017290805408265442
product O 0 1.3655831935466267e-05
complexes O 0 7.129691766749602e-06
with O 0 3.4629957212928275e-07
the O 0 8.507935262969113e-07
transferrin O 0 3.934498818125576e-05
receptor O 0 1.1366111721144989e-05
and O 0 6.364855380525114e-07
lowers O 0 1.9735349269467406e-05
its O 0 6.263829845920554e-07
affinity O 0 2.1475600533449324e-06
for O 0 6.058122039576119e-07
ligand O 0 2.790083635773044e-05
binding O 0 4.064136737724766e-05
. O 0 1.9720000636880286e-05

We O 0 2.4341501557501033e-05
recently O 0 5.2004608733113855e-05
reported O 0 9.61599016591208e-06
the O 0 6.796527713959222e-07
positional O 0 1.2513635738287121e-05
cloning O 0 3.5837001632899046e-06
of O 0 1.7814507202729146e-07
a O 0 2.0337579371698666e-06
candidate O 0 7.851733244024217e-06
gene O 0 2.9133214411558583e-05
for O 0 4.087827983312309e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9750882387161255
HFE O 1 0.9985588192939758
. O 0 0.00018978345906361938

The O 0 1.735483056108933e-05
gene O 0 3.59356272383593e-05
product O 0 2.046638201136375e-06
, O 0 1.6807217662062612e-07
a O 0 2.1609847067338706e-07
member O 0 2.2601896887408657e-07
of O 0 4.67476439780512e-08
the O 0 1.9614633117726044e-07
major O 0 1.0051149956780137e-06
histocompatibility O 0 9.626567043596879e-05
complex O 0 6.342850610963069e-06
class O 0 4.167693532508565e-06
I O 0 4.713474481832236e-06
- O 0 7.1131271397462115e-06
like O 0 8.976244458835936e-08
family O 0 8.689458468325029e-07
, O 0 1.5022234833850234e-07
was O 0 6.096069682826055e-06
found O 0 2.0866271199793118e-07
to O 0 9.210587847974239e-08
have O 0 1.025469273940871e-07
a O 0 1.0906538818744593e-06
mutation O 0 7.2800044108589645e-06
, O 0 1.1307504337310093e-06
Cys O 0 0.0009527780348435044
- O 0 2.0009381842100993e-05
282 O 0 1.4461175851465669e-05
- O 0 0.00011573202209547162
- O 0 9.77110248641111e-05
> O 0 2.3135349692893215e-05
Tyr O 0 8.895071368897334e-05
( O 0 1.7298282273259247e-06
C282Y O 0 7.486371487175347e-06
) O 0 2.654522859302233e-07
, O 0 8.28763617732875e-08
in O 0 1.283388968431609e-07
85 O 0 7.67099550103012e-07
% O 0 2.451897103128431e-07
of O 0 5.674219210050069e-07
patient O 0 0.0001418789615854621
chromosomes O 0 8.704825449967757e-05
. O 0 3.26862427755259e-05

This O 0 3.402832226129249e-05
mutation O 0 7.568077853647992e-05
eliminates O 0 2.38490647461731e-05
the O 0 1.0478686363057932e-06
ability O 0 1.1296240245428635e-06
of O 0 2.3179539709872188e-07
HFE O 0 0.00048718208563514054
to O 0 8.448756148027314e-07
associate O 0 1.5214002360153245e-06
with O 0 5.709425749955699e-07
beta2 O 0 0.003406499046832323
- O 0 0.002490418031811714
microglobulin O 0 0.00037921557668596506
( O 0 1.2856298781116493e-06
beta2m O 0 1.9899827748304233e-05
) O 0 3.272812705290562e-07
and O 0 3.118719291705929e-07
prevents O 0 2.527119704609504e-06
cell O 0 5.5664459068793803e-05
- O 0 6.642698281211779e-05
surface O 0 2.4967421268229373e-05
expression O 0 1.781888204277493e-05
. O 0 2.0343772121123038e-05

A O 0 5.776655598310754e-05
second O 0 1.8526943676988594e-05
mutation O 0 2.018857776420191e-05
that O 0 4.770877808368823e-07
has O 0 3.281901683749311e-07
no O 0 1.5417244014770404e-07
effect O 0 6.038458764123789e-07
on O 0 8.455269266960386e-07
beta2m O 0 7.8401921200566e-05
association O 0 1.0410753930045757e-06
, O 0 2.0097579067623883e-07
H63D O 0 5.874354610568844e-05
, O 0 2.816794903992559e-07
was O 0 4.6443046812782995e-06
found O 0 1.62418089644234e-07
in O 0 5.09428943473722e-08
eight O 0 5.2614957724017586e-08
out O 0 5.283338211370392e-08
of O 0 5.4618730871425214e-08
nine O 0 9.053089797816938e-07
patients O 0 2.8258373276912607e-06
heterozygous O 0 3.3084825190599076e-06
for O 0 2.794328111122013e-07
the O 0 1.4883386256769882e-06
C282Y O 0 0.0001111161764129065
mutant O 0 0.0002031580952461809
. O 0 2.752450564003084e-05

In O 0 1.796803917386569e-05
this O 0 2.7631904231384397e-06
report O 0 4.256135980540421e-06
, O 0 2.2532898924509936e-07
we O 0 7.984383643133697e-08
demonstrate O 0 3.70391717297025e-07
in O 0 3.3132300814031623e-07
cultured O 0 5.382106792239938e-06
293 O 0 1.0317123269487638e-05
cells O 0 1.2795793736586347e-05
overexpressing O 0 9.396077803103253e-05
wild O 0 4.418768185132649e-06
- O 0 5.8610541600501165e-05
type O 0 8.698058991285507e-06
or O 0 9.843798807196436e-07
mutant O 0 1.0550751539994963e-05
HFE O 0 9.965948265744373e-05
proteins O 0 8.741198485040513e-07
that O 0 7.746069030645231e-08
both O 0 1.0080739087925394e-07
the O 0 1.314259776563631e-07
wild O 0 5.667907885253953e-07
- O 0 1.892816180770751e-05
type O 0 5.609339041257044e-06
and O 0 8.892461664800067e-07
H63D O 0 0.0027268270496279
HFE O 0 0.003213691059499979
proteins O 0 2.370389893258107e-06
form O 0 1.1794611509685637e-06
stable O 0 9.328909072792158e-06
complexes O 0 2.8270449092815397e-06
with O 0 4.095477947885229e-07
the O 0 2.2316482954920502e-06
transferrin O 0 0.00028436907450668514
receptor O 0 9.018796845339239e-05
( O 0 7.728839591436554e-06
TfR O 0 0.0002544242888689041
) O 0 8.313033504236955e-06
. O 0 1.9985202015959658e-05

The O 0 7.713426020927727e-05
C282Y O 0 0.0005598579300567508
mutation O 0 7.002693018876016e-05
nearly O 0 4.5853707888454664e-06
completely O 0 4.736144092021277e-06
prevents O 0 1.3298422345542349e-06
the O 0 3.214979358290293e-07
association O 0 5.945487373537617e-07
of O 0 1.5570709877010813e-07
the O 0 1.1770745231842739e-06
mutant O 0 5.574472379521467e-05
HFE O 0 0.00042387910070829093
protein O 0 4.2108890738745686e-06
with O 0 1.5606120769007248e-06
the O 0 1.1840293154818937e-05
TfR O 0 0.001339159207418561
. O 0 3.263245162088424e-05

Studies O 0 0.00010600013047223911
on O 0 1.5555597201455384e-05
cell O 0 0.0001962365349754691
- O 0 6.904054316692054e-05
associated O 0 6.242835752345854e-06
transferrin O 0 2.4473269149893895e-05
at O 0 1.342529003522941e-06
37 O 0 2.284552920173155e-06
degrees O 0 3.62342370863189e-06
C O 0 6.122956983745098e-05
suggest O 0 8.738322776480345e-07
that O 0 1.858287959066729e-07
the O 0 4.932424531034485e-07
overexpressed O 0 3.396241299924441e-05
wild O 0 2.7752357709687203e-06
- O 0 4.213375723338686e-05
type O 0 1.1269188689766452e-05
HFE O 0 9.701034286990762e-05
protein O 0 2.1102523533045314e-06
decreases O 0 9.973767873816541e-07
the O 0 1.6040620209878398e-07
affinity O 0 8.699093996256124e-07
of O 0 2.2996677273567911e-07
the O 0 2.4375872271775734e-06
TfR O 0 0.00016832469555083662
for O 0 3.653308567663771e-06
transferrin O 0 0.00046088104136288166
. O 0 2.714985930651892e-05

The O 0 6.356606900226325e-05
overexpressed O 0 0.0012597156455740333
H63D O 0 0.0011693098349496722
protein O 0 1.7029100490617566e-05
does O 0 7.795051715220325e-07
not O 0 8.405937990119128e-08
have O 0 3.9897010140066413e-08
this O 0 2.5540224157794e-08
effect O 0 1.7515937145162752e-07
, O 0 1.9256500394249088e-08
providing O 0 1.7686776487835232e-08
the O 0 2.2556756462677185e-08
first O 0 4.3902620205926723e-08
direct O 0 9.096564212995872e-08
evidence O 0 1.0664577132502018e-07
for O 0 4.186198054867418e-08
a O 0 5.963261173747014e-07
functional O 0 1.5445175449713133e-06
consequence O 0 1.092001639335649e-06
of O 0 2.1851215592505469e-07
the O 0 4.763935066876002e-06
H63D O 0 0.2743115723133087
mutation O 0 0.0003006610495503992
. O 0 3.3398035157006234e-05

Addition O 0 4.111978705623187e-05
of O 0 7.917014045233373e-06
soluble O 0 8.340046042576432e-05
wild O 0 1.6877094822120853e-05
- O 0 0.0015436772955581546
type O 0 0.000351386348484084
HFE O 0 0.25255897641181946
/ O 0 0.0008080327534116805
beta2m O 0 0.00020243821199983358
heterodimers O 0 3.542743070283905e-05
to O 0 9.190597438646364e-07
cultured O 0 6.766984824935207e-06
cells O 0 3.745566118595889e-06
also O 0 3.158866093144752e-07
decreased O 0 8.449642905361543e-07
the O 0 1.5159791644236975e-07
apparent O 0 1.5508940123254433e-06
affinity O 0 6.089429689382087e-07
of O 0 7.095771081822022e-08
the O 0 3.904251570929773e-07
TfR O 0 1.0628228665154893e-05
for O 0 6.644179251225069e-08
its O 0 2.590685426184791e-07
ligand O 0 1.8289350691702566e-06
under O 0 6.707059583277442e-07
steady O 0 6.675531039945781e-06
- O 0 7.922556505945977e-06
state O 0 2.0696882074844325e-07
conditions O 0 9.005652259475028e-07
, O 0 6.017693721105388e-08
both O 0 7.707897964337462e-08
in O 0 1.5967160038599104e-07
293 O 0 3.851621841022279e-06
cells O 0 2.0906156805722276e-06
and O 0 3.434398649915238e-07
in O 0 1.9989038264611736e-06
HeLa O 0 0.0008330262498930097
cells O 0 6.975699216127396e-05
. O 0 1.7098163880291395e-05

Furthermore O 0 0.00011371415894245729
, O 0 4.688838998845313e-06
at O 0 1.7736675772539456e-06
4 O 0 1.4694750234411913e-06
degrees O 0 4.290715878596529e-06
C O 0 3.8244572351686656e-05
, O 0 1.9548619434317516e-07
the O 0 4.04821946631273e-07
added O 0 1.8352775441599078e-06
soluble O 0 5.1829761105182115e-06
complex O 0 9.781724656932056e-07
of O 0 8.410441978412564e-07
HFE O 0 0.39400678873062134
/ O 0 0.005148830823600292
beta2m O 0 0.00028790620854124427
inhibited O 0 2.124258389812894e-05
binding O 0 2.7721143851522356e-06
of O 0 4.2583462800394045e-07
transferrin O 0 2.1784913769806735e-05
to O 0 1.8670575627766084e-06
HeLa O 0 0.00022988207638263702
cell O 0 0.000137247028760612
TfR O 0 8.7811189587228e-05
in O 0 1.433635588909965e-06
a O 0 2.793182147797779e-06
concentration O 0 4.053523298352957e-05
- O 0 8.151217480190098e-05
dependent O 0 9.287728062190581e-06
manner O 0 1.4836712580290623e-05
. O 0 1.588183658896014e-05

Scatchard O 0 0.0009803047869354486
plots O 0 3.74919363821391e-05
of O 0 1.0194077049163752e-06
these O 0 2.505646250483551e-07
data O 0 6.163208468024095e-07
indicate O 0 5.400195846050337e-07
that O 0 8.140308693782572e-08
the O 0 2.139657624411484e-07
added O 0 9.825322422329918e-07
heterodimer O 0 2.1066747649456374e-05
substantially O 0 1.027366852213163e-05
reduced O 0 1.4550404330293532e-06
the O 0 5.38038420927478e-07
affinity O 0 3.7026527479611104e-06
of O 0 1.091287458621082e-06
TfR O 0 0.0001654756342759356
for O 0 4.241738679411355e-06
transferrin O 0 0.0007625645375810564
. O 0 2.9767377782263793e-05

These O 0 2.1376383301685564e-05
results O 0 1.4779716366319917e-05
establish O 0 3.953446139348671e-06
a O 0 1.7976532262764522e-06
molecular O 0 5.3426319936988875e-06
link O 0 1.2120842256990727e-05
between O 0 1.4904293266226887e-06
HFE O 0 0.0006105777574703097
and O 0 3.34273039470645e-07
a O 0 6.005419663779321e-07
key O 0 5.745843054683064e-07
protein O 0 4.403370041927701e-07
involved O 0 1.5646222095710982e-07
in O 0 3.016511413989065e-07
iron O 0 0.0005971478531137109
transport O 0 6.217583631951129e-06
, O 0 9.23466956237462e-08
the O 0 2.0245165899268613e-07
TfR O 0 1.9679944671224803e-05
, O 0 9.153372104719892e-08
and O 0 4.9010647984459865e-08
raise O 0 1.5364111050075735e-07
the O 0 7.738670859680497e-08
possibility O 0 2.951978785858955e-07
that O 0 9.579925830394131e-08
alterations O 0 6.010701326886192e-06
in O 0 2.078466536659107e-07
this O 0 1.5331237079863058e-07
regulatory O 0 9.46658656175714e-06
mechanism O 0 7.140164143493166e-06
may O 0 1.2029463505314197e-06
play O 0 1.0249824100583282e-07
a O 0 1.5686053700392222e-07
role O 0 2.2270127431056608e-07
in O 0 1.86791822898158e-07
the O 0 9.895076118482393e-07
pathogenesis O 0 6.599762127734721e-05
of O 0 1.7646058040554635e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0001670428755460307
. O 0 6.21124854660593e-05

Genomic O 0 0.00048445616266690195
organization O 0 1.983942092920188e-05
of O 0 1.5459764881597948e-06
the O 0 5.119301022205036e-06
UBE3A O 0 0.00807230919599533
/ O 0 0.0012652676086872816
E6 O 0 0.00035971018951386213
- O 0 0.0013672339264303446
AP O 0 0.00017089868197217584
gene O 0 1.3035168194619473e-05
and O 0 1.3521387245418737e-06
related O 0 1.0901289897446986e-05
pseudogenes O 0 0.00016332510858774185
. O 0 2.7945308829657733e-05

The O 0 0.00010556769120739773
UBE3A O 0 0.0022022556513547897
gene O 0 8.831849845591933e-05
encodes O 0 2.7097532438347116e-05
the O 0 2.8365402613417245e-06
E6 O 0 6.99438969604671e-05
- O 0 7.948480924824253e-05
AP O 0 3.8294536352623254e-05
ubiquitin O 0 1.889575105451513e-05
- O 0 6.3164893617795315e-06
protein O 0 8.644676086078107e-07
ligase O 0 1.5348601891673752e-06
and O 0 1.8612819019381277e-07
has O 0 2.0578103487878252e-07
recently O 0 1.6452313502668403e-06
been O 0 1.7961332332561142e-07
shown O 0 2.1449511677928967e-07
to O 0 1.5671848530018906e-07
be O 0 4.436390952378133e-07
mutated O 0 0.00012716824130620807
in O 1 0.6885777711868286
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.011251327581703663
who O 0 4.332805929152528e-06
lack O 0 5.882774530618917e-06
15q11 O 0 0.00020919140661135316
- O 0 0.0002105300809489563
q13 O 0 6.837263936176896e-05
deletions O 0 4.329706644057296e-05
or O 0 5.2357258937263396e-06
chromosome O 0 7.552460738224909e-05
15 O 0 1.6784289982751943e-05
paternal O 0 0.0032199150882661343
uniparental B-Disease 1 0.8277538418769836
disomy I-Disease 0 0.26501625776290894
. O 0 0.00020659496658481658

Previous O 0 0.0004605007416103035
UBE3A O 0 0.00235199392773211
cDNA O 0 0.00025460970937274396
analysis O 0 2.5798994101933204e-05
has O 0 2.496468596291379e-06
shown O 0 1.8962423382617999e-06
a O 0 1.4214429029379971e-06
coding O 0 5.356708243198227e-06
region O 0 7.093605063346331e-07
of O 0 3.2086325063573895e-07
approximately O 0 2.703846803342458e-06
2 O 0 9.648242667026352e-06
. O 0 1.5644249288016e-05

6 O 0 0.00018553753034211695
kb O 0 0.0018535330891609192
and O 0 3.1820220556255663e-06
a O 0 3.920566996384878e-06
3 O 0 5.427236828836612e-06
- O 0 2.4451108401990496e-05
untranslated O 0 3.878166899085045e-05
region O 0 4.280388111510547e-06
( O 0 2.012160166486865e-06
UTR O 0 1.6567408238188364e-05
) O 0 4.721595132650691e-07
of O 0 1.892046554985427e-07
< O 0 3.0929347758501535e-06
50 O 0 5.283056339067116e-07
bp O 0 7.577154065074865e-06
, O 0 1.3310904023455805e-07
whereas O 0 4.846012302550662e-07
Northern O 0 5.909433298256772e-07
analysis O 0 5.073973738944915e-07
has O 0 1.783844254532596e-07
indicated O 0 6.837172463747265e-07
mRNA O 0 5.774710984951525e-07
sizes O 0 5.833166483171226e-07
of O 0 1.2283096850751463e-07
5 O 0 1.6265677231785958e-06
- O 0 6.508276419481263e-05
8 O 0 1.2961721040483098e-05
kb O 0 0.005955307744443417
. O 0 2.6175035600317642e-05

We O 0 1.7878166545415297e-05
have O 0 2.206860926889931e-06
analyzed O 0 2.6828438421944156e-06
additional O 0 7.842190257179027e-07
cDNA O 0 8.389674803765956e-06
clones O 0 6.7586524892249145e-06
and O 0 2.2111281339221023e-07
provide O 0 1.2792709469522379e-07
evidence O 0 1.6488819198912097e-07
for O 0 7.12025567395358e-08
an O 0 2.325160579630392e-07
additional O 0 1.677925297371985e-06
0 O 0 8.680697646923363e-06
. O 0 1.1050381544919219e-05

5 O 0 0.00012256410263944417
kb O 0 0.00035720874438993633
of O 0 1.742414838190598e-06
5 O 0 4.618857474270044e-06
- O 0 1.9889430404873565e-05
UTR O 0 3.4077973396051675e-05
and O 0 9.842474355536979e-07
> O 0 6.608187504753005e-06
2 O 0 1.5745044947834685e-06
kb O 0 6.24071981292218e-05
of O 0 5.415358828031458e-07
3 O 0 5.712678103009239e-06
- O 0 0.00015487527707591653
UTR O 0 0.00039031225605867803
. O 0 2.6619291020324454e-05

We O 0 1.0015221050707623e-05
have O 0 9.260179467673879e-07
established O 0 8.084911655714677e-07
the O 0 3.2782105563455843e-07
genomic O 0 2.5726606054377044e-06
organization O 0 4.842432304030808e-07
of O 0 3.773650405491935e-07
UBE3A O 0 7.509423448937014e-05
and O 0 3.1014866408440867e-07
the O 0 3.573699984826817e-07
sequence O 0 1.2805955975636607e-06
of O 0 6.586641916328517e-07
intron O 0 0.00038760059396736324
- O 0 0.00021671818103641272
exon O 0 0.00014371862926054746
borders O 0 4.3743297283072025e-05
. O 0 2.442164986860007e-05

We O 0 1.707147566776257e-05
have O 0 2.2255740077525843e-06
also O 0 6.619481496272783e-07
mapped O 0 4.115902811463457e-06
two O 0 2.6085749027515703e-07
highly O 0 6.356102630888927e-07
homologous O 0 2.64740356215043e-06
processed O 0 1.491190005253884e-06
pseudogenes O 0 5.5726013670209795e-06
, O 0 3.5469241765895276e-07
UBE3AP1 O 0 2.313830736966338e-05
and O 0 3.3114355346697266e-07
UBE3AP2 O 0 7.476491009583697e-05
, O 0 1.4897784694767324e-07
to O 0 1.6036214844916685e-07
chromosomes O 0 5.60979231067904e-07
2 O 0 1.563818159411312e-07
and O 0 5.626981547379728e-08
21 O 0 1.6001413882804627e-07
, O 0 3.9011393226928703e-08
respectively O 0 1.9234553860769665e-07
, O 0 5.411910919406182e-08
and O 0 1.0198867528288247e-07
determined O 0 6.470922926382627e-07
their O 0 9.498638178229157e-07
genomic O 0 1.8673157683224417e-05
organization O 0 1.0211757398792543e-05
. O 0 1.2636025530810002e-05

These O 0 9.066655366041232e-06
results O 0 4.079828613612335e-06
will O 0 2.101984222235842e-07
form O 0 1.3251057850993675e-07
the O 0 4.8132967833680596e-08
basis O 0 1.102482869441701e-07
for O 0 4.968711664332659e-08
studies O 0 1.859261118397626e-07
of O 0 1.4951929472317715e-07
mutation O 0 6.34867865301203e-06
and O 0 1.0756675692391582e-06
imprinting O 0 0.00012036281987093389
of O 0 5.6415487961203326e-06
UBE3A O 0 0.005718012806028128
. O 0 7.102277595549822e-05

Mutation O 0 0.003086174838244915
spectrum O 0 0.0004983054823242128
and O 0 2.5479033865849487e-05
genotype O 0 0.0009122715564444661
- O 0 0.02290601283311844
phenotype O 0 0.005390354432165623
analyses O 0 3.7012148823123425e-05
in O 0 4.526515112956986e-05
Cowden B-Disease 1 0.9994528889656067
disease I-Disease 0 0.17039363086223602
and O 0 1.5694711692049168e-05
Bannayan B-Disease 1 0.995195209980011
- I-Disease 1 0.9999986886978149
Zonana I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999992847442627
, O 0 2.232372025900986e-06
two O 0 6.433936505345628e-06
hamartoma B-Disease 1 0.9991059899330139
syndromes I-Disease 1 0.8480951189994812
with O 0 7.782129250699654e-05
germline O 1 0.5820028185844421
PTEN O 1 0.9112367033958435
mutation O 0 0.0024113962426781654
. O 0 8.50118522066623e-05

The O 0 0.0005495703080669045
tumour B-Disease 1 0.999984622001648
suppressor O 0 0.1588083952665329
gene O 0 0.0006767380400560796
PTEN O 0 0.010035641491413116
, O 0 2.068012463496416e-06
which O 0 1.124649315897841e-06
maps O 0 5.258874807623215e-06
to O 0 3.97160056309076e-06
10q23 O 0 0.00021859693515580148
. O 0 2.1588935851468705e-05

3 O 0 6.114182178862393e-05
and O 0 5.087864337838255e-06
encodes O 0 1.2270234037714545e-05
a O 0 3.6360613648867e-06
403 O 0 1.204056570713874e-05
amino O 0 4.514591182669392e-06
acid O 0 7.05697948433226e-06
dual O 0 1.1383946002752054e-05
specificity O 0 1.710530705167912e-05
phosphatase O 0 0.003989283461123705
( O 0 2.199402160840691e-06
protein O 0 4.225403245072812e-06
tyrosine O 0 6.684943218715489e-05
phosphatase O 0 0.0015639233170077205
; O 0 1.2795896964234998e-06
PTPase O 0 1.656077256484423e-05
) O 0 2.513333186016098e-07
, O 0 7.857808981270864e-08
was O 0 1.0178855518461205e-06
shown O 0 5.632623469864484e-07
recently O 0 1.8133060848413152e-06
to O 0 8.185804034610555e-08
play O 0 1.2696425244485e-07
a O 0 5.484876055561472e-07
broad O 0 1.7456133036830579e-06
role O 0 1.6189305824809708e-06
in O 0 2.0459162897168426e-06
human O 0 1.0486471182957757e-05
malignancy B-Disease 0 0.007576574571430683
. O 0 2.559173481131438e-05

Somatic O 0 0.005901365540921688
PTEN O 0 0.08553529530763626
deletions O 0 0.0014832653105258942
and O 0 2.6012938178610057e-05
mutations O 0 8.763126243138686e-05
were O 0 1.1858855941682123e-06
observed O 0 3.267758984293323e-06
in O 0 1.3158553429093445e-06
sporadic B-Disease 0 0.0021270085126161575
breast I-Disease 0 0.08464886248111725
, I-Disease 0 5.51653192815138e-06
brain I-Disease 0 0.12105245143175125
, I-Disease 0 2.2262798665906303e-05
prostate I-Disease 1 0.9986647367477417
and I-Disease 0 0.0405317060649395
kidney I-Disease 1 0.9998681545257568
cancer I-Disease 1 0.9275634288787842
cell O 0 0.001984718255698681
lines O 0 9.075652997125871e-06
and O 0 2.3196081144760683e-07
in O 0 2.3227957512972353e-07
several O 0 5.181411779631162e-07
primary O 0 3.796281453105621e-05
tumours B-Disease 1 0.9990235567092896
such O 0 1.009342440738692e-06
as O 0 5.962949217064306e-05
endometrial B-Disease 1 0.9997453093528748
carcinomas I-Disease 1 1.0
, O 1 0.9992296695709229
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9998688697814941
thyroid B-Disease 1 1.0
tumours I-Disease 1 0.9999998807907104
. O 0 0.00034036359284073114

In O 0 1.1516596714500338e-05
addition O 0 4.516693024925189e-06
, O 0 1.5046365433590836e-06
PTEN O 0 0.0010375818237662315
was O 0 2.4102106181089766e-05
identified O 0 1.0852047580556246e-06
as O 0 2.1295279850619409e-07
the O 0 4.115005936000671e-07
susceptibility O 0 1.4687864677398466e-05
gene O 0 3.1750107609695988e-06
for O 0 5.563057925428438e-07
two O 0 3.4958884498337284e-05
hamartoma B-Disease 1 0.999997615814209
syndromes I-Disease 1 0.9999992847442627
Cowden B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9998025298118591
( O 0 2.364980537095107e-05
CD B-Disease 0 0.0013068905100226402
; O 0 8.39153926790459e-06
MIM O 0 0.000637632270809263
158350 O 0 4.2064773879246786e-05
) O 0 1.2687071375694359e-06
and O 0 1.065196784111322e-06
Bannayan B-Disease 0 0.0003418021951802075
- I-Disease 0 0.0063026114366948605
Zonana I-Disease 0 0.0016899951733648777
( I-Disease 0 6.4947898863465525e-06
BZS I-Disease 0 6.058775761630386e-05
) I-Disease 0 8.356906278095266e-07
or I-Disease 0 1.9829944903904106e-06
Ruvalcaba I-Disease 0 0.0002460226241964847
- I-Disease 0 0.0007789350929670036
Riley I-Disease 0 0.005971862934529781
- I-Disease 1 0.9935418367385864
Smith I-Disease 1 0.9945803284645081
syndrome I-Disease 1 0.9999957084655762
( O 0 3.2819552870932966e-05
MIM O 0 0.022500913590192795
153480 O 0 0.0004504074458964169
) O 0 2.0458091967157088e-05
. O 0 2.354592470510397e-05

Constitutive O 0 0.0006355815567076206
DNA O 0 6.437102274503559e-05
from O 0 5.371369297790807e-06
37 O 0 5.059042450739071e-06
CD B-Disease 0 2.1714455215260386e-05
families O 0 9.07354888113332e-07
and O 0 4.916728926218639e-07
seven O 0 1.4074519185669487e-06
BZS B-Disease 0 0.00011196418927283958
families O 0 2.9859229471185245e-06
was O 0 1.1218449799343944e-05
screened O 0 2.2371255909092724e-05
for O 0 8.26202449388802e-06
germline O 0 0.006488127633929253
PTEN O 0 0.43590274453163147
mutations O 0 0.0017724641365930438
. O 0 9.852989751379937e-05

PTEN O 1 0.9636591076850891
mutations O 0 0.008531035855412483
were O 0 8.776893082540482e-06
identified O 0 3.05070625472581e-06
in O 0 3.624739974839031e-07
30 O 0 2.7045538786296675e-07
of O 0 8.425086406305127e-08
37 O 0 5.722202445213043e-07
( O 0 3.49006626265691e-07
81 O 0 7.878471706135315e-07
% O 0 1.1848044323414797e-07
) O 0 1.0387730497996017e-07
CD B-Disease 0 6.266324362513842e-06
families O 0 1.689949016281389e-07
, O 0 6.284874132234108e-08
including O 0 1.7085363879232318e-07
missense O 0 1.1907828593393788e-05
and O 0 4.473544379379746e-07
nonsense O 0 1.0780752745631617e-05
point O 0 2.6788761715579312e-06
mutations O 0 7.661077688680962e-06
, O 0 2.9063346573821036e-07
deletions O 0 6.40552298136754e-06
, O 0 2.6919835249827884e-07
insertions O 0 9.912758287100587e-06
, O 0 3.5494824146553583e-07
a O 0 2.9296227239683503e-06
deletion O 0 0.00015211351274047047
/ O 0 0.00011988207552349195
insertion O 0 1.942433118529152e-05
and O 0 2.2853503196529346e-06
splice O 0 0.00033505322062410414
site O 0 0.00016188641893677413
mutations O 0 0.00015989803068805486
. O 0 1.797220465959981e-05

These O 0 2.2335018002195284e-05
mutations O 0 8.550535858375952e-05
were O 0 1.0006256161432248e-06
scattered O 0 7.596628961437091e-07
over O 0 1.9614390112110414e-07
the O 0 1.97841089288886e-07
entire O 0 3.5754044347413583e-07
length O 0 5.682775281456998e-07
of O 0 2.0692263547061884e-07
PTEN O 0 0.00043842027662321925
, O 0 1.1424489088085465e-07
with O 0 4.3733379584409704e-08
the O 0 9.079506924081215e-08
exception O 0 1.3327085923720006e-07
of O 0 1.9575047360831377e-08
the O 0 6.227134008440771e-08
first O 0 1.6720964879368694e-07
, O 0 1.1043181302738958e-07
fourth O 0 1.1783931768150069e-06
and O 0 5.859230896021472e-07
last O 0 5.13416443936876e-06
exons O 0 7.287997868843377e-05
. O 0 1.841828452597838e-05

A O 0 0.00013550269068218768
hot O 0 9.741276153363287e-05
spot O 0 1.4583311894966755e-05
for O 0 1.8211151200375753e-06
PTEN O 0 0.0006048719515092671
mutation O 0 7.542210369138047e-06
in O 0 5.091710590932053e-07
CD B-Disease 0 0.00015926262130960822
was O 0 2.461051190039143e-05
identified O 0 1.108020455831138e-06
in O 0 4.6174037038326787e-07
exon O 0 7.856407137296628e-06
5 O 0 3.6393637969922565e-07
that O 0 7.963637926877709e-08
contains O 0 1.6968385807558661e-07
the O 0 2.0968626301964832e-07
PTPase O 0 7.928905688459054e-06
core O 0 1.2764305665768916e-06
motif O 0 1.5620727253917721e-06
, O 0 6.179769940217739e-08
with O 0 3.9837090071159764e-08
13 O 0 1.014853125980153e-07
of O 0 4.952258336743398e-08
30 O 0 2.784928767596284e-07
( O 0 3.034064661733282e-07
43 O 0 5.5434099976992e-07
% O 0 2.591122552075831e-07
) O 0 2.961684799629438e-07
CD B-Disease 0 0.00014017264766152948
mutations O 0 1.5898245692369528e-05
identified O 0 1.075207023859548e-06
in O 0 6.940551884326851e-07
this O 0 1.8498868712413241e-06
exon O 0 0.00012358026287984103
. O 0 1.5082428944879211e-05

Seven O 0 2.1289835785864852e-05
of O 0 2.27817372433492e-06
30 O 0 1.9296614937047707e-06
( O 0 7.715582341916161e-07
23 O 0 6.859587529106648e-07
% O 0 1.312535005126847e-07
) O 0 7.587500761019328e-08
were O 0 5.814532855197285e-08
within O 0 5.4008975070019005e-08
the O 0 5.150221582539416e-08
core O 0 5.632467718896805e-07
motif O 0 7.865559155106894e-07
, O 0 3.9381912841918165e-08
the O 0 4.883875703853846e-08
majority O 0 1.317148274893043e-07
( O 0 9.453609806087115e-08
five O 0 3.0740533674133985e-08
of O 0 2.4230814688053215e-08
seven O 0 5.50043957048274e-08
) O 0 7.020905457011395e-08
of O 0 3.642272972115279e-08
which O 0 3.0848789833726187e-07
were O 0 7.390179916910711e-07
missense O 0 4.217821333440952e-05
mutations O 0 6.0518495956785046e-06
, O 0 1.6410304226610606e-07
possibly O 0 5.73370755319047e-07
pointing O 0 1.1752460977731971e-06
to O 0 1.7539339580707747e-07
the O 0 2.188454146789809e-07
functional O 0 5.841388315275253e-07
significance O 0 2.7041127736993076e-07
of O 0 1.5198848757336236e-07
this O 0 8.991106597022736e-07
region O 0 1.3405867321125697e-05
. O 0 1.415639417245984e-05

Germline O 1 0.8675033450126648
PTEN O 1 0.9989606142044067
mutations O 0 0.24261407554149628
were O 0 1.285714915866265e-05
identified O 0 5.018696356273722e-06
in O 0 3.058044910630997e-07
four O 0 2.081231542661044e-07
of O 0 1.2968216367426066e-07
seven O 0 1.1408748150643078e-06
( O 0 1.433809188711166e-06
57 O 0 3.3380233617208432e-06
% O 0 1.1256419156779884e-06
) O 0 1.85578153377719e-06
BZS B-Disease 0 0.00011399664799682796
families O 0 4.085797627340071e-06
studied O 0 3.2779702451080084e-05
. O 0 2.7401256375014782e-05

Interestingly O 0 0.00037074286956340075
, O 0 4.61328454548493e-06
none O 0 9.653696224631858e-07
of O 0 2.0635901876175922e-07
these O 0 4.6966701461315097e-07
mutations O 0 1.1981184798059985e-05
was O 0 8.812464329821523e-06
observed O 0 1.5785351479280507e-06
in O 0 6.739747391293349e-07
the O 0 1.5439093203895027e-06
PTPase O 0 0.00013180146925151348
core O 0 3.673309038276784e-05
motif O 0 9.469132783124223e-05
. O 0 1.7715085050440393e-05

It O 0 1.3104892786941491e-05
is O 0 1.5075148667165195e-06
also O 0 4.3557272988437035e-07
worthy O 0 3.0626239322373294e-07
of O 0 8.157903863548199e-08
note O 0 9.433630339117371e-07
that O 0 6.676930297544459e-08
a O 0 3.372689718617039e-07
single O 0 6.915787480465951e-07
nonsense O 0 1.8549393416833482e-06
point O 0 4.707715106633259e-07
mutation O 0 2.4646367364766775e-06
, O 0 2.054674723694916e-07
R233X O 0 4.284941951482324e-06
, O 0 1.8849829075406888e-07
was O 0 1.3203505204728572e-06
observed O 0 2.9383423338913417e-07
in O 0 1.003110128294793e-07
the O 0 2.268397452098725e-07
germline O 0 1.2122010048187803e-05
DNA O 0 7.565836881440191e-07
from O 0 1.6720009909931832e-07
two O 0 1.4948179227758374e-07
unrelated O 0 1.3710905477637425e-06
CD B-Disease 0 2.6675957997213118e-05
families O 0 6.68114012114529e-07
and O 0 5.271048735266959e-07
one O 0 1.534328930574702e-06
BZS B-Disease 0 0.00044594111386686563
family O 0 5.303480429574847e-05
. O 0 2.763950396911241e-05

Genotype O 0 0.058475010097026825
- O 1 0.6589374542236328
phenotype O 0 0.07888367027044296
studies O 0 1.2712718671537004e-05
were O 0 1.5077162061061244e-06
not O 0 2.380992611961119e-07
performed O 0 5.688555120286765e-07
on O 0 2.3143512350998208e-07
this O 0 5.484902487751242e-08
small O 0 1.740938699867911e-07
group O 0 6.848050588814658e-07
of O 0 3.7354811865952797e-07
BZS B-Disease 0 0.00014477716467808932
families O 0 6.008770014886977e-06
. O 0 1.2216933100717142e-05

However O 0 6.593974831048399e-05
, O 0 9.001040780276526e-06
genotype O 0 0.0003123286587651819
- O 0 0.00037516525480896235
phenotype O 0 0.00017254521662835032
analysis O 0 2.752577756837127e-06
inthe O 0 4.713371890829876e-05
group O 0 1.1046399777114857e-06
of O 0 1.7299525723046827e-07
CD B-Disease 0 3.447430572123267e-05
families O 0 3.8808499880360614e-07
revealed O 0 1.0604208000586368e-06
two O 0 1.0343444500904297e-07
possible O 0 2.929224365288974e-07
associations O 0 4.879862558482273e-07
worthy O 0 3.4888981303993205e-07
of O 0 8.339615220620544e-08
follow O 0 8.771268653617881e-07
- O 0 8.37737024994567e-06
up O 0 2.948810617908748e-07
in O 0 2.946069912468374e-07
independent O 0 2.1627590740536107e-06
analyses O 0 1.3140133887645788e-05
. O 0 8.718963727005757e-06

The O 0 8.835799235384911e-06
first O 0 4.274620096111903e-06
was O 0 5.295492883305997e-06
an O 0 3.4443894492142135e-07
association O 0 9.355541124023148e-07
noted O 0 3.1558488444716204e-07
in O 0 9.253112409624009e-08
the O 0 1.372439015767668e-07
group O 0 3.1130912248045206e-07
of O 0 9.914234766483787e-08
CD B-Disease 0 2.394400507910177e-05
families O 0 1.3132903404766694e-06
with O 0 3.274136543041095e-05
breast B-Disease 1 0.999854564666748
disease I-Disease 0 0.24777193367481232
. O 0 3.145334267173894e-05

A O 0 7.487492985092103e-05
correlation O 0 3.264842234784737e-05
was O 0 1.4102321983955335e-05
observed O 0 1.0691742318158504e-06
between O 0 2.420303530925594e-07
the O 0 1.886130149841847e-07
presence O 0 1.3389105788519373e-06
/ O 0 2.2105128664406948e-05
absence O 0 6.867048796266317e-07
of O 0 1.6471577168886142e-07
a O 0 7.5119683060620446e-06
PTEN O 0 0.07219590246677399
mutation O 0 7.758239007671364e-06
and O 0 2.2253482256928692e-07
the O 0 2.5365338274241367e-07
type O 0 4.482090389501536e-06
of O 0 7.431908102262241e-07
breast O 0 0.007651241030544043
involvement O 0 5.4820011428091675e-05
( O 0 1.3082516488793772e-05
unaffected O 0 0.0012318346416577697
versus O 0 0.001060894108377397
benign O 1 0.9881187081336975
versus O 0 0.06262622773647308
malignant O 1 0.9993923902511597
) O 0 2.336561374249868e-05
. O 0 1.78996106114937e-05

Specifically O 0 2.468723505444359e-05
and O 0 1.0675867088139057e-06
more O 0 1.2834465223932057e-07
directly O 0 2.433229155940353e-07
, O 0 8.177002541742695e-08
an O 0 1.315747084618124e-07
association O 0 1.2571219940582523e-06
was O 0 1.3681850759894587e-05
also O 0 1.8369534870998905e-07
observed O 0 1.255169053138161e-07
between O 0 3.426856665100786e-08
the O 0 4.7463533547897896e-08
presence O 0 1.0154688112606891e-07
of O 0 7.96357753074517e-08
a O 0 4.88422028865898e-06
PTEN O 0 0.23057493567466736
mutation O 0 0.0001250012865057215
and O 0 0.0035399659536778927
malignant B-Disease 1 1.0
breast I-Disease 1 0.9999982118606567
disease I-Disease 1 0.9712196588516235
. O 0 5.6180255342042074e-05

Secondly O 0 0.0010116613702848554
, O 0 2.734279405558482e-06
there O 0 3.5351382621229277e-07
appeared O 0 1.2524586736617493e-06
to O 0 1.8415350666600716e-07
be O 0 9.809426870788229e-08
an O 0 2.116392323614491e-07
interdependent O 0 1.3742370356339961e-05
association O 0 1.468362711420923e-06
between O 0 4.0585678107163403e-07
mutations O 0 3.340099738124991e-06
upstream O 0 9.270721079701616e-07
and O 0 9.531481026670008e-08
within O 0 1.0760157920230995e-07
the O 0 2.8838161370003945e-07
PTPase O 0 1.8218835975858383e-05
core O 0 2.165770411011181e-06
motif O 0 2.48832270699495e-06
, O 0 7.591944495288772e-08
the O 0 9.085848517997874e-08
core O 0 6.46092075839988e-07
motif O 0 8.313567718687409e-07
containing O 0 1.773569806573505e-07
the O 0 7.335411567055417e-08
majority O 0 1.6651932810418657e-07
of O 0 7.436133842020354e-08
missense O 0 3.136940722470172e-05
mutations O 0 3.55589622813568e-06
, O 0 6.516129502642798e-08
and O 0 3.0786768689949895e-08
the O 0 5.6336180165317273e-08
involvement O 0 2.70525532641841e-07
of O 0 5.47307301701494e-08
all O 0 7.462917750444831e-08
major O 0 9.081479106498591e-07
organ O 0 0.007914019748568535
systems O 0 0.004929634742438793
( O 0 1.0205653779848944e-06
central O 0 2.9596787953778403e-06
nervous O 0 4.9177320761373267e-05
system O 0 1.5508509022765793e-05
, O 0 4.001405613962561e-06
thyroid O 0 0.12385178357362747
, O 0 7.546527285740012e-06
breast O 0 0.21105216443538666
, O 0 2.3847245756769553e-05
skin O 1 0.9999840259552002
and O 1 0.5132261514663696
gastrointestinal O 1 0.9999991655349731
tract O 1 0.998801589012146
) O 0 3.362166171427816e-05
. O 0 3.95554379792884e-05

However O 0 1.9514174709911458e-05
, O 0 5.421735522759263e-07
these O 0 9.633411224285737e-08
observations O 0 5.453284757095389e-07
would O 0 1.421892790176571e-07
need O 0 8.775755588885659e-08
to O 0 7.018670089564694e-08
be O 0 3.8401818613920113e-08
confirmed O 0 2.2499636997963535e-07
by O 0 3.83301781425871e-08
studying O 0 7.698142212575476e-08
a O 0 1.5060261659982643e-07
larger O 0 1.4684339078030462e-07
number O 0 4.6157129673929376e-08
of O 0 1.264564701841664e-07
CD B-Disease 0 7.146246935008094e-05
families O 0 5.768981282017194e-06
. O 0 1.1655616617645137e-05

Molecular O 0 0.4140162169933319
defects O 1 0.9765607714653015
leading O 0 1.1927900231967214e-05
to O 0 2.0810857677133754e-06
human O 0 1.8445738305672421e-06
complement B-Disease 0 1.5484287359868176e-05
component I-Disease 0 0.4925220012664795
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
in O 0 5.603055228675657e-07
an O 0 2.4241657570200914e-07
African O 0 6.737826083735854e-07
- O 0 8.115586751955561e-06
American O 0 1.9300498479424277e-06
family O 0 1.437855462427251e-05
. O 0 1.371267808281118e-05

Complement B-Disease 0 0.002687482861801982
component I-Disease 1 0.9543634057044983
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.9334183384198695e-05
C6D B-Disease 0 0.21463242173194885
) O 0 3.377688699401915e-05
was O 0 0.1106308177113533
diagnosed O 0 0.1393415331840515
in O 0 3.502510423913918e-07
a O 0 1.239849666490045e-06
16 O 0 1.4870206541672815e-06
- O 0 1.6327052435372025e-05
year O 0 7.389214715658454e-07
- O 0 3.4423148917994695e-06
old O 0 1.242141024704324e-06
African O 0 2.9103702559041267e-07
- O 0 2.1642467800120357e-06
American O 0 4.90108334361139e-07
male O 0 1.9624790184025187e-06
with O 0 5.116349711897783e-05
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999982118606567
. O 0 0.00014415316400118172

The O 0 4.8641748435329646e-05
patients O 0 0.00014303301577456295
father O 0 2.0760169718414545e-05
and O 0 4.3523348836060904e-07
two O 0 2.613450647004356e-07
brothers O 0 3.0035651434445754e-05
also O 0 7.866954661039927e-07
had O 0 2.4235980617959285e-06
C6D B-Disease 0 0.00014840552466921508
, O 0 2.076138798656757e-07
but O 0 1.2355538103747676e-07
gave O 0 4.194706377802504e-07
no O 0 1.276575005704217e-07
history O 0 4.7480645548603206e-07
of O 0 8.673149523019674e-07
meningitis B-Disease 1 0.9948564767837524
or O 0 1.9972935660916846e-06
other O 0 2.221413524239324e-06
neisserial B-Disease 1 0.8563130497932434
infection I-Disease 0 0.36470115184783936
. O 0 3.5365424992050976e-05

By O 0 1.9182643882231787e-05
using O 0 1.520962450740626e-05
exon O 0 0.00012898314162157476
- O 0 2.2686390366288833e-05
specific O 0 2.7607486572378548e-06
polymerase O 0 3.752248449018225e-05
chain O 0 0.00011437173816375434
reaction O 0 1.8404431102680974e-05
( O 0 2.6517750484345015e-06
PCR O 0 6.682432285742834e-05
) O 0 1.0891591273320955e-06
/ O 0 4.697924850916024e-06
single O 0 6.059976840333547e-07
- O 0 7.061705218802672e-06
strand O 0 6.660243798251031e-06
conformation O 0 9.594574294169433e-06
polymorphism O 0 5.707869604520965e-06
as O 0 2.7455439521872904e-07
a O 0 5.221471610639128e-07
screening O 0 1.6824278645799495e-06
step O 0 5.651671131090552e-07
and O 0 1.7399511875737517e-07
nucleotide O 0 9.775225180419511e-07
sequencing O 0 4.791610876964114e-07
of O 0 7.883510022566043e-08
target O 0 9.001556691146106e-07
exons O 0 3.0935807444620878e-06
, O 0 9.457667005108306e-08
we O 0 4.243095830247512e-08
determined O 0 1.4256742986162863e-07
that O 0 3.386196212318282e-08
the O 0 1.9486189728468162e-07
proband O 0 5.533573857974261e-05
was O 0 2.753636181296315e-06
a O 0 7.898731837485684e-07
compound O 0 5.4476836339745205e-06
heterozygote O 0 1.3026767192059197e-05
for O 0 5.440339805318217e-07
two O 0 2.766288616840029e-06
C6 O 0 0.05011343955993652
gene O 0 0.0003757853410206735
mutations O 0 0.00027116184355691075
. O 0 3.478747748886235e-05

The O 0 1.4315548469312489e-05
first O 0 4.916077159577981e-06
, O 0 8.599188845437311e-07
1195delC O 0 8.8809365479392e-06
located O 0 1.41784960305813e-06
in O 0 5.299658027979604e-07
exon O 0 1.1554396223800723e-05
7 O 0 1.2068027217537747e-06
, O 0 1.4163303774239466e-07
is O 0 6.575019284582595e-08
a O 0 2.420786131551722e-07
novel O 0 9.616913985155406e-07
mutation O 0 1.4152071798889665e-06
, O 0 4.36303153605877e-08
while O 0 2.8117618455780757e-08
the O 0 4.1209744949810556e-08
second O 0 1.2858414777383587e-07
, O 0 7.231804488583293e-08
1936delG O 0 1.5696168702561408e-06
in O 0 1.7070674118713214e-07
exon O 0 2.4651610601722496e-06
12 O 0 3.8378539102268405e-07
, O 0 1.0231249802927778e-07
has O 0 2.0038423542700912e-07
been O 0 2.0503136965999147e-07
described O 0 9.664159961175756e-07
before O 0 3.8124935031191853e-07
to O 0 5.142319992046396e-07
cause O 0 4.854953658650629e-06
C6D B-Disease 0 7.224627916002646e-05
in O 0 3.330463584916288e-07
an O 0 2.5830547656369163e-07
unrelated O 0 2.2808303583587985e-06
African O 0 1.2085648677384597e-06
- O 0 1.456838162994245e-05
American O 0 2.7718474484572653e-06
individual O 0 3.837531949102413e-06
. O 0 1.3853110431227833e-05

Both O 0 0.00010451516573084518
mutations O 0 0.0009025459294207394
result O 0 3.1782783480593935e-05
in O 0 2.2203243133844808e-05
premature O 0 0.0029919808730483055
termination O 0 0.0001562011311762035
codons O 0 7.071300933603197e-05
and O 0 1.4699650819238741e-05
C6 O 0 0.08364583551883698
null O 0 0.0004500864015426487
alleles O 0 0.00028119824128225446
. O 0 5.176839476916939e-05

Allele O 0 0.002194165252149105
- O 0 0.0001807617663871497
specific O 0 7.833184099581558e-06
PCR O 0 9.933917317539454e-05
indicated O 0 8.88599424797576e-06
that O 0 2.2221458095827984e-07
the O 0 2.1873546529604937e-07
probands O 0 1.0184848179051187e-05
two O 0 3.9297430021179025e-07
brothers O 0 4.577188883558847e-05
also O 0 1.2910506939078914e-06
inherited O 0 4.0834678657120094e-05
the O 0 5.907072591071483e-07
1195delC O 0 3.48414687323384e-05
mutation O 0 3.0880921713105636e-06
from O 0 3.099239620496519e-07
their O 0 3.4912213209281617e-07
heterozygous O 0 1.5775491192471236e-05
mother O 0 6.003460384818027e-06
and O 0 1.592230347569057e-07
the O 0 3.80789316523078e-07
1936delG O 0 3.113129423581995e-05
mutation O 0 5.095881533634383e-06
from O 0 3.5837712175634806e-07
their O 0 7.894349209891516e-07
homozygous O 0 5.448708179756068e-05
father O 0 3.6927249311702326e-05
. O 0 2.923014108091593e-06
. O 0 9.571097507432569e-06

PAX6 O 1 0.9797520041465759
mutations O 1 0.8360448479652405
reviewed O 0 0.004518715664744377
. O 0 0.000457848102087155

Mutations O 0 0.0035636653192341328
in O 0 3.152327917632647e-05
PAX6 O 0 0.000790575344581157
are O 0 9.831338729782146e-07
responsible O 0 1.2803465097022126e-06
for O 0 1.844271508844031e-07
human O 0 8.13461042525887e-07
aniridia B-Disease 1 0.999560534954071
and O 0 1.1232151564399828e-06
have O 0 1.2205119048758206e-07
also O 0 1.6256359458566294e-07
been O 0 1.9885477797743079e-07
found O 0 4.04081362148645e-07
in O 0 1.2942583680342068e-06
patients O 0 1.0033672879217193e-05
with O 0 2.59804364759475e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999982118606567
, O 0 2.3617531041963957e-05
with O 0 0.2793070077896118
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999977350234985
, O 0 4.560756678984035e-06
with O 0 6.158711130410666e-06
autosomal B-Disease 0 0.3557458817958832
dominant I-Disease 0 0.007131212390959263
keratitis I-Disease 1 0.790127158164978
, O 0 1.989573320315685e-06
and O 0 1.0986618690367322e-06
with O 0 7.808809641574044e-06
isolated B-Disease 0 0.139179065823555
foveal I-Disease 1 0.9999991655349731
hypoplasia I-Disease 1 0.9999995231628418
. O 0 0.00029660790460184216

No O 0 4.1513441829010844e-05
locus O 0 7.81675917096436e-05
other O 0 1.1314203902657027e-06
than O 0 5.06999811022979e-07
chromosome O 0 7.696871762163937e-06
11p13 O 0 8.565961252315901e-06
has O 0 6.176624083309434e-07
been O 0 4.1250530102843186e-07
implicated O 0 3.852716417895863e-06
in O 0 1.1147144505230244e-06
aniridia B-Disease 1 0.9995710253715515
, O 0 1.0222720447927713e-06
and O 0 4.896103860119183e-07
PAX6 O 0 0.00013928365660831332
is O 0 3.367370595697139e-07
clearly O 0 2.0396672084643797e-07
the O 0 5.8114281387133815e-08
major O 0 1.5543069764589745e-07
, O 0 6.185170775552251e-08
if O 0 3.8570874494325835e-08
not O 0 3.442553264676462e-08
only O 0 3.396597492155706e-08
, O 0 1.4037266282684868e-07
gene O 0 3.3634082683420274e-06
responsible O 0 6.244371888897149e-06
. O 0 1.1386529877199791e-05

Twenty O 0 6.336144724627957e-05
- O 0 2.7929108910029754e-05
eight O 0 1.3137125733919675e-06
percent O 0 1.0881116168093286e-06
of O 0 3.107431609805644e-07
identified O 0 6.85808299749624e-06
PAX6 O 0 0.003338128561154008
mutations O 0 7.615358481416479e-05
are O 0 6.686207711936731e-07
C O 0 0.00036879171966575086
- O 0 0.01892605610191822
T O 0 0.0003681645030155778
changes O 0 2.5522995201754384e-06
at O 0 2.0660038444475504e-06
CpG O 0 3.770189869101159e-05
dinucleotides O 0 3.381436545168981e-05
, O 0 1.59520311626693e-07
20 O 0 1.2919976200009842e-07
% O 0 7.928491640996072e-08
are O 0 2.6568473643351354e-08
splicing O 0 1.4082439747653552e-06
errors O 0 5.816395969304722e-07
, O 0 5.653381052184159e-08
and O 0 2.7207551767105542e-08
more O 0 2.024633616315441e-08
than O 0 3.8624836662393136e-08
30 O 0 2.685649747036223e-07
% O 0 1.2972125773558218e-07
are O 0 9.22108185363868e-08
deletion O 0 7.851942427805625e-06
or O 0 2.407695546935429e-06
insertion O 0 3.242619277443737e-05
events O 0 1.1589236237341538e-05
. O 0 2.483311436662916e-05

There O 0 1.4037659639143385e-05
is O 0 2.288019686602638e-06
a O 0 4.480646111915121e-06
noticeably O 0 0.00013054268492851406
elevated O 0 3.95741117245052e-05
level O 0 4.1393974470338435e-07
of O 0 1.5320260615681036e-07
mutation O 0 1.957856056833407e-06
in O 0 2.4528745257157425e-07
the O 0 2.415274593658978e-07
paired O 0 2.286470817125519e-06
domain O 0 8.856956696945417e-07
compared O 0 3.793626319748e-07
with O 0 7.287189873750322e-08
the O 0 1.548177834820308e-07
rest O 0 2.248985424557759e-07
of O 0 6.82937866258726e-08
the O 0 8.176127153092239e-07
gene O 0 2.129653876181692e-05
. O 0 6.873856818856439e-06

Increased O 0 0.00012780317047145218
mutation O 0 9.724337724037468e-05
in O 0 2.9646057555510197e-06
the O 0 2.26689326154883e-06
homeodomain O 0 7.066655962262303e-05
is O 0 5.655774657498114e-07
accounted O 0 7.060022539917554e-07
for O 0 1.4758620636712294e-07
by O 0 4.888032094640948e-07
the O 0 2.663804480107501e-06
hypermutable O 0 0.002256987150758505
CpG O 0 0.0006062648608349264
dinucleotide O 0 0.00016179274825844914
in O 0 5.348683771444485e-06
codon O 0 9.580503683537245e-05
240 O 0 4.60359915450681e-05
. O 0 2.668038541742135e-05

Very O 0 1.9404038539505564e-05
nearly O 0 3.8585335460084025e-06
all O 0 4.681064069700369e-07
mutations O 0 1.1532675671332981e-05
appear O 0 2.3031207092572004e-06
to O 0 1.4079109860176686e-06
cause O 0 1.9580820662667975e-05
loss O 0 4.725568032881711e-06
of O 0 7.346417163489605e-08
function O 0 1.843517196675748e-07
of O 0 4.323104008108203e-08
the O 0 3.085802973146201e-07
mutant O 0 6.884557024022797e-06
allele O 0 4.277111202100059e-06
, O 0 9.242070575510297e-08
and O 0 4.506090434119869e-08
more O 0 2.1073226719181548e-08
than O 0 4.174047063543185e-08
80 O 0 1.329077292666625e-07
% O 0 6.769630545022665e-08
of O 0 8.477718438371085e-08
exonic O 0 4.974123294232413e-05
substitutions O 0 6.983322236919776e-06
result O 0 1.946274778674706e-06
in O 0 3.0121070722088916e-06
nonsense O 0 5.3438718168763444e-05
codons O 0 0.00013418603339232504
. O 0 2.13205366890179e-05

In O 0 1.8120328604709357e-05
a O 0 6.930637482582824e-06
gene O 0 7.3483192863932345e-06
with O 0 3.432457162944047e-07
such O 0 2.328402501916571e-07
extraordinarily O 0 4.43870339950081e-06
high O 0 7.190568567239097e-07
sequence O 0 3.241291324229678e-07
conservation O 0 1.9903083625649742e-07
throughout O 0 8.645503157822532e-08
evolution O 0 2.2847831360195414e-07
, O 0 6.022585097298361e-08
there O 0 4.483825222223459e-08
are O 0 5.3771639585420417e-08
presumed O 0 4.469814939511707e-06
undiscovered O 0 1.1861100574606098e-05
missense O 0 6.56407282804139e-05
mutations O 0 8.469065505778417e-06
, O 0 1.2619179301509575e-07
these O 0 5.842458250526761e-08
are O 0 4.6012182508547994e-08
hypothesized O 0 2.0006716567877447e-06
to O 0 1.898928445598358e-07
exist O 0 1.779467453388861e-07
in O 0 9.856689331400048e-08
as O 0 1.9884986102169933e-07
- O 0 8.205973244912457e-06
yet O 0 7.515211564168567e-07
unidentified O 0 1.3949968888482545e-05
phenotypes O 0 4.074544631293975e-05
. O 0 1.8292561207999825e-06
. O 0 9.22794879443245e-06

Genetic O 0 0.001184117398224771
heterogeneity O 0 0.0007852539420127869
and O 0 2.0660156224039383e-05
penetrance O 0 0.00023013581812847406
analysis O 0 3.6169535633234773e-06
of O 0 3.963511403526354e-07
the O 0 1.6568310456932522e-06
BRCA1 O 0 7.237992394948378e-05
and O 0 2.1820449092047056e-06
BRCA2 O 0 0.00012381593114696443
genes O 0 8.26440464152256e-06
in O 0 7.620334508828819e-05
breast B-Disease 1 0.9999089241027832
cancer I-Disease 1 0.7078010439872742
families O 0 2.392918941040989e-05
. O 0 3.6660370824392885e-05

The O 0 0.037741269916296005
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999990463256836
Linkage O 0 0.013104449957609177
Consortium O 0 0.0013176955981180072
. O 0 0.00014621249283663929

The O 0 1.5238734704325907e-05
contribution O 0 1.1464393537607975e-05
of O 0 2.5276042379118735e-06
BRCA1 O 0 9.759824752109125e-05
and O 0 1.0869979632843751e-05
BRCA2 O 0 0.026350151747465134
to O 0 0.05496535077691078
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.14803257584571838
assessed O 0 7.364469183812616e-06
by O 0 1.2629295724764233e-06
linkage O 0 3.145943264826201e-05
and O 0 1.2975754088984104e-06
mutation O 0 3.5261118682683446e-06
analysis O 0 3.7233743910292105e-07
in O 0 1.9796998174115288e-07
237 O 0 1.688207476036041e-06
families O 0 1.7282837916354765e-07
, O 0 4.288218136139221e-08
each O 0 1.902449753288238e-08
with O 0 3.513036972435657e-08
at O 0 1.1531982124779461e-07
least O 0 5.087317234142574e-08
four O 0 5.835153160660411e-08
cases O 0 1.9661885630739562e-07
of O 0 1.2365904922262416e-06
breast B-Disease 1 0.9969731569290161
cancer I-Disease 0 0.03869825229048729
, O 0 2.227739201998702e-07
collected O 0 2.5653693569438474e-07
by O 0 1.1059206599384197e-06
the O 0 0.04154878854751587
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999980926513672
Linkage O 0 0.0007278135162778199
Consortium O 0 0.00011992609506705776
. O 0 3.819034463958815e-05

Families O 0 3.221531005692668e-05
were O 0 2.5245185497624334e-06
included O 0 6.958599101380969e-07
without O 0 2.4223749051088816e-07
regard O 0 2.4135707121786254e-07
to O 0 1.2454559339403204e-07
the O 0 2.850215992111771e-07
occurrence O 0 2.9269976948853582e-06
of O 0 1.366494416288333e-06
ovarian B-Disease 0 0.4469139575958252
or I-Disease 0 4.339546649134718e-06
other I-Disease 0 2.7990140551992226e-06
cancers I-Disease 0 0.0008957828977145255
. O 0 2.7529547878657468e-05

Overall O 0 0.0006127385422587395
, O 0 8.909027383197099e-05
disease O 0 0.04481862857937813
was O 0 0.00012248918937984854
linked O 0 5.6653745559742674e-05
to O 0 1.7182323972519953e-06
BRCA1 O 0 1.9275339582236484e-05
in O 0 2.4168389245460276e-07
an O 0 1.0806765260440443e-07
estimated O 0 1.8388780631539703e-07
52 O 0 2.924958835137659e-07
% O 0 6.291566734262233e-08
of O 0 3.307906482064027e-08
families O 0 1.0192721333623922e-07
, O 0 8.109206817152881e-08
to O 0 2.6311514034205175e-07
BRCA2 O 0 6.329642019409221e-06
in O 0 1.6286402626519703e-07
32 O 0 3.0506231496474356e-07
% O 0 5.525539137352098e-08
of O 0 2.7233719279706747e-08
families O 0 1.3240877194675704e-07
, O 0 6.134673213864517e-08
and O 0 6.854787670818041e-08
to O 0 1.8080930885844282e-07
neither O 0 6.013127631376847e-07
gene O 0 7.22643960671121e-07
in O 0 1.6083110665476852e-07
16 O 0 3.3106715591202374e-07
% O 0 1.002848009079571e-07
( O 0 1.853475595225973e-07
95 O 0 5.819347279611975e-07
% O 0 3.144409106425883e-07
confidence O 0 4.629998329619411e-06
interval O 0 9.733988918014802e-06
[ O 0 6.608238436456304e-06
CI O 0 0.00013284570013638586
] O 0 2.2775220713810995e-06
6 O 0 7.200841309895623e-07
% O 0 2.6526097940404725e-07
- O 0 3.1986221529223258e-06
28 O 0 5.333293984222109e-07
% O 0 1.5143088205604727e-07
) O 0 1.4262604963732883e-07
, O 0 1.0351318735501991e-07
suggesting O 0 1.3002610330659081e-06
other O 0 5.368109441405977e-07
predisposition O 0 6.486281199613586e-05
genes O 0 1.7248112271772698e-05
. O 0 1.389840599586023e-05

The O 0 2.0306772057665512e-05
majority O 0 1.006109596346505e-05
( O 0 2.662626002347679e-06
81 O 0 3.4387089726806153e-06
% O 0 2.754878494215518e-07
) O 0 1.4229698308554362e-07
of O 0 9.505863829417649e-08
the O 0 3.126667070318945e-05
breast B-Disease 1 0.9999985694885254
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.1870441767314333e-06
were O 0 5.095071173855104e-07
due O 0 1.8715071519181947e-06
to O 0 8.721505651010375e-07
BRCA1 O 0 1.994911872316152e-05
, O 0 7.441951765940757e-08
with O 0 4.866320324481421e-08
most O 0 6.892414461390217e-08
others O 0 2.102565588302241e-07
( O 0 3.832192305708304e-07
14 O 0 5.384233645600034e-07
% O 0 2.889977679387812e-07
) O 0 5.002269176657137e-07
due O 0 6.040743755875155e-06
to O 0 7.706817086727824e-06
BRCA2 O 0 0.0008370078285224736
. O 0 3.5410983400652185e-05

Conversely O 0 0.0001890278363134712
, O 0 1.8376578054812853e-06
the O 0 3.17598420451759e-07
majority O 0 2.9622384545291425e-07
of O 0 5.42139488857174e-08
families O 0 1.3539656151806412e-07
with O 0 1.4426393590838416e-07
male B-Disease 0 4.611964357081888e-07
and I-Disease 0 1.1075132988480618e-06
female I-Disease 0 3.0937611882109195e-05
breast I-Disease 1 0.9953190684318542
cancer I-Disease 0 0.13272257149219513
were O 0 8.231676247305586e-07
due O 0 6.9624952629965264e-06
to O 0 3.65238201993634e-06
BRCA2 O 0 0.00022396855638362467
( O 0 2.366595253988635e-06
76 O 0 9.803011380427051e-06
% O 0 1.9512817743816413e-06
) O 0 3.7792292459926102e-06
. O 0 1.0729099813033827e-05

The O 0 2.1416946765384637e-05
largest O 0 1.4445364286075346e-05
proportion O 0 4.609810275724158e-06
( O 0 1.192076751976856e-06
67 O 0 1.234902924807102e-06
% O 0 1.2966398799107992e-07
) O 0 5.450779028137731e-08
of O 0 2.5652168389456165e-08
families O 0 7.452803885144021e-08
due O 0 3.398017440758849e-07
to O 0 5.77855665540028e-08
other O 0 3.6928064162111696e-08
genes O 0 3.085020239268488e-07
was O 0 4.287824140192242e-06
found O 0 2.5441627826694457e-07
in O 0 1.652833674370413e-07
families O 0 6.10490786812079e-08
with O 0 5.197212971097542e-08
four O 0 9.245172805094626e-08
or O 0 9.475252937818368e-08
five O 0 6.954227416144931e-08
cases O 0 1.200941284196233e-07
of O 0 2.522037050312065e-07
female O 0 0.0001853183057392016
breast B-Disease 1 0.9995023012161255
cancer I-Disease 0 0.2522734999656677
only O 0 6.308639513008529e-06
. O 0 3.4518514439696446e-05

These O 0 6.9790212364750914e-06
estimates O 0 7.192898920038715e-06
were O 0 1.292838305744226e-06
not O 0 3.1845735293245525e-07
substantially O 0 7.247155735967681e-06
affected O 0 5.479862466017948e-07
either O 0 2.1414069806269254e-07
by O 0 2.353504555685504e-07
changing O 0 8.158344826370012e-07
the O 0 4.3000002847293217e-07
assumed O 0 1.0862477211048827e-05
penetrance O 0 1.4567756807082333e-05
model O 0 2.480579723851406e-06
for O 0 3.6381146628627903e-07
BRCA1 O 0 2.428863081149757e-05
or O 0 1.9284146901554777e-07
by O 0 1.3390491915288294e-07
including O 0 1.9024902542241762e-07
or O 0 1.3724642258239328e-06
excluding O 0 3.3434458600822836e-05
BRCA1 O 0 0.0009502613102085888
mutation O 0 8.08185213827528e-05
data O 0 2.6707319193519652e-05
. O 0 2.0277993826312013e-05

Among O 0 7.414135325234383e-06
those O 0 1.0073105158880935e-06
families O 0 6.768552225366875e-07
with O 0 2.7912728910450824e-06
disease O 0 0.002691062865778804
due O 0 1.728191455185879e-05
to O 0 4.794705546373734e-06
BRCA1 O 0 8.539143891539425e-05
that O 0 4.116132572562492e-07
were O 0 4.6583517132603447e-07
tested O 0 1.47237017245061e-06
by O 0 5.887001108817458e-08
one O 0 2.921617969775525e-08
of O 0 3.204604226425545e-08
the O 0 2.1108108683165483e-07
standard O 0 6.280276011239039e-06
screening O 0 1.7806281675802893e-06
methods O 0 1.0958229950119858e-06
, O 0 4.5686695671065536e-07
mutations O 0 4.192601409158669e-06
were O 0 5.525274673345848e-07
detected O 0 3.7204249565547798e-06
in O 0 3.4146498251175217e-07
the O 0 3.36459720529092e-07
coding O 0 4.732382421934744e-06
sequence O 0 8.951092240749858e-07
or O 0 2.5345246967845014e-07
splice O 0 4.5043989302939735e-06
sites O 0 2.463724513290799e-07
in O 0 9.101128739530395e-08
an O 0 8.889895042329954e-08
estimated O 0 2.3070857935181266e-07
63 O 0 9.656255315348972e-07
% O 0 1.9676009799241e-07
( O 0 3.112812123617914e-07
95 O 0 1.2504513051680988e-06
% O 0 6.229498126231192e-07
CI O 0 2.612107346067205e-05
51 O 0 2.0374775431264425e-06
% O 0 5.5263399190153e-07
- O 0 6.25347820459865e-06
77 O 0 3.6332853596832138e-06
% O 0 1.5024915001049521e-06
) O 0 3.680427653307561e-06
. O 0 8.965710549091455e-06

The O 0 1.7932896298589185e-05
estimated O 0 6.605182079510996e-06
sensitivity O 0 9.647368642617948e-06
was O 0 5.46274986845674e-06
identical O 0 1.3682771395906457e-06
for O 0 1.0910110859185806e-07
direct O 0 5.533511853172968e-07
sequencing O 0 1.4417853435588768e-06
and O 0 3.306244877876452e-07
other O 0 7.802533446010784e-07
techniques O 0 2.044469329121057e-05
. O 0 1.837018680816982e-05

The O 0 2.985779065056704e-05
penetrance O 0 0.00033538497518748045
of O 0 5.945237262494629e-06
BRCA2 O 0 0.0006534909480251372
was O 0 1.728245842969045e-05
estimated O 0 1.363688852507039e-06
by O 0 1.0324891945856507e-06
maximizing O 0 4.327833721617935e-06
the O 0 1.6361640291506774e-06
LOD O 0 0.0008068259339779615
score O 0 2.144148538718582e-06
in O 0 2.3142572445067344e-06
BRCA2 O 0 0.0004152801411692053
- O 0 0.0006994657451286912
mutation O 0 5.025085101806326e-06
families O 0 3.076754921949032e-07
, O 0 1.3650495134243101e-07
over O 0 2.359621902314757e-07
all O 0 1.698554683571274e-07
possible O 0 2.7245309865975287e-06
penetrance O 0 0.00012161956692580134
functions O 0 1.5952738976920955e-05
. O 0 2.045145993179176e-05

The O 0 1.8337734218221158e-05
estimated O 0 1.2477908967412077e-05
cumulative O 0 1.562775651109405e-05
risk O 0 6.7870660132030025e-06
of O 0 1.7772605360732996e-06
breast B-Disease 1 0.9920974969863892
cancer I-Disease 0 0.07343503087759018
reached O 0 3.0577057259506546e-06
28 O 0 2.1460000425577164e-06
% O 0 2.6817082243724144e-07
( O 0 3.6750788012795965e-07
95 O 0 1.4160942782837083e-06
% O 0 6.477319516307034e-07
CI O 0 4.8214980779448524e-05
9 O 0 1.947734290297376e-06
% O 0 3.2681933248568384e-07
- O 0 2.820135478032171e-06
44 O 0 4.734685035145958e-07
% O 0 9.297072978142751e-08
) O 0 6.708166466751209e-08
by O 0 7.518323741351196e-08
age O 0 1.0037933151352263e-07
50 O 0 6.858750367655375e-08
years O 0 8.881979596253586e-08
and O 0 1.1569401436872795e-07
84 O 0 7.617065307385928e-07
% O 0 2.0076220152986934e-07
( O 0 2.287726488248154e-07
95 O 0 8.052085149756749e-07
% O 0 3.9408215002367797e-07
CI O 0 2.7044454327551648e-05
43 O 0 1.2185433888589614e-06
% O 0 2.3024459494536131e-07
- O 0 2.0471438801905606e-06
95 O 0 6.514650863209681e-07
% O 0 1.3298506473802263e-07
) O 0 1.3106624408010248e-07
by O 0 2.133961913841631e-07
age O 0 1.0002296448874404e-06
70 O 0 1.864799401118944e-06
years O 0 3.3831506698334124e-06
. O 0 1.3001262232137378e-05

The O 0 0.00042717327596619725
corresponding O 1 0.9992669224739075
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.003815059084445238
were O 0 2.9063668989692815e-05
0 O 0 5.9844369388883933e-05
. O 0 2.757048059720546e-05

4 O 0 5.3884112276136875e-05
% O 0 4.583010195347015e-06
( O 0 1.3371725344768493e-06
95 O 0 1.867356672846654e-06
% O 0 5.395038442657096e-07
CI O 0 2.5123099476331845e-05
0 O 0 1.0641175549608306e-06
% O 0 3.205522034477326e-07
- O 0 3.445888751230086e-06
1 O 0 2.244297405695761e-07
% O 0 7.902539067572434e-08
) O 0 4.806700104609263e-08
by O 0 4.8914362338337014e-08
age O 0 7.462704587624103e-08
50 O 0 5.739748232258535e-08
years O 0 9.181961502235936e-08
and O 0 1.077848068575804e-07
27 O 0 1.0215137535851682e-06
% O 0 1.5923335183742893e-07
( O 0 2.498699700481666e-07
95 O 0 9.796111726245726e-07
% O 0 6.041004780854564e-07
CI O 0 2.0358251276775263e-05
0 O 0 8.015830417207326e-07
% O 0 2.419126587938081e-07
- O 0 2.423924115646514e-06
47 O 0 1.0070233429360087e-06
% O 0 2.0908481701553683e-07
) O 0 1.97874470586612e-07
by O 0 4.0922955690803064e-07
age O 0 7.022833869996248e-07
70 O 0 1.3196129202697193e-06
years O 0 5.4495903896167874e-06
. O 0 1.1841986633953638e-05

The O 0 4.062660445924848e-05
lifetime O 0 6.768512685084715e-05
risk O 0 2.0291225155233406e-05
of O 0 6.8718186412297655e-06
breast B-Disease 1 0.9999855756759644
cancer I-Disease 1 0.9774405360221863
appears O 0 1.3368804502533749e-05
similar O 0 1.6584040167799685e-06
to O 0 3.254101841321244e-07
the O 0 4.584320549838594e-07
risk O 0 7.081263220243272e-07
in O 0 2.934346525762521e-07
BRCA1 O 0 1.0479912816663273e-05
carriers O 0 7.031867994555796e-07
, O 0 7.396823065164426e-08
but O 0 3.808023052442877e-08
there O 0 3.503020451489647e-08
was O 0 1.6316344897404633e-07
some O 0 1.577390840168391e-08
suggestion O 0 1.8964543357924413e-07
of O 0 3.744825960438902e-08
a O 0 9.969564871425973e-07
lower O 0 0.00016653633792884648
risk O 0 3.3334392810502322e-06
in O 0 2.2966964934312273e-06
BRCA2 O 0 0.0001165934736491181
carriers O 0 1.1552082469279412e-05
< O 0 7.116771030268865e-06
50 O 0 7.817430400791636e-07
years O 0 4.842469252253068e-07
of O 0 5.090016088615812e-07
age O 0 1.2303171388339251e-05
. O 0 1.3347898857318796e-05

Eye B-Disease 1 0.7308366894721985
movement I-Disease 0 0.4084801971912384
abnormalities I-Disease 1 0.9988800883293152
correlate O 0 0.00011418552458053455
with O 0 1.493323998147389e-05
genotype O 0 0.01853305660188198
in O 0 6.278840737650171e-05
autosomal O 1 0.996793806552887
dominant O 1 0.9791706800460815
cerebellar B-Disease 1 0.999993085861206
ataxia I-Disease 1 0.9999998807907104
type I-Disease 1 0.994096040725708
I I-Disease 0 0.0010044191731140018
. O 0 4.361574974609539e-05

We O 0 4.937341873301193e-05
compared O 0 3.5125438444083557e-05
horizontal O 0 0.0001006626189337112
eye O 0 0.00046923631452955306
movements O 0 6.061647582100704e-05
( O 0 4.566588359011803e-06
visually O 0 6.157712505228119e-06
guided O 0 2.0795243472093716e-05
saccades O 0 0.0005297611933201551
, O 0 1.143658209912246e-06
antisaccades O 0 3.8234178646234795e-05
, O 0 1.9356778580004175e-07
and O 0 1.821063335682993e-07
smooth O 0 1.9317753867653664e-06
pursuit O 0 3.9802230276109185e-06
) O 0 5.207353979130858e-07
in O 0 2.9345142138481606e-07
control O 0 9.343056262878235e-06
subjects O 0 2.101131258314126e-06
( O 0 8.505752475684858e-07
n O 0 5.172828878130531e-06
= O 0 1.8433780724080862e-06
14 O 0 2.884663388158515e-07
) O 0 1.815095487245344e-07
and O 0 2.7869933205693087e-07
patients O 0 4.030972320379078e-07
with O 0 6.236369642920181e-08
three O 0 1.443224135755372e-07
forms O 0 6.321469641079602e-07
of O 0 8.467510497212061e-07
autosomal O 0 0.16851384937763214
dominant O 0 0.0044677117839455605
cerebellar B-Disease 1 0.6311479210853577
ataxias I-Disease 1 0.891325056552887
type I-Disease 0 0.20565275847911835
I I-Disease 0 0.00016705432790331542
spinocerebellar B-Disease 1 0.6549054384231567
ataxias I-Disease 0 0.0002118340489687398
1 I-Disease 0 9.824328799368232e-07
and I-Disease 0 3.0737314204998256e-07
2 I-Disease 0 1.029849727274268e-06
( O 0 1.0056808150693541e-06
SCA1 B-Disease 0 4.787012585438788e-05
, O 0 5.172095711714064e-07
n O 0 5.337117272574687e-06
= O 0 3.2554783047089586e-06
11 O 0 1.010366190712375e-06
; O 0 6.891296493449772e-07
SCA2 B-Disease 0 7.284391904249787e-05
, O 0 5.389936745814339e-07
n O 0 3.796481450990541e-06
= O 0 1.7503491562820273e-06
10 O 0 2.925633850736631e-07
) O 0 3.2470893529534806e-07
and O 0 8.901633918867446e-07
SCA3 B-Disease 1 0.9999332427978516
/ O 0 0.024175899103283882
Machado B-Disease 0 0.00011672663094941527
- I-Disease 0 0.1981654018163681
Joseph I-Disease 0 0.02766706980764866
disease I-Disease 0 0.12920606136322021
( O 0 1.4730719158251304e-05
MJD B-Disease 1 0.9999810457229614
) O 0 6.652073807345005e-06
( O 0 2.851438694051467e-06
n O 0 1.5978563169483095e-05
= O 0 1.5189621990430169e-05
16 O 0 4.179889401711989e-06
) O 0 4.967374479747377e-06
. O 0 1.367058212053962e-05

In O 0 0.00012040036381222308
SCA1 B-Disease 0 0.0009304862469434738
, O 0 7.321389148273738e-06
saccade O 0 0.00010475372982909903
amplitude O 0 2.0526767912087962e-05
was O 0 6.94123355060583e-06
significantly O 0 3.637285772128962e-06
increased O 0 1.4809309050178854e-06
, O 0 5.007481149732484e-07
resulting O 0 4.7901903599267825e-06
in O 0 4.944061402056832e-06
hypermetria B-Disease 0 0.001966698095202446
. O 0 4.3076728616142645e-05

The O 0 3.306815415271558e-05
smooth O 0 5.8569199609337375e-05
pursuit O 0 3.630030550993979e-05
gain O 0 3.918061338481493e-05
was O 0 0.00013210457109380513
decreased O 0 0.00010317183478036895
. O 0 2.4216773454099894e-05

In O 0 0.00013523330562748015
SCA2 B-Disease 0 0.001704186201095581
, O 0 1.4135552191874012e-05
saccade O 0 0.000569575815461576
velocity O 0 0.00014505727449432015
was O 0 0.0001027409452944994
markedly O 0 0.00035543704871088266
decreased O 0 0.00028059864416718483
. O 0 3.551053669070825e-05

The O 0 8.350122698175255e-06
percentage O 0 4.595531208906323e-06
of O 0 4.81100244087429e-07
errors O 0 1.5213335018415819e-06
in O 0 8.103777418000391e-07
antisaccades O 0 0.000351557886460796
was O 0 1.8885753888753243e-05
greatly O 0 1.514756490905711e-06
increased O 0 1.232771978720848e-06
and O 0 2.567564649780252e-07
was O 0 9.294054507336114e-06
significantly O 0 4.570727469399571e-06
correlated O 0 3.08964467876649e-06
with O 0 7.127272851903399e-07
age O 0 7.008434749877779e-06
at O 0 0.00014530467160511762
disease O 0 0.41460391879081726
onset O 1 0.5679067969322205
. O 0 6.209240382304415e-05

In O 0 1.6705229427316226e-05
addition O 0 4.037395683553768e-06
, O 0 5.587068585555244e-07
a O 0 8.73215810770489e-07
correlation O 0 1.4497976508209831e-06
between O 0 3.565771180547017e-07
smooth O 0 3.2844109227880836e-06
pursuit O 0 4.387392436910886e-06
gain O 0 2.8789681891794316e-06
and O 0 1.1236614483323137e-07
the O 0 1.3098714646275766e-07
number O 0 9.557896873957361e-08
of O 0 3.4438969009897846e-07
trinucleotide O 0 0.000646030530333519
repeats O 0 0.00011026607535313815
was O 0 4.659128171624616e-05
found O 0 1.0130454029422253e-05
. O 0 1.4154544260236435e-05

In O 0 0.00012503871403168887
SCA3 B-Disease 1 0.9992396831512451
, O 0 2.2757916667615063e-05
gaze B-Disease 0 0.000289180432446301
- I-Disease 0 0.002148468978703022
evoked I-Disease 0 0.0007249320624396205
nystagmus I-Disease 0 0.05798342823982239
was O 0 0.00011008945148205385
often O 0 1.0972672725984012e-06
present O 0 4.225134944135789e-07
as O 0 4.4342002070152375e-07
was O 0 4.119374352740124e-06
saccade O 0 3.259938966948539e-05
hypometria O 0 4.080093276570551e-05
and O 0 7.258903451656806e-07
smooth O 0 4.4448161133914255e-06
pursuit O 0 7.5441312219481915e-06
gain O 0 3.3762909879442304e-05
was O 0 0.0001600002433406189
markedly O 0 0.0005013902555219829
decreased O 0 0.0002642668259795755
. O 0 2.8240321626071818e-05

Three O 0 2.0675233827205375e-05
major O 0 1.8234964954899624e-05
criteria O 0 1.1586340406211093e-05
, O 0 1.8623628648128943e-06
saccade O 0 5.1133982196915895e-05
amplitude O 0 1.905986573547125e-05
, O 0 6.539686410178547e-07
saccade O 0 2.1612831915263087e-05
velocity O 0 5.05286561747198e-06
, O 0 2.398200535935757e-07
and O 0 1.4818941451721912e-07
presence O 0 4.30531002848511e-07
of O 0 2.2773562591282825e-07
gaze B-Disease 0 5.3897634643362835e-05
- I-Disease 0 0.00019777854322455823
evoked I-Disease 0 6.217541522346437e-05
nystagmus I-Disease 0 7.253172225318849e-05
, O 0 2.7297721771901706e-07
permitted O 0 2.4064459580586117e-07
the O 0 2.733140433974768e-07
correct O 0 1.7229285731445998e-06
assignment O 0 5.576140438279253e-07
of O 0 3.5279569488011475e-08
90 O 0 1.503590709717173e-07
% O 0 4.4445723546004956e-08
of O 0 2.3573722529590668e-08
the O 0 1.3167638712729968e-07
SCA1 B-Disease 0 1.731545307848137e-05
, O 0 8.629505998669629e-08
90 O 0 8.679820240331537e-08
% O 0 3.66988075484187e-08
of O 0 1.858294496059898e-08
the O 0 1.1668663546515745e-07
SCA2 B-Disease 0 2.8913696951349266e-05
, O 0 7.213014185936117e-08
and O 0 4.1588684496218775e-08
93 O 0 2.769707236893737e-07
% O 0 3.7697727606200715e-08
of O 0 2.0767776831576157e-08
the O 0 6.594875685550505e-07
patients O 0 1.3366957318794448e-06
with O 0 4.84002214307111e-07
SCA3 B-Disease 1 0.9999794960021973
to O 0 6.18448723344045e-07
their O 0 4.235806727592717e-07
genetically O 0 2.8034241950081196e-06
confirmed O 0 9.435120773559902e-06
patient O 0 9.044788384926505e-06
group O 0 6.823948979217676e-07
and O 0 2.3524836478827638e-07
, O 0 1.952102905988795e-07
therefore O 0 2.6756694637697365e-07
, O 0 2.2270847921390668e-07
may O 0 1.0795820344355889e-06
help O 0 5.254821644484764e-07
orient O 0 0.00012063560279784724
diagnoses O 0 3.5293898690724745e-05
of O 0 3.7196016933194187e-07
SCA1 B-Disease 0 0.00011914053175132722
, O 0 6.579296609743324e-07
SCA2 B-Disease 0 8.79482104210183e-05
, O 0 2.9927343803137774e-07
and O 0 7.217685720206646e-07
SCA3 B-Disease 1 0.9981434345245361
at O 0 2.906333747887402e-06
early O 0 9.420896276424173e-06
clinical O 0 4.874030310020316e-06
stages O 0 2.4800119717838243e-06
of O 0 3.514592492592783e-07
the O 0 5.019171294406988e-05
diseases O 0 0.06421827524900436
. O 0 4.617307695298223e-06
. O 0 2.1679546989616938e-05

Genetic O 0 0.00030050487839616835
basis O 0 1.3240956832305528e-05
and O 0 4.0722175072005484e-06
molecular O 0 7.904127414803952e-05
mechanism O 0 0.00031131875584833324
for O 0 0.00219231890514493
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0019286723108962178

Ventricular B-Disease 1 0.9999955892562866
fibrillation I-Disease 1 0.9999929666519165
causes O 0 0.0005961020942777395
more O 0 1.3039466466580052e-06
than O 0 3.348227721744479e-07
300 O 0 5.962453428765002e-07
, O 0 2.310829216867205e-07
000 O 0 6.636769285250921e-07
sudden O 0 1.4863477190374397e-05
deaths O 0 2.1631694835377857e-06
each O 0 1.0090549551478034e-07
year O 0 2.4536231535421393e-07
in O 0 2.879408214084833e-07
the O 0 2.7934884201386012e-06
USA O 0 0.0005044512799941003
alone O 0 2.8537910111481324e-05
. O 0 2.043481254077051e-05

In O 0 1.1991599421889987e-05
approximately O 0 3.008372232216061e-06
5 O 0 1.6734826431274996e-06
- O 0 3.6661524518422084e-06
12 O 0 3.530482217684039e-07
% O 0 5.98504783511089e-08
of O 0 2.6516579154645115e-08
these O 0 2.8912339189446357e-08
cases O 0 5.273733094668387e-08
, O 0 5.310464956664873e-08
there O 0 5.123503044046629e-08
are O 0 4.063342373683554e-08
no O 0 6.555835057042714e-07
demonstrable O 0 0.0035061431117355824
cardiac O 1 0.937279999256134
or O 0 7.5129714787181e-06
non O 0 2.3295571736525744e-05
- O 1 0.9855402112007141
cardiac O 1 0.996036946773529
causes O 0 7.324783382500755e-06
to O 0 2.31677830697663e-07
account O 0 2.685065680907428e-07
for O 0 7.004226176832162e-08
the O 0 1.5428202004841296e-07
episode O 0 1.1024613968402264e-06
, O 0 1.0773589309565068e-07
which O 0 1.7891733250507968e-07
is O 0 1.421645947630168e-07
therefore O 0 8.182555006897019e-07
classified O 0 1.6837966541061178e-05
as O 0 0.0010032218415290117
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.4234302043914795
IVF B-Disease 1 0.9999990463256836
) O 0 5.5146298109320924e-05
. O 0 4.093480674782768e-05

A O 0 4.186587830190547e-05
distinct O 0 1.2644200069189537e-05
group O 0 6.3924699134076945e-06
of O 0 2.6074012566823512e-06
IVF B-Disease 1 1.0
patients O 0 0.00044372279080562294
has O 0 2.300289224876906e-06
been O 0 8.596286988904467e-07
found O 0 3.053076511605468e-07
to O 0 1.240560010273839e-07
present O 0 1.4066158371406345e-07
with O 0 1.346927263057296e-07
a O 0 2.157977178285364e-06
characteristic O 0 2.7570902602747083e-05
electrocardiographic O 0 0.015424595214426517
pattern O 0 0.0003463358152657747
. O 0 2.583952300483361e-05

Because O 0 9.85897258942714e-06
of O 0 5.025613631914894e-07
the O 0 2.85755902496021e-07
small O 0 2.591379768546176e-07
size O 0 2.959925495815696e-07
of O 0 4.2913928410825974e-08
most O 0 6.810049768546378e-08
pedigrees O 0 3.3108212846855167e-06
and O 0 1.0131048355788153e-07
the O 0 2.8039409016855643e-07
high O 0 4.324722794990521e-06
incidence O 0 6.764223144273274e-06
of O 0 1.2117023118207726e-07
sudden B-Disease 0 0.0011762881185859442
death I-Disease 0 0.00018170164548791945
, O 0 1.602060706318298e-07
however O 0 1.9921866112326825e-07
, O 0 9.771910214340096e-08
molecular O 0 2.4668754576850915e-06
genetic O 0 1.2255813999217935e-06
studies O 0 4.548597019038425e-07
of O 0 5.677629246747529e-07
IVF B-Disease 1 0.9999982118606567
have O 0 1.822767558223859e-06
not O 0 2.1640701675096352e-07
yet O 0 4.6112430140965444e-07
been O 0 1.3580096265286556e-06
done O 0 4.1160596992995124e-06
. O 0 8.855437954480294e-06

Because O 0 0.007222075015306473
IVF B-Disease 1 0.9999997615814209
causes O 1 0.8959276080131531
cardiac O 1 0.9999345541000366
rhythm O 1 0.8529135584831238
disturbance O 0 0.4508697986602783
, O 0 2.6108200472663157e-06
we O 0 4.483162854285183e-07
investigated O 0 1.405463171977317e-05
whether O 0 1.2475188668759074e-06
malfunction O 0 0.00026940772659145296
of O 0 2.7167865823685133e-07
ion O 0 1.9756005713134073e-05
channels O 0 2.2151389202917926e-06
could O 0 1.7559417528900667e-06
cause O 0 5.248954039416276e-06
the O 0 5.896716174902394e-06
disorder O 0 0.016356760635972023
by O 0 5.19544869348465e-07
studying O 0 1.7069498881028267e-06
mutations O 0 7.625840680702822e-06
in O 0 4.459947717805335e-07
the O 0 4.014037585875485e-06
cardiac O 1 0.5773487091064453
sodium O 0 0.00015479139983654022
channel O 0 0.00013149529695510864
gene O 0 0.00014310026017483324
SCN5A O 0 0.0010598941007629037
. O 0 3.417133848415688e-05

We O 0 1.475082081014989e-05
have O 0 2.900809477068833e-06
now O 0 1.067563289325335e-06
identified O 0 1.5212480093396152e-06
a O 0 2.218821919086622e-06
missense O 0 0.00010179306264035404
mutation O 0 9.333411981060635e-06
, O 0 2.803919301186397e-07
a O 0 7.577209544251673e-07
splice O 0 0.00013819371815770864
- O 0 0.0006295692292042077
donor O 0 6.347576800180832e-06
mutation O 0 6.021211902407231e-06
, O 0 2.3758776990234765e-07
and O 0 3.8216015241232526e-07
a O 0 1.1249238923483063e-05
frameshift O 0 0.06596579402685165
mutation O 0 9.357332601211965e-06
in O 0 4.2833465840885765e-07
the O 0 5.666486231348244e-07
coding O 0 5.335341029422125e-06
region O 0 7.576126108688186e-07
of O 0 2.670827825568267e-07
SCN5A O 0 0.00016820050950627774
in O 0 1.9814822280750377e-06
three O 0 2.310825720996945e-06
IVF B-Disease 1 0.999497652053833
families O 0 1.4874253793095704e-05
. O 0 2.1329891751520336e-05

We O 0 1.0461299098096788e-05
show O 0 4.58037084172247e-06
that O 0 5.419853437160782e-07
sodium O 0 2.7920343654841417e-06
channels O 0 8.115873697533971e-07
with O 0 1.1698335100618351e-07
the O 0 5.205293405197153e-07
missense O 0 5.559077544603497e-05
mutation O 0 8.921248081605881e-06
recover O 0 1.455392521165777e-05
from O 0 6.506070349132642e-07
inactivation O 0 6.789211329305544e-05
more O 0 1.7704249444250308e-07
rapidly O 0 1.009789230010938e-06
than O 0 6.158659715538306e-08
normal O 0 3.970654347540403e-07
and O 0 1.3308567758940626e-07
that O 0 1.0630053282056906e-07
the O 0 9.99823441816261e-07
frameshift O 0 0.0051735397428274155
mutation O 0 1.1386518053768668e-05
causes O 0 1.4825079688307596e-06
the O 0 2.4340718596249644e-07
sodium O 0 3.8133330235723406e-06
channel O 0 1.994145577555173e-06
to O 0 2.3929277404022287e-07
be O 0 1.7090856374579744e-07
non O 0 7.593000646011205e-07
- O 0 2.253155798825901e-05
functional O 0 9.928095096256584e-06
. O 0 1.0088785529660527e-05

Our O 0 2.1962201572023332e-05
results O 0 1.1878496479766909e-05
indicate O 0 8.160281140590087e-06
that O 0 1.347962097497657e-06
mutations O 0 1.3047281754552387e-05
in O 0 2.1313860543159535e-06
cardiac O 0 0.06496380269527435
ion O 0 0.0002916824596468359
- O 0 6.92433604854159e-05
channel O 0 4.198871010885341e-06
genes O 0 6.576323698936903e-07
contribute O 0 1.6264129953924567e-07
to O 0 8.840874698989865e-08
the O 0 2.3078955280197988e-07
risk O 0 8.578531378589105e-07
of O 0 3.733992457455315e-07
developing O 0 4.1333736589876935e-05
IVF B-Disease 1 0.9998816251754761
. O 0 6.7244750425743405e-06
. O 0 1.815747054934036e-05

Molecular O 0 0.0006618850748054683
heterogeneity O 0 0.00040616808109916747
in O 0 1.3628876331495121e-05
mucopolysaccharidosis B-Disease 0 0.0010067970724776387
IVA I-Disease 0 0.00435984181240201
in O 0 5.846950898558134e-06
Australia O 0 3.02251487482863e-06
and O 0 4.360244929557666e-07
Northern O 0 2.4815260530886007e-06
Ireland O 0 7.760613698337693e-06
: O 0 2.3383962854950369e-07
nine O 0 2.702702488477371e-07
novel O 0 1.2389514267852064e-06
mutations O 0 1.79374183062464e-06
including O 0 2.3794535763954627e-07
T312S O 0 8.695264114066958e-06
, O 0 2.3684280847646733e-07
a O 0 5.828534312968259e-07
common O 0 1.467129436605319e-06
allele O 0 2.4055283574853092e-05
that O 0 1.1354454727552366e-06
confers O 0 2.8696113076875918e-05
a O 0 9.196301107294858e-05
mild O 1 0.9972776770591736
phenotype O 1 0.8612996339797974
. O 0 8.117172546917573e-05

Mucopolysaccharidosis B-Disease 0 0.04116538166999817
IVA I-Disease 1 0.968735933303833
( O 0 0.0013791872188448906
MPS B-Disease 1 0.9999525547027588
IVA I-Disease 1 0.999990701675415
) O 0 9.378148206451442e-06
is O 0 1.5606163970005582e-06
an O 0 5.841316578880651e-06
autosomal B-Disease 1 0.9877946376800537
recessive I-Disease 1 0.999946117401123
lysosomal I-Disease 1 0.9999994039535522
storage I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9999942779541016
caused O 0 0.0004780396993737668
by O 0 3.095266038144473e-06
a O 0 0.02487930655479431
genetic B-Disease 1 0.999817430973053
defect I-Disease 1 0.9997678399085999
in O 0 6.9494535637204535e-06
N O 0 0.00011561620340216905
- O 0 8.380865619983524e-05
acetylgalactosamine O 0 0.00019503897055983543
- O 0 0.00011388105485821143
6 O 0 1.3591611605079379e-05
- O 0 0.0182389784604311
sulfate O 0 0.002968468703329563
sulfatase O 0 0.002381526865065098
( O 0 1.7995615053223446e-05
GALNS O 0 0.0009475554688833654
) O 0 2.23968927457463e-05
. O 0 2.209357808169443e-05

Previous O 0 9.521994070382789e-05
studies O 0 1.7294099961873144e-05
of O 0 1.3601068076241063e-06
patients O 0 7.280274985532742e-06
from O 0 4.755474094508827e-07
a O 0 2.51662436312472e-06
British O 0 0.00012501618766691536
- O 0 0.00011226931383134797
Irish O 0 2.1879150153836235e-06
population O 0 1.32662705709663e-07
showed O 0 5.082439429315855e-07
that O 0 6.636555127670363e-08
the O 0 2.1173856623590837e-07
I113F O 0 1.2526698810688686e-05
mutation O 0 2.2829453882877715e-06
is O 0 5.026130622809433e-08
the O 0 6.110477102083678e-08
most O 0 6.878664038367788e-08
common O 0 2.3083535438672698e-07
single O 0 9.617591558708227e-07
mutation O 0 3.6620429000322474e-06
among O 0 8.914699947126792e-07
MPS B-Disease 1 0.9998605251312256
IVA I-Disease 1 0.9999998807907104
patients O 0 0.0012532776454463601
and O 0 2.621673502289923e-06
produces O 0 3.181280771968886e-05
a O 0 0.0005770832067355514
severe O 1 0.9999071359634399
clinical O 1 0.5988585948944092
phenotype O 1 0.974250078201294
. O 0 0.0001299905270570889

We O 0 3.212811498087831e-05
studied O 0 4.668886322178878e-05
mutations O 0 5.178646824788302e-05
in O 0 1.7100080640375381e-06
the O 0 1.4524894140777178e-06
GALNS O 0 0.00014091990306042135
gene O 0 6.973486506467452e-06
from O 0 8.693189101904863e-07
23 O 0 1.8230562091048341e-06
additional O 0 2.062100293187541e-06
MPS B-Disease 1 0.9999361038208008
IVA I-Disease 1 0.9999995231628418
patients O 0 0.0008766392711549997
( O 0 5.350044034457824e-07
15 O 0 2.619766235056886e-07
from O 0 1.8953534208776546e-07
Australia O 0 2.534812040266843e-07
, O 0 5.857074825144082e-08
8 O 0 1.8968414394748834e-07
from O 0 1.1779543740431109e-07
Northern O 0 5.84727445129829e-07
Ireland O 0 2.9196683044574456e-06
) O 0 1.416054971059566e-07
, O 0 3.4777624335902146e-08
with O 0 5.981338802030223e-08
various O 0 3.96699050497773e-07
clinical O 0 0.00015860400162637234
phenotypes O 0 0.018343472853302956
( O 0 1.3322996892384253e-05
severe O 0 0.14195142686367035
, O 0 4.981080792276771e-07
16 O 0 1.0576293334452203e-06
cases O 0 3.977157518875174e-07
; O 0 3.747574055523728e-07
intermediate O 0 1.06514198705554e-06
, O 0 1.8892302477979683e-07
4 O 0 9.764492006070213e-07
cases O 0 8.352157578883634e-07
; O 0 4.045389232487651e-06
mild O 0 0.2550162076950073
, O 0 1.6967670717349392e-06
3 O 0 2.9124323646101402e-06
cases O 0 2.3026771032164106e-06
) O 0 4.588323463394772e-06
. O 0 1.036967023537727e-05

We O 0 1.0455813935550395e-05
found O 0 2.096253638228518e-06
two O 0 5.022565687795577e-07
common O 0 1.2515274647739716e-06
mutations O 0 2.4160381144611165e-06
that O 0 6.141744535170801e-08
together O 0 1.0607166700538073e-07
accounted O 0 1.6918116330089106e-07
for O 0 3.062103814954753e-08
32 O 0 1.698791294302282e-07
% O 0 3.622631083999295e-08
of O 0 2.5605583431342893e-08
the O 0 1.5451068691163528e-07
44 O 0 1.1745872825486003e-06
unrelated O 0 7.405161795759341e-06
alleles O 0 8.642305147077423e-06
in O 0 1.3039963278060895e-06
these O 0 1.8938892480946379e-06
patients O 0 5.1748647820204496e-05
. O 0 2.5626024580560625e-05

One O 0 1.5245696886267979e-05
is O 0 1.666589810156438e-06
the O 0 1.3742165947405738e-06
T312S O 0 4.3965530494460836e-05
mutation O 0 1.3151467101124581e-05
, O 0 4.004854758932197e-07
a O 0 1.177904323412804e-06
novel O 0 3.4030902043014066e-06
mutation O 0 4.033358891319949e-06
found O 0 4.2324990090492065e-07
exclusively O 0 1.394865876136464e-06
in O 0 4.599525709636509e-06
milder O 1 0.9167783260345459
patients O 0 0.0015114264097064734
. O 0 3.7949423131067306e-05

The O 0 9.870788744592573e-06
other O 0 6.646599786108709e-07
is O 0 2.848843791980471e-07
the O 0 3.289716801191389e-07
previously O 0 3.214149955965695e-06
described O 0 8.044149581110105e-06
I113F O 0 1.3563344509748276e-05
that O 0 4.872906060882087e-07
produces O 0 6.7538458097260445e-06
a O 0 4.082681698491797e-05
severe O 1 0.9977497458457947
phenotype O 1 0.8147150278091431
. O 0 0.00011540450213942677

The O 0 4.612343036569655e-05
I113F O 0 0.00016876566223800182
and O 0 6.4477635532966815e-06
T312S O 0 6.057175778551027e-05
mutations O 0 1.792296279745642e-05
accounted O 0 2.0339596176199848e-06
for O 0 2.1484991918896412e-07
8 O 0 1.0370602012699237e-06
( O 0 5.408030006037734e-07
18 O 0 3.4432235906933784e-07
% O 0 1.3004827792428841e-07
) O 0 1.0403672945358267e-07
and O 0 1.5035749356684391e-07
6 O 0 4.084037925622397e-07
( O 0 2.153237517177331e-07
14 O 0 2.2121530207641626e-07
% O 0 8.635417003688417e-08
) O 0 6.689192844078207e-08
of O 0 4.962962663057624e-08
44 O 0 1.2181924375909148e-06
unrelated O 0 8.24194103188347e-06
alleles O 0 1.6659967513987795e-05
, O 0 1.8019338767771842e-06
respectively O 0 1.3378969015320763e-05
. O 0 1.2983643500774633e-05

The O 0 4.339378938311711e-05
relatively O 0 2.4148439479176886e-05
high O 0 1.4257519978855271e-05
residual O 0 1.8955130144604482e-05
GALNS O 0 9.636762843001634e-05
activity O 0 3.983233909821138e-06
seen O 0 8.567387794755632e-07
when O 0 3.38096924679121e-07
the O 0 2.8710010724353197e-07
T312S O 0 6.188372935866937e-06
mutant O 0 3.840255430986872e-06
cDNA O 0 3.5845855563820805e-06
is O 0 2.684420508103358e-07
overexpressed O 0 6.543981271533994e-06
in O 0 2.4829247990965087e-07
mutant O 0 3.875888978654984e-06
cells O 0 1.2843578360843821e-06
provides O 0 1.8535693868670933e-07
an O 0 9.55740446784148e-08
explanation O 0 3.355548017225374e-07
for O 0 1.228529953323232e-07
the O 0 1.3714816304855049e-06
mild O 1 0.9788092970848083
phenotype O 1 0.7614148855209351
in O 0 2.7033494916395284e-05
patients O 0 1.8364424249739386e-05
with O 0 1.2275384051463334e-06
this O 0 5.836187938257353e-06
mutation O 0 0.00016166598652489483
. O 0 2.2592061213799752e-05

The O 0 1.5137071386561729e-05
distribution O 0 4.8811753003974445e-06
and O 0 4.167119698195165e-07
relative O 0 6.359492203955597e-07
frequencies O 0 9.33292426452681e-07
of O 0 4.109969609089603e-08
the O 0 1.7939420615675772e-07
I113F O 0 5.147082447365392e-06
and O 0 4.903233730146894e-07
T312S O 0 1.9508852346916683e-05
mutations O 0 4.9088198466051836e-06
in O 0 2.6532219976616034e-07
Australia O 0 3.981521956575307e-07
corresponded O 0 9.539971870253794e-07
to O 0 1.4679116588922625e-07
those O 0 7.847533822769037e-08
observed O 0 3.472974015039654e-07
in O 0 9.836161751763939e-08
Northern O 0 4.218805713662732e-07
Ireland O 0 1.6559274627070408e-06
and O 0 9.368042697133205e-08
are O 0 9.686082158566478e-09
unique O 0 3.052237573797356e-08
to O 0 3.562931993883467e-08
these O 0 1.7950812392086846e-08
two O 0 2.9277485324996633e-08
populations O 0 1.0440268738420855e-07
, O 0 4.31694076041822e-08
suggesting O 0 3.482336410343123e-07
that O 0 5.843183004117236e-08
both O 0 1.2518218284185423e-07
mutations O 0 1.7570088175489218e-06
were O 0 1.26687268675596e-07
probably O 0 2.2900533735992212e-07
introduced O 0 9.940030167854275e-07
to O 0 1.270777403306056e-07
Australia O 0 2.711389868181868e-07
by O 0 1.7891785830670415e-07
Irish O 0 8.860521916176367e-07
migrants O 0 3.607146084050328e-07
during O 0 9.821668527365546e-07
the O 0 7.798501542310987e-07
19th O 0 1.5518924556090496e-05
century O 0 2.783208947221283e-05
. O 0 1.9850433091050945e-05

Haplotype O 0 0.005463773850351572
analysis O 0 5.9206169680692255e-05
using O 0 1.2557114132505376e-05
6 O 0 8.652802534925286e-06
RFLPs O 0 4.794866617885418e-05
provides O 0 1.0096533742398606e-06
additional O 0 3.949610629661038e-07
data O 0 6.902135396558151e-07
that O 0 1.10333068903401e-07
the O 0 4.636386279344151e-07
I113F O 0 2.450895590300206e-05
mutation O 0 6.554174433404114e-06
originated O 0 1.765506340234424e-06
from O 0 5.747673412770382e-07
a O 0 2.6898583200818393e-06
common O 0 7.046030987112317e-06
ancestor O 0 5.5429849453503266e-05
. O 0 1.9873541532433592e-05

The O 0 6.026668870617868e-06
other O 0 7.687019092372793e-07
9 O 0 3.3486792290204903e-06
novel O 0 3.860734523186693e-06
mutations O 0 8.77928778209025e-06
identified O 0 7.94592210695555e-07
in O 0 2.1848882170161232e-07
these O 0 1.9213435109577404e-07
23 O 0 8.878082553565037e-06
patients O 0 2.691659801712376e-06
were O 0 1.7848840627721074e-07
each O 0 6.263357477109821e-08
limited O 0 3.941892998682306e-07
to O 0 2.1286528806285787e-07
a O 0 8.708980203664396e-07
single O 0 4.05506898459862e-06
family O 0 2.556821891630534e-05
. O 0 1.3655636394105386e-05

These O 0 9.087127182283439e-06
data O 0 4.965697826264659e-06
provide O 0 7.384812192867685e-07
further O 0 4.987887791685353e-07
evidence O 0 3.385363811503339e-07
for O 0 1.9624289393505023e-07
extensive O 0 3.4198681078123627e-06
allelic O 0 5.1858216465916485e-05
heterogeneity O 0 6.02988620812539e-05
in O 0 2.6801824787980877e-05
MPS B-Disease 1 0.999873161315918
IVA I-Disease 1 0.9998109936714172
in O 0 1.2088924449926708e-05
British O 0 0.0030503813177347183
- O 0 0.10157908499240875
Irish O 0 2.390316512901336e-05
patients O 0 1.792226726138324e-06
and O 0 8.697702469362412e-08
provide O 0 6.133386420970055e-08
evidence O 0 4.831554889506151e-08
for O 0 2.975760438062025e-08
their O 0 1.3538583232275414e-07
transmission O 0 0.00033606396755203605
to O 0 1.1248044273770574e-07
Australia O 0 1.6730855634250474e-07
by O 0 1.1123257337430914e-07
British O 0 5.634145509247901e-06
- O 0 1.2988905837119091e-05
Irish O 0 2.3890543161542155e-06
migrants O 0 1.2837026588385925e-06
. O 0 1.1343880714775878e-06
. O 0 8.584501301811542e-06

Identification O 0 6.722301623085514e-05
of O 0 8.505537152814213e-06
constitutional O 0 0.00012924883048981428
WT1 O 1 0.8007032871246338
mutations O 0 0.0007560833473689854
, O 0 2.077116050713812e-06
in O 0 3.097430408161017e-06
patients O 0 1.3058484000794124e-05
with O 0 3.487272579150158e-06
isolated O 0 0.1455223113298416
diffuse B-Disease 1 0.99998939037323
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 5.453354788187426e-06
and O 0 4.759080809435545e-07
analysis O 0 1.1117207350253011e-06
of O 0 1.0284932159265736e-06
genotype O 0 0.18052959442138672
/ O 1 0.6417682766914368
phenotype O 0 0.0014822282828390598
correlations O 0 8.473759407934267e-06
by O 0 4.3367310809117043e-07
use O 0 4.582554424814589e-07
of O 0 2.4605407134004054e-07
a O 0 6.2899621298129205e-06
computerized O 0 0.001947730896063149
mutation O 0 0.0001177669400931336
database O 0 4.330962474341504e-05
. O 0 3.0716015317011625e-05

Constitutional O 0 0.0003211981966160238
mutations O 0 0.0001432926655979827
of O 0 1.859615395005676e-06
the O 0 2.6427017019159393e-06
WT1 O 0 0.0005696795415133238
gene O 0 1.2774712558893953e-05
, O 0 5.21639037742716e-07
encoding O 0 2.4152639070962323e-06
a O 0 3.3082330901379464e-06
zinc O 0 0.0018618293106555939
- O 0 3.1972631404642016e-05
finger O 0 1.2003166375507135e-05
transcription O 0 4.416421688802075e-06
factor O 0 8.769696364652191e-07
involved O 0 2.8392906870067236e-07
in O 0 1.2774717106367461e-06
renal O 0 0.1420266181230545
and O 0 8.598852900831844e-07
gonadal O 0 0.0001877288450486958
development O 0 6.899950335537142e-07
, O 0 8.730795286737703e-08
are O 0 1.627235945989014e-08
found O 0 8.695430153693451e-08
in O 0 1.234345461398334e-07
most O 0 2.6407565201225225e-07
patients O 0 3.377061375431367e-06
with O 0 4.204685410513775e-06
Denys B-Disease 1 0.9998121857643127
- I-Disease 1 0.9999972581863403
Drash I-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 8.246160723501816e-05
DDS B-Disease 1 0.9999998807907104
) O 0 5.847241027368e-06
, O 0 2.076999180644634e-06
or O 0 5.163704190636054e-05
diffuse B-Disease 1 0.9998261332511902
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.002678503282368183
DMS B-Disease 1 0.9941698312759399
) O 0 2.167200136682368e-06
associated O 0 2.426005266897846e-06
with O 0 1.3003726735405507e-06
pseudohermaphroditism B-Disease 1 0.9999854564666748
and O 0 9.080394374905154e-05
/ O 0 0.4032112956047058
or O 0 0.00022419373271986842
Wilms B-Disease 1 0.9987885355949402
tumor I-Disease 1 0.9375502467155457
( O 0 7.68908066675067e-05
WT B-Disease 1 0.993485152721405
) O 0 1.795332536858041e-05
. O 0 1.9076633179793134e-05

Most O 0 0.00012099423474865034
mutations O 0 0.0041748229414224625
in O 0 0.0005696423468180001
DDS B-Disease 1 1.0
patients O 1 0.6080920696258545
lie O 0 3.4822434827219695e-05
in O 0 4.116350282856729e-06
exon O 0 4.372336115920916e-05
8 O 0 2.590188842077623e-06
or O 0 9.53646974721778e-07
exon O 0 1.779330887075048e-05
9 O 0 1.8087724811266526e-06
, O 0 4.7473716335844074e-07
encoding O 0 5.871621397091076e-06
zinc O 0 0.00011924908903893083
finger O 0 1.8922279195976444e-05
2 O 0 7.503638244088506e-07
or O 0 7.550153213742306e-07
zinc O 0 2.1198648028075695e-05
finger O 0 4.34720141129219e-06
3 O 0 2.4588376845713356e-07
, O 0 5.990769835761967e-08
respectively O 0 2.0615583196104126e-07
, O 0 3.6424466998141725e-08
with O 0 8.38308906736529e-08
a O 0 1.900040274449566e-06
hot O 0 5.215931378188543e-05
spot O 0 9.039735232363455e-06
( O 0 1.23687948416773e-06
R394W O 0 9.864070307230577e-06
) O 0 7.216467565740459e-07
in O 0 1.243397264261148e-06
exon O 0 5.08272678416688e-05
9 O 0 2.0226927517796867e-05
. O 0 1.9024710127268918e-05

We O 0 1.1491309123812243e-05
analyzed O 0 1.0717319128161762e-05
a O 0 8.381128964174422e-07
series O 0 1.0110766197612975e-06
of O 0 2.2919520858977194e-07
24 O 0 4.169673502474325e-06
patients O 0 2.2146257379063172e-06
, O 0 1.498268886734877e-07
10 O 0 2.2824004020094435e-07
with O 0 1.0036877711172565e-06
isolated B-Disease 0 0.008069477044045925
DMS I-Disease 1 0.9972183704376221
( O 0 8.66461869009072e-06
IDMS B-Disease 0 0.002251716796308756
) O 0 4.105849029656383e-07
, O 0 1.3817199828736193e-07
10 O 0 1.731238228330767e-07
with O 0 6.184887979543419e-07
DDS B-Disease 1 0.9999998807907104
, O 0 6.416544238163624e-07
and O 0 2.5054691832337994e-07
4 O 0 1.2109587714803638e-06
with O 0 5.348826562112663e-06
urogenital B-Disease 1 0.9997894167900085
abnormalities I-Disease 1 0.9999655485153198
and O 0 9.109241364058107e-05
/ O 0 0.36496540904045105
or O 0 0.00019601921667344868
WT B-Disease 1 0.9996829032897949
. O 0 4.974436160409823e-05

We O 0 6.5552034357097e-05
report O 0 5.6650718761375174e-05
WT1 O 0 0.001333603635430336
heterozygous O 0 0.00024944887263700366
mutations O 0 5.342240910977125e-05
in O 0 2.2760671072319383e-06
16 O 0 7.161905159591697e-06
patients O 0 5.6913831940619275e-06
, O 0 1.698864053878424e-07
4 O 0 3.3369781249348307e-07
of O 0 2.052616423497966e-07
whom O 0 3.33658795170777e-06
presented O 0 9.21780701901298e-06
with O 0 1.4563519471266773e-05
IDMS B-Disease 1 0.7471038699150085
. O 0 6.128699897089973e-05

One O 0 9.027415217133239e-06
male O 0 5.62502418688382e-06
and O 0 6.109056016612158e-07
two O 0 8.892020559869707e-07
female O 0 1.4472860129899345e-05
IDMS B-Disease 1 0.975093424320221
patients O 0 7.559711229987442e-05
with O 0 2.536600732128136e-05
WT1 O 1 0.9968991279602051
mutations O 0 0.024699563160538673
underwent O 1 0.9730494618415833
normal O 0 0.00041653256630524993
puberty O 0 0.0011548909824341536
. O 0 6.833301449660212e-05

Two O 0 4.806674041901715e-05
mutations O 0 0.0004025412490591407
associated O 0 2.3807935576769523e-05
with O 0 4.34239473179332e-06
IDMS B-Disease 0 0.054843395948410034
are O 0 1.74269615627054e-07
different O 0 8.630328807157639e-08
from O 0 2.3935530180096976e-07
those O 0 3.6333054254100716e-07
described O 0 0.00014974713849369437
in O 0 0.0038917232304811478
DDS B-Disease 1 1.0
patients O 1 0.5197307467460632
. O 0 6.0208429204067215e-05

No O 0 9.224670066032559e-05
WT1 O 0 0.010461771860718727
mutations O 0 0.00022936823370400816
were O 0 2.3568652522953926e-06
detected O 0 4.993307811673731e-06
in O 0 2.1178743736527395e-07
the O 0 1.574762649170225e-07
six O 0 3.7901583027633023e-07
other O 0 6.968753041292075e-07
IDMS B-Disease 1 0.8991864323616028
patients O 0 2.0800796846742742e-05
, O 0 7.857717037040857e-07
suggesting O 0 9.015851901494898e-06
genetic O 0 4.995689323550323e-06
heterogeneity O 0 1.4147284673526883e-05
of O 0 1.0820568832059507e-06
this O 0 7.022446516202763e-05
disease O 0 0.13669075071811676
. O 0 3.251360612921417e-05

We O 0 5.4086020099930465e-05
analyzed O 0 0.0002236951404483989
genotype O 0 0.011090459302067757
/ O 0 0.3707793056964874
phenotype O 0 0.0045160818845033646
correlations O 0 1.0428190762468148e-05
, O 0 1.677100129882092e-07
on O 0 1.4233458500712004e-07
the O 0 8.292063569115271e-08
basis O 0 5.6676103810104905e-08
of O 0 2.7045350847743066e-08
the O 0 1.473544415375727e-07
constitution O 0 6.067459707992384e-07
of O 0 9.797534517019812e-08
a O 0 2.890211590056424e-06
WT1 O 0 0.0006628673290833831
mutation O 0 4.407757842272986e-06
database O 0 6.693965701742854e-07
of O 0 1.4994324715189578e-07
84 O 0 5.177374077902641e-06
germ O 0 0.018626820296049118
- O 0 0.08170776814222336
line O 0 0.00035690818913280964
mutations O 0 6.334750651149079e-06
, O 0 1.2457148557132314e-07
to O 0 1.353813132709547e-07
compare O 0 4.097540511338593e-07
the O 0 1.2994659925880114e-07
distribution O 0 3.5203692050345126e-07
and O 0 1.1301116842332704e-07
type O 0 1.4760959174964228e-06
of O 0 1.2535073778963124e-07
mutations O 0 4.6128311623760965e-06
, O 0 6.620460624162661e-08
according O 0 9.580620030646969e-08
to O 0 2.1471308286891144e-07
the O 0 9.942401675289148e-07
different O 0 5.222978870733641e-06
symptoms O 0 0.14190258085727692
. O 0 3.291094253654592e-05

This O 0 2.6784116926137358e-05
demonstrated O 0 2.6112031264347024e-05
( O 0 3.0822077405900927e-06
1 O 0 6.494688022939954e-07
) O 0 2.0575141945755604e-07
the O 0 1.2275087613033975e-07
association O 0 8.705060849933943e-07
between O 0 4.164767517522705e-07
mutations O 0 3.5384543934924295e-06
in O 0 3.264729571128555e-07
exons O 0 3.243216497139656e-06
8 O 0 6.64173967379611e-07
and O 0 2.277970878594715e-07
9 O 0 2.097597644024063e-06
and O 0 3.908031885657692e-06
DMS B-Disease 1 0.9299958348274231
; O 0 1.7952853568203864e-06
( O 0 3.896886369147978e-07
2 O 0 4.096575594303431e-07
) O 0 2.8260780027267174e-07
among O 0 2.0331633265868732e-07
patients O 0 1.2508068039096543e-06
with O 0 1.6882976296983543e-06
DMS B-Disease 1 0.974049985408783
, O 0 2.2213534123238787e-07
a O 0 4.3080740397272166e-07
higher O 0 4.157945454608125e-07
frequency O 0 1.5425054016304784e-06
of O 0 1.283056150214179e-07
exon O 0 9.650028005125932e-06
8 O 0 1.2210362001496833e-06
mutations O 0 2.6529687602305785e-06
among O 0 1.6760591847742035e-07
46 O 0 9.860597174338182e-07
, O 0 2.326856019863044e-06
XY O 0 0.29218941926956177
patients O 0 2.339246748306323e-06
with O 0 4.534499282726756e-07
female O 0 1.6632172901154263e-06
phenotype O 0 3.44328727805987e-05
than O 0 1.1344807404611856e-07
among O 0 2.2852755421354232e-07
46 O 0 2.1931855371803977e-06
, O 0 1.0170104360440746e-05
XY O 1 0.8683986663818359
patients O 0 9.22134131542407e-06
with O 0 4.230949457451061e-07
sexual O 0 1.7203096831508446e-06
ambiguity O 0 2.823046770572546e-06
or O 0 2.232523229395156e-06
male O 0 3.923701569874538e-06
phenotype O 0 0.00042507683974690735
; O 0 1.1166179092469974e-06
and O 0 6.53224446978129e-07
( O 0 6.044410838512704e-07
3 O 0 5.044724957770086e-07
) O 0 2.406457326742384e-07
statistically O 0 4.358997500730766e-07
significant O 0 2.1061379129605484e-07
evidence O 0 4.5994812580829603e-07
that O 0 4.860221451963298e-07
mutations O 0 2.8206143269926542e-06
in O 0 2.3284667349798838e-07
exons O 0 3.750548785319552e-06
8 O 0 6.717153837598744e-07
and O 0 4.1029915109902504e-07
9 O 0 1.9334800072101643e-06
preferentially O 0 8.10319761512801e-06
affect O 0 1.6616714901829255e-06
amino O 0 1.69996599197475e-06
acids O 0 8.658644787828962e-07
with O 0 9.667887468367553e-08
different O 0 2.3210508004467556e-07
functions O 0 1.5435176692335517e-06
. O 0 1.2454005400286405e-06
. O 0 7.15228816261515e-06

The O 0 0.00010570619633654132
185delAG O 0 0.0015572640113532543
BRCA1 O 0 0.0019092053407803178
mutation O 0 7.060721691232175e-05
originated O 0 8.14904342405498e-06
before O 0 9.642029681344866e-07
the O 0 4.084080842403637e-07
dispersion O 0 2.075546262858552e-06
of O 0 7.623302167303336e-08
Jews O 0 2.2486271689103887e-07
in O 0 7.570948667989796e-08
the O 0 8.139532781115122e-08
diaspora O 0 6.960025302760187e-07
and O 0 1.709010604145078e-07
is O 0 1.4140158555164817e-07
not O 0 1.2967660723006702e-07
limited O 0 1.3198142596593243e-06
to O 0 2.6841898943530396e-06
Ashkenazim O 0 0.0002210200618719682
. O 0 1.4978052604419645e-05

The O 0 5.204489207244478e-05
185delAG O 0 0.0003378096444066614
mutation O 0 7.21995165804401e-05
in O 0 5.300323209667113e-06
BRCA1 O 0 5.9006189985666424e-05
is O 0 5.386216344049899e-07
detected O 0 4.319714662415208e-06
in O 0 7.733431743872643e-07
Ashkenazi O 0 2.3587728719576262e-05
Jews O 0 8.085419835879293e-07
both O 0 4.469259238248924e-07
in O 0 3.6761482533620438e-06
familial B-Disease 1 0.9814188480377197
breast I-Disease 1 0.9999725818634033
and I-Disease 1 0.9994810223579407
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 1.0543100188442622e-06
in O 0 3.681020643853117e-07
the O 0 4.596854239480308e-07
general O 0 2.066740762529662e-06
population O 0 1.6641629372315947e-06
. O 0 7.219025519589195e-06

All O 0 3.0258197512011975e-05
tested O 0 0.00023377913748845458
Ashkenazi O 0 0.0008517911774106324
mutation O 0 5.8613892178982496e-05
carriers O 0 1.1236481441301294e-05
share O 0 1.68181509252463e-06
the O 0 7.048968768685882e-07
same O 0 1.57246358867269e-06
allelic O 0 3.744984496734105e-05
pattern O 0 1.6851523469085805e-05
at O 0 3.0123655960778706e-06
the O 0 7.340838237723801e-06
BRCA1 O 0 0.00043951786938123405
locus O 0 0.0002828920551110059
. O 0 4.4314270780887455e-05

Our O 0 1.4436495803238358e-05
previous O 0 7.748396456008777e-06
study O 0 1.4937263586034533e-06
showed O 0 1.5093476122274296e-06
that O 0 1.4338336029595666e-07
this O 0 2.595707826458238e-07
Ashkenazi O 0 0.00011318708857288584
mutation O 0 4.860522494709585e-06
also O 0 3.5528216812963365e-07
occurs O 0 2.632692428505834e-07
in O 0 1.5484833681966848e-07
Iraqi O 0 5.809044978377642e-07
Jews O 0 2.7911241318179236e-07
with O 0 1.4613453913625563e-07
a O 0 1.2139119007770205e-06
similar O 0 9.329630302090663e-06
allelic O 0 0.0003400870773475617
pattern O 0 0.0004455896560102701
. O 0 4.787373109138571e-05

We O 0 7.02064971846994e-06
extended O 0 5.9706180763896555e-06
our O 0 6.627408879467112e-07
analysis O 0 4.6732091618650884e-07
to O 0 1.3176357072097744e-07
other O 0 1.0165617680968353e-07
non O 0 6.462448709498858e-07
- O 0 3.2358911994379014e-06
Ashkenazi O 0 5.200041414354928e-06
subsets O 0 1.1091748319813632e-06
354 O 0 1.6375313407479553e-06
of O 0 7.966828974304008e-08
Moroccan O 0 2.089294412144227e-06
origin O 0 3.751718224975775e-07
, O 0 1.4624718858158303e-07
200 O 0 3.024510988325346e-07
Yemenites O 0 6.717654741805745e-06
and O 0 2.0471074435590708e-07
150 O 0 7.920100983938028e-07
Iranian O 0 3.756322030312731e-06
Jews O 0 6.655126526311506e-06
. O 0 1.2838622751587536e-05

Heteroduplex O 0 0.004174954257905483
analysis O 0 6.442844460252672e-05
complemented O 0 4.332102253101766e-05
by O 0 1.6895492080948316e-06
direct O 0 1.5107127637747908e-06
DNA O 0 2.5620884116506204e-06
sequencing O 0 2.064940190393827e-06
of O 0 5.826978508594038e-07
abnormally O 0 6.41031438135542e-05
migrating O 0 3.4041063372569624e-06
bands O 0 4.394922143546864e-06
were O 0 2.03910235541116e-06
employed O 0 1.6922076611081138e-05
. O 0 1.5269386494765058e-05

Four O 0 7.387167897832114e-06
of O 0 7.817235996299132e-07
Moroccan O 0 8.341478860529605e-06
origin O 0 1.0879434739763383e-06
( O 0 4.988291948393453e-07
1 O 0 1.5030057909370953e-07
. O 0 4.760996219488334e-08
1 O 0 9.426672420431714e-08
% O 0 6.752775760787699e-08
) O 0 3.436170459281129e-08
and O 0 2.4080707206053376e-08
none O 0 3.767860334846773e-08
of O 0 1.457588183484404e-08
the O 0 1.7515971251214069e-07
Yemenites O 0 1.2381679880490992e-05
or O 0 2.4983256707855617e-07
Iranians O 0 3.255293563597661e-07
was O 0 8.260719255304139e-07
a O 0 3.8960538972787617e-07
carrier O 0 4.981749498256249e-06
of O 0 2.0213158791193564e-07
the O 0 2.4391079023189377e-06
185delAG O 0 0.00027731063892133534
mutation O 0 0.00011213514517294243
. O 0 1.9020881154574454e-05

BRCA1 O 0 0.040893398225307465
allelic O 0 0.004434983711689711
patterns O 0 0.0005357213085517287
were O 0 5.601576503977412e-06
determined O 0 1.6912032378968433e-06
for O 0 8.044197841172718e-08
four O 0 5.91186868348359e-08
of O 0 2.508241969678693e-08
these O 0 4.97929946163822e-08
individuals O 0 2.2995113369006503e-08
and O 0 3.807703663483153e-08
for O 0 4.857260194057744e-08
12 O 0 2.3028081841403036e-07
additional O 0 4.100378419025219e-07
non O 0 1.5124051060411148e-06
- O 0 7.431637641275302e-05
Ashkenazi O 0 0.00014715436554979533
185delAG O 0 6.537698936881498e-05
mutation O 0 2.6424764655530453e-05
carriers O 0 9.675812179921195e-06
who O 0 1.357558630843414e-05
had O 1 0.9494049549102783
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001262403529835865

Six O 0 3.034138717339374e-05
non O 0 1.7456985005992465e-05
- O 0 8.941556006902829e-05
Ashkenazi O 0 3.8510417653014883e-05
individuals O 0 2.0865853400664491e-07
shared O 0 2.917119843459659e-07
the O 0 3.7245035855448805e-07
common O 0 3.7889942632318707e-06
Ashkenazi O 0 0.00808950886130333
haplotype O 0 0.0030064459424465895
, O 0 4.381641645068157e-07
four O 0 1.623513554704914e-07
had O 0 7.768423415654979e-07
a O 0 4.629877992101683e-07
closely O 0 1.4231492286853609e-06
related O 0 1.8968934227814316e-06
pattern O 0 6.359677627187921e-06
, O 0 1.0166665731503599e-07
and O 0 5.2996885102629676e-08
the O 0 2.5448494511692843e-07
rest O 0 1.644981921344879e-06
( O 0 1.3622330925500137e-06
n O 0 6.84113911120221e-06
= O 0 3.468327349764877e-06
6 O 0 7.341353125411842e-07
) O 0 3.724567534391099e-07
displayed O 0 1.4052229744265787e-06
a O 0 2.5469794309174176e-06
distinct O 0 1.1852653187816031e-05
BRCA1 O 0 0.00043016180279664695
allelic O 0 0.0005710179102607071
pattern O 0 0.0007869531982578337
. O 0 5.090619015390985e-05

We O 0 1.5973258996382356e-05
conclude O 0 1.791098475223407e-05
that O 0 6.371973881869053e-07
the O 0 1.1285020491413889e-06
185delAG O 0 0.00010752146772574633
BRCA1 O 0 0.00033571250969544053
mutation O 0 9.423906703887042e-06
occurs O 0 5.741981112805661e-07
in O 0 1.300190035635751e-07
some O 0 9.157022162753492e-08
non O 0 6.606143756471283e-07
- O 0 1.7375134120811708e-05
Ashkenazi O 0 2.193419641116634e-05
populations O 0 8.632993626633834e-07
at O 0 5.833066438754031e-07
rates O 0 1.704602368590713e-06
comparable O 0 4.871502596870414e-07
with O 0 1.1637678909437454e-07
that O 0 2.0555980029257626e-07
of O 0 8.573371133024921e-07
Ashkenazim O 0 0.00027700065402314067
. O 0 2.4284345272462815e-05

The O 0 1.4580404240405187e-05
majority O 0 4.406803782330826e-06
of O 0 4.649253639854578e-07
Jewish O 0 4.751815140480176e-06
185delAG O 0 0.00011474436178104952
mutation O 0 2.594440957182087e-05
carriers O 0 3.945273419958539e-06
have O 0 2.5853566398836847e-07
a O 0 3.748646122403443e-07
common O 0 7.607033012391184e-07
allelic O 0 2.2204343622433953e-05
pattern O 0 9.730490091897082e-06
, O 0 1.2244349534284993e-07
supporting O 0 1.4469478060163965e-07
the O 0 9.43129521147057e-08
founder O 0 4.383452960610157e-06
effect O 0 3.093404643550457e-07
notion O 0 1.613677653722334e-07
, O 0 5.172835315647717e-08
but O 0 3.8739933927445236e-08
dating O 0 1.895995183076593e-07
the O 0 1.1472560856873315e-07
mutations O 0 7.19741592547507e-07
origin O 0 7.686961822628291e-08
to O 0 7.380545952173634e-08
an O 0 7.7742953408233e-08
earlier O 0 9.205729156747111e-07
date O 0 5.654188726111897e-07
than O 0 2.459297263612825e-07
currently O 0 1.4369617247211863e-06
estimated O 0 4.453238034329843e-06
. O 0 1.4724636457685847e-05

However O 0 1.8277203707839362e-05
, O 0 1.1607944543357007e-06
the O 0 4.3356644141567813e-07
different O 0 2.4875939175217354e-07
allelic O 0 9.561072147334926e-06
pattern O 0 6.889594715175917e-06
at O 0 7.583665819765883e-07
the O 0 1.8990402850249666e-06
BRCA1 O 0 6.976590520935133e-05
locus O 0 9.81447101366939e-06
even O 0 3.1610690598427027e-07
in O 0 1.4273693693667155e-07
some O 0 9.371421327841745e-08
Jewish O 0 1.3449330253934022e-06
mutation O 0 6.464572379627498e-06
carriers O 0 2.5642393666203134e-06
, O 0 2.7398812108003767e-07
might O 0 4.949505978402158e-07
suggest O 0 4.879523203271674e-07
that O 0 9.305571069262442e-08
the O 0 6.19955642378045e-07
mutation O 0 8.51392815093277e-06
arose O 0 4.081007773493184e-06
independently O 0 4.74033686259645e-06
. O 0 1.936868557095295e-06
. O 0 6.6336583586235065e-06

Crystal O 0 0.0018912660889327526
structure O 0 5.3207852033665404e-05
of O 0 3.4346155644016108e-06
the O 0 1.7380836652591825e-05
hemochromatosis B-Disease 1 0.9999990463256836
protein O 0 4.667514804168604e-05
HFE O 0 0.005517198704183102
and O 0 1.0221277761957026e-06
characterization O 0 2.0529914763756096e-06
of O 0 1.1741511229956814e-07
its O 0 4.2779902287293226e-07
interaction O 0 9.65075059866649e-07
with O 0 2.3278705612028716e-06
transferrin O 0 0.0002984846942126751
receptor O 0 0.00014376291073858738
. O 0 2.1482039301190525e-05

HFE O 0 0.3609634339809418
is O 0 3.5964145354228094e-05
an O 0 1.2234467249072623e-05
MHC O 0 0.0018096596468240023
- O 0 0.00047113196342252195
related O 0 2.8083375127607724e-06
protein O 0 1.4094546259002527e-06
that O 0 1.7511995054064755e-07
is O 0 1.63257922736193e-07
mutated O 0 2.24184896069346e-06
in O 0 3.4688792993620154e-07
the O 0 3.861695859086467e-06
iron B-Disease 1 0.9998981952667236
- I-Disease 1 0.9999974966049194
overload I-Disease 1 0.9999982118606567
disease I-Disease 1 0.9999959468841553
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00257306732237339

HFE O 0 0.01853957772254944
binds O 0 0.0004009306721854955
to O 0 3.8774567656219006e-05
transferrin O 0 0.000551172939594835
receptor O 0 0.0001143928020610474
( O 0 6.262381702981656e-06
TfR O 0 6.124907667981461e-05
) O 0 6.08576101512881e-07
and O 0 1.451158624377058e-07
reduces O 0 1.1697469517457648e-06
its O 0 4.158694935085805e-07
affinity O 0 1.28674855659483e-06
for O 0 2.534573013690533e-07
iron O 0 0.00017192101222462952
- O 0 1.3448634490487166e-05
loaded O 0 8.686942237545736e-06
transferrin O 0 4.613949204212986e-05
, O 0 1.5045302461658139e-06
implicating O 0 0.00014891655882820487
HFE O 0 0.001968556782230735
in O 0 1.3492465768649708e-05
iron O 0 0.3744107186794281
metabolism O 0 0.002800490241497755
. O 0 3.191304494976066e-05

The O 0 0.00017683648911770433
2 O 0 0.00022768655617255718
. O 0 0.00016379843873437494

6 O 0 0.00011988195910817012
A O 0 3.688639117171988e-05
crystal O 0 0.0001437849859939888
structure O 0 5.918445367569802e-06
of O 0 8.83681821051141e-07
HFE O 0 0.0013217899249866605
reveals O 0 5.958291694696527e-06
the O 0 4.968541134076077e-07
locations O 0 9.965953040591558e-07
of O 0 1.0731869224400725e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 8.361404616152868e-05
and O 0 5.705452394977328e-07
a O 0 3.0321577924041776e-06
patch O 0 0.01372424978762865
of O 0 1.6411914316449838e-07
histidines O 0 0.000589090574067086
that O 0 3.566410384792107e-07
could O 0 3.28689452544495e-07
be O 0 1.1128540933214026e-07
involved O 0 4.070254249199934e-07
in O 0 2.284827360199415e-06
pH O 0 0.00036624757922254503
- O 0 0.00011609101784415543
dependent O 0 1.2139096725150011e-05
interactions O 0 9.788689567358233e-06
. O 0 8.359891580766998e-06

We O 0 1.4067692063690629e-05
also O 0 3.278878011769848e-06
demonstrate O 0 4.364306732895784e-06
that O 0 1.516580709903792e-06
soluble O 0 2.9211636501713656e-05
TfR O 0 7.5746480433736e-05
and O 0 2.2007345705787884e-06
HFE O 0 0.001528327353298664
bind O 0 1.19630321933073e-05
tightly O 0 2.023410524998326e-05
at O 0 8.926670034270501e-07
the O 0 3.4565417195153714e-07
basic O 0 6.930511062819278e-07
pH O 0 2.756068852249882e-06
of O 0 4.655029783862119e-08
the O 0 2.1059508981124964e-07
cell O 0 1.1266760338912718e-05
surface O 0 3.575462869775947e-06
, O 0 1.1052831894176052e-07
but O 0 8.426774655845293e-08
not O 0 8.211888058440309e-08
at O 0 2.7020402626476425e-07
the O 0 1.282793391510495e-06
acidic O 0 0.0001799336023395881
pH O 0 1.8999760868609883e-05
of O 0 8.654162115817599e-07
intracellular O 0 9.650905121816322e-05
vesicles O 0 0.00034445623168721795
. O 0 2.580593354650773e-05

TfR O 1 0.5075462460517883
HFE O 1 0.5739213228225708
stoichiometry O 0 0.0032327475491911173
( O 0 7.068509148666635e-05
2 O 0 1.0767199455585796e-05
1 O 0 2.541660478527774e-06
) O 0 9.771963505045278e-07
differs O 0 2.4125681648001773e-06
from O 0 1.1026506854250329e-06
TfR O 0 9.951001266017556e-05
transferrin O 0 5.124078597873449e-05
stoichiometry O 0 1.4663247384305578e-05
( O 0 8.378236202588596e-07
2 O 0 2.985206037919852e-07
2 O 0 3.3185679626512865e-07
) O 0 2.0662862709741603e-07
, O 0 1.1983202341525612e-07
implying O 0 4.872505883213307e-07
a O 0 1.0544211903606993e-07
different O 0 3.7814100295463504e-08
mode O 0 3.917783715223777e-07
of O 0 5.1592177641168746e-08
binding O 0 5.730001362280746e-07
for O 0 3.15612879830951e-07
HFE O 0 0.00010462036152603105
and O 0 7.547877771685307e-07
transferrin O 0 2.7347428840585053e-05
to O 0 1.2904216646347777e-06
TfR O 0 5.394961408455856e-05
, O 0 1.6241003208961047e-07
consistent O 0 3.169823514781456e-07
with O 0 7.361285270235385e-08
our O 0 1.9309543120016315e-07
demonstration O 0 1.2231014352437342e-06
that O 0 3.629104980973352e-07
HFE O 0 7.86887903814204e-05
, O 0 4.0879544371819065e-07
transferrin O 0 2.901324478443712e-05
, O 0 4.4532450260703627e-07
and O 0 1.3383385066845221e-06
TfR O 0 8.2983031461481e-05
form O 0 1.881395974123734e-06
a O 0 6.252941147977253e-06
ternary O 0 5.5702908866805956e-05
complex O 0 4.074785465491004e-05
. O 0 2.5619987354730256e-05

Identification O 0 3.661383379949257e-05
of O 0 2.6507029815547867e-06
three O 0 1.1804932000814006e-06
novel O 0 4.017618721263716e-06
mutations O 0 9.70007386058569e-06
and O 0 2.0985250159810676e-07
a O 0 5.754737344432215e-07
high O 0 1.169340976048261e-06
frequency O 0 1.1320420298943645e-06
of O 0 7.404558033385911e-08
the O 0 5.639229243570298e-07
Arg778Leu O 0 0.00013165851123631
mutation O 0 6.622084583796095e-06
in O 0 9.701032013254007e-07
Korean O 0 6.226543973752996e-06
patients O 0 1.8924409232567996e-05
with O 0 2.0110179320909083e-05
Wilson B-Disease 1 0.7828866243362427
disease I-Disease 0 0.4318661391735077
. O 0 3.364257645444013e-05

Four O 0 7.79472611611709e-05
mutations O 0 0.0003638261987362057
- O 0 7.244531298056245e-05
- O 0 1.6570758816669695e-05
R778L O 0 1.4752537026652135e-05
, O 0 4.245111711043137e-07
A874V O 0 3.782012527153711e-06
, O 0 1.5652683771349984e-07
L1083F O 0 2.090294856316177e-06
, O 0 1.1224791052200089e-07
and O 0 1.5430541111527418e-07
2304delC O 0 1.079040885088034e-05
- O 0 1.6990557924145833e-05
- O 0 3.467341912255506e-06
in O 0 1.1073552741436288e-07
the O 0 1.8683064695323992e-07
copper O 0 1.1892439033545088e-05
- O 0 2.239763261968619e-06
transporting O 0 8.611630732957565e-07
enzyme O 0 2.155303491235827e-06
, O 0 3.30109998003536e-07
P O 0 6.168071558931842e-05
- O 0 2.998656600539107e-05
type O 0 1.6188785593840294e-05
ATPase O 0 4.515848195296712e-05
( O 0 9.683109283287195e-07
ATP7B O 0 2.792804480122868e-05
) O 0 1.7068882129933627e-07
, O 0 4.6930523467381136e-08
were O 0 9.72125206999408e-08
identified O 0 2.4866994863259606e-07
in O 0 3.711972169639921e-07
Korean O 0 3.598783223424107e-06
Patients O 0 6.217500867933268e-06
with O 0 9.948111255653203e-06
Wilson B-Disease 1 0.6453296542167664
disease I-Disease 0 0.22194817662239075
. O 0 2.9713433832512237e-05

Arg778Leu O 0 0.0012413895456120372
, O 0 4.112850092496956e-06
the O 0 6.119457793829497e-07
most O 0 3.360572691235575e-07
frequently O 0 1.980924707822851e-06
reported O 0 1.4404672583623324e-05
mutation O 0 1.1661670669127489e-06
of O 0 5.545853554167479e-08
this O 0 1.1371833608109227e-07
enzyme O 0 1.0482184507054626e-06
, O 0 1.2046461961290333e-07
was O 0 2.156238679162925e-06
found O 0 8.649923444181695e-08
in O 0 3.5862221636762115e-08
six O 0 7.643933486178867e-08
of O 0 4.1467576039622145e-08
eight O 0 9.270306122743932e-07
unrelated O 0 7.321461453102529e-05
patients O 0 5.960036560281878e-06
studied O 0 1.5688746088926564e-06
, O 0 2.667256637778337e-07
an O 0 4.0575656612418243e-07
allele O 0 8.555306521884631e-06
frequency O 0 4.104997969989199e-06
of O 0 5.224470100984036e-07
37 O 0 1.0365467460360378e-05
. O 0 1.2062724636052735e-05

5 O 0 2.4722578018554486e-05
% O 0 1.5826562957954593e-06
, O 0 2.8572239330060256e-07
which O 0 1.3758764794147282e-07
is O 0 1.178191482154034e-07
considerably O 0 1.5679562466175412e-06
higher O 0 3.9260868334167753e-07
than O 0 3.623335942393169e-08
those O 0 3.599990350267035e-08
in O 0 1.0479391221451806e-07
other O 0 1.5980444345586875e-07
Asian O 0 2.0330248844402377e-06
populations O 0 1.07267260318622e-05
. O 0 1.374659132125089e-05

The O 0 2.0995104932808317e-05
novel O 0 1.560205600981135e-05
single O 0 4.7912958507367875e-06
nucleotide O 0 8.35185892356094e-06
deletion O 0 1.1105530575150624e-05
, O 0 5.50791355635738e-07
2304delC O 0 1.0968593414872885e-05
, O 0 2.800178151574073e-07
was O 0 3.1523948109679623e-06
found O 0 4.973471732228063e-07
in O 0 5.775112867922871e-07
one O 0 2.114291419275105e-06
patient O 0 0.00010469562403159216
. O 0 1.5163974239840172e-05

Since O 0 0.00010269098856952041
a O 0 3.5410645068623126e-05
mutation O 0 7.593812915729359e-05
at O 0 6.364974524331046e-06
cDNA O 0 5.8430625358596444e-05
nucleotide O 0 2.970927016576752e-05
2302 O 0 0.0002244876086479053
( O 0 2.1987666514178272e-06
2302insC O 0 1.7000802472466603e-05
) O 0 6.539411856465449e-07
had O 0 1.5443099528056337e-06
been O 0 3.077256849337573e-07
previously O 0 6.984681135691062e-07
described O 0 1.4545049680236843e-06
, O 0 4.907902706463574e-08
this O 0 3.150345762037432e-08
region O 0 1.1976678138125862e-07
of O 0 6.915313832678294e-08
the O 0 8.548967116439599e-07
ATP7B O 0 0.13381245732307434
gene O 0 7.458958134520799e-05
may O 0 1.2167225577286445e-05
be O 0 4.83171163523366e-07
susceptible O 0 5.845005034643691e-06
to O 0 1.5660853023291565e-06
gene O 0 4.1983705159509555e-05
rearrangements O 0 0.0011061507975682616
causing O 0 0.03219371661543846
Wilson B-Disease 0 0.39908525347709656
disease I-Disease 0 0.3980605900287628
. O 0 5.5276927014347166e-05

Disruption O 0 0.00059371383395046
of O 0 7.0165669967536815e-06
splicing O 0 6.51231748634018e-05
regulated O 0 1.5879262718954124e-05
by O 0 1.9168535345670534e-06
a O 0 3.6891251511406153e-06
CUG O 0 0.0004270111967343837
- O 0 2.7074233003077097e-05
binding O 0 7.59173599362839e-06
protein O 0 1.2434775271685794e-05
in O 0 8.232513209804893e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0003024164179805666

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9970296621322632
DM B-Disease 1 1.0
) O 0 2.680274519661907e-05
is O 0 1.0449407454871107e-06
caused O 0 3.079895350310835e-06
by O 0 3.2700796737117344e-07
a O 0 1.4982360880821943e-06
CTG O 0 6.593974831048399e-05
expansion O 0 1.0377101489211782e-06
in O 0 1.3503021989436093e-07
the O 0 1.3913768270867877e-07
3 O 0 4.978155629942194e-07
untranslated O 0 3.694631914186175e-06
region O 0 6.304131829892867e-07
of O 0 2.84076435264069e-07
the O 0 1.7284370187553577e-05
DM B-Disease 1 0.9999998807907104
gene O 0 0.0002580010041128844
. O 0 2.3418706405209377e-05

One O 0 5.5360014812322333e-05
model O 0 7.912045839475468e-05
of O 0 1.8436156096868217e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.03133891522884369
suggests O 0 1.090528257918777e-05
that O 0 5.680223011950147e-07
RNAs O 0 1.2444657841115259e-05
from O 0 3.4481462307667243e-07
the O 0 1.9433205977748003e-07
expanded O 0 1.0674849590941449e-06
allele O 0 3.047237441933248e-06
create O 0 2.7606543540059647e-07
a O 0 2.773632274966076e-07
gain O 0 1.3708030337511445e-06
- O 0 2.7122221126774093e-06
of O 0 1.1363280094656147e-07
- O 0 1.4741707673238125e-05
function O 0 5.840859671479848e-07
mutation O 0 4.828984287996718e-07
by O 0 5.720839624245855e-08
the O 0 1.2662759729664685e-07
inappropriate O 0 5.622560479423555e-07
binding O 0 3.53140478637215e-07
of O 0 5.990049345427906e-08
proteins O 0 3.1247211040863476e-07
to O 0 3.2455105269946216e-07
the O 0 2.207380703111994e-06
CUG O 0 0.002396982628852129
repeats O 0 0.0002349928254261613
. O 0 2.0448573195608333e-05

Data O 0 5.562922160606831e-05
presented O 0 1.9079307094216347e-05
here O 0 1.2985285593458684e-06
indicate O 0 1.4896677384967916e-06
that O 0 1.9149466368162393e-07
the O 0 3.388025220374402e-07
conserved O 0 3.137716021228698e-06
heterogeneous O 0 6.2917561081121676e-06
nuclear O 0 1.5002340660430491e-05
ribonucleoprotein O 0 6.137618765933439e-05
, O 0 7.668758144063759e-07
CUG O 0 4.7182373236864805e-05
- O 0 9.561354090692475e-06
binding O 0 2.8656663744186517e-06
protein O 0 1.888714564302063e-06
( O 0 9.083436793844157e-07
CUG O 0 7.30485626263544e-05
- O 0 7.972316234372556e-05
BP O 0 3.004103564308025e-05
) O 0 3.9758566572345444e-07
, O 0 1.3438557289191522e-07
may O 0 4.1839791720121866e-07
mediate O 0 3.1829963518248405e-06
the O 0 6.566483534697909e-07
trans O 0 2.039093305938877e-05
- O 0 6.433549424400553e-05
dominant O 0 4.84591510030441e-06
effect O 0 1.001861278382421e-06
of O 0 1.9341095480740478e-07
the O 0 1.833951500884723e-06
RNA O 0 3.3576743589947e-05
. O 0 1.4426475900108926e-05

CUG O 0 0.15931084752082825
- O 0 0.4144632816314697
BP O 0 0.02514030411839485
was O 0 5.0788745284080505e-05
found O 0 8.587797992731794e-07
to O 0 2.989781933138147e-07
bind O 0 1.3317434195414535e-06
to O 0 2.3210196786749293e-07
the O 0 8.518716185790254e-07
human O 0 1.2086688002455048e-05
cardiac O 1 0.9986281394958496
troponin O 1 0.9998472929000854
T O 1 0.6565400958061218
( O 0 3.3516791972942883e-06
cTNT O 0 1.4442114661505911e-05
) O 0 9.561795195622835e-07
pre O 0 1.1546332643774804e-05
- O 0 1.034016258927295e-05
messenger O 0 5.5238965614989866e-06
RNA O 0 1.6721809288355871e-06
and O 0 3.161168251608615e-07
regulate O 0 1.9578653791541e-06
its O 0 1.271807150260429e-06
alternative O 0 8.375756806344725e-06
splicing O 0 0.00013111117004882544
. O 0 2.263899295940064e-05

Splicing O 0 0.0003209548885934055
of O 0 1.5423480363097042e-05
cTNT O 0 0.0003508969093672931
was O 0 0.00011596875265240669
disrupted O 0 0.0002584424219094217
in O 0 7.329090294661e-05
DM B-Disease 1 1.0
striated O 1 0.970282793045044
muscle O 0 0.06778231263160706
and O 0 1.4100838825470419e-06
in O 0 6.395472951226111e-07
normal O 0 5.635096840705955e-06
cells O 0 5.949212663836079e-06
expressing O 0 4.14274427384953e-06
transcripts O 0 6.72252554068109e-06
that O 0 1.0054179711005418e-06
contain O 0 8.704689207661431e-06
CUG O 0 0.0006903450703248382
repeats O 0 0.0003454471006989479
. O 0 3.070345337619074e-05

Altered O 0 0.0005544606246985495
expression O 0 3.972013291786425e-05
of O 0 2.593765429992345e-06
genes O 0 1.2935948689118959e-05
regulated O 0 8.024932867556345e-06
posttranscriptionally O 0 2.278580177517142e-05
by O 0 1.0449746241647517e-06
CUG O 0 0.0012470940127968788
- O 0 0.0025612800382077694
BP O 0 7.868076500017196e-05
therefore O 0 7.814925879756629e-07
may O 0 8.885120337254193e-07
contribute O 0 1.2926781209898763e-06
to O 0 1.3482060239766724e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.016559209674596786
. O 0 5.860153578396421e-06
. O 0 1.3187687727622688e-05

Identification O 0 2.749806117208209e-05
of O 0 2.0175232293695444e-06
a O 0 5.4537235882889945e-06
novel O 0 1.0868268873309717e-05
nonsense O 0 4.513333988143131e-05
mutation O 0 1.8324046322959475e-05
and O 0 7.849013741179078e-07
a O 0 1.559668589834473e-06
missense O 0 2.070923255814705e-05
substitution O 0 1.9382302980375243e-06
in O 0 4.2454516346879245e-07
the O 0 4.90485263071605e-07
vasopressin O 0 2.868672709155362e-05
- O 0 5.086901364848018e-05
neurophysin O 0 9.561921615386382e-05
II O 0 0.0003212551528122276
gene O 0 3.0132391657389235e-06
in O 0 2.7316107775732235e-07
two O 0 2.3699780626884603e-07
Spanish O 0 3.375638243596768e-06
kindreds O 0 4.681084101321176e-05
with O 0 1.1346390238031745e-05
familial B-Disease 1 0.9888217449188232
neurohypophyseal I-Disease 1 0.9999840259552002
diabetes I-Disease 1 0.9999986886978149
insipidus I-Disease 1 0.9993160963058472
. O 0 0.00028518386534415185

Familial B-Disease 1 0.9997918009757996
neurohypophyseal I-Disease 1 0.9999974966049194
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999899864196777
( O 0 0.014748181216418743
FNDI B-Disease 1 0.9999995231628418
) O 0 8.766035534790717e-06
is O 0 1.024645712277561e-06
an O 0 3.765428573387908e-06
autosomal B-Disease 1 0.9912918210029602
dominant I-Disease 1 0.9944686889648438
disease I-Disease 1 0.9939972162246704
caused O 0 0.06965751945972443
by O 0 0.003331761807203293
deficiency O 1 0.9736927151679993
in O 0 1.5099176380317658e-06
the O 0 6.087094334361609e-06
antidiuretic O 0 0.0009627485414966941
hormone O 0 8.98002545000054e-05
arginine O 0 7.855294097680598e-05
vasopressin O 0 7.10057865944691e-05
( O 0 3.947979166696314e-06
AVP O 0 2.205829332524445e-05
) O 0 2.8622474701478495e-07
encoded O 0 4.779881237482186e-07
by O 0 1.717711626270102e-07
the O 0 6.158554697321961e-07
AVP O 0 9.154714643955231e-05
- O 0 9.972354746423662e-05
neurophysin O 0 0.00045564392348751426
II O 0 0.037495531141757965
( O 0 4.531219474301906e-06
AVP O 0 0.00016572640743106604
- O 0 7.077702321112156e-05
NPII O 0 0.00017560069682076573
) O 0 2.2082037958170986e-06
gene O 0 8.259070455096662e-06
on O 0 4.213219199300511e-06
chromosome O 0 8.56125625432469e-05
20p13 O 0 0.00023182340373750776
. O 0 2.792122722894419e-05

In O 0 1.7271189790335484e-05
this O 0 2.2209583221410867e-06
study O 0 1.938413333846256e-06
, O 0 3.652510542906384e-07
we O 0 1.1785904519001633e-07
analyzed O 0 5.708641879209608e-07
two O 0 8.816255814281249e-08
families O 0 2.163581029890338e-07
with O 0 3.8049637396397884e-07
FNDI B-Disease 1 0.8972034454345703
using O 0 8.946756793193344e-07
direct O 0 8.807286917544843e-07
automated O 0 1.05856024674722e-05
fluorescent O 0 2.0584773665177636e-05
, O 0 1.55133477619529e-07
solid O 0 6.101661256252555e-07
phase O 0 1.112339077735669e-06
, O 0 1.2972571994396276e-07
single O 0 6.306260047495016e-07
- O 0 5.185388999962015e-06
stranded O 0 1.4570496205124073e-06
DNA O 0 1.414261532772798e-06
sequencing O 0 1.7844105286712875e-06
of O 0 1.0469736935192486e-06
PCR O 0 0.00023798400070518255
- O 0 0.0001703582238405943
amplified O 0 0.00014467698929365724
AVP O 0 0.00042172885150648654
- O 0 0.00013249285984784365
NPII O 0 0.0006207685801200569
DNA O 0 0.0001144989873864688
. O 0 5.10486243001651e-05

In O 0 1.0019940418715123e-05
one O 0 5.01897488902614e-07
of O 0 1.071217923254153e-07
the O 0 2.7992840045953926e-07
families O 0 5.149730668563279e-07
, O 0 2.507001681806287e-07
affected O 0 4.545323406546231e-07
individuals O 0 9.714023718743192e-08
presented O 0 5.142113650435931e-07
a O 0 1.7533062646180042e-06
novel O 0 4.226757482683752e-06
nonsense O 0 2.0473842596402392e-05
mutation O 0 4.083238309249282e-06
in O 0 3.4781544400175335e-07
exon O 0 3.420504299356253e-06
3 O 0 2.0810826129036286e-07
of O 0 3.7829465782124316e-08
the O 0 1.4013856741712516e-07
gene O 0 9.057952183866291e-07
, O 0 6.155865150958562e-08
consisting O 0 1.3276242327719956e-07
in O 0 2.464880708430428e-07
a O 0 3.4701240565482294e-06
G O 0 0.004832936450839043
to O 0 2.8814349661843153e-06
T O 0 0.00023416797921527177
transition O 0 2.5425404146517394e-06
at O 0 5.931385658186628e-07
nucleotide O 0 2.401893198111793e-06
2101 O 0 1.4168117559165694e-05
, O 0 1.3647242269598792e-07
which O 0 1.3504798346275493e-07
produces O 0 4.349703885964118e-07
a O 0 3.217718074211007e-07
stop O 0 1.287050395148981e-06
signal O 0 4.16161719840602e-06
in O 0 5.725702294512303e-07
codon O 0 9.832288924371824e-06
82 O 0 4.861824891122524e-06
( O 0 3.521467533573741e-06
Glu O 0 0.0007641015108674765
) O 0 1.4334332263388205e-06
of O 0 1.1787516314143431e-06
NPII O 0 0.0008602142916060984
. O 0 2.9715418349951506e-05

The O 0 7.759661093587056e-05
premature O 0 0.0013994368491694331
termination O 0 0.00013926402607467026
eliminates O 0 2.3311973563977517e-05
part O 0 1.4531932492900523e-06
of O 0 2.4719994939914613e-07
the O 0 1.600043674443441e-06
C O 0 0.00027368724113330245
- O 0 4.409918255987577e-05
terminal O 0 6.539888545376016e-06
domain O 0 6.626801791753678e-07
of O 0 1.259162587530227e-07
NPII O 0 3.137258318020031e-05
, O 0 9.96819835563656e-08
including O 0 7.677335389644213e-08
a O 0 2.068823903300654e-07
cysteine O 0 2.0313543700467562e-06
residue O 0 2.943706704172655e-06
in O 0 1.839920145130236e-07
position O 0 7.076388897075958e-07
85 O 0 3.2767289326329774e-07
, O 0 6.051948275853647e-08
which O 0 1.255744876971221e-07
could O 0 1.6476526809583447e-07
be O 0 5.618155185516116e-08
involved O 0 1.0860738797191516e-07
in O 0 1.4269991766013845e-07
the O 0 1.045179942593677e-06
correct O 0 2.6294323106412776e-05
folding O 0 1.1876662028953433e-05
of O 0 3.5511615692485066e-07
the O 0 4.896098289464135e-06
prohormone O 0 0.002685895888134837
. O 0 2.294800287927501e-05

In O 0 9.710449376143515e-06
the O 0 2.0994689293729607e-06
second O 0 1.43632883009559e-06
family O 0 1.1698651860569953e-06
, O 0 1.3475710147758946e-07
a O 0 2.290330769483262e-07
G279A O 0 2.8841841412940994e-06
substitution O 0 8.056310321080673e-07
at O 0 3.0692319796798984e-07
position O 0 7.573084985779133e-07
- O 0 1.2986722595087485e-06
1 O 0 8.53285797575154e-08
of O 0 2.5690754412721617e-08
the O 0 1.2817743311188678e-07
signal O 0 4.719128810393158e-06
peptide O 0 2.1461883079609834e-06
was O 0 1.8849087837224943e-06
observed O 0 4.4343946115077415e-07
in O 0 1.4911957180174795e-07
all O 0 1.5661642294162448e-07
affected O 0 2.3791706098563736e-06
individuals O 0 1.749681587170926e-06
. O 0 1.3556490557675716e-05

This O 0 7.73399806348607e-05
missense O 0 0.0014556249370798469
mutation O 0 0.00014539863332174718
, O 0 2.189599399571307e-06
which O 0 1.4355481425809558e-06
replaces O 0 8.438855002168566e-05
Ala O 0 0.0003571796405594796
with O 0 1.0551590321483673e-06
Thr O 0 0.018332717940211296
, O 0 3.046811514195724e-07
is O 0 1.1327023230478517e-07
frequent O 0 1.2717185882138438e-06
among O 0 7.792449991939066e-07
FNDI B-Disease 1 0.9999998807907104
patients O 0 0.0014223373727872968
and O 0 7.975735911713855e-07
is O 0 2.236200060679039e-07
thought O 0 2.1178158249313128e-07
to O 0 1.3345285765353765e-07
reduce O 0 8.236639246206323e-07
the O 0 2.121379480968244e-07
efficiency O 0 1.5879296597631765e-06
of O 0 2.2708584879183036e-07
cleavage O 0 5.508509730134392e-06
by O 0 1.322123353020288e-06
signal O 0 4.2307849071221426e-05
peptidases O 0 0.00016282037540804595
. O 0 3.3071983125410043e-06
. O 0 1.1004006410075817e-05

Genetic O 0 0.0006846687174402177
heterogeneity O 0 0.0003150011762045324
of O 0 1.69112845469499e-05
Saethre B-Disease 0 0.43044501543045044
- I-Disease 1 0.9996813535690308
Chotzen I-Disease 1 0.9999773502349854
syndrome I-Disease 1 0.9999996423721313
, O 0 1.5113670315258787e-06
due O 0 3.5934299376094714e-06
to O 0 1.4197601103660418e-06
TWIST O 0 0.0001092902384698391
and O 0 1.4599453606933821e-05
FGFR O 0 0.41573888063430786
mutations O 0 0.0005580941797234118
. O 0 3.0060926292208023e-05

Thirty O 0 0.0001377208245685324
- O 0 0.00013198042870499194
two O 0 1.2938164672959829e-06
unrelated O 0 2.599555409688037e-05
patients O 0 2.4525195385649567e-06
with O 0 2.1175613085233636e-07
features O 0 9.668862048783922e-07
of O 0 3.619875599270017e-07
Saethre B-Disease 0 0.35987716913223267
- I-Disease 1 0.9997387528419495
Chotzen I-Disease 1 0.9999533891677856
syndrome I-Disease 1 0.9999977350234985
, O 0 5.919360432926624e-07
a O 0 7.538450063293567e-06
common O 0 7.279065175680444e-05
autosomal B-Disease 0 0.3472992777824402
dominant I-Disease 0 0.0048147449269890785
condition I-Disease 0 0.0026217536069452763
of O 0 2.1702362573705614e-06
craniosynostosis B-Disease 1 0.9947023987770081
and O 0 0.003201252082362771
limb B-Disease 1 0.9991795420646667
anomalies I-Disease 0 0.42759042978286743
, O 0 7.18952605893719e-07
were O 0 5.278986918710871e-07
screened O 0 4.70474014946376e-06
for O 0 4.0852884808373346e-07
mutations O 0 4.691155936598079e-06
in O 0 5.901751478631923e-07
TWIST O 0 3.07303162117023e-05
, O 0 1.31115916701674e-06
FGFR2 O 0 0.00013517928891815245
, O 0 8.204324331018142e-07
and O 0 1.603679493200616e-06
FGFR3 O 0 0.000804156472440809
. O 0 1.9073031580774114e-05

Nine O 0 2.236355430795811e-05
novel O 0 1.0385594578110613e-05
and O 0 7.907172516752325e-07
three O 0 5.054491225564561e-07
recurrent O 0 0.0002958414552267641
TWIST O 0 0.006852459162473679
mutations O 0 7.545838161604479e-05
were O 0 9.545159400659031e-07
found O 0 6.276207500377495e-07
in O 0 5.84758083732595e-07
12 O 0 2.7781723019870697e-06
families O 0 4.145372713537654e-06
. O 0 1.392046488035703e-05

Seven O 0 1.3314487659954466e-05
families O 0 2.6459042601345573e-06
were O 0 4.87468128085311e-07
found O 0 2.45312264723907e-07
to O 0 1.1119883680521525e-07
have O 0 6.25266238785116e-08
the O 0 2.3793627690338326e-07
FGFR3 O 0 7.758226274745539e-05
P250R O 0 3.0410448744078167e-05
mutation O 0 3.2954487778624753e-06
, O 0 6.617089809424215e-08
and O 0 3.518092839271958e-08
one O 0 2.0747307871715748e-08
individual O 0 2.1888212131671025e-08
was O 0 3.423549060244113e-06
found O 0 1.2335664223428466e-07
to O 0 9.400960720995499e-08
have O 0 5.7451480017789436e-08
an O 0 4.442869112608605e-07
FGFR2 O 0 0.00020575575763359666
VV269 O 0 7.51389961806126e-05
- O 0 3.970142643083818e-05
270 O 0 2.484600008756388e-05
deletion O 0 0.0002122450532624498
. O 0 2.268576281494461e-05

To O 0 1.8898635971709155e-05
date O 0 3.5433913581073284e-06
, O 0 2.573347614998056e-07
our O 0 2.2467237670298346e-07
detection O 0 1.9623105345090153e-06
rate O 0 1.0394730907137273e-06
for O 0 1.9325423750160553e-07
TWIST O 0 1.3603943443740718e-05
or O 0 2.3058944407239323e-06
FGFR O 0 0.00044337540748529136
mutations O 0 6.275881787587423e-06
is O 0 1.8094868892148952e-07
68 O 0 1.1036627256544307e-06
% O 0 1.1791008347472598e-07
in O 0 1.6125345325690432e-07
our O 0 9.24018081605027e-07
Saethre B-Disease 0 0.3697313070297241
- I-Disease 1 0.9999676942825317
Chotzen I-Disease 1 0.9999988079071045
syndrome I-Disease 1 1.0
patients O 0 3.797925455728546e-05
, O 0 2.1284294859924557e-07
including O 0 9.5767838104166e-08
our O 0 1.9259279326888645e-07
five O 0 4.873137982031039e-07
patients O 0 3.096535692748148e-06
elsewhere O 0 2.4671201117598685e-06
reported O 0 3.0437548048212193e-05
with O 0 3.049025053769583e-06
TWIST O 0 0.03522365912795067
mutations O 0 0.0004145565035287291
. O 0 2.0056551875313744e-05

More O 0 6.929579740244662e-06
than O 0 9.446657713851891e-07
35 O 0 1.337917524324439e-06
different O 0 3.4738121712507564e-07
TWIST O 0 0.00011465293209766969
mutations O 0 3.334943176014349e-05
are O 0 1.9783976767939748e-07
now O 0 1.860696130506767e-07
known O 0 3.540064028584311e-07
in O 0 2.874716358292062e-07
the O 0 7.004840654190048e-07
literature O 0 6.087436759116827e-06
. O 0 1.4317391105578281e-05

The O 0 9.848880836216267e-06
most O 0 1.125603262153163e-06
common O 0 1.1000490758306114e-06
phenotypic O 0 5.84299868933158e-06
features O 0 3.159443167533027e-06
, O 0 1.3721432878810447e-07
present O 0 1.2859457854119682e-07
in O 0 8.374954774126309e-08
more O 0 3.189092367961166e-08
than O 0 1.985780428981343e-08
a O 0 1.3254029340714624e-07
third O 0 2.28495935061801e-07
of O 0 5.4486481104731865e-08
our O 0 5.191134846427303e-07
patients O 0 1.086844235942408e-06
with O 0 3.3173779456774355e-07
TWIST O 0 0.006561746820807457
mutations O 0 2.185479024774395e-05
, O 0 2.0501828146279877e-07
are O 0 1.1968651847382716e-07
coronal B-Disease 0 2.389409564784728e-05
synostosis I-Disease 0 7.016595918685198e-05
, O 0 5.240778477855201e-07
brachycephaly B-Disease 0 4.5262429921422154e-05
, O 0 9.378302365803393e-07
low B-Disease 0 2.26173251576256e-05
frontal I-Disease 1 0.7722263932228088
hairline I-Disease 1 0.9999779462814331
, O 0 2.6997709937859327e-05
facial B-Disease 1 0.9836683869361877
asymmetry I-Disease 0 0.01604059897363186
, O 0 2.029503957601264e-05
ptosis B-Disease 1 0.7590898275375366
, O 0 2.303599558217684e-06
hypertelorism B-Disease 0 0.002050593262538314
, O 0 1.049510842676682e-06
broad B-Disease 0 4.771023213834269e-06
great I-Disease 0 5.738166237279074e-06
toes I-Disease 0 0.00010361838940298185
, O 0 8.468617807011469e-07
and O 0 2.5743393052835017e-06
clinodactyly B-Disease 0 0.0006141249905340374
. O 0 2.0095185391255654e-05

Significant O 0 0.00010028734686784446
intra O 0 0.0002741186472121626
- O 0 0.0002767137484624982
and O 0 5.394398158387048e-06
interfamilial O 0 0.0001757884892867878
phenotypic O 0 4.4024272938258946e-05
variability O 0 5.605369369732216e-05
is O 0 8.618351330369478e-07
present O 0 7.160847985687724e-07
for O 0 3.809320503478375e-07
either O 0 4.540420377452392e-06
TWIST O 0 0.0018191194394603372
mutations O 0 0.0001629837934160605
or O 0 1.0801044481922872e-05
FGFR O 0 0.034838393330574036
mutations O 0 0.0006145255174487829
. O 0 3.313358683953993e-05

The O 0 2.138329546141904e-05
overlap O 0 1.3242611203168053e-05
in O 0 2.6063794393849093e-06
clinical O 0 5.4445513342216145e-06
features O 0 1.5785608411533758e-06
and O 0 1.3536789822410356e-07
the O 0 1.0625694812915754e-07
presence O 0 2.746678262610658e-07
, O 0 5.416196202645551e-08
in O 0 4.615431237198209e-08
the O 0 6.569140253986916e-08
same O 0 1.0017028273523465e-07
genes O 0 2.4591423652964295e-07
, O 0 3.149925120737862e-08
of O 0 3.5851144275511615e-08
mutations O 0 6.959481311241689e-07
for O 0 3.182833197001855e-08
more O 0 2.578815738729645e-08
than O 0 6.239974226218692e-08
one O 0 1.7139120700448984e-07
craniosynostotic B-Disease 0 0.0012693100143224
condition I-Disease 0 6.337794184219092e-05
- O 0 3.4813112961273873e-06
such O 0 7.946508162604005e-08
as O 0 2.2313025738185388e-07
Saethre B-Disease 0 2.0412100639077835e-05
- I-Disease 0 1.3628928172693122e-05
Chotzen I-Disease 0 1.1466645446489565e-05
, I-Disease 0 2.733700625867641e-07
Crouzon I-Disease 0 8.096647434285842e-06
, I-Disease 0 3.1823057611291006e-07
and I-Disease 0 2.8637759896810167e-06
Pfeiffer I-Disease 0 0.41065335273742676
syndromes I-Disease 0 0.009988383390009403
- O 0 1.939145840879064e-05
support O 0 4.7283720050472766e-07
the O 0 3.015205720657832e-07
hypothesis O 0 9.579566722095478e-07
that O 0 8.151464214734006e-08
TWIST O 0 2.842476305886521e-06
and O 0 2.400426808435441e-07
FGFRs O 0 7.138686214602785e-06
are O 0 2.3675918114918204e-08
components O 0 9.49595104771106e-08
of O 0 1.2484520972577684e-08
the O 0 5.932438540412477e-08
same O 0 1.5378242324004532e-07
molecular O 0 1.1817603535746457e-06
pathway O 0 7.869610385569104e-07
involved O 0 1.5985261825335328e-07
in O 0 1.7318755851647438e-07
the O 0 2.720050531479501e-07
modulation O 0 7.13102463123505e-06
of O 0 4.990880597688374e-07
craniofacial O 0 0.4334655702114105
and O 0 1.099399923987221e-05
limb O 0 0.017600001767277718
development O 0 1.38782945668936e-06
in O 0 9.88637907539669e-07
humans O 0 3.1878691970632644e-06
. O 0 2.035281113421661e-06
. O 0 9.720928574097343e-06

Mutation O 0 0.0014908582670614123
analysis O 0 8.752978465054184e-05
of O 0 2.2274500224739313e-05
UBE3A O 1 0.9960337281227112
in O 1 0.9999306201934814
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9834569096565247
. O 0 0.00024776969803497195

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0319046713411808
AS B-Disease 1 0.7773050665855408
) O 0 3.7314473502192413e-06
is O 0 3.3264706189584103e-07
caused O 0 2.9582056413346436e-06
by O 0 7.589684969389054e-07
chromosome O 0 1.1977634130744264e-05
15q11 O 0 2.094806586683262e-05
- O 0 9.904499165713787e-06
q13 O 0 1.1398828974051867e-05
deletions O 0 4.3378418013162445e-06
of O 0 2.766309989965521e-07
maternal O 0 7.923494194983505e-06
origin O 0 6.264373269004864e-07
, O 0 2.8565889920173504e-07
by O 0 1.234249452863878e-06
paternal O 0 0.0017430036095902324
uniparental B-Disease 1 0.706052839756012
disomy I-Disease 1 0.7710289359092712
( O 0 4.630063631338999e-05
UPD B-Disease 1 0.9999799728393555
) O 0 8.987325941234303e-07
15 O 0 2.785255617254734e-07
, O 0 9.188969585238738e-08
by O 0 6.222794013410748e-07
imprinting O 1 0.7451976537704468
defects O 1 0.9547364711761475
, O 0 1.5290645194454555e-07
and O 0 1.0931378113809842e-07
by O 0 6.16622457982885e-07
mutations O 0 3.826776264759246e-06
in O 0 4.733876721729757e-07
the O 0 3.400005198272993e-06
UBE3A O 0 0.001371275051496923
gene O 0 6.836964166723192e-05
. O 0 2.3753507775836624e-05

UBE3A O 0 0.009801539592444897
encodes O 0 0.0003085674543399364
a O 0 4.038240513182245e-05
ubiquitin O 0 0.0001873819128377363
- O 0 4.771225940203294e-05
protein O 0 6.68006532578147e-06
ligase O 0 1.2125420653319452e-05
and O 0 1.1910858574992744e-06
shows O 0 6.524488526338246e-06
brain O 0 0.0010958272032439709
- O 0 6.626829417655244e-05
specific O 0 7.862868187658023e-06
imprinting O 0 0.0006359729450196028
. O 0 2.8330145141808316e-05

Here O 0 7.442083733621985e-05
we O 0 6.838099579908885e-06
describe O 0 4.3334901420166716e-05
UBE3A O 0 0.0009961358737200499
coding O 0 0.00044687942136079073
- O 0 0.00042165323975495994
region O 0 1.2619732842722442e-05
mutations O 0 4.4405387598089874e-05
detected O 0 9.436272193852346e-06
by O 0 1.0102332907990785e-06
SSCP O 0 6.158519681775942e-05
analysis O 0 1.0064761681860546e-06
in O 0 4.769149200001266e-07
13 O 0 1.055038296726707e-06
AS B-Disease 0 0.00045016405056230724
individuals O 0 5.292865239425737e-07
or O 0 1.7780149619284202e-06
families O 0 4.7779540182091296e-06
. O 0 1.560159398650285e-05

Two O 0 2.4199318431783468e-05
identical O 0 5.552958100452088e-05
de O 0 4.947206252836622e-05
novo O 0 8.133025403367355e-05
5 O 0 5.539105586649384e-06
- O 0 3.57314056600444e-05
bp O 0 2.4382065021200106e-05
duplications O 0 1.1106822967121843e-05
in O 0 1.2633656751859235e-06
exon O 0 1.931051883730106e-05
16 O 0 2.7442665668786503e-06
were O 0 1.542658310427214e-06
found O 0 6.382619631040143e-06
. O 0 1.330336817773059e-05

Among O 0 1.0494535672478378e-05
the O 0 2.0777638383151498e-06
other O 0 4.455517625956418e-07
11 O 0 1.0839335118362214e-06
unique O 0 9.18695207019482e-07
mutations O 0 4.937813173455652e-06
, O 0 1.5739234981992922e-07
8 O 0 2.9675229029635375e-07
were O 0 2.1330443189526704e-07
small O 0 3.3092132412093633e-07
deletions O 0 4.7975963752833195e-06
or O 0 5.74252851492929e-07
insertions O 0 9.305673302151263e-06
predicted O 0 9.38978155318182e-06
to O 0 6.118372652963444e-07
cause O 0 5.180011612537783e-06
frameshifts O 0 6.491348176496103e-05
, O 0 2.6170846467721276e-07
1 O 0 3.8855270645399287e-07
was O 0 2.931347125922912e-06
a O 0 1.4435120192501927e-06
mutation O 0 1.9064710841121268e-06
to O 0 1.6931642221607035e-07
a O 0 5.917893304285826e-07
stop O 0 1.5279740637197392e-06
codon O 0 2.7165917799720773e-06
, O 0 1.1678002920234576e-07
1 O 0 1.6500868582625117e-07
was O 0 6.2362738617594e-07
a O 0 8.604308163739915e-07
missense O 0 3.465090412646532e-05
mutation O 0 3.4972504181496333e-06
, O 0 1.184442908197525e-07
and O 0 1.3537589893530821e-07
1 O 0 3.26392296301492e-07
was O 0 9.789595424081199e-06
predicted O 0 4.8131369112525135e-06
to O 0 3.1606950301465986e-07
cause O 0 1.1080901458626613e-06
insertion O 0 1.3150988706911448e-06
of O 0 6.737312219229352e-08
an O 0 3.09163510792132e-07
isoleucine O 0 0.00017348722030874342
in O 0 2.2503262187001383e-07
the O 0 3.3374013241882494e-07
hect O 0 9.84403413895052e-06
domain O 0 7.633850032107148e-07
of O 0 7.446339367334076e-08
the O 0 2.5376564849466376e-07
UBE3A O 0 3.304397250758484e-05
protein O 0 9.857476470642723e-07
, O 0 7.593958173401916e-08
which O 0 7.038335780862326e-08
functions O 0 1.8268836754486983e-07
in O 0 3.1581129178448464e-07
E2 O 0 2.2335932953865267e-05
binding O 0 2.9897669264755677e-06
and O 0 1.5022765182948206e-06
ubiquitin O 0 5.082004645373672e-05
transfer O 0 1.855224218161311e-05
. O 0 1.8456597899785265e-05

Eight O 0 8.72825512487907e-06
of O 0 8.945494300860446e-07
the O 0 6.435756745304388e-07
cases O 0 5.62044306207099e-07
were O 0 5.157466489436047e-07
familial O 0 1.6568166756769642e-05
, O 0 2.0658902144532476e-07
and O 0 2.2263820653734e-07
five O 0 4.897719350083207e-07
were O 0 1.1585847232709057e-06
sporadic O 0 8.173087553586811e-05
. O 0 1.872930079116486e-05

In O 0 2.0528001186903566e-05
two O 0 4.020964752271539e-06
familial O 0 0.0004336025449447334
cases O 0 1.3596243206848158e-06
and O 0 3.601721516588441e-07
one O 0 2.0135162515089178e-07
sporadic O 0 1.961464477062691e-05
case O 0 1.956586856977083e-06
, O 0 4.569680243093899e-07
mosaicism O 0 3.596726310206577e-05
for O 0 6.905045211169636e-07
UBE3A O 0 0.0006172495195642114
mutations O 0 2.132247027475387e-05
was O 0 5.786845122202067e-06
detected O 0 1.7024466387738357e-06
in O 0 8.25603478915582e-08
the O 0 1.3795106212910468e-07
mother O 0 5.997331982143805e-07
of O 0 2.545856325752993e-08
three O 0 1.1772861796544021e-07
AS B-Disease 0 0.02653861604630947
sons O 0 0.00026712118415161967
, O 0 4.5076806287625004e-08
in O 0 7.225020937084992e-08
the O 0 2.2631512308635138e-07
maternal O 0 1.0119880244019441e-05
grandfather O 0 4.682895450969227e-06
of O 0 3.7657624574194415e-08
two O 0 1.32481275727514e-07
AS B-Disease 0 3.055122579098679e-05
first O 0 6.061647468413867e-07
cousins O 0 3.6198730413161684e-06
, O 0 5.145106030113311e-08
and O 0 3.871305054303775e-08
in O 0 5.971706684704259e-08
the O 0 1.6709806516246317e-07
mother O 0 1.5609469983246527e-06
of O 0 7.992291273239971e-08
an O 0 5.552394100050151e-07
AS B-Disease 0 0.09587422013282776
daughter O 0 0.14308419823646545
. O 0 1.782360595825594e-05

The O 0 1.0591054888209328e-05
frequencies O 0 1.340015387540916e-05
with O 0 9.903496902552433e-07
which O 0 6.532998213515384e-07
we O 0 3.440046612013248e-07
detected O 0 1.3753068742516916e-05
mutations O 0 4.073289346706588e-06
were O 0 2.189305945421438e-07
5 O 0 3.998485169631749e-07
( O 0 2.2850532843676774e-07
14 O 0 1.888938356842118e-07
% O 0 7.860702311290879e-08
) O 0 4.3946183581056175e-08
of O 0 2.248497921186754e-08
35 O 0 1.7514183525690896e-07
in O 0 1.5603099257077702e-07
sporadic O 0 7.081370313244406e-06
cases O 0 3.653468638731283e-07
and O 0 1.3922594632731489e-07
8 O 0 4.824574943995685e-07
( O 0 1.6945890024544497e-07
80 O 0 1.2078096744971845e-07
% O 0 4.0686391145072776e-08
) O 0 2.3416159677935866e-08
of O 0 2.1089672230800716e-08
10 O 0 2.1865872668058728e-07
in O 0 1.0241923291687272e-06
familial O 0 0.0012898052809759974
cases O 0 4.689804882218596e-06
. O 0 2.6603620426612906e-06
. O 0 8.966736459115054e-06

The O 0 0.0006116322474554181
hemochromatosis B-Disease 1 0.9999967813491821
845 O 0 0.0326751247048378
G O 0 0.4585908055305481
- O 0 0.05730032920837402
- O 0 0.00021086636115796864
> O 0 8.560138667235151e-06
A O 0 2.2284880287770648e-06
and O 0 5.033911634200194e-07
187 O 0 4.456730493984651e-06
C O 0 0.00010698106052586809
- O 0 0.0004446716629900038
- O 0 0.0006155053270049393
> O 0 5.718164538848214e-05
G O 0 0.006556899286806583
mutations O 0 3.692140307975933e-05
: O 0 8.677301934767456e-07
prevalence O 0 5.4080792324384674e-06
in O 0 5.248736556495714e-07
non O 0 1.8675349338082015e-06
- O 0 4.870951670454815e-05
Caucasian O 0 3.4570628486108035e-05
populations O 0 1.4377237675944343e-05
. O 0 1.0857982488232665e-05

Hemochromatosis B-Disease 1 0.9997946619987488
, O 0 0.00020040136587340385
the O 0 0.02053494192659855
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
of I-Disease 0 4.251307927916059e-06
iron I-Disease 1 0.841745913028717
metabolism I-Disease 0 0.0016332789091393352
, O 0 5.406931222751155e-07
leads O 0 1.8402762407276896e-06
, O 0 4.765102801229659e-07
if O 0 4.3736176280617656e-07
untreated O 0 2.333590600755997e-05
, O 0 1.5103123018889164e-07
to O 0 7.054705406517314e-07
progressive O 0 0.23044167459011078
iron B-Disease 1 0.9987689852714539
overload I-Disease 1 0.6110286116600037
and O 0 3.245629704906605e-05
premature B-Disease 0 0.019550928846001625
death I-Disease 0 0.0003621893119998276
. O 0 3.0339941076817922e-05

The O 0 0.0001896166941151023
hemochromatosis B-Disease 1 0.9999953508377075
gene O 0 0.0002346303517697379
, O 0 5.161470198800089e-06
HFE O 0 0.0010046317474916577
, O 0 8.379155360671575e-07
recently O 0 4.160164735367289e-06
has O 0 2.8480124569796317e-07
been O 0 2.788357278404874e-07
identified O 0 2.9123162903488264e-07
, O 0 4.619491278390342e-08
and O 0 7.934966816947053e-08
characterization O 0 5.480321760842344e-07
of O 0 3.063786380153033e-08
this O 0 1.009784682537429e-07
gene O 0 1.345850364486978e-06
has O 0 2.0811401668652252e-07
shown O 0 1.8358082343183924e-07
that O 0 3.1360709584760116e-08
it O 0 2.6513193418509218e-08
contains O 0 6.755931991619946e-08
two O 0 1.0702866859446658e-07
mutations O 0 1.3891469734517159e-06
that O 0 8.133449114211544e-08
result O 0 2.731355266405444e-07
in O 0 4.6828768063278403e-07
amino O 0 2.614971435832558e-06
acid O 0 4.528554200078361e-06
substitutions O 0 5.215960300120059e-06
- O 0 8.146231266437098e-06
cDNA O 0 2.1736666894867085e-05
nucleotides O 0 1.3624209714180324e-05
845 O 0 6.749556632712483e-05
G O 0 0.0005883708945475519
- O 0 0.0002363991370657459
- O 0 5.453708581626415e-05
> O 0 8.922482265916187e-06
A O 0 3.0393607630685437e-06
( O 0 7.871021807659417e-07
C282Y O 0 5.722973583033308e-06
) O 0 3.3255125231335114e-07
and O 0 2.103873413261681e-07
187 O 0 2.5593681129976176e-06
C O 0 3.964708957937546e-05
- O 0 0.0002406295679975301
- O 0 0.0006409482448361814
> O 0 5.698068343917839e-05
G O 0 0.0008786621619947255
( O 0 7.433322025462985e-06
H63D O 0 0.0007366443751379848
) O 0 1.096656433219323e-05
. O 0 1.7593461961951107e-05

Although O 0 0.0030844619031995535
hemochromatosis B-Disease 1 0.9999997615814209
is O 0 1.3264921108202543e-05
common O 0 3.6456099223869387e-06
in O 0 2.05643641493225e-06
Caucasians O 0 5.9057879298052285e-06
, O 0 8.172322623067885e-07
affecting O 0 3.4559459436422912e-06
> O 0 7.877759344410151e-06
= O 0 5.025478458264843e-06
1 O 0 7.435353381879395e-07
/ O 0 3.166694796163938e-06
300 O 0 1.2857778131092346e-07
individuals O 0 2.2294047496984604e-08
of O 0 1.4096663392137998e-08
northern O 0 2.963311942494329e-07
European O 0 3.183674834872363e-07
origin O 0 2.8909039428981487e-07
, O 0 1.049519369189511e-07
it O 0 8.112284888284194e-08
has O 0 1.1897740392896594e-07
not O 0 3.544563043078597e-08
been O 0 4.9940990010099995e-08
recognized O 0 1.0404743733261057e-07
in O 0 1.326387888411773e-07
other O 0 2.3748877708840155e-07
populations O 0 4.669863756134873e-06
. O 0 9.163710274151526e-06

The O 0 1.0583553375909105e-05
present O 0 4.308790721552214e-06
study O 0 1.54790029682772e-06
used O 0 1.2239544275871594e-06
PCR O 0 2.1918953279964626e-05
and O 0 4.3490902612575155e-07
restriction O 0 4.847449872613652e-06
- O 0 4.2924108129227534e-05
enzyme O 0 3.4947968288179254e-06
digestion O 0 2.922777184721781e-06
to O 0 2.142955679573788e-07
analyze O 0 4.338137671311415e-07
the O 0 1.0120965754367717e-07
frequency O 0 6.238743139874714e-07
of O 0 4.9447546501824036e-08
the O 0 3.204635561360192e-07
845 O 0 1.7997621398535557e-05
G O 0 0.002711030887439847
- O 0 0.00045845095883123577
- O 0 2.871946526283864e-05
> O 0 2.0803913685085718e-06
A O 0 7.956804211062263e-07
and O 0 3.710839848736214e-07
187 O 0 3.0916901323507773e-06
C O 0 6.779972318327054e-05
- O 0 0.0001195207005366683
- O 0 0.00010990601003868505
> O 0 1.91039071069099e-05
G O 0 0.00038539362139999866
mutations O 0 2.2741949578630738e-05
in O 0 2.6065138172270963e-06
HLA O 0 0.015378100797533989
- O 0 1.8165193978347816e-05
typed O 0 3.963378730986733e-06
samples O 0 6.819849431849434e-07
from O 0 3.1241907549883763e-07
non O 0 6.684123263767106e-07
- O 0 4.6241821110015735e-06
Caucasian O 0 2.464545104885474e-06
populations O 0 3.8736322949262103e-07
, O 0 6.262007445911877e-08
comprising O 0 1.1297107960217545e-07
Australian O 0 4.609334780525387e-07
Aboriginal O 0 5.040618020757393e-07
, O 0 6.13642896496458e-08
Chinese O 0 6.589230849840533e-08
, O 0 1.4621400623582304e-07
and O 0 5.003957994631492e-07
Pacific O 0 1.2757509466609918e-05
Islanders O 0 6.794263026677072e-05
. O 0 1.8320690287509933e-05

Results O 0 7.479222404072061e-05
showed O 0 1.5692003216827288e-05
that O 0 8.078791893240123e-07
the O 0 1.2554818340504426e-06
845 O 0 7.373836706392467e-05
G O 0 0.006849890109151602
- O 0 0.0021299030631780624
- O 0 0.00010071245924336836
> O 0 5.411448000813834e-06
A O 0 4.41295651398832e-06
mutation O 0 8.94386539584957e-06
was O 0 5.6593644330860116e-06
present O 0 3.323711723624001e-07
in O 0 1.8715056171458855e-07
these O 0 1.2169762442226784e-07
populations O 0 4.883815449829854e-07
( O 0 4.120806522678322e-07
allele O 0 1.961622047019773e-06
frequency O 0 1.8053326584777096e-06
0 O 0 2.41111848708897e-07
. O 0 6.633871407757397e-08
32 O 0 1.6263228985735623e-07
% O 0 6.999205481861281e-08
) O 0 6.410886044250219e-08
, O 0 3.373676449314189e-08
and O 0 5.096349298128189e-08
, O 0 5.585556550613546e-08
furthermore O 0 2.1742417288805882e-07
, O 0 4.806196329809609e-08
it O 0 7.562375259340115e-08
was O 0 2.7171981855644844e-06
always O 0 1.3884488225812675e-07
seen O 0 1.7307743860328628e-07
in O 0 7.292974402162145e-08
conjunction O 0 7.104532642188133e-07
with O 0 1.0473362408447429e-06
HLA O 0 0.0069546764716506
haplotypes O 0 1.8163063941756263e-05
common O 0 7.654787168576149e-07
in O 0 5.307873038873367e-07
Caucasians O 0 1.8351673816141556e-06
, O 0 2.0683424395429029e-07
suggesting O 0 1.4685153928439831e-06
that O 0 3.712298166647088e-07
845 O 0 1.425345635652775e-05
G O 0 0.0006337167578749359
- O 0 0.0005606218473985791
- O 0 0.00013835627760272473
> O 0 2.4787279926385963e-06
A O 0 5.771110863861395e-06
may O 0 4.325951977079967e-06
have O 0 8.467278433954561e-08
been O 0 1.6190635676593956e-07
introduced O 0 8.921367680159165e-07
into O 0 1.6582963269229367e-07
these O 0 1.4679633864034258e-07
populations O 0 7.510826662837644e-07
by O 0 1.6056933418440167e-06
Caucasian O 0 6.205676618264988e-05
admixture O 0 0.0002704693761188537
. O 0 4.5849563321098685e-05

187 O 0 0.0006284527480602264
C O 0 0.0015093666734173894
- O 0 0.0018676469335332513
- O 0 0.0003651347942650318
> O 0 3.9579848817083985e-05
G O 0 0.0008227821672335267
was O 0 1.6932730432017706e-05
present O 0 6.150344233901706e-07
at O 0 3.7041996847619885e-07
an O 0 3.020346071025415e-07
allele O 0 7.41461599318427e-06
frequency O 0 4.256001830071909e-06
of O 0 6.555053460033378e-07
2 O 0 7.669286787859164e-06
. O 0 1.7111311535700224e-05

68 O 0 0.0001665699965087697
% O 0 4.605951744451886e-06
in O 0 7.394177146125003e-07
the O 0 4.0985838722917833e-07
two O 0 3.1481658879783936e-07
populations O 0 9.743524742589216e-07
analyzed O 0 2.4110133836074965e-06
( O 0 7.54586324092088e-07
Australian O 0 1.255319148185663e-06
Aboriginal O 0 1.4092570381762926e-06
and O 0 2.9958584946143674e-07
Chinese O 0 5.103256057736871e-07
) O 0 3.4931440495711286e-06
. O 0 9.581216545484494e-06

In O 0 1.4452392861130647e-05
the O 0 3.102687060163589e-06
Australian O 0 5.424194569059182e-06
Aboriginal O 0 3.7346658245951403e-06
samples O 0 1.4956420955059002e-06
, O 0 2.831913832324062e-07
187 O 0 2.347640929656336e-06
C O 0 5.198824146646075e-05
- O 0 0.00045142098679207265
- O 0 0.0006410466157831252
> O 0 1.6626112483209e-05
G O 0 0.005957712884992361
was O 0 4.414913564687595e-05
found O 0 3.4930664583043836e-07
to O 0 1.6210070441502467e-07
be O 0 1.2554970396649878e-07
associated O 0 5.295172513797297e-07
with O 0 9.032979164658173e-07
HLA O 0 0.013272713869810104
haplotypes O 0 1.3603541447082534e-05
common O 0 6.004669330650358e-07
in O 0 4.140419775922055e-07
Caucasians O 0 8.21545768303622e-07
, O 0 9.661270894412155e-08
suggesting O 0 7.672195465602272e-07
that O 0 8.21448864485319e-08
it O 0 1.0948133422061801e-07
was O 0 1.9646436157927383e-06
introduced O 0 1.555475364511949e-06
by O 0 7.801328365530935e-07
recent O 0 5.300787961459719e-06
admixture O 0 9.195670281769708e-05
. O 0 2.448342456773389e-05

In O 0 1.0194184142164886e-05
the O 0 1.56146506924415e-06
Chinese O 0 5.180181119612826e-07
samples O 0 1.1651110298771528e-06
analyzed O 0 2.8894839942950057e-06
, O 0 3.3506810837025114e-07
187 O 0 2.3804664124327246e-06
C O 0 3.393068618606776e-05
- O 0 0.00019793171668425202
- O 0 0.00021560871391557157
> O 0 9.101247087528463e-06
G O 0 0.0003046162019018084
was O 0 1.2682556189247407e-05
present O 0 5.520987542695366e-07
in O 0 4.126327723952272e-07
association O 0 3.282584088992735e-07
with O 0 6.351467618515017e-08
a O 0 3.4098468404408777e-07
wide O 0 3.422441636757867e-07
variety O 0 2.4087810857054137e-07
of O 0 3.541543094343069e-07
HLA O 0 0.0056775338016450405
haplotypes O 0 1.5898896890575998e-05
, O 0 1.590412210816794e-07
showing O 0 8.066451187005441e-07
this O 0 9.704597658810599e-08
mutation O 0 1.128831513597106e-06
to O 0 1.335585437800546e-07
be O 0 1.1016126677532156e-07
widespread O 0 4.885925477537967e-07
and O 0 2.0450588067433273e-07
likely O 0 7.975827429618221e-07
to O 0 1.7077545066968014e-07
predate O 0 3.101565653196303e-06
the O 0 1.8811864777035225e-07
more O 0 1.1667894739275653e-07
genetically O 0 1.187302359539899e-06
restricted O 0 1.4331488955576788e-06
845 O 0 3.34633223246783e-05
G O 0 0.024994196370244026
- O 0 0.007437501568347216
- O 0 0.00017750752158463
> O 0 1.2915240404254291e-05
A O 0 2.268065873067826e-05
mutation O 0 0.0001498906931374222
. O 0 1.945180156326387e-05

Genotype O 0 0.32608816027641296
- O 1 0.6130931973457336
phenotype O 0 0.11837819963693619
correlations O 0 0.0022507421672344208
in O 0 0.0008588395430706441
attenuated B-Disease 1 0.9999092817306519
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999967813491821
coli I-Disease 1 0.9999852180480957
. O 0 0.001078812056221068

Germ O 0 0.3793875575065613
- O 0 0.034129366278648376
line O 0 0.00014978468243498355
mutations O 0 1.886330937850289e-05
of O 0 3.916442210538662e-07
the O 0 2.527688593545463e-06
tumor B-Disease 0 0.00042814374319277704
suppressor O 0 0.0007602781406603754
APC O 0 0.00012017818517051637
are O 0 1.0929945801763097e-06
implicated O 0 5.925310688326135e-05
in O 0 7.081922376528382e-05
attenuated B-Disease 1 0.9999035596847534
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999994039535522
( O 0 0.009703334420919418
AAPC B-Disease 1 0.9999984502792358
) O 0 6.715169547533151e-06
, O 0 4.977291041541321e-07
a O 0 2.3323279947362607e-06
variant O 0 0.0005827367422170937
of O 0 4.129080116399564e-05
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999998807907104
( O 0 0.0049429708160459995
FAP B-Disease 0 0.02833794616162777
) O 0 4.6060842578299344e-05
. O 0 3.946169817936607e-05

AAPC B-Disease 1 0.9999881982803345
is O 0 2.9682536478503607e-05
recognized O 0 6.745991868228884e-06
by O 0 1.5453795185749186e-06
the O 0 1.0489775377209298e-06
occurrence O 0 4.236458607920213e-06
of O 0 6.090521651458403e-07
< O 0 1.3592505638371222e-05
100 O 0 1.8691313243834884e-06
colonic B-Disease 0 0.0005335522582754493
adenomas I-Disease 0 0.00015468928904738277
and O 0 8.816866738925455e-07
a O 0 1.9912474726879736e-06
later O 0 0.00016930628044065088
onset O 1 0.9665495157241821
of O 1 0.5386768579483032
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.461525870487094e-05
age O 0 9.102670446736738e-06
> O 0 8.7512016762048e-06
40 O 0 2.1302867025951855e-06
years O 0 3.7298320876288926e-06
) O 0 6.1391497183649335e-06
. O 0 1.4529365216731094e-05

The O 0 1.2346647963568103e-05
aim O 0 6.361066425597528e-06
of O 0 2.424972933567915e-07
this O 0 3.068161049668561e-07
study O 0 7.210537660284899e-07
was O 0 2.6048637664644048e-06
to O 0 6.277715556279873e-07
assess O 0 1.5064577382872812e-05
genotype O 0 0.0001891529536806047
- O 0 0.0016964483074843884
phenotype O 0 0.0006134602008387446
correlations O 0 8.56497063068673e-05
in O 0 4.528371573542245e-05
AAPC B-Disease 1 0.9999908208847046
families O 0 6.04880005994346e-05
. O 0 5.187434726394713e-05

By O 0 5.315338057698682e-05
protein O 0 6.438452692236751e-05
- O 0 5.825425614602864e-05
truncation O 0 0.00010221247794106603
test O 0 1.2992548363399692e-05
( O 0 2.813575520121958e-06
PTT O 0 1.535218871140387e-05
) O 0 3.613853323258809e-07
assay O 0 2.944844027297222e-06
, O 0 6.842417121788458e-08
the O 0 8.574297538643805e-08
entire O 0 3.0388136451620085e-07
coding O 0 1.2540410807559965e-06
region O 0 1.6795553392512375e-07
of O 0 6.302760624521397e-08
the O 0 4.936212576467369e-07
APC B-Disease 0 2.705926090129651e-05
gene O 0 4.10709662901354e-06
was O 0 6.5111676121887285e-06
screened O 0 4.8820365918800235e-06
in O 0 6.387829216691898e-07
affected O 0 1.1356512459315127e-06
individuals O 0 1.91635322721595e-07
from O 0 6.375912562361918e-07
11 O 0 8.632297976873815e-06
AAPC B-Disease 1 0.9999426603317261
kindreds O 0 0.00010959236533381045
, O 0 5.547169621422654e-07
and O 0 2.4365334638787317e-07
their O 0 4.0013767943491985e-07
phenotypic O 0 8.21781486592954e-06
differences O 0 9.15813598112436e-06
were O 0 1.1199603250133805e-05
examined O 0 0.0006813898216933012
. O 0 3.320779433124699e-05

Five O 0 6.742776167811826e-05
novel O 0 0.00010285348253091797
germ O 0 0.003138688625767827
- O 0 0.013771667145192623
line O 0 0.00030845156288705766
APC B-Disease 0 0.000623439671471715
mutations O 0 1.8604030628921464e-05
were O 0 8.425534474554297e-07
identified O 0 1.7316341427431325e-06
in O 0 2.0946790755260736e-06
seven O 0 7.627855211467249e-06
kindreds O 0 0.0003831630165223032
. O 0 3.96156137867365e-05

Mutations O 0 0.0024292527232319117
were O 0 6.845831649116008e-06
located O 0 3.751815029318095e-06
in O 0 3.5766657902058796e-07
three O 0 1.3419922595403477e-07
different O 0 6.868490487477175e-08
regions O 0 1.7605400159936835e-07
of O 0 6.992292611585071e-08
the O 0 6.602987809856131e-07
APC B-Disease 0 4.7757726861163974e-05
gene O 0 3.173926870658761e-06
( O 0 3.488858340006118e-07
1 O 0 2.8476404168031877e-07
) O 0 1.418489148363733e-07
at O 0 1.1481152739634126e-07
the O 0 1.0583845266864955e-07
5 O 0 2.836300438957551e-07
end O 0 3.880901715547225e-07
spanning O 0 4.2297554614378896e-07
exons O 0 1.3793635389447445e-06
4 O 0 2.3139033089591976e-07
and O 0 8.970202003411032e-08
5 O 0 2.4093876049846585e-07
, O 0 1.1308242875429642e-07
( O 0 1.7025718079821672e-07
2 O 0 1.3468026338614436e-07
) O 0 9.13572080207814e-08
within O 0 1.30236912809778e-07
exon O 0 1.9203373540221946e-06
9 O 0 4.3901073354390974e-07
, O 0 7.777470045766677e-08
and O 0 7.580181460298263e-08
( O 0 1.4566910522262333e-07
3 O 0 1.6636980149087321e-07
) O 0 7.681479985421902e-08
at O 0 8.409401885955958e-08
the O 0 1.4430121098030213e-07
3 O 0 3.552387681793334e-07
distal O 0 9.869885616353713e-06
end O 0 6.283537459239597e-07
of O 0 1.622869376660674e-07
the O 0 2.02771161639248e-06
gene O 0 3.079204179812223e-05
. O 0 1.3524299902201165e-05

Variability O 0 0.0005219538579694927
in O 0 8.662768777867313e-06
the O 0 2.23415668187954e-06
number O 0 9.856686347120558e-07
of O 0 8.845849151839502e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999992847442627
was O 0 0.015616092830896378
most O 0 2.594579484593851e-07
apparent O 0 4.591470315062907e-06
in O 0 2.4526642050659575e-07
individuals O 0 5.374785061462717e-08
with O 0 1.223306327347018e-07
mutations O 0 1.8271430235472508e-06
in O 0 1.1472932470724118e-07
region O 0 3.519650704220112e-07
1 O 0 2.6143902687181253e-07
, O 0 1.8386747058229957e-07
and O 0 6.472120048783836e-07
upper O 0 0.1811046004295349
- O 1 0.9987238049507141
gastrointestinal O 1 0.936525821685791
manifestations O 0 5.795769902761094e-05
were O 0 1.5803758515176014e-06
more O 0 3.0120932592581084e-07
severe O 0 0.029711199924349785
in O 0 1.7265637097807485e-06
them O 0 1.8488691466700402e-06
. O 0 1.6516547475475818e-05

In O 0 2.5531526262057014e-05
individuals O 0 2.0506845430645626e-06
with O 0 8.090132723737042e-07
mutations O 0 9.361875527247321e-06
in O 0 2.3459931242086896e-07
either O 0 4.017938124434295e-07
region O 0 5.267571054901055e-07
2 O 0 3.782492399295734e-07
or O 0 1.4919025659310137e-07
region O 0 2.4030748591030715e-07
3 O 0 1.48036733094159e-07
, O 0 3.350705668481169e-08
the O 0 5.2676210060553785e-08
average O 0 1.645225182755894e-07
number O 0 5.061929542193866e-08
of O 0 1.0225357982562855e-07
adenomas B-Disease 0 2.7041718567488715e-05
tended O 0 7.375630502792774e-06
to O 0 3.209100611911708e-07
be O 0 1.2663304005400278e-07
lower O 0 1.1388290204195073e-06
than O 0 3.666270487201473e-08
those O 0 3.441496332357019e-08
in O 0 4.485382021357509e-08
individuals O 0 2.514881636273003e-08
with O 0 1.1666270438581705e-07
mutations O 0 1.7427389593649423e-06
in O 0 1.194444365637537e-07
region O 0 3.101111190062511e-07
1 O 0 2.4368472395508434e-07
, O 0 1.1319269788145903e-07
although O 0 5.842993004989694e-07
age O 0 1.244194436367252e-06
at O 0 1.4036039829079527e-05
diagnosis O 0 0.31718379259109497
was O 0 0.00012726080603897572
similar O 0 3.6148103390587494e-05
. O 0 2.085267442453187e-05

In O 0 8.105361484922469e-05
all O 0 1.3670321095560212e-05
AAPC B-Disease 1 0.9997768998146057
kindreds O 0 0.0004250075144227594
, O 0 3.092551196459681e-06
a O 0 2.4575815587013494e-06
predominance O 0 2.2357968191499822e-05
of O 0 1.7522564803584828e-06
right O 0 0.0007779095321893692
- O 1 0.9996635913848877
sided O 1 0.9999990463256836
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999970197677612
and O 0 0.0019521948415786028
rectal B-Disease 1 0.9997959733009338
polyp I-Disease 1 0.9802820682525635
sparing O 0 0.00044634068035520613
was O 0 0.00097031204495579
observed O 0 9.254521137336269e-05
. O 0 3.436542829149403e-05

No O 0 0.0003091840771958232
desmoid B-Disease 1 0.9645944237709045
tumors I-Disease 1 0.9999980926513672
were O 0 1.150996467913501e-05
found O 0 2.9066552542644786e-06
in O 0 1.7713550732878502e-06
these O 0 2.177807800762821e-06
kindreds O 0 0.0002677060547284782
. O 0 3.806635504588485e-05

Our O 0 2.443031371512916e-05
data O 0 8.088242793746758e-06
suggest O 0 2.086596168737742e-06
that O 0 1.5874587688813335e-07
, O 0 1.2379918246097077e-07
in O 0 9.379893981531495e-07
AAPC B-Disease 1 0.9999854564666748
families O 0 5.873754957974597e-07
, O 0 7.039262328589757e-08
the O 0 5.944421488379703e-08
location O 0 2.1880305212107487e-07
of O 0 8.827984032677705e-08
the O 0 2.361578935961006e-06
APC B-Disease 0 0.012442228384315968
mutation O 0 5.1508777687558904e-05
may O 0 1.5139583410928026e-05
partially O 0 3.480334271444008e-05
predict O 0 7.800073035468813e-06
specific O 0 2.3835423235141207e-06
phenotypic O 0 3.004851532750763e-05
expression O 0 2.6420077119837515e-05
. O 0 2.8665070203715004e-05

This O 0 9.776692422747146e-06
should O 0 1.2707765790764824e-06
help O 0 3.747305754586705e-07
in O 0 1.3670650389485672e-07
the O 0 1.284593906802911e-07
design O 0 1.6351250451407395e-06
of O 0 1.9942376638937276e-07
tailored O 0 0.00010627380106598139
clinical O 0 0.0006823093281127512
- O 0 0.36068445444107056
management O 0 0.00010447739623486996
protocols O 0 2.8394493710948154e-05
in O 0 3.1185081184048613e-07
this O 0 2.08854828542826e-07
subset O 0 1.1092319027738995e-06
of O 0 1.1793464409493026e-06
FAP B-Disease 0 0.013995779678225517
patients O 0 5.5393811635440215e-05
. O 0 3.255823230574606e-06
. O 0 1.888436781882774e-05

Wilms B-Disease 1 0.982813835144043
' I-Disease 0 0.0007530250586569309
tumor I-Disease 0 0.0009061524760909379
1 O 0 4.1336988942930475e-06
and O 0 1.7728305010678014e-06
Dax O 1 0.554366409778595
- O 0 5.235062417341396e-05
1 O 0 1.8638819483385305e-06
modulate O 0 2.318776387255639e-05
the O 0 1.341822439826501e-06
orphan O 0 1.7456568457419053e-05
nuclear O 0 1.7593511074665003e-05
receptor O 0 3.332816413603723e-05
SF O 0 0.004343536216765642
- O 0 1.0196410585194826e-05
1 O 0 5.291734623824595e-07
in O 0 2.9290092129485856e-07
sex O 0 1.4384975202119676e-06
- O 0 7.925700629130006e-06
specific O 0 1.8135015125153586e-06
gene O 0 1.7813938029576093e-05
expression O 0 1.2022115697618574e-05
. O 0 1.5071215784701053e-05

Products O 0 0.00011311167327221483
of O 0 8.21663979877485e-06
steroidogenic O 0 0.0005142877926118672
factor O 0 1.1294956493657082e-05
1 O 0 4.0889553929446265e-06
( O 0 4.624332177627366e-06
SF O 1 0.5308169722557068
- O 0 4.56467860203702e-05
1 O 0 9.111868166655768e-07
) O 0 4.83023711694841e-07
and O 0 1.4313554856926203e-06
Wilms B-Disease 0 0.06682036072015762
tumor I-Disease 0 0.0008301577181555331
1 O 0 1.6695262274879497e-06
( O 0 2.488588506821543e-06
WT1 O 0 0.0001361939066555351
) O 0 5.4412737426901e-07
genes O 0 3.82596624604048e-07
are O 0 4.092158434332305e-08
essential O 0 9.788512755903866e-08
for O 0 1.3772483953289338e-07
mammalian O 0 8.26743143989006e-06
gonadogenesis O 0 5.491811680258252e-05
prior O 0 4.086514763912419e-06
to O 0 1.893195758384536e-06
sexual O 0 1.1197072126378771e-05
differentiation O 0 5.4177700803847983e-05
. O 0 3.200524588464759e-05

In O 0 7.023559010121971e-05
males O 0 3.3707281545503065e-05
, O 0 4.504450316744624e-06
SF O 0 0.34785157442092896
- O 0 4.3237068894086406e-05
1 O 0 9.3410181989384e-07
participates O 0 1.0030792054749327e-06
in O 0 1.699531679832944e-07
sexual O 0 2.583340403816692e-07
development O 0 1.743005384469143e-07
by O 0 2.6419962750878767e-07
regulating O 0 2.0305583348090295e-06
expression O 0 5.184955398362945e-07
of O 0 2.052279768349763e-07
the O 0 1.5638166814824217e-06
polypeptide O 0 0.00015865571913309395
hormone O 0 0.00016921781934797764
Mullerian O 0 0.0005808580317534506
inhibiting O 0 0.00014588329941034317
substance O 0 0.00017776023014448583
( O 0 2.469990613462869e-05
MIS O 0 0.0006458738935180008
) O 0 1.5624240404576994e-05
. O 0 1.629376674827654e-05

Here O 0 2.2672438717563637e-05
, O 0 2.3820766728022136e-06
we O 0 4.0903566400629643e-07
show O 0 1.945823896676302e-06
that O 0 1.2016095070066513e-06
WT1 O 0 0.0003093639388680458
- O 0 7.423824717989191e-05
KTS O 0 0.000249602337135002
isoforms O 0 2.066924025712069e-05
associate O 0 4.240695034241071e-06
and O 0 6.940419439160905e-07
synergize O 0 4.253727092873305e-05
with O 0 3.6922610888723284e-06
SF O 1 0.8568643927574158
- O 0 4.347099820734002e-05
1 O 0 9.036778578774829e-07
to O 0 8.314043498103274e-07
promote O 0 6.0686443248414434e-06
MIS O 0 0.00038231906364671886
expression O 0 2.7012232749257237e-05
. O 0 1.6525447790627368e-05

In O 0 4.0562266804045066e-05
contrast O 0 5.808362766401842e-05
, O 0 1.0135111551790033e-05
WT1 O 0 0.014168862253427505
missense O 0 0.0014533457579091191
mutations O 0 9.211089491145685e-05
, O 0 8.164937526089489e-07
associated O 0 1.188920350614353e-06
with O 0 5.502973294824187e-07
male B-Disease 0 4.646018624043791e-06
pseudohermaphroditism I-Disease 1 0.9983336329460144
in O 0 5.2530951506923884e-05
Denys B-Disease 1 0.9980995059013367
- I-Disease 1 0.9999375343322754
Drash I-Disease 1 0.9999867677688599
syndrome I-Disease 1 0.9999997615814209
, O 0 3.7340923881856725e-06
fail O 0 2.2816222553956322e-05
to O 0 1.5713274024165003e-06
synergize O 0 0.000106904684798792
with O 0 8.612390047346707e-06
SF O 1 0.9972453117370605
- O 0 0.0005187757196836174
1 O 0 1.5052685739647131e-05
. O 0 1.5081077435752377e-05

Additionally O 0 6.708795262966305e-05
, O 0 1.8646251191967167e-06
the O 0 1.2008054000034463e-06
X O 0 0.0005484878201968968
- O 0 0.00020777211466338485
linked O 0 1.1991576684522443e-05
, O 0 2.607975488899683e-07
candidate O 0 1.4201420981407864e-06
dosage O 0 2.7336529456079006e-05
- O 0 3.55526281055063e-05
sensitive O 0 7.355126854236005e-06
sex O 0 3.180677822456346e-06
- O 0 9.656112524680793e-06
reversal O 0 4.659192200051621e-06
gene O 0 2.7882426820724504e-06
, O 0 3.736685414423846e-07
Dax O 0 0.010715744458138943
- O 0 1.9827049982268363e-05
1 O 0 6.847149620625714e-07
, O 0 3.149120573198161e-07
antagonizes O 0 1.3433560525299981e-05
synergy O 0 7.003771315794438e-06
between O 0 1.900768779705686e-06
SF O 0 0.16859088838100433
- O 0 2.376343218202237e-05
1 O 0 5.776864213657973e-07
and O 0 3.460539517163852e-07
WT1 O 0 0.00011425370030337945
, O 0 1.9324133404552413e-07
most O 0 9.105677634124731e-08
likely O 0 2.620993200252997e-07
through O 0 1.6363107135930477e-07
a O 0 3.3579678415662784e-07
direct O 0 6.111491188676155e-07
interaction O 0 1.3851135918230284e-06
with O 0 2.6415125375933712e-06
SF O 1 0.9651869535446167
- O 0 0.0003297670918982476
1 O 0 1.7895770724862814e-05
. O 0 1.4972025383030996e-05

We O 0 1.612970299902372e-05
propose O 0 4.18092604377307e-05
that O 0 2.485637878635316e-06
WT1 O 0 0.00019482278730720282
and O 0 2.7834842057927744e-06
Dax O 0 0.4951082170009613
- O 0 5.002336547477171e-05
1 O 0 5.762739192505251e-07
functionally O 0 2.2115254978416488e-06
oppose O 0 4.731254250600614e-07
each O 0 3.555722116743709e-08
other O 0 3.684890614863434e-08
in O 0 2.133361789447008e-07
testis O 0 1.5847021131776273e-05
development O 0 1.0056538712888141e-06
by O 0 1.3250974006950855e-06
modulating O 0 0.0017070886678993702
SF O 1 0.7598310112953186
- O 0 5.262562262942083e-05
1 O 0 2.3281033918465255e-06
- O 0 3.6674216971732676e-05
mediated O 0 9.75432776613161e-05
transactivation O 0 0.00024515760014764965
. O 0 5.562120350077748e-06
. O 0 1.3973749446449801e-05

A O 0 0.00021992884285282344
mouse O 0 0.0007932946900837123
model O 0 0.0001038935297401622
for O 0 6.828337791375816e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9692410826683044
- O 1 0.9530181884765625
centre O 0 0.05756533145904541
mutations O 0 0.0011252750409767032
. O 0 4.3894066038774326e-05

Imprinting O 0 0.0015911281807348132
in O 0 1.3800812666886486e-05
the O 0 3.14542467094725e-06
15q11 O 0 6.0906193539267406e-05
- O 0 1.708869240246713e-05
q13 O 0 1.1534017176018097e-05
region O 0 9.866730579233263e-07
involves O 0 5.035736307945626e-07
an O 0 4.783360623150656e-07
imprinting O 0 9.844575833994895e-05
centre O 0 0.00010278416448272765
( O 0 2.022798071266152e-06
IC O 0 3.7231595342746004e-05
) O 0 4.220536027332855e-07
, O 0 7.633239818005677e-08
mapping O 0 3.930140053398645e-07
in O 0 1.0254008486754174e-07
part O 0 1.338768385039657e-07
to O 0 7.725957829052277e-08
the O 0 1.3879946436645696e-07
promoter O 0 2.6390348466520663e-06
and O 0 2.327163883819594e-07
first O 0 1.1059070175178931e-06
exon O 0 2.0127889001742005e-05
of O 0 2.3167592644313117e-06
SNRPN O 0 0.001886702491901815
. O 0 3.376242966623977e-05

Deletion O 0 0.0006470949738286436
of O 0 6.611856861127308e-06
this O 0 5.972429335088236e-06
IC O 0 0.0003577844181563705
abolishes O 0 0.0003350433544255793
local O 0 7.8925586421974e-06
paternally O 0 0.00014508827007375658
derived O 0 6.120103989815107e-06
gene O 0 4.970473582943669e-06
expression O 0 1.6563127474000794e-06
and O 0 5.92355604567274e-07
results O 0 7.4823460636253e-06
in O 0 0.0001708605414023623
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.006141616031527519
PWS B-Disease 1 0.9999995231628418
) O 0 3.951826147385873e-05
. O 0 2.6677382265916094e-05

We O 0 7.785663001413923e-06
have O 0 1.3089814956401824e-06
created O 0 1.5899889831416658e-06
two O 0 4.5204924958852644e-07
deletion O 0 2.6799678380484693e-05
mutations O 0 1.6336491171387024e-05
in O 0 1.8889145394496154e-06
mice O 0 0.00012263492681086063
to O 0 3.8011335163901094e-06
understand O 0 1.544047518109437e-05
PWS B-Disease 1 0.9999980926513672
and O 0 5.568493293139909e-07
the O 0 3.5381705743020575e-07
mechanism O 0 1.0306140438842704e-06
of O 0 3.427801971156441e-07
this O 0 2.901216248574201e-06
IC O 0 0.0007384323398582637
. O 0 2.9075647034915164e-05

Mice O 0 0.0031347002368420362
harbouring O 0 0.0008687790250405669
an O 0 9.726287316880189e-06
intragenic O 0 0.0006130294059403241
deletion O 0 9.889286593534052e-05
in O 0 3.227908337066765e-06
Snrpn O 0 0.0001493519957875833
are O 0 4.3321966813891777e-07
phenotypically O 0 2.8744481824105605e-05
normal O 0 4.386836280900752e-06
, O 0 4.818082288693404e-07
suggesting O 0 2.523584271330037e-06
that O 0 2.8283778874538257e-07
mutations O 0 1.7951347217604052e-06
of O 0 1.3552794086990616e-07
SNRPN O 0 0.00014004705008119345
are O 0 9.286917901363267e-08
not O 0 1.83758771754583e-07
sufficient O 0 9.96088829197106e-07
to O 0 3.9656315493630245e-06
induce O 0 0.0008805772522464395
PWS B-Disease 1 0.9999973773956299
. O 0 7.462494249921292e-05

Mice O 0 0.001356048509478569
with O 0 5.440664153866237e-06
a O 0 6.241395112738246e-06
larger O 0 5.848105047334684e-06
deletion O 0 2.0847126506851055e-05
involving O 0 2.2847291347716236e-06
both O 0 7.274412610058789e-07
Snrpn O 0 4.185115176369436e-05
and O 0 9.136189191849553e-07
the O 0 3.612537511799019e-06
putative O 0 0.003795573255047202
PWS O 1 0.9999995231628418
- O 0 0.13570672273635864
IC O 0 0.0004718897398561239
lack O 0 3.961964921472827e-06
expression O 0 1.350833031210641e-06
of O 0 2.487053052391275e-07
the O 0 1.5616377595506492e-06
imprinted O 0 0.00016623869305476546
genes O 0 9.112032785196789e-06
Zfp127 O 0 4.700771751231514e-05
( O 0 1.8567924371382105e-06
mouse O 0 1.1259156963205896e-05
homologue O 0 1.9410923414397985e-05
of O 0 4.6686344035151706e-07
ZNF127 O 0 0.0001540086232125759
) O 0 1.1711545084835961e-06
, O 0 4.857260478274839e-07
Ndn O 0 8.414113835897297e-05
and O 0 7.123318255253253e-07
Ipw O 0 0.00010860779002541676
, O 0 2.764107875918853e-07
and O 0 3.24302618537331e-07
manifest O 0 9.92841614788631e-06
several O 0 1.0707435649237595e-06
phenotypes O 0 4.08348350902088e-05
common O 0 7.1562244556844234e-06
to O 0 0.0003716212813742459
PWS B-Disease 1 1.0
infants O 1 0.801659882068634
. O 0 5.210428935242817e-05

These O 0 1.0139558980881702e-05
data O 0 6.022968591423705e-06
demonstrate O 0 1.920546310429927e-06
that O 0 1.1340545569282767e-07
both O 0 5.837635796979157e-08
the O 0 8.975148091394658e-08
position O 0 2.060241541812502e-07
of O 0 3.0229792002955946e-08
the O 0 1.4227093458885065e-07
IC O 0 1.157656606665114e-05
and O 0 8.318105670923615e-08
its O 0 1.7823548148498958e-07
role O 0 1.4852955132482748e-07
in O 0 6.76930795862063e-08
the O 0 6.689856490993407e-08
coordinate O 0 5.345148110791342e-07
expression O 0 2.007248696145325e-07
of O 0 4.5207684706838336e-08
genes O 0 2.8305476007517427e-07
is O 0 3.3999551618535406e-08
conserved O 0 1.4712766471802752e-07
between O 0 8.466454914923816e-08
mouse O 0 2.2094636733527295e-06
and O 0 1.0630662217181452e-07
human O 0 7.121885658989413e-08
, O 0 3.278729110434142e-08
and O 0 4.9235985954965145e-08
indicate O 0 2.390681004271755e-07
that O 0 4.598849301373775e-08
the O 0 1.4771350720366172e-07
mouse O 0 3.1589643185725436e-06
is O 0 8.426211905998571e-08
a O 0 1.4778804313664295e-07
suitable O 0 3.9969373233361694e-07
model O 0 1.6218527889577672e-06
system O 0 9.705390766612254e-07
in O 0 1.303458958545889e-07
which O 0 1.0851938014866391e-07
to O 0 7.930609058348637e-08
investigate O 0 4.086979856765538e-07
the O 0 1.514752199227587e-07
molecular O 0 1.0838012940439512e-06
mechanisms O 0 4.993185029888991e-07
of O 0 8.680515861669846e-08
imprinting O 0 1.1299040124868043e-05
in O 0 2.579376996436622e-07
this O 0 7.195274775995131e-08
region O 0 1.617839444634228e-07
of O 0 5.3071740779842e-08
the O 0 4.1684390339469246e-07
genome O 0 5.577971478487598e-06
. O 0 2.475321480233106e-06
. O 0 1.3853453310730401e-05

Mutations O 0 0.0005756337195634842
of O 0 4.104097570234444e-06
the O 0 5.176870217837859e-06
ATM O 0 0.00012222121586091816
gene O 0 3.578139512683265e-05
detected O 0 2.769964157778304e-05
in O 0 3.904686309397221e-06
Japanese O 0 0.004536144435405731
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.01764609105885029
: O 0 5.272868861538882e-07
possible O 0 4.283011492134392e-07
preponderance O 0 1.6581018371653045e-06
of O 0 4.955092691716345e-08
the O 0 2.387684787663602e-07
two O 0 4.6835555167490384e-07
founder O 0 5.888106898055412e-05
mutations O 0 1.837563468143344e-05
4612del165 O 0 4.1434257582295686e-05
and O 0 5.865431376150809e-06
7883del5 O 0 0.0003103464550804347
. O 0 4.915097451885231e-05

The O 0 4.358173464424908e-05
ATM O 0 0.0009095502318814397
( O 0 4.2247454985044897e-05
A O 1 0.9894058108329773
- O 1 0.9998469352722168
T O 1 0.9999947547912598
, O 0 1.3540911822929047e-06
mutated O 0 1.3013393072469626e-05
) O 0 7.560102517345513e-07
gene O 0 1.8303746855963254e-06
on O 0 8.009678822418209e-07
human O 0 3.1883646443020552e-06
chromosome O 0 9.793059871299192e-05
11q22 O 0 0.00019698093819897622
. O 0 3.926840872736648e-05

3 O 0 4.9581351049710065e-05
has O 0 6.161354576761369e-06
recently O 0 1.2796612281817943e-05
been O 0 5.791764010609768e-07
identified O 0 4.1580841525501455e-07
as O 0 9.745999562937868e-08
the O 0 2.2397922805339476e-07
gene O 0 1.0294893399986904e-06
responsible O 0 3.0839055398246273e-07
for O 0 8.17626926163939e-08
the O 0 1.1788978326876531e-06
human O 0 0.00010660245607141405
recessive B-Disease 1 0.9999972581863403
disease I-Disease 1 0.9999979734420776
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0007947898702695966
A B-Disease 1 0.999934196472168
- I-Disease 1 0.9999943971633911
T I-Disease 1 0.9999955892562866
) O 0 2.0381874492159113e-05
. O 0 1.749715011101216e-05

In O 0 1.8701510271057487e-05
order O 0 3.231117716495646e-06
to O 0 6.814154858147958e-07
define O 0 1.5097564300958766e-06
the O 0 4.92214780933864e-07
types O 0 8.195675036404282e-07
of O 0 5.610508537756687e-07
disease O 0 0.0028974241577088833
- O 0 0.00031050833058543503
causing O 0 1.7261801986023784e-05
ATM O 0 0.00019042528583668172
mutations O 0 9.379587936564349e-06
in O 0 4.372987802980788e-07
Japanese O 0 6.45866884951829e-06
A B-Disease 1 0.9999985694885254
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.0031423597829416e-05
as O 0 1.8893527453656134e-07
well O 0 6.603334412602635e-08
as O 0 6.332162172384415e-08
to O 0 8.09043569915957e-08
look O 0 2.398813592208171e-07
for O 0 1.1697051860437568e-07
possible O 0 8.372301749659528e-07
mutational O 0 6.266004493227229e-05
hotspots O 0 1.2737315955746453e-05
, O 0 4.799783823727921e-07
reverse O 0 6.659176960965851e-06
- O 0 4.387434273667168e-06
transcribed O 0 2.3282855181605555e-06
RNA O 0 1.1657356253635953e-06
derived O 0 3.289986807430978e-07
from O 0 1.2155935280588892e-07
ten O 0 1.9820272711967846e-07
patients O 0 4.286031014544278e-07
belonging O 0 6.161351393529912e-07
to O 0 1.53471674479988e-07
eight O 0 3.0435381859206245e-07
unrelated O 0 2.787349330901634e-06
Japanese O 0 4.168918167124502e-06
A B-Disease 1 0.9997324347496033
- I-Disease 1 0.999996542930603
T I-Disease 1 0.9999997615814209
families O 0 1.384545726068609e-06
was O 0 1.1426844139350578e-05
analyzed O 0 1.4851655123493401e-06
for O 0 3.097443084243423e-07
mutations O 0 3.044358891202137e-06
by O 0 3.1207900974550284e-07
the O 0 1.257695089407207e-06
restriction O 0 1.8121036191587336e-05
endonuclease O 0 0.00022773387900087982
fingerprinting O 0 6.299190135905519e-05
method O 0 2.278032661706675e-05
. O 0 1.9252229321864434e-05

As O 0 1.916759356390685e-05
has O 0 3.6910253129462944e-06
been O 0 1.0794460649776738e-06
reported O 0 4.9156969907926396e-06
by O 0 4.0110967347573023e-07
others O 0 5.750403602178267e-07
, O 0 3.9006266661090194e-07
mutations O 0 1.9664526007545646e-06
that O 0 1.0321824817083325e-07
lead O 0 7.373882908723317e-07
to O 0 6.264707508307765e-07
exon O 0 1.4242355973692611e-05
skipping O 0 7.442841706506442e-06
or O 0 3.201988420187263e-06
premature O 0 2.6001876904047094e-05
protein O 0 2.282196646774537e-06
truncation O 0 1.1644172445812728e-05
were O 0 7.340554475376848e-07
also O 0 7.349759130192979e-07
predominant O 0 4.911226824333426e-06
in O 0 1.2073276138835354e-06
our O 0 4.891893240710488e-06
mutants O 0 0.0002825516276061535
. O 0 2.4030290660448372e-05

Six O 0 2.3163829609984532e-05
different O 0 5.9218609749223106e-06
mutations O 0 3.240996375097893e-05
were O 0 6.542680921484134e-07
identified O 0 6.2522212829208e-07
on O 0 3.451159500400536e-07
12 O 0 2.1046881215625035e-07
of O 0 8.698746967183979e-08
the O 0 6.634199962718412e-07
16 O 0 6.186283826536965e-06
alleles O 0 5.239967140369117e-05
examined O 0 0.00022583130339626223
. O 0 2.6977737434208393e-05

Four O 0 1.6871959815034643e-05
were O 0 3.1115168894757517e-06
deletions O 0 1.9198565496481024e-05
involving O 0 2.3342818167293444e-06
a O 0 6.2859567151463125e-06
loss O 0 2.3069296730682254e-05
of O 0 2.671459640168905e-07
a O 0 2.171366759284865e-06
single O 0 4.48924356533098e-06
exon O 0 3.80104138457682e-05
exon O 0 3.567788371583447e-05
7 O 0 3.049124188692076e-06
, O 0 4.6286331212286314e-07
exon O 0 1.327708287135465e-05
16 O 0 1.6512863112438936e-06
, O 0 8.936098652156943e-07
exon O 0 2.3362272258964367e-05
33 O 0 5.182768745726207e-06
or O 0 3.51580365531845e-06
exon O 0 7.394497515633702e-05
35 O 0 2.5467008526902646e-05
. O 0 3.0384009733097628e-05

The O 0 1.9351207811268978e-05
others O 0 5.4612655731034465e-06
were O 0 1.003630359264207e-06
minute O 0 2.9073235054966062e-06
deletions O 0 1.208814046549378e-05
, O 0 6.825517289144045e-07
4649delA O 0 1.0193679372605402e-05
in O 0 1.0911822982961894e-06
exon O 0 2.1874142476008274e-05
33 O 0 2.455070216456079e-06
and O 0 7.158827202147222e-07
7883del5 O 0 2.7652529752231203e-05
in O 0 4.8409497139800806e-06
exon O 0 0.0001527859567431733
55 O 0 4.1351362597197294e-05
. O 0 2.9292255931068212e-05

The O 0 3.8916670746402815e-05
mutations O 0 0.0001424828078597784
4612del165 O 0 5.399624933488667e-05
and O 0 1.2730897651636042e-06
7883del5 O 0 1.862279350461904e-05
were O 0 7.674171911276062e-07
found O 0 1.6290486826164852e-07
in O 0 5.012134707271798e-08
more O 0 1.6718184170372297e-08
than O 0 2.1866803479042574e-08
two O 0 7.016674885562679e-08
unrelated O 0 7.841712204026408e-07
families O 0 1.9262017758592265e-07
; O 0 2.1582681597465125e-07
44 O 0 3.4560508765935083e-07
% O 0 1.5412318532526115e-07
( O 0 1.5143507425818825e-07
7 O 0 1.782081113788081e-07
of O 0 5.1071019413484464e-08
16 O 0 2.3979788466022e-07
) O 0 6.652471995494125e-08
of O 0 2.309872471073504e-08
the O 0 1.410923005096265e-07
mutant O 0 5.587640771409497e-06
alleles O 0 2.1105422547407215e-06
had O 0 5.01263684782316e-07
one O 0 5.4047099240506213e-08
of O 0 4.9839933069506515e-08
the O 0 5.696057883142203e-07
two O 0 2.3951270122779533e-06
mutations O 0 8.41973305796273e-05
. O 0 1.686977338977158e-05

The O 0 3.0014518415555358e-05
4612del165 O 0 0.0003185721579939127
mutations O 0 3.0628852982772514e-05
in O 0 5.91630737289961e-07
three O 0 1.1360592822029503e-07
different O 0 6.684269493462125e-08
families O 0 1.235650444186831e-07
were O 0 1.0090607105439631e-07
all O 0 3.3983472036425155e-08
ascribed O 0 1.1896520391019294e-06
to O 0 1.1206221728343735e-07
the O 0 2.0770319508756074e-07
same O 0 1.2244914842085564e-06
T O 0 0.027534062042832375
- O 0 5.0301481678616256e-05
- O 0 9.100517672777642e-06
> O 0 1.1000238373526372e-06
A O 0 2.861221446437412e-07
substitution O 0 5.341917130863294e-07
at O 0 2.5071116738217825e-07
the O 0 5.759201258115354e-07
splice O 0 3.117582673439756e-05
donor O 0 6.328126801236067e-06
site O 0 6.354136530717369e-06
in O 0 4.798813279194292e-06
intron O 0 0.0003487691283226013
33 O 0 4.036800964968279e-05
. O 0 1.9831248209811747e-05

Microsatellite O 0 0.004711481276899576
genotyping O 0 0.0009107873775064945
around O 0 1.3362635399971623e-05
the O 0 2.3836150830902625e-06
ATM O 0 2.9240542062325403e-05
locus O 0 1.4628983990405686e-05
also O 0 1.0397756113889045e-06
indicated O 0 1.8361406546318904e-06
that O 0 5.548699633095566e-08
a O 0 4.2216470319544896e-07
common O 0 1.2725532769763959e-06
haplotype O 0 0.0016811434179544449
was O 0 7.701203685428482e-06
shared O 0 3.57609991397112e-07
by O 0 1.4605525677779951e-07
the O 0 3.6484061638475396e-07
mutant O 0 1.1048600754293147e-05
alleles O 0 5.694358605978778e-06
in O 0 6.782826176277013e-07
both O 0 2.2335689209285192e-06
mutations O 0 9.684749966254458e-05
. O 0 1.4163538253342267e-05

This O 0 1.3317293451109435e-05
suggests O 0 6.781372576369904e-06
that O 0 2.9726865591328533e-07
these O 0 1.3401326270923164e-07
two O 0 4.6858252744641504e-07
founder O 0 0.0012606472009792924
mutations O 0 9.435223910259083e-05
may O 0 2.871342758226092e-06
be O 0 1.8376333343894657e-07
predominant O 0 2.5465833459747955e-06
among O 0 3.947268396586878e-07
Japanese O 0 6.134110662969761e-06
ATM O 0 0.00021974164701532573
mutant O 0 0.00023549860634375364
alleles O 0 0.00012201217759866267
. O 0 2.659716301423032e-05

W474C O 0 0.0034504723735153675
amino O 0 0.00033618221641518176
acid O 0 9.503118781140074e-05
substitution O 0 2.125275568687357e-05
affects O 0 7.053789886413142e-06
early O 0 2.268058779009152e-06
processing O 0 8.86736927441234e-07
of O 0 9.56743591018494e-08
the O 0 2.494487887361174e-07
alpha O 0 2.202340510848444e-06
- O 0 1.69373572589393e-06
subunit O 0 6.789867939005489e-07
of O 0 8.214080793322864e-08
beta O 0 1.5563894066872308e-06
- O 0 6.071272764529567e-06
hexosaminidase O 0 1.1996803550573532e-05
A O 0 1.1728992603821098e-06
and O 0 2.35676807847085e-07
is O 0 3.408458155718108e-07
associated O 0 2.968421995319659e-06
with O 0 8.841412636684254e-06
subacute O 1 0.9903395771980286
G B-Disease 0 0.24376605451107025
( I-Disease 0 1.4008212019689381e-05
M2 I-Disease 0 0.0002785355900414288
) I-Disease 0 7.822449333616532e-06
gangliosidosis I-Disease 0 0.000328823080053553
. O 0 2.553585909481626e-05

Mutations O 0 0.002282427391037345
in O 0 1.432159751857398e-05
the O 0 6.728760126861744e-06
HEXA O 0 0.0023704026825726032
gene O 0 2.8900247343699448e-05
, O 0 7.798932415425952e-07
encoding O 0 2.241757101728581e-06
the O 0 4.4241218688512163e-07
alpha O 0 2.6796965357789304e-06
- O 0 1.5749790236441186e-06
subunit O 0 8.148959409481904e-07
of O 0 1.1351668405268356e-07
beta O 0 2.7024934752262197e-06
- O 0 6.662975465587806e-06
hexosaminidase O 0 2.1468358681886457e-05
A O 0 3.6753278891410446e-06
( O 0 7.988791708157805e-07
Hex O 0 5.832805072714109e-06
A O 0 1.08974620616209e-06
) O 0 2.41935964595541e-07
, O 0 6.880500791339728e-08
that O 0 9.042712179052614e-08
abolish O 0 3.953834493586328e-06
Hex O 0 7.117347649909789e-06
A O 0 1.7164471728392527e-06
enzyme O 0 1.0935953469015658e-05
activity O 0 2.048237729468383e-05
cause O 0 0.05141128972172737
Tay B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9625929594039917
( O 0 1.6426789443357848e-05
TSD B-Disease 0 0.00897102802991867
) O 0 1.248856847269053e-06
, O 0 2.4634192641315167e-07
the O 0 1.4501835039482103e-06
fatal O 1 0.8189952373504639
infantile B-Disease 0 0.030932921916246414
form I-Disease 0 3.460167135926895e-06
of I-Disease 0 1.2506445727922255e-06
G I-Disease 0 0.00440568570047617
( I-Disease 0 3.4240356399095617e-06
M2 I-Disease 0 8.74440956977196e-05
) I-Disease 0 1.0538145716054714e-06
gangliosidosis I-Disease 0 5.172407327336259e-05
, I-Disease 0 8.951766972131736e-07
Type I-Disease 0 9.325342944066506e-06
1 I-Disease 0 7.192789325927151e-06
. O 0 1.3351284906093497e-05

Less O 0 0.0003471423697192222
severe O 1 0.9731982946395874
, O 0 6.575462612090632e-05
subacute O 1 0.9731433987617493
( O 0 6.827556353528053e-05
juvenile O 0 0.086360864341259
- O 1 0.9089598655700684
onset O 1 0.9656307101249695
) O 0 1.568494008097332e-05
and O 0 6.365905574057251e-05
chronic O 1 0.9753212928771973
( O 0 5.201941803534282e-06
adult O 0 9.910517292155419e-06
- O 0 0.10342668741941452
onset O 0 0.1189752146601677
) O 0 8.823486723485985e-07
variants O 0 3.0786120532866335e-06
are O 0 9.50417771150569e-08
characterized O 0 1.339904315500462e-06
by O 0 2.0950875523340073e-07
a O 0 7.990025778781273e-07
broad O 0 4.788184924109373e-06
spectrum O 0 6.6972947934118565e-06
of O 0 1.5878796943979978e-07
clinical O 0 2.068493267870508e-05
manifestations O 0 2.5567000193404965e-05
and O 0 1.0500795042389655e-06
are O 0 5.7104173833977256e-08
associated O 0 2.9036002047178044e-07
with O 0 1.7344738978408714e-07
residual O 0 9.545400644128677e-06
levels O 0 6.476615226347349e-07
of O 0 1.8729217288182554e-07
Hex O 0 1.4788853150093928e-05
A O 0 4.490365427045617e-06
enzyme O 0 1.814670213207137e-05
activity O 0 1.6502270227647386e-05
. O 0 1.3018247045692988e-05

We O 0 2.9925548005849123e-05
identified O 0 2.8269587346585467e-05
a O 0 2.1613675926346332e-05
1422 O 0 0.15573757886886597
G O 0 0.10200123488903046
- O 0 0.024432066828012466
- O 0 0.0016214849893003702
> O 0 2.9128434107406065e-05
C O 0 3.5978140658698976e-05
( O 0 1.4469840152742108e-06
amino O 0 1.6088908978417749e-06
acid O 0 3.3698231618473073e-06
W474C O 0 5.406759100878844e-06
) O 0 2.1029305230513273e-07
substitution O 0 3.3060462101275334e-07
in O 0 7.992702677483976e-08
the O 0 1.2026409024201712e-07
first O 0 1.7889652781377663e-07
position O 0 4.1728372934812796e-07
of O 0 9.529372846373008e-08
exon O 0 3.6560097669280367e-06
13 O 0 2.3451609365565673e-07
of O 0 1.2330148990713496e-07
HEXA O 0 0.00011022968828910962
of O 0 1.6032757343964477e-07
a O 0 6.797046125939232e-07
non O 0 9.663551736593945e-07
- O 0 1.0237617971142754e-05
Jewish O 0 3.4529282402218087e-06
proband O 0 0.0005211465759202838
who O 0 5.181414508115267e-06
manifested O 0 7.907709368737414e-05
a O 0 3.7056783185107633e-05
subacute O 1 0.5203147530555725
variant O 0 0.0007803254411555827
of O 0 3.7092333968757885e-06
G B-Disease 0 0.015668509528040886
( I-Disease 0 1.0033586477220524e-05
M2 I-Disease 0 0.0002146389160770923
) I-Disease 0 6.859555014671059e-06
gangliosidosis I-Disease 0 0.0002763169468380511
. O 0 2.1346824723877944e-05

On O 0 2.1473026208695956e-05
the O 0 2.876695816667052e-06
second O 0 1.5305207853089087e-05
maternally O 0 0.010945495218038559
inherited O 0 0.028949394822120667
allele O 0 4.6569421101594344e-05
, O 0 6.322615604403836e-07
we O 0 1.580421127300724e-07
identified O 0 5.909597007303091e-07
the O 0 5.979765091979061e-07
common O 0 4.4911113946000114e-05
infantile O 1 0.999932050704956
disease O 1 0.8354619741439819
- O 0 0.005314615089446306
causing O 0 2.7609366952674463e-05
4 O 0 3.78391018784896e-06
- O 0 5.0497525080572814e-05
bp O 0 2.2688227545586415e-05
insertion O 0 9.542788575345185e-06
, O 0 1.1828833521576598e-06
+ O 0 1.4953218851587735e-05
TATC O 0 0.00022955464373808354
1278 O 0 0.0002663445193320513
, O 0 8.469021395285381e-07
in O 0 1.4092624951445032e-06
exon O 0 7.351951353484765e-05
11 O 0 1.5805515431566164e-05
. O 0 1.7611893781577237e-05

Pulse O 0 0.006659514736384153
- O 0 0.000533841666765511
chase O 0 8.142655860865489e-05
analysis O 0 4.851417997997487e-06
using O 0 3.6388746593729593e-06
proband O 0 0.00010403211490483955
fibroblasts O 0 4.84941374452319e-05
revealed O 0 9.241113730240613e-06
that O 0 2.562034353559284e-07
the O 0 4.63160461094958e-07
W474C O 0 1.2994171811442357e-05
- O 0 4.681439804699039e-06
containing O 0 7.402319397442625e-07
alpha O 0 1.5713707171016722e-06
- O 0 1.2829744946429855e-06
subunit O 0 1.30724117752834e-06
precursor O 0 2.1765747533208923e-06
was O 0 1.4695842764922418e-06
normally O 0 3.5859798686033173e-07
synthesized O 0 2.0027239315822953e-06
, O 0 8.479707247488477e-08
but O 0 3.969866213537898e-08
not O 0 7.151506054015044e-08
phosphorylated O 0 2.8476151783252135e-06
or O 0 2.648022245921311e-07
secreted O 0 9.911566394293914e-07
, O 0 7.439638238793123e-08
and O 0 5.6485305321984924e-08
the O 0 2.951207420665014e-07
mature O 0 2.0676613985415315e-06
lysosomal O 0 5.1778661145363e-05
alpha O 0 4.922068001178559e-06
- O 0 7.1234048846235964e-06
subunit O 0 3.940110673283925e-06
was O 0 6.584106813534163e-06
not O 0 1.3187410559112323e-06
detected O 0 4.429555337992497e-05
. O 0 9.371772648592014e-06

When O 0 3.363368887221441e-05
the O 0 6.373806172632612e-06
W474C O 0 6.680144724668935e-05
- O 0 1.2491101188061293e-05
containing O 0 1.2399808611007757e-06
alpha O 0 2.1340486000553938e-06
- O 0 3.406792075111298e-06
subunit O 0 3.3782855552999536e-06
was O 0 2.7975381726719206e-06
transiently O 0 2.5466644729021937e-05
co O 0 1.3540391591959633e-05
- O 0 3.6821481899096398e-06
expressed O 0 2.1728342858295946e-07
with O 0 5.508197986614505e-08
the O 0 1.3405200149918528e-07
beta O 0 1.1363749763404485e-06
- O 0 1.3316227978066308e-06
subunit O 0 7.74436955452984e-07
to O 0 2.0975225822894572e-07
produce O 0 2.916760877269553e-07
Hex O 0 5.5707628234813455e-06
A O 0 1.9157864699081983e-06
( O 0 9.15275848001329e-07
alphabeta O 0 1.523279115644982e-05
) O 0 4.1449754917266546e-07
in O 0 6.516800681310997e-07
COS O 0 0.0007846694206818938
- O 0 9.807883543544449e-06
7 O 0 7.656598199901055e-07
cells O 0 7.415313234560017e-07
, O 0 3.806491122304578e-08
the O 0 7.944037605511767e-08
mature O 0 1.8971816473367653e-07
alpha O 0 5.074825821793638e-07
- O 0 8.235052746385918e-07
subunit O 0 4.837115170630568e-07
was O 0 5.449239779409254e-07
present O 0 9.471242634617738e-08
, O 0 2.326204651126318e-08
but O 0 2.0620669616278064e-08
its O 0 5.365106048316193e-08
level O 0 1.1747066253064986e-07
was O 0 1.107986577153497e-06
much O 0 9.60341637323836e-08
lower O 0 1.1504107533255592e-06
than O 0 3.81581024555544e-08
that O 0 4.338766501632563e-08
from O 0 9.938695910705064e-08
normal O 0 5.087463250674773e-07
alpha O 0 1.220141143676301e-06
- O 0 1.6727615275158314e-06
subunit O 0 1.4069996723264921e-06
transfections O 0 6.560764632013161e-06
, O 0 1.1671401267676629e-07
although O 0 9.702173286996185e-08
higher O 0 1.2541016758405021e-07
than O 0 3.2533563398828846e-08
in O 0 1.0689034724009616e-07
those O 0 1.0082700185876092e-07
cells O 0 1.081106915989949e-06
transfected O 0 7.869537512306124e-06
with O 0 1.4092165656620637e-07
an O 0 2.674500763077958e-07
alpha O 0 3.0721623716090107e-06
- O 0 6.965424290683586e-06
subunit O 0 7.378754162346013e-06
associated O 0 5.900237283640308e-06
with O 0 8.729362889425829e-06
infantile O 1 0.6664916276931763
TSD B-Disease 0 0.27751126885414124
. O 0 7.645154983038083e-05

Furthermore O 0 7.816803554305807e-05
, O 0 2.9117989015503554e-06
the O 0 9.76143837760901e-07
precursor O 0 4.027961495012278e-06
level O 0 5.372672831072123e-07
of O 0 9.934754530149803e-08
the O 0 3.993234258814482e-07
W474C O 0 6.088667760195676e-06
alpha O 0 2.5558776997058885e-06
- O 0 2.6899892873188946e-06
subunit O 0 1.0747068017735728e-06
was O 0 1.0411856692371657e-06
found O 0 3.0848377718939446e-07
to O 0 2.3818283523269201e-07
accumulate O 0 2.525221589166904e-06
in O 0 1.2498045975917194e-07
comparison O 0 2.2815301292666845e-07
to O 0 1.3079129246307275e-07
the O 0 2.868756894258695e-07
normal O 0 1.5012195717645227e-06
alpha O 0 3.8128639516799012e-06
- O 0 1.2832221727876458e-05
subunit O 0 2.3600125132361427e-05
precursor O 0 3.258096330682747e-05
levels O 0 2.4672124709468335e-05
. O 0 1.432784029020695e-05

We O 0 1.9929873815272003e-05
conclude O 0 1.7613068848731928e-05
that O 0 1.1255904155405005e-06
the O 0 3.3349974728480447e-06
1422 O 0 0.03449707105755806
G O 0 0.04125785455107689
- O 0 0.01140013337135315
- O 0 0.0018798528471961617
> O 0 2.497894638509024e-05
C O 0 4.1905823309207335e-05
mutation O 0 3.337876933073858e-06
is O 0 1.1008607003759607e-07
the O 0 3.730987998551427e-07
cause O 0 2.499388983778772e-06
of O 0 3.372155958913936e-07
Hex B-Disease 0 0.0003372289938852191
A I-Disease 0 0.37374600768089294
enzyme I-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999966621398926
in O 0 1.5382980791400769e-06
the O 0 5.718128704756964e-06
proband O 0 0.004019781947135925
. O 0 3.328655657242052e-05

The O 0 2.9341072149691172e-05
resulting O 0 6.369088077917695e-05
W474C O 0 0.0001208549365401268
substitution O 0 1.6149497241713107e-05
clearly O 0 2.990804887303966e-06
interferes O 0 5.048217644798569e-06
with O 0 2.4989239477690717e-07
alpha O 0 1.3907176708016777e-06
- O 0 8.386158469875227e-07
subunit O 0 9.252861445929739e-07
processing O 0 3.2886316603253363e-07
, O 0 5.175341755148111e-08
but O 0 2.9592387207344473e-08
because O 0 2.4773184392756775e-08
the O 0 4.7336239816786474e-08
base O 0 2.5414300353077124e-07
substitution O 0 5.701568852600758e-07
falls O 0 1.4463974366663024e-05
at O 0 7.592379347443057e-08
the O 0 3.8821450942805313e-08
first O 0 9.488383767575215e-08
position O 0 1.7030914989391022e-07
of O 0 7.345548880266506e-08
exon O 0 6.052115168131422e-06
13 O 0 3.7295470178833057e-07
, O 0 1.4967793049436295e-07
aberrant O 0 3.3997293940046802e-06
splicing O 0 5.722940386476694e-06
may O 0 1.5084756341821048e-06
also O 0 1.4036275786111219e-07
contribute O 0 2.2692586298944661e-07
to O 0 4.35183693525687e-07
Hex B-Disease 0 0.0002579926513135433
A I-Disease 0 0.05261296033859253
deficiency I-Disease 0 0.49848657846450806
in O 0 6.120216653471289e-07
this O 0 1.1827886510218377e-06
proband O 0 0.0007662544376216829
. O 0 3.9177079997898545e-06
. O 0 8.917829291021917e-06

Two O 0 0.00013063506048638374
frequent O 0 0.0009530240786261857
missense O 0 0.2852995991706848
mutations O 0 0.1324843466281891
in O 0 0.0366070456802845
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005115394596941769

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.021583639085292816
an O 1 0.9967505931854248
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.99899822473526
by O 0 0.00030498698470182717
early O 1 0.9695687294006348
childhood O 1 0.9999949932098389
deafness B-Disease 1 1.0
and O 1 0.9885244965553284
goiter B-Disease 1 1.0
. O 0 0.0005081018316559494

A O 0 3.5050950828008354e-05
century O 0 9.697798304841854e-06
after O 0 2.8311487767496146e-06
its O 0 8.203971901821205e-07
recognition O 0 7.885763579906779e-07
as O 0 1.3278753385748132e-06
a O 0 0.00677634309977293
syndrome O 1 0.999824583530426
by O 0 2.881366071960656e-06
Vaughan O 0 0.00021548250515479594
Pendred O 0 6.86947169015184e-05
, O 0 4.94765117764473e-07
the O 0 3.308147825009655e-06
disease O 0 0.0010475307935848832
gene O 0 1.5132163753150962e-05
( O 0 2.9443524454109138e-06
PDS O 0 0.0004567794385366142
) O 0 6.556115863531886e-07
was O 0 2.9505029033316532e-06
mapped O 0 9.902799320116173e-06
to O 0 2.4130972633429337e-06
chromosome O 0 4.9072947149397805e-05
7q22 O 0 8.029094897210598e-05
- O 0 0.00012925980263389647
q31 O 0 0.00025066500529646873
. O 0 2.2551337679033168e-05

1 O 0 1.348392561340006e-05
and O 0 1.8916113049272099e-06
, O 0 6.447975806622708e-07
recently O 0 7.663343239983078e-06
, O 0 3.018445511315804e-07
found O 0 3.9430358356185025e-07
to O 0 2.754200920662697e-07
encode O 0 3.529395144141745e-06
a O 0 8.59110241435701e-06
putative O 0 0.0009113620035350323
sulfate O 0 0.019543884322047234
transporter O 0 0.003859864082187414
. O 0 6.341088737826794e-05

We O 0 2.6903640900854953e-05
performed O 0 3.1351435609394684e-05
mutation O 0 2.2491347408504225e-05
analysis O 0 1.1156556638525217e-06
of O 0 1.4587736529847461e-07
the O 0 6.133714123279788e-07
PDS B-Disease 0 0.0006336393998935819
gene O 0 7.63022035243921e-06
in O 0 8.65407173478161e-07
patients O 0 1.988095846172655e-06
from O 0 2.3005627269867546e-07
14 O 0 5.349946832211572e-07
Pendred B-Disease 0 1.711418190097902e-05
families O 0 2.571855759470054e-07
originating O 0 6.74384295962227e-07
from O 0 1.9219262981096108e-07
seven O 0 1.6058007190622448e-07
countries O 0 9.371081688414051e-08
and O 0 2.7463900664770335e-07
identified O 0 2.691539293664391e-06
all O 0 8.409311362811422e-07
mutations O 0 5.554711242439225e-05
. O 0 1.293038803851232e-05

The O 0 2.5215027562808245e-05
mutations O 0 5.0292852392885834e-05
include O 0 1.02948138192005e-06
three O 0 3.276122697570827e-07
single O 0 8.204762025343371e-07
base O 0 1.7384297734679421e-06
deletions O 0 6.552623744937591e-06
, O 0 2.176341098447665e-07
one O 0 2.7736246011045296e-07
splice O 0 4.38786628365051e-05
site O 0 1.3407798178377561e-05
mutation O 0 1.1228510629734956e-05
and O 0 1.0799228675750783e-06
10 O 0 4.838757377001457e-06
missense O 0 0.0008390824077650905
mutations O 0 0.0004106617998331785
. O 0 3.6956560506951064e-05

One O 0 7.934523455332965e-05
missense O 0 0.002125311875715852
mutation O 0 0.0002080714621115476
( O 0 6.840473815827863e-06
L236P O 0 3.2645089959260076e-05
) O 0 1.090574755835405e-06
was O 0 2.793768317133072e-06
found O 0 1.8209746599495702e-07
in O 0 1.1609854766447825e-07
a O 0 4.3493557200235955e-07
homozygous O 0 4.304798494558781e-06
state O 0 1.2013055084025837e-07
in O 0 7.987063810332984e-08
two O 0 1.617566454115149e-07
consanguineous O 0 2.0615299945347942e-05
families O 0 2.2246987896323844e-07
and O 0 1.6258283608294732e-07
in O 0 2.0654843524425814e-07
a O 0 1.2611002375706448e-06
heterozygous O 0 4.382361566968029e-06
state O 0 1.418809745246108e-07
in O 0 1.1783341591353746e-07
five O 0 1.4418085925171908e-07
additional O 0 2.1809350414514483e-07
non O 0 1.8651035134098493e-06
- O 0 9.874012903310359e-05
consanguineous O 0 0.00024101301096379757
families O 0 8.588898708694614e-06
. O 0 1.325065841228934e-05

Another O 0 0.0002634932170622051
missense O 0 0.006240596529096365
mutation O 0 0.00037860884913243353
( O 0 8.186026207113173e-06
T416P O 0 3.613024819060229e-05
) O 0 1.4398054872799548e-06
was O 0 2.365728960285196e-06
found O 0 1.7983339262173104e-07
in O 0 7.6311579277899e-08
a O 0 3.0372666515177116e-07
homozygous O 0 1.799134906832478e-06
state O 0 8.06289151000783e-08
in O 0 1.2227638990225387e-07
one O 0 1.4708375317695754e-07
family O 0 1.374520707031479e-06
and O 0 1.1676767286417089e-07
in O 0 1.2977496055555093e-07
a O 0 8.180744544006302e-07
heterozygous O 0 3.988707703683758e-06
state O 0 2.3795035986040602e-07
in O 0 4.4381852148944745e-07
four O 0 1.266157937607204e-06
families O 0 6.22372954239836e-06
. O 0 1.5431720385095105e-05

Pendred B-Disease 1 0.8604138493537903
patients O 0 0.00033242831705138087
in O 0 2.5595486476959195e-06
three O 0 7.212229320430197e-07
non O 0 2.3246757336892188e-06
- O 0 2.9235801775939763e-05
consanguineous O 0 3.853194721159525e-05
families O 0 5.706518777515157e-07
were O 0 2.755517130026419e-07
shown O 0 3.125215926047531e-07
to O 0 1.6516786160991614e-07
be O 0 1.577119377316194e-07
compound O 0 3.775864342969726e-06
heterozygotes O 0 8.995593816507608e-06
for O 0 3.5338572956788994e-07
L236P O 0 1.5721841919003054e-05
and O 0 3.162542043355643e-06
T416P O 0 0.00014511110202874988
. O 0 2.0415645849425346e-05

In O 0 6.734486305504106e-06
total O 0 8.958351713772572e-07
, O 0 1.603889216994503e-07
one O 0 4.9515403333089125e-08
or O 0 4.362715344541357e-08
both O 0 2.3928699022235378e-08
of O 0 2.7986263972934466e-08
these O 0 1.2950717120929767e-07
mutations O 0 2.839571834556409e-06
were O 0 3.252271483233926e-07
found O 0 1.7658906870110513e-07
in O 0 8.070045964814199e-08
nine O 0 8.995800726552261e-08
of O 0 4.7692214621974927e-08
the O 0 3.785671651712619e-07
14 O 0 1.4810439097345807e-06
families O 0 1.479392267356161e-06
analyzed O 0 1.9899884136975743e-05
. O 0 1.3901056263421196e-05

The O 0 1.0174013368668966e-05
identification O 0 3.238101498936885e-06
of O 0 3.442750937665551e-07
two O 0 4.798374106940173e-07
frequent O 0 2.322407999599818e-05
PDS B-Disease 0 0.16965259611606598
mutations O 0 1.6223806596826762e-05
will O 0 3.759827507110458e-07
facilitate O 0 9.001547596199089e-07
the O 0 1.6695772728780867e-06
molecular O 0 0.00030211443663574755
diagnosis O 1 0.6197823286056519
of O 0 0.0002991787623614073
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001620712864678353

Insertional O 0 0.01023286022245884
mutation O 0 0.0008097111713141203
by O 0 1.5058429198688827e-05
transposable O 0 0.00015635938325431198
element O 0 1.1206472663616296e-05
, O 0 1.955851757884375e-06
L1 O 0 0.0007490179850719869
, O 0 9.237670610673376e-07
in O 0 6.50219988074241e-07
the O 0 4.0010509110288695e-06
DMD B-Disease 1 0.999997615814209
gene O 0 6.0599199059652165e-05
results O 0 7.5513730735110585e-06
in O 0 6.369304173858836e-06
X B-Disease 1 0.862282395362854
- I-Disease 1 0.8891931176185608
linked I-Disease 1 0.7636846899986267
dilated I-Disease 1 0.9772889018058777
cardiomyopathy I-Disease 1 0.9999991655349731
. O 0 0.0001698801788734272

X B-Disease 1 0.9958122372627258
- I-Disease 1 0.9967599511146545
linked I-Disease 1 0.9923505187034607
dilated I-Disease 1 0.9998225569725037
cardiomyopathy I-Disease 1 1.0
( O 0 0.00016172457253560424
XLDCM B-Disease 0 0.056581925600767136
) O 0 1.1769195680244593e-06
is O 0 2.426006915356993e-07
a O 0 1.5211884374366491e-06
clinical O 0 2.5100778657360934e-05
phenotype O 0 7.066527177812532e-05
of O 0 4.701981026755675e-07
dystrophinopathy B-Disease 0 0.007989952340722084
which O 0 3.42846965395438e-06
is O 0 5.483056497723737e-07
characterized O 0 9.172662430501077e-06
by O 0 1.7916833030540147e-06
preferential O 0 3.432638186495751e-05
myocardial B-Disease 1 0.9037608504295349
involvement I-Disease 0 1.1578928933886345e-05
without O 0 7.576559255539905e-07
any O 0 6.974537427595351e-07
overt O 0 1.643177165533416e-05
clinical O 0 6.309097079792991e-05
signs O 0 0.00017883347754832357
of O 0 8.925821748562157e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0008550528436899185

To O 0 1.2027689081151038e-05
date O 0 5.921307547396282e-06
, O 0 5.558704287977889e-07
several O 0 8.214619242608023e-07
mutations O 0 8.75891691975994e-06
in O 0 8.916434239836235e-07
the O 0 2.4273140297736973e-05
Duchenne B-Disease 1 0.9999949932098389
muscular I-Disease 1 0.9999940395355225
dystrophy I-Disease 1 0.9999957084655762
gene O 0 0.0013857240555807948
, O 0 1.9344472093507648e-05
DMD O 1 0.9999996423721313
, O 0 1.2712019952232367e-06
have O 0 2.0986550453017117e-07
been O 0 3.39033960017332e-07
identified O 0 1.0979622402373934e-06
in O 0 1.1448028089944273e-06
patients O 0 2.30044270210783e-06
with O 0 5.169270025362493e-07
XLDCM B-Disease 0 0.15297940373420715
, O 0 4.388156753520889e-07
but O 0 1.0867327659980219e-07
a O 0 4.98708857321617e-07
pathogenic O 0 3.1712734198663384e-06
correlation O 0 8.109019518087734e-07
of O 0 1.6314524486915616e-07
these O 0 5.240094083092117e-07
cardiospecific O 0 0.0012359187239781022
mutations O 0 2.2577307390747592e-05
in O 0 2.0559130007313797e-06
DMD O 1 0.9997350573539734
with O 0 1.234765250046621e-06
the O 0 2.246900294267107e-06
XLDCM B-Disease 0 0.14777497947216034
phenotype O 0 0.008665353059768677
has O 0 4.0829231693351176e-06
remained O 0 1.669385892455466e-05
to O 0 1.1588443840082618e-06
be O 0 2.082376340695191e-06
elucidated O 0 0.00021722209930885583
. O 0 1.8020053175860085e-05

We O 0 1.583063385623973e-05
report O 0 8.754231203056406e-06
here O 0 4.4003181187690643e-07
the O 0 1.2416678885074361e-07
identification O 0 3.388406355497864e-07
of O 0 8.605738344158453e-08
a O 0 7.346094434979022e-07
unique O 0 1.0933647445199313e-06
de O 0 1.0000722795666661e-05
novo O 0 3.559485776349902e-05
L1 O 0 5.900928590563126e-05
insertion O 0 5.404568128142273e-06
in O 0 4.2792390786416945e-07
the O 0 8.311855026477133e-07
muscle O 0 8.46682523842901e-05
exon O 0 1.9936642274842598e-05
1 O 0 9.496056918578688e-07
in O 0 2.2569038264919072e-06
DMD O 1 0.9999909400939941
in O 0 2.142605353583349e-06
three O 0 9.475124329583196e-07
XLDCM B-Disease 1 0.6092200875282288
patients O 0 5.111880454933271e-06
from O 0 2.7476343689158966e-07
two O 0 2.8041307587045594e-07
unrelated O 0 4.525954864220694e-06
Japanese O 0 1.0063072295452002e-05
families O 0 1.1111420462839305e-05
. O 0 2.0414301616256125e-05

The O 0 1.7139727788162418e-05
insertion O 0 6.551116530317813e-05
was O 0 1.7288821254624054e-05
a O 0 1.5673791722292663e-06
5 O 0 1.1628397942331503e-06
- O 0 3.463092298261472e-06
truncated O 0 3.5889161154045723e-06
form O 0 4.2425497781550803e-07
of O 0 1.1076721762037778e-07
human O 0 4.335102232744248e-07
L1 O 0 6.476040289271623e-05
inversely O 0 1.1550219824130181e-05
integrated O 0 4.075368451594841e-06
in O 0 2.207710281254549e-07
the O 0 2.3180557207069796e-07
5 O 0 4.939905124956567e-07
- O 0 4.2846395444939844e-06
untranslated O 0 5.238747235125629e-06
region O 0 4.994727760276874e-07
in O 0 2.0382807974783645e-07
the O 0 4.551595793600427e-07
muscle O 0 4.105882180738263e-05
exon O 0 6.617021881538676e-06
1 O 0 2.5069871867344773e-07
, O 0 1.1045624148664501e-07
which O 0 1.3367245799145167e-07
affected O 0 1.554913211521125e-07
the O 0 7.470708140999704e-08
transcription O 0 4.1234639525100647e-07
or O 0 4.623290550398451e-08
the O 0 3.6306552431142336e-08
stability O 0 1.5666363140098838e-07
of O 0 1.4644404799923905e-08
the O 0 2.217099392964883e-07
muscle O 0 1.8411665223538876e-05
form O 0 2.8807704666178324e-07
of O 0 1.1158574153569134e-07
dystrophin O 0 4.292537778383121e-05
transcripts O 0 5.59867157789995e-06
but O 0 1.4672313852770458e-07
not O 0 2.6623105497947108e-08
that O 0 1.176782848943958e-08
of O 0 1.7649099959271553e-08
the O 0 4.352696123532951e-07
brain O 0 0.0002599149593152106
or O 0 1.1384250910850824e-06
Purkinje O 0 0.00016591549501754344
cell O 0 3.7878446164540946e-05
form O 0 1.1859386859214283e-06
, O 0 3.469802436484315e-07
probably O 0 1.0471035238879267e-06
due O 0 7.141479159145092e-07
to O 0 6.976733146757397e-08
its O 0 1.9288891905944183e-07
unique O 0 2.6631872174220916e-07
site O 0 9.598871884008986e-07
of O 0 3.8533744373125955e-07
integration O 0 9.096334906644188e-06
. O 0 1.1861110579047818e-05

We O 0 1.8847485989681445e-05
speculate O 0 3.000564538524486e-05
that O 0 5.725576102122432e-07
this O 0 1.7885132308492757e-07
insertion O 0 1.0904448117798893e-06
of O 0 6.2032114556132e-08
an O 0 2.512590242531587e-07
L1 O 0 0.00013520830543711782
sequence O 0 2.2410899873648304e-06
in O 0 5.089208571007475e-06
DMD O 1 0.9999990463256836
is O 0 8.648634093333385e-07
responsible O 0 5.810363745695213e-07
for O 0 3.917237378914251e-08
some O 0 2.3328871279204577e-08
of O 0 2.4510313778591808e-08
the O 0 9.494809916077429e-08
population O 0 1.0204958300619182e-07
of O 0 8.299753773144403e-08
Japanese O 0 5.234951913735131e-06
patients O 0 6.07782521910849e-06
with O 0 1.3479581184583367e-06
XLDCM B-Disease 0 0.02242228388786316
. O 0 6.05044169788016e-06
. O 0 1.7052241673809476e-05

Severe O 1 0.9141066670417786
early O 0 0.06070604547858238
- O 1 0.9998799562454224
onset O 1 0.9999984502792358
obesity B-Disease 1 1.0
, O 0 0.011078756302595139
adrenal B-Disease 1 0.9999997615814209
insufficiency I-Disease 1 0.9999985694885254
and O 0 2.5952724172384478e-05
red O 0 0.03170580044388771
hair O 1 0.9995608925819397
pigmentation O 1 0.9977512955665588
caused O 0 0.0019745577592402697
by O 0 1.9340966900927015e-05
POMC O 1 0.9537071585655212
mutations O 0 0.00019428464293014258
in O 0 5.832448550791014e-06
humans O 0 1.8012957298196852e-05
. O 0 1.551966488477774e-05

Sequential O 0 0.0005654104170389473
cleavage O 0 0.0002556459221523255
of O 0 1.7051812619683915e-06
the O 0 1.6675151073286543e-06
precursor O 0 9.910763765219599e-06
protein O 0 3.8025330013624625e-06
pre O 0 1.6653468264848925e-05
- O 0 5.304451769916341e-05
pro O 0 2.898312777688261e-05
- O 0 0.00014339502376969904
opiomelanocortin O 0 0.0003594349545892328
( O 0 6.295952061918797e-06
POMC O 0 0.00022444418573286384
) O 0 8.092825964922667e-07
generates O 0 1.4472502698481549e-06
the O 0 1.045365365826001e-06
melanocortin O 0 0.00020180034334771335
peptides O 0 5.194413461140357e-05
adrenocorticotrophin O 0 0.00017522185225971043
( O 0 7.277901204361115e-06
ACTH O 0 0.000156045745825395
) O 0 1.1482526360850898e-06
, O 0 8.448926109849708e-07
melanocyte O 0 7.30977626517415e-05
- O 0 6.406232569133863e-05
stimulating O 0 1.9833329133689404e-05
hormones O 0 2.3654361939406954e-05
( O 0 3.3323585739708506e-06
MSH O 0 0.0001408429234288633
) O 0 6.646827728218341e-07
alpha O 0 8.681838039592549e-07
, O 0 9.797160771540803e-08
beta O 0 2.9956154889987374e-07
and O 0 6.00013549956202e-08
gamma O 0 5.033921297581401e-07
as O 0 6.125553397851036e-08
well O 0 5.311072825975316e-08
as O 0 8.223988601230303e-08
the O 0 4.704353386841831e-07
opioid O 0 4.838327367906459e-05
- O 0 3.918875881936401e-05
receptor O 0 3.0230941774789244e-05
ligand O 0 3.022292730747722e-05
beta O 0 4.022851135232486e-05
- O 0 0.0002454729110468179
endorphin O 0 0.0024899488780647516
. O 0 3.615679088397883e-05

While O 0 1.5541971151833422e-05
a O 0 3.723044301295886e-06
few O 0 7.041933827167668e-07
cases O 0 5.410464609667542e-07
of O 0 6.940471735106257e-07
isolated O 0 0.26234662532806396
ACTH B-Disease 1 0.9999959468841553
deficiency I-Disease 1 0.98819899559021
have O 0 1.0644564554240787e-06
been O 0 2.547163830968202e-06
reported O 0 3.733014455065131e-05
( O 0 2.776768496914883e-06
OMIM O 0 0.0004523783572949469
201400 O 0 2.2210104361874983e-05
) O 0 3.942467969864083e-07
, O 0 1.253642523124654e-07
an O 0 7.511929425163544e-07
inherited O 1 0.9675076603889465
POMC O 1 0.9995113611221313
defect O 0 0.22876563668251038
has O 0 2.819205064952257e-06
not O 0 4.2190228555227804e-07
been O 0 9.24435028082371e-07
described O 0 6.058669441699749e-06
so O 0 8.709353664926311e-07
far O 0 4.045427886012476e-06
. O 0 1.350267484667711e-05

Recent O 0 5.756759492214769e-05
studies O 0 1.0769264008558821e-05
in O 0 1.6573872017033864e-06
animal O 0 4.486572379391873e-06
models O 0 6.444923201343045e-06
elucidated O 0 1.2696192243311089e-05
a O 0 6.326487778096634e-07
central O 0 4.6728260372219665e-07
role O 0 2.951719864086044e-07
of O 0 1.3493172446032986e-07
alpha O 0 3.4326769764447818e-06
- O 0 4.4373013224685565e-05
MSH O 0 0.00010139228106709197
in O 0 1.5426613231284136e-07
the O 0 1.707668104700133e-07
regulation O 0 8.487504601362161e-07
of O 0 1.0427134355950329e-07
food O 0 8.70887220116856e-07
intake O 0 1.892008185677696e-06
by O 0 1.5894508464953105e-07
activation O 0 1.5184896255959757e-06
of O 0 1.9482342850096757e-07
the O 0 2.1716982701036613e-06
brain O 0 0.0008492917404510081
melanocortin O 0 0.0005241130711510777
- O 0 4.693868322647177e-05
4 O 0 3.6198248380969744e-06
- O 0 3.334253415232524e-05
receptor O 0 1.747497299220413e-05
( O 0 2.899849732784787e-06
MC4 O 0 0.0016909721307456493
- O 0 0.0003651782753877342
R O 0 0.000270871416432783
; O 0 7.152254966058536e-07
refs O 0 7.476960945496103e-06
3 O 0 6.493945079455443e-07
- O 0 4.187889771856135e-06
5 O 0 2.3259744352799316e-07
) O 0 5.0340361212874996e-08
and O 0 2.0440381831576815e-08
the O 0 4.91217342357686e-08
linkage O 0 8.41742291868286e-07
of O 0 9.601217954013919e-08
human O 0 1.8632262026585522e-06
obesity B-Disease 1 0.7865644693374634
to O 0 5.839617642777739e-07
chromosome O 0 2.114704784617061e-06
2 O 0 1.8072276475322724e-07
in O 0 1.0329800659292232e-07
close O 0 3.206032488378696e-07
proximity O 0 4.5578244112221e-07
to O 0 1.2219805967106367e-07
the O 0 3.8221079989853024e-07
POMC O 0 0.00017581766587682068
locus O 0 3.4317538393224822e-06
, O 0 9.909168596777818e-08
led O 0 2.470708011514944e-07
to O 0 6.832219412444829e-08
the O 0 6.8832839872357e-08
proposal O 0 4.6105833462206647e-07
of O 0 5.3780766506861255e-08
an O 0 1.8980972527060658e-07
association O 0 1.0895487321249675e-06
of O 0 4.7324726892838953e-07
POMC O 0 0.007249368354678154
with O 0 4.983516646461794e-06
human O 0 7.061327778501436e-05
obesity B-Disease 1 0.9970623850822449
. O 0 6.471181404776871e-05

The O 0 1.4315821317723021e-05
dual O 0 1.6913058061618358e-05
role O 0 2.7084379325970076e-06
of O 0 4.2190509930151165e-07
alpha O 0 8.786055332166143e-06
- O 0 4.085454565938562e-05
MSH O 0 0.00015312418690882623
in O 0 4.28484185022171e-07
regulating O 0 2.5623305646149674e-06
food O 0 1.0428034329379443e-06
intake O 0 4.199435807095142e-06
and O 0 3.6124200164522335e-07
influencing O 0 5.747608611272881e-06
hair O 0 0.2147369086742401
pigmentation O 0 0.4057365357875824
predicts O 0 6.115984433563426e-05
that O 0 1.9431018927207333e-07
the O 0 8.85455847310368e-07
phenotype O 0 0.0003556926385499537
associated O 0 1.364137688142364e-06
with O 0 2.630646918078128e-07
a O 0 5.1832012104569e-05
defect O 0 0.00425576651468873
in O 0 3.070126922466443e-06
POMC O 0 0.0017965756123885512
function O 0 1.73665500824427e-06
would O 0 9.797615803108783e-07
include O 0 1.7967053054235294e-06
obesity B-Disease 1 0.9113757610321045
, O 0 9.413014936399122e-07
alteration O 0 4.2746978579089046e-05
in O 0 2.2511369024869055e-05
pigmentation O 1 0.9888062477111816
and O 0 0.28986451029777527
ACTH B-Disease 1 0.9999841451644897
deficiency I-Disease 1 0.9952464699745178
. O 0 4.9708469305187464e-05

The O 0 1.888433143903967e-05
observation O 0 2.1389823814388365e-05
of O 0 6.231957740965299e-07
these O 0 9.794337074708892e-07
symptoms O 0 9.28655790630728e-05
in O 0 3.379454085461475e-07
two O 0 3.424279668706731e-07
probands O 0 6.778860552003607e-05
prompted O 0 4.129672106500948e-06
us O 0 3.927270029180363e-07
to O 0 1.4812118820373144e-07
search O 0 6.659175255663285e-07
for O 0 3.9057934486663726e-07
mutations O 0 8.924788744479883e-06
within O 0 1.2257778507773764e-06
their O 0 5.643938493449241e-06
POMC O 0 0.06198349595069885
genes O 0 0.00010310093784937635
. O 0 4.134690607315861e-05

Patient O 0 0.0024235567543655634
1 O 0 1.3578369362221565e-05
was O 0 3.3296910260105506e-05
found O 0 3.60128893817091e-07
to O 0 1.1858048054591563e-07
be O 0 6.27745819770098e-08
a O 0 1.992393663385883e-07
compound O 0 1.431381292604783e-06
heterozygote O 0 4.2341080188634805e-06
for O 0 7.298819326706507e-08
two O 0 1.8905782894762524e-07
mutations O 0 2.423299747533747e-06
in O 0 3.4995287023775745e-07
exon O 0 6.3280485846917145e-06
3 O 0 8.137962481669092e-07
( O 0 4.6940058950895036e-07
G7013T O 0 7.9757137427805e-06
, O 0 2.398216452093038e-07
C7133delta O 0 1.3673723515239544e-05
) O 0 1.9916414828458073e-07
which O 0 9.549842161504785e-08
interfere O 0 4.898369070360786e-07
with O 0 1.3087888817153726e-07
appropriate O 0 3.1760779961587104e-07
synthesis O 0 9.272286547457043e-07
of O 0 2.7367579491510696e-07
ACTH O 0 9.312798647442833e-05
and O 0 1.3686828879144741e-06
alpha O 0 2.7776433853432536e-05
- O 0 0.0005585957551375031
MSH O 0 0.008150160312652588
. O 0 2.6591405912768096e-05

Patient O 0 0.001656506210565567
2 O 0 2.2753401935915463e-05
was O 0 2.8514976293081418e-05
homozygous O 0 1.4265164281823672e-05
for O 0 2.481807257481705e-07
a O 0 1.5467508092115168e-06
mutation O 0 6.801054496463621e-06
in O 0 8.249909342339379e-07
exon O 0 2.13075072679203e-05
2 O 0 2.0620097984647145e-06
( O 0 1.5848931980144698e-06
C3804A O 0 1.4780335732211825e-05
) O 0 1.0948702993118786e-06
which O 0 3.575462869775947e-06
abolishes O 0 0.0009255792247131467
POMC O 0 0.005697440821677446
translation O 0 0.00010699697304517031
. O 0 3.440326327108778e-05

These O 0 9.473015779803973e-06
findings O 0 1.0482761354069225e-05
represent O 0 6.44412807560002e-07
the O 0 1.6017062876017008e-07
first O 0 1.6069803621121537e-07
examples O 0 1.6382547585180873e-07
of O 0 7.766441001422209e-08
a O 0 9.506552305538207e-05
genetic B-Disease 1 0.9935004115104675
defect I-Disease 1 0.9842472076416016
within O 0 6.599846074095694e-07
the O 0 2.6564298423181754e-06
POMC O 0 0.004554697312414646
gene O 0 4.0499676288163755e-06
and O 0 2.3571030283164873e-07
define O 0 1.341226266049489e-06
a O 0 2.510966623958666e-06
new O 0 0.0003348523750901222
monogenic B-Disease 1 0.9991563558578491
endocrine I-Disease 1 0.9999202489852905
disorder I-Disease 1 0.9625598192214966
resulting O 0 9.32185685087461e-06
in O 0 1.7374866274622036e-06
early O 0 0.00096199254039675
- O 1 0.9992367029190063
onset O 1 0.9999986886978149
obesity B-Disease 1 1.0
, O 0 0.009843501262366772
adrenal B-Disease 1 0.9999998807907104
insufficiency I-Disease 1 0.9999984502792358
and O 0 1.1981276657024864e-05
red O 0 0.005957933608442545
hair O 1 0.9979811310768127
pigmentation O 1 0.9622423052787781
. O 0 8.208172403101344e-06
. O 0 1.6180312741198577e-05

A O 0 0.00015068374341353774
European O 0 7.306556653929874e-05
multicenter O 0 0.006321099121123552
study O 0 3.524925705278292e-05
of O 0 3.7115143641131e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.552981863525929e-06
classification O 0 4.3557993194554e-06
of O 0 2.4425963829344255e-07
105 O 0 6.605119324376574e-06
mutations O 0 8.477484698232729e-06
and O 0 1.6066708496964566e-07
a O 0 1.4140821349428734e-06
general O 0 2.8271904284338234e-06
system O 0 1.0243486940453295e-05
for O 0 6.966706109778897e-07
genotype O 0 8.876438369043171e-05
- O 0 6.925385969225317e-05
based O 0 4.625469955499284e-06
prediction O 0 2.5037377781700343e-05
of O 0 3.389645371498773e-06
metabolic O 0 0.2193073332309723
phenotype O 0 0.02649843506515026
. O 0 5.081267954665236e-05

Phenylketonuria B-Disease 1 0.9996726512908936
( O 0 0.0015409962506964803
PKU B-Disease 1 0.9075577259063721
) O 0 3.002276389452163e-05
and O 0 1.2551630788948387e-05
mild B-Disease 1 0.9990365505218506
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.07951759546995163
MHP B-Disease 1 0.9999998807907104
) O 0 1.0637751074682456e-05
are O 0 1.550525780658063e-06
allelic B-Disease 0 0.4172463119029999
disorders I-Disease 1 0.999920129776001
caused O 0 0.0001197731908177957
by O 0 3.218904339519213e-06
mutations O 0 1.4058143278816715e-05
in O 0 6.194444495122298e-07
the O 0 3.1601964565197704e-06
gene O 0 6.87909487169236e-05
encoding O 0 7.9245277447626e-05
phenylalanine O 0 0.011218644678592682
hydroxylase O 0 0.1930384337902069
( O 0 8.14660161267966e-05
PAH O 0 0.0033955390099436045
) O 0 2.1973641196382232e-05
. O 0 2.5414847186766565e-05

Previous O 0 0.0001484178501414135
studies O 0 2.994827264046762e-05
have O 0 1.968578089872608e-06
suggested O 0 4.315205842431169e-06
that O 0 3.1115121146285674e-07
the O 0 6.196518711476529e-07
highly O 0 4.589789114106679e-06
variable O 0 0.00017076070071198046
metabolic O 0 0.12676963210105896
phenotypes O 0 0.0005922429845668375
of O 0 3.235157419112511e-05
PAH B-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.9991212487220764
correlate O 0 0.0002303366782143712
with O 0 0.00015523290494456887
PAH O 1 0.9825007319450378
genotypes O 0 0.005318603478372097
. O 0 0.00011325877858325839

We O 0 2.8715165171888657e-05
identified O 0 3.470504088909365e-05
both O 0 5.3754074542666785e-06
causative O 0 8.022313704714179e-05
mutations O 0 8.458044612780213e-05
in O 0 5.966155640635407e-06
686 O 0 0.00041695788968354464
patients O 0 1.891385363705922e-05
from O 0 9.147697141997924e-07
seven O 0 1.4914814983058022e-06
European O 0 8.390003131353296e-06
centers O 0 2.6400233764434233e-05
. O 0 2.464508179400582e-05

On O 0 1.139411142503377e-05
the O 0 1.0210628715867642e-06
basis O 0 2.754878494215518e-07
of O 0 5.63961712884975e-08
the O 0 2.749021064119006e-07
phenotypic O 0 2.1954540443402948e-06
characteristics O 0 8.067058274718875e-07
of O 0 2.1055193144547957e-07
297 O 0 1.4152209587336984e-05
functionally O 0 0.0001158256345661357
hemizygous O 0 0.037350334227085114
patients O 0 1.0263112017128151e-05
, O 0 1.0930356353355819e-07
105 O 0 3.3470877269792254e-07
of O 0 5.0080732449941934e-08
the O 0 7.819279517207178e-07
mutations O 0 4.541057023743633e-06
were O 0 1.5485085214095307e-07
assigned O 0 4.55150882316957e-07
to O 0 9.42972988582369e-08
one O 0 3.8445350014626456e-08
of O 0 4.975720102606829e-08
four O 0 3.000432968747191e-07
arbitrary O 0 4.9682271310302895e-06
phenotype O 0 0.0004574316553771496
categories O 0 1.2763704035023693e-05
. O 0 1.4637706044595689e-05

We O 0 1.4456045391852967e-05
proposed O 0 1.3385847523750272e-05
and O 0 1.424377956027456e-06
tested O 0 7.150358214857988e-06
a O 0 8.783933935774257e-07
simple O 0 7.56787926547986e-07
model O 0 1.4814196447332506e-06
for O 0 1.426014222261074e-07
correlation O 0 2.1958098841423634e-06
between O 0 1.7194240626849933e-06
genotype O 0 3.693020698847249e-05
and O 0 2.2392334813048365e-06
phenotypic O 0 4.0956278098747134e-05
outcome O 0 3.2972704502753913e-05
. O 0 4.0813662053551525e-05

The O 0 5.481975313159637e-05
observed O 0 9.152548591373488e-05
phenotype O 0 0.000563326757401228
matched O 0 1.3211315490480047e-05
the O 0 2.097319566018996e-06
predicted O 0 3.689739605761133e-05
phenotype O 0 9.221583604812622e-05
in O 0 4.7659619895057403e-07
79 O 0 1.8679409095057053e-06
% O 0 1.1252078024881484e-07
of O 0 3.74756972121304e-08
the O 0 1.7857627199191484e-07
cases O 0 1.6944386516115628e-07
, O 0 7.092103970762764e-08
and O 0 6.164042076761689e-08
in O 0 7.577781246936866e-08
only O 0 3.1095421348936725e-08
5 O 0 8.588668265474553e-08
of O 0 5.362149479992695e-08
184 O 0 6.113168637966737e-06
patients O 0 1.0435054718982428e-05
was O 0 1.9389053704799153e-05
the O 0 1.6952644728007726e-06
observed O 0 1.6906866221688688e-05
phenotype O 0 3.988003300037235e-05
more O 0 9.924754351686715e-08
than O 0 7.031358251197162e-08
one O 0 1.0047703113968964e-07
category O 0 2.6479591497263755e-07
away O 0 2.1982540943099593e-07
from O 0 2.752489081103704e-07
that O 0 4.806159950021538e-07
expected O 0 9.42797942116158e-06
. O 0 1.1168320270371623e-05

Among O 0 5.626976872008527e-06
the O 0 1.1722964927685098e-06
seven O 0 7.074168593135255e-07
contributing O 0 1.2193430620754953e-06
centers O 0 6.137669856798311e-07
, O 0 1.0543909212401559e-07
the O 0 1.1980355907326157e-07
proportion O 0 3.076558527936868e-07
of O 0 1.1606024230559342e-07
patients O 0 1.1054777360186563e-06
for O 0 1.2350083977707982e-07
whom O 0 6.781506840525253e-07
the O 0 6.11161965480278e-07
observed O 0 2.16408989217598e-05
phenotype O 0 0.0010444228537380695
did O 0 8.877361779013881e-07
not O 0 7.09083280980849e-08
match O 0 2.3740565779917233e-07
the O 0 5.511050176210119e-07
predicted O 0 3.389375706319697e-05
phenotype O 0 5.540004713111557e-05
was O 0 1.7315646800852846e-06
4 O 0 3.544218998285942e-07
% O 0 2.2233668062199285e-07
- O 0 4.15259364672238e-06
23 O 0 1.0123319498234196e-06
% O 0 2.726545744735631e-07
( O 0 1.0120104434463428e-06
P O 0 9.88570463960059e-05
< O 0 4.351025381765794e-06
. O 0 2.7693059223565797e-07
0001 O 0 4.729909778689034e-05
) O 0 1.8799168799432664e-07
, O 0 5.043204964749748e-08
suggesting O 0 2.7402393243392e-07
that O 0 4.662476271732885e-08
differences O 0 1.7278718189572828e-07
in O 0 9.835768821631063e-08
methods O 0 2.8429352028069843e-07
used O 0 2.3869083065619634e-07
for O 0 1.5645102280359424e-07
mutation O 0 3.944896889152005e-06
detection O 0 7.210715011751745e-06
or O 0 7.993471626832616e-06
phenotype O 0 0.04850940406322479
classification O 0 0.000442260381532833
may O 0 7.602959158248268e-06
account O 0 2.8143864483354264e-07
for O 0 5.219355969643402e-08
a O 0 3.054387036627304e-07
considerable O 0 1.100110921470332e-06
proportion O 0 7.216990525193978e-07
of O 0 1.1101940344815375e-06
genotype O 0 0.004066225606948137
- O 0 0.48254823684692383
phenotype O 0 0.04730428755283356
inconsistencies O 0 0.00041114710620604455
. O 0 4.572476973407902e-05

Our O 0 3.0126584533718415e-05
data O 0 1.11482504507876e-05
indicate O 0 3.4663366932363715e-06
that O 0 4.4786929720430635e-07
the O 0 2.8063454919902142e-06
PAH O 0 0.04276271536946297
- O 0 0.0007774663390591741
mutation O 0 1.5527273717452772e-05
genotype O 0 1.253961818292737e-05
is O 0 1.8595058293158218e-07
the O 0 2.634704401316412e-07
main O 0 9.575181820764556e-07
determinant O 0 3.7389136195997708e-06
of O 0 1.0184097618548549e-06
metabolic O 0 0.10904117673635483
phenotype O 0 0.0008241808973252773
in O 0 3.0687626804137835e-06
most O 0 4.736834853247274e-06
patients O 0 0.0011242990149185061
with O 0 0.019856790080666542
PAH B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.999405026435852
. O 0 6.398912228178233e-05

In O 0 9.09976279217517e-06
the O 0 1.8979503693117294e-06
present O 0 1.042355961544672e-06
study O 0 5.542870553654211e-07
, O 0 1.1110661546354095e-07
the O 0 1.8271344970344217e-07
classification O 0 2.245428731839638e-06
of O 0 3.48585189158257e-07
105 O 0 0.00012993912969250232
PAH O 1 0.9908780455589294
mutations O 0 6.516019493574277e-05
may O 0 9.940353038473404e-07
allow O 0 2.1473255173987127e-07
the O 0 1.9080630409007426e-07
prediction O 0 1.496803633926902e-06
of O 0 6.523590911911015e-08
the O 0 7.016394079073507e-07
biochemical O 0 5.357699410524219e-05
phenotype O 0 9.933272667694837e-05
in O 0 6.800664777983911e-07
> O 0 2.2417250420403434e-06
10 O 0 1.9637823811535782e-07
, O 0 1.0739490363675941e-07
000 O 0 3.150388181438757e-07
genotypes O 0 4.592241111822659e-06
, O 0 1.6275036784918484e-07
which O 0 1.1594247553148307e-06
may O 0 2.9072984943923075e-06
be O 0 5.070326025702343e-08
useful O 0 5.2755439128304715e-08
for O 0 3.6507096012883267e-08
the O 0 2.5794952307478525e-07
management O 0 2.540897185099311e-06
of O 0 5.901148938391998e-07
hyperphenylalaninemia B-Disease 1 0.999990701675415
in O 0 0.00018146842194255441
newborns O 0 0.006310667376965284
. O 0 1.890364546852652e-05

Somatic O 0 0.0024134584236890078
instability O 0 0.0004878236504737288
of O 0 5.392756975197699e-06
the O 0 1.007991795631824e-05
CTG O 0 0.0007825829088687897
repeat O 0 3.735297286766581e-05
in O 0 2.5157894469884923e-06
mice O 0 1.641401286178734e-05
transgenic O 0 5.020620847062673e-06
for O 0 5.265230242912367e-07
the O 0 2.374021460127551e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.3978987226437312e-05
is O 0 1.549024204905436e-06
age O 0 9.261160016649228e-07
dependent O 0 5.258335704638739e-07
but O 0 1.0381075554732888e-07
not O 0 9.279818158347553e-08
correlated O 0 1.0568488733042614e-06
to O 0 1.241280784824994e-07
the O 0 3.090190716648067e-07
relative O 0 2.3503380361944437e-06
intertissue O 0 3.5825305531034246e-05
transcription O 0 1.087285181711195e-05
levels O 0 5.702602720702998e-06
and O 0 3.922182713722577e-06
proliferative O 0 0.004141926299780607
capacities O 0 0.00012798121315427125
. O 0 2.294025762239471e-05

A O 0 0.00020203580788802356
( O 0 3.5259748983662575e-05
CTG O 0 0.0003820547426585108
) O 0 2.9101086056471104e-06
nexpansion O 0 1.7316955563728698e-05
in O 0 3.6915321288688574e-07
the O 0 3.7468984714905673e-07
3 O 0 1.4167183053359622e-06
- O 0 1.4511418157781009e-05
untranslated O 0 1.9924857042497024e-05
region O 0 3.4350118767179083e-06
( O 0 1.6438275451946538e-06
UTR O 0 1.1664389603538439e-05
) O 0 3.1699232749815565e-07
of O 0 1.4751472576790547e-07
the O 0 2.059576900137472e-06
DM O 1 0.9999961853027344
protein O 0 2.1691563233616762e-05
kinase O 0 0.00020507414592429996
gene O 0 1.3837779988534749e-05
( O 0 1.3279196764415246e-06
DMPK O 0 6.369550101226196e-05
) O 0 5.090647050565167e-07
is O 0 2.070647724394803e-07
responsible O 0 1.1230952168261865e-06
for O 0 2.2480835468741134e-06
causing O 1 0.9561138153076172
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9609430432319641
DM B-Disease 1 1.0
) O 0 8.752711437409744e-05
. O 0 5.9479556512087584e-05

Major O 0 7.596921204822138e-05
instability O 0 7.533701864304021e-05
, O 0 6.505896408270928e-07
with O 0 2.5693873340060236e-07
very O 0 2.730055825850286e-07
large O 0 2.3919579916764633e-07
expansions O 0 3.1524457426712615e-06
between O 0 3.709021143549762e-07
generations O 0 3.6148392723589495e-07
and O 0 1.1366628882569785e-07
high O 0 5.235557978267025e-07
levels O 0 2.868198976102576e-07
of O 0 1.355722787366176e-07
somatic O 0 2.277441853948403e-05
mosaicism O 0 0.0002849340671673417
, O 0 6.196861477292259e-07
is O 0 3.398347985239525e-07
observed O 0 3.421160045036231e-06
in O 0 8.195462214644067e-06
patients O 0 0.00011458113294793293
. O 0 2.664338899194263e-05

There O 0 1.2012064871669281e-05
is O 0 1.968822289200034e-06
a O 0 1.1981161378571414e-06
good O 0 4.637677761820669e-07
correlation O 0 7.848864242987474e-07
between O 0 2.559174845373491e-07
repeat O 0 2.1267101146804634e-06
size O 0 1.0315777672076365e-06
( O 0 1.789613719438421e-07
at O 0 9.615420992759027e-08
least O 0 6.146209585722318e-08
in O 0 2.2778493757869e-07
leucocytes O 0 0.00010420250328024849
) O 0 3.6630382282965e-07
, O 0 2.247152366408045e-07
clinical O 0 3.307249016870628e-06
severity O 0 0.00014437381469178945
and O 0 2.8249507977307076e-06
age O 0 1.972919562831521e-06
of O 0 2.0988563846913166e-06
onset O 0 0.4751826822757721
. O 0 4.441551209311001e-05

The O 0 0.00013570621376857162
trinucleotide O 0 0.008843488059937954
repeat O 0 0.00043696604552678764
instability O 0 9.968438826035708e-05
mechanisms O 0 1.0382168511569034e-05
involved O 0 2.840259639924625e-06
in O 0 1.1040058780054096e-05
DM B-Disease 1 1.0
and O 0 2.004313500947319e-06
other O 0 6.149692808321561e-07
human O 0 3.860403739963658e-05
genetic B-Disease 1 0.9999759197235107
diseases I-Disease 1 0.9999951124191284
are O 0 2.3827194581826916e-06
unknown O 0 2.4517883502994664e-05
. O 0 2.652937291713897e-05

We O 0 3.871187072945759e-05
studied O 0 4.760195952258073e-05
somatic O 0 0.00011743949289666489
instability O 0 4.544235343928449e-05
by O 0 1.9737137790798442e-06
measuring O 0 3.7926456570858136e-06
the O 0 1.733415274429717e-06
CTG O 0 0.00011621651356108487
repeat O 0 4.710091161541641e-06
length O 0 1.0488224688742775e-06
at O 0 1.894610619501691e-07
several O 0 1.5984041112915293e-07
ages O 0 3.7922083606645174e-07
in O 0 6.198374080668145e-08
various O 0 1.0123650184823418e-07
tissues O 0 1.814923734855256e-06
of O 0 1.2942408034177788e-07
transgenic O 0 5.529278041649377e-06
mice O 0 7.531551545980619e-06
carrying O 0 9.274409080717305e-07
a O 0 1.6903824189284933e-06
( O 0 1.742481344990665e-06
CTG O 0 5.9168356528971344e-05
) O 0 3.909512713562435e-07
55expansion O 0 3.1035274332680274e-06
surrounded O 0 5.45101784155122e-07
by O 0 1.4187867236614693e-07
45 O 0 3.215714912130352e-07
kb O 0 1.0989544534822926e-05
of O 0 5.8256890866914546e-08
the O 0 5.078413209957944e-07
human O 0 2.9685777462873375e-06
DM B-Disease 1 0.9999996423721313
region O 0 2.626591140142409e-06
, O 0 1.936473807973016e-07
using O 0 6.258079565668595e-07
small O 0 1.0627413757902104e-06
- O 0 0.00012856736429966986
pool O 0 3.535678843036294e-05
PCR O 0 0.00041905741090886295
. O 0 2.9334691134863533e-05

These O 0 1.276559032703517e-05
mice O 0 8.25738170533441e-05
have O 0 5.832371243741363e-07
been O 0 2.263662679524714e-07
shown O 0 2.3534417437076627e-07
to O 0 1.740790906978873e-07
reproduce O 0 2.0666363980126334e-06
the O 0 2.6537307462604076e-07
intergenerational O 0 3.0793225960223936e-06
and O 0 3.6910955714120064e-07
somatic O 0 5.788009730167687e-06
instability O 0 1.9424994661676465e-06
of O 0 1.1442097758163072e-07
the O 0 5.056699023953115e-07
55 O 0 1.9204912860004697e-06
CTG O 0 6.979585305089131e-05
repeat O 0 4.834320407098858e-06
suggesting O 0 1.6113029914777144e-06
that O 0 7.887300057518587e-08
surrounding O 0 2.453510887789889e-07
sequences O 0 3.036102214082348e-07
and O 0 7.145315805701102e-08
the O 0 1.990896976167278e-07
chromatin O 0 7.564310635643778e-06
environment O 0 1.832007569646521e-06
are O 0 1.0388404092509518e-07
involved O 0 4.986218300473411e-07
in O 0 1.9438912204350345e-06
instability O 0 8.891246397979558e-05
mechanisms O 0 7.60603288654238e-05
. O 0 2.447224142088089e-05

As O 0 1.0907436262641568e-05
observed O 0 7.632519555045292e-06
in O 0 4.308365930683067e-07
some O 0 8.786240357494535e-08
of O 0 5.62198216869092e-08
the O 0 6.278081059463148e-07
tissues O 0 5.5447300837840885e-05
of O 0 1.4576497960661072e-05
DM B-Disease 1 1.0
patients O 0 0.024390989914536476
, O 0 4.088414584657585e-07
there O 0 8.748381219447765e-08
is O 0 9.472977069435728e-08
a O 0 4.42105545062077e-07
tendency O 0 1.2152173667345778e-06
for O 0 1.217607774606222e-07
repeat O 0 2.1449402538564755e-06
length O 0 4.534698234692769e-07
and O 0 2.6964079324898194e-07
somatic O 0 4.826014901482267e-06
mosaicism O 0 1.861331293184776e-05
to O 0 1.8492752928978007e-07
increase O 0 1.1637956021104401e-07
with O 0 5.807184777495422e-08
the O 0 1.802867330980007e-07
age O 0 3.228913385555643e-07
of O 0 1.1848982239826e-07
the O 0 2.9416551114991307e-06
mouse O 0 0.00035871335421688855
. O 0 3.665834083221853e-05

Furthermore O 0 0.00019528978737071157
, O 0 3.94712060369784e-06
we O 0 6.767184004274895e-07
observed O 0 7.617610435772804e-07
no O 0 1.4043264684460155e-07
correlation O 0 4.022443249596108e-07
between O 0 1.561613913736437e-07
the O 0 3.842966691536276e-07
somatic O 0 2.0839632270508446e-05
mutation O 0 8.801922376733273e-06
rate O 0 2.041624384219176e-06
and O 0 1.3633767821374931e-06
tissue O 0 0.000125438193208538
proliferation O 0 4.247432298143394e-05
capacity O 0 1.3476005733537022e-05
. O 0 9.351204425911419e-06

The O 0 2.6478521249373443e-05
somatic O 0 0.00018313905457034707
mutation O 0 6.0832415329059586e-05
rates O 0 6.6005663938994985e-06
in O 0 4.3558770812524017e-07
different O 0 2.2557601653261372e-07
tissues O 0 1.6483094441355206e-05
were O 0 4.989662443222187e-07
also O 0 3.1178183235169854e-07
not O 0 1.1705721902899313e-07
correlated O 0 8.648139555589296e-07
to O 0 7.321657591319308e-08
the O 0 1.0684590989740173e-07
relative O 0 6.676592647636426e-07
inter O 0 6.633847988268826e-06
- O 0 0.006032153032720089
tissue O 0 2.3935055651236326e-05
difference O 0 3.260140317706828e-07
in O 0 1.8956082215026981e-07
transcriptional O 0 1.964921011676779e-06
levels O 0 2.070774058893221e-07
of O 0 4.206712489462916e-08
the O 0 1.2302287188958871e-07
three O 0 1.2498321666498668e-07
genes O 0 8.125492172439408e-07
( O 0 3.8022250237190747e-07
DMAHP O 0 2.0034185581607744e-05
, O 0 2.9272806045810285e-07
DMPK O 0 2.5421126338187605e-05
and O 0 4.401128137487831e-07
59 O 0 1.4279169135988923e-06
) O 0 3.4357910294602334e-07
surrounding O 0 1.1497241985125584e-06
the O 0 8.6608832816637e-07
repeat O 0 2.3160670025390573e-05
. O 0 2.6088039248861605e-06
. O 0 9.869208042800892e-06

A O 0 0.00025542668299749494
novel O 0 0.00020446149574127048
missense O 0 0.0026736047584563494
mutation O 0 0.0002535194216761738
in O 0 8.71595420903759e-06
patients O 0 1.4127115719020367e-05
from O 0 1.3142588386472198e-06
a O 0 1.1219818588870112e-05
retinoblastoma B-Disease 0 0.03660578280687332
pedigree O 0 0.00013593236508313566
showing O 0 3.487796493573114e-05
only O 0 9.038347457135387e-07
mild O 0 0.0003062568139284849
expression O 0 1.2150921975262463e-06
of O 0 4.379410825094965e-07
the O 0 2.2339214410749264e-05
tumor B-Disease 0 0.3987119793891907
phenotype O 0 0.004778241738677025
. O 0 4.510262078838423e-05

We O 0 1.7545809896546416e-05
have O 0 1.480024479860731e-06
used O 0 1.201572899844905e-06
single O 0 1.4182824088493362e-06
strand O 0 1.0151517926715314e-05
conformation O 0 1.7583832232048735e-05
polymorphism O 0 1.3160425623937044e-05
analysis O 0 8.736606105230749e-07
to O 0 3.608422503020847e-07
study O 0 3.5773686590800935e-07
the O 0 3.456264892065519e-07
27 O 0 1.0092029469888075e-06
exons O 0 1.505213390373683e-06
of O 0 1.7676227059837402e-07
the O 0 1.5064484841786907e-06
RB1 O 0 0.0005401130183599889
gene O 0 3.52252891389071e-06
in O 0 3.25441192217113e-07
individuals O 0 1.1230315521970624e-07
from O 0 2.2470022997822525e-07
a O 0 2.319591203558957e-06
family O 0 3.4039159800158814e-05
showing O 0 3.8653695810353383e-05
mild O 0 0.008547757752239704
expression O 0 2.2411691134038847e-06
of O 0 5.640541758111794e-07
the O 0 1.8625689335749485e-05
retinoblastoma B-Disease 1 0.893773078918457
phenotype O 0 0.08027750998735428
. O 0 6.36262193438597e-05

In O 0 1.6134317775140516e-05
this O 0 3.0451717520918464e-06
family O 0 8.067972885328345e-06
affected O 0 2.297820401508943e-06
individuals O 0 4.08197848855707e-07
developed O 0 1.2959780178789515e-05
unilateral B-Disease 0 0.09930254518985748
tumors I-Disease 1 0.9999998807907104
and O 0 3.6518702017929172e-06
, O 0 1.7112351713421958e-07
as O 0 1.2087245693237492e-07
a O 0 5.154570317245089e-07
result O 0 2.575252722181176e-07
of O 0 7.998223594540832e-08
linkage O 0 6.120227226347197e-06
analysis O 0 9.245601972907025e-07
, O 0 2.2446269554166065e-07
unaffected O 0 1.2384372894302942e-05
mutation O 0 4.318944320402807e-06
carriers O 0 1.1873906942128087e-06
were O 0 2.449148723826511e-07
also O 0 4.181314636753086e-07
identified O 0 8.773477588874812e-07
within O 0 5.270043175187311e-07
the O 0 3.472070602583699e-06
pedigree O 0 0.00038058718200773
. O 0 2.9233850000309758e-05

A O 0 0.00011490926408441737
single O 0 2.3204485842143185e-05
band O 0 1.9211256585549563e-05
shift O 0 1.0915384336840361e-05
using O 0 2.412154117337195e-06
SSCP O 0 0.00018746196292340755
was O 0 1.1811986041720957e-05
identified O 0 1.6107728697534185e-06
in O 0 5.162643788025889e-07
exon O 0 1.3707801372220274e-05
21 O 0 1.0105551382366684e-06
which O 0 3.638843395492586e-07
resulted O 0 1.8033779269899242e-06
in O 0 4.39785537764692e-07
a O 0 3.3863498174468987e-06
missense O 0 7.970012666191906e-05
mutation O 0 1.1029999768652488e-05
converting O 0 3.240511432522908e-06
a O 0 7.9910014392226e-06
cys O 1 0.9390382170677185
- O 0 0.01798858493566513
- O 0 0.0004561184614431113
> O 0 1.9627257643151097e-05
arg O 0 3.955445936298929e-05
at O 0 1.2124553450121311e-06
nucleotide O 0 3.0984733712102752e-06
position O 0 1.5054173445605556e-06
28 O 0 1.3780722838419024e-06
in O 0 8.755206408750382e-07
the O 0 5.36363495484693e-06
exon O 0 0.0002255033905385062
. O 0 1.9928429537685588e-05

The O 0 6.305529677774757e-05
mutation O 0 0.00014339914196170866
destroyed O 0 3.383291550562717e-05
an O 0 4.103463197679957e-06
NdeI O 0 0.00016806040366645902
restriction O 0 4.188640741631389e-05
enzyme O 0 4.973919203621335e-05
site O 0 3.854852548101917e-05
. O 0 2.1170242689549923e-05

Analysis O 0 3.939687667298131e-05
of O 0 1.4220041748558288e-06
all O 0 5.907562581342063e-07
family O 0 1.7960114746529143e-06
members O 0 3.172312403876276e-07
demonstrated O 0 9.087959256248723e-07
that O 0 1.5350387627677264e-07
the O 0 5.80425535190443e-07
missense O 0 6.200974166858941e-05
mutation O 0 1.93895903066732e-05
co O 0 6.370448681991547e-05
- O 0 6.373024370986968e-05
segregated O 0 3.5339487567398464e-06
with O 0 5.26703388459282e-07
patients O 0 7.1314193519356195e-06
with O 0 6.073491385905072e-05
tumors B-Disease 1 0.9999998807907104
or O 0 1.355520998913562e-05
who O 0 1.754604227244272e-06
, O 0 1.1015076495368703e-07
as O 0 7.115069422525266e-08
a O 0 2.817434392454743e-07
result O 0 1.4577221918443684e-07
of O 0 4.177925916337699e-08
linkage O 0 2.8338392894511344e-06
analysis O 0 2.6719845891420846e-07
had O 0 1.4314332474896219e-06
been O 0 3.520825657687965e-07
predicted O 0 1.5871029290792649e-06
to O 0 1.9290510522296245e-07
carry O 0 9.90700186775939e-07
the O 0 3.661463551907218e-06
predisposing O 0 0.00017430400475859642
mutation O 0 8.481540135107934e-05
. O 0 1.7910129827214405e-05

These O 0 6.772272627131315e-06
observations O 0 1.0440689948154613e-05
point O 0 1.145724695561512e-06
to O 0 3.0396950023714453e-07
another O 0 2.59824901149841e-07
region O 0 3.576352014533768e-07
of O 0 8.594944489459522e-08
the O 0 9.65701133281982e-07
RB1 O 0 0.0002608909271657467
gene O 0 3.386989192222245e-06
where O 0 4.857978979089239e-07
mutations O 0 3.4548979783721734e-06
only O 0 1.124986823697327e-07
modify O 0 1.3707690413866658e-06
the O 0 9.81784964437793e-08
function O 0 1.1204426897393205e-07
of O 0 2.2549270894955953e-08
the O 0 1.1035095326406008e-07
gene O 0 6.946617077119299e-07
and O 0 7.224814169148885e-08
raise O 0 2.414871573819255e-07
important O 0 6.102416705289215e-08
questions O 0 1.61170888191009e-07
for O 0 1.2918718539367546e-07
genetic O 0 2.1833186565345386e-06
counseling O 0 3.032218501175521e-06
in O 0 7.330236257985234e-07
families O 0 2.265390293132441e-07
with O 0 1.544921133245225e-07
these O 0 3.270996558057959e-07
distinctive O 0 6.959486927371472e-05
phenotypes O 0 0.0003102860937360674
. O 0 3.7061643070046557e-06
. O 0 1.8757364159682766e-05

Maternal B-Disease 0 0.007712875492870808
disomy I-Disease 0 0.22638581693172455
and O 0 0.11535823345184326
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.420260691200383e-05
with O 0 2.075378006338724e-06
gamete O 0 4.6470675442833453e-05
complementation O 0 0.005430249031633139
in O 0 9.94001197796024e-07
a O 0 1.2916035529997316e-06
case O 0 9.006716936710291e-07
of O 0 6.558235554621206e-07
familial O 0 0.0004079503705725074
translocation O 0 0.00019818797591142356
( O 0 2.132695499312831e-06
3 O 0 1.3095520898787072e-06
; O 0 4.527921930730372e-07
15 O 0 6.825341074545577e-07
) O 0 5.000055693926697e-07
( O 0 7.612200079165632e-07
p25 O 0 1.875539601314813e-05
; O 0 9.234482263309474e-07
q11 O 0 1.048228114086669e-05
. O 0 6.641948857577518e-07
2 O 0 2.4734054022701457e-06
) O 0 3.6374487990542548e-06
. O 0 8.342974979314022e-06

Maternal B-Disease 0 0.2754356861114502
uniparental I-Disease 1 0.9861090779304504
disomy I-Disease 1 0.976898193359375
( I-Disease 0 0.0010917825857177377
UPD I-Disease 1 0.9999961853027344
) I-Disease 0 5.2037721616216e-06
for I-Disease 0 4.708334984115936e-07
chromosome I-Disease 0 4.398595137899974e-06
15 I-Disease 0 2.8161102250123804e-07
is O 0 6.16780582163301e-08
responsible O 0 1.610312381217227e-07
for O 0 3.977195106585896e-08
an O 0 7.805601853760891e-08
estimated O 0 1.8839477888832334e-07
30 O 0 1.746299744809221e-07
% O 0 5.633628674672764e-08
of O 0 5.215544618408785e-08
cases O 0 1.0245674957332085e-06
of O 0 2.8796828701160848e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.053653717041015625
PWS B-Disease 1 0.9999995231628418
) O 0 6.888718053232878e-05
. O 0 4.134134724154137e-05

We O 0 1.8919914509751834e-05
report O 0 7.373309472313849e-06
on O 0 6.935066494406783e-07
an O 0 2.035603898775662e-07
unusual O 0 3.388367417755944e-07
case O 0 2.472787059559778e-07
of O 0 1.8653777544841432e-07
maternal B-Disease 0 1.718560633889865e-05
disomy I-Disease 0 0.00013361021410673857
15 I-Disease 0 3.0114292712823953e-06
in O 0 8.683174200996291e-06
PWS B-Disease 1 0.9999996423721313
that O 0 1.0044183227364556e-06
is O 0 1.0172833242449997e-07
most O 0 3.60984344638382e-08
consistent O 0 2.2534466381785023e-07
with O 0 7.603247809129243e-08
adjacent O 0 1.5496593732677866e-06
- O 0 6.574769940925762e-06
1 O 0 3.481177373032551e-07
segregation O 0 8.517505989402707e-07
of O 0 8.151464214734006e-08
a O 0 2.966336296594818e-06
paternal O 0 0.016881754621863365
t O 0 0.003293292596936226
( O 0 7.04839749232633e-07
3 O 0 3.880065264638688e-07
; O 0 1.8922432332146855e-07
15 O 0 2.161823715596256e-07
) O 0 2.702457777559175e-07
( O 0 3.4822434713532857e-07
p25 O 0 1.0298271263309289e-05
; O 0 4.4766727569367504e-07
q11 O 0 3.949466645281063e-06
. O 0 1.0399248395742688e-07
2 O 0 1.4851653418190836e-07
) O 0 7.707530613743074e-08
with O 0 6.564918919593765e-08
simultaneous O 0 1.978872205654625e-06
maternal O 0 4.130441811867058e-05
meiotic O 0 0.0004265612515155226
nondisjunction O 0 0.0004716302501037717
for O 0 2.93580660581938e-06
chromosome O 0 0.00010674058285076171
15 O 0 1.5555433492409065e-05
. O 0 2.063339707092382e-05

The O 0 8.180215809261426e-05
patient O 0 0.001189770526252687
( O 0 1.4019530681252945e-05
J O 0 0.09597326815128326
. O 0 1.0750327419373207e-06
B O 0 2.8306762942520436e-06
. O 0 9.544288559482084e-08
) O 0 7.566819704152294e-08
, O 0 4.013055132645604e-08
a O 0 1.5797429853137146e-07
17 O 0 4.0618240859657817e-07
- O 0 2.934292297140928e-06
year O 0 2.443628659420938e-07
- O 0 3.8251050682447385e-06
old O 0 1.479426146033802e-06
white O 0 1.120863203141198e-06
male O 0 3.88113846838678e-07
with O 0 1.319699663326901e-06
PWS B-Disease 1 0.9999997615814209
, O 0 1.3379710708250059e-06
was O 0 7.461546374543104e-06
found O 0 1.4336791309688124e-07
to O 0 7.243648525445678e-08
have O 0 5.362282351484282e-08
47 O 0 3.4970130968758895e-07
chromosomes O 0 4.6567970457545016e-07
with O 0 1.1592208437605223e-07
a O 0 2.3084025997377466e-06
supernumerary O 0 0.0002678219461813569
, O 0 3.839237706415588e-06
paternal O 0 0.006501143332570791
der O 0 0.10808989405632019
( O 0 1.0994082231263747e-06
15 O 0 2.488654331500584e-07
) O 0 5.106839040536215e-08
consisting O 0 4.333125858124731e-08
of O 0 3.6265028313664516e-08
the O 0 1.9310849097564642e-07
short O 0 2.7348582989361603e-06
arm O 0 0.0002722703502513468
and O 0 2.8946644192728854e-07
the O 0 6.410115815924655e-07
proximal O 0 0.0002575787657406181
long O 0 1.496287586633116e-05
arm O 0 0.0001141674438258633
of O 0 2.4853318336681696e-07
chromosome O 0 4.334260665928014e-06
15 O 0 6.248740191949764e-07
, O 0 3.168321427438059e-07
and O 0 1.6281228454317898e-06
distal O 0 0.017983328551054
chromosome O 0 0.003115667263045907
arm O 1 0.8721156120300293
3p O 0 0.2864611744880676
. O 0 7.885863306000829e-05

The O 0 7.764280599076301e-05
t O 0 0.0021378197707235813
( O 0 4.506960067374166e-06
3 O 0 7.494391525142419e-07
; O 0 2.3485002031975455e-07
15 O 0 1.767443933431423e-07
) O 0 1.364212778298679e-07
was O 0 4.387554213280964e-07
present O 0 7.942704627339481e-08
in O 0 5.1691461777636505e-08
the O 0 7.189348849578892e-08
balanced O 0 3.5008235954592237e-07
state O 0 7.899133436239936e-08
in O 0 1.2192553811019025e-07
the O 0 1.6000848290786962e-06
patients O 0 9.790528565645218e-06
father O 0 1.3330596630112268e-05
and O 0 5.913137783863931e-07
a O 0 1.1952107342949603e-05
sister O 0 0.01058290433138609
. O 0 1.2325484931352548e-05

Fluorescent O 0 0.0012279697693884373
in O 0 1.783952393452637e-05
situ O 0 5.641658208332956e-05
hybridization O 0 1.1495813851070125e-05
analysis O 0 2.4555947675253265e-06
demonstrated O 0 2.197477442678064e-06
that O 0 2.713260016662389e-07
the O 0 2.1818220830027713e-06
PWS B-Disease 1 0.9998047947883606
critical O 0 2.727099627009011e-06
region O 0 1.2830748801206937e-06
resided O 0 4.161538072366966e-06
on O 0 3.230065317438857e-07
the O 0 2.353017691802961e-07
derivative O 0 2.202756604674505e-06
chromosome O 0 1.8391287994745653e-06
3 O 0 1.562674754040927e-07
and O 0 7.650934463754311e-08
that O 0 5.0652808170070784e-08
there O 0 6.776284067200322e-08
was O 0 1.8335213098907843e-06
no O 0 1.4533939918237593e-07
deletion O 0 1.3414731938610203e-06
of O 0 1.0849475273744247e-07
the O 0 1.6278588645946002e-06
PWS B-Disease 1 0.9997618794441223
region O 0 8.335622396771214e-07
on O 0 3.224377849164739e-07
the O 0 1.7768270765827765e-07
normal O 0 6.542762207573105e-07
pair O 0 5.787640020571416e-07
of O 0 2.2686202783006593e-07
15s O 0 1.5591418559779413e-05
present O 0 3.0872206480125897e-06
in O 0 6.889220003358787e-06
J O 0 0.12874135375022888
. O 0 3.444580943323672e-05

B O 0 0.008708609268069267
. O 0 0.0005496310768648982

Methylation O 0 0.0005655917339026928
analysis O 0 5.342954318621196e-05
at O 0 7.107729288691189e-06
exon O 0 3.146381277474575e-05
alpha O 0 4.14789974456653e-06
of O 0 1.2479002009513351e-07
the O 0 3.8737317709092167e-07
small O 0 7.187571782196756e-07
nuclear O 0 1.6204201529035345e-05
ribonucleoprotein O 0 0.00019336430705152452
- O 0 8.05579184088856e-05
associated O 0 5.123398750583874e-06
polypeptide O 0 1.881835123640485e-05
N O 0 2.124669663317036e-05
( O 0 9.88866986517678e-07
SNRPN O 0 4.848821845371276e-05
) O 0 6.618673751290771e-07
gene O 0 1.8799253211909672e-06
showed O 0 1.033549210660567e-06
a O 0 6.698296033391671e-07
pattern O 0 2.24043833441101e-06
characteristic O 0 4.5383623614725366e-07
of O 0 4.760133620607121e-08
only O 0 8.65427978169464e-08
the O 0 7.045574648145703e-07
maternal O 0 2.31287758651888e-05
chromosome O 0 1.1485951290524099e-05
15 O 0 2.067379455183982e-06
in O 0 6.671406936220592e-06
J O 0 0.16818414628505707
. O 0 3.4859112929552794e-05

B O 0 0.006470055319368839
. O 0 0.0005187661154195666

Maternal B-Disease 0 0.02427211031317711
disomy I-Disease 0 0.36904802918434143
was O 0 0.00040993522270582616
confirmed O 0 1.8589718820294365e-05
by O 0 1.7849857840701588e-06
polymerase O 0 2.2264242943492718e-05
chain O 0 5.75863232370466e-05
reaction O 0 6.659189239144325e-06
analysis O 0 1.268293431166967e-06
of O 0 3.0194183864296065e-07
microsatellite O 0 6.656178447883576e-05
repeats O 0 1.2141666957177222e-05
at O 0 7.465023372787982e-07
the O 0 6.134966383797291e-07
gamma O 0 1.3022518032812513e-05
- O 0 3.885151818394661e-05
aminobutyric O 0 7.264025771291927e-05
acid O 0 2.123012745869346e-05
receptor O 0 3.5543402191251516e-05
beta3 O 0 4.8874931962927803e-05
subunit O 0 2.6120427719433792e-05
( O 0 8.480848919134587e-06
GABRB3 O 0 0.0002535955572966486
) O 0 1.5582427295157686e-05
locus O 0 0.00019869583775289357
. O 0 3.9502592699136585e-05

A O 0 0.00039432913763448596
niece O 0 0.2665257453918457
( O 0 1.7080041288863868e-05
B O 0 1.1100436495325994e-05
. O 0 4.0785539567878004e-07
B O 0 1.053833557307371e-06
. O 0 5.886473886107524e-08
) O 0 4.5919950508732654e-08
with O 0 3.945040205621808e-08
45 O 0 1.1445284542332956e-07
chromosomes O 0 2.2904684726654523e-07
and O 0 4.743393944295349e-08
the O 0 1.2513049796325504e-07
derivative O 0 7.527117986683152e-07
3 O 0 2.487755068614206e-07
but O 0 6.72511575317003e-08
without O 0 6.804025076689868e-08
the O 0 3.3387860298716987e-07
der O 0 0.001054142601788044
( O 0 3.185758430390706e-07
15 O 0 1.571175829440108e-07
) O 0 9.079178653337294e-08
demonstrated O 0 4.6454417201857723e-07
a O 0 2.127651214323123e-06
phenotype O 0 0.00015225948300212622
consistent O 0 1.5604675809299806e-06
with O 0 2.4813456889205554e-07
that O 0 1.7679093389233458e-07
reported O 0 4.945942691847449e-06
for O 0 3.5924253438679443e-07
haploinsufficiency O 0 2.5565292162355036e-05
of O 0 6.816630957473535e-07
distal O 0 0.0017992312787100673
3 O 0 3.421092333155684e-05
p O 0 0.004654239397495985
. O 0 3.129816832370125e-05

Uniparental B-Disease 1 0.9999861717224121
disomy I-Disease 1 0.9999786615371704
associated O 0 0.0006576558225788176
with O 0 1.0232366548734717e-05
unbalanced O 0 0.0006803646101616323
segregation O 0 3.634260065155104e-05
of O 0 4.970598297404649e-07
non O 0 2.278758074680809e-06
- O 0 2.247897646157071e-05
Robertsonian O 0 2.5840408852673136e-05
translocations O 0 2.0789393602171913e-05
has O 0 1.0002333965530852e-06
been O 0 4.1955425444939465e-07
reported O 0 6.1761506913171615e-06
previously O 0 7.120241889424506e-07
but O 0 5.513096112963467e-08
has O 0 8.732011025358588e-08
not O 0 2.239642071799608e-08
, O 0 1.5890591953393596e-08
to O 0 2.316693681336801e-08
our O 0 3.5631018135973136e-08
knowledge O 0 5.716127660093662e-08
, O 0 4.400834185958047e-08
been O 0 1.050578859462803e-07
observed O 0 3.769503393868945e-07
in O 0 1.9131941542127606e-07
a O 0 1.3301009857968893e-06
case O 0 3.754080807993887e-06
of O 0 5.74358136873343e-06
PWS B-Disease 1 0.9999963045120239
. O 0 5.969685298623517e-05

Furthermore O 0 0.00012559856986626983
, O 0 5.849316039530095e-06
our O 0 1.5092713283593184e-06
findings O 0 5.947080353507772e-06
are O 0 1.7040338207152672e-07
best O 0 3.185864727583976e-07
interpreted O 0 1.1525071386131458e-06
as O 0 3.6950825688109035e-07
true O 0 1.8046475815935992e-06
gamete O 0 4.124967017560266e-05
complementation O 0 0.00027226307429373264
resulting O 0 2.3460886950488202e-05
in O 0 2.795393993437756e-05
maternal B-Disease 0 0.34208935499191284
UPD I-Disease 1 0.9999948740005493
15 I-Disease 0 0.00014983784058131278
and O 0 0.00027401960687711835
PWS B-Disease 1 0.9999912977218628

Schwartz B-Disease 1 0.9250895977020264
- I-Disease 1 0.999614953994751
Jampel I-Disease 1 0.9999164342880249
syndrome I-Disease 1 0.9999974966049194
type I-Disease 0 7.506566180381924e-05
2 I-Disease 0 6.286388270382304e-06
and O 0 6.078920705476776e-06
Stuve B-Disease 1 0.9294252991676331
- I-Disease 1 0.9999970197677612
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
: O 0 1.244295276592311e-06
a O 0 2.7021610549127217e-06
case O 0 2.80348854175827e-06
for O 0 3.7932574059595936e-07
" O 0 1.5040253629194922e-06
lumping O 0 3.655675027403049e-05
" O 0 9.592306014383212e-06
. O 0 1.3720907190872822e-05

Recent O 0 8.575268293498084e-05
studies O 0 1.0054438462248072e-05
demonstrated O 0 5.6576914175821e-06
the O 0 7.588570838379383e-07
existence O 0 7.833161816961365e-07
of O 0 8.838261322807739e-08
a O 0 1.1323032822474488e-06
genetically O 0 1.5977823295543203e-06
distinct O 0 6.581819320672366e-07
, O 0 1.9584166466302122e-07
usually O 0 2.568818615600321e-07
lethal O 0 1.0061086186397006e-06
form O 0 2.3425836559454183e-07
of O 0 1.1351689721550429e-07
the O 0 2.935129032266559e-06
Schwartz B-Disease 0 0.21920421719551086
- I-Disease 1 0.9911484718322754
Jampel I-Disease 1 0.9993306398391724
syndrome I-Disease 1 0.9999988079071045
( O 0 1.6997202692436986e-05
SJS B-Disease 1 0.6681376695632935
) O 0 8.867327210282383e-07
of O 0 5.307265382725745e-07
myotonia B-Disease 1 0.8819037675857544
and O 0 8.113039802992716e-05
skeletal B-Disease 1 0.9998729228973389
dysplasia I-Disease 1 0.9999711513519287
, O 0 1.8046407603833359e-06
which O 0 1.5914666846583714e-06
we O 0 6.392205023075803e-07
called O 0 9.467318886891007e-05
SJS B-Disease 1 0.9890139698982239
type I-Disease 0 4.318795618019067e-05
2 I-Disease 0 1.0946607289952226e-05
. O 0 1.013691053231014e-05

This O 0 0.0004169555031694472
disorder O 1 0.9582074284553528
is O 0 1.11669362468092e-06
reminiscent O 0 8.4445873653749e-06
of O 0 2.2034257085579156e-07
another O 0 1.245300722985121e-06
rare O 0 3.7742656786576845e-06
condition O 0 0.00010855115397134796
, O 0 2.3195593712443952e-07
the O 0 2.0345648863440147e-06
Stuve B-Disease 1 0.9635536074638367
- I-Disease 1 0.999997615814209
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 5.285546649247408e-05
SWS B-Disease 1 0.9976533055305481
) O 0 6.032714168213715e-07
, O 0 8.003213736174075e-08
which O 0 8.647779026205171e-08
comprises O 0 1.7883427005926933e-07
campomelia B-Disease 0 1.1484943570394535e-05
at O 0 7.634701546521683e-07
birth O 0 7.109539637895068e-06
with O 0 5.596055871137651e-06
skeletal B-Disease 1 0.9998207688331604
dysplasia I-Disease 1 0.9999834299087524
, O 0 4.541685029835207e-06
contractures B-Disease 0 0.05081547796726227
, O 0 8.701882165951247e-07
and O 0 5.964000138192205e-07
early B-Disease 0 2.1649693735525943e-05
death I-Disease 0 0.0005084673757664859
. O 0 2.1671177819371223e-05

To O 0 2.1398451281129383e-05
test O 0 7.250066119013354e-06
for O 0 5.291981324262451e-07
possible O 0 1.71865679021721e-06
nosologic O 0 6.439183925976977e-05
identity O 0 2.284633410454262e-06
between O 0 7.351336535066366e-07
these O 0 2.0102095277252374e-06
disorders O 0 0.46328631043434143
, O 0 2.4445097324132803e-07
we O 0 6.695779575238703e-08
reviewed O 0 4.685119279201899e-07
the O 0 1.0220190915788407e-07
literature O 0 1.1363225382865494e-07
and O 0 7.912432664625157e-08
obtained O 0 2.5796575187087e-07
a O 0 3.360127038831706e-07
follow O 0 7.624231557201711e-07
- O 0 3.0990968298283406e-06
up O 0 6.221969073294531e-08
of O 0 1.5031371702889373e-08
the O 0 5.543040870747973e-08
only O 0 3.3257023801525065e-08
two O 0 7.83628664180469e-08
surviving O 0 1.1190016266482417e-05
patients O 0 1.5972810842868057e-06
, O 0 9.736690742556675e-08
one O 0 1.3920562480507215e-07
with O 0 1.6554284911762807e-06
SJS B-Disease 1 0.9905351996421814
type I-Disease 0 6.687089808110613e-06
2 I-Disease 0 3.407116366815899e-07
at O 0 3.632408436260448e-07
age O 0 1.995023239942384e-07
10 O 0 5.752735532382758e-08
years O 0 1.014272612565037e-07
and O 0 6.112527728419082e-08
another O 0 2.603110544896481e-07
with O 0 1.8941007056128e-06
SWS B-Disease 1 0.9969283938407898
at O 0 3.718772177307983e-06
age O 0 1.3755329746345524e-06
7 O 0 2.6700206490204437e-06
years O 0 3.7993320347595727e-06
. O 0 1.0032657883130014e-05

Patients O 0 0.009888422675430775
reported O 0 0.00020707101793959737
as O 0 3.567839712559362e-06
having O 0 7.509833267249633e-06
either O 0 7.21604228601791e-05
neonatal O 1 0.9999998807907104
SJS B-Disease 1 0.9999985694885254
or O 0 0.00011839444050565362
SWS B-Disease 1 0.9945695996284485
presented O 0 2.7783682980953017e-06
a O 0 9.151667086371162e-07
combination O 0 9.83208906291111e-07
of O 0 9.336345385690947e-08
a O 0 8.465293831250165e-06
severe O 1 0.6193814873695374
, O 0 2.7407661036704667e-05
prenatal O 1 0.9922913908958435
- O 1 0.9999935626983643
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.00010970570292556658
with O 0 0.0008410275913774967
congenital B-Disease 1 0.9999998807907104
joint I-Disease 1 0.8740021586418152
contractures I-Disease 1 0.9999786615371704
, O 0 0.0014880471862852573
respiratory O 1 0.9979846477508545
and O 0 6.371733434207272e-06
feeding O 0 1.2045687981299125e-05
difficulties O 0 2.8089373245165916e-06
, O 0 2.5664826353022363e-07
tendency O 0 2.4221515104727587e-06
to O 0 1.5556266816929565e-06
hyperthermia B-Disease 0 0.4834921360015869
, O 0 1.3147199240393093e-07
and O 0 9.975407522233581e-08
frequent O 0 1.7863379753180197e-06
death O 0 0.0002818655630107969
in O 0 3.561489393177908e-06
infancy O 0 0.003985488787293434
) O 0 2.426775154162897e-07
with O 0 1.7132337859493418e-07
a O 0 1.4349486718856497e-06
distinct O 0 9.334186870546546e-06
campomelic B-Disease 0 0.09044335782527924
- I-Disease 1 0.7254444360733032
metaphyseal I-Disease 1 0.9719731211662292
skeletal I-Disease 1 0.9998483657836914
dysplasia I-Disease 1 0.9999575614929199
. O 0 7.960245420690626e-05

The O 0 9.85086262517143e-06
similarity O 0 3.928464138880372e-06
of O 0 2.8994355716349673e-07
the O 0 7.683676699343778e-07
clinical O 0 5.955377218924696e-06
and O 0 2.749988198047504e-06
radiographic O 0 0.27823710441589355
findings O 0 0.0002222601033281535
is O 0 3.2662086368873133e-07
so O 0 1.1593368753892719e-07
extensive O 0 1.0689733471735963e-06
that O 0 8.05810827841924e-07
these O 0 3.0771736874157796e-06
disorders O 1 0.9657965898513794
appear O 0 6.4282576204277575e-06
to O 0 2.441413471387932e-07
be O 0 1.3509860252725048e-07
a O 0 8.925129577619373e-07
single O 0 3.38864356308477e-06
entity O 0 3.5086173738818616e-05
. O 0 2.014665187743958e-05

The O 0 2.326273897779174e-05
follow O 0 1.2834926565119531e-05
- O 0 1.7989488696912304e-05
up O 0 4.403609352721105e-07
observation O 0 7.775109338581387e-07
of O 0 5.089705013006096e-08
an O 0 7.078117647552062e-08
identical O 0 1.489054170633608e-06
and O 0 9.323461824806145e-08
unique O 0 1.5081892001944652e-07
pattern O 0 4.72305418952601e-06
of O 0 9.2153999275979e-07
progressive O 1 0.9904378056526184
bone B-Disease 1 0.9998332262039185
dysplasia I-Disease 1 0.9999291896820068
in O 0 2.1436558199638966e-06
the O 0 1.0467470019648317e-06
two O 0 2.8887068310723407e-06
patients O 0 1.4881929928378668e-05
( O 0 2.898210880175611e-07
one O 0 1.2639620194931922e-07
with O 0 2.466623755026376e-06
SJS B-Disease 1 0.9981939196586609
type I-Disease 0 7.022203135420568e-06
2 I-Disease 0 3.6452621543503483e-07
, O 0 8.462257028440945e-08
one O 0 8.973095333431047e-08
with O 0 6.288363465500879e-07
SWS B-Disease 1 0.9748803973197937
) O 0 5.384752626014233e-07
surviving O 0 1.2878878123956383e-06
beyond O 0 1.2951880989930942e-06
infancy O 0 6.463977479143068e-05
adds O 0 1.5277220200005104e-06
to O 0 1.0945669970396921e-07
the O 0 1.1084161144481186e-07
evidence O 0 2.2369061980498373e-07
in O 0 1.938201279472196e-07
favor O 0 6.084193842070817e-07
of O 0 4.5231314516058774e-07
identity O 0 1.4659639418823645e-05
. O 0 1.4717465091962367e-05

The O 0 6.228235724847764e-05
hypothesis O 0 9.368744940729812e-05
that O 0 4.808773610420758e-06
SWS B-Disease 1 0.974280059337616
and O 0 2.1456404283526354e-05
SJS B-Disease 1 0.9944843649864197
type I-Disease 0 1.3772834790870547e-05
2 I-Disease 0 3.8701352877978934e-07
are O 0 3.7790162110695746e-08
the O 0 3.3056488746296964e-07
same O 0 0.00033661178895272315
disorder O 1 0.9270499348640442
should O 0 5.759673626926087e-07
be O 0 1.9116748717351584e-07
testable O 0 1.8662777847566758e-06
by O 0 2.8259162832000584e-07
molecular O 0 2.334593546038377e-06
methods O 0 1.9657513803394977e-06
. O 0 1.4822054481555824e-06
. O 0 1.0961985026369803e-05

A O 0 0.00017149155610240996
mouse O 0 0.00038278038846328855
model O 0 4.378269295557402e-05
of O 0 9.555958058626857e-06
severe O 1 0.9999992847442627
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.49201321601867676
defects O 1 0.9999829530715942
in O 0 0.00011076169175794348
hemostasis O 1 0.9988961219787598
and O 0 0.01192425936460495
thrombosis B-Disease 1 0.9999079704284668
. O 0 0.00018933085084427148

von B-Disease 1 0.999489426612854
Willebrand I-Disease 1 0.9989954829216003
factor I-Disease 0 0.002067131921648979
( I-Disease 0 0.00050485780229792
vWf I-Disease 1 0.5219746828079224
) I-Disease 1 0.5032278299331665
deficiency I-Disease 1 0.9999949932098389
causes O 1 0.9297230243682861
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0005831250455230474
humans O 0 0.00013054205919615924
. O 0 4.994033224647865e-05

We O 0 1.2985487046535127e-05
generated O 0 8.987292858364526e-06
a O 0 2.2587423700315412e-06
mouse O 0 1.3601946193375625e-05
model O 0 2.4144233066181187e-06
for O 0 3.673148114557989e-07
this O 0 1.0133092018804746e-06
disease O 0 1.8416405509924516e-05
by O 0 4.849243850912899e-07
using O 0 2.545711595303146e-06
gene O 0 1.8933651517727412e-05
targeting O 0 3.150125121464953e-05
. O 0 2.1387109882198274e-05

vWf B-Disease 0 0.09119217842817307
- I-Disease 1 0.9865463972091675
deficient I-Disease 1 0.6796425580978394
mice O 0 0.0003916347923222929
appeared O 0 1.6432728443760425e-05
normal O 0 3.4135337045881897e-06
at O 0 1.7066649888874963e-06
birth O 0 2.7160967874806374e-05
; O 0 4.4308816882221436e-07
they O 0 1.0883695011898453e-07
were O 0 3.15347222112905e-07
viable O 0 1.4092166793489014e-06
and O 0 1.0086573638545815e-06
fertile O 0 1.8346971046412364e-05
. O 0 1.5428144251927733e-05

Neither O 0 0.0017820971552282572
vWf O 0 0.008623415604233742
nor O 0 0.0006249736761674285
vWf O 0 0.0020939221139997244
propolypeptide O 0 0.0033051446080207825
( O 0 8.300115587189794e-05
von B-Disease 1 0.7203661203384399
Willebrand I-Disease 1 0.8877900242805481
antigen O 0 0.005020449869334698
II O 0 0.22665324807167053
) O 0 1.4713917835251777e-06
were O 0 4.877583137385955e-07
detectable O 0 2.41015345636697e-06
in O 0 2.9979162263771286e-07
plasma O 0 6.866564945084974e-06
, O 0 3.4477287158551917e-07
platelets O 0 1.1804597306763753e-05
, O 0 2.0471426864787645e-07
or O 0 5.957946314083529e-07
endothelial O 0 2.1487652702489868e-05
cells O 0 1.479324510000879e-06
of O 0 2.0240531739545986e-07
the O 0 2.094295496135601e-06
homozygous O 0 0.0001369138335576281
mutant O 0 0.00020672324171755463
mice O 0 0.00029666957561858
. O 0 2.4973589461296797e-05

The O 0 0.00011237877333769575
mutant O 0 0.0012099999003112316
mice O 0 0.13807053864002228
exhibited O 1 0.9317676424980164
defects O 1 0.9995075464248657
in O 0 8.479692951368634e-06
hemostasis O 0 0.003955699969083071
with O 0 2.2007932329870528e-06
a O 0 1.815341784094926e-05
highly O 0 3.892513268510811e-05
prolonged O 1 0.9465523362159729
bleeding O 1 0.7566067576408386
time O 0 1.8272579609401873e-06
and O 0 1.6697999853931833e-06
spontaneous O 0 1.8879436538554728e-05
bleeding O 0 0.0012740949168801308
events O 0 4.217719435928302e-07
in O 0 1.994602740751361e-07
approximately O 0 2.9892859743085864e-07
10 O 0 4.570177054574742e-07
% O 0 5.283751534079784e-07
of O 0 1.6553210571146337e-06
neonates O 0 0.0015474610263481736
. O 0 3.510548413032666e-05

As O 0 8.452652764390223e-06
in O 0 1.3970385452921619e-06
the O 0 1.0477647265361156e-06
human O 0 4.576013452606276e-06
disease O 0 7.830314279999584e-05
, O 0 1.7541412944410695e-07
the O 0 3.7602291058647097e-07
factor O 0 1.0407934496470261e-06
VIII O 0 0.000366658583516255
level O 0 3.7789951079503226e-07
in O 0 2.3206303012557328e-07
these O 0 1.9168979292771837e-07
mice O 0 1.287399572902359e-05
was O 0 4.507789526542183e-06
reduced O 0 1.204518071062921e-06
strongly O 0 1.3476523008648655e-06
as O 0 8.253531547097737e-08
a O 0 1.404414717853797e-07
result O 0 5.485112097858291e-08
of O 0 1.6740136388193605e-08
the O 0 8.711233334679491e-08
lack O 0 2.0057886729318852e-07
of O 0 1.289351132527372e-07
protection O 0 3.4202594179078005e-06
provided O 0 2.723180386965396e-06
by O 0 7.237603767862311e-06
vWf O 0 0.00035386206582188606
. O 0 2.6184121452388354e-05

Defective O 1 0.9924650192260742
thrombosis B-Disease 1 0.9994577765464783
in O 0 6.182167999213561e-05
mutant O 0 0.0034812414087355137
mice O 0 0.025380145758390427
was O 0 7.192628982011229e-05
also O 0 1.1990624670943362e-06
evident O 0 1.661983674239309e-06
in O 0 2.4291577460644476e-07
an O 0 2.16959364252034e-07
in O 0 6.50976289762184e-07
vivo O 0 3.0188537493813783e-05
model O 0 6.669848517049104e-06
of O 0 5.105692707729759e-06
vascular B-Disease 1 0.9999973773956299
injury I-Disease 1 0.9672909379005432
. O 0 8.35696337162517e-05

In O 0 1.1883878869412001e-05
this O 0 1.1828880133180064e-06
model O 0 2.4508055957994657e-06
, O 0 2.6746232606456033e-07
the O 0 6.486740176114836e-07
exteriorized O 0 6.010917786625214e-05
mesentery O 0 0.00017846943228505552
was O 0 2.0324188881204464e-05
superfused O 0 6.0671936807921156e-05
with O 0 2.315807250852231e-06
ferric O 0 0.1789267361164093
chloride O 0 5.1222268666606396e-05
and O 0 5.032269996263494e-07
the O 0 4.717584545232967e-07
accumulation O 0 5.144079295860138e-06
of O 0 5.293637173053867e-07
fluorescently O 0 0.0015756328357383609
labeled O 0 0.0008084379369392991
platelets O 0 0.0003399933921173215
was O 0 1.1801424079749268e-05
observed O 0 4.59695593235665e-06
by O 0 2.3538461846328573e-06
intravital O 0 0.0005619506700895727
microscopy O 0 0.0006518587470054626
. O 0 3.170655691064894e-05

We O 0 1.8966900825034827e-05
conclude O 0 2.4193734134314582e-05
that O 0 1.346936642221408e-06
these O 0 5.550753030547639e-07
mice O 0 8.17025556898443e-06
very O 0 5.530620796889707e-07
closely O 0 6.207594651641557e-06
mimic O 0 0.0037124871741980314
severe O 1 0.9870001673698425
human O 0 0.01722484827041626
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0001419234467903152
will O 0 2.8364052013785113e-06
be O 0 1.6993210749660648e-07
very O 0 7.867662077387649e-08
useful O 0 6.649504058486855e-08
for O 0 3.578582763452687e-08
investigating O 0 3.354626301188546e-07
the O 0 1.4396458425380843e-07
role O 0 2.74212396789153e-07
of O 0 1.8652211508651817e-07
vWf O 0 1.0047881914942991e-05
in O 0 6.0839153093184e-07
normal O 0 3.305265636299737e-06
physiology O 0 2.6244471882819198e-05
and O 0 2.3329732812271686e-06
in O 0 4.9944763304665685e-05
disease O 0 0.02386488765478134
models O 0 1.9592100215959363e-05
. O 0 2.905585461121518e-06
. O 0 1.2240185242262669e-05

Oral O 0 0.0036297438200563192
contraceptives O 0 0.01234085951000452
and O 0 5.80239020564477e-06
the O 0 2.8718986868625507e-06
risk O 0 1.5731920939288102e-05
of O 0 2.711862907744944e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00035432656295597553

Hereditary B-Disease 1 0.9999997615814209
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999834299087524
Clinical O 0 0.02175932750105858
Study O 0 0.00018765387358143926
Group O 0 0.00011476295912871137
. O 0 6.728721928084269e-05

BACKGROUND O 0 0.00045935407979413867
Women O 0 1.172188603959512e-05
with O 0 2.343802179893828e-06
mutations O 0 2.4846616724971682e-05
in O 0 7.943186801639968e-07
either O 0 6.096577749303833e-07
the O 0 7.335229383897968e-07
BRCA1 O 0 2.810335899994243e-05
or O 0 4.260068635630887e-07
the O 0 1.1402994459785987e-06
BRCA2 O 0 4.590469325194135e-05
gene O 0 3.3067317417589948e-06
have O 0 1.7275620223244914e-07
a O 0 6.275099622143898e-07
high O 0 5.987747954350198e-06
lifetime O 0 1.3192191545385867e-05
risk O 0 5.217528450884856e-05
of O 0 0.0019435180583968759
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00024144908820744604

Oral O 0 0.0016787457279860973
contraceptives O 0 0.08761357516050339
protect O 0 0.00028316190582700074
against O 1 0.9748653173446655
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
in O 0 3.507852625261876e-06
general O 0 3.351209670654498e-06
, O 0 2.9943842605462123e-07
but O 0 1.1361080254346234e-07
it O 0 9.314485538425288e-08
is O 0 4.334547654138987e-08
not O 0 3.785883961882064e-08
known O 0 1.0747871215244231e-07
whether O 0 7.639313537310954e-08
they O 0 4.553019294917249e-08
also O 0 1.070149906468032e-07
protect O 0 2.474544658070954e-07
against O 0 7.534458177360648e-07
hereditary B-Disease 0 0.0038260282017290592
forms I-Disease 0 7.241932053148048e-06
of I-Disease 0 0.008333224803209305
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0001701794535620138

METHODS O 0 0.00011408647696953267
We O 0 2.9761745281575713e-06
enrolled O 0 5.642199994326802e-06
207 O 0 8.760879609326366e-06
women O 0 1.5251846434694016e-06
with O 0 0.00021793076302856207
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.3838421182299498e-06
161 O 0 1.2989646620553685e-06
of O 0 8.673234219713777e-08
their O 0 2.9104785426170565e-07
sisters O 0 2.653191586432513e-06
as O 0 1.4729613440067624e-07
controls O 0 3.7750073715869803e-06
in O 0 1.5751261628338398e-07
a O 0 1.164591026281414e-06
case O 0 6.1319760789046995e-06
- O 0 0.00021006926544941962
control O 0 6.706562999170274e-05
study O 0 1.0452423339302186e-05
. O 0 1.8468939742888324e-05

All O 0 9.245035471394658e-06
the O 0 4.4423245526559185e-06
patients O 0 8.868334589351434e-06
carried O 0 3.7569348023680504e-06
a O 0 3.7485783650481608e-06
pathogenic O 0 3.285615821368992e-05
mutation O 0 1.075408454198623e-05
in O 0 1.0665283980415552e-06
either O 0 2.5813308184297057e-06
BRCA1 O 0 3.5171597119187936e-05
( O 0 7.777816222187539e-07
179 O 0 2.339771072001895e-06
women O 0 5.433672072285844e-07
) O 0 5.883818516849715e-07
or O 0 2.4887617655622307e-06
BRCA2 O 0 8.735759183764458e-05
( O 0 2.271285893584718e-06
28 O 0 4.708744199888315e-06
women O 0 2.463621740389499e-06
) O 0 4.854740836890414e-06
. O 0 8.48971012601396e-06

The O 0 1.760739178280346e-05
control O 0 3.879550058627501e-05
women O 0 1.1282126024525496e-06
were O 0 3.973400737322663e-07
enrolled O 0 7.442575338245661e-07
regardless O 0 2.1734042832122213e-07
of O 0 4.783579399258997e-08
whether O 0 3.158378092393832e-07
or O 0 3.6498607869361877e-07
not O 0 1.3590251057848945e-07
they O 0 1.9660629391182738e-07
had O 0 2.0912777927151183e-06
either O 0 4.151117082074052e-06
mutation O 0 5.635082197841257e-05
. O 0 1.6046806194935925e-05

Lifetime O 0 0.00025063776411116123
histories O 0 5.386890552472323e-05
of O 0 2.0484621927607805e-06
oral O 0 3.228080822736956e-05
- O 0 0.005193567369133234
contraceptive O 0 0.00010516869951970875
use O 0 6.449606075875636e-07
were O 0 1.7704958565900597e-07
obtained O 0 1.69785181469706e-07
by O 0 1.0287272544928783e-07
interview O 0 6.122649665485369e-06
or O 0 2.1440963848817773e-07
by O 0 1.6051009765760682e-07
written O 0 2.224546022944196e-07
questionnaire O 0 1.0477427849764354e-06
and O 0 1.1176274483659654e-07
were O 0 2.0274725898161705e-07
compared O 0 4.0902708065004845e-07
between O 0 6.224645971997234e-07
patients O 0 2.46456875174772e-06
and O 0 4.6063729541856446e-07
control O 0 7.306034240173176e-05
women O 0 1.9106616377939645e-07
, O 0 6.875476543655168e-08
after O 0 5.784963263977261e-07
adjustment O 0 9.731732006912353e-07
for O 0 5.896306021213604e-08
year O 0 1.9327043787598086e-07
of O 0 1.8707598314904317e-07
birth O 0 3.801193815888837e-05
and O 0 2.0700231289083604e-06
parity O 0 3.437185296206735e-05
. O 0 1.0240986739518121e-05

RESULTS O 0 0.0001526578125776723
The O 0 1.5733661712147295e-05
adjusted O 0 0.00013010982365813106
odds O 0 0.00010394000128144398
ratio O 0 3.621904761530459e-05
for O 0 0.03236057236790657
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.7575152014615014e-05
with O 0 2.3726285292013927e-07
any O 0 1.3416070032690186e-07
past O 0 3.4035210205729527e-07
use O 0 3.172270055529225e-07
of O 0 4.263698372142244e-07
oral O 0 0.0001598974340595305
contraceptives O 0 0.1507946401834488
was O 0 0.00012746313586831093
0 O 0 2.1852352801943198e-05
. O 0 1.2742200851789676e-05

5 O 0 5.812772724311799e-05
( O 0 8.63074092194438e-06
95 O 0 3.475472794889356e-06
percent O 0 2.054777951343567e-06
confidence O 0 1.8937737422675127e-06
interval O 0 1.29520776681602e-06
, O 0 1.0333702959997026e-07
0 O 0 2.575999360487913e-07
. O 0 4.3600035581903285e-08
3 O 0 1.5364521743777004e-07
to O 0 2.0833959979427163e-07
0 O 0 7.790956146891403e-07
. O 0 3.6562920513460995e-07
8 O 0 2.4477481019857805e-06
) O 0 3.0935987069824478e-06
. O 0 6.521316208818462e-06

The O 0 3.9411002944689244e-05
risk O 0 3.784970613196492e-05
decreased O 0 1.1956371963606216e-05
with O 0 8.325707199219323e-07
increasing O 0 1.5691693988628685e-06
duration O 0 2.5608599116822006e-06
of O 0 1.912424352212838e-07
use O 0 2.2479332528746454e-06
( O 0 1.6707479062461061e-06
P O 0 3.5273271350888535e-05
for O 0 1.8801031842485827e-07
trend O 0 1.8855038206311292e-06
, O 0 3.3633395446486247e-07
< O 0 1.9607111880759476e-06
0 O 0 4.758681484418048e-07
. O 0 1.2601032040038262e-07
001 O 0 2.0063637293787906e-06
) O 0 1.1621308715348277e-07
; O 0 4.015612375951605e-08
use O 0 4.676494924638064e-08
for O 0 2.6991394008746283e-08
six O 0 7.912598931625325e-08
or O 0 6.472231461884803e-08
more O 0 3.1616263385103593e-08
years O 0 2.029215409038443e-07
was O 0 2.587862809377839e-06
associated O 0 2.0821525481551362e-07
with O 0 5.137026093393615e-08
a O 0 4.787924581250991e-07
60 O 0 9.655316262069391e-07
percent O 0 3.2284133339999244e-06
reduction O 0 7.500378615077352e-06
in O 0 5.573451744567137e-06
risk O 0 3.6174831620883197e-05
. O 0 1.6595588022028096e-05

Oral O 0 0.0006346759619191289
- O 0 0.00123674888163805
contraceptive O 0 0.0003894570400007069
use O 0 7.583804745081579e-06
protected O 0 7.871296111261472e-05
against O 1 0.968461275100708
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999961853027344
both O 0 6.666342642347445e-07
for O 0 2.923575550539681e-07
carriers O 0 1.0996892569892225e-06
of O 0 1.8567061488283798e-07
the O 0 4.323361736169318e-06
BRCA1 O 0 0.001658163615502417
mutation O 0 2.782887895591557e-05
( O 0 1.4701996633448289e-06
odds O 0 7.80462687544059e-06
ratio O 0 1.2287928257137537e-06
, O 0 1.2561210382955323e-07
0 O 0 2.8983353672629164e-07
. O 0 6.388743400975727e-08
5 O 0 1.5831696487111913e-07
; O 0 1.4862860098219244e-07
95 O 0 5.308252752911358e-07
percent O 0 1.1408280897740042e-06
confidence O 0 1.5374664599221433e-06
interval O 0 1.2584114301716909e-06
, O 0 1.1614572059670536e-07
0 O 0 1.9671169582125003e-07
. O 0 3.7667753360892675e-08
3 O 0 9.905729569936739e-08
to O 0 6.637365146389129e-08
0 O 0 1.667325904008976e-07
. O 0 4.0030940340329835e-08
9 O 0 2.11269991723384e-07
) O 0 7.465409623819141e-08
and O 0 3.2136266980842265e-08
for O 0 3.4983532515298066e-08
carriers O 0 2.0602709582817624e-07
of O 0 4.570386380464697e-08
the O 0 2.160240001103375e-06
BRCA2 O 0 0.000615336059127003
mutation O 0 1.1802841981989332e-05
( O 0 1.235298668689211e-06
odds O 0 5.88470493312343e-06
ratio O 0 8.653798886371078e-07
, O 0 8.81085924220315e-08
0 O 0 1.5881599324529816e-07
. O 0 4.072373371855065e-08
4 O 0 1.4310086271507316e-07
; O 0 1.0451365994867956e-07
95 O 0 3.416278673284978e-07
percent O 0 9.553374411552795e-07
confidence O 0 9.744901490194025e-07
interval O 0 7.429271704495477e-07
, O 0 8.783878513440868e-08
0 O 0 1.63998208790872e-07
. O 0 4.8082590353715204e-08
2 O 0 1.1186105552951631e-07
to O 0 1.069827462174544e-07
1 O 0 2.0881300599739916e-07
. O 0 2.354276773530728e-07
1 O 0 1.2181320698800846e-06
) O 0 2.5479023406660417e-06
. O 0 1.0290083082509227e-05

CONCLUSIONS O 0 0.0003170351264998317
Oral O 0 0.00026311332476325333
- O 0 0.012947039678692818
contraceptive O 0 0.0009688829304650426
use O 0 3.654803776953486e-06
may O 0 3.452276359894313e-06
reduce O 0 1.0758891448858776e-06
the O 0 8.126282295961573e-07
risk O 0 6.273631242947886e-06
of O 0 0.0001496784680057317
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 8.162265658029355e-06
women O 0 9.179000244330382e-07
with O 0 8.085589797701687e-07
pathogenic O 0 3.140326225548051e-05
mutations O 0 9.195698112307582e-06
in O 0 8.380289955312037e-07
the O 0 8.317886567965616e-06
BRCA1 O 0 0.0011393538443371654
or O 0 8.455562056042254e-05
BRCA2 O 0 0.003071417799219489
gene O 0 0.001052436069585383

A O 0 8.741401688894257e-05
Japanese O 0 3.75461058865767e-05
family O 0 4.4645246816799045e-05
with O 0 9.511732969258446e-06
adrenoleukodystrophy B-Disease 1 0.9999903440475464
with O 0 2.6896275358012645e-06
a O 0 6.749814474460436e-06
codon O 0 2.7845999284181744e-05
291 O 0 1.3379683878156357e-05
deletion O 0 2.5249270038329996e-05
: O 0 4.1444417320235516e-07
a O 0 9.042813076121092e-07
clinical O 0 1.1601046935538761e-05
, O 0 6.74503951358929e-07
biochemical O 0 2.9072458346490748e-05
, O 0 6.929096798558021e-07
pathological O 0 1.1702909432642628e-05
, O 0 6.148273996586795e-07
and O 0 2.2074880234868033e-06
genetic O 0 4.928446651319973e-05
report O 0 4.9506470531923696e-05
. O 0 2.184309960284736e-05

We O 0 2.0778985344804823e-05
report O 0 1.113690268539358e-05
a O 0 2.3774216515448643e-06
Japanese O 0 4.382048246043269e-06
family O 0 3.281466706539504e-05
with O 0 4.055375393363647e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.09829152375459671
ALD B-Disease 1 0.9999998807907104
) O 0 1.1311894922982901e-06
with O 0 1.1732601734593118e-07
a O 0 2.840869797182677e-07
three O 0 1.2657181969188969e-07
base O 0 8.991491995402612e-07
pair O 0 2.9006851036683656e-06
deletion O 0 2.0705083443317562e-05
( O 0 1.6493850125698373e-06
delGAG O 0 1.7253820260521024e-05
291 O 0 4.457453087525209e-06
) O 0 5.712797133128333e-07
in O 0 8.313678563354188e-07
the O 0 1.9826671632472426e-05
ALD B-Disease 1 0.9999994039535522
gene O 0 0.00040391815127804875
. O 0 4.40890908066649e-05

A O 0 3.599962656153366e-05
variety O 0 5.268010681902524e-06
of O 0 1.513322672508366e-06
phenotypes O 0 0.00012177900498500094
were O 0 1.0284226164003485e-06
observed O 0 9.918242085404927e-07
within O 0 4.2028349866995995e-07
this O 0 8.988320132630179e-07
family O 0 3.266791827627458e-05
. O 0 1.8716355043579824e-05

While O 0 1.5138874914555345e-05
the O 0 5.548970875679515e-06
proband O 0 0.0024226645473390818
( O 0 8.304752554977313e-06
patient O 0 9.425425560039002e-06
1 O 0 5.86273586122843e-07
) O 0 2.7894077447854215e-07
was O 0 2.9490904580598e-06
classified O 0 4.135258393489494e-07
as O 0 9.381186316659296e-08
having O 0 3.384175784049148e-07
a O 0 1.0008842536990414e-06
rare O 0 2.7797943857876817e-06
intermediate O 0 1.996267201320734e-06
type O 0 2.4012151698116213e-06
of O 0 1.786205388043527e-07
adult O 0 6.234934517124202e-06
cerebral O 0 0.0009149366524070501
and O 0 1.7109281316152192e-06
cerebello O 0 0.3378128111362457
- O 1 0.6076088547706604
brain O 0 0.0005228859954513609
stem O 0 2.5953938802558696e-06
forms O 0 3.236670522710483e-07
, O 0 1.2247724612279853e-07
his O 0 4.357274519861676e-06
younger O 0 2.0491639588726684e-05
brother O 0 0.004687189124524593
( O 0 2.913610160248936e-06
patient O 0 6.4371893131465185e-06
2 O 0 5.540191523323301e-07
) O 0 2.4825459377098014e-07
and O 0 9.857860732154222e-07
nephew O 1 0.5928964018821716
( O 0 5.168420102563687e-06
patient O 0 1.1245656423852779e-05
3 O 0 1.926432787513477e-06
) O 0 7.145362701521663e-07
had O 0 7.906163773441222e-06
a O 0 8.584816532675177e-05
childhood O 1 0.958938717842102
ALD B-Disease 1 0.9999998807907104
type O 0 0.17569556832313538
. O 0 8.629383228253573e-05

Another O 0 0.00021436957467813045
nephew O 1 0.817017674446106
( O 0 6.314808706520125e-05
patient O 0 8.393967436859384e-05
4 O 0 2.9733434985246276e-06
) O 0 3.4756874356389744e-07
of O 0 1.4705864259667578e-07
patient O 0 1.171968506241683e-05
1 O 0 1.3300249293024535e-06
was O 0 5.9044690715381876e-05
classified O 0 1.6383124830099405e-06
as O 0 3.077700228004687e-07
having O 0 6.577477051905589e-07
an O 0 1.0466322919455706e-06
adolescent O 0 0.00012304128904361278
form O 0 1.451169555366505e-05
. O 0 2.6630919819581322e-05

The O 0 1.987797804758884e-05
tau O 0 5.254112329566851e-05
level O 0 3.1072024739842163e-06
in O 0 1.023754975904012e-06
the O 0 3.997110979980789e-06
cerebrospinal O 1 0.6624293923377991
fluid O 0 0.030618956312537193
( O 0 2.5840705347945914e-05
CSF O 1 0.9781603217124939
) O 0 6.454774847952649e-07
in O 0 8.105501478894439e-07
patient O 0 4.8678980419936124e-06
1 O 0 4.578671166655113e-07
was O 0 1.3365248378249817e-05
as O 0 1.564726659353255e-07
high O 0 6.79869287978363e-07
as O 0 8.551171504223021e-08
that O 0 8.149630303933009e-08
of O 0 3.125078649190982e-07
patients O 0 4.608285235008225e-05
with O 0 0.012622855603694916
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9925161004066467
( O 0 1.0062659384857398e-05
AD B-Disease 0 0.00015774130588397384
) O 0 6.021085482643684e-06
. O 0 1.0605811439745594e-05

His O 0 0.0007764491019770503
brain O 1 0.5227594375610352
magnetic O 0 0.0008283901261165738
resonance O 0 0.0016785317566245794
image O 0 0.007394840009510517
( O 0 1.700873144727666e-05
MRI O 1 0.5670271515846252
) O 0 2.1852310965186916e-06
showed O 0 0.00024896275135688484
abnormalities B-Disease 0 0.04539233818650246
in I-Disease 0 1.3298266310357576e-07
the I-Disease 0 1.6309934380842606e-07
bilateral I-Disease 0 1.712619337013166e-06
cerebellar I-Disease 0 0.0008453243644908071
hemispheres I-Disease 0 2.0931292965542525e-05
and O 0 5.15497640662943e-06
brain O 0 0.01616193912923336
stem O 0 1.4727206689713057e-05
, O 0 1.7332338586584228e-07
but O 0 7.561683190715485e-08
not O 0 5.0543075502673673e-08
in O 0 9.997978622777737e-08
the O 0 1.4822450111751095e-06
cerebral O 0 0.010930345393717289
white O 0 1.7031146853696555e-05
matter O 0 3.37441065312305e-07
, O 0 9.128109468292678e-08
where O 0 9.34213488790192e-08
marked O 0 4.868599603469193e-07
reductions O 0 9.306854735768866e-07
of O 0 5.7027225608408116e-08
the O 0 1.4860892179058283e-06
cerebral O 0 0.00378628121688962
blood O 0 7.385498975054361e-06
flow O 0 1.6950655208347598e-06
and O 0 9.179647690871207e-07
oxygen O 0 5.301543933455832e-05
metabolism O 0 3.036703674297314e-05
were O 0 6.556521725542552e-07
clearly O 0 1.247376076207729e-06
demonstrated O 0 2.9128157166269375e-06
by O 0 2.222797547801747e-06
positron O 0 0.0007071637082844973
emission O 0 0.0010215674992650747
tomography O 0 0.066140316426754
( O 0 2.0490993847488426e-05
PET O 0 0.00018627352255862206
) O 0 1.0855373147933278e-05
. O 0 1.1193954378541093e-05

In O 0 8.633318793727085e-05
patients O 0 2.4273973394883797e-05
2 O 0 1.031475449053687e-06
and O 0 2.004616277417881e-07
3 O 0 2.757664958608075e-07
, O 0 7.891513575941644e-08
the O 0 5.159833449397411e-07
autopsy O 0 0.36625710129737854
findings O 0 1.543592952657491e-05
showed O 0 1.1477389307401609e-05
massive O 0 2.987242623930797e-05
demyelination B-Disease 1 0.9981608986854553
of I-Disease 0 3.245442599109083e-07
the I-Disease 0 1.2232740118633956e-05
cerebral I-Disease 1 0.5705083012580872
white I-Disease 0 1.922269439091906e-05
matter I-Disease 0 2.239766558886913e-07
with O 0 1.2783903002855368e-07
sparing O 0 5.552855100177112e-07
of O 0 5.962248650348556e-08
the O 0 3.731286994934635e-07
U O 0 0.0015856563113629818
- O 0 0.01916317455470562
fibers O 0 4.6481443860102445e-05
, O 0 8.1950204844361e-08
compatible O 0 2.5053356011994765e-07
with O 0 6.584971856682387e-08
the O 0 3.211556247606495e-07
findings O 0 6.8683461904583964e-06
of O 0 3.7536333366006147e-06
childhood O 1 0.733701229095459
ALD B-Disease 1 0.9999997615814209
. O 0 0.00018824705330189317

Oleic O 0 0.010471120476722717
and O 0 5.566551772062667e-05
erucic O 0 0.00289722578600049
acids O 0 4.763433389598504e-05
( O 0 4.852935489907395e-06
Lorenzos O 0 2.9737020668108016e-05
Oil O 0 3.645676315500168e-06
) O 0 4.3304822838763357e-07
were O 0 2.1007255668337166e-07
administered O 0 9.146859838438104e-07
to O 0 1.4011200164532056e-06
patients O 0 1.8218395325675374e-06
1 O 0 2.5451890905969776e-07
and O 0 1.3158110334643425e-07
4 O 0 3.7548181808233494e-07
, O 0 1.0816972917382373e-07
but O 0 9.559428093552924e-08
sufficient O 0 5.364067305890785e-07
effectiveness O 0 3.953487976104952e-06
was O 0 8.85293775354512e-06
not O 0 6.536974410664698e-07
obtained O 0 1.2042965863656718e-05
. O 0 1.4472625480266288e-05

The O 0 2.3367909307125956e-05
findings O 0 1.7636870325077325e-05
in O 0 1.3077886933388072e-06
this O 0 2.2848810488085292e-07
family O 0 2.007872126341681e-06
suggest O 0 3.4007405247393763e-07
that O 0 7.185797556985563e-08
delGAG291 O 0 2.3785196390235797e-06
is O 0 6.226480309123872e-08
part O 0 7.415484049033694e-08
of O 0 3.263461678670865e-08
the O 0 2.994176213633182e-07
cause O 0 3.0482574402412865e-06
of O 0 4.896551786259806e-07
Japanese O 0 0.00010040580673376098
ALD B-Disease 1 0.9999988079071045
with O 0 1.1605527106439695e-05
phenotypic O 0 0.00016289381892420352
variations O 0 0.00015562372573185712
. O 0 4.994023765902966e-05

Moreover O 0 5.2422659791773185e-05
, O 0 1.7937143184099114e-06
although O 0 3.335886731292703e-07
the O 0 1.204699060508574e-07
scale O 0 2.2183260739438992e-07
of O 0 3.13051913281015e-08
the O 0 1.2815580419101025e-07
study O 0 2.358780619715617e-07
is O 0 8.455852196220803e-08
limited O 0 4.865568712375534e-07
, O 0 7.18112573849794e-08
there O 0 3.363204115203189e-08
is O 0 2.3576598451313657e-08
a O 0 1.4193335573509103e-07
possibility O 0 3.2445512943013455e-07
that O 0 2.6414443254907383e-07
PET O 0 2.7469650376588106e-05
can O 0 6.170477604428015e-07
detect O 0 8.600619366916362e-06
an O 0 1.1810685691671097e-06
insidious B-Disease 0 0.0022485540248453617
lesion I-Disease 1 0.9366583228111267
which O 0 1.6257846482403693e-06
is O 0 4.998711915504828e-07
undetectable O 0 6.741708602930885e-06
by O 0 5.84158954097802e-07
computed O 0 9.74825888988562e-06
tomogram O 0 0.0004321172891650349
( O 0 6.812875653849915e-06
CT O 1 0.854499340057373
) O 0 7.515684501413489e-07
or O 0 7.359726055256033e-07
MRI O 0 0.0011140438728034496
analysis O 0 3.5692210076376796e-07
, O 0 7.896587561617707e-08
and O 0 5.105465561427991e-08
that O 0 3.451600250059528e-08
the O 0 7.86574148037289e-08
higher O 0 2.8630390147554863e-07
level O 0 1.1097573349161394e-07
of O 0 5.563355642834722e-08
tau O 0 1.0734120223787613e-06
reflects O 0 2.598727348868124e-07
the O 0 1.0385075910335217e-07
process O 0 1.9208708579299127e-07
of O 0 3.3978875535467523e-07
neuronal B-Disease 0 0.0003441423177719116
degeneration I-Disease 1 0.9237157106399536
in O 0 0.00021003541769459844
ALD B-Disease 1 0.9999998807907104
. O 0 0.00012162756320321932

Lorenzos O 0 0.002034100703895092
Oil O 0 6.470415974035859e-05
should O 0 1.9169119696016423e-06
be O 0 1.762166021990197e-07
given O 0 1.1825861889747102e-07
in O 0 9.727224181688143e-08
the O 0 2.2890009176990134e-07
early O 0 2.7513208351592766e-06
stage O 0 9.459465218242258e-06
. O 0 2.8223898880241904e-06
. O 0 9.339913049188908e-06

Nonsense O 0 0.0024550450034439564
mutation O 0 0.0008769963751547039
in O 0 1.7232885511475615e-05
exon O 0 0.00010976712655974552
4 O 0 2.7502926513989223e-06
of O 0 2.6864233859669184e-07
human O 0 6.85014072132617e-07
complement O 0 2.7015967134502716e-06
C9 O 0 0.00023500245879404247
gene O 0 5.081662038719514e-06
is O 0 1.7017990217027545e-07
the O 0 1.6746867004258092e-07
major O 0 4.787568173014733e-07
cause O 0 1.4892530089127831e-06
of O 0 2.8476918600972567e-07
Japanese O 0 2.8234235287527554e-05
complement B-Disease 0 0.0010084223467856646
C9 I-Disease 1 0.9999500513076782
deficiency I-Disease 1 0.998698353767395
. O 0 6.823937292210758e-05

Deficiency B-Disease 1 0.9649721384048462
of I-Disease 0 2.3707698346697725e-06
the I-Disease 0 1.3180067526263883e-06
ninth I-Disease 0 3.897097485605627e-06
component I-Disease 0 9.531296427667257e-07
of I-Disease 0 1.826961977258179e-07
human I-Disease 0 4.0339986639992276e-07
complement I-Disease 0 1.8487722854843014e-06
( O 0 1.3578439848060952e-06
C9 O 0 0.00010345636837882921
) O 0 2.930207756435266e-07
is O 0 7.314734062902062e-08
the O 0 1.4260332648063923e-07
most O 0 1.3975513013519958e-07
common O 0 8.033745871216524e-06
complement B-Disease 1 0.999797523021698
deficiency I-Disease 1 0.9999990463256836
in O 0 8.071799015851866e-07
Japan O 0 2.3696622974966886e-06
but O 0 2.219760801835946e-07
is O 0 7.15898451630892e-08
rare O 0 3.379876432063611e-07
in O 0 2.201908984034162e-07
other O 0 1.721664091292041e-07
countries O 0 6.319318117675721e-07
. O 0 7.835486030671746e-06

We O 0 1.3374045011005364e-05
studied O 0 8.442429134447593e-06
the O 0 7.880125281189976e-07
molecular O 0 2.9634268230438465e-06
basis O 0 7.320630857066135e-07
of O 0 1.7130963669842458e-06
C9 B-Disease 1 0.9999431371688843
deficiency I-Disease 1 0.9769062399864197
in O 0 8.884400131137227e-07
four O 0 9.691249260868062e-07
Japanese O 0 2.1185411242186092e-05
C9 B-Disease 1 0.9957565665245056
- I-Disease 1 0.9999120235443115
deficient I-Disease 1 0.9988784193992615
patients O 0 0.00018821923003997654
who O 0 2.7893014703295194e-05
had O 0 0.18018308281898499
suffered O 1 0.9999979734420776
from O 0 0.2549116909503937
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999997615814209
. O 0 0.00023742057965137064

Direct O 0 7.831023685866967e-05
sequencing O 0 5.639178561978042e-05
of O 0 2.009412128245458e-06
amplified O 0 5.415502891992219e-05
C9 O 0 0.0001969503500731662
cDNA O 0 3.696311614476144e-05
and O 0 2.6924685698759276e-06
DNA O 0 1.0442003258503973e-05
revealed O 0 1.7737569578457624e-05
a O 0 2.711694605750381e-06
nonsense O 0 1.1524945875862613e-05
substitution O 0 5.8642567637434695e-06
( O 0 3.573001549739274e-06
CGA O 0 0.0001738473802106455
- O 0 0.00012457054981496185
- O 0 5.677781518897973e-05
> O 0 1.8490316506358795e-05
TGA O 0 0.00015148473903536797
) O 0 8.688149932822853e-07
at O 0 5.697334586329816e-07
codon O 0 2.039055743807694e-06
95 O 0 6.515694508379966e-07
in O 0 3.3090142892433505e-07
exon O 0 4.557538886729162e-06
4 O 0 4.71900648335577e-07
in O 0 1.5533451858118497e-07
the O 0 2.850172222679248e-07
four O 0 1.2960789490534808e-06
C9 B-Disease 0 0.10367943346500397
- I-Disease 1 0.6464766263961792
deficient I-Disease 0 0.003284327918663621
individuals O 0 2.8994129479542607e-06
. O 0 1.5248459931171965e-05

An O 0 4.268636621418409e-05
allele O 0 0.0001933897437993437
- O 0 3.5147419112036005e-05
specific O 0 1.4893311117702979e-06
polymerase O 0 1.7586582544026896e-05
chain O 0 4.515283944783732e-05
reaction O 0 7.818854101060424e-06
system O 0 5.755430265708128e-06
designed O 0 2.0246572603355162e-05
to O 0 3.652528164366231e-07
detect O 0 2.7101123123429716e-06
exclusively O 0 1.7740164537372038e-07
only O 0 2.2952040268364726e-08
one O 0 1.798131066266251e-08
of O 0 1.1538765498642078e-08
the O 0 5.649737389035181e-08
normal O 0 3.4913313129436574e-07
and O 0 1.752539446897572e-07
mutant O 0 3.623195425461745e-06
alleles O 0 1.5925097613944672e-06
indicated O 0 8.768926704760815e-07
that O 0 3.138512383316083e-08
all O 0 1.2290545470250436e-08
the O 0 4.632638450630111e-08
four O 0 2.9147506097615405e-07
patients O 0 1.086325141841371e-06
were O 0 2.401487222414289e-07
homozygous O 0 1.7787203887564829e-06
for O 0 5.6884911003862726e-08
the O 0 1.5308255285617633e-07
mutation O 0 1.4651971014245646e-06
in O 0 3.2176018294194364e-07
exon O 0 4.2331107579229865e-06
4 O 0 3.927090403976763e-07
and O 0 6.85179486481502e-08
that O 0 4.769294648099276e-08
the O 0 1.9785768756719335e-07
parents O 0 7.427415766869672e-07
of O 0 2.690892415557755e-07
patient O 0 2.8175600164104253e-05
2 O 0 3.882262717525009e-06
were O 0 4.15412250731606e-06
heterozygous O 0 0.0001273710367968306
. O 0 2.2349229766405188e-05

The O 0 2.9731208996963687e-05
common O 0 2.0800598576897755e-05
mutation O 0 3.773757998715155e-05
at O 0 2.7120386221213266e-06
codon O 0 1.6340964066330343e-05
95 O 0 1.6589781353104627e-06
in O 0 5.165401262274827e-07
exon O 0 1.1517827260831837e-05
4 O 0 1.2899897683382733e-06
might O 0 5.078306912764674e-07
be O 0 8.035672038886332e-08
responsible O 0 2.781756904823851e-07
for O 0 1.251691656989351e-07
most O 0 3.987860281995381e-07
Japanese O 0 0.0001920113427331671
C9 B-Disease 1 0.9999963045120239
deficiency I-Disease 1 0.9994950294494629
. O 0 4.948999958287459e-06
. O 0 1.5999175957404077e-05

BRCA1 O 0 0.004247423727065325
required O 0 3.442075467319228e-05
for O 0 4.199035629426362e-06
transcription O 0 5.742509529227391e-05
- O 0 0.003964651841670275
coupled O 0 0.005152280442416668
repair O 0 0.023371396586298943
of O 0 1.8543732949183322e-06
oxidative O 0 0.008291134610772133
DNA O 0 0.00031687223236076534
damage O 0 0.009664326906204224
. O 0 0.00010215596557827666

The O 0 0.00025958361220546067
breast B-Disease 1 0.9997066855430603
and I-Disease 1 0.9872433543205261
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 0 0.11096315830945969
gene O 0 0.00035608571488410234
BRCA1 O 0 0.0003302017867099494
encodes O 0 2.6130939659196883e-05
a O 0 2.3791955754859373e-05
zinc O 0 0.0025286972522735596
finger O 0 7.258334517246112e-05
protein O 0 2.5381796149304137e-06
of O 0 2.7102703370474046e-07
unknown O 0 3.2923326216405258e-06
function O 0 7.667290446988773e-06
. O 0 1.1197734238521662e-05

Association O 0 4.224902659188956e-05
of O 0 1.6789770143077476e-06
the O 0 1.430004658686812e-06
BRCA1 O 0 2.5444847778999247e-05
protein O 0 8.011741670088668e-07
with O 0 1.6383219758608902e-07
the O 0 6.405581416402129e-07
DNA O 0 1.5082947356859222e-05
repair O 0 0.015460481867194176
protein O 0 4.768357939610723e-06
Rad51 O 0 5.1659699238371104e-05
and O 0 4.2016569068437093e-07
changes O 0 3.2729843724155216e-07
in O 0 9.684147528332687e-08
the O 0 1.0000115224784167e-07
phosphorylation O 0 1.4029598105480545e-06
and O 0 1.8412471547435416e-07
cellular O 0 1.3027757859163103e-06
localization O 0 8.900428269953409e-07
of O 0 5.541317449342387e-08
the O 0 1.5342411074925622e-07
protein O 0 6.435523687287059e-07
after O 0 9.225609005625302e-07
exposure O 0 2.252018930448685e-06
to O 0 3.3758303175090987e-07
DNA O 0 3.2386203656642465e-06
- O 0 3.935598215321079e-05
damaging O 0 6.972615665290505e-06
agents O 0 7.38930623356282e-07
are O 0 4.351155880044644e-08
consistent O 0 1.3648711671976343e-07
with O 0 7.589165562649214e-08
a O 0 4.538397320175136e-07
role O 0 5.965229092907975e-07
for O 0 4.769776751345489e-07
BRCA1 O 0 3.385957461432554e-05
in O 0 3.5949756238551345e-06
DNA O 0 0.00015454200911335647
repair O 1 0.9156152009963989
. O 0 4.156442082603462e-05

Here O 0 2.55182330874959e-05
, O 0 1.3881233371648705e-06
it O 0 2.7069199859397486e-07
is O 0 9.29581460695772e-08
shown O 0 2.1819084849994397e-07
that O 0 1.0727985255698513e-07
mouse O 0 6.796386060159421e-06
embryonic O 0 1.3117772141413298e-05
stem O 0 2.117638177878689e-05
cells O 0 2.2017729861545376e-05
deficient B-Disease 0 7.819040183676407e-05
in I-Disease 0 1.706886450847378e-06
BRCA1 I-Disease 0 7.142582762753591e-05
are O 0 1.850443140938296e-07
defective O 0 5.9785212215501815e-05
in O 0 2.1100902358739404e-07
the O 0 1.2861507059369615e-07
ability O 0 2.472405071785033e-07
to O 0 9.3428120351291e-08
carry O 0 2.708828503728e-07
out O 0 1.3880780613817478e-07
transcription O 0 1.6579816701778327e-06
- O 0 3.2856594771146774e-05
coupled O 0 7.611038017785177e-05
repair O 0 0.00024161052715498954
of O 0 2.3354211009518622e-07
oxidative O 0 0.0001382240152452141
DNA O 0 1.2458111086743884e-05
damage O 0 0.00023254378174897283
, O 0 4.483312352476787e-07
and O 0 2.744753544448031e-07
are O 0 1.4552178129179083e-07
hypersensitive O 0 0.0001497140183346346
to O 0 3.029657591469004e-06
ionizing O 0 0.0002842091489583254
radiation O 0 0.0017382195219397545
and O 0 5.3758280955662485e-06
hydrogen O 0 0.00018671879661269486
peroxide O 0 0.0064727249555289745
. O 0 3.302028198959306e-05

These O 0 1.5353052731370553e-05
results O 0 9.358277566207107e-06
suggest O 0 3.0064707061683293e-06
that O 0 5.535802642953058e-07
BRCA1 O 0 1.899477865663357e-05
participates O 0 2.4872360882000066e-06
, O 0 2.1395067051344085e-07
directly O 0 4.757819453971024e-07
or O 0 3.368629961642e-07
indirectly O 0 1.2039449757139664e-06
, O 0 1.3276053323352244e-07
in O 0 1.7557212572683056e-07
transcription O 0 5.1295933189976495e-06
- O 0 0.0007160466630011797
coupled O 0 0.0008000755915418267
repair O 0 0.00630983617156744
of O 0 8.029571176848549e-07
oxidative O 0 0.0023323127534240484
DNA O 0 9.869851055555046e-05
damage O 0 0.0008677126606926322
. O 0 7.140749403333757e-06
. O 0 2.1406696760095656e-05

Truncation O 0 0.008956178091466427
mutations O 0 0.0022340775467455387
in O 0 5.875127953913761e-06
the O 0 2.405207624178729e-06
transactivation O 0 5.219559170654975e-05
region O 0 2.6993200208380586e-06
of O 0 8.443037700089917e-07
PAX6 O 0 0.0010818750597536564
result O 0 4.037106918985955e-06
in O 0 2.2549202185473405e-06
dominant O 0 8.285090007120743e-05
- O 0 0.0005764993838965893
negative O 0 4.276679828763008e-05
mutants O 0 0.00011100975098088384
. O 0 1.4660701708635315e-05

PAX6 O 0 0.057385724037885666
is O 0 2.3260299713001586e-05
a O 0 5.67608731216751e-06
transcription O 0 8.331065146194305e-06
factor O 0 1.288805606236565e-06
with O 0 1.3996654502079764e-07
two O 0 2.669669356691884e-07
DNA O 0 2.233892473668675e-06
- O 0 8.3153645391576e-06
binding O 0 1.7769029909686651e-06
domains O 0 1.8778484900394687e-06
( O 0 4.216508955323661e-07
paired O 0 1.150989078269049e-06
box O 0 3.42401926900493e-06
and O 0 4.3113541892125795e-07
homeobox O 0 1.6220032193814404e-05
) O 0 2.2957277678870014e-07
and O 0 1.226791255248827e-07
a O 0 9.893338983602007e-07
proline O 0 0.00013303509331308305
- O 0 5.396139749791473e-05
serine O 0 5.28691234649159e-05
- O 0 8.277469896711409e-05
threonine O 0 0.00014030635065864772
( O 0 4.137686573812971e-06
PST O 0 0.0002003260888159275
) O 0 2.988290134453564e-06
- O 0 1.4831845874141436e-05
rich O 0 6.4197784013231285e-06
transactivation O 0 0.00013315286196302623
domain O 0 4.288028503651731e-05
. O 0 1.5208101103780791e-05

PAX6 O 0 0.025885606184601784
regulates O 0 0.001471258932724595
eye O 0 0.0006420448189601302
development O 0 7.923222256067675e-06
in O 0 1.6143592347361846e-06
animals O 0 7.930092351671192e-07
ranging O 0 1.699698486845591e-06
from O 0 1.173865030068555e-06
jellyfish O 0 9.162591595668346e-06
to O 0 8.47766727929411e-07
Drosophila O 0 7.5334050961828325e-06
to O 0 1.9143983536196174e-06
humans O 0 9.397638677910436e-06
. O 0 1.458829046896426e-05

Heterozygous O 0 0.012471474707126617
mutations O 0 0.001723575172945857
in O 0 8.403480023844168e-06
the O 0 3.6909618756908458e-06
human O 0 6.065652996767312e-06
PAX6 O 0 0.0006773413042537868
gene O 0 1.4949140677344985e-05
result O 0 1.4746635770279681e-06
in O 0 3.6183158158564765e-07
various O 0 4.415118723954947e-07
phenotypes O 0 1.957704807864502e-05
, O 0 4.060623268742347e-07
including O 0 1.2645710967262858e-06
aniridia B-Disease 1 0.9999994039535522
, O 0 0.0025364691391587257
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999991655349731
, O 0 3.533939889166504e-05
autosomal B-Disease 0 0.33028319478034973
dominant I-Disease 0 0.0007668515900149941
keratitis I-Disease 0 0.4352376461029053
, O 0 4.665910637413617e-06
and O 0 1.6684674847056158e-05
familial B-Disease 1 0.8872743248939514
foveal I-Disease 1 0.9997127652168274
dysplasia I-Disease 1 0.9999896287918091
. O 0 0.00022680600523017347

It O 0 9.039692486112472e-06
is O 0 1.380914000037592e-06
believed O 0 9.267433256354707e-07
that O 0 2.0752500518028683e-07
the O 0 4.860407329942973e-07
mutated O 0 1.5064979379530996e-05
allele O 0 9.65070921665756e-06
of O 0 4.824758548238606e-07
PAX6 O 0 7.207438466139138e-05
produces O 0 2.6471864202903816e-06
an O 0 3.8195315710254363e-07
inactive O 0 2.6845636966754682e-06
protein O 0 8.800040518508467e-07
and O 0 3.3345699534947926e-07
aniridia B-Disease 1 0.997050404548645
is O 0 1.069049858415383e-06
caused O 0 9.916455383063294e-06
due O 0 6.135702278697863e-06
to O 0 2.9914210699644173e-06
genetic O 0 6.815553933847696e-05
haploinsufficiency O 0 0.006223226431757212
. O 0 5.724712536903098e-05

However O 0 2.7447391403256916e-05
, O 0 1.8086551563101239e-06
several O 0 7.611103569615807e-07
truncation O 0 8.846777927828953e-05
mutations O 0 3.222827581339516e-05
have O 0 4.4768776774617436e-07
been O 0 3.1103934361453867e-07
found O 0 3.314772243356856e-07
to O 0 2.1108047576490208e-07
occur O 0 1.7890420167532284e-07
in O 0 1.2602077958945301e-07
the O 0 7.561091024399502e-07
C O 0 5.8830049965763465e-05
- O 0 1.218373654410243e-05
terminal O 0 2.823717295541428e-06
half O 0 1.4001433612520486e-07
of O 0 1.1342373085199142e-07
PAX6 O 0 0.00026697758585214615
in O 0 4.107770564587554e-06
patients O 0 5.19100376550341e-06
with O 0 1.0818102964549325e-06
Aniridia B-Disease 1 0.9982777833938599
resulting O 0 4.792319487023633e-06
in O 0 4.646062166102638e-07
mutant O 0 4.992702997697052e-06
proteins O 0 4.194074278984772e-07
that O 0 6.971731636440381e-08
retain O 0 3.157414312227047e-07
the O 0 9.007647605585589e-08
DNA O 0 1.0950426485578646e-06
- O 0 5.182017503102543e-06
binding O 0 7.117960194591433e-07
domains O 0 5.930175461799081e-07
but O 0 8.774299686820086e-08
have O 0 6.77186520192663e-08
lost O 0 5.712481083719467e-07
most O 0 3.7203992775403094e-08
of O 0 8.739258561263341e-08
the O 0 1.3195046904002083e-06
transactivation O 0 0.00016393141413573176
domain O 0 2.9784188882331364e-05
. O 0 1.4441756320593413e-05

It O 0 9.446591320738662e-06
is O 0 7.978657095009112e-07
not O 0 1.7320292045042152e-07
clear O 0 2.1764222424280888e-07
whether O 0 2.110911481167932e-07
such O 0 1.6737654107146227e-07
mutants O 0 6.337655213428661e-05
really O 0 1.6081592093541985e-06
behave O 0 1.2306212511248305e-06
as O 0 2.4637762408019626e-07
loss O 0 5.429157681646757e-06
- O 0 3.0075605081947288e-06
of O 0 8.770233961286067e-08
- O 0 1.0449104593135417e-05
function O 0 5.003724368179974e-07
mutants O 0 4.213781721773557e-06
as O 0 3.5642787565848266e-07
predicted O 0 4.750614607473835e-06
by O 0 2.0616205347323557e-06
haploinsufficiency O 0 0.0005196678102947772
. O 0 2.22772632696433e-05

Contrary O 0 7.441538036800921e-05
to O 0 2.979258397317608e-06
this O 0 3.11569891664476e-07
theory O 0 4.453678172922082e-07
, O 0 9.37499677888809e-08
our O 0 7.186619654930837e-08
data O 0 3.7378654837993963e-07
showed O 0 6.635016234213253e-07
that O 0 5.631394373040166e-08
these O 0 6.345485559222652e-08
mutants O 0 2.5994834231823916e-06
are O 0 9.413754753495596e-08
dominant O 0 2.8035635750711663e-06
- O 0 1.4131507668935228e-05
negative O 0 1.8617517980601406e-06
in O 0 4.288467891910841e-07
transient O 0 1.4459341400652193e-05
transfection O 0 0.0003017091366928071
assays O 0 3.8241472793743014e-05
when O 0 9.844681017057155e-07
they O 0 1.859708049778419e-07
are O 0 9.995729755019056e-08
coexpressed O 0 6.023301921231905e-06
with O 0 6.051487275726686e-07
wild O 0 5.925194273004308e-06
- O 0 0.0011289395624771714
type O 0 0.00027531900559552014
PAX6 O 0 0.003286270424723625
. O 0 3.418561755097471e-05

We O 0 1.2461010555853136e-05
found O 0 3.2580935567239067e-06
that O 0 3.452107648627134e-07
the O 0 5.067465167485352e-07
dominant O 0 2.1438547264551744e-05
- O 0 0.0003083313349634409
negative O 0 3.457485263425042e-06
effects O 0 1.5457642348337686e-06
result O 0 2.2045460923436622e-07
from O 0 1.0866830280065187e-07
the O 0 1.2548638039788784e-07
enhanced O 0 2.260602286696667e-06
DNA O 0 1.7340699969281559e-06
binding O 0 1.0350149750593118e-06
ability O 0 6.843963546998566e-07
of O 0 2.802232756948797e-07
these O 0 1.525677816971438e-06
mutants O 0 8.976353274192661e-05
. O 0 1.582735603733454e-05

Kinetic O 0 0.00032551123877055943
studies O 0 1.4974096302466933e-05
of O 0 8.638363055979426e-07
binding O 0 4.557304237096105e-06
and O 0 8.64407468270656e-07
dissociation O 0 2.1659647245542146e-05
revealed O 0 9.772683370101731e-06
that O 0 1.1291033530369532e-07
various O 0 2.0543377843296184e-07
truncation O 0 1.695541686785873e-05
mutants O 0 1.8910732251242734e-05
have O 0 3.3002814348037646e-07
3 O 0 7.216880248961388e-07
- O 0 5.23571088706376e-06
5 O 0 7.197772333711328e-07
- O 0 4.732369234261569e-06
fold O 0 2.051572664640844e-06
higher O 0 2.855001355328568e-07
affinity O 0 4.048420407798403e-07
to O 0 8.987602484467061e-08
various O 0 1.0389335614036099e-07
DNA O 0 9.866486152532161e-07
- O 0 4.355292730906513e-06
binding O 0 6.266153604883584e-07
sites O 0 3.3350147532473784e-07
when O 0 1.5315424661821453e-07
compared O 0 2.2380692143997294e-07
with O 0 9.004040180116135e-08
the O 0 5.522014134839992e-07
wild O 0 6.75368437441648e-06
- O 0 0.0019793447572737932
type O 0 0.0002510625054128468
PAX6 O 0 0.0035554911009967327
. O 0 4.651319613913074e-05

These O 0 7.406842996715568e-06
results O 0 4.502608135226183e-06
provide O 0 6.228571010069572e-07
a O 0 7.335173677347484e-07
new O 0 8.741656642996531e-07
insight O 0 1.665369609327172e-06
into O 0 1.6143209791152913e-07
the O 0 1.7725231771237304e-07
role O 0 3.7765309457427065e-07
of O 0 3.0712467946614197e-07
mutant O 0 2.5802883101277985e-05
PAX6 O 0 0.00023922203399706632
in O 0 5.020338448957773e-06
causing O 0 0.00022047954553272575
aniridia B-Disease 1 0.9996052384376526
. O 0 1.60640302055981e-05
. O 0 3.3172032999573275e-05

Reversal O 0 0.0038346832152456045
of O 0 0.00010638270032359287
severe O 1 0.9999873638153076
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 0.0009097695001401007
excellent O 0 7.810314127709717e-05
neuropsychologic O 0 0.050680387765169144
outcome O 0 1.2780317774740979e-05
in O 0 1.4010679478815291e-06
very B-Disease 0 1.8808058257491211e-06
- I-Disease 0 5.9634327044477686e-05
long I-Disease 0 6.710253273922717e-06
- I-Disease 0 5.260981561150402e-05
chain I-Disease 0 3.7087189411977306e-05
acyl I-Disease 0 6.88318905304186e-05
- I-Disease 0 0.00010285514872521162
coenzyme I-Disease 0 8.98836151463911e-05
A I-Disease 0 0.0005559278069995344
dehydrogenase I-Disease 1 0.9980839490890503
deficiency I-Disease 1 0.9781244993209839
. O 0 3.275582639616914e-05

Very B-Disease 0 6.347635644488037e-05
- I-Disease 0 0.000182790492544882
long I-Disease 0 1.909166712721344e-05
- I-Disease 0 4.357849320513196e-05
chain I-Disease 0 2.8982243748032488e-05
acyl I-Disease 0 5.4836375056765974e-05
- I-Disease 0 3.963767449022271e-05
coenzyme I-Disease 0 1.726262598822359e-05
A I-Disease 0 1.2955257261637598e-05
dehydrogenase I-Disease 0 0.0006985984509810805
( I-Disease 0 1.192605668620672e-05
VLCAD I-Disease 1 0.6373303532600403
) I-Disease 0 0.000610395974945277
deficiency I-Disease 0 0.292398601770401
is O 0 4.4945713284505473e-07
a O 0 1.8068922145175748e-05
disorder O 0 0.11086229979991913
of O 0 4.323120776916767e-07
fatty O 0 1.9972263544332236e-05
acid O 0 6.673990355920978e-06
beta O 0 1.7987849787459709e-06
oxidation O 0 1.923699073813623e-06
that O 0 1.6746292885727598e-07
reportedly O 0 2.3856141524447594e-06
has O 0 4.768948542732687e-07
high O 0 1.95969414562569e-06
rates O 0 2.622191232148907e-06
of O 0 1.4323591130960267e-06
morbidity O 1 0.6586609482765198
and O 0 4.7391113184858114e-05
mortality O 0 0.0007300428696908057
. O 0 4.427642488735728e-05

We O 0 7.184932201198535e-06
describe O 0 4.8457764023623895e-06
the O 0 6.118851274550252e-07
outcome O 0 6.968586490074813e-07
of O 0 1.0850096288095301e-07
a O 0 5.583520987784141e-07
5 O 0 5.809012009194703e-07
- O 0 9.154136932920665e-06
year O 0 3.2064087918115547e-07
- O 0 1.7866439520730637e-05
old O 0 1.4872382052999455e-05
girl O 0 5.3295552788767964e-05
with O 0 9.561538900015876e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 4.94093637826154e-06
was O 0 7.2964903665706515e-06
first O 0 5.877789703845337e-07
seen O 0 6.355041932692984e-07
at O 0 1.8951075730910816e-07
5 O 0 1.9305933562918653e-07
months O 0 3.4869856335717486e-07
of O 0 7.252551625924752e-08
age O 0 1.0576605973255937e-06
with O 0 1.1758732398448046e-05
severe O 1 0.9999957084655762
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 1 0.9155307412147522
hepatomegaly B-Disease 1 1.0
, O 0 0.36293312907218933
encephalopathy B-Disease 1 0.9996144771575928
, O 0 9.485454938840121e-06
and O 0 1.881679054349661e-05
hypotonia B-Disease 1 0.9857048988342285
. O 0 5.861976387677714e-05

Biochemical O 0 0.009601314552128315
studies O 0 0.0021453246008604765
indicated O 1 0.999967098236084
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.000911122711841017
by O 0 2.122568503182265e-06
a O 0 6.163711532281013e-06
stable O 0 0.00021318145445547998
yet O 0 1.0216102054982912e-05
inactive O 0 0.00010973394091706723
enzyme O 0 8.342082583112642e-05
. O 0 2.160394797101617e-05

Molecular O 0 0.0012515687849372625
genetic O 0 0.00011916575749637559
analysis O 0 1.004404930426972e-05
of O 0 9.31992929054104e-07
her O 0 1.920909562613815e-05
VLCAD O 0 0.02600480429828167
gene O 0 3.491064489935525e-05
revealed O 0 2.1386536900536157e-05
a O 0 4.975851879862603e-06
T1372C O 0 5.671125472872518e-05
( O 0 4.4068415263609495e-06
F458L O 0 5.4384709073929116e-05
) O 0 3.860068318317644e-06
missense O 0 7.917744369478896e-05
mutation O 0 1.4146663488645572e-05
and O 0 1.0754931736300932e-06
a O 0 2.3892660465207882e-05
1668 O 1 0.9640054702758789
ACAG O 1 0.6617175340652466
1669 O 0 0.031353265047073364
splice O 0 0.0018652741564437747
site O 0 0.0004583325353451073
mutation O 0 0.0005132493679411709
. O 0 6.863164890091866e-05

After O 0 0.000157686707098037
initial O 0 7.778374856570736e-05
treatment O 0 5.333653825800866e-05
with O 0 1.9584667825256474e-06
intravenous O 0 4.2864376155193895e-05
glucose O 0 0.00015287571295630187
and O 0 1.6750076383686974e-06
carnitine O 0 9.641357610234991e-05
, O 0 1.5440109280007164e-07
the O 0 3.049078429739893e-07
patient O 0 6.3044772105058655e-06
has O 0 5.954123025730951e-07
thrived O 0 2.691744384719641e-06
on O 0 4.4838895973953186e-07
a O 0 7.121294061107619e-07
low O 0 9.53533799474826e-06
- O 0 5.7980476412922144e-05
fat O 0 5.809133654111065e-06
diet O 0 2.448359737172723e-06
supplemented O 0 1.4154919654174591e-06
with O 0 1.501272492987482e-07
medium O 0 2.19763683162455e-06
- O 0 4.300186446926091e-06
chain O 0 3.969695626437897e-06
triglyceride O 0 3.8115442748676287e-06
oil O 0 1.4151884215607424e-06
and O 0 4.7390307145178667e-07
carnitine O 0 3.821591235464439e-05
and O 0 5.749619731432176e-07
avoidance O 0 1.032669115375029e-05
of O 0 1.3070392697045463e-06
fasting O 0 0.00019574225007090718
. O 0 2.4757777282502502e-05

Her O 0 0.0030289767310023308
ventricular O 1 0.999237060546875
hypertrophy O 1 0.9947590231895447
resolved O 0 0.000280690670479089
significantly O 0 3.2155086955754086e-05
over O 0 1.3930738305134582e-06
1 O 0 5.312597863849078e-07
year O 0 3.942438127069181e-07
, O 0 1.2514506408933812e-07
and O 0 3.186329422533163e-07
cognitively O 0 0.00023168684856500477
, O 0 2.40905421833304e-07
she O 0 2.39531829038242e-07
is O 0 3.897086386928095e-08
in O 0 5.6369284351376336e-08
the O 0 1.0488629698102159e-07
superior O 0 1.984318714676192e-06
range O 0 1.3111279031363665e-06
for O 0 8.149721111294639e-07
age O 0 7.343506695178803e-06
. O 0 1.1286730114079546e-05

Clinical O 0 0.0003670483420137316
recognition O 0 3.1842002499615774e-05
of O 0 0.00012669680290855467
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.3412671933110687e-06
important O 0 1.5468097558368754e-07
because O 0 1.4111813584349875e-07
it O 0 5.527700253082912e-08
is O 0 2.1436829200638385e-08
one O 0 1.5137853637270382e-08
of O 0 1.3515654373463803e-08
the O 0 1.307833059627228e-07
few O 0 4.160781656992185e-07
directly O 0 1.2124483873776626e-05
treatable O 0 0.03657275065779686
causes O 0 8.473969501210377e-06
of O 0 1.976957719307393e-06
cardiomyopathy B-Disease 1 1.0
in O 0 7.91472484706901e-05
children O 0 1.1439525223977398e-05
. O 0 2.1014459434809396e-06
. O 0 1.1173560778843239e-05

Cloning O 0 0.00015154224820435047
of O 0 3.6359681416797685e-06
a O 0 2.271925040986389e-06
novel O 0 1.5744143411211553e-06
member O 0 4.281492351765337e-07
of O 0 9.05099497572337e-08
the O 0 6.054165737623407e-07
low O 0 9.7811316663865e-06
- O 0 6.0065627621952444e-05
density O 0 1.0256359928462189e-05
lipoprotein O 0 0.000522804562933743
receptor O 0 9.807171591091901e-05
family O 0 3.817581455223262e-05
. O 0 2.0870740627287887e-05

A O 0 0.0001700264838291332
gene O 0 0.00017950245819520205
encoding O 0 5.201988824410364e-05
a O 0 1.0704214219003916e-05
novel O 0 1.0014780855271965e-05
transmembrane O 0 2.7890835553989746e-05
protein O 0 3.620325287556625e-06
was O 0 4.2953051888616756e-06
identified O 0 6.587810617020295e-07
by O 0 2.0904613506900205e-07
DNA O 0 6.651837907156732e-07
sequence O 0 3.5181071211809467e-07
analysis O 0 3.417585219267494e-07
within O 0 2.9672369805666676e-07
the O 0 1.3529706848203205e-06
insulin B-Disease 0 0.29254335165023804
- I-Disease 1 0.9978858828544617
dependent I-Disease 1 0.9865735769271851
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 4.951431037625298e-05
IDDM B-Disease 0 0.03041127882897854
) O 0 8.338027328136377e-06
locus O 0 5.482362030306831e-05
IDDM4 O 0 0.00023566866002511233
on O 0 2.746993959590327e-05
chromosome O 0 0.0002833231701515615
11q13 O 0 0.0006555145373567939
. O 0 5.205412526265718e-05

Based O 0 3.849944187095389e-05
on O 0 3.5689217838807963e-06
its O 0 2.809773150147521e-06
chromosomal O 0 0.00032945029670372605
position O 0 5.2769005378650036e-06
, O 0 2.023587910571223e-07
this O 0 1.2716492392428336e-07
gene O 0 6.827294214417634e-07
is O 0 5.065193775521948e-08
a O 0 2.0799457445264125e-07
candidate O 0 3.937448127544485e-07
for O 0 1.7130966512013401e-07
conferring O 0 1.9652879927889444e-05
susceptibility O 0 0.0022330456413328648
to O 0 0.0002705815713852644
diabetes B-Disease 1 0.9975103139877319
. O 0 5.2739564125658944e-05

The O 0 3.584484875318594e-05
gene O 0 9.893673268379644e-05
, O 0 4.477280072023859e-06
termed O 0 3.0143713956931606e-05
low O 0 1.9937575416406617e-05
- O 0 5.087148383609019e-05
density O 0 7.184014066297095e-06
lipoprotein O 0 8.790402353042737e-05
receptor O 0 1.1345493476255797e-05
related O 0 2.2410965812014183e-06
protein O 0 1.7350179177810787e-06
5 O 0 6.80376501804858e-07
( O 0 1.0151034075533971e-06
LRP5 O 0 8.329809497809038e-05
) O 0 2.558440144184715e-07
, O 0 7.035248472675448e-08
encodes O 0 4.907439574708405e-07
a O 0 2.1033838493167423e-07
protein O 0 3.547526432612358e-07
of O 0 9.693258107290603e-08
1615 O 0 7.356979767791927e-05
amino O 0 9.393376103616902e-07
acids O 0 4.43375199665752e-07
that O 0 5.679828518623253e-08
contains O 0 1.0355821444818503e-07
conserved O 0 3.677455708839261e-07
modules O 0 1.1028872677343315e-06
which O 0 1.1386690346171235e-07
are O 0 2.1109189063395206e-08
characteristic O 0 1.8946774105188524e-07
of O 0 4.9668827273308125e-08
the O 0 8.12061955457466e-07
low O 0 3.3530279324622825e-05
- O 0 0.0004968910361640155
density O 0 2.2664569769403897e-05
lipoprotein O 0 0.001060960697941482
( O 0 1.3445659533317667e-05
LDL O 0 0.00022458804596681148
) O 0 7.882103091105819e-06
receptor O 0 5.837147909915075e-05
family O 0 3.0637234885944054e-05
. O 0 1.7959489923669025e-05

These O 0 1.067756147676846e-05
modules O 0 1.680056084296666e-05
include O 0 1.3342223610379733e-06
a O 0 1.0877485010496457e-06
putative O 0 9.436020263819955e-06
signal O 0 5.386409156926675e-06
peptide O 0 1.6209280602197396e-06
for O 0 1.4095620315401902e-07
protein O 0 3.5582399959821487e-07
export O 0 2.2710210600962455e-07
, O 0 7.355418318866214e-08
four O 0 2.1982685893817688e-07
epidermal O 0 1.4756815289729275e-05
growth O 0 3.491405323075014e-06
factor O 0 2.809175612128456e-06
( O 0 1.5262598935805727e-06
EGF O 0 3.994656799477525e-05
) O 0 7.656817047063669e-07
repeats O 0 3.9394008126691915e-06
with O 0 3.7023878007858e-07
associated O 0 2.4054829736996908e-06
spacer O 0 4.04027450713329e-05
domains O 0 5.7651368479127996e-06
, O 0 4.386596117456065e-07
three O 0 5.557151325774612e-07
LDL O 0 0.0001378658489556983
- O 0 0.00010818780720001087
receptor O 0 1.64719076565234e-05
( O 0 1.4924447668818175e-06
LDLR O 0 6.052203752915375e-05
) O 0 5.147918500369997e-07
repeats O 0 2.659829306139727e-06
, O 0 1.1825038370716356e-07
a O 0 2.941025343261572e-07
single O 0 6.833130896666262e-07
transmembrane O 0 3.2396058031736175e-06
spanning O 0 1.1478879287096788e-06
domain O 0 1.2013459809168126e-06
, O 0 1.5636391026419005e-07
and O 0 1.6741007868859015e-07
a O 0 2.073035830107983e-06
cytoplasmic O 0 3.9453196222893894e-05
domain O 0 3.251301677664742e-05
. O 0 2.46542040258646e-05

The O 0 1.3184493582230061e-05
encoded O 0 2.016175858443603e-05
protein O 0 4.423013706400525e-06
has O 0 3.9844277921474713e-07
a O 0 2.074573046684236e-07
unique O 0 1.6021493820517207e-07
organization O 0 2.5473576670265174e-07
of O 0 1.766316728435413e-07
EGF O 0 2.686856714717578e-05
and O 0 5.830913778481772e-07
LDLR O 0 0.000124892991152592
repeats O 0 1.7300762920058332e-05
; O 0 7.721449151176785e-07
therefore O 0 5.062653940512973e-07
, O 0 2.61399634382542e-07
LRP5 O 0 0.00011769375123549253
likely O 0 1.8003346440309542e-06
represents O 0 5.07855361320253e-07
a O 0 3.934505343750061e-07
new O 0 5.207497792980575e-07
category O 0 4.841448344450328e-07
of O 0 1.4109242840731895e-07
the O 0 1.8062626168102724e-06
LDLR O 0 0.011260724626481533
family O 0 8.298936154460534e-05
. O 0 1.9223389244871214e-05

Both O 0 1.7705660866340622e-05
human O 0 6.433421276597073e-06
and O 0 2.5931694835890085e-06
mouse O 0 4.573227488435805e-05
LRP5 O 0 0.0007371843094006181
cDNAs O 0 9.911283268593252e-05
have O 0 7.704016411480552e-07
been O 0 4.55738131677208e-07
isolated O 0 9.505951652499789e-07
and O 0 1.0609736733613317e-07
the O 0 9.85353167948233e-08
encoded O 0 6.180625291563047e-07
mature O 0 3.6871412589789543e-07
proteins O 0 1.416607346982346e-07
are O 0 1.518397674260541e-08
95 O 0 1.2643066327200359e-07
% O 0 6.294375509696692e-08
identical O 0 8.421276902481623e-07
, O 0 8.392593286998817e-08
indicating O 0 1.110299990614294e-06
a O 0 7.46952480312757e-07
high O 0 1.7589937897355412e-06
degree O 0 7.261908194777789e-07
of O 0 2.7196352903047227e-07
evolutionary O 0 8.28599604574265e-06
conservation O 0 4.331773197918665e-06
. O 0 2.4918610961321974e-06
. O 0 1.7445601770305075e-05

The O 0 4.878869003732689e-05
APC B-Disease 0 0.0002821674570441246
variants O 0 3.5885863326257095e-05
I1307K O 0 4.6851080696797e-05
and O 0 1.2672850289163762e-06
E1317Q O 0 1.5256344340741634e-05
are O 0 2.9550434987868357e-07
associated O 0 1.1871385140693747e-05
with O 1 0.9505166411399841
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.289309385465458e-05
but O 0 6.793391662540671e-07
not O 0 1.1588085868652342e-07
always O 0 5.4930165305222545e-08
with O 0 5.539024527934089e-08
a O 0 1.8515389683670946e-06
family O 0 1.8254802853334695e-05
history O 0 5.599782070930814e-06
. O 0 2.2636359062744305e-05

Classical O 0 0.12276610732078552
familial B-Disease 1 0.9999991655349731
adenomatous I-Disease 1 0.9999984502792358
polyposis I-Disease 1 0.9999998807907104
( O 0 0.020791521295905113
FAP B-Disease 0 0.05765143409371376
) O 0 7.247100256790873e-06
is O 0 8.275724212580826e-07
a O 0 1.8225694020657102e-06
high O 0 4.088876812602393e-05
- O 1 0.6788186430931091
penetrance O 1 0.7949835062026978
autosomal B-Disease 1 0.9988362193107605
dominant I-Disease 1 0.9296275973320007
disease I-Disease 0 0.0916890874505043
that O 0 6.300081167864846e-07
predisposes O 0 9.982399205910042e-06
to O 0 2.07565364007678e-07
hundreds O 0 1.925496491139711e-07
or O 0 1.9082430924299842e-07
thousands O 0 2.603460416139569e-07
of O 0 1.2634579434234183e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.983590304851532
carcinoma I-Disease 1 1.0
and O 0 7.09091909811832e-06
that O 0 4.447053356670949e-07
results O 0 1.686609493845026e-06
from O 0 9.40034794894018e-07
truncating O 0 0.0001015727684716694
mutations O 0 1.7339034457108937e-05
in O 0 7.895816906966502e-07
the O 0 2.742963488344685e-06
APC B-Disease 0 0.0004244439478497952
gene O 0 0.00010314498649677262
. O 0 2.2669973986921832e-05

A O 0 0.00019351791706867516
variant O 0 0.00041362864430993795
of O 0 1.2888073797512334e-05
FAP B-Disease 0 0.0024294168688356876
is O 0 5.975631938781589e-05
attenuated B-Disease 1 0.9570835828781128
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999963045120239
coli I-Disease 1 0.9999639987945557
, O 0 2.707164867388201e-06
which O 0 6.407964292520774e-07
results O 0 6.191680768097285e-07
from O 0 6.384211701515596e-07
germ O 0 0.003325928468257189
- O 0 0.0069349524565041065
line O 0 3.182458021910861e-05
mutations O 0 1.905720409922651e-06
in O 0 9.451644444880003e-08
the O 0 1.321845672919153e-07
5 O 0 2.388818813869875e-07
and O 0 9.322945260237248e-08
3 O 0 2.0011457024793344e-07
regions O 0 1.6543758363241068e-07
of O 0 9.011703383521308e-08
the O 0 1.8383115047981846e-06
APC B-Disease 0 0.0001951185695361346
gene O 0 5.842493919772096e-05
. O 0 1.5351370166172273e-05

Attenuated B-Disease 1 0.9999369382858276
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
patients O 1 0.9814392924308777
have O 0 1.2898057320853695e-05
" O 0 6.702131486235885e-06
multiple O 0 8.396016346523538e-05
" O 1 0.6629400849342346
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
( O 0 1.387542943120934e-05
typically O 0 1.725763468130026e-06
fewer O 0 2.8312007316344534e-07
than O 0 6.225649684665768e-08
100 O 0 1.414808963318137e-07
) O 0 1.3641736984482122e-07
without O 0 1.2009297734039137e-07
the O 0 8.027795388443337e-07
florid O 0 0.0004682814178522676
phenotype O 0 0.0002339100174140185
of O 0 2.019515477513778e-06
classical O 0 5.572771260631271e-05
FAP B-Disease 0 0.0039855982176959515
. O 0 3.384640149306506e-05

Another O 0 4.1712533857207745e-05
group O 0 1.4855287190584932e-05
of O 0 9.526261806058756e-07
patients O 0 2.8109338927606586e-06
with O 0 3.6276480841479497e-07
multiple O 0 8.08404729468748e-06
adenomas B-Disease 0 0.00067365966970101
has O 0 1.7114469983425806e-06
no O 0 5.211606435295835e-07
mutations O 0 2.5783097044040915e-06
in O 0 1.7832932996952877e-07
the O 0 4.685959424932662e-07
APC B-Disease 0 1.3762713024334516e-05
gene O 0 1.1171472351634293e-06
, O 0 7.493313347595176e-08
and O 0 8.616381563797404e-08
their O 0 4.926050110043434e-07
phenotype O 0 0.0012209794949740171
probably O 0 2.6898583200818393e-06
results O 0 5.995651122248091e-07
from O 0 1.4687154248349543e-07
variation O 0 6.439115054490685e-07
at O 0 2.9891290864725306e-07
a O 0 9.002475280794897e-07
locus O 0 5.576578132604482e-06
, O 0 2.2082092243635998e-07
or O 0 4.073857837738615e-07
loci O 0 1.537435537102283e-06
, O 0 1.4772182055367011e-07
elsewhere O 0 5.041396775595786e-07
in O 0 5.197867380957177e-07
the O 0 1.80244603598112e-06
genome O 0 3.9466180169256404e-05
. O 0 2.4039734853431582e-05

Recently O 0 0.0004485055978875607
, O 0 4.31150783697376e-06
however O 0 1.4936138086341089e-06
, O 0 3.565710073871742e-07
a O 0 9.596180916560115e-07
missense O 0 2.0454248442547396e-05
variant O 0 1.4222484423953574e-05
of O 0 4.742652208733489e-07
APC B-Disease 0 0.00011467393051134422
( O 0 1.700961661299516e-06
I1307K O 0 7.87735370977316e-06
) O 0 4.855472752751666e-07
was O 0 3.0066312319831923e-06
described O 0 1.2167411114205606e-06
that O 0 1.1099012198201308e-07
confers O 0 1.402704356223694e-06
an O 0 2.7550390768738e-07
increased O 0 8.825659278954845e-06
risk O 0 1.549747867102269e-05
of O 0 0.0029534115456044674
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.7360550777520984e-06
including O 0 9.279885375690355e-07
multiple O 0 1.659159897826612e-05
adenomas B-Disease 0 0.00101132458075881
, O 0 3.7163008528295904e-06
in O 0 1.077293109119637e-05
Ashkenazim O 0 0.0008514057262800634
. O 0 4.193552740616724e-05

We O 0 1.5287338101188652e-05
have O 0 2.0756449430336943e-06
studied O 0 2.43972203861631e-06
a O 0 6.920920441189082e-07
set O 0 3.4576561347421375e-07
of O 0 1.4473397413894418e-07
164 O 0 1.0698447113099974e-05
patients O 0 5.226436314842431e-06
with O 0 6.160238172014942e-06
multiple O 1 0.9985246062278748
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 0 0.17687515914440155
/ I-Disease 1 0.9997501969337463
or I-Disease 0 0.14546988904476166
carcinoma I-Disease 1 1.0
and O 0 7.772731805744115e-06
analyzed O 0 2.7860211048391648e-05
codons O 0 4.672467548516579e-05
1263 O 0 0.0008247939986176789
- O 0 0.0005211211973801255
1377 O 0 0.0009328643791377544
( O 0 4.481193172978237e-06
exon O 0 2.4928593120421283e-05
15G O 0 1.9940025595133193e-05
) O 0 2.677920747373719e-07
of O 0 5.088579158041284e-08
the O 0 2.7380710321267543e-07
APC B-Disease 0 1.3671417036675848e-05
gene O 0 2.614435288705863e-06
for O 0 5.816839916406025e-07
germ O 0 0.0003181490465067327
- O 0 0.0001868231629487127
line O 0 3.9970957004697993e-05
variants O 0 7.07486760802567e-05
. O 0 1.8503300452721305e-05

Three O 0 3.765554356505163e-05
patients O 0 2.4702309019630775e-05
with O 0 8.485254738843651e-07
the O 0 9.097740871766291e-07
I1307K O 0 3.246697815484367e-05
allele O 0 2.3251983293448575e-05
were O 0 8.365773283003364e-07
detected O 0 4.050956249557203e-06
, O 0 1.5550023135801894e-07
each O 0 2.422264060442103e-07
of O 0 8.222410201597086e-07
Ashkenazi O 0 0.0009718936635181308
descent O 0 0.0005370280705392361
. O 0 4.785118653671816e-05

Four O 0 5.678702291334048e-05
patients O 0 0.00010620856483001262
had O 0 7.499041203118395e-06
a O 0 4.868604264629539e-06
germ O 0 0.0008135169628076255
- O 0 0.00017470434249844402
line O 0 1.5078576325322501e-05
E1317Q O 0 2.546817449911032e-05
missense O 0 2.70077507593669e-05
variant O 0 1.3210408724262379e-05
of O 0 3.5755954286287306e-07
APC O 0 4.483293741941452e-05
that O 0 1.7926524265021726e-07
was O 0 1.4304793012342998e-06
not O 0 3.932209224899452e-08
present O 0 6.747522718342225e-08
in O 0 1.1384279474668801e-07
controls O 0 2.0839970602537505e-05
; O 0 9.24457381756838e-08
one O 0 1.606337463044838e-08
of O 0 1.295614726615213e-08
these O 0 1.8994983363995743e-08
individuals O 0 1.505774349652711e-08
had O 0 3.2960636531242926e-07
an O 0 6.552846798513201e-08
unusually O 0 3.4861020594689762e-06
large O 0 1.0411414308464373e-07
number O 0 7.464184648142691e-08
of O 0 1.5210578396818164e-07
metaplastic B-Disease 0 0.001865828176960349
polyps I-Disease 0 6.042550376150757e-05
of I-Disease 0 5.342940880836977e-07
the I-Disease 0 3.954407929995796e-06
colorectum I-Disease 0 0.0015979702584445477
. O 0 3.276882489444688e-05

There O 0 7.934570930956397e-06
is O 0 8.217040203817305e-07
increasing O 0 8.692732649251411e-07
evidence O 0 2.6379427708889125e-07
that O 0 1.0690074248032033e-07
there O 0 9.41589064495929e-08
exist O 0 2.97802131399294e-07
germ O 0 2.5004566850839183e-05
- O 0 1.1389102837711107e-05
line O 0 1.1422935131122358e-06
variants O 0 5.237935738477972e-07
of O 0 5.1534836842392906e-08
the O 0 3.756207718197402e-07
APC B-Disease 0 1.4798558368056547e-05
gene O 0 1.3346168543648673e-06
that O 0 6.673848673699467e-08
predispose O 0 8.33144213174819e-07
to O 0 7.38319272386434e-08
the O 0 7.663568624138861e-08
development O 0 2.094995608104e-07
of O 0 4.4800128762290115e-07
multiple O 1 0.95225989818573
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9954960346221924
carcinoma I-Disease 1 1.0
, O 0 2.2388148863683455e-06
but O 0 2.558874712121906e-07
without O 0 2.6068241254506574e-07
the O 0 5.840753374286578e-07
florid O 0 0.00026183383306488395
phenotype O 0 4.6650500735268e-05
of O 0 2.0866650629614014e-07
classical O 0 2.586421942396555e-06
FAP B-Disease 0 6.591353303520009e-05
, O 0 2.369630038856485e-07
and O 0 8.472690637972846e-08
possibly O 0 1.7152478903881274e-07
with O 0 9.706540993192903e-08
importance O 0 1.176318164652912e-06
for O 1 0.7697268724441528
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 5.149679054738954e-05
in O 0 7.291527026609401e-07
the O 0 5.37992264071363e-07
general O 0 2.1030218704254366e-06
population O 0 1.0451310572534567e-06
. O 0 1.6866160876816139e-06
. O 0 8.356806574738584e-06

Genomic O 0 0.0008290664409287274
structure O 0 5.487404632731341e-05
of O 0 2.8137071694800397e-06
the O 0 4.131182504352182e-05
human O 1 0.6908478736877441
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.009362729266285896
CLD B-Disease 1 0.9994327425956726
) O 0 7.545910921180621e-05
gene O 0 0.0002767089754343033
. O 0 3.882970122504048e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.07511719316244125
CLD B-Disease 1 0.9998661279678345
) O 0 9.828369911701884e-06
is O 0 8.179114274753374e-07
caused O 0 5.5715440794301685e-06
by O 0 8.058077582973056e-07
mutations O 0 3.891615506290691e-06
in O 0 2.0783734555607225e-07
a O 0 1.2074658570782049e-06
gene O 0 2.8586948701558867e-06
which O 0 5.275670105220343e-07
encodes O 0 6.4507034949201625e-06
an O 0 8.24921517050825e-06
intestinal O 1 0.9730761051177979
anion O 0 0.002461093245074153
transporter O 0 0.004310486372560263
. O 0 5.695688014384359e-05

We O 0 9.626607607060578e-06
report O 0 5.028373834647937e-06
here O 0 3.9891082792564703e-07
the O 0 2.0488400309659482e-07
complete O 0 4.903893682239868e-07
genomic O 0 2.234161229353049e-06
organization O 0 2.2666351640054927e-07
of O 0 5.032509875491087e-08
the O 0 2.459186987380235e-07
human O 0 1.1378606359357946e-06
CLD B-Disease 0 0.007034287787973881
gene O 0 6.206606485648081e-06
which O 0 3.673729338515841e-07
spans O 0 1.1081725688200095e-06
approximately O 0 3.9105046312215563e-07
39kb O 0 2.7387541194912046e-05
, O 0 3.239202612803638e-07
and O 0 3.0496136105284677e-07
comprises O 0 2.0738209514092887e-06
21 O 0 1.1357130460964981e-05
exons O 0 0.00013986635894980282
. O 0 2.32553302339511e-05

All O 0 5.369534846977331e-05
exon O 0 0.0010823338525369763
/ O 0 0.00028184536495245993
intron O 0 0.00023397538461722434
boundaries O 0 6.895819751662202e-06
conform O 0 1.9185516066499986e-05
to O 0 1.1847236009998596e-06
the O 0 6.000060238875449e-06
GT O 0 0.27362456917762756
/ O 1 0.930450439453125
AG O 1 0.9997988343238831
rule O 0 0.00017633844981901348
. O 0 3.7673326005460694e-05

An O 0 6.377363206411246e-06
analysis O 0 2.41162047132093e-06
of O 0 3.529031289417617e-07
the O 0 1.0392035392214893e-06
putative O 0 2.387944914516993e-05
promoter O 0 1.2398731996654533e-05
region O 0 1.279291950595507e-06
sequence O 0 8.414838816861447e-07
shows O 0 4.084844533736032e-07
a O 0 9.505707225798687e-07
putative O 0 4.253982478985563e-05
TATA O 0 0.0015930479858070612
box O 0 1.0238632967229933e-05
and O 0 8.048676818361855e-07
predicts O 0 8.083592547336593e-06
multiple O 0 1.9044812233914854e-06
transcription O 0 7.933806955406908e-06
factor O 0 2.403483449597843e-06
binding O 0 5.040439646109007e-06
sites O 0 9.310262612416409e-06
. O 0 1.426330072717974e-05

The O 0 2.1929510694462806e-05
genomic O 0 8.368478302145377e-05
structure O 0 2.2105296011432074e-05
was O 0 1.3972628948977217e-05
determined O 0 1.4417194051929982e-06
using O 0 6.048827572158189e-07
DNA O 0 8.663923267704376e-07
from O 0 1.4388058389158687e-07
several O 0 6.082824199893366e-08
sources O 0 1.3819098398926144e-07
including O 0 1.0804291861177262e-07
multiple O 0 7.2186560373666e-07
large O 0 8.536665063729743e-07
- O 0 0.00012189297558506951
insert O 0 8.087604510365054e-05
libaries O 0 3.7839206925127655e-05
and O 0 6.828609571130073e-07
genomic O 0 7.893107976997271e-06
DNA O 0 5.9533790590649005e-06
from O 0 4.3852169255842455e-06
Finnish O 0 0.2223379909992218
CLD B-Disease 1 0.9999716281890869
patients O 0 0.0009297595242969692
and O 0 6.429189397749724e-06
controls O 0 0.0013614739291369915
. O 0 4.1650051571195945e-05

Exon O 0 0.003055298700928688
- O 0 0.0005020940443500876
specific O 0 1.3070095519651659e-05
primers O 0 0.00011173563689226285
developed O 0 1.4354565792018548e-05
in O 0 6.249359785215347e-07
this O 0 2.584207834388508e-07
study O 0 4.380668201520166e-07
will O 0 2.43960528223397e-07
facilitate O 0 7.881853321123344e-07
mutation O 0 4.30092450187658e-06
screening O 0 2.0128818505327217e-06
studies O 0 4.4217850359018485e-07
of O 0 2.2943007138565008e-07
patients O 0 7.716678737779148e-06
with O 0 1.6172069763342733e-06
the O 0 0.0008874246850609779
disease O 1 0.6841005682945251
. O 0 2.3987933673197404e-05

Genomic O 0 0.0009950607782229781
sequencing O 0 7.549193105660379e-05
of O 0 4.828744749829639e-06
a O 0 4.6581415517721325e-05
BAC O 1 0.5175943374633789
clone O 0 0.03897489234805107
H O 1 0.9986503720283508
_ O 0 2.3469917778129457e-06
RG364P16 O 0 1.119874923460884e-05
revealed O 0 3.25187261296378e-06
the O 0 1.9600871326019842e-07
presence O 0 2.646429209107737e-07
of O 0 5.528575286462001e-08
another O 0 2.6283649390279606e-07
, O 0 1.4322537822408776e-07
highly O 0 4.510424389536638e-07
homologous O 0 2.361763563385466e-06
gene O 0 1.120709271162923e-06
3 O 0 2.3159211082202091e-07
of O 0 7.303330562535848e-08
the O 0 1.1178271961398423e-06
CLD B-Disease 0 0.418220192193985
gene O 0 6.758523340977263e-06
, O 0 1.3380687846620276e-07
with O 0 8.066091794489694e-08
a O 0 4.391267225400952e-07
similar O 0 7.044808967293648e-07
genomic O 0 2.723912984947674e-06
structure O 0 1.3935894003225258e-06
, O 0 1.413047812093282e-07
recently O 0 1.6610487136858865e-06
identified O 0 6.132065095698636e-07
as O 0 3.210622026017518e-07
the O 0 0.00010410725371912122
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.0006019804277457297
( O 0 1.0549343642196618e-05
PDS B-Disease 0 0.0006812107167206705
) O 0 3.0466301268461393e-06
. O 0 1.4587027408197173e-06
. O 0 7.4252452577638905e-06

The O 0 4.95301210321486e-05
APCI1307K O 0 0.0035533460322767496
allele O 0 0.0009970749961212277
and O 0 7.639353862032294e-05
cancer B-Disease 0 0.09715106338262558
risk O 0 3.4161130315624177e-06
in O 0 3.2316182796421344e-07
a O 0 1.0629460120981093e-06
community O 0 1.3085846148896962e-06
- O 0 3.189482231391594e-05
based O 0 1.0206509841736988e-06
study O 0 5.005542789149331e-07
of O 0 5.443894792733772e-07
Ashkenazi O 0 0.00027247786056250334
Jews O 0 2.9105749490554444e-05
. O 0 3.523473787936382e-05

Mutations O 0 0.0038253809325397015
in O 0 3.938346344511956e-05
APC O 0 0.0007154177874326706
are O 0 2.2000861008564243e-06
classically O 0 0.000543943140655756
associated O 0 5.277357195154764e-05
with O 0 0.000534937484189868
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
( O 0 0.0005685333744622767
FAP B-Disease 0 0.0013614349300041795
) O 0 1.978241925826296e-06
, O 0 5.055118208474596e-07
a O 0 4.239247573423199e-06
highly O 0 0.0002105320745613426
penetrant O 1 0.9999961853027344
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999997615814209
disorder I-Disease 1 1.0
characterized O 0 0.09146988391876221
by O 0 1.3717020920012146e-05
multiple O 0 0.00223553623072803
intestinal O 1 0.9999808073043823
polyps B-Disease 0 0.0800722986459732
and O 0 1.0909649290624657e-06
, O 0 2.1902351932112651e-07
without O 0 2.989744700698793e-07
surgical O 0 2.738845614658203e-05
intervention O 0 3.626493480624049e-06
, O 0 1.3897059147893742e-07
the O 0 2.564481178524147e-07
development O 0 2.131396058757673e-06
of O 0 0.005230431444942951
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00028637968352995813
CRC B-Disease 0 0.0659244954586029
) O 0 1.2189665540063288e-05
. O 0 1.8032946172752418e-05

APC B-Disease 0 0.006599008571356535
is O 0 2.6498375518713146e-05
a O 0 5.750121272285469e-05
tumour O 1 0.9999977350234985
- O 0 0.00535076716914773
suppressor O 0 0.0004095948243048042
gene O 0 1.1100257324869744e-05
, O 0 4.07030483984272e-07
and O 0 5.729295935452683e-07
somatic O 0 4.4563923438545316e-05
loss O 0 0.00022300220734905452
occurs O 0 1.3120298717694823e-05
in O 0 7.290186476893723e-05
tumours B-Disease 1 0.9999983310699463
. O 0 6.755332287866622e-05

The O 0 8.535813685739413e-05
germline O 0 0.016189370304346085
T O 0 0.1677822470664978
- O 0 9.68797248788178e-05
to O 0 1.694171942290268e-06
- O 0 8.658019396534655e-06
A O 0 2.0402655991347274e-06
transversion O 0 3.867854684358463e-05
responsible O 0 1.0527155609452166e-06
for O 0 1.5136373576751794e-07
the O 0 6.971264951971534e-07
APC O 0 2.2967224140302278e-05
I1307K O 0 1.3715582099393941e-05
allele O 0 5.7219690461352e-06
converts O 0 1.4952171341064968e-06
the O 0 2.6311138867640693e-07
wild O 0 7.460013762283779e-07
- O 0 1.2304532901907805e-05
type O 0 1.1027831305909785e-06
sequence O 0 4.826249551115325e-07
to O 0 2.4878286808416306e-07
a O 0 5.090781087346841e-06
homopolymer O 1 0.7480177283287048
tract O 1 0.8667178153991699
( O 0 1.216440705320565e-05
A8 O 0 0.05350760743021965
) O 0 1.0519388524699025e-06
that O 0 3.579163774247718e-07
is O 0 5.564501748267503e-07
genetically O 0 6.232437044673134e-06
unstable O 0 0.00014178630954120308
and O 0 2.0044969915034017e-06
prone O 0 2.133939415216446e-05
to O 0 3.8504467738675885e-06
somatic O 0 0.00034090736880898476
mutation O 0 0.00019692817295435816
. O 0 2.631097777339164e-05

The O 0 3.601147182052955e-05
I1307K O 0 0.0003086586657445878
allele O 0 0.00026928496663458645
was O 0 2.367600245634094e-05
found O 0 2.3182335553428857e-06
in O 0 2.887315758925979e-06
6 O 0 1.7944526916835457e-05
. O 0 2.2005808204994537e-05

1 O 0 2.9666971386177465e-05
% O 0 2.509496880520601e-06
of O 0 8.584661372879054e-07
unselected O 0 8.205779158743098e-05
Ashkenazi O 0 8.704501669853926e-05
Jews O 0 2.4876701445464278e-06
and O 0 6.084031838327064e-07
higher O 0 1.336791228823131e-06
proportions O 0 1.535823685117066e-06
of O 0 2.61408615642722e-07
Ashkenazim O 0 3.0148545192787424e-05
with O 0 1.1534912118804641e-06
family O 0 2.502990719221998e-05
or O 0 1.0285697271683603e-06
personal O 0 6.876131465105573e-06
histories O 0 5.332115506462287e-06
of O 0 1.5373829000964179e-06
CRC B-Disease 0 0.13737083971500397
( O 0 9.594154107617214e-06
ref O 0 0.00020963128190487623
. O 0 7.294253236977966e-07
2 O 0 2.4124901756295003e-06
) O 0 3.228031573598855e-06
. O 0 8.336040082213003e-06

To O 0 1.4687248949485365e-05
evaluate O 0 8.888859156286344e-06
the O 0 6.544983648382185e-07
role O 0 9.265179983231064e-07
of O 0 1.805479143968114e-07
I1307K O 0 2.6182922738371417e-05
in O 0 1.442576012777863e-05
cancer B-Disease 0 0.0021611421834677458
, O 0 4.187276374523208e-07
we O 0 3.198327647169208e-07
genotyped O 0 1.5095797607500572e-05
5 O 0 1.0393146112619434e-06
, O 0 7.315919674510951e-07
081 O 0 7.262882718350738e-05
Ashkenazi O 0 2.8127597033744678e-05
volunteers O 0 1.2745488220389234e-06
in O 0 4.025839359655947e-07
a O 0 2.1343660137063125e-06
community O 0 4.740418262372259e-06
survey O 0 4.139231896260753e-05
. O 0 1.4179323443386238e-05

Risk O 0 0.00021265506802592427
of O 0 6.394390311470488e-06
developing O 0 0.0002460613031871617
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 9.702126408228651e-05
breast I-Disease 0 0.010380160994827747
and I-Disease 0 1.3352431551538757e-06
other I-Disease 0 8.535077995475149e-07
cancers I-Disease 0 0.0004932790761813521
were O 0 4.096884254067845e-07
compared O 0 5.476758815348148e-07
between O 0 3.948567552924942e-07
genotyped O 0 4.3700678361346945e-05
I1307K O 0 2.3010656150290743e-05
carriers O 0 2.466873183948337e-06
and O 0 1.474380866284264e-07
non O 0 4.878457957602222e-07
- O 0 4.3999125409754924e-06
carriers O 0 3.507173005345976e-07
and O 0 5.328982766172885e-08
their O 0 9.700396930156785e-08
first O 0 5.486477334670781e-07
- O 0 1.0748814020189457e-05
degree O 0 4.912046733807074e-06
relatives O 0 1.7664746337686665e-05
. O 0 1.4193014976626728e-05

Sperm O 0 0.000399032753193751
DNA O 0 0.00010275986278429627
analysis O 0 1.2628558579308446e-05
in O 0 4.034020548715489e-06
a O 0 4.413642454892397e-05
Friedreich B-Disease 1 0.997261643409729
ataxia I-Disease 1 0.9998936653137207
premutation O 0 0.48528367280960083
carrier O 0 0.0033238285686820745
suggests O 0 5.7681008911458775e-06
both O 0 6.056914685359516e-07
meiotic O 0 4.91559476358816e-05
and O 0 7.540726301158429e-07
mitotic O 0 4.127347710891627e-05
expansion O 0 4.998910753784003e-06
in O 0 1.2641575040106545e-06
the O 0 5.258057626633672e-06
FRDA B-Disease 0 0.0017499069217592478
gene O 0 0.00017798323824536055
. O 0 3.632946754805744e-05

Friedreich B-Disease 1 0.9999655485153198
ataxia I-Disease 1 0.9999985694885254
is O 0 8.913666533771902e-05
usually O 0 1.5232572877721395e-05
caused O 0 1.1656594324449543e-05
by O 0 4.0600815509606036e-07
an O 0 1.5742986647637736e-07
expansion O 0 9.2674684992744e-07
of O 0 1.7919636263741268e-07
a O 0 3.5339455735083902e-06
GAA O 0 0.00022085131786298007
trinucleotide O 0 0.000236405452596955
repeat O 0 1.5602248822688125e-05
in O 0 1.962190935955732e-06
intron O 0 4.347991125541739e-05
1 O 0 7.276001383615949e-07
of O 0 3.06837165453544e-07
the O 0 2.5650169845903292e-06
FRDA B-Disease 0 0.0018529456574469805
gene O 0 0.00014302277122624218
. O 0 2.3157557734521106e-05

Occasionally O 0 9.836618119152263e-05
, O 0 2.476024974384927e-06
a O 0 1.578316982886463e-06
fully O 0 1.4888724990669289e-06
expanded O 0 1.5633006569260033e-06
allele O 0 4.369167072582059e-06
has O 0 2.815940831624175e-07
been O 0 2.011362738585376e-07
found O 0 2.0093516184260807e-07
to O 0 1.693991151796581e-07
arise O 0 3.8681611158608575e-07
from O 0 1.5405235842536058e-07
a O 0 7.34954198833293e-07
premutation O 0 1.5879064449109137e-05
of O 0 2.0396615241224936e-07
100 O 0 5.906802016397705e-07
or O 0 1.0992027910106117e-06
less O 0 4.073961463291198e-06
triplet O 0 0.006621166598051786
repeats O 0 0.00045182392932474613
. O 0 3.4756838431349024e-05

We O 0 1.4276446563599166e-05
have O 0 1.9967928892583586e-06
examined O 0 6.25786924501881e-06
the O 0 4.711501162546483e-07
sperm O 0 1.5724051536381012e-06
DNA O 0 1.189771069221024e-06
of O 0 2.42190594690328e-07
a O 0 8.862695722200442e-06
premutation O 0 0.028490101918578148
carrier O 0 0.006395046599209309
. O 0 2.598873652459588e-05

This O 0 3.0263219741755165e-05
mans O 0 0.00018581727636046708
leucocyte O 0 0.00044048024574294686
DNA O 0 2.955218769784551e-05
showed O 0 8.76991543918848e-06
one O 0 4.7149444526439765e-07
normal O 0 1.3387688113652985e-06
allele O 0 4.075372089573648e-06
and O 0 1.4715601537318435e-07
one O 0 1.0906615699468603e-07
allele O 0 1.8560276657808572e-06
of O 0 1.0392903249112351e-07
approximately O 0 4.787029865838122e-07
100 O 0 2.212896788478247e-06
repeats O 0 6.265400588745251e-05
. O 0 1.4470017958956305e-05

His O 0 4.007798634120263e-05
sperm O 0 2.7165166102349758e-05
showed O 0 9.242752639693208e-06
an O 0 6.879234319967509e-07
expanded O 0 2.5312106117780786e-06
allele O 0 5.252409209788311e-06
in O 0 2.9678540158784017e-07
a O 0 5.537270340028044e-07
tight O 0 6.591633791686036e-06
range O 0 5.822756179441058e-07
centering O 0 1.6261055861832574e-06
on O 0 4.0327176975551993e-07
a O 0 6.300200539044454e-07
size O 0 6.948333179934707e-07
of O 0 2.3366909829292126e-07
approximately O 0 2.6968909878632985e-06
320 O 0 3.2985724828904495e-05
trinucleotide O 0 0.0016116066835820675
repeats O 0 0.0003768329042941332
. O 0 3.487533831503242e-05

His O 0 0.00024086459598038346
affected O 0 0.00014923952403478324
son O 0 0.0044149295426905155
has O 0 3.6957417250960134e-06
repeat O 0 1.0737523552961648e-05
sizes O 0 3.129766128040501e-06
of O 0 6.118144710853812e-07
1040 O 0 7.341421587625518e-05
and O 0 3.444607273195288e-06
540 O 0 8.593597158323973e-05
. O 0 2.2908950995770283e-05

These O 0 1.1167211596330162e-05
data O 0 6.211271738720825e-06
suggest O 0 2.593149702079245e-06
that O 0 2.8156213716101774e-07
expansion O 0 1.7466256849729689e-06
occurs O 0 4.98323345254903e-07
in O 0 9.361649233596836e-08
two O 0 5.365822275393839e-08
stages O 0 4.7360802568618965e-07
, O 0 5.081237119952675e-08
the O 0 9.178022253308882e-08
first O 0 2.7184478312847205e-07
during O 0 1.618098622202524e-06
meiosis O 0 2.7700925784301944e-06
followed O 0 6.507968919322593e-07
by O 0 3.2225150903286703e-07
a O 0 1.0412551318950136e-06
second O 0 4.9659679461910855e-06
mitotic O 0 0.0006490666419267654
expansion O 0 9.740606765262783e-05
. O 0 2.5954457669286057e-05

We O 0 9.241607585863676e-06
also O 0 2.5105523491220083e-06
show O 0 1.1470825711512589e-06
that O 0 1.2702140850251453e-07
in O 0 9.395511568754955e-08
all O 0 3.646137614055078e-08
informative O 0 4.306965024625242e-07
carrier O 0 3.490564995445311e-05
father O 0 4.388819888845319e-06
to O 0 3.139435023058468e-07
affected O 0 5.596838263954851e-07
child O 0 1.413463223798317e-06
transmissions O 0 2.8988129997742362e-05
, O 0 4.4150848310664514e-08
with O 0 2.8600693369185137e-08
the O 0 7.859667761067612e-08
notable O 0 1.5322613933221874e-07
exception O 0 8.922288685653257e-08
of O 0 3.4716055807848534e-08
the O 0 3.054981334571494e-07
premutation O 0 7.734514656476676e-05
carrier O 0 1.678076841926668e-05
, O 0 8.469378087738733e-08
the O 0 1.235166280366684e-07
expansion O 0 1.8202973706138437e-06
size O 0 2.7017356387659675e-06
decreases O 0 6.606410806853091e-06
. O 0 1.318968656960351e-06
. O 0 7.415294930979144e-06

The O 0 4.084270403836854e-05
R496H O 0 0.0002507747558411211
mutation O 0 5.223094194661826e-05
of O 0 1.226226800099539e-06
arylsulfatase O 0 0.0004709470085799694
A O 0 4.0219572838395834e-05
does O 0 6.402804956451291e-06
not O 0 6.721282261423767e-06
cause O 0 0.001237879041582346
metachromatic B-Disease 1 0.9999933242797852
leukodystrophy I-Disease 1 0.9999973773956299
. O 0 0.00015289818111341447

Deficiency B-Disease 1 0.9970170259475708
of I-Disease 0 2.3757473172736354e-05
arylsulfatase I-Disease 0 0.0023225138429552317
A I-Disease 0 0.00014547837781719863
( O 0 2.6781637643580325e-05
ARSA O 0 0.007128261961042881
) O 0 6.143096015875926e-06
enzyme O 0 2.2608246581512503e-05
activity O 0 2.7898442567675374e-05
causes O 0 0.0005365699180401862
metachromatic B-Disease 1 0.9999958276748657
leukodystrophy I-Disease 1 1.0
( O 0 0.003752606688067317
MLD B-Disease 1 0.9999920129776001
) O 0 5.9253903600620106e-05
. O 0 3.0896371754352e-05

A O 0 5.6897006288636476e-05
number O 0 5.965928266959963e-06
of O 0 3.3459466521890135e-06
ARSA O 0 0.3033389449119568
gene O 0 0.00015510462981183082
mutations O 0 5.3974628826836124e-05
responsible O 0 5.648008936987026e-06
for O 0 2.9328709842957323e-06
MLD B-Disease 1 0.9999865293502808
have O 0 2.99013754556654e-06
been O 0 2.9353138870646944e-06
identified O 0 1.1223179171793163e-05
. O 0 1.0327459676773287e-05

Recently O 0 0.0002427187719149515
, O 0 3.4516806408646517e-06
the O 0 2.0173097254883032e-06
R496H O 0 4.5927681640023366e-05
mutation O 0 1.1346520295774098e-05
of O 0 7.319645760617277e-07
ARSA O 0 0.05987522006034851
was O 0 2.359483733016532e-05
proposed O 0 2.5674080461612903e-06
to O 0 4.612799955339142e-07
be O 0 1.373360731804496e-07
a O 0 1.1710484386640019e-06
cause O 0 5.8742257351696026e-06
of O 0 1.3569973589255824e-06
MLD B-Disease 1 0.9999935626983643
( O 0 9.357449016533792e-06
Draghia O 0 0.0001223435247084126
et O 0 3.187405673088506e-05
al O 0 1.0304970601282548e-05
. O 0 3.609544307892065e-07
, O 0 4.338845087659138e-07
1997 O 0 4.3751751945819706e-06
) O 0 4.337246082286583e-06
. O 0 1.0699672202463262e-05

We O 0 1.1336472198308911e-05
have O 0 1.6126758737300406e-06
investigated O 0 5.471874828799628e-06
the O 0 8.386766126022849e-07
R496H O 0 3.247713902965188e-05
mutation O 0 7.65611093811458e-06
and O 0 3.0241216109061497e-07
found O 0 3.091151654643909e-07
this O 0 1.5215729831652425e-07
mutation O 0 1.3328271961654536e-06
at O 0 3.39614473432448e-07
a O 0 7.14632335530041e-07
relatively O 0 1.112088739319006e-06
high O 0 1.414937401023053e-06
frequency O 0 2.6607679046719568e-06
in O 0 1.451699773724613e-07
an O 0 9.876769979655364e-08
African O 0 1.3171620594221167e-07
American O 0 1.8614059626997914e-07
population O 0 3.074452479268075e-07
( O 0 8.084803653218842e-07
f O 0 1.1210535376449116e-05
= O 0 3.3487910968688084e-06
0 O 0 7.31843158519041e-07
. O 0 2.7078056064056e-07
09 O 0 4.466397513169795e-06
, O 0 6.942200343473814e-07
n O 0 1.3882880921300966e-05
= O 0 1.248182434210321e-05
61 O 0 8.392747076868545e-06
subjects O 0 8.757555406191386e-06
) O 0 7.101448318280745e-06
. O 0 1.6280502677545883e-05

The O 0 7.628652383573353e-05
ARSA O 0 0.004343594424426556
enzyme O 0 7.985022239154205e-05
activity O 0 9.001872967928648e-06
in O 0 7.508270414291474e-07
subjects O 0 5.466635002449038e-07
with O 0 1.8938445123239944e-07
and O 0 1.6666866997638863e-07
without O 0 9.944194800937112e-08
the O 0 3.180036571848177e-07
R496H O 0 2.0929855963913724e-05
mutation O 0 6.125675099610817e-06
was O 0 2.7342296107235597e-06
determined O 0 9.643390512792394e-07
and O 0 3.027942341304879e-07
found O 0 6.535128704854287e-07
to O 0 4.84383633647667e-07
be O 0 8.016319270609529e-07
normal O 0 1.2827987120545004e-05
. O 0 1.1504740541568026e-05

It O 0 1.1174701285199262e-05
is O 0 2.2851497760711936e-06
therefore O 0 9.487077932135435e-07
concluded O 0 1.0398014183010673e-06
that O 0 9.117425747717789e-08
the O 0 4.0122671407516464e-07
R496H O 0 1.4737097444594838e-05
mutation O 0 5.003422756999498e-06
of O 0 4.355515557108447e-07
ARSA O 0 0.015376534312963486
does O 0 1.1678587270580465e-06
not O 0 2.1627063517826173e-07
negatively O 0 7.506186534556036e-07
influence O 0 2.744203868587647e-07
the O 0 1.5595215074881708e-07
activity O 0 4.3140849470546527e-07
of O 0 1.586753484161818e-07
ARSA O 0 0.009115501306951046
and O 0 4.5851948016206734e-07
is O 0 1.195936363274086e-07
not O 0 1.193713359270987e-07
a O 0 2.0619036149582826e-06
cause O 0 3.85484891012311e-05
of O 0 1.9667711967485957e-05
MLD B-Disease 1 0.999994158744812

Down O 0 0.0002679800381883979
- O 0 0.00010080412175739184
regulation O 0 1.9137765775667503e-05
of O 0 2.2430551780416863e-06
transmembrane O 0 8.719629840925336e-05
carbonic O 0 0.0006023236783221364
anhydrases O 0 0.01781381480395794
in O 0 0.001173915108665824
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999984502792358
carcinoma I-Disease 1 1.0
cell O 0 0.09410905838012695
lines O 0 1.9975388568127528e-05
by O 0 1.5442863059433876e-06
wild O 0 4.720600372820627e-06
- O 0 0.0011106085730716586
type O 0 0.0003933966509066522
von B-Disease 1 0.9489865303039551
Hippel I-Disease 1 0.9870184063911438
- I-Disease 1 0.9115318655967712
Lindau I-Disease 1 0.5184003114700317
transgenes O 0 0.003813736606389284
. O 0 0.0001290685177082196

To O 0 6.397758261300623e-05
discover O 0 9.442857117392123e-05
genes O 0 3.2494233892066404e-05
involved O 0 6.192381988512352e-06
in O 0 7.78280445956625e-06
von B-Disease 1 0.927655816078186
Hippel I-Disease 1 0.9972255229949951
- I-Disease 1 0.9898528456687927
Lindau I-Disease 1 0.9276643395423889
( O 0 1.4145704881229904e-05
VHL B-Disease 0 0.00031622068490833044
) O 0 2.0203535768814618e-06
- O 0 1.560535929456819e-05
mediated O 0 3.5260385629953817e-05
carcinogenesis O 0 0.000129691296024248
, O 0 3.962547623359569e-07
we O 0 2.7960982151853386e-07
used O 0 0.0001565548445796594
renal B-Disease 1 0.9999978542327881
cell I-Disease 1 0.9999886751174927
carcinoma I-Disease 1 1.0
cell O 0 0.05394565314054489
lines O 0 5.767975380877033e-05
stably O 0 0.00013622974802274257
transfected O 0 0.00011024935520254076
with O 0 1.306515855503676e-06
wild O 0 7.4004524321935605e-06
- O 0 0.0014711510157212615
type O 0 0.00029671285301446915
VHL O 0 0.005954382009804249
- O 0 0.0006415123352780938
expressing O 0 9.921724267769605e-05
transgenes O 0 0.0007798586157150567
. O 0 4.9590009439270943e-05

Large O 0 6.549867248395458e-05
- O 0 7.26336074876599e-05
scale O 0 1.0876471606025007e-05
RNA O 0 1.0739049685071222e-05
differential O 0 6.42000486550387e-06
display O 0 7.3807736953313e-06
technology O 0 3.647783614724176e-06
applied O 0 7.625532703059434e-07
to O 0 3.025330386208225e-07
these O 0 1.073179163313398e-07
cell O 0 1.0500541975488886e-05
lines O 0 2.026254151132889e-06
identified O 0 5.757372605330602e-07
several O 0 2.7658191470436577e-07
differentially O 0 4.837114829570055e-06
expressed O 0 7.676455311411701e-07
genes O 0 7.702208790760778e-07
, O 0 1.1437919766876803e-07
including O 0 1.1770391949994519e-07
an O 0 7.754013040539576e-07
alpha O 0 2.0837327610934153e-05
carbonic O 0 0.00026381670613773167
anhydrase O 0 0.00041277860873378813
gene O 0 4.723653546534479e-05
, O 0 2.6025793431472266e-06
termed O 0 0.00010425386426504701
CA12 O 0 0.0034601271618157625
. O 0 7.004134386079386e-05

The O 0 2.301875429111533e-05
deduced O 0 5.1877115765819326e-05
protein O 0 5.172236797079677e-06
sequence O 0 1.818805003495072e-06
was O 0 5.055140718468465e-06
classified O 0 1.0432520411995938e-06
as O 0 1.3991329694817978e-07
a O 0 3.2633752766741964e-07
one O 0 2.0590688620814035e-07
- O 0 3.2695279514882714e-05
pass O 0 4.2714859773695935e-06
transmembrane O 0 2.3508544472861104e-05
CA O 0 3.4328470519540133e-06
possessing O 0 9.265913263334369e-07
an O 0 4.458735247681034e-07
apparently O 0 6.960238351894077e-06
intact O 0 9.484250767854974e-06
catalytic O 0 1.0447799468238372e-05
domain O 0 1.6260590882666293e-06
in O 0 4.5209966970105597e-07
the O 0 9.036322126121377e-07
extracellular O 0 3.317165464977734e-05
CA O 0 5.4974083468550816e-05
module O 0 0.00029241672018542886
. O 0 2.0236730051692575e-05

Reintroduced O 0 0.002218673937022686
wild O 0 0.00020240890444256365
- O 0 0.0019319832790642977
type O 0 0.00019937008619308472
VHL B-Disease 0 0.0008411661838181317
strongly O 0 3.6711797292809933e-05
inhibited O 0 1.8439355699229054e-05
the O 0 8.883595796760346e-07
overexpression O 0 7.768937393848319e-06
of O 0 2.0246960730219143e-07
the O 0 9.706695891509298e-07
CA12 O 0 9.615466115064919e-05
gene O 0 3.7774632346554426e-06
in O 0 4.853167183682672e-07
the O 0 3.9414635466528125e-06
parental O 1 0.9586203694343567
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999992847442627
carcinoma I-Disease 1 1.0
cell O 1 0.6514241695404053
lines O 0 0.00042583930189721286
. O 0 4.2354109609732404e-05

Similar O 0 0.00012345459253992885
results O 0 2.5093335352721624e-05
were O 0 2.1737159840995446e-06
obtained O 0 1.8940554582513869e-06
with O 0 1.287423629037221e-06
CA9 O 0 0.021691789850592613
, O 0 7.422204930662701e-07
encoding O 0 3.1840711471886607e-06
another O 0 1.963437398444512e-06
transmembrane O 0 5.417140346253291e-05
CA O 0 5.125485586177092e-06
with O 0 1.5770817185511987e-07
an O 0 6.448055955843301e-07
intact O 0 2.2094442101661116e-05
catalytic O 0 5.502474232343957e-05
domain O 0 2.5085993911488913e-05
. O 0 1.2754905583278742e-05

Although O 0 2.1880166968912818e-05
both O 0 2.345796701774816e-06
domains O 0 4.90409865960828e-06
of O 0 2.7606833441495837e-07
the O 0 8.695899964550335e-07
VHL B-Disease 0 0.0001252512593055144
protein O 0 2.496747129043797e-06
contribute O 0 6.348535634970176e-07
to O 0 2.6814933562491206e-07
regulation O 0 1.1405354598537087e-06
of O 0 2.604046471788024e-07
CA12 O 0 0.00018011282372754067
expression O 0 1.7432026879760087e-06
, O 0 2.135996055585565e-07
the O 0 3.594800261907949e-07
elongin O 0 2.395391493337229e-05
binding O 0 3.93062282455503e-06
domain O 0 4.520390120887896e-06
alone O 0 2.367012939430424e-06
could O 0 2.3318632429436548e-06
effectively O 0 1.3509140444512013e-05
regulate O 0 7.269416528288275e-05
CA9 O 0 0.005672725848853588
expression O 0 8.086817979346961e-05
. O 0 3.436483893892728e-05

We O 0 9.199958731187508e-05
mapped O 0 0.0005289859254844487
CA12 O 0 0.0017568424809724092
and O 0 2.4076580302789807e-05
CA9 O 0 0.01180997584015131
loci O 0 5.995827086735517e-05
to O 0 3.4029962989734486e-06
chromosome O 0 2.3551358026452363e-05
bands O 0 9.629085980122909e-06
15q22 O 0 5.200123632675968e-05
and O 0 7.599878244946012e-06
17q21 O 0 0.0002770067367237061
. O 0 3.2742773328209296e-05

2 O 0 5.592927846009843e-05
respectively O 0 2.3833174054743722e-05
, O 0 1.7684669728623703e-06
regions O 0 3.7457086818903917e-06
prone O 0 1.2558060916489922e-05
to O 0 8.501252182213648e-07
amplification O 0 2.9242826713016257e-05
in O 0 7.634599796801922e-07
some O 0 1.080688321053458e-06
human O 0 2.2054360670153983e-05
cancers B-Disease 0 0.0144901592284441
. O 0 3.8866674003656954e-05

Additional O 0 2.1709050997742452e-05
experiments O 0 1.5597948731738143e-05
are O 0 3.4146012239943957e-07
needed O 0 4.6831226541144133e-07
to O 0 1.1921807185899524e-07
define O 0 3.470219382961659e-07
the O 0 1.2092895929072256e-07
role O 0 2.780473380425974e-07
of O 0 2.449449993946473e-07
CA O 0 0.0001306535123148933
IX O 0 0.10428109019994736
and O 0 7.04091280567809e-06
CA O 0 0.0002729117695707828
XII O 0 0.016214687377214432
enzymes O 0 3.362272764206864e-06
in O 0 3.112354818313179e-07
the O 0 2.7184321993445337e-07
regulation O 0 2.128341293428093e-06
of O 0 1.7970583598980738e-07
pH O 0 6.565096100530354e-06
in O 0 1.7682971531485236e-07
the O 0 2.36126538766257e-07
extracellular O 0 3.1033439427119447e-06
microenvironment O 0 1.2696276826318353e-05
and O 0 1.5106421358268562e-07
its O 0 2.630391122693254e-07
potential O 0 2.7944133762503043e-07
impact O 0 8.605038033238088e-07
on O 0 1.5512679965468124e-05
cancer B-Disease 0 0.02074618823826313
cell O 0 0.00015717737551312894
growth O 0 2.820232111844234e-05
. O 0 1.583001358085312e-05

A O 0 0.00013115930778440088
gene O 0 8.785683894529939e-05
encoding O 0 2.8900991310365498e-05
a O 0 4.218929007038241e-06
transmembrane O 0 2.481554838595912e-05
protein O 0 2.4029723135754466e-06
is O 0 2.809709371831559e-07
mutated O 0 9.9697072073468e-06
in O 0 3.317971049909829e-06
patients O 0 0.000758862413931638
with O 1 0.9427415728569031
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9876826405525208
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999998807907104
( O 1 0.9984623193740845
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.3597203330136836e-05
. O 0 4.3666441342793405e-05

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.026069562882184982
WFS B-Disease 1 0.9987717270851135
; O 0 0.0003601243661250919
OMIM O 1 0.7782282829284668
222300 O 0 0.0018366641597822309
) O 0 9.434626008442137e-06
is O 0 2.6835630251298426e-06
an O 0 4.736875416710973e-05
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999994039535522
defined O 0 2.6732699552667327e-05
by O 0 4.386170985526405e-06
young O 0 5.790444447484333e-06
- O 0 0.0011905340943485498
onset O 0 0.0035849427804350853
non O 0 1.2773482012562454e-05
- O 0 0.03620104864239693
immune O 0 0.0016354098916053772
insulin B-Disease 0 0.36519283056259155
- I-Disease 1 0.997585654258728
dependent I-Disease 1 0.9762685298919678
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.059527020901441574
progressive O 1 0.9999873638153076
optic B-Disease 1 0.9999996423721313
atrophy I-Disease 1 0.9991748929023743
. O 0 0.00013439949543680996

Linkage O 0 0.0008104614680632949
to O 0 2.538631269999314e-05
markers O 0 4.017460378236137e-05
on O 0 9.989636964746751e-06
chromosome O 0 0.0003579380572773516
4p O 1 0.6159301400184631
was O 0 3.863796155201271e-05
confirmed O 0 6.503367330878973e-06
in O 0 6.260562486204435e-07
five O 0 8.638857593723515e-07
families O 0 3.4581119052745635e-06
. O 0 1.6717391190468334e-05

On O 0 1.2148397217970341e-05
the O 0 1.1201206007172004e-06
basis O 0 6.465278374889749e-07
of O 0 5.323984169081086e-07
meiotic O 0 0.0006497477297671139
recombinants O 0 0.04405348747968674
and O 0 7.372150139417499e-05
disease O 0 0.023718638345599174
- O 0 0.0009381034760735929
associated O 0 8.994024028652348e-06
haplotypes O 0 3.333973290864378e-05
, O 0 5.88106388477172e-07
the O 0 1.0574074167379877e-06
WFS B-Disease 0 0.009395736269652843
gene O 0 1.6509306078660302e-05
was O 0 5.812697509099962e-06
localized O 0 8.910058568289969e-06
to O 0 7.642430546184187e-07
a O 0 7.649557119293604e-06
BAC O 0 0.012131856754422188
/ O 0 0.00011943423305638134
P1 O 0 7.979344809427857e-05
contig O 0 1.7448845028411597e-05
of O 0 2.4120771513480577e-07
less O 0 7.149772613956884e-07
than O 0 4.894861831417074e-07
250 O 0 7.607680345245171e-06
kb O 0 0.006734529510140419
. O 0 2.525406307540834e-05

Mutations O 0 0.00231244252063334
in O 0 1.7358110198983923e-05
a O 0 1.4316230590338819e-05
novel O 0 1.9647690351121128e-05
gene O 0 2.2315580281428993e-05
( O 0 2.048626129180775e-06
WFS1 O 0 4.422709025675431e-05
) O 0 5.470379846883588e-07
encoding O 0 1.4974218629504321e-06
a O 0 4.944415081808984e-07
putative O 0 5.3975572882336564e-06
transmembrane O 0 5.6991016208485235e-06
protein O 0 6.316775511550077e-07
were O 0 1.0174986897482086e-07
found O 0 1.26199864780574e-07
in O 0 1.2009229521936504e-07
all O 0 8.159973674537468e-08
affected O 0 3.411525142382743e-07
individuals O 0 7.773554244749903e-08
in O 0 1.495053254529921e-07
six O 0 1.14810143259092e-06
WFS B-Disease 0 0.030279066413640976
families O 0 5.33049217210646e-07
, O 0 1.1715706449422214e-07
and O 0 1.4620549393384863e-07
these O 0 1.7183030820433487e-07
mutations O 0 4.066788278578315e-06
were O 0 3.356597915171733e-07
associated O 0 7.714058938290691e-07
with O 0 8.808361826595501e-07
the O 0 0.00108444900251925
disease O 1 0.9031538963317871
phenotype O 0 0.04977642744779587
. O 0 5.0447761168470606e-05

WFS1 O 0 0.025925593450665474
appears O 0 7.043182995403185e-05
to O 0 4.067521331307944e-06
function O 0 2.06100708055601e-06
in O 0 7.552003467026225e-07
survival O 0 5.9893350226047914e-06
of O 0 6.193789090502833e-07
islet O 0 2.4712369850021787e-05
beta O 0 1.3656092050950974e-05
- O 0 0.00010272351210005581
cells O 0 4.401179921842413e-06
and O 0 6.191792749632441e-07
neurons O 0 1.5363335478468798e-05
. O 0 2.5720842131704558e-06
. O 0 1.051072194968583e-05

Stable O 0 0.0003013414388988167
interaction O 0 9.790202057047281e-06
between O 0 1.0636223350957152e-06
the O 0 3.927633542843978e-07
products O 0 5.726035396946827e-07
of O 0 1.312476172188326e-07
the O 0 1.5535896409346606e-06
BRCA1 O 0 8.881171379471198e-05
and O 0 4.549271125142695e-06
BRCA2 O 0 0.0003422157315071672
tumor B-Disease 0 0.0001297306444030255
suppressor O 0 7.862870552344248e-05
genes O 0 4.979516688763397e-06
in O 0 1.3466052450894495e-06
mitotic O 0 0.0002144891768693924
and O 0 9.659787792770658e-06
meiotic O 0 0.011593755334615707
cells O 0 0.00027079423307441175
. O 0 4.954382166033611e-05

BRCA1 O 0 0.06123525649309158
and O 0 4.891979187959805e-05
BRCA2 O 0 0.00035924892290495336
account O 0 2.9240095500426833e-06
for O 0 1.9111681126560143e-07
most O 0 1.2087417644579546e-07
cases O 0 1.4259556735396473e-07
of O 0 1.208372992778095e-07
familial O 0 0.00010104548709932715
, O 0 1.2383228522594436e-06
early O 0 0.0001043324446072802
onset O 1 0.9943458437919617
breast B-Disease 1 0.5946851372718811
and I-Disease 0 0.00046201987424865365
/ I-Disease 1 0.9999914169311523
or I-Disease 1 0.9998065829277039
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
and O 0 1.1750107660191134e-06
encode O 0 2.654993750184076e-06
products O 0 1.5949277667459683e-06
that O 0 9.468190143024913e-08
each O 0 1.7661432138993405e-07
interact O 0 8.326628631039057e-07
with O 0 1.3036296877544373e-06
hRAD51 O 0 0.0001656025560805574
. O 0 2.007626426347997e-05

Results O 0 9.243267413694412e-05
presented O 0 1.6957439584075473e-05
here O 0 1.3346193554752972e-06
show O 0 2.188186044804752e-06
that O 0 4.4062431925340206e-07
BRCA1 O 0 2.179694638471119e-05
and O 0 1.4284576081990963e-06
BRCA2 O 0 5.124660674482584e-05
coexist O 0 2.562851022958057e-06
in O 0 3.8767069554523914e-07
a O 0 1.4706538422615267e-06
biochemical O 0 1.018172042677179e-05
complex O 0 1.2407675740178092e-06
and O 0 4.383860812140483e-07
colocalize O 0 2.8295804440858774e-05
in O 0 5.826478286508063e-07
subnuclear O 0 2.459108509356156e-05
foci O 0 1.206408160214778e-05
in O 0 4.870415750701795e-07
somatic O 0 1.0088708222610876e-05
cells O 0 2.9010609523538733e-06
and O 0 1.2043958008689515e-07
on O 0 1.4240220025385497e-07
the O 0 8.90139872922191e-08
axial O 0 1.0522057891648728e-06
elements O 0 3.4936863357870607e-07
of O 0 2.3366150969650334e-07
developing O 0 5.765796686318936e-06
synaptonemal O 0 0.0004775578563567251
complexes O 0 0.000103526130260434
. O 0 1.755086486809887e-05

Like O 0 0.00019392652029637247
BRCA1 O 0 0.0013487000251188874
and O 0 2.4937580747064203e-05
RAD51 O 0 0.00510818138718605
, O 0 1.649441765039228e-05
BRCA2 O 0 0.00044443350634537637
relocates O 0 0.00017718755407258868
to O 0 5.703141141566448e-06
PCNA O 0 0.0007883135695010424
+ O 0 3.164137160638347e-05
replication O 0 1.3654529539053328e-05
sites O 0 2.2549888853973243e-06
following O 0 1.8393849359199521e-06
exposure O 0 3.99019108954235e-06
of O 0 5.427363589660672e-07
S O 0 8.856391650624573e-05
phase O 0 1.1388245184207335e-05
cells O 0 1.076200442184927e-05
to O 0 2.266960336783086e-06
hydroxyurea O 0 0.0006309375748969615
or O 0 2.103894075844437e-05
UV O 0 0.05189351737499237
irradiation O 0 0.0005873811314813793
. O 0 3.748289236682467e-05

Thus O 0 7.091816223692149e-05
, O 0 9.212920303980354e-06
BRCA1 O 0 7.734027167316526e-05
and O 0 2.3379552658298053e-06
BRCA2 O 0 2.48239521170035e-05
participate O 0 4.840257474825194e-07
, O 0 1.2558827222619584e-07
together O 0 1.2361041967778874e-07
, O 0 4.940022790833609e-08
in O 0 7.651971145605785e-08
a O 0 9.708612651593285e-07
pathway O 0 3.525187139530317e-06
( O 0 9.236551932190196e-07
s O 0 4.5726475946139544e-05
) O 0 2.19644974208677e-07
associated O 0 2.0112419463202968e-07
with O 0 4.563678857039122e-08
the O 0 1.4236634626740852e-07
activation O 0 1.1883536217283108e-06
of O 0 9.245085408338127e-08
double O 0 2.406047315162141e-06
- O 0 4.930608338327147e-05
strand O 0 1.746714042383246e-05
break O 0 1.736858939693775e-05
repair O 0 0.21309639513492584
and O 0 6.807465524616418e-06
/ O 0 0.00045653042616322637
or O 0 3.176736981913564e-06
homologous O 0 3.3546690247021616e-05
recombination O 0 9.782252163859084e-05
. O 0 2.1755287889391184e-05

Dysfunction O 0 0.04827757179737091
of O 0 4.896738118986832e-06
this O 0 2.0349491478555137e-06
pathway O 0 9.808538379729725e-06
may O 0 3.650428652690607e-06
be O 0 7.553855851938351e-08
a O 0 1.861448595263937e-07
general O 0 3.3874565019687e-07
phenomenon O 0 4.930773798150767e-07
in O 0 7.14042442950813e-08
the O 0 1.0134758809954292e-07
majority O 0 1.341035300583826e-07
of O 0 3.742905363424143e-08
cases O 0 1.3461182390983595e-07
of O 0 2.105170011645896e-07
hereditary B-Disease 1 0.9992815852165222
breast I-Disease 1 0.9275674223899841
and I-Disease 0 0.014025012962520123
/ I-Disease 1 0.9999992847442627
or I-Disease 1 0.9999938011169434
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.1587633707677014e-05
. O 0 2.7945201509282924e-05

A O 0 0.00018123153131455183
novel O 0 9.782364213606343e-05
Arg362Ser O 0 0.00035963254049420357
mutation O 0 2.6362919015809894e-05
in O 0 1.1229024039494107e-06
the O 0 1.4930242286936846e-06
sterol O 0 8.191526285372674e-05
27 O 0 1.5131255167943891e-05
- O 0 0.00013377096911426634
hydroxylase O 0 0.0002914667420554906
gene O 0 1.7610816939850338e-05
( O 0 2.0676850454037776e-06
CYP27 O 0 0.00010715820826590061
) O 0 5.844330530635489e-07
: O 0 1.7948455877103697e-07
its O 0 4.4452130509853305e-07
effects O 0 2.5738040676515084e-06
on O 0 7.798293495397957e-07
pre O 0 8.647835784358904e-06
- O 0 2.774798986138194e-06
mRNA O 0 2.4695070806046715e-06
splicing O 0 6.539476999023464e-06
and O 0 9.675669616626692e-07
enzyme O 0 1.1807636838057078e-05
activity O 0 1.8616225133882836e-05
. O 0 1.3083626072329935e-05

A O 0 0.00011702328629326075
novel O 0 4.5235508878249675e-05
C O 0 5.26216063008178e-05
to O 0 7.668143098271685e-07
A O 0 2.9998548143339576e-06
mutation O 0 5.768332357547479e-06
in O 0 5.616140583697415e-07
the O 0 1.2620722600331646e-06
sterol O 0 6.435906107071787e-05
27 O 0 1.3216608749644365e-05
- O 0 9.378863614983857e-05
hydroxylase O 0 0.00013773958198726177
gene O 0 6.373617452481994e-06
( O 0 8.955455541581614e-07
CYP27 O 0 5.825447806273587e-05
) O 0 5.439945311991323e-07
was O 0 1.4674261592517723e-06
identified O 0 5.949281671746576e-07
by O 0 2.6504932293391903e-07
sequencing O 0 1.9282983885204885e-06
amplified O 0 2.668598244781606e-05
CYP27 O 0 0.000121602053695824
gene O 0 6.525919616251485e-06
products O 0 1.379545096824586e-06
from O 0 2.7221420850764844e-07
a O 0 1.3594311667475267e-06
patient O 0 2.2015903596184216e-05
with O 0 9.66166680882452e-06
cerebrotendinous B-Disease 1 0.9999983310699463
xanthomatosis I-Disease 1 0.9999979734420776
( O 0 0.0001185073924716562
CTX B-Disease 0 0.2560034394264221
) O 0 2.2169537260197103e-05
. O 0 2.6104537028004415e-05

The O 0 4.6366385504370555e-05
mutation O 0 0.000189641272299923
changed O 0 1.6930114725255407e-05
the O 0 3.647240873760893e-06
adrenodoxin O 0 9.337181836599484e-05
cofactor O 0 3.7740890547866e-05
binding O 0 5.897880328120664e-06
residue O 0 1.1165508112753741e-05
362Arg O 0 3.0251590942498296e-05
to O 0 2.8699876111204503e-06
362Ser O 0 6.755067443009466e-05
( O 0 5.148363470652839e-06
CGT O 0 8.785633690422401e-05
362Arg O 0 3.349678809172474e-05
to O 0 2.579775582489674e-06
AGT O 0 0.0005804268876090646
362Ser O 0 4.0191964217228815e-05
) O 0 5.035909111938963e-07
, O 0 8.870856049725262e-08
and O 0 1.2558886908209388e-07
was O 0 4.942784016748192e-06
responsible O 0 3.6010867461300222e-06
for O 0 5.679401510860771e-06
deficiency O 0 0.031699810177087784
in O 0 4.5479683308258245e-07
the O 0 7.027081210253527e-07
sterol O 0 2.7892112484551035e-05
27 O 0 3.0000092010595836e-06
- O 0 7.278046723513398e-06
hydroxylase O 0 1.886259087768849e-05
activity O 0 7.388989615719765e-07
, O 0 6.010214548268777e-08
as O 0 4.3731958498938184e-08
confirmed O 0 2.8858906375717197e-07
by O 0 1.282429735738333e-07
expression O 0 3.185709545050486e-07
of O 0 1.6579959094542573e-07
mutant O 0 5.816118573420681e-06
cDNA O 0 1.0128116628038697e-05
into O 0 2.5245519736927235e-06
COS O 0 0.0005150373326614499
- O 0 3.675443076645024e-05
1 O 0 4.5200586100691e-06
cells O 0 2.3762368073221296e-05
. O 0 1.0618888154567685e-05

Quantitative O 0 0.0003199786879122257
analysis O 0 3.094416388194077e-05
showed O 0 1.3479862900567241e-05
that O 0 4.1969391872953565e-07
the O 0 3.288923267064092e-07
expression O 0 6.882324896650971e-07
of O 0 1.426023743533733e-07
CYP27 O 0 2.4027263862080872e-05
gene O 0 3.076234634136199e-06
mRNA O 0 2.091499254675e-06
in O 0 4.955244321536156e-07
the O 0 1.0002974022427225e-06
patient O 0 1.4222077879821882e-05
represented O 0 6.04937986281584e-06
52 O 0 2.8129261409048922e-05
. O 0 2.485192453605123e-05

5 O 0 5.603824320132844e-05
% O 0 3.3250380511162803e-06
of O 0 4.207242056963878e-07
the O 0 1.58805073624535e-06
normal O 0 9.450953257328365e-06
level O 0 1.0709727575886063e-05
. O 0 1.3601698810816742e-05

As O 0 2.4425213268841617e-05
the O 0 9.597382813808508e-06
mutation O 0 5.6003249483183026e-05
occurred O 0 8.274049832834862e-06
at O 0 1.006674892778392e-06
the O 0 4.271227567187452e-07
penultimate O 0 7.551710950792767e-06
nucleotide O 0 2.6070756575791165e-06
of O 0 1.7358259185584757e-07
exon O 0 1.0075516911456361e-05
6 O 0 1.0523532409933978e-06
( O 0 8.015830417207326e-07
- O 0 2.243915332655888e-06
2 O 0 2.9389673272817163e-07
position O 0 3.607799499150133e-07
of O 0 1.0698396835095991e-07
exon O 0 9.952705113391858e-06
6 O 0 2.076812961604446e-06
- O 0 1.835559851315338e-05
intron O 0 3.193371958332136e-05
6 O 0 1.5269499726855429e-06
splice O 0 1.7375399693264626e-05
site O 0 1.677304567238025e-06
) O 0 7.344063845948767e-08
of O 0 2.67209845361549e-08
the O 0 1.5700524613748712e-07
gene O 0 1.0450314675836125e-06
, O 0 9.355722596637861e-08
we O 0 5.725566509795499e-08
hypothesized O 0 8.61897547110857e-07
that O 0 6.800652130323215e-08
the O 0 6.140562049949949e-07
mutation O 0 2.01262955670245e-05
may O 0 4.3495692807482556e-06
partially O 0 5.674279691447737e-06
affect O 0 3.066148508423794e-07
the O 0 1.7722122436225618e-07
normal O 0 8.484129807584395e-07
splicing O 0 4.514363354246598e-06
efficiency O 0 2.162305236197426e-06
in O 0 4.3284674688948144e-07
exon O 0 1.076842181646498e-05
6 O 0 8.228803949350549e-07
and O 0 2.5136114345514216e-07
cause O 0 1.2555777857414796e-06
alternative O 0 6.551035198754107e-07
splicing O 0 3.1224501526594395e-06
elsewhere O 0 8.40083828279603e-07
, O 0 6.407585573242613e-08
which O 0 6.977425215382027e-08
resulted O 0 3.58143751100215e-07
in O 0 2.1776615710678016e-07
decreased O 0 3.788166850426933e-06
transcript O 0 1.7361255231662653e-05
in O 0 7.085681090757134e-07
the O 0 3.036924226762494e-06
patient O 0 0.00022687909950036556
. O 0 1.4772388567507733e-05

Transfection O 0 0.002986099338158965
of O 0 1.7032769392244518e-05
constructed O 0 0.00015283608809113503
minigenes O 0 0.0006236304761841893
, O 0 4.58363416555585e-07
with O 0 1.707296917174972e-07
or O 0 1.9727811206848855e-07
without O 0 9.223421670867538e-08
the O 0 1.5760080884774652e-07
mutation O 0 1.0236162779619917e-06
, O 0 7.120323175513477e-08
into O 0 3.562521726507839e-07
COS O 0 0.0007752266246825457
- O 0 7.259142876137048e-06
1 O 0 3.706517759383132e-07
cells O 0 6.768184448446846e-07
confirmed O 0 2.517250266009796e-07
that O 0 4.1331837508096214e-08
the O 0 1.5852032220209367e-07
mutant O 0 3.876095888699638e-06
minigene O 0 3.025857404281851e-05
was O 0 2.5084748358494835e-06
responsible O 0 3.86784762440584e-07
for O 0 1.1606412186893067e-07
a O 0 5.416830504145764e-07
mRNA O 0 2.1508149075089023e-06
species O 0 3.3848343150566507e-07
alternatively O 0 2.1154571641091025e-06
spliced O 0 1.4792124602536205e-05
at O 0 9.635595006329822e-07
an O 0 8.557842079426337e-07
activated O 0 0.0001794225536286831
cryptic O 0 7.880667908466421e-06
5 O 0 8.681813596922439e-07
splice O 0 1.3679501535079908e-05
site O 0 1.8823974414772238e-06
88 O 0 2.5634371922933497e-06
bp O 0 5.760455223935423e-06
upstream O 0 9.188967169393436e-07
from O 0 1.3941276222340093e-07
the O 0 1.2098408319616283e-07
3 O 0 2.4254933350675856e-07
end O 0 4.550206824660563e-07
of O 0 4.606399386375415e-07
exon O 0 6.194495654199272e-05
6 O 0 1.3110367945046164e-05
. O 0 1.4030686543264892e-05

Our O 0 1.827235973905772e-05
data O 0 7.428177013935056e-06
suggest O 0 1.649223008826084e-06
that O 0 1.278078372024538e-07
the O 0 2.1567043972936517e-07
C O 0 4.49888239018037e-06
to O 0 2.0373050801936188e-07
A O 0 2.226091964985244e-06
mutation O 0 2.716498784138821e-06
at O 0 2.854032175036991e-07
the O 0 2.0076410578440118e-07
penultimate O 0 4.452168013813207e-06
nucleotide O 0 9.542392263028887e-07
of O 0 1.1821306600268144e-07
exon O 0 3.3735527722456027e-06
6 O 0 2.0975745940177148e-07
of O 0 3.495324918389997e-08
the O 0 2.565653005603963e-07
CYP27 O 0 0.00038466978003270924
gene O 0 2.4882872367015807e-06
not O 0 1.3398617682014446e-07
only O 0 1.1820032597142927e-07
causes O 0 2.2344509034155635e-06
the O 0 9.391815183334984e-06
deficiency B-Disease 0 0.010781302116811275
in I-Disease 0 2.863325789803639e-07
the I-Disease 0 6.170047868181427e-07
sterol I-Disease 0 3.6209996324032545e-05
27 I-Disease 0 4.088085461262381e-06
- I-Disease 0 1.0113049938809127e-05
hydroxylase I-Disease 0 2.3019281798042357e-05
activity I-Disease 0 1.0397557161923032e-06
, O 0 7.812349167579669e-08
but O 0 7.696512938082378e-08
also O 0 1.649454333119138e-07
partially O 0 2.439103354845429e-06
leads O 0 3.859045420995244e-07
to O 0 1.0243707038171124e-07
alternative O 0 5.829118094879959e-07
pre O 0 3.3640178571658907e-06
- O 0 1.530921849735023e-06
mRNA O 0 1.200872929985053e-06
splicing O 0 3.091557573497994e-06
of O 0 1.8861696560179553e-07
the O 0 1.4500479892376461e-06
gene O 0 3.314373316243291e-05
. O 0 1.2243618584761862e-05

To O 0 6.2293293012771755e-06
our O 0 1.017226622934686e-06
knowledge O 0 4.67524642999706e-07
, O 0 6.496559024071757e-08
this O 0 3.313873975230308e-08
is O 0 4.188905577962032e-08
the O 0 1.0320230359184279e-07
first O 0 5.203472142056853e-07
report O 0 2.5984400053857826e-06
regarding O 0 7.769313015160151e-07
effects O 0 3.2486118470842484e-06
on O 0 7.965709869495186e-07
pre O 0 5.764856268797303e-06
- O 0 1.6659191715007182e-06
mRNA O 0 3.9790771211301035e-07
splicing O 0 8.965222946244467e-07
of O 0 4.7023796412304364e-08
a O 0 2.6093414362549083e-07
mutation O 0 9.449811955164478e-07
at O 0 1.8215479258287814e-07
the O 0 2.1294488306011772e-07
- O 0 3.852522240777034e-06
2 O 0 2.0486386631546338e-07
position O 0 2.676894439446187e-07
of O 0 5.426815619102854e-08
a O 0 1.1519609870447312e-06
5 O 0 3.541681962815346e-06
splice O 0 0.00011904072016477585
site O 0 3.0275372409960255e-05
. O 0 1.4910840945958626e-05

ATM O 0 0.017383864149451256
germline O 0 0.4545099437236786
mutations O 0 0.006428020540624857
in O 0 6.515342101920396e-05
classical O 0 0.029023507609963417
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.021349510177969933
in O 0 1.8172549971495755e-06
the O 0 2.5930976335075684e-06
Dutch O 0 0.0001239176344824955
population O 0 9.192076504405122e-06
. O 0 1.2102407708880492e-05

Germline O 1 0.7224473357200623
mutations O 0 0.0024030699860304594
in O 0 9.339823009213433e-06
the O 0 4.057328169437824e-06
ATM O 0 0.00011834996985271573
gene O 0 1.2585850527102593e-05
are O 0 1.951278250089672e-07
responsible O 0 1.4505403669318184e-06
for O 0 1.8265541257278528e-06
the O 1 0.8033228516578674
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.014385281130671501
A B-Disease 1 0.999976634979248
- I-Disease 1 0.9999935626983643
T I-Disease 1 0.9999977350234985
) O 0 2.17187207454117e-05
. O 0 2.2051730411476456e-05

In O 0 1.4466237189481035e-05
our O 0 2.71723183686845e-06
study O 0 1.565032675898692e-06
, O 0 3.018502923168853e-07
we O 0 7.39579348874031e-08
have O 0 1.0676992445723954e-07
determined O 0 4.770204213855322e-07
the O 0 2.95929908133985e-07
ATM O 0 3.251091038691811e-05
mutation O 0 4.767484824697021e-06
spectrum O 0 2.3183970370155293e-06
in O 0 3.3130658039226546e-07
19 O 0 8.419045229857147e-07
classical O 0 1.991283625102369e-06
A B-Disease 1 0.9999788999557495
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.764998710830696e-06
, O 0 5.482120712940741e-08
including O 0 3.6270009218242194e-08
some O 0 4.886801718839706e-08
immigrant O 0 6.470700668614882e-07
populations O 0 2.2291183654488123e-07
, O 0 5.263222035978288e-08
as O 0 5.848155737453453e-08
well O 0 6.61831407455793e-08
as O 0 5.875055109072491e-08
12 O 0 1.207381217227521e-07
of O 0 7.997247308821898e-08
Dutch O 0 3.849840595648857e-06
ethnic O 0 9.920361208060058e-07
origin O 0 3.953005034418311e-06
. O 0 1.0170627319894265e-05

Both O 0 1.7441807358409278e-05
the O 0 5.330992280505598e-06
protein O 0 1.0946867405436933e-05
truncation O 0 5.08822085976135e-05
test O 0 1.1064861610066146e-05
( O 0 1.9354540654603625e-06
PTT O 0 1.3106243386573624e-05
) O 0 3.05563418123711e-07
and O 0 9.976987058735176e-08
the O 0 3.2575823638580914e-07
restriction O 0 4.825458290724782e-06
endonuclease O 0 9.166542440652847e-05
fingerprinting O 0 2.328813206986524e-05
( O 0 3.0375642836588668e-06
REF O 0 0.00012666538532357663
) O 0 2.435039903048164e-07
method O 0 1.671254921120635e-07
were O 0 8.262099271405532e-08
used O 0 9.409087198264388e-08
and O 0 4.853093216183879e-08
compared O 0 7.7794872765935e-08
for O 0 2.8112150829429083e-08
their O 0 5.439977357468706e-08
detection O 0 8.400919000450813e-07
efficiency O 0 9.425797884432541e-07
, O 0 7.847339844602175e-08
identifying O 0 2.922510873304418e-07
76 O 0 7.534990231761185e-07
% O 0 9.803871847680057e-08
and O 0 5.5405038779099414e-08
60 O 0 1.1509228414752215e-07
% O 0 5.928626478635124e-08
of O 0 4.249713114745646e-08
the O 0 1.3201604360801866e-06
mutations O 0 3.468350041657686e-05
, O 0 1.0964942021018942e-06
respectively O 0 1.03053052953328e-05
. O 0 1.2300895832595415e-05

Most O 0 4.389716559671797e-05
patients O 0 0.00011816548794740811
were O 0 1.550447336740035e-06
found O 0 1.314792939410836e-06
to O 0 7.697436217313225e-07
be O 0 1.1761117093556095e-06
compound O 0 6.255837070057169e-05
heterozygote O 0 0.00036985412589274347
. O 0 3.4833992685889825e-05

Seventeen O 0 0.00026763256755657494
mutations O 0 0.00025337369879707694
were O 0 1.2370010153972544e-06
distinct O 0 1.0694127468013903e-06
, O 0 1.2047232189615897e-07
of O 0 5.130700486688511e-08
which O 0 2.488875168182858e-07
10 O 0 2.25305555545674e-07
were O 0 4.551109498152073e-07
not O 0 4.199769989554625e-07
reported O 0 3.910987652488984e-05
previously O 0 3.610596832004376e-05
. O 0 1.593440174474381e-05

Mutations O 0 0.001375418622046709
are O 0 4.435817118064733e-06
small O 0 2.4423852664767765e-06
deletions O 0 3.2674714020686224e-05
or O 0 2.6776194772537565e-06
point O 0 4.5792266973876394e-06
mutations O 0 3.9137667044997215e-05
frequently O 0 1.0340961125621106e-05
affecting O 0 1.4394566278497223e-05
splice O 0 0.00032923617982305586
sites O 0 4.5450113248080015e-05
. O 0 3.2629432098474354e-05

Moreover O 0 0.00020072588813491166
, O 0 1.0515163012314588e-05
a O 0 1.3585105989477597e-05
16 O 0 3.211273724446073e-05
. O 0 2.269054311909713e-05

7 O 0 0.0003548785753082484
- O 0 0.0006057347636669874
kb O 0 0.0010781853925436735
genomic O 0 6.176199531182647e-05
deletion O 0 3.143061258015223e-05
of O 0 4.0503820741832897e-07
the O 0 2.8268678420317883e-07
3 O 0 2.399246170625702e-07
end O 0 2.0327095739958168e-07
of O 0 4.1426940100564025e-08
the O 0 1.266770084384916e-07
gene O 0 7.663793439860456e-07
, O 0 4.0350521146592655e-08
most O 0 3.9486081959694275e-08
likely O 0 1.2900693491246784e-07
a O 0 2.0017012047901517e-07
result O 0 1.1880528916208277e-07
of O 0 4.043619483695693e-08
recombination O 0 5.944443728367332e-07
between O 0 7.446183047932209e-08
two O 0 9.034006609454082e-08
LINE O 0 4.116232503292849e-06
elements O 0 8.265739097623737e-07
, O 0 3.3102611496360623e-07
was O 0 6.625274636462564e-06
identified O 0 7.474722224287689e-06
. O 0 1.048483136401046e-05

The O 0 9.613734619051684e-06
most O 0 1.4304888509286684e-06
frequently O 0 2.6692873689171392e-06
found O 0 1.0083140296046622e-06
mutation O 0 2.155015636162716e-06
, O 0 1.844554731178505e-07
identified O 0 2.982812929985812e-07
in O 0 1.0763525182255762e-07
three O 0 8.457561762043042e-08
unrelated O 0 1.6323174349963665e-06
Turkish O 0 5.251697530184174e-06
A B-Disease 1 0.998267412185669
- I-Disease 1 0.9999574422836304
T I-Disease 1 0.9999922513961792
individuals O 0 1.6742347952458658e-07
, O 0 1.9782768845288956e-07
was O 0 6.1063101384206675e-06
previously O 0 2.3401817088597454e-06
described O 0 3.563520976967993e-06
to O 0 1.3317557545633463e-07
be O 0 5.047256124157684e-08
a O 0 3.383894977559976e-07
Turkish O 0 4.417731361172628e-06
A B-Disease 1 0.9982230067253113
- I-Disease 1 0.9999891519546509
T I-Disease 1 0.9999995231628418
founder O 0 0.03158051520586014
mutation O 0 0.0003398051776457578
. O 0 2.5982393708545715e-05

The O 0 1.2751756003126502e-05
presence O 0 7.19321451470023e-06
of O 0 5.289862770041509e-07
a O 0 2.7498151666804915e-06
founder O 0 8.018214430194348e-05
mutation O 0 7.742199159110896e-06
among O 0 2.439884099203482e-07
relatively O 0 3.467212366103922e-07
small O 0 2.0846580639499734e-07
ethnic O 0 1.3506873131063912e-07
population O 0 7.833805426571416e-08
groups O 0 4.581103496548167e-08
in O 0 7.35738296953059e-08
Western O 0 4.578583627790067e-07
Europe O 0 2.005705709962058e-06
could O 0 4.4357818751450395e-07
indicate O 0 4.357293619250413e-07
a O 0 7.823277314855659e-07
high O 0 4.6243185352068394e-06
carrier O 0 2.1407675376394764e-05
frequency O 0 4.6393024604185484e-06
in O 0 4.4491866901807953e-07
such O 0 5.156950351192791e-07
communities O 0 5.529404461412923e-06
. O 0 1.3568661415774841e-05

In O 0 8.232944674091414e-05
patients O 0 2.5654582714196295e-05
of O 0 6.926123887751601e-07
Dutch O 0 6.5527992774150334e-06
ethnic O 0 4.081884981133044e-07
origin O 0 4.145793752741156e-07
, O 0 1.5625153082510224e-07
however O 0 1.4471852693986875e-07
, O 0 6.69557564947354e-08
no O 0 1.0323281429691633e-07
significant O 0 2.94130586553365e-07
founder O 0 1.5814714060979895e-05
effect O 0 1.6111370086946408e-06
could O 0 8.559727007195761e-07
be O 0 5.964057550045254e-07
identified O 0 5.887197403353639e-06
. O 0 6.7353334998188075e-06

The O 0 3.216253753635101e-05
observed O 0 4.0134509617928416e-05
genetic O 0 1.5646384781575762e-05
heterogeneity O 0 1.458602309867274e-05
including O 0 4.810938207810977e-07
the O 0 4.937742801303102e-07
relative O 0 1.98651332539157e-06
high O 0 2.6032867026515305e-06
percentage O 0 7.742079901618126e-07
of O 0 2.1207705458436976e-07
splice O 0 0.00014662019384559244
- O 0 0.014370943419635296
site O 0 7.758802530588582e-05
mutations O 0 1.6996780686895363e-05
had O 0 1.8350081063545076e-06
no O 0 2.622215902192693e-07
reflection O 0 1.9906703982996987e-06
on O 0 1.7419131381757325e-06
the O 0 9.507742106507067e-06
phenotype O 0 0.0013604860287159681
. O 0 2.0934166968800128e-05

All O 0 3.821110294666141e-05
patients O 0 0.00011584861931623891
manifested O 0 9.256223711417988e-05
classical O 0 1.628441532375291e-05
A B-Disease 1 0.9994097948074341
- I-Disease 1 0.9997476935386658
T I-Disease 1 0.9999392032623291
and O 0 1.64710104400001e-06
increased O 0 5.59272621103446e-06
cellular O 0 4.0912131225923076e-05
radioresistant O 0 0.0001962047244887799
DNA O 0 5.025281643611379e-05
synthesis O 0 0.00010469681728864089
. O 0 3.64102452294901e-05

Determination O 0 6.475872942246497e-05
of O 0 2.6722570964921033e-06
the O 0 1.4913193808752112e-06
genomic O 0 8.09328139439458e-06
structure O 0 9.119187893702474e-07
of O 0 1.0343976697413382e-07
the O 0 3.7834195154573536e-07
COL4A4 O 0 0.00010819925955729559
gene O 0 2.1325226953194942e-06
and O 0 1.638998554653881e-07
of O 0 3.705181654822809e-07
novel O 0 7.179910608101636e-05
mutations O 0 0.06476401537656784
causing O 0 0.38462573289871216
autosomal B-Disease 1 0.9999984502792358
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00034883234184235334

Autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 8.017595246201381e-05
a O 0 0.00013855460565537214
progressive O 1 0.8591720461845398
hematuric B-Disease 1 0.9977599382400513
glomerulonephritis I-Disease 1 0.9999995231628418
characterized O 0 0.030716422945261
by O 0 2.4436769308522344e-05
glomerular B-Disease 1 0.9457719922065735
basement I-Disease 1 0.9994613528251648
membrane I-Disease 1 0.7796557545661926
abnormalities I-Disease 1 0.9977791905403137
and O 0 1.694810180197237e-06
associated O 0 2.6889915716310497e-06
with O 0 8.330083005603228e-07
mutations O 0 1.034810338751413e-05
in O 0 2.5617779897402215e-07
either O 0 2.5596654040782596e-07
the O 0 4.799454131898528e-07
COL4A3 O 0 0.0004187118320260197
or O 0 3.677048994177312e-07
the O 0 3.737694100891531e-07
COL4A4 O 0 0.00010066521645057946
gene O 0 2.5168114916596096e-06
, O 0 1.093577921551514e-07
which O 0 6.62988739463799e-08
encode O 0 4.5766236667077465e-07
the O 0 2.4027815470617497e-07
alpha3 O 0 1.3273121112433728e-05
and O 0 6.460403483288246e-07
alpha4 O 0 0.0005622875178232789
type O 0 0.006392802111804485
IV O 1 0.9994148015975952
collagen O 0 0.04605288431048393
chains O 0 0.00018047452613245696
, O 0 2.457773689457099e-06
respectively O 0 1.0055118764284998e-05
. O 0 1.1118330803583376e-05

To O 0 1.7351123460684903e-05
date O 0 6.774953362764791e-06
, O 0 1.199889538838761e-06
mutation O 0 3.023717226824374e-06
screening O 0 9.936277365341084e-07
in O 0 1.8926529321561247e-07
the O 0 1.325768153037643e-07
two O 0 1.1646294950651281e-07
genes O 0 5.122116135680699e-07
has O 0 2.1791990434394393e-07
been O 0 1.6329731522546354e-07
hampered O 0 4.77543017041171e-06
by O 0 2.2608277561175782e-07
the O 0 2.265070691009896e-07
lack O 0 5.432091825241514e-07
of O 0 2.671146432930982e-07
genomic O 0 2.33383325394243e-05
structure O 0 1.347134184470633e-05
information O 0 6.121610113041243e-06
. O 0 1.3007735105929896e-05

We O 0 1.2336680811131373e-05
report O 0 5.760053682024591e-06
here O 0 2.584212950296205e-07
the O 0 1.5307801959352219e-07
complete O 0 5.568865049099259e-07
characterization O 0 1.379168907078565e-06
of O 0 9.238774367759106e-08
the O 0 3.0369133696694917e-07
48 O 0 6.001222914164828e-07
exons O 0 7.688617529311159e-07
of O 0 4.999722236220805e-08
the O 0 2.6916677597910166e-07
COL4A4 O 0 8.886778960004449e-05
gene O 0 2.491991608621902e-06
, O 0 7.228025111771785e-08
a O 0 2.3181881658729253e-07
comprehensive O 0 1.253818709301413e-06
gene O 0 1.2141631486883853e-06
screen O 0 1.0720217460402637e-06
, O 0 5.467126129587996e-08
and O 0 4.8486523240853785e-08
the O 0 6.291110565825875e-08
subsequent O 0 6.355454047479725e-07
detection O 0 1.1791956922024838e-06
of O 0 9.040384441050264e-08
10 O 0 2.5820966698120174e-07
novel O 0 1.455205506317725e-06
mutations O 0 3.892751465173205e-06
in O 0 6.963132364035118e-07
eight O 0 0.00015493921819142997
patients O 1 0.9887110590934753
diagnosed O 1 0.9999946355819702
with O 1 0.7378332614898682
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0004798007139470428

Furthermore O 0 9.128631063504145e-05
, O 0 3.944855507143075e-06
we O 0 3.987541106198478e-07
identified O 0 9.671407497080509e-07
a O 0 1.0022433798440034e-06
glycine O 0 2.324577326362487e-05
to O 0 6.694247076666215e-07
alanine O 0 8.519184120814316e-06
substitution O 0 1.4225223594621639e-06
in O 0 2.3745661792418105e-07
the O 0 2.2019112577709166e-07
collagenous O 0 2.5912022465490736e-05
domain O 0 8.28132954211469e-07
that O 0 1.2538446014787041e-07
is O 0 1.0690522600498298e-07
apparently O 0 6.768468097106961e-07
silent O 0 1.2186875437691924e-06
in O 0 1.2314143305047764e-07
the O 0 5.147094270796515e-07
heterozygous O 0 7.221449777716771e-06
carriers O 0 1.2022950386381126e-06
, O 0 2.491632642431796e-07
in O 0 7.427734658449481e-07
11 O 0 9.579764082445763e-06
. O 0 1.2454311217879876e-05

5 O 0 3.1279669201467186e-05
% O 0 1.5187154076556908e-06
of O 0 1.47717884146914e-07
all O 0 9.927897082206982e-08
control O 0 3.449518544584862e-06
individuals O 0 8.361053005501162e-08
, O 0 4.9446605032699154e-08
and O 0 6.084796666527836e-08
in O 0 1.5839367506487179e-07
one O 0 1.1121071707975716e-07
control O 0 1.948191311385017e-06
individual O 0 1.6266687907773303e-07
homozygous O 0 2.957590822916245e-06
for O 0 1.8042398153284012e-07
this O 0 4.081775841768831e-07
glycine O 0 0.0001061814182321541
substitution O 0 4.474072193261236e-05
. O 0 1.9788987628999166e-05

There O 0 1.1237445505685173e-05
has O 0 2.182257048843894e-06
been O 0 3.666131362933811e-07
no O 0 7.372835142405165e-08
previous O 0 2.3219517686356994e-07
finding O 0 8.875036883182474e-08
of O 0 3.6075032738835944e-08
a O 0 3.3053842685148993e-07
glycine O 0 6.522124294860987e-06
substitution O 0 5.352044354367536e-07
that O 0 1.4682615301353508e-07
is O 0 7.731500772933941e-08
not O 0 4.071635473223978e-08
associated O 0 1.3100263629439723e-07
with O 0 8.55848156788852e-08
any O 0 3.1542361966785393e-07
obvious O 0 3.5696298255061265e-06
phenotype O 0 0.0001756758865667507
in O 0 3.830942659988068e-06
homozygous O 0 0.00012026461627101526
individuals O 0 5.71610053157201e-06
. O 0 1.9328521375427954e-05

Founder O 0 0.004493215586990118
BRCA1 O 0 0.003455857979133725
and O 0 2.9737731892964803e-05
BRCA2 O 0 0.0009819449624046683
mutations O 0 4.8881920520216227e-05
in O 0 2.4231705992860952e-06
French O 0 5.480071922647767e-05
Canadian O 0 0.0659748911857605
breast B-Disease 1 0.9999523162841797
and I-Disease 1 0.9998183846473694
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 7.267718319781125e-05
. O 0 5.7303539506392553e-05

We O 0 9.99512576527195e-06
have O 0 1.2657147863137652e-06
identified O 0 1.437320861441549e-06
four O 0 5.834735361531784e-07
mutations O 0 2.3068446353136096e-06
in O 0 1.1235285768407266e-07
each O 0 6.5994690601201e-08
of O 0 1.1806660182855921e-07
the O 0 3.722676410689019e-05
breast B-Disease 1 0.9971893429756165
cancer I-Disease 0 0.14338155090808868
- O 0 0.001280479016713798
susceptibility O 0 4.031668504467234e-05
genes O 0 3.3643675578787224e-06
, O 0 8.748537538849632e-07
BRCA1 O 0 2.129336826328654e-05
and O 0 1.8844037867893348e-06
BRCA2 O 0 2.250151737825945e-05
, O 0 2.3803433180091815e-07
in O 0 3.935969061785727e-07
French O 0 1.8536469724494964e-05
Canadian O 0 0.025760870426893234
breast B-Disease 1 0.999786913394928
cancer I-Disease 1 0.9955062866210938
and O 1 0.519138514995575
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.0468376533244736e-05
from O 0 2.2801845261710696e-05
Quebec O 0 0.0011529943440109491
. O 0 5.329006307874806e-05

To O 0 3.5007891710847616e-05
identify O 0 2.8593207389349118e-05
founder O 0 0.00014617266424465925
effects O 0 4.112771057407372e-05
, O 0 4.818840579901007e-07
we O 0 2.2256791964991862e-07
examined O 0 5.2137770580884535e-06
independently O 0 2.269517153763445e-06
ascertained O 0 4.4115677155787125e-06
French O 0 8.043144589464646e-06
Canadian O 0 0.0003372803039383143
cancer B-Disease 0 0.003279545810073614
families O 0 1.475323188060429e-07
for O 0 3.8360674636805925e-08
the O 0 1.3737825099724432e-07
distribution O 0 2.3822305195153604e-07
of O 0 1.0360701452327703e-07
these O 0 2.0700119307548448e-07
eight O 0 2.8633116926357616e-06
mutations O 0 8.08937766123563e-05
. O 0 1.58924849529285e-05

Mutations O 0 0.0029726484790444374
were O 0 1.1201686902495567e-05
found O 0 2.3731720375508303e-06
in O 0 8.469651220366359e-07
41 O 0 2.3067784695740556e-06
of O 0 3.295796489055647e-07
97 O 0 1.592495209479239e-05
families O 0 1.1480148714326788e-05
. O 0 2.8823124011978507e-05

Six O 0 1.2214370144647546e-05
of O 0 1.1654722129605943e-06
eight O 0 3.481822659523459e-06
mutations O 0 2.7687730835168622e-05
were O 0 1.0409165724922786e-06
observed O 0 2.795730097204796e-06
at O 0 8.520422625224455e-07
least O 0 1.4206744936018367e-06
twice O 0 1.5160909242695197e-05
. O 0 1.9156885173288174e-05

The O 0 0.00010723149171099067
BRCA1 O 0 0.0010590879246592522
C4446T O 0 0.000340110098477453
mutation O 0 7.144606206566095e-05
was O 0 6.281606147240382e-06
the O 0 2.9357067887758603e-07
most O 0 1.5027593747163337e-07
common O 0 1.3304752428666689e-06
mutation O 0 9.261325430998113e-06
found O 0 6.135978765087202e-07
, O 0 9.2413294794369e-08
followed O 0 4.687586283580458e-07
by O 0 4.1296388531009143e-07
the O 0 3.016286655110889e-06
BRCA2 O 0 0.000464126089354977
8765delAG O 0 0.000421321572503075
mutation O 0 0.0002311334974365309
. O 0 2.443576704536099e-05

Together O 0 2.8368483981466852e-05
, O 0 2.786177219604724e-06
these O 0 5.702133876184234e-07
mutations O 0 5.372301984607475e-06
were O 0 2.550817157498386e-07
found O 0 1.5225585059397417e-07
in O 0 9.740183060102936e-08
28 O 0 2.5557869776093867e-07
of O 0 5.8526300250605345e-08
41 O 0 1.0608154070723685e-06
families O 0 3.072720176078292e-07
identified O 0 8.022851147870824e-07
to O 0 4.2241157416356145e-07
have O 0 4.907219590677414e-07
a O 0 7.802275831636507e-06
mutation O 0 0.00010427794040879235
. O 0 1.5613724826835096e-05

The O 0 2.2584177713724785e-05
odds O 0 3.969956742366776e-05
of O 0 5.188744580664206e-07
detection O 0 1.9882986634911504e-06
of O 0 7.546439206862487e-08
any O 0 6.657626272499328e-08
of O 0 4.511250395466959e-08
the O 0 2.938126613116765e-07
four O 0 1.5621635611751117e-06
BRCA1 O 0 0.00041306266211904585
mutations O 0 4.094807809451595e-05
was O 0 3.040476622118149e-05
18 O 0 1.1640908269328065e-05
. O 0 1.5746782082715072e-05

7x O 0 0.006543782074004412
greater O 0 2.0312174456194043e-05
if O 0 1.6347835298802238e-06
one O 0 3.164374788866553e-07
or O 0 2.5704827066874714e-07
more O 0 9.040142856520106e-08
cases O 0 5.06694334490021e-07
of O 0 0.0022095448803156614
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.3671911801793613e-05
also O 0 1.0832515044967295e-06
present O 0 5.722421292375657e-07
in O 0 5.725030405301368e-07
the O 0 2.900737626987393e-06
family O 0 6.0381953517207876e-05
. O 0 2.6746673029265366e-05

The O 0 1.905572207760997e-05
odds O 0 2.5813485990511253e-05
of O 0 6.371694212248258e-07
detection O 0 2.1271969217195874e-06
of O 0 7.66182921552172e-08
any O 0 6.954572029371775e-08
of O 0 5.578550599238952e-08
the O 0 3.456838442161825e-07
four O 0 1.9182380128768273e-06
BRCA2 O 0 0.0005666477954946458
mutations O 0 3.052632382605225e-05
was O 0 1.4345724594022613e-05
5 O 0 1.201780469273217e-05
. O 0 1.274672285944689e-05

3x O 0 0.0017917908262461424
greater O 0 1.9366474589332938e-05
if O 0 1.6798402384665678e-06
there O 0 2.789285531434871e-07
were O 0 1.7098794558023656e-07
at O 0 1.4063206776881998e-07
least O 0 7.037275651100572e-08
five O 0 9.892324470683889e-08
cases O 0 2.194711896663648e-07
of O 0 1.0474520877323812e-06
breast B-Disease 1 0.9986183643341064
cancer I-Disease 0 0.019632000476121902
in O 0 8.808286224848416e-07
the O 0 6.426810614357237e-06
family O 0 0.0001238852710230276
. O 0 1.948139470187016e-05

Interestingly O 0 0.00021325548004824668
, O 0 2.9000709673709935e-06
the O 0 9.150428468274185e-07
presence O 0 1.0826793186424766e-06
of O 0 6.55725386877748e-07
a O 0 0.004962381441146135
breast B-Disease 1 0.999933123588562
cancer I-Disease 0 0.2707230746746063
case O 0 3.7039490052848123e-06
< O 0 5.9161257013329305e-06
36 O 0 6.472021141235018e-07
years O 0 1.7268141050408303e-07
of O 0 6.996255308422406e-08
age O 0 1.1361008773747017e-06
was O 0 6.995786861807574e-06
strongly O 0 1.874509848676098e-06
predictive O 0 8.214744866563706e-07
of O 0 3.0155042907153984e-08
the O 0 7.62794201136785e-08
presence O 0 9.573678738661329e-08
of O 0 1.9877774093401968e-08
any O 0 3.597930842147434e-08
of O 0 3.2253552717520506e-08
the O 0 3.2640352287671703e-07
eight O 0 2.2248354980547447e-06
mutations O 0 4.037220423924737e-05
screened O 0 6.406464672181755e-05
. O 0 1.794853051251266e-05

Carriers O 0 6.85000341036357e-05
of O 0 9.868970209936379e-07
the O 0 6.977144835218496e-07
same O 0 8.675457365825423e-07
mutation O 0 3.5428677165327827e-06
, O 0 1.148714332543932e-07
from O 0 6.194876078779998e-08
different O 0 2.7998650509175604e-08
families O 0 5.485781429115377e-08
, O 0 5.3645532460677714e-08
shared O 0 2.7729581120183866e-07
similar O 0 9.892236221276107e-07
haplotypes O 0 5.836905984324403e-06
, O 0 9.61987822734045e-08
indicating O 0 2.801254765927297e-07
that O 0 3.230256240271956e-08
the O 0 9.263742839493716e-08
mutant O 0 2.8325937364570564e-06
alleles O 0 1.3368995723794797e-06
were O 0 1.2777321956036758e-07
likely O 0 2.2246818787152733e-07
to O 0 7.829937231917938e-08
be O 0 4.234106043554675e-08
identical O 0 4.1386672933185764e-07
by O 0 9.802375444678546e-08
descent O 0 7.59759302582097e-07
for O 0 6.806400421055514e-08
a O 0 9.178606319437677e-07
mutation O 0 2.269140622956911e-06
in O 0 2.520116026971664e-07
the O 0 7.188518225120788e-07
founder O 0 3.6359553632792085e-05
population O 0 4.578977495839354e-06
. O 0 1.442438497178955e-05

The O 0 1.4281919902714435e-05
identification O 0 1.0248635589960031e-05
of O 0 1.4454446954914602e-06
common O 0 8.274372703453992e-06
BRCA1 O 0 0.0004511723527684808
and O 0 1.7788983313948847e-05
BRCA2 O 0 0.0018749171867966652
mutations O 0 4.5362812670646235e-05
will O 0 7.443086360581219e-07
facilitate O 0 1.7569350347912405e-06
carrier O 0 1.5727915524621494e-05
detection O 0 4.428285137692001e-06
in O 0 8.687901527082431e-07
French O 0 2.6596961106406525e-05
Canadian O 0 0.03337496146559715
breast B-Disease 1 0.9999568462371826
cancer I-Disease 1 0.9986529350280762
and O 1 0.828174352645874
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.091211980674416e-05
. O 0 4.326074486016296e-05

Are O 0 3.2170726626645774e-05
Dp71 O 0 0.00039719586493447423
and O 0 1.1910531611647457e-05
Dp140 O 0 0.0007640934782102704
brain O 0 0.0034983381628990173
dystrophin O 0 0.0009561717743054032
isoforms O 0 4.632002310245298e-05
related O 0 8.875838830135763e-06
to O 0 7.117830136849079e-06
cognitive B-Disease 0 0.0005466911243274808
impairment I-Disease 0 0.34989336133003235
in O 0 0.0791485458612442
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
? O 0 0.003316574962809682

Molecular O 0 0.0006665901746600866
study O 0 3.873354580719024e-05
and O 0 7.911330612841994e-06
neuropsychological O 0 0.00044603849528357387
analysis O 0 3.672083494166145e-06
were O 0 1.1780626891777501e-06
performed O 0 1.3498002999767778e-06
concurrently O 0 1.8321474044569186e-06
on O 0 1.4783795450057369e-06
49 O 0 1.0712740731833037e-05
patients O 0 1.9028137103305198e-05
with O 0 0.00010413662676000968
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.016681231558322906
DMD B-Disease 1 0.9999998807907104
) O 0 3.2300517887051683e-06
in O 0 3.8300950677694345e-07
order O 0 1.4890625266161805e-07
to O 0 1.1511468045455331e-07
find O 0 1.5580572210183163e-07
a O 0 3.1875816830506665e-07
molecular O 0 1.5245403801600332e-06
explanation O 0 7.156376113925944e-07
for O 0 1.8587435590688983e-07
the O 0 2.394149532847223e-06
cognitive B-Disease 0 0.00022768070630263537
impairment I-Disease 0 0.0003541848564054817
observed O 0 9.739838787936606e-06
in O 0 6.3344728005176876e-06
most O 0 0.0001201038176077418
DMD B-Disease 1 1.0
patients O 1 0.5884270668029785
. O 0 9.722640970721841e-05

Complete O 0 4.3069423554698005e-05
analysis O 0 6.260452664719196e-06
of O 0 5.721220759369317e-07
the O 0 1.4442184692597948e-06
dystrophin O 0 0.00041877233888953924
gene O 0 1.620939656277187e-05
was O 0 5.870199402124854e-06
performed O 0 9.44574765071593e-07
to O 0 1.9832486941595562e-07
define O 0 4.5379641733234166e-07
the O 0 1.8922631284112867e-07
localization O 0 1.5942404161251034e-06
of O 0 1.4235956768970937e-07
deletions O 0 5.7364591157238465e-06
and O 0 3.674346373827575e-07
duplications O 0 3.103829385509016e-06
in O 0 3.5275138543511275e-07
relation O 0 5.083350629320194e-07
to O 0 2.920359634117631e-07
the O 0 9.185865224026202e-07
different O 0 3.815049694821937e-06
DMD B-Disease 1 0.9999934434890747
promoters O 0 0.0003807973116636276
. O 0 3.9646147342864424e-05

Qualitative O 0 0.00016927285469137132
analysis O 0 9.123649761022534e-06
of O 0 5.393001174525125e-07
the O 0 9.350135883323674e-07
Dp71 O 0 5.0730803195619956e-05
transcript O 0 3.281257158960216e-05
and O 0 4.38321279716547e-07
testing O 0 3.6445530327000597e-07
for O 0 2.5069315512382673e-08
the O 0 4.9094197152044217e-08
specific O 0 5.933332047902695e-08
first O 0 1.485894784991615e-07
exon O 0 1.4158688372845063e-06
of O 0 1.1395749766052177e-07
Dp140 O 0 5.3127564569876995e-06
were O 0 4.02273457211777e-07
also O 0 3.4322539477216196e-07
carried O 0 2.0358827441668836e-06
out O 0 1.4482236565527273e-06
. O 0 7.480577096430352e-06

Neuropsychological O 0 0.019006619229912758
analysis O 0 9.023012535180897e-05
assessed O 0 2.9887471100664698e-05
verbal O 0 2.7474627131596208e-05
and O 0 3.821641257673036e-06
visuospatial O 0 0.00027073791716247797
intelligence O 0 4.254436498740688e-05
, O 0 8.002921276784036e-07
verbal O 0 6.334847057587467e-06
memory O 0 0.00018137728329747915
, O 0 5.378153105084493e-07
and O 0 9.6408803074155e-07
reading O 0 1.4096875929681119e-05
skills O 0 2.884374771383591e-05
. O 0 2.2298689145827666e-05

Comparison O 0 6.526435754494742e-05
of O 0 2.91881633529556e-06
molecular O 0 1.9999519281554967e-05
and O 0 2.817315589709324e-06
psychometric O 0 0.00015056683332659304
findings O 0 1.4061884940019809e-05
demonstrated O 0 3.0501360015477985e-06
that O 0 2.4299504275404615e-07
deletions O 0 4.954614269081503e-06
and O 0 2.979907662847836e-07
duplications O 0 3.2527475468668854e-06
that O 0 1.5972034361766418e-07
were O 0 2.1978746644890634e-07
localized O 0 1.5228257552735158e-06
in O 0 1.0819820062124563e-07
the O 0 1.4393039293736365e-07
distal O 0 7.819645361450966e-06
part O 0 1.5427731625550223e-07
of O 0 3.8661688961383334e-08
the O 0 3.3975896940319217e-07
gene O 0 2.1524667772609973e-06
seemed O 0 8.485789066980942e-07
to O 0 1.5900269545454648e-07
be O 0 1.7685569275727175e-07
preferentially O 0 3.5082673548458843e-06
associated O 0 1.3371469549383619e-06
with O 0 2.723562147366465e-06
cognitive B-Disease 0 0.0009947180515155196
impairment I-Disease 0 0.02089856006205082
. O 0 5.247337685432285e-05

Two O 0 3.6089859349885955e-05
altered O 0 0.00021058908896520734
Dp71 O 0 0.00013785349437966943
transcripts O 0 2.3254531697602943e-05
and O 0 7.27595988792018e-07
two O 0 3.4874278753704857e-07
deleted O 0 5.465329195430968e-06
Dp140 O 0 7.071814252412878e-06
DNA O 0 1.6821326198623865e-06
sequences O 0 7.964380301928031e-07
were O 0 2.426654930332006e-07
found O 0 2.3179117647487146e-07
in O 0 1.7115729633587762e-07
four O 0 7.905951520115195e-07
patients O 0 1.1945224287046585e-05
with O 0 0.00015446334145963192
severe O 1 1.0
cerebral B-Disease 1 0.9999997615814209
dysfunction I-Disease 1 0.9999511241912842
. O 0 0.00014071352779865265

These O 0 1.2851412975578569e-05
findings O 0 2.2085383534431458e-05
suggest O 0 3.4557219805719797e-06
that O 0 1.7886053171878302e-07
some O 0 9.197052719400745e-08
sequences O 0 3.494792508718092e-07
located O 0 3.3383119557583996e-07
in O 0 1.0147853402031615e-07
the O 0 1.3990222669235663e-07
distal O 0 4.9885097723745275e-06
part O 0 1.9738671142022213e-07
of O 0 4.031298317386245e-08
the O 0 1.3762925732407894e-07
gene O 0 5.649855552292138e-07
and O 0 8.245239513371416e-08
, O 0 6.38993782331454e-08
in O 0 9.790865362901968e-08
particular O 0 2.2250445397276053e-07
, O 0 9.384604027218302e-08
some O 0 1.5521324314704543e-07
DMD B-Disease 1 0.9871240854263306
isoforms O 0 3.676996811918798e-06
expressed O 0 4.852838628721656e-07
in O 0 2.2160762114253885e-07
the O 0 4.484074452193454e-06
brain O 1 0.661431074142456
may O 0 5.6978678912855685e-06
be O 0 5.272908865094905e-08
related O 0 2.2291757773018617e-07
to O 0 1.5538607556209172e-07
the O 0 1.2939646012455341e-06
cognitive B-Disease 0 0.00046827158075757325
impairment I-Disease 0 0.016478465870022774
associated O 0 4.031103526358493e-05
with O 0 0.0001263429585378617
DMD B-Disease 1 0.9999998807907104
. O 0 4.171436376054771e-05
. O 0 4.136576171731576e-05

I1307K O 0 0.004753225948661566
APC O 0 0.0030765116680413485
and O 0 2.4534772819606587e-05
hMLH1 O 0 0.0004108027496840805
mutations O 0 5.8731729950523004e-05
in O 0 7.944497610878898e-07
a O 0 1.1484858077892568e-06
non O 0 1.3055044973953045e-06
- O 0 6.663668500550557e-06
Jewish O 0 1.567585513839731e-06
family O 0 2.8850095077359583e-06
with O 0 2.297853143318207e-06
hereditary B-Disease 1 0.9507896900177002
non I-Disease 0 0.1319248527288437
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00036794276093132794

We O 0 1.8125461792806163e-05
describe O 0 1.496090590080712e-05
a O 0 4.426233317644801e-06
French O 0 1.4179431673255749e-05
Canadian O 0 6.245893746381626e-05
hereditary B-Disease 1 0.9807866215705872
non I-Disease 0 0.11810552328824997
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.19016852974891663
HNPCC B-Disease 1 0.999933123588562
) O 0 1.6551141015952453e-05
kindred O 0 0.0002879567036870867
which O 0 1.5937083617245662e-06
carries O 0 2.0880274860246573e-06
a O 0 2.57203259934613e-06
novel O 0 9.21737591852434e-06
truncating O 0 0.00014945841394364834
mutation O 0 5.6047221733024344e-05
in O 0 9.470712939219084e-06
hMLH1 O 0 0.0005961761926300824
. O 0 4.173142951913178e-05

Interestingly O 0 0.00043595978058874607
, O 0 4.894548510492314e-06
the O 0 3.7630234146490693e-06
I1307K O 0 8.673685806570575e-05
APC O 0 0.0001516547054052353
polymorphism O 0 3.3431108022341505e-05
, O 0 6.287326073106669e-07
associated O 0 4.605116714628821e-07
with O 0 9.073569628981204e-08
an O 0 1.7728596901633864e-07
increased O 0 1.1811748663603794e-05
risk O 0 2.4278373530250974e-05
of O 0 0.005858960561454296
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.717010031323298e-06
is O 0 2.5297600814155885e-07
also O 0 2.2709147629029758e-07
present O 0 2.3593497644469608e-07
in O 0 2.723053285080823e-07
this O 0 8.875880439518369e-07
family O 0 2.679546014405787e-05
. O 0 1.2321818758209702e-05

The O 0 3.471914533292875e-05
I1307K O 0 0.0002735257730819285
polymorphism O 0 0.0001927358825923875
has O 0 4.354536940809339e-06
previously O 0 2.770008222796605e-06
only O 0 1.4969393191677227e-07
been O 0 2.0654174193168728e-07
identified O 0 3.360941320806887e-07
in O 0 1.0165773289827484e-07
individuals O 0 3.6661237601265384e-08
of O 0 8.095962300558313e-08
self O 0 2.2418284061132e-05
- O 0 0.008861993439495564
reported O 0 0.00010211145126959309
Ashkenazi O 0 7.04945923644118e-05
Jewish O 0 1.4616851331084035e-05
origins O 0 8.287887612823397e-05
. O 0 4.078432175447233e-05

In O 0 1.3174036212149076e-05
addition O 0 2.195753268097178e-06
, O 0 3.207405541161279e-07
in O 0 1.851341551173391e-07
this O 0 1.0265299721368137e-07
family O 0 1.0060481372420327e-06
, O 0 6.191048385062459e-08
there O 0 4.053465119113753e-08
appears O 0 3.6357459975988604e-07
to O 0 6.497525362192391e-08
be O 0 4.7062560071253756e-08
no O 0 2.9341327589804678e-08
relationship O 0 1.0035138586772518e-07
between O 0 6.166935406781704e-08
the O 0 1.30241403439868e-07
I1307K O 0 3.82835287382477e-06
polymorphism O 0 2.2432752757595154e-06
and O 0 7.92775125546541e-08
the O 0 1.1807527044993549e-07
presence O 0 3.2802932992126443e-07
or O 0 2.9260885980875173e-07
absence O 0 8.278771019831765e-07
of O 0 1.1555258652151679e-06
cancer B-Disease 0 0.008394099771976471
. O 0 3.492764108159463e-06
. O 0 1.1916711628146004e-05

Identification O 0 4.677514516515657e-05
of O 0 2.0385814423207194e-06
a O 0 4.3466457100294065e-06
novel O 0 4.668612746172585e-06
mutation O 0 2.5599345008231467e-06
of O 0 1.138598406669189e-07
the O 0 3.7163360389058653e-07
CPO O 0 4.6544300857931376e-05
gene O 0 2.5946735604520654e-06
in O 0 2.7450440143184096e-07
a O 0 7.503896313210134e-07
Japanese O 0 1.2889142453786917e-05
hereditary B-Disease 1 0.5165489315986633
coproporphyria I-Disease 0 0.051515933126211166
family O 0 0.00021425717568490654
. O 0 2.6885047191171907e-05

Hereditary B-Disease 1 0.999751627445221
coproporphyria I-Disease 1 0.9806622266769409
( O 0 0.0007987382705323398
HCP B-Disease 0 0.49773043394088745
) O 0 2.3469469851988833e-06
is O 0 5.73314423490956e-07
an O 0 2.571279537733062e-06
autosomal B-Disease 1 0.9062870144844055
dominant I-Disease 1 0.9564315676689148
disease I-Disease 1 0.8836315870285034
characterized O 0 0.00024369546736124903
by O 0 8.544258889742196e-06
a O 0 0.12144269049167633
deficiency B-Disease 1 0.8593233227729797
of I-Disease 0 7.77532477513887e-07
coproporphyrinogen I-Disease 0 0.09944039583206177
oxidase I-Disease 0 0.00022372011153493077
( O 0 2.9632376481458778e-06
CPO O 0 0.00010541107621975243
) O 0 4.1791219018705306e-07
caused O 0 7.88695160736097e-07
by O 0 1.4391214619990933e-07
a O 0 8.671345881339221e-07
mutation O 0 4.429206001077546e-06
in O 0 7.978078997439297e-07
the O 0 4.402645117806969e-06
CPO O 0 0.0007799537270329893
gene O 0 8.36826438899152e-05
. O 0 1.523425817140378e-05

Only O 0 1.2154040632594842e-05
11 O 0 8.587105185142718e-06
mutations O 0 8.510933184879832e-06
of O 0 1.8544321278568532e-07
the O 0 5.111799623591651e-07
gene O 0 2.95756262858049e-06
have O 0 4.2237653019583377e-07
been O 0 9.52789775965357e-07
reported O 0 3.735436257557012e-05
in O 0 1.8915043256129138e-05
HCP B-Disease 1 0.9945270419120789
patients O 0 0.00046453013783320785
. O 0 3.223731619073078e-05

We O 0 1.7048532754415646e-05
report O 0 1.3787158422928769e-05
another O 0 2.367089791732724e-06
mutation O 0 8.89164766704198e-06
in O 0 7.716590744166751e-07
a O 0 1.872442680905806e-06
Japanese O 0 1.5608722605975345e-05
family O 0 5.8627927501220256e-05
. O 0 1.696206527412869e-05

Polymerase O 0 0.0035668308846652508
chain O 0 0.003969991579651833
reaction O 0 0.00023506590514443815
- O 0 0.00015565860667265952
single O 0 7.95086452853866e-06
strand O 0 4.369938687887043e-05
conformational O 0 4.684129817178473e-05
polymorphism O 0 3.6871511838398874e-05
and O 0 6.002356371936912e-07
direct O 0 8.912141424843867e-07
sequence O 0 1.2828055560021312e-06
analyses O 0 2.000942686208873e-06
demonstrated O 0 1.5786059748279513e-06
a O 0 2.5648262180766324e-06
C O 0 3.723535701283254e-05
to O 0 8.519423317920882e-07
T O 0 1.957178392331116e-05
substitution O 0 8.16121655589086e-07
in O 0 3.548080940163345e-07
exon O 0 3.094047087870422e-06
1 O 0 1.4894474986704154e-07
of O 0 4.9354927256217707e-08
the O 0 2.528016409542033e-07
CPO O 0 1.898316986626014e-05
gene O 0 1.5398538835142972e-06
at O 0 3.4444650509612984e-07
nucleotide O 0 7.670030299777864e-07
position O 0 3.0254889793468465e-07
85 O 0 3.7758644566565636e-07
, O 0 7.19207733368421e-08
which O 0 1.0131318362027741e-07
lies O 0 2.2559903811725235e-07
in O 0 1.4480991694654222e-07
the O 0 4.100597266187833e-07
putative O 0 8.033745871216524e-06
presequence O 0 1.0700824532250408e-05
for O 0 3.3098885410254297e-07
targeting O 0 4.455693215277279e-06
to O 0 3.0933979360270314e-06
mitochondria O 0 0.00010966700210701674
. O 0 2.103986480506137e-05

This O 0 1.773807525751181e-05
mutation O 0 6.18480407865718e-05
changes O 0 4.675844593293732e-06
the O 0 9.471356747781101e-07
codon O 0 1.1221188287890982e-05
for O 0 3.593994790662691e-07
glutamine O 0 1.087331838789396e-05
to O 0 6.434762553908513e-07
a O 0 1.5534888007096015e-06
termination O 0 1.219151363329729e-05
codon O 0 1.3467501958075445e-05
at O 0 1.000794554784079e-06
amino O 0 2.9731450013059657e-06
acid O 0 8.870551027939655e-06
position O 0 6.949698672542581e-06
29 O 0 1.5701569282100536e-05
. O 0 8.688201887707692e-06

MaeI O 0 0.0028368670027703047
restriction O 0 0.00011443535186117515
analysis O 0 1.2135462384321727e-05
showed O 0 4.101378181076143e-06
two O 0 2.322567524970509e-07
other O 0 1.6047917483774654e-07
carriers O 0 1.0044174132417538e-06
in O 0 2.9749469376838533e-07
the O 0 1.417279122506443e-06
family O 0 4.11895671277307e-05
. O 0 1.4399467545445077e-05

The O 0 0.00014931353507563472
C O 0 0.03591354936361313
- O 0 0.3845272958278656
T O 0 0.06253591179847717
mutation O 0 1.4328838915389497e-05
is O 0 1.987675659620436e-07
located O 0 4.6342645987351716e-07
within O 0 2.1048205667284492e-07
a O 0 9.58317627919314e-07
recently O 0 5.351086656446569e-06
proposed O 0 1.7633270772421383e-06
putative O 0 1.1237702892685775e-05
alternative O 0 1.5881856825217255e-06
translation O 0 4.452066150406608e-06
initiation O 0 5.861942099727457e-06
codon O 0 2.547322765167337e-05
( O 0 2.7506334845384117e-06
TIC O 0 5.52386227354873e-05
- O 0 7.6158185038366355e-06
1 O 0 2.4129792564053787e-07
) O 0 8.724302347218327e-08
, O 0 3.071427556733397e-08
supporting O 0 8.727381839435111e-08
that O 0 1.1690639212247333e-07
TIC O 0 6.195139576448128e-05
- O 0 6.782090167689603e-06
1 O 0 1.6590493601142953e-07
is O 0 5.7514299101057986e-08
the O 0 1.7543254671181785e-07
real O 0 1.6363386521334178e-06
TIC O 0 4.541661837720312e-05
rather O 0 5.952896913186123e-07
than O 0 5.611579467768024e-07
TIC O 0 0.00013513443991541862
- O 0 2.0546154701150954e-05
2 O 0 1.8212246004623012e-06
. O 0 1.1585339052544441e-06
. O 0 6.377010322466958e-06

Human B-Disease 0 0.00017726377700455487
complement I-Disease 0 0.0003827028558589518
factor I-Disease 0 0.005999394692480564
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999970197677612
associated O 0 0.0491178072988987
with O 1 0.9877856969833374
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0009031740482896566

This O 0 1.3266349924379028e-05
study O 0 3.6141159398539457e-06
reports O 0 4.317399998399196e-06
on O 0 8.528365356141876e-07
six O 0 5.944761483078764e-07
cases O 0 5.032179046793317e-07
of O 0 1.6715049468984944e-06
deficiency B-Disease 0 0.26302433013916016
in I-Disease 0 3.6488097521214513e-07
the I-Disease 0 6.003775752105867e-07
human I-Disease 0 1.247293994310894e-06
complement I-Disease 0 4.76761215395527e-06
regulatory I-Disease 0 3.3469135814812034e-05
protein I-Disease 0 1.2519699339463841e-05
Factor I-Disease 0 9.327744010079186e-06
H I-Disease 1 0.9451239109039307
( O 0 8.468960004393011e-06
FH O 0 0.0012106108479201794
) O 0 3.8217726228140236e-07
in O 0 1.2763365475620958e-07
the O 0 1.0354103352483435e-07
context O 0 2.781528962714219e-07
of O 0 3.2674765293450037e-07
an O 0 0.0012948265066370368
acute B-Disease 1 0.9999998807907104
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0006963925552554429

Five O 0 6.125348136265529e-06
of O 0 4.5609684207192913e-07
the O 0 4.950757102051284e-07
cases O 0 4.7536920533275406e-07
were O 0 4.3201450239394035e-07
observed O 0 1.1161622524014092e-06
in O 0 7.172241112129996e-07
children O 0 1.366508740829886e-06
presenting O 0 2.6564108338789083e-05
with O 1 0.8494425415992737
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4824998378753662
HUS B-Disease 1 0.9999986886978149
) O 0 0.00010060927888844162
. O 0 6.04671222390607e-05

Two O 0 3.7008665003668284e-06
of O 0 5.789742658635078e-07
the O 0 6.029729320289334e-07
children O 0 7.957714842632413e-07
exhibited O 0 6.302842666627839e-05
a O 0 0.007401528302580118
homozygous O 1 0.9998364448547363
deficiency O 1 0.9878014922142029
characterized O 0 1.2726485692837741e-05
by O 0 4.210614008570701e-07
the O 0 2.311832076884457e-07
absence O 0 6.848566158623726e-07
of O 0 4.480892812352977e-08
the O 0 1.8309266636151733e-07
150 O 0 1.0439615607538144e-06
- O 0 2.0866877093794756e-05
kD O 0 1.8087197531713173e-05
form O 0 2.949401221030712e-07
of O 0 1.2116029779463133e-07
Factor O 0 7.973074502842792e-07
H O 0 0.054239168763160706
and O 0 7.614684705004038e-08
the O 0 9.824125157820163e-08
presence O 0 2.7962420290350565e-07
, O 0 7.022258330380282e-08
upon O 0 1.9888285862634802e-07
immunoblotting O 0 5.035010417486774e-06
, O 0 4.2394717070237675e-08
of O 0 2.4206793014514005e-08
the O 0 2.5143472726085747e-07
42 O 0 3.0861078812449705e-06
- O 0 5.4628748330287635e-05
kD O 0 0.00014429810107685626
Factor O 0 3.890435436915141e-06
H O 0 0.41157057881355286
- O 0 1.1687005098792724e-05
like O 0 4.16564148508769e-07
protein O 0 7.622981001986773e-07
1 O 0 4.7444345341318694e-07
( O 0 7.960826451380854e-07
FHL O 0 0.0001575179339852184
- O 0 1.4210092558641918e-05
1 O 0 2.930207756435266e-07
) O 0 2.0391227906202403e-07
and O 0 1.3777791707525466e-07
other O 0 2.7087949661108723e-07
FH O 0 0.008244800381362438
- O 0 5.296798553899862e-05
related O 0 3.857599040202331e-06
protein O 0 4.527513283392182e-06
( O 0 3.1247498100128723e-06
FHR O 0 0.00015630126290488988
) O 0 4.751308097183937e-06
bands O 0 2.7680469429469667e-05
. O 0 1.9667691958602518e-05

Southern O 0 0.0003020035510417074
blot O 0 0.004502908792346716
and O 0 9.146780939772725e-06
PCR O 0 5.803733438369818e-05
analysis O 0 1.091073045245139e-06
of O 0 1.0336442812786117e-07
DNA O 0 9.26093036923703e-07
of O 0 1.346395492873853e-07
one O 0 4.346544528743834e-07
patient O 0 1.6102438166853972e-05
with O 0 4.248951518093236e-05
homozygous O 1 0.9985188841819763
deficiency O 1 0.9693889021873474
ruled O 0 4.026621354569215e-06
out O 0 1.2935251447743212e-07
the O 0 5.096106292512559e-08
presence O 0 9.447030180353977e-08
of O 0 2.420120814861093e-08
a O 0 1.425993758630284e-07
large O 0 2.1351344514641823e-07
deletion O 0 1.8526905023463769e-06
of O 0 1.0756279777979216e-07
the O 0 1.732473151605518e-06
FH O 0 0.016361447051167488
gene O 0 2.708660304051591e-06
as O 0 2.1881621137254115e-07
the O 0 6.383031063705857e-07
underlying O 0 5.426178177003749e-05
defect O 0 8.540877752238885e-05
for O 0 1.2252063470441499e-06
the O 0 0.0003503776388242841
deficiency O 1 0.9583775997161865
. O 0 4.134544724365696e-05

The O 0 6.774921530450229e-06
other O 0 5.587121449934784e-07
four O 0 2.90313238338058e-07
children O 0 2.3066567678142746e-07
presented O 0 8.697185762684967e-07
with O 0 4.408060704008676e-06
heterozygous O 0 0.4461233913898468
deficiency O 0 0.2934386134147644
and O 0 5.425614517662325e-07
exhibited O 0 2.307913382537663e-05
a O 0 4.512731720751617e-06
normal O 0 9.33531737246085e-06
immunoblotting O 0 9.888182830763981e-05
pattern O 0 3.4176771350757917e-06
of O 0 1.1865129323496149e-07
proteins O 0 5.781406002824951e-07
of O 0 2.1364115809774376e-07
the O 0 3.265288341935957e-06
FH O 0 0.381736159324646
family O 0 7.149785233195871e-05
. O 0 2.2427781004807912e-05

Factor B-Disease 1 0.9304292798042297
H I-Disease 1 1.0
deficiency I-Disease 1 0.9997965693473816
is O 0 3.0211258490453474e-06
the O 0 2.010033313126769e-06
only O 0 3.7888787574047456e-06
complement B-Disease 1 0.9994413256645203
deficiency I-Disease 1 0.9999998807907104
associated O 0 3.0566294299205765e-05
with O 0 4.514418833423406e-05
HUS B-Disease 1 0.9999927282333374
. O 0 7.192038901848719e-05

These O 0 7.893989277363289e-06
observations O 0 1.3510159078577999e-05
suggest O 0 3.77430183107208e-06
a O 0 7.937893542475649e-07
role O 0 9.636477216190542e-07
for O 0 4.879992729911464e-07
FH O 0 0.01601230911910534
and O 0 2.652480588949402e-06
/ O 0 0.0022164552938193083
or O 0 6.535100055771181e-06
FH O 0 0.008344353176653385
receptors O 0 1.3320366633706726e-05
in O 0 5.755094321102661e-07
the O 0 1.3163348739908542e-06
pathogenesis O 0 6.973079143790528e-05
of O 0 5.581276582233841e-06
idiopathic O 1 0.9999933242797852
HUS B-Disease 1 0.9999982118606567
. O 0 3.299283707747236e-05
. O 0 4.369684756966308e-05

Further O 0 2.1435378585010767e-05
evidence O 0 4.421895937412046e-06
for O 0 4.107372433281853e-07
a O 0 1.2879049791081343e-06
major O 0 1.7398543832314317e-06
ancient O 0 1.2302913091843948e-05
mutation O 0 0.0019174752524122596
underlying O 1 0.5861715078353882
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 6.166195817058906e-05
linkage O 0 0.0038379745092242956
disequilibrium O 0 0.012444634921848774
studies O 0 2.5169699711113935e-06
in O 0 5.329704322321049e-07
the O 0 6.176848046379746e-07
Japanese O 0 3.673491619338165e-06
population O 0 3.0426115245063556e-06
. O 0 9.65459275903413e-06

The O 0 0.018150825053453445
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.99042809009552
DM B-Disease 1 1.0
) O 0 8.453594637103379e-05
mutation O 0 4.881368295173161e-05
is O 0 1.001066607386747e-06
an O 0 1.1443989933468401e-06
unstable O 0 0.0002560066932346672
( O 0 1.6879146187420702e-06
CTG O 0 7.463995279977098e-05
) O 0 5.59722252546635e-07
n O 0 2.154559524569777e-06
repeat O 0 1.8617075738802669e-06
, O 0 9.507512999107348e-08
present O 0 1.2940074611833552e-07
at O 0 1.6552122872326436e-07
a O 0 2.2807469690633297e-07
copy O 0 7.9082815318543e-07
number O 0 6.039033451088471e-08
of O 0 6.130462537612402e-08
5 O 0 5.715821771445917e-07
- O 0 1.4098489373282064e-05
37 O 0 1.1563527095859172e-06
repeats O 0 4.135055405640742e-06
on O 0 6.058347139514808e-07
normal O 0 1.501998667663429e-06
chromosomes O 0 1.250484729098389e-06
but O 0 1.3479115068548708e-07
amplified O 0 3.7609643186442554e-06
to O 0 3.3714354685798753e-07
50 O 0 6.10931238043122e-07
- O 0 2.6407067252876004e-06
3000 O 0 5.385546501202043e-06
copies O 0 3.5632901926874183e-06
on O 0 5.899471216253005e-05
DM B-Disease 1 0.9999996423721313
chromosomes O 0 0.0001172282500192523
. O 0 3.079589077970013e-05

Previous O 0 0.00014685203495901078
findings O 0 5.438134030555375e-05
in O 0 3.299146783319884e-06
Caucasian O 0 1.2848568985646125e-05
populations O 0 2.257952246509376e-06
of O 0 4.1490764601803676e-07
a O 0 0.00010874002327909693
DM B-Disease 1 1.0
founder O 0 0.03518075868487358
chromosome O 0 2.0687595679191872e-05
raise O 0 1.6648280052322662e-06
a O 0 1.032404497891548e-06
question O 0 2.9211176411081397e-07
about O 0 9.608876183619941e-08
the O 0 1.2890289724509785e-07
molecular O 0 1.1994387705271947e-06
events O 0 3.5496853456606914e-07
involved O 0 2.6762688776216237e-07
in O 0 3.2396846449955774e-07
the O 0 1.4724586208103574e-06
expansion O 0 7.718517736066133e-05
mutation O 0 0.00012883955787401646
. O 0 1.716318365652114e-05

To O 0 3.295698843430728e-05
investigate O 0 5.1102884754072875e-05
whether O 0 5.245641204965068e-06
a O 0 2.5803908556554234e-06
founder O 0 2.381933700235095e-05
chromosome O 0 7.85618249210529e-06
for O 0 4.247355320785573e-07
the O 0 1.6964815586106852e-05
DM B-Disease 1 1.0
mutation O 0 4.695131065091118e-05
exists O 0 7.278409839273081e-07
in O 0 1.0058689525749287e-07
the O 0 9.835130754254351e-08
Japanese O 0 3.5877550885743403e-07
population O 0 1.4639077505762543e-07
, O 0 1.0796154725767337e-07
we O 0 1.2878481925326923e-07
genotyped O 0 1.5055729818413965e-05
families O 0 3.6782273582502967e-07
using O 0 7.172590130721801e-07
polymorphic O 0 1.9691546185640618e-05
markers O 0 3.252893066019169e-06
near O 0 2.9247846669022692e-06
the O 0 6.77623177125497e-07
( O 0 2.8557849418575643e-06
CTG O 0 9.535387653158978e-05
) O 0 9.65437720878981e-07
n O 0 2.877853603422409e-06
repeat O 0 3.68985342902306e-06
region O 0 1.4714913731950219e-06
and O 0 1.6380469105570228e-06
constructed O 0 0.0001004128935164772
haplotypes O 0 0.00036603669286705554
. O 0 2.309566843905486e-05

Six O 0 1.8555019778432325e-05
different O 0 3.3505384635645896e-06
haplotypes O 0 3.3111726224888116e-05
were O 0 1.8734785953711253e-06
found O 0 2.8069182462786557e-06
and O 0 3.6066769098397344e-05
DM B-Disease 1 1.0
alleles O 0 0.00021083379397168756
were O 0 6.121645128587261e-06
always O 0 7.001447556831408e-06
haplotype O 0 0.0004535730986390263
A O 0 5.6925491662696004e-05
. O 0 3.843154263449833e-05

To O 0 1.3265957932162564e-05
find O 0 1.7718838307700935e-06
an O 0 4.495330188092339e-07
origin O 0 5.077400828668033e-07
of O 0 1.9360508929366915e-07
the O 0 7.475995289496495e-07
( O 0 3.5088362437818432e-06
CTG O 0 0.0001764471089700237
) O 0 1.060205477187992e-06
n O 0 3.391213567738305e-06
repeat O 0 2.5292561076639686e-06
mutation O 0 1.7109965710915276e-06
and O 0 1.078633715678734e-07
to O 0 1.1244183184544454e-07
investigate O 0 5.399897418101318e-07
the O 0 1.2172803565135837e-07
mechanism O 0 3.4819046845768753e-07
of O 0 2.9483821606390848e-08
the O 0 1.0736786748566374e-07
expansion O 0 7.478149086637131e-07
mutation O 0 8.887739681995299e-07
in O 0 6.124385265593446e-08
the O 0 6.798667584462237e-08
Japanese O 0 3.339171428251575e-07
population O 0 9.788046639869208e-08
we O 0 3.436989715055461e-08
have O 0 4.480833126763173e-08
studied O 0 2.1390822269040655e-07
90 O 0 2.966507111068495e-07
Japanese O 0 8.689536116435193e-06
DM B-Disease 1 0.9999991655349731
families O 0 7.70079907397303e-07
comprising O 0 7.198788694040559e-07
190 O 0 1.9030196654057363e-06
affected O 0 1.33757816911384e-06
and O 0 4.3299701246724e-07
130 O 0 3.4525794490036787e-06
unaffected O 0 5.165078255231492e-05
members O 0 4.752132554131094e-06
. O 0 1.6530335415154696e-05

The O 0 2.4423654394922778e-05
results O 0 1.2123074156988878e-05
suggest O 0 2.197712319684797e-06
that O 0 1.5503231054481148e-07
a O 0 2.9285706659720745e-07
few O 0 1.4708375317695754e-07
common O 0 2.9876639473513933e-07
ancestral O 0 1.180619619844947e-05
mutations O 0 3.961239599448163e-06
in O 0 1.6522032808552467e-07
both O 0 1.504610622760083e-07
Caucasian O 0 1.4139715176497702e-06
and O 0 1.2513014269188716e-07
Japanese O 0 5.682699679709913e-07
populations O 0 3.3767349805202684e-07
have O 0 7.803205193113172e-08
originated O 0 3.8211641140151187e-07
by O 0 9.016585522658715e-08
expansion O 0 2.392770284131984e-07
of O 0 5.718494122675111e-08
an O 0 1.8508455923438305e-07
ancestral O 0 9.299250450567342e-06
n O 0 8.836575034365524e-06
= O 0 3.093545501542394e-06
5 O 0 6.235655973796383e-07
repeat O 0 3.2186003409151454e-06
to O 0 7.4462957400101e-07
n O 0 9.456163752474822e-06
= O 0 6.922135980858002e-06
19 O 0 2.205619466622011e-06
- O 0 1.3123265489412006e-05
37 O 0 6.398135610652389e-06
copies O 0 7.269153684319463e-06
. O 0 1.3883742212783545e-05

These O 0 1.1401622941775713e-05
data O 0 7.5639213719114196e-06
support O 0 2.451266027492238e-06
multistep O 0 4.369168163975701e-05
models O 0 3.917831236321945e-06
of O 0 5.685995461135462e-07
triplet O 0 9.453543316340074e-05
repeat O 0 6.8414783527259715e-06
expansion O 0 1.8808398181136e-06
that O 0 1.4184418262175313e-07
have O 0 6.983788836123495e-08
been O 0 9.191757044391125e-08
proposed O 0 3.2870511290639115e-07
for O 0 1.6092086241314973e-07
both O 0 2.8830813789681997e-06
DM B-Disease 1 1.0
and O 0 0.00012785178842023015
Friedreichs B-Disease 1 0.7839746475219727
ataxia I-Disease 1 0.9981860518455505
. O 0 1.1884457308042329e-05
. O 0 2.501272683730349e-05

The O 0 1.9697145035024732e-05
molecular O 0 3.0019786208868027e-05
basis O 0 4.8549723032920156e-06
of O 0 2.2858122974867e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.2489878145061084e-06
the O 0 7.342774210883363e-07
western O 0 2.699114020288107e-06
Cape O 0 2.3548169338027947e-05
, O 0 5.340388611330127e-07
South O 0 2.7021428650186863e-06
Africa O 0 7.854369869164657e-06
. O 0 1.2323652299528476e-05

Deficiency B-Disease 1 0.9866101145744324
of I-Disease 0 1.69921054293809e-06
the I-Disease 0 1.04151229152194e-06
sixth I-Disease 0 3.2864038530533435e-06
component I-Disease 0 1.2692262316704728e-06
of I-Disease 0 1.208550486353488e-07
human I-Disease 0 2.994673025114025e-07
complement I-Disease 0 1.147311195381917e-06
( O 0 1.513506049377611e-06
C6 O 0 0.00018997318693436682
) O 0 2.798205684939603e-07
has O 0 1.73773230471852e-07
been O 0 3.115799813713238e-07
reported O 0 1.4866194533169619e-06
in O 0 5.956940896112428e-08
a O 0 8.833778508687828e-08
number O 0 1.923191028652127e-08
of O 0 1.970642671267342e-08
families O 0 3.955543448341814e-08
from O 0 4.389793062387071e-08
the O 0 7.691200920589836e-08
western O 0 1.1007017519659712e-06
Cape O 0 1.676928332017269e-05
, O 0 4.785263172379928e-07
South O 0 1.7788086097425548e-06
Africa O 0 1.0001094778999686e-05
. O 0 1.3332796697795857e-05

Meningococcal B-Disease 1 0.9999603033065796
disease I-Disease 1 0.9987890124320984
is O 0 9.853558367467485e-06
endemic O 0 3.2992080377880484e-05
in O 0 7.491632914025104e-07
the O 0 9.94004039966967e-07
Cape O 0 2.545632560213562e-05
and O 0 2.710859803300991e-07
almost O 0 1.3343338878257782e-07
all O 0 3.7589234835877505e-08
pedigrees O 0 1.597564391886408e-06
of O 0 3.12710909611269e-07
total O 0 7.263859879458323e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 9.489054718869738e-06
C6Q0 O 0 0.0073102242313325405
) O 0 4.593957498855161e-07
have O 0 9.952469071095038e-08
been O 0 2.903912843521539e-07
ascertained O 0 2.981569423354813e-06
because O 0 4.4239192220629775e-07
of O 0 1.4362042293214472e-06
recurrent O 1 0.9974530339241028
disease O 1 0.9287026524543762
. O 0 5.7903995184460655e-05

We O 0 9.570495421939995e-06
have O 0 1.6514312619619886e-06
sequenced O 0 5.381234132073587e-06
the O 0 5.3594709470417e-07
expressed O 0 7.525173373323923e-07
exons O 0 1.4495584537144168e-06
of O 0 1.1866464433296642e-07
the O 0 5.017807325202739e-07
C6 O 0 0.00010903509974014014
gene O 0 1.3713312227991992e-06
from O 0 1.4387427427209332e-07
selected O 0 1.4748646037787694e-07
cases O 0 9.075040452444227e-08
and O 0 7.636268151145487e-08
have O 0 8.415611318923766e-08
found O 0 1.3900559281410096e-07
three O 0 1.991506479726013e-07
molecular O 0 0.00034170947037637234
defects O 0 0.3795091211795807
leading O 0 1.5155497976593324e-06
to O 0 1.335294086857175e-06
total O 0 3.261762230977183e-06
deficiency O 0 0.1159382313489914
879delG O 0 2.0892643078695983e-05
, O 0 2.3325186759848293e-07
which O 0 1.3179611357827525e-07
is O 0 4.6725538993541704e-08
the O 0 1.3814313604143535e-07
common O 0 2.131798737536883e-06
defect O 0 2.5348886993015185e-05
in O 0 1.8029153636689443e-07
the O 0 2.748588201484381e-07
Cape O 0 7.540204023825936e-06
and O 0 3.2562468277319567e-07
hitherto O 0 4.335575340519426e-06
unreported O 0 1.2929431250086054e-06
, O 0 1.60559238793212e-07
and O 0 1.7333660196072742e-07
1195delC O 0 4.8313013394363225e-06
and O 0 1.9526576977568766e-07
1936delG O 0 8.050387805269565e-06
, O 0 9.199719386288052e-08
which O 0 9.509417964181921e-08
have O 0 4.878745940573026e-08
been O 0 8.775856485954137e-08
previously O 0 4.3446544850667124e-07
reported O 0 1.1389473684175755e-06
in O 0 2.1781849568469625e-07
African O 0 8.505484743182024e-07
- O 0 3.245245898142457e-05
Americans O 0 3.1715305794932647e-06
. O 0 8.476215953123756e-06

We O 0 8.764188351051416e-06
also O 0 1.8308896869712044e-06
show O 0 9.715919304653653e-07
that O 0 1.2643718605431786e-07
the O 0 3.327387219087541e-07
879delG O 0 1.140541735367151e-05
and O 0 2.6977861580235185e-06
1195delC O 0 0.29601040482521057
defects O 1 0.9156736135482788
are O 0 1.8668887946660107e-07
associated O 0 8.116198841889855e-07
with O 0 6.749485805812583e-07
characteristic O 0 0.00017485934949945658
C6 O 1 0.9617476463317871
/ O 0 0.027870122343301773
C7 O 0 0.0014498510863631964
region O 0 4.156642717134673e-06
DNA O 0 9.580960977473296e-06
marker O 0 1.8268734493176453e-05
haplotypes O 0 2.5269793695770204e-05
, O 0 3.9305299992520304e-07
although O 0 2.7258542445451894e-07
small O 0 3.511724742111255e-07
variations O 0 2.171254891436547e-06
were O 0 1.5818505971765262e-06
observed O 0 1.700462780718226e-05
. O 0 1.2674563549808227e-05

The O 0 5.6808468798408285e-05
1936delG O 0 0.0023207454942166805
defect O 0 0.023795688524842262
was O 0 1.7791408026823774e-05
observed O 0 1.7389587583238608e-06
only O 0 1.2739712929032976e-07
once O 0 4.175050491994625e-07
in O 0 1.2527080173185823e-07
the O 0 2.423791443106893e-07
Cape O 0 9.063673132914118e-06
, O 0 9.860375627113172e-08
but O 0 6.704777177901633e-08
its O 0 6.103919076849706e-07
associated O 0 9.944449629983865e-06
haplotype O 0 0.0006134531577117741
could O 0 3.4665781640796922e-06
be O 0 1.7088750610128045e-06
deduced O 0 4.5510394556913525e-05
. O 0 1.3735321772401221e-05

The O 0 8.24698872747831e-06
data O 0 4.1863286242005415e-06
from O 0 6.331594022412901e-07
the O 0 3.8787260336903273e-07
haplotypes O 0 1.161985801445553e-05
indicate O 0 5.747163527303201e-07
that O 0 6.185111800505183e-08
these O 0 2.9052417360730942e-08
three O 0 9.481363605345905e-08
molecular O 0 5.231933027971536e-05
defects O 0 0.055110469460487366
account O 0 3.555407772637409e-07
for O 0 1.0634778391249711e-07
the O 0 2.6735020583146252e-05
defects O 1 0.9046385288238525
in O 0 1.5567233901947475e-07
all O 0 4.3400905980206517e-08
the O 0 2.2708022129336314e-07
38 O 0 1.487223357798939e-06
unrelated O 0 5.1184615585953e-06
C6Q0 O 0 0.0008406569832004607
individuals O 0 3.4073599408657174e-07
we O 0 1.5148215481985972e-07
have O 0 9.425468761037337e-08
studied O 0 5.361837907003064e-07
from O 0 4.5236492951516993e-07
the O 0 1.8855686221286305e-06
Cape O 0 0.00020492717158049345
. O 0 1.923831950989552e-05

We O 0 1.0223119716101792e-05
have O 0 1.1875515610881848e-06
also O 0 6.487488803941233e-07
observed O 0 9.120415143115679e-07
the O 0 6.674740120615752e-07
879delG O 0 0.00011743489449145272
defect O 0 3.6581237509381026e-05
in O 0 4.858122224504768e-07
two O 0 8.197253578146046e-07
Dutch O 0 0.35003024339675903
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9998619556427002
deficient I-Disease 1 0.9999282360076904
kindreds O 0 4.335598350735381e-05
, O 0 2.6600218916428275e-07
but O 0 9.700692515934861e-08
the O 0 4.366336838756979e-07
879delG O 0 6.817172834416851e-05
defect O 0 2.467026570229791e-05
in O 0 2.913866694598255e-07
the O 0 7.977607197062753e-07
Cape O 0 0.00017117723473347723
probably O 0 3.934084361389978e-06
did O 0 3.308708187432785e-07
not O 0 5.429145488733411e-08
come O 0 5.971718053388031e-08
from O 0 8.534583884056701e-08
The O 0 2.784652792797715e-07
Netherlands O 0 1.392046488035703e-05
. O 0 2.1755370198661694e-06
. O 0 9.961667274183128e-06

Complement B-Disease 1 0.9872699975967407
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 6.29187024969724e-06
seven O 0 1.7065316342268488e-06
further O 0 4.325919235270703e-06
molecular O 0 0.000886698195245117
defects O 1 0.5192685723304749
and O 0 6.823642593190016e-07
their O 0 1.6467712384837796e-06
associated O 0 6.707452121190727e-05
marker O 0 0.0003377753891982138
haplotypes O 0 0.0008694109274074435
. O 0 4.1117982618743554e-05

Seven O 0 3.2303170883096755e-05
further O 0 7.56349572839099e-06
molecular O 0 2.102035068674013e-05
bases O 0 1.1890375390066765e-05
of O 0 9.696790220914409e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.345418801676715e-06
described O 0 0.0002496296656318009
. O 0 4.822178016183898e-05

All O 0 5.829857400385663e-06
these O 0 1.5629027529939776e-06
new O 0 5.873503141629044e-06
molecular O 0 0.0001785593049135059
defects O 0 0.00878820475190878
involve O 0 8.103004915938072e-07
single O 0 1.381807123834733e-06
- O 0 6.556574589922093e-06
nucleotide O 0 1.1215249742235756e-06
events O 0 2.949716133571201e-07
, O 0 9.070384976439527e-08
deletions O 0 1.0110342145708273e-06
and O 0 1.0578739306765783e-07
substitutions O 0 6.709292392770294e-07
, O 0 6.81916105804703e-08
some O 0 2.022954248559472e-08
of O 0 5.7277180331993804e-08
which O 0 4.010630050288455e-07
alter O 0 8.831258128338959e-06
splice O 0 1.5910683941910975e-05
sites O 0 8.96023095720011e-07
, O 0 2.422534350898786e-07
and O 0 3.791282665588369e-07
others O 0 2.1752216525783297e-06
codons O 0 3.140334956697188e-05
. O 0 1.0473928341525607e-05

They O 0 1.12128873297479e-05
are O 0 5.819202897328069e-07
distributed O 0 7.790280278641148e-07
along O 0 3.145818823213631e-07
the O 0 6.091695468057878e-07
C7 O 0 0.00024926839978434145
gene O 0 4.365072982182028e-06
, O 0 1.576830612748381e-07
but O 0 7.333439810963682e-08
predominantly O 0 1.8330528916976618e-07
towards O 0 2.3097760504242615e-07
the O 0 4.72505462312256e-07
3 O 0 1.7840156942838803e-06
end O 0 8.993106348498259e-06
. O 0 1.2300719390623271e-05

All O 0 7.203937911981484e-06
were O 0 2.2474982870335225e-06
found O 0 1.5164317801463767e-06
in O 0 1.5055636595207034e-06
compound O 0 3.7069366953801364e-05
heterozygous O 0 0.00010148195724468678
individuals O 0 6.137077434686944e-06
. O 0 1.5943705875542946e-05

The O 0 0.00031322918948717415
C6 O 1 0.8499593138694763
/ O 0 0.20455339550971985
C7 O 0 0.053904470056295395
marker O 0 0.00018070300575345755
haplotypes O 0 0.00021937780547887087
associated O 0 1.290686759602977e-05
with O 0 2.5014205675688572e-06
most O 0 2.7236086680204608e-05
C7 B-Disease 1 0.999996542930603
defects I-Disease 1 0.999872088432312
are O 0 1.1989778840870713e-06
tabulated O 0 3.609794657677412e-05
. O 0 4.418991466081934e-06
. O 0 1.4249596461013425e-05

A O 0 8.778699702816084e-05
genome O 0 5.589195643551648e-05
- O 0 2.21050013351487e-05
wide O 0 2.2417400487029226e-06
search O 0 1.4552568927683751e-06
for O 0 5.057200951341656e-07
chromosomal O 0 0.00011730942787835374
loci O 0 1.4415831174119376e-05
linked O 0 0.00024139639572240412
to O 0 2.9604485462186858e-05
mental O 0 0.22800706326961517
health O 0 7.919027848402038e-05
wellness O 0 0.00011220852320548147
in O 0 1.6943868104135618e-06
relatives O 0 3.955509328079643e-06
at O 0 4.44754232375999e-06
high O 0 0.00013160354865249246
risk O 0 4.5540527935372666e-05
for O 0 0.0004926815745420754
bipolar B-Disease 1 1.0
affective I-Disease 1 0.999994158744812
disorder I-Disease 1 0.9984180927276611
among O 0 5.538865366361279e-07
the O 0 1.4216299177860492e-06
Old O 0 1.7050015230779536e-05
Order O 0 3.954498424718622e-06
Amish O 0 0.0002460188406985253
. O 0 1.70479961525416e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9999997615814209
( O 0 0.03452342748641968
BPAD B-Disease 1 0.9999998807907104
; O 1 0.7360713481903076
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9990799427032471
) O 0 5.0479529818403535e-06
is O 0 5.418659725364705e-07
characterized O 0 5.4062847993918695e-06
by O 0 3.7598420021822676e-07
episodes O 0 2.2852066194900544e-06
of O 0 5.606085551335127e-07
mania B-Disease 0 0.05220333859324455
and O 0 7.199686478998046e-06
/ O 0 0.0063534448854625225
or O 0 5.870367203897331e-06
hypomania B-Disease 0 0.001330521423369646
interspersed O 0 1.5593946955050342e-05
with O 0 1.450987269890902e-06
periods O 0 1.2266781595826615e-05
of O 0 4.847440322919283e-06
depression B-Disease 1 0.5163875222206116
. O 0 5.0486454711062834e-05

Compelling O 0 6.63922110106796e-05
evidence O 0 5.44263548363233e-06
supports O 0 4.400684701977298e-06
a O 0 1.3329047305887798e-06
significant O 0 9.57697238845867e-07
genetic O 0 2.0730319647555007e-06
component O 0 1.4480399386229692e-06
in O 0 5.570554435507802e-07
the O 0 1.332210786131327e-06
susceptibility O 0 4.211748091620393e-05
to O 0 4.200052444502944e-06
develop O 0 0.000162036856636405
BPAD B-Disease 1 0.9999698400497437
. O 0 8.069130853982642e-05

To O 0 1.0541418305365369e-05
date O 0 3.940351234632544e-06
, O 0 4.7340211040136637e-07
however O 0 4.00153737700748e-07
, O 0 1.3329741932466277e-07
linkage O 0 2.6409836664242903e-06
studies O 0 3.882989574321982e-07
have O 0 9.975007486673348e-08
attempted O 0 1.5292379202946904e-06
only O 0 9.586835858499398e-08
to O 0 2.979703026539937e-07
identify O 0 2.2166605049278587e-06
chromosomal O 0 8.730238914722577e-05
loci O 0 4.204091965220869e-06
that O 0 6.457058816522476e-07
cause O 0 3.198887498001568e-06
or O 0 2.2196381621597538e-07
increase O 0 3.927150373783661e-07
the O 0 6.040670541551663e-07
risk O 0 1.9008704157386092e-06
of O 0 7.901639946794603e-07
developing O 0 5.203655382501893e-05
BPAD B-Disease 1 0.9999618530273438
. O 0 0.0001116655403166078

To O 0 1.1692757652781438e-05
determine O 0 5.5710074775561225e-06
whether O 0 1.1022353874068358e-06
there O 0 1.7331726098746003e-07
could O 0 2.769950242509367e-07
be O 0 1.3440325119518093e-07
protective O 0 1.3855792531103361e-05
alleles O 0 2.023218712565722e-06
that O 0 1.1627860629914721e-07
prevent O 0 5.992444016555964e-07
or O 0 2.4721836666685704e-07
reduce O 0 6.755082040399429e-07
the O 0 2.423724367872637e-07
risk O 0 4.0142535340237373e-07
of O 0 9.489541241691768e-08
developing O 0 3.6705150705529377e-06
BPAD B-Disease 1 0.9999864101409912
, O 0 6.923654041202099e-07
similar O 0 4.955466579303902e-07
to O 0 1.310759927264371e-07
what O 0 4.728353886207515e-08
is O 0 4.435053924112253e-08
observed O 0 2.2999725501904322e-07
in O 0 2.0206279316425935e-07
other O 0 3.8049813610996353e-06
genetic B-Disease 1 0.9999960660934448
disorders I-Disease 1 1.0
, O 0 3.0547735150321387e-06
we O 0 7.614755759277614e-07
used O 0 0.000803549715783447
mental O 1 0.8549948930740356
health O 0 0.003842616453766823
wellness O 0 0.00282117142342031
( O 0 1.0079601224788348e-06
absence O 0 1.1734229019566556e-06
of O 0 2.4948639065769385e-07
any O 0 4.193084532744251e-05
psychiatric B-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9994792342185974
) O 0 9.747985814101412e-07
as O 0 3.213728518858261e-07
the O 0 6.084472374823235e-07
phenotype O 0 5.031765249441378e-05
in O 0 3.0519586857735703e-07
our O 0 2.1169272201859712e-07
genome O 0 1.254896460523014e-06
- O 0 4.53302209280082e-06
wide O 0 1.086815245798789e-06
linkage O 0 8.36960862216074e-06
scan O 0 1.7778856999939308e-05
of O 0 7.36697387537788e-08
several O 0 9.251999699699809e-08
large O 0 2.7272713509773894e-07
multigeneration O 0 2.7266440156381577e-05
Old O 0 4.489153525355505e-06
Order O 0 9.846587545325747e-07
Amish O 0 2.037802551058121e-05
pedigrees O 0 1.8394008293398656e-05
exhibiting O 0 6.159286840556888e-06
an O 0 1.161690306616947e-06
extremely O 0 3.254034527344629e-05
high O 0 5.070628321846016e-05
incidence O 0 0.0001974553888430819
of O 0 6.119088538980577e-06
BPAD B-Disease 1 0.999997615814209
. O 0 0.00010779618605738506

We O 0 9.435922038392164e-06
have O 0 9.229754027728632e-07
found O 0 3.778537234211399e-07
strong O 0 4.1728137034624524e-07
evidence O 0 2.0122203636674385e-07
for O 0 8.337372747746485e-08
a O 0 7.264796977324295e-07
locus O 0 1.0586521966615692e-05
on O 0 7.580862074973993e-06
chromosome O 0 0.00010543700045673177
4p O 0 0.0017740780021995306
at O 0 3.542935019140714e-06
D4S2949 O 0 2.338619015063159e-05
( O 0 1.6785335219537956e-06
maximum O 0 2.988960204675095e-06
GENEHUNTER O 0 0.00017465787823311985
- O 0 2.061111263174098e-05
PLUS O 0 6.0196794038347434e-06
nonparametric O 0 3.0326231353683397e-05
linkage O 0 2.013485755014699e-05
score O 0 2.293949364684522e-06
= O 0 7.346364327531774e-06
4 O 0 1.1554344609976397e-06
. O 0 4.061045615344483e-07
05 O 0 1.0921080502157565e-05
, O 0 6.513470225399942e-07
P O 0 5.040347241447307e-05
= O 0 2.0654895251936978e-06
5 O 0 2.538627086323686e-07
. O 0 8.963737485601087e-08
22 O 0 4.037716792026913e-07
x O 0 5.187856459087925e-06
10 O 0 4.023148960641265e-07
( O 0 5.013435497858154e-07
- O 0 5.509197762876283e-06
4 O 0 7.791870189066685e-07
) O 0 4.0009189206102747e-07
; O 0 5.425687277238467e-07
SIBPAL O 0 3.198178092134185e-05
Pempirical O 0 1.816484655137174e-05
value O 0 5.449853119898762e-07
< O 0 2.6992738639819436e-06
3 O 0 5.363551167647529e-07
x O 0 7.817214282113127e-06
10 O 0 5.47231081782229e-07
( O 0 6.032886972207052e-07
- O 0 3.7897493712080177e-06
5 O 0 2.593325234556687e-07
) O 0 1.2087821232853457e-07
) O 0 1.1437396096880548e-07
and O 0 9.983344995134757e-08
suggestive O 0 1.9232002159697004e-06
evidence O 0 2.6613111003825907e-07
for O 0 1.3688274691503466e-07
a O 0 9.138437349065498e-07
locus O 0 1.7525273506180383e-05
on O 0 1.7365659005008638e-05
chromosome O 0 0.0005112215294502676
4q O 1 0.7071093916893005
at O 0 2.4525895696569933e-06
D4S397 O 0 1.8722013919614255e-05
( O 0 1.8283421923115384e-06
maximum O 0 2.1042797015979886e-06
GENEHUNTER O 0 0.0002754156303126365
- O 0 4.1336261347169057e-05
PLUS O 0 5.414380666479701e-06
nonparametric O 0 3.078666850342415e-05
linkage O 0 1.660199814068619e-05
score O 0 2.1493283384188544e-06
= O 0 3.613174840211286e-06
3 O 0 5.187908413972764e-07
. O 0 1.387624024573597e-07
29 O 0 1.1293569741610554e-06
, O 0 4.0405055301562243e-07
P O 0 5.4342453950084746e-05
= O 0 2.2669903501082445e-06
2 O 0 3.003728465955646e-07
. O 0 9.311465021255572e-08
57 O 0 9.796933682082454e-07
x O 0 5.777922979177674e-06
10 O 0 3.312048306725046e-07
( O 0 6.900713742652442e-07
- O 0 4.410369001561776e-06
3 O 0 7.111921149771661e-07
) O 0 4.005034384135797e-07
; O 0 3.4366101431260176e-07
SIBPAL O 0 2.6425268515595235e-05
Pempirical O 0 2.275305632792879e-05
value O 0 7.691346013416478e-07
< O 0 2.1409528017102275e-06
1 O 0 3.6287556781644525e-07
x O 0 3.0863786832924234e-06
10 O 0 2.38284627585017e-07
( O 0 3.615108141730161e-07
- O 0 6.774068424419966e-06
3 O 0 2.8075183422515693e-07
) O 0 1.1127266930088808e-07
) O 0 6.141674901982697e-08
that O 0 3.099410506024469e-08
are O 0 5.8683689019289886e-08
linked O 0 9.638824849389493e-06
to O 0 6.41069937046268e-06
mental O 0 0.03219423443078995
health O 0 0.0003396092215552926
wellness O 0 0.0018808284075930715
. O 0 4.3645963160088286e-05

These O 0 1.4035304047865793e-05
findings O 0 1.9267419702373445e-05
are O 0 1.972677807771106e-07
consistent O 0 4.1176519971486414e-07
with O 0 1.1702162083793155e-07
the O 0 2.8946945462848817e-07
hypothesis O 0 1.2420651955835638e-06
that O 0 6.565695542803951e-08
certain O 0 1.6070232788933936e-07
alleles O 0 1.61780542384804e-06
could O 0 2.487081474100705e-07
prevent O 0 5.372857003749232e-07
or O 0 2.835508041698631e-07
modify O 0 4.8249289648083504e-06
the O 0 6.050241267985257e-07
clinical O 0 6.286016287049279e-06
manifestations O 0 6.229252448974876e-06
of O 0 6.632315034948988e-07
BPAD B-Disease 1 0.9999933242797852
and O 0 2.529034190956736e-06
perhaps O 0 8.248745189121109e-07
other O 0 8.113149760902161e-07
related O 0 0.007016275078058243
affective B-Disease 1 0.9999396800994873
disorders I-Disease 1 0.9999828338623047
. O 0 0.00013630511239171028

Segregation O 0 0.021107273176312447
distortion O 0 0.34673893451690674
in O 0 0.020338717848062515
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.003097883425652981

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9991051554679871
DM B-Disease 1 1.0
) O 0 5.643251279252581e-05
is O 0 1.4587695886802976e-06
an O 0 2.5756555714906426e-06
autosomal B-Disease 1 0.7522286772727966
dominant I-Disease 1 0.6785199046134949
disease I-Disease 0 0.027383562177419662
which O 0 4.3736176280617656e-07
, O 0 5.3705626612554624e-08
in O 0 7.49274136069289e-08
the O 0 1.5329437985656114e-07
typical O 0 1.590133024365059e-06
pedigree O 0 4.627464477380272e-06
, O 0 1.3560253364630626e-07
shows O 0 3.283304010892607e-07
a O 0 5.943763312643568e-07
three O 0 1.0649987416400108e-06
generation O 0 1.0326474694011267e-05
anticipation O 0 4.5142893213778734e-05
cascade O 0 0.00034713424975052476
. O 0 2.585879701655358e-05

This O 0 2.285864502482582e-05
results O 0 2.3731547116767615e-05
in O 0 5.599801806965843e-05
infertility B-Disease 1 0.9977583885192871
and O 1 0.9086467027664185
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00027333415346220136
CDM B-Disease 0 0.00041637796675786376
) O 0 4.964084610037389e-07
with O 0 1.2673584137701255e-07
the O 0 3.5554009514271456e-07
disappearance O 0 8.563061783206649e-06
of O 0 2.012035565712722e-06
DM B-Disease 1 1.0
in O 0 4.7738089961057995e-06
that O 0 4.43423550677835e-06
pedigree O 0 0.00019039935432374477
. O 0 2.5926703528966755e-05

The O 0 1.1510315744089894e-05
concept O 0 6.2276071730593685e-06
of O 0 1.072629288501048e-06
segregation O 0 3.172863580402918e-05
distortion O 0 6.342546112136915e-05
, O 0 2.1187874210681912e-07
where O 0 9.879803286594324e-08
there O 0 5.423101612223036e-08
is O 0 6.120846762769361e-08
preferential O 0 6.014532800691086e-07
transmission O 0 9.256469638785347e-06
of O 0 4.572104117528397e-08
the O 0 1.672457017320994e-07
larger O 0 7.843776188565244e-07
allele O 0 5.906182195758447e-06
at O 0 6.613518053200096e-07
the O 0 2.4883631795091787e-06
DM B-Disease 1 0.9999992847442627
locus O 0 9.936258720699698e-06
, O 0 1.6911630495997088e-07
has O 0 9.21208069826207e-08
been O 0 9.002288692272487e-08
put O 0 1.6794272994502535e-07
forward O 0 2.5899490196934494e-07
to O 0 2.3416208705384634e-07
explain O 0 8.890833100849704e-07
partially O 0 2.4811733965179883e-06
the O 0 2.8706344323836674e-07
maintenance O 0 8.309561962960288e-06
of O 0 6.499192863884673e-07
DM B-Disease 1 0.9999997615814209
in O 0 1.3360788670979673e-06
the O 0 1.4042877864994807e-06
population O 0 2.698105390663841e-06
. O 0 8.570626960135996e-06

In O 0 3.8028469134587795e-05
a O 0 1.4770415873499587e-05
survey O 0 1.265987339138519e-05
of O 0 1.3416510000752169e-06
DM B-Disease 1 0.9999994039535522
in O 0 2.3396662527375156e-06
Northern O 0 4.2636393118300475e-06
Ireland O 0 4.7831053961999714e-06
, O 0 4.80776407130179e-07
59 O 0 4.734919912152691e-06
pedigrees O 0 4.412177804624662e-05
were O 0 7.696020475123078e-06
ascertained O 0 0.00020491465693339705
. O 0 3.401972571737133e-05

Sibships O 0 0.0006321938126347959
where O 0 4.812682163901627e-06
the O 0 6.338844400488597e-07
status O 0 2.6107028361366247e-07
of O 0 3.206016430112868e-08
all O 0 1.562335860683106e-08
the O 0 4.48793251450752e-08
members O 0 8.617515590003677e-08
had O 0 1.1338895546941785e-06
been O 0 3.248780728881684e-07
identified O 0 5.154447535460349e-07
were O 0 4.274809555226966e-07
examined O 0 3.6356946111482102e-06
to O 0 1.2689670825238863e-07
determine O 0 1.6662147572787944e-07
the O 0 1.9695647779371939e-07
transmission O 0 1.2425270142557565e-05
of O 0 8.02969637447859e-08
the O 0 1.1801048458437435e-06
DM B-Disease 1 0.9999933242797852
expansion O 0 8.727997737878468e-06
from O 0 1.2653829344344558e-06
affected O 0 1.978251475520665e-06
parents O 0 5.564718890127551e-07
to O 0 3.60268359145266e-07
their O 0 1.215669385601359e-06
offspring O 0 1.8086853742715903e-05
. O 0 8.746044841245748e-06

Where O 0 1.4961377019062638e-05
the O 0 8.259046808234416e-06
transmitting O 0 0.0001444397639716044
parent O 0 4.4716285628965124e-05
was O 0 6.006987860018853e-06
male O 0 2.9686202651646454e-06
, O 0 2.0807206055906136e-06
58 O 0 2.314801895408891e-05
. O 0 1.7803273294703104e-05

3 O 0 2.1434234440675937e-05
% O 0 8.424811426266388e-07
of O 0 1.011033532449801e-07
the O 0 1.686851049953475e-07
offspring O 0 9.541008694213815e-07
were O 0 2.272810633030531e-07
affected O 0 2.5639727141424373e-07
, O 0 4.847496271054297e-08
and O 0 6.910962468964499e-08
in O 0 1.0387176274662124e-07
the O 0 1.5097795369456435e-07
case O 0 2.231979578937171e-07
of O 0 7.518222844282718e-08
a O 0 1.2016541859338759e-06
female O 0 2.6769505439006025e-06
transmitting O 0 9.634557500248775e-05
parent O 0 4.0848313801689073e-05
, O 0 2.1924663542449707e-06
68 O 0 2.731351924012415e-05
. O 0 1.680636160017457e-05

7 O 0 0.00021828596072737128
% O 0 2.111236062773969e-05
were O 0 9.089311788557097e-06
affected O 0 3.582673889468424e-05
. O 0 2.9672941309399903e-05

Studies O 0 0.00011201587039977312
on O 0 1.3448711797536816e-05
meiotic O 0 0.0004328806244302541
drive O 0 0.00011872693721670657
in O 0 3.334291250212118e-05
DM B-Disease 1 0.9999998807907104
have O 0 1.1505380825838074e-06
shown O 0 9.49450850384892e-07
increased O 0 1.671136715231114e-06
transmission O 0 2.560071698098909e-05
of O 0 9.748026030820256e-08
the O 0 3.765051985737955e-07
larger O 0 1.4818422187090619e-06
allele O 0 6.245777512958739e-06
at O 0 1.205289095196349e-06
the O 0 2.8787294468202163e-06
DM B-Disease 1 0.9999963045120239
locus O 0 2.4551671231165528e-05
in O 0 1.4767254015168874e-06
non O 0 9.449313438381068e-06
- O 0 0.3977214992046356
DM O 1 0.9999996423721313
heterozygotes O 0 0.0005122972070239484
for O 0 8.965411325334571e-06
CTGn O 0 0.0009431564249098301
. O 0 5.435225466499105e-05

This O 0 1.0840321010618936e-05
study O 0 3.851173914881656e-06
provides O 0 1.1821390444310964e-06
further O 0 4.947145839651057e-07
evidence O 0 3.5315025570525904e-07
that O 0 2.618392613840115e-07
the O 0 2.078633997371071e-06
DM B-Disease 1 0.9999985694885254
expansion O 0 2.8593534807441756e-05
tends O 0 9.629021405999083e-06
to O 0 1.0231692613160703e-06
be O 0 1.2911675639770692e-06
transmitted O 0 0.00010461138299433514
preferentially O 0 5.507592868525535e-05
. O 0 1.2084866284567397e-05

Diagnosis O 1 0.9742029309272766
of O 0 0.00042234238935634494
hemochromatosis B-Disease 1 0.9999997615814209
. O 0 0.0008709340472705662

If O 0 0.0004926514811813831
untreated O 1 0.6769145727157593
, O 0 0.000674517301376909
hemochromatosis B-Disease 1 1.0
can O 0 0.019859610125422478
cause O 0 0.22773586213588715
serious O 0 0.06198417395353317
illness O 1 0.7054057717323303
and O 0 2.9396221634669928e-06
early B-Disease 0 0.0002048675814876333
death I-Disease 0 0.0016907185781747103
, O 0 4.3167435137547727e-07
but O 0 2.2368978136455553e-07
the O 0 3.7641289054590743e-06
disease O 0 0.00010868309618672356
is O 0 1.75461480012018e-07
still O 0 5.287174076329393e-07
substantially O 0 2.472998312441632e-05
under O 0 0.0006571208359673619
- O 1 0.999735414981842
diagnosed O 1 0.9932419657707214
. O 0 3.577740426408127e-05

The O 0 1.0835038665391039e-05
cornerstone O 0 3.439775173319504e-05
of O 0 8.602831371717912e-07
screening O 0 4.548828655970283e-06
and O 0 6.178403282319778e-07
case O 0 1.1828112747025443e-06
detection O 0 3.367606268511736e-06
is O 0 2.2200445926046086e-07
the O 0 3.954525880089932e-07
measurement O 0 1.797742356757226e-06
of O 0 4.854833832723671e-07
serum O 0 4.2121864680666476e-05
transferrin O 0 4.834499486605637e-05
saturation O 0 1.331505882262718e-05
and O 0 9.686832527222577e-07
the O 0 3.2859775274118874e-06
serum O 0 0.00012770875764545053
ferritin O 0 0.00022402471222449094
level O 0 2.2293501388048753e-05
. O 0 1.596777656232007e-05

Once O 0 4.855429506278597e-05
the O 0 1.0861130249395501e-05
diagnosis O 0 0.0007373670232482255
is O 0 8.665129485052603e-07
suspected O 0 1.309092840529047e-05
, O 0 1.2579002941492945e-06
physicians O 0 2.4140758796420414e-06
must O 0 5.589755005530606e-07
use O 0 1.6661703057252453e-06
serum O 0 4.2135525291087106e-05
ferritin O 0 8.324823284056038e-05
levels O 0 2.5300378183601424e-06
and O 0 1.172790916825761e-06
hepatic O 0 0.0010830867104232311
iron O 0 0.005493531934916973
stores O 0 2.031940130109433e-05
on O 0 0.0001461712527088821
liver O 0 0.25613898038864136
biopsy O 0 0.3086889684200287
specimens O 0 7.072495463944506e-06
to O 0 4.5154179133533034e-06
assess O 0 6.0161244618939236e-05
patients O 0 2.2070860268286197e-06
for O 0 5.2116362780907366e-08
the O 0 1.8493491893423197e-07
presence O 0 5.919518457631057e-07
of O 0 8.022713018362992e-07
iron B-Disease 1 0.9036428928375244
overload I-Disease 0 0.016184426844120026
. O 0 1.7490312529844232e-05

Liver O 1 0.9992960691452026
biopsy O 1 0.9652283787727356
is O 0 3.535539917720598e-06
also O 0 6.163020316307666e-07
used O 0 2.515529899937974e-07
to O 0 9.612249129986594e-08
establish O 0 2.1611145939459675e-07
the O 0 9.03893564441205e-08
presence O 0 3.1246733556145045e-07
or O 0 1.4764070499495574e-07
absence O 0 5.12089457060938e-07
of O 0 2.2015687761722802e-07
cirrhosis B-Disease 0 0.0877315029501915
, O 0 6.399243943633337e-07
which O 0 1.1122159548904165e-06
can O 0 1.0728286952144117e-06
affect O 0 5.386460998124676e-06
prognosis O 0 0.0008391576120629907
and O 0 8.53486835694639e-06
management O 0 0.00025385827757418156
. O 0 3.246896085329354e-05

A O 0 0.00015894067473709583
DNA O 0 6.903633038746193e-05
- O 0 0.00023030483862385154
based O 0 3.02381522487849e-06
test O 0 1.1690220844684518e-06
for O 0 1.74001414166014e-07
the O 0 6.17232558397518e-07
HFE O 0 0.0002895503712352365
gene O 0 2.857746494555613e-06
is O 0 1.5680204512591445e-07
commercially O 0 4.091987761967175e-07
available O 0 1.2657906722779444e-07
, O 0 2.5247246071558038e-08
but O 0 1.4650439972285767e-08
its O 0 5.355853005539757e-08
place O 0 7.65029284366392e-08
in O 0 1.3835224876856955e-07
the O 0 9.365976438857615e-07
diagnosis O 0 0.0009466552291996777
of O 0 1.9951805825257907e-06
hemochromatosis B-Disease 1 1.0
is O 0 3.825002750090789e-06
still O 0 2.9780937893519877e-06
being O 0 5.064845026936382e-06
evaluated O 0 3.8673457311233506e-05
. O 0 1.4901601389283314e-05

Currently O 0 2.02576211449923e-05
, O 0 8.004600999811373e-07
the O 0 2.503503822026687e-07
most O 0 9.058507544068561e-08
useful O 0 1.245845453468064e-07
role O 0 1.2327808462941903e-07
for O 0 4.220141391897414e-08
this O 0 7.185344941262883e-08
test O 0 4.791752417077078e-07
is O 0 5.3395940113887264e-08
in O 0 5.53797860902705e-08
the O 0 1.0853159437829163e-07
detection O 0 1.4771478618058609e-06
of O 0 4.880151323050086e-07
hemochromatosis B-Disease 1 0.999996542930603
in O 0 4.3191897702854476e-07
the O 0 1.6178641715214326e-07
family O 0 6.824976708230679e-07
members O 0 9.028339320593659e-08
of O 0 9.426169356174796e-08
patients O 0 1.8397356598143233e-06
with O 0 1.785967072009953e-07
a O 0 4.979386358172633e-05
proven O 0 1.8871118300012313e-05
case O 0 7.276022415680927e-07
of O 0 4.259776176240848e-07
the O 0 3.648274650913663e-05
disease O 0 0.019547736272215843
. O 0 3.110749094048515e-05

It O 0 1.6312174921040423e-05
is O 0 4.205708137305919e-06
crucial O 0 8.291592166642658e-06
to O 0 4.01777469960507e-05
diagnose O 1 0.9999808073043823
hemochromatosis B-Disease 1 1.0
before O 1 0.5694857835769653
hepatic B-Disease 1 0.9999961853027344
cirrhosis I-Disease 1 0.9999819993972778
develops O 0 0.1485891044139862
because O 0 6.80079756421037e-05
phlebotomy O 1 0.9913433790206909
therapy O 1 0.9672347903251648
can O 0 0.0001369071687804535
avert O 1 0.9907777309417725
serious O 1 0.9999306201934814
chronic O 1 1.0
disease O 1 0.9996659755706787
and O 0 1.1053543857997283e-05
can O 0 8.198238674594904e-07
even O 0 3.8743269215046894e-07
lead O 0 1.100145595955837e-06
to O 0 5.459789349515631e-07
normal O 0 4.341359726822702e-06
life O 0 4.352672476670705e-06
expectancy O 0 1.0797244613058865e-05
. O 0 1.841232915467117e-06
. O 0 1.1357856237736996e-05

Prevalence O 0 0.00043023822945542634
of O 0 2.9553154945460847e-06
the O 0 4.428403372003231e-06
I1307K O 0 8.083463035291061e-05
APC B-Disease 0 6.458173447754234e-05
gene O 0 9.05824617802864e-06
variant O 0 9.431594662601128e-06
in O 0 3.643135357833671e-07
Israeli O 0 2.6861259811994387e-06
Jews O 0 5.229919111116033e-07
of O 0 8.05216444632606e-08
differing O 0 4.4200564275342913e-07
ethnic O 0 2.9274926305333793e-07
origin O 0 1.126292659137107e-06
and O 0 2.9424045351333916e-06
risk O 0 8.280879410449415e-05
for O 0 0.35719385743141174
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00047469406854361296

BACKGROUND O 0 0.0009734351770021021
& O 0 0.0005667090299539268
AIMS O 0 2.9639622880495153e-05
Israeli O 0 1.3561701962316874e-05
Jews O 0 1.6377921383536886e-06
of O 0 2.1907804637066874e-07
European O 0 3.369906607986195e-06
birth O 0 0.00033308277488686144
, O 0 7.273608275681909e-07
i O 0 8.817742127575912e-07
. O 0 1.235373616736979e-07
e O 0 6.632751592405839e-07
. O 0 6.386720485807018e-08
, O 0 9.971660119845183e-08
Ashkenazim O 0 2.5897836621879833e-06
, O 0 1.0771863401259907e-07
have O 0 9.36195192480227e-08
the O 0 2.094235469485284e-06
highest O 1 0.9204890131950378
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0019611732568591833
of O 0 2.506525902390422e-07
any O 0 1.964188811598433e-07
Israeli O 0 8.265421456599142e-06
ethnic O 0 2.5398237539775437e-06
group O 0 1.2678117855102755e-05
. O 0 1.2820320080209058e-05

The O 0 4.803883348358795e-05
I1307K O 0 0.00044222394353710115
APC B-Disease 0 0.0006192221771925688
gene O 0 6.895987462485209e-05
variant O 0 0.00016473163850605488
was O 0 2.5353843739139847e-05
found O 0 2.09142740459356e-06
in O 0 3.549746679709642e-06
6 O 0 2.0548155589494854e-05
. O 0 1.5973258996382356e-05

1 O 0 2.0180050341878086e-05
% O 0 1.6140174921019934e-06
of O 0 2.0153238722286915e-07
American O 0 4.1236057768401224e-07
Jews O 0 4.470333578865393e-07
, O 0 1.1250125453443616e-07
28 O 0 2.3040865926304832e-07
% O 0 6.971465182914471e-08
of O 0 1.161782918757126e-07
their O 0 0.0006231589941307902
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.6296129362890497e-05
, O 0 1.018849957290513e-06
but O 0 1.8988468752922927e-07
not O 0 1.074268638490139e-07
in O 0 3.3371529184478277e-07
non O 0 1.9531173620634945e-06
- O 0 2.8058639145456254e-05
Jews O 0 8.407751920458395e-06
. O 0 1.3277614925755188e-05

We O 0 1.4376592844200786e-05
assessed O 0 1.4073380953050219e-05
the O 0 1.6910789781832136e-06
I1307K O 0 3.5866734833689407e-05
prevalence O 0 1.5493342289119028e-05
in O 0 4.783739200320269e-07
Israeli O 0 1.8709966980168247e-06
Jews O 0 6.444305995501054e-07
of O 0 1.1628870311142236e-07
differing O 0 6.197133757268602e-07
ethnic O 0 3.0541249884663557e-07
origin O 0 7.515913580391498e-07
and O 0 1.8460680166754173e-06
risk O 0 4.082109808223322e-05
for O 0 0.26442134380340576
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003841146535705775

METHODS O 0 8.93106625881046e-05
DNA O 0 2.8320797355263494e-05
samples O 0 4.218944923195522e-06
from O 0 6.137178161225165e-07
500 O 0 4.980515768693294e-07
unrelated O 0 9.685085160526796e-07
Jews O 0 2.2567671464912564e-07
of O 0 5.491759580422695e-08
European O 0 3.8065715557422664e-07
or O 0 2.771155038772122e-07
non O 0 1.74070123648562e-07
- O 0 8.512325848641922e-07
European O 0 1.3867561676761397e-07
origin O 0 9.597483341394764e-08
, O 0 3.635173229099564e-08
with O 0 4.428029853897897e-08
or O 0 1.0856099663669738e-07
without O 0 3.9958848674359615e-08
a O 0 3.0402401307583204e-07
personal O 0 2.630842800499522e-06
and O 0 2.425241973469383e-06
/ O 0 0.003746143076568842
or O 0 3.919098787719122e-07
family O 0 6.113800168350281e-07
history O 0 1.721260076692488e-07
of O 0 1.798491666704649e-07
neoplasia B-Disease 0 0.011305675841867924
, O 0 5.081276412965963e-07
were O 0 5.601702923740959e-07
examined O 0 4.937549419992138e-06
for O 0 1.2652571967919357e-07
the O 0 5.217778493715741e-07
I1307K O 0 1.5363979400717653e-05
variant O 0 1.672182224865537e-05
by O 0 5.375019895836886e-07
the O 0 7.281034299921885e-07
allele O 0 1.4233041838451754e-05
- O 0 7.607985480717616e-06
specific O 0 1.8876341982831946e-06
oligonucleotide O 0 0.00011686763173202053
( O 0 8.716668162378483e-06
ASO O 0 0.027358895167708397
) O 0 5.35197477802285e-06
method O 0 1.1756837011489552e-05
. O 0 1.768962829373777e-05

RESULTS O 0 0.0001366099895676598
In O 0 2.838889486156404e-06
persons O 0 1.229968802363146e-06
at O 0 1.186253257401404e-06
average O 0 7.1408035182685126e-06
risk O 0 3.315745561849326e-05
for O 0 0.03546890616416931
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.986380761489272e-06
I1307K O 0 0.00024437630781903863
was O 0 0.000365640182280913
found O 0 2.589284804344061e-06
in O 0 1.791385898286535e-06
5 O 0 7.751145858492237e-06
. O 0 2.155747642973438e-05

0 O 0 5.5316530051641166e-05
% O 0 2.722209273997578e-06
of O 0 2.7337242158864683e-07
120 O 0 1.5797987771293265e-06
European O 0 1.8754343500404502e-06
and O 0 1.5656790992579772e-06
1 O 0 7.74161617300706e-06
. O 0 1.7033516996889375e-05

6 O 0 0.00013873107673134655
% O 0 6.122357262938749e-06
of O 0 8.644148579151079e-07
188 O 0 5.80520691073616e-06
non O 0 2.865108854166465e-06
- O 0 1.4607820958190132e-05
European O 0 3.599359843065031e-06
Jews O 0 5.0818657655327115e-06
( O 0 4.14487840316724e-06
P O 0 0.00023822531511541456
= O 0 1.1547576832526829e-05
0 O 0 2.182785920012975e-06
. O 0 8.877624395609018e-07
08 O 0 2.4295557523146272e-05
) O 0 5.1567171794886235e-06
. O 0 1.269821405003313e-05

It O 0 3.7599496863549575e-05
occurred O 0 5.315591624821536e-05
in O 0 7.340894626395311e-06
15 O 0 2.411463538010139e-05
. O 0 3.2664305763319135e-05

4 O 0 4.39062096120324e-05
% O 0 2.9902460028097266e-06
of O 0 6.620441581617342e-07
52 O 0 7.179308795457473e-06
Ashkenazi O 0 9.518462320556864e-05
Israelis O 0 2.278032661706675e-05
with O 0 9.618887270335108e-05
familial O 1 0.9999613761901855
cancer B-Disease 1 0.9974251985549927
( O 0 1.6910091289901175e-05
P O 0 0.006048901006579399
= O 0 9.88973715720931e-06
0 O 0 1.046271904669993e-06
. O 0 2.0788193921816855e-07
02 O 0 3.7785659969813423e-06
) O 0 1.1578342196116864e-07
and O 0 1.3216074989941262e-07
was O 0 1.9947942746512126e-06
not O 0 8.290260211651912e-08
detected O 0 8.613922091171844e-07
in O 0 1.1701146007681018e-07
51 O 0 6.695242973364657e-07
non O 0 3.2332488331121567e-07
- O 0 1.801246639843157e-06
European O 0 4.709452809947834e-07
Jews O 0 8.951971608439635e-07
at O 0 3.833489699900383e-06
increased O 0 0.0003806048189289868
cancer B-Disease 0 0.32589322328567505
risk O 0 4.0868650103220716e-05
. O 0 2.1964757252135314e-05

Colorectal B-Disease 1 0.9999654293060303
neoplasia I-Disease 1 0.9965466856956482
occurred O 0 0.0038327693473547697
personally O 0 0.0002762452932074666
or O 0 1.9379622244741768e-06
in O 0 4.104807374005759e-07
the O 0 2.0135853162628337e-07
families O 0 1.553893298478215e-07
of O 0 5.072986297705029e-08
13 O 0 2.0984090554065915e-07
of O 0 9.856464089352812e-08
20 O 0 5.92632488860545e-07
Ashkenazi O 0 1.685769711912144e-05
I1307K O 0 1.8141165128326975e-05
carriers O 0 1.3731030321650906e-06
, O 0 1.0358764512830021e-07
8 O 0 1.78259611516296e-07
of O 0 5.176822526209435e-08
whom O 0 3.2211383427238616e-07
also O 0 5.002269176657137e-07
had O 0 1.2136201803514268e-06
a O 0 9.614235523258685e-07
personal O 0 1.1307426575513091e-05
or O 0 1.2601744856510777e-06
family O 0 2.745685378613416e-06
history O 0 1.5798093500052346e-06
of O 0 3.0306430289783748e-06
noncolonic O 0 0.4167921245098114
neoplasia B-Disease 1 0.7812525629997253
. O 0 7.319339783862233e-05

CONCLUSIONS O 0 0.0002669266832526773
The O 0 2.5497678507235833e-05
I1307K O 0 0.0005547339096665382
APC O 0 0.0019176634959876537
variant O 0 0.001132547971792519
may O 0 6.1001060203125235e-06
represent O 0 6.359321673699014e-07
a O 0 2.0018130726384697e-06
susceptibility O 0 3.920991730410606e-05
gene O 0 1.1803989764302969e-05
for O 0 3.853576345136389e-06
colorectal B-Disease 1 0.9999969005584717
, I-Disease 0 9.162007472696132e-07
or I-Disease 0 3.778108634833188e-07
other I-Disease 0 1.25207492374102e-07
, I-Disease 0 6.91561638177518e-07
cancers I-Disease 0 1.147007969848346e-05
in O 0 4.091882033208094e-07
Ashkenazi O 0 2.9177839678595774e-05
Jews O 0 7.196180149549036e-07
, O 0 2.0883430806861725e-07
and O 0 5.284442181618942e-07
partially O 0 2.4612720153527334e-05
explains O 0 1.1313167078697006e-06
the O 0 3.1105923881113995e-07
higher O 0 5.732696990889963e-06
incidence O 0 0.0047223567962646484
of O 0 0.0015432062791660428
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.93989999894984e-06
European O 0 2.1774694687337615e-05
Israelis O 0 8.543729200027883e-05
. O 0 2.6030384105979465e-05

Systematic O 0 0.0003174739540554583
analysis O 0 7.568814180558547e-05
of O 0 1.1857877325383015e-05
coproporphyrinogen O 0 0.1500285118818283
oxidase O 0 0.10862040519714355
gene O 0 0.09676952660083771
defects O 1 0.9885486364364624
in O 0 1.7592050426173955e-05
hereditary B-Disease 1 0.978506863117218
coproporphyria I-Disease 1 0.754059374332428
and O 0 8.445318962913007e-05
mutation O 0 0.0007431319099850953
update O 0 0.0012451955117285252
. O 0 6.228217534953728e-05

Hereditary B-Disease 1 0.9991637468338013
coproporphyria I-Disease 1 0.9419881701469421
( O 0 0.00025209347950294614
HC B-Disease 1 0.6051130890846252
) O 0 6.022979960107477e-06
is O 0 1.0421323395348736e-06
an O 0 5.224562755756779e-06
acute O 1 0.9922834038734436
hepatic B-Disease 1 0.9999911785125732
porphyria I-Disease 1 0.9999996423721313
with O 0 0.01915574073791504
autosomal O 1 0.9999362230300903
dominant O 1 0.549603283405304
inheritance O 0 0.02313038520514965
caused O 0 0.0003172812284901738
by O 0 2.893664486691705e-06
deficient B-Disease 0 6.338766979752108e-05
activity I-Disease 0 2.0218917597958352e-06
of I-Disease 0 6.253557671698218e-07
coproporphyrinogen I-Disease 0 0.02955310419201851
III I-Disease 1 0.9460894465446472
oxidase I-Disease 0 0.0003248155699111521
( O 0 1.4300429029390216e-05
CPO O 0 0.00023050782328937203
) O 0 1.1508778698043898e-05
. O 0 1.4366820323630236e-05

Clinical O 0 0.0006106682703830302
manifestations O 0 0.00011853610340040177
of O 0 2.2413701117329765e-06
the O 0 0.00016068242257460952
disease O 0 0.15684019029140472
are O 0 3.811388182839437e-07
characterized O 0 4.4990807509748265e-05
by O 0 7.663496035092976e-06
acute O 0 0.03155381977558136
attacks O 0 0.0031702301930636168
of O 0 0.00014368943811859936
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999384880065918
often O 0 6.119805766502395e-05
precipitated O 0 0.0021783297415822744
by O 0 2.1088621906528715e-06
drugs O 0 5.7515508160577156e-06
, O 0 4.953562324772065e-07
fasting O 0 2.4420158297289163e-05
, O 0 1.648402189857734e-06
cyclical O 0 0.0009769025491550565
hormonal O 0 0.00019729486666619778
changes O 0 5.6585113270557486e-06
, O 0 2.111351477651624e-06
or O 0 9.127987141255289e-05
infectious B-Disease 1 0.9271644949913025
diseases I-Disease 1 0.8388155102729797
. O 0 5.4943473514867947e-05

Skin O 1 0.9999990463256836
photosensitivity O 1 0.9999891519546509
may O 0 0.03750113770365715
also O 0 7.322150395339122e-06
be O 0 1.2803294566765544e-06
present O 0 4.633156549971318e-06
. O 0 1.1476600775495172e-05

The O 0 1.9524282834026963e-05
seven O 0 7.827285116945859e-06
exons O 0 3.078296867897734e-05
, O 0 6.114418056313298e-07
the O 0 5.815236363559961e-07
exon O 0 2.95926565740956e-05
/ O 0 1.9227571101509966e-05
intron O 0 1.7900090824696235e-05
boundaries O 0 3.8616886399722716e-07
and O 0 9.751690299708571e-08
part O 0 1.6545810410661943e-07
of O 0 1.1159723101172858e-07
3 O 0 7.545726248281426e-07
noncoding O 0 2.4678122372279176e-06
sequence O 0 2.2840727353923285e-07
of O 0 5.3320530213341044e-08
the O 0 2.4383280106121674e-07
CPO O 0 2.964346822409425e-05
gene O 0 2.301114136571414e-06
were O 0 3.983831220466527e-07
systematically O 0 2.6042675926873926e-06
analyzed O 0 1.0946740758299711e-06
by O 0 1.6435252803148614e-07
an O 0 2.764840871805063e-07
exon O 0 1.2642535693885293e-05
- O 0 5.636268269881839e-06
by O 0 1.0061968396257726e-06
- O 0 2.7548956495593302e-05
exon O 0 3.93995396734681e-05
denaturing O 0 0.00023239704023580998
gradient O 0 0.0001674047962296754
gel O 0 0.0008381390944123268
electrophoresis O 0 9.969979146262631e-05
( O 0 3.531715037752292e-06
DGGE O 0 4.909537165076472e-05
) O 0 6.1645255300391e-07
strategy O 0 7.343761581068975e-07
followed O 0 3.852143777294259e-07
by O 0 1.1638456243190376e-07
direct O 0 2.617573784391425e-07
sequencing O 0 4.527753674210544e-07
in O 0 2.5774713208193134e-07
seven O 0 7.249225291161565e-07
unrelated O 0 1.1009149602614343e-05
heterozygous O 0 8.606324263382703e-05
HC B-Disease 1 0.6817180514335632
patients O 0 2.7902726287720725e-05
from O 0 8.401735840379843e-07
France O 0 2.460602809151169e-05
, O 0 7.483357080673159e-07
Holland O 0 8.450668246950954e-05
, O 0 3.753651185434137e-07
and O 0 5.953436357231112e-07
Czech O 0 2.4415361622232012e-05
Republic O 0 2.377123018959537e-05
. O 0 2.0578530893544666e-05

Seven O 0 3.998918327852152e-05
novel O 0 3.7828525819350034e-05
mutations O 0 3.713478508871049e-05
and O 0 1.0117026931766304e-06
two O 0 7.525266596530855e-07
new O 0 7.810425813659094e-06
polymorphisms O 0 6.282548565650359e-05
were O 0 5.897222308703931e-06
detected O 0 0.00010195530921919271
. O 0 2.5629786250647157e-05

Among O 0 1.7551266864757054e-05
these O 0 1.8076309515890898e-06
mutations O 0 1.1554704542504624e-05
two O 0 4.160206401593314e-07
are O 0 2.385765753842861e-07
missense O 0 1.8155391444452107e-05
( O 0 1.1990464372502174e-06
G197W O 0 6.525994649564382e-06
, O 0 3.0014606977601943e-07
W427R O 0 5.63514004170429e-06
) O 0 2.093194382268848e-07
, O 0 5.0389644457027316e-08
two O 0 5.4795282977693205e-08
are O 0 5.1605365314344454e-08
nonsense O 0 1.5119695717658033e-06
( O 0 5.594991989710252e-07
Q306X O 0 4.570456894725794e-06
, O 0 2.0316417703725165e-07
Q385X O 0 4.150526820012601e-06
) O 0 1.2735971210986463e-07
, O 0 3.3251630782160646e-08
two O 0 2.1251066684158104e-08
are O 0 2.718125458045506e-08
small O 0 1.3802871023926855e-07
deletions O 0 5.985470124869607e-06
( O 0 8.71207021191367e-07
662de14bp O 0 1.1161760085087735e-05
; O 0 5.854472533428634e-07
1168del3bp O 0 1.3853361451765522e-05
removing O 0 1.218403895109077e-06
a O 0 1.0101099405801506e-06
glycine O 0 1.8112003090209328e-05
at O 0 5.272159455671499e-07
position O 0 8.189065852093336e-07
390 O 0 1.4716921441504383e-06
) O 0 1.855125475458408e-07
, O 0 5.155538929102477e-08
and O 0 3.7980637301870956e-08
one O 0 4.4223327222425723e-08
is O 0 7.148041447635478e-08
a O 0 7.212187824734428e-07
splicing O 0 1.7611153452889994e-05
mutation O 0 1.3551812116929796e-05
( O 0 1.7400602700945456e-06
IVS1 O 0 9.018745186040178e-05
- O 0 5.0697191909421235e-05
15c O 0 0.00010973573080264032
- O 0 0.0005659004673361778
- O 0 0.00013062510697636753
> O 0 1.0097871381731238e-05
g O 0 1.675361636443995e-05
) O 0 2.2001961497153388e-07
which O 0 1.3157533373941988e-07
creates O 0 7.867254225857323e-07
a O 0 9.801316309676622e-07
new O 0 3.422902636884828e-06
acceptor O 0 3.755050784093328e-05
splice O 0 0.0001801851176423952
site O 0 5.4930427722865716e-05
. O 0 2.037728700088337e-05

The O 0 3.2915806514211e-05
pathological O 0 5.4633750551147386e-05
significance O 0 3.931027549697319e-06
of O 0 4.168443012986245e-07
the O 0 8.914691420613963e-07
point O 0 1.5391226497740718e-06
mutations O 0 6.271932306844974e-06
G197W O 0 6.447412943089148e-06
, O 0 2.456629886182782e-07
W427R O 0 3.989586275565671e-06
, O 0 1.4342849397053214e-07
and O 0 5.7869723235626225e-08
the O 0 1.541956748951634e-07
in O 0 4.1343710677210765e-07
- O 0 1.8297016140422784e-05
frame O 0 5.774166857008822e-05
deletion O 0 7.055324203975033e-06
390delGly O 0 7.046628979878733e-06
were O 0 2.575456505837792e-07
assessed O 0 6.472978384408634e-07
by O 0 1.1751145478910985e-07
their O 0 1.229692827564577e-07
respective O 0 4.7342740572275943e-07
expression O 0 5.568939513977966e-07
in O 0 2.1907804637066874e-07
a O 0 6.899766162860033e-07
prokaryotic O 0 1.9139145024382742e-06
system O 0 2.6888887987297494e-06
using O 0 1.3831071328240796e-06
site O 0 8.997591976367403e-06
- O 0 1.826082734623924e-05
directed O 0 1.3744820535066538e-05
mutagenesis O 0 0.00013480675988830626
. O 0 2.2490681658382528e-05

These O 0 2.183435390179511e-05
mutations O 0 0.00015509309014305472
resulted O 0 1.0763298632809892e-05
in O 0 9.859676310952636e-07
the O 0 1.176834302896168e-06
absence O 0 3.3345172596455086e-06
or O 0 4.5823708205716684e-07
a O 0 6.979034878895618e-07
dramatic O 0 4.726514816866256e-06
decrease O 0 6.449288775911555e-06
of O 0 1.3368742202146677e-06
CPO O 0 0.00030590547248721123
activity O 0 2.7148589651915245e-05
. O 0 1.9403927581151947e-05

The O 0 1.959254950634204e-05
two O 0 3.870991349685937e-06
polymorphisms O 0 4.688241097028367e-05
were O 0 1.7878292055684142e-06
localized O 0 1.5237265870382544e-05
in O 0 1.1672274240481784e-06
noncoding O 0 1.1727454875654075e-05
part O 0 4.7324954266514396e-07
of O 0 1.0329564048561224e-07
the O 0 3.1971811154107854e-07
gene O 0 2.1022497094236314e-06
1 O 0 4.138517226692784e-07
) O 0 4.3016612494284345e-07
a O 0 2.6166203497268725e-06
C O 0 0.0012619940098375082
/ O 0 0.000335109158186242
G O 0 4.9078938900493085e-05
polymorphism O 0 4.246263415552676e-06
in O 0 3.03562757153486e-07
the O 0 3.716492074090638e-07
promotor O 0 3.557667514542118e-05
region O 0 9.154382496490143e-07
, O 0 2.383109887205137e-07
142 O 0 1.1593496083150967e-06
bp O 0 7.194092177087441e-06
upstream O 0 1.3707455082112574e-06
from O 0 2.2116805098448822e-07
the O 0 1.9824487651476375e-07
transcriptional O 0 4.342469310358865e-06
initiation O 0 2.6314251044823322e-06
site O 0 5.396826963988133e-06
( O 0 1.8044513581116917e-06
- O 0 1.299862105952343e-05
142C O 0 3.793639916693792e-05
/ O 0 0.00012103762855986133
G O 0 3.069341983064078e-05
) O 0 1.967589753348875e-07
, O 0 5.55914461131124e-08
and O 0 4.820205745659223e-08
2 O 0 1.5144445342230028e-07
) O 0 1.4406388970655826e-07
a O 0 4.2254657728335587e-07
6 O 0 1.7052105931725237e-06
bp O 0 2.6501913453103043e-05
deletion O 0 1.713247002044227e-05
polymorphism O 0 6.5654530772008e-06
in O 0 2.1378320980147691e-07
the O 0 2.446830364988273e-07
3 O 0 6.881392664581654e-07
noncoding O 0 2.6289919787814142e-06
part O 0 1.874460195949723e-07
of O 0 6.723075784975663e-08
the O 0 3.7871848235226935e-07
CPO O 0 3.8399524783017114e-05
gene O 0 3.080732540183817e-06
, O 0 1.765841801670831e-07
574 O 0 2.3267230062629096e-06
bp O 0 3.3091796467488166e-06
downstream O 0 5.686624717782252e-07
of O 0 3.247553337359932e-08
the O 0 9.497635744537547e-08
last O 0 3.4757007938424067e-07
base O 0 2.9222431408015836e-07
of O 0 6.3589581600354e-08
the O 0 5.021934157412034e-07
normal O 0 7.170187927840743e-06
termination O 0 3.9041824493324384e-05
codon O 0 3.922652467736043e-05
( O 0 4.988719410903286e-06
+ O 0 1.9224085917812772e-05
574 O 0 4.9041424063034356e-05
delATTCTT O 0 0.00017232458048965782
) O 0 1.5172971870924812e-05
. O 0 1.9326234905747697e-05

Five O 0 3.129136894131079e-05
intragenic O 0 0.0007106448756530881
dimorphisms O 0 0.0005637051654048264
are O 0 6.721633667439164e-07
now O 0 4.586813417972735e-07
well O 0 1.8268541168708907e-07
characterized O 0 3.190314373568981e-06
and O 0 1.281652117768317e-07
the O 0 2.7081773623649497e-07
high O 0 1.1595906244110665e-06
degree O 0 6.551553610734118e-07
of O 0 2.2487580508823157e-07
allelic O 0 3.938571899197996e-05
heterogeneity O 0 4.0566559619037434e-05
in O 0 6.0799352468166035e-06
HC B-Disease 1 0.7178351283073425
is O 0 1.6270704463750008e-06
demonstrated O 0 1.259233840755769e-06
with O 0 1.2801299931197718e-07
seven O 0 1.6846276196247345e-07
new O 0 3.6457419128055335e-07
different O 0 6.417125320012929e-08
mutations O 0 8.50295407417434e-07
making O 0 4.528431674089006e-08
a O 0 1.1473020578023352e-07
total O 0 7.426071135796519e-08
of O 0 1.226879078330967e-07
nineteen O 0 4.5807205424353015e-06
CPO O 1 0.5247641205787659
gene B-Disease 0 0.1002361923456192
defects I-Disease 1 0.9835470914840698
reported O 0 3.5457142075756565e-05
so O 0 7.104613359842915e-07
far O 0 1.4095714959694305e-06
. O 0 1.924058778968174e-06
. O 0 1.0721070793806575e-05

Coincidence O 0 0.0001307888887822628
of O 0 2.7369144390831934e-06
two O 0 1.8307359823666047e-06
novel O 0 6.043111625331221e-06
arylsulfatase O 0 6.874044629512355e-05
A O 0 7.575954441563226e-06
alleles O 0 1.7833093806984834e-05
and O 0 1.4208221728040371e-06
mutation O 0 2.086214408336673e-05
459 O 0 2.5438417651457712e-05
+ O 0 3.226246917620301e-05
1G O 0 0.00026531529147177935
> O 0 5.481030257215025e-06
A O 0 7.789217306708451e-07
within O 0 3.5622770155896433e-07
a O 0 3.1731824492453597e-06
family O 0 1.6964620954240672e-05
with O 0 1.8501164959161542e-05
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999992847442627
: O 0 2.347703457417083e-06
molecular O 0 4.635282039089361e-06
basis O 0 1.1427521258156048e-06
of O 0 1.388842292726622e-06
phenotypic O 0 0.00012008928752038628
heterogeneity O 0 0.00046854576794430614
. O 0 6.60838995827362e-05

In O 0 2.1223184376140125e-05
a O 0 8.36008257465437e-06
family O 0 3.2973412089631893e-06
with O 0 2.1974764763399435e-07
three O 0 2.761725852451491e-07
siblings O 0 4.17960245613358e-06
, O 0 1.1333960969750478e-07
one O 0 1.466552959072942e-07
developed O 0 2.5089464088523528e-06
classical O 0 9.454821338295005e-06
late O 0 0.40010958909988403
infantile O 1 0.9999778270721436
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 0.0011579463025555015
MLD B-Disease 1 0.9999874830245972
) O 0 3.876535629387945e-06
, O 0 9.616362603992457e-07
fatal O 0 0.0010042431531473994
at O 0 3.1444676551473094e-06
age O 0 1.010301730275387e-06
5 O 0 4.537609470389725e-07
years O 0 3.5413674481787893e-07
, O 0 1.5504679140576627e-07
with O 0 1.1752720183721976e-06
deficient O 0 0.0026534050703048706
arylsulfatase O 0 0.0001889325212687254
A O 0 2.0265581042622216e-05
( O 0 3.2033810839493526e-06
ARSA O 0 0.0002567539631854743
) O 0 4.4597558712666796e-07
activity O 0 7.002676056799828e-07
and O 0 2.5133093117801764e-07
increased O 0 3.77842889065505e-06
galactosylsulfatide O 0 0.000608673959504813
( O 0 3.287299114163034e-05
GS O 1 0.9994620680809021
) O 0 1.2707760106422938e-05
excretion O 0 8.522759890183806e-05
. O 0 1.559573138365522e-05

The O 0 8.019286724447738e-06
two O 0 1.2716760693365359e-06
other O 0 4.7092282784433337e-07
siblings O 0 4.611564691003878e-06
, O 0 2.714442928208882e-07
apparently O 0 2.952630666186451e-06
healthy O 0 1.0263044032399193e-06
at O 0 3.7103654904058203e-07
12 O 0 5.504468845174415e-07
( O 0 3.491294648938492e-07
1 O 0 4.5165279516368173e-07
/ O 0 4.947452453052392e-06
2 O 0 1.9118900240755465e-07
) O 0 7.02169558053356e-08
and O 0 4.2084941753728344e-08
15 O 0 6.965085930232817e-08
years O 0 6.667169571983322e-08
, O 0 3.378622182026447e-08
respectively O 0 1.0664679450655967e-07
, O 0 2.3744297195094077e-08
and O 0 2.524300590778239e-08
their O 0 8.751084834557332e-08
father O 0 1.5064289982547052e-05
, O 0 2.2887586226261192e-07
apparently O 0 4.7242347136489116e-06
healthy O 0 4.058292688569054e-07
as O 0 5.666000291171258e-08
well O 0 7.099669829813138e-08
, O 0 8.159163655818702e-08
presented O 0 1.512132598691096e-06
ARSA O 0 0.024058734998106956
and O 0 4.215357421344379e-06
GS O 1 0.9548738598823547
values O 0 8.201867558454978e-07
within O 0 2.655079924807069e-07
the O 0 3.1914143505673565e-07
range O 0 2.5280648969783215e-06
of O 0 4.743140834762016e-06
MLD B-Disease 1 0.9999997615814209
patients O 0 0.00878925621509552
. O 0 5.339546260074712e-05

Mutation O 0 0.001004713005386293
screening O 0 6.646308611379936e-05
and O 0 1.9456902009551413e-06
sequence O 0 2.1123726128280396e-06
analysis O 0 1.0150888556381688e-06
disclosed O 0 3.3905150758073432e-06
the O 0 3.3380379704794905e-07
involvement O 0 7.035288831502839e-07
of O 0 9.737099304629737e-08
three O 0 1.9988854660368816e-07
different O 0 5.743218594034261e-07
ARSA O 1 0.7897219061851501
mutations O 0 1.938350760610774e-05
being O 0 6.696954528706556e-07
the O 0 3.649909672276408e-07
molecular O 0 2.555068476794986e-06
basis O 0 9.575830972607946e-07
of O 0 1.3864669199392665e-06
intrafamilial O 0 0.000676808413118124
phenotypic O 0 0.000265930691966787
heterogeneity O 0 0.0007864647777751088
. O 0 6.305619899649173e-05

The O 0 5.170089934836142e-05
late O 0 0.04777848348021507
infantile O 1 0.9999210834503174
patient O 1 0.9314334392547607
inherited O 1 0.9006118774414062
from O 0 2.244822780994582e-06
his O 0 1.7566169844940305e-05
mother O 0 6.445622420869768e-05
the O 0 8.795585699772346e-07
frequent O 0 8.700008947926108e-06
0 O 0 5.104665433464106e-06
- O 0 0.00018982109031639993
type O 0 2.9028797143837437e-05
mutation O 0 1.585857171448879e-05
459 O 0 1.3581400708062574e-05
+ O 0 1.126003644458251e-05
1G O 0 7.777129212627187e-05
> O 0 3.881148586515337e-06
A O 0 1.1281007346042315e-06
, O 0 1.4054558050702326e-07
and O 0 8.756043712310202e-08
from O 0 8.825711006466008e-08
his O 0 2.140752940249513e-06
father O 0 0.00011069663742091507
a O 0 1.9400038127059815e-06
novel O 0 1.224636207552976e-06
, O 0 1.3643844454236387e-07
single O 0 4.617069180312683e-07
basepair O 0 1.4183638086251449e-05
microdeletion O 0 8.6684049165342e-06
of O 0 1.9095521963663487e-07
guanine O 0 3.1452957500732737e-06
at O 0 6.66784330860537e-07
nucleotide O 0 2.5921631277014967e-06
7 O 0 1.0562393981672358e-06
in O 0 8.271265983239573e-07
exon O 0 2.5790775907807983e-05
1 O 0 3.5422222026681993e-06
( O 0 5.238632638793206e-06
7delG O 0 0.00010600700625218451
) O 0 8.659877494210377e-06
. O 0 8.669272574479692e-06

The O 0 2.8797734557883814e-05
two O 0 9.282786777475849e-06
clinically O 0 0.0005010010791011155
unaffected O 0 0.00019156916823703796
siblings O 0 1.5351955880760215e-05
carried O 0 5.251287348073674e-06
the O 0 1.4228587588149821e-06
maternal O 0 0.00010955526522593573
mutation O 0 3.548007589415647e-05
459 O 0 3.502582694636658e-05
+ O 0 2.376066731812898e-05
1G O 0 0.00016977022460196167
> O 0 7.615433332830435e-06
A O 0 1.7714395426082774e-06
and O 0 2.960442486710235e-07
, O 0 7.932408863098317e-08
on O 0 2.1392841631495685e-07
their O 0 3.1182196380541427e-07
paternal O 0 2.7026919269701466e-05
allele O 0 7.473981440853095e-06
, O 0 2.233489198033567e-07
a O 0 5.796035225102969e-07
novel O 0 1.7907506162373465e-06
cytosine O 0 5.959956979495473e-06
to O 0 7.31078671378782e-07
thymidine O 0 3.08862654492259e-05
transition O 0 5.025559858040651e-06
at O 0 1.46212062190898e-06
nucleotide O 0 5.194000095798401e-06
2435 O 0 4.2427036532899365e-05
in O 0 9.775785656529479e-07
exon O 0 9.108296580961905e-06
8 O 0 8.543644298697473e-07
, O 0 1.054690699220373e-07
resulting O 0 4.335544474542985e-07
in O 0 2.0809696366086428e-07
substitution O 0 6.984282094890659e-07
of O 0 3.161050869948667e-07
alanine O 0 7.054287561913952e-05
464 O 0 2.716620292630978e-05
by O 0 6.534813564940123e-06
valine O 0 0.005622504279017448
( O 0 1.1498764251882676e-05
A464V O 0 0.00010695067612687126
) O 0 1.2169488400104456e-05
. O 0 1.4699341591040138e-05

The O 0 6.392350042006001e-05
fathers O 0 0.0001657750690355897
genotype O 0 0.0003011381486430764
thus O 0 1.789397902030032e-05
was O 0 3.734146957867779e-05
7delG O 0 0.0004138862423133105
/ O 0 0.0006728618172928691
A464V O 0 0.00043447641655802727
. O 0 4.480639108805917e-05

Mutation O 0 0.0009944528574123979
A464V O 0 0.0007953254389576614
was O 0 5.831395537825301e-05
not O 0 6.976958957238821e-07
found O 0 7.498574063902197e-07
in O 0 7.96285348769743e-07
18 O 0 7.128896413632901e-06
unrelated O 0 0.010292991995811462
MLD B-Disease 1 1.0
patients O 0 0.0005872636684216559
and O 0 2.002979726967169e-06
50 O 0 5.612303539237473e-06
controls O 0 0.0003484829794615507
. O 0 3.4535540180513635e-05

A464V O 0 0.0013113630702719092
, O 0 1.4547223145200405e-05
although O 0 5.198311100684805e-06
clearly O 0 5.594818048848538e-06
modifying O 0 4.00246208300814e-05
ARSA O 0 0.005994377192109823
and O 0 9.240338840754703e-06
GS O 1 0.9980201721191406
levels O 0 2.752213049461716e-06
, O 0 3.609472116750112e-07
apparently O 0 3.084139734710334e-06
bears O 0 1.8171198234995245e-06
little O 0 5.750200671172934e-07
significance O 0 6.335719717753818e-07
for O 0 3.662538858861808e-07
clinical O 0 6.828448476881022e-06
manifestation O 0 1.0309040590072982e-05
of O 0 2.4085450149868848e-06
MLD B-Disease 1 0.9999960660934448
, O 0 1.6467728300995077e-06
mimicking O 0 2.065783155558165e-05
the O 0 3.207624331480474e-06
frequent O 0 9.013724775286391e-05
ARSA O 1 0.5228439569473267
pseudodeficiency O 0 0.0059265270829200745
allele O 0 0.000748852442484349
. O 0 5.668795347446576e-05

Our O 0 3.2733216357883066e-05
results O 0 1.586344478710089e-05
demonstrate O 0 6.626014055655105e-06
that O 0 4.5049691266285663e-07
in O 0 6.449076863646042e-07
certain O 0 1.5880447108429507e-06
genetic O 0 2.466680780344177e-05
conditions O 0 0.0030319401994347572
MLD B-Disease 1 0.9999973773956299
- O 0 0.01328945904970169
like O 0 4.0164391066355165e-06
ARSA O 0 0.07361258566379547
and O 0 9.531528121442534e-06
GS O 1 0.9990033507347107
values O 0 1.3646957768287393e-06
need O 0 2.093897251143062e-07
not O 0 8.57940136711477e-08
be O 0 6.084007964091143e-08
paralleled O 0 1.8784019175654976e-06
by O 0 1.4185961845214479e-06
clinical O 0 0.005077824927866459
disease O 0 0.004694260191172361
, O 0 1.1412586786718748e-07
a O 0 3.753106909698545e-07
finding O 0 3.128466232737992e-07
with O 0 1.1341750223436975e-06
serious O 0 0.00016942768706940114
diagnostic O 0 0.029686853289604187
and O 0 3.2345651561627164e-05
prognostic O 0 0.00472829258069396
implications O 0 0.00022010525572113693
. O 0 5.284790677251294e-05

Moreover O 0 0.00017227463831659406
, O 0 1.0139703590539284e-05
further O 0 1.5846841051825322e-05
ARSA O 0 0.014535339549183846
alleles O 0 6.59455981804058e-05
functionally O 0 1.7769161786418408e-05
similar O 0 1.7941969190360396e-06
to O 0 5.963835860711697e-07
A464V O 0 2.363255771342665e-05
might O 0 1.077722231457301e-06
exist O 0 2.3252891878655646e-07
which O 0 6.943372454770724e-08
, O 0 2.9257780198577166e-08
together O 0 5.212551101863028e-08
with O 0 7.798890067078901e-08
0 O 0 2.091906026180368e-06
- O 0 0.004375185817480087
type O 0 0.000566797680221498
mutations O 0 2.422490251774434e-05
, O 0 9.622573315937188e-07
may O 0 1.3755049621977378e-05
cause O 0 1.3360557204578072e-05
pathological O 0 4.5323035010369495e-05
ARSA O 0 0.33737772703170776
and O 0 1.9942879589507356e-05
GS O 1 0.9999641180038452
levels O 0 2.16319222090533e-06
, O 0 1.5450066825906106e-07
but O 0 1.332872585635414e-07
not O 0 2.988980725149304e-07
clinical O 0 4.1568173401174136e-06
outbreak O 0 5.463229172164574e-06
of O 0 3.260295784457412e-07
the O 0 5.868985681445338e-05
disease O 0 0.11540636420249939
. O 0 4.35722040492692e-06
. O 0 1.377940225211205e-05

Human O 0 0.007133677136152983
MLH1 O 1 0.999981164932251
deficiency O 1 0.9999701976776123
predisposes O 0 0.006070790812373161
to O 0 0.00020686538482550532
hematological B-Disease 1 0.999337375164032
malignancy I-Disease 1 0.9997782111167908
and O 0 0.0224319975823164
neurofibromatosis B-Disease 1 0.9999974966049194
type I-Disease 0 0.09962870180606842
1 I-Disease 0 4.615317811840214e-05
. O 0 3.490298695396632e-05

Heterozygous O 0 0.0041517759673297405
germ O 0 0.06714342534542084
- O 0 0.03235297650098801
line O 0 8.934328070608899e-05
mutations O 0 1.767854882928077e-05
in O 0 5.113944894219458e-07
the O 0 1.3568031818067539e-06
DNA O 0 2.7578527806326747e-05
mismatch O 0 0.0007951133302412927
repair O 0 0.050030093640089035
genes O 0 9.548132766212802e-06
lead O 0 8.797004738880787e-06
to O 0 3.532477421686053e-05
hereditary B-Disease 1 0.9999988079071045
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00046785292215645313

The O 0 0.00015672660083509982
disease O 0 0.02730751596391201
susceptibility O 0 5.36522529728245e-05
of O 0 6.909669991728151e-07
individuals O 0 5.480677600644412e-07
who O 0 2.8689644295809558e-06
constitutionally O 0 1.8560382159193978e-05
lack O 0 1.3045835203229217e-06
both O 0 3.9590537426192896e-07
wild O 0 3.1811146072868723e-06
- O 0 0.007945813238620758
type O 0 3.6972422094549984e-05
alleles O 0 8.044334208534565e-06
is O 0 7.581741670037445e-07
unknown O 0 6.989758730924223e-06
. O 0 1.1314200492051896e-05

We O 0 9.074761692318134e-06
have O 0 1.3196519148550578e-06
identified O 0 1.5300490758818341e-06
three O 0 3.272949982147111e-07
offspring O 0 2.3663110368943308e-06
in O 0 6.836448847025167e-07
a O 0 4.690950663643889e-05
hereditary B-Disease 1 0.9999979734420776
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.5381256937980652
who O 0 0.0001308240316575393
developed O 0 0.13402189314365387
hematological B-Disease 1 0.9986639022827148
malignancy I-Disease 1 0.8479238152503967
at O 0 3.193797056155745e-06
a O 0 1.983083393497509e-06
very O 0 5.0028847908834e-07
early O 0 8.336748578585684e-06
age O 0 7.688024084018252e-07
, O 0 6.984961942180234e-08
and O 0 8.38270537428798e-08
at O 0 1.1222071805150335e-07
least O 0 4.779192863679782e-08
two O 0 2.5359453204032434e-08
of O 0 3.195345499307223e-08
them O 0 4.652012108863346e-08
displayed O 0 2.404320184723474e-06
signs O 0 4.523012194113107e-06
of O 0 1.253903633369191e-06
neurofibromatosis B-Disease 1 0.9988088607788086
type I-Disease 0 0.0002595106197986752
1 I-Disease 0 1.0912730431300588e-05
( O 0 1.8914970496552996e-05
NF1 B-Disease 0 0.0011192939709872007
) O 0 1.6538266208954155e-05
. O 0 1.9097111362498254e-05

DNA O 0 0.00020934386702720076
sequence O 0 3.67592328984756e-05
analysis O 0 9.410148777533323e-06
and O 0 1.4103433159107226e-06
allele O 0 1.1452896615082864e-05
- O 0 5.44928388990229e-06
specific O 0 5.887292786610487e-07
amplification O 0 6.087814199418062e-06
in O 0 3.4763604617182864e-07
two O 0 6.431842507481633e-07
siblings O 0 2.2097518012742512e-05
revealed O 0 2.577585109975189e-05
a O 0 2.0236499040038325e-05
homozygous O 0 0.0006653610616922379
MLH1 O 0 0.10523752123117447
mutation O 0 8.534641528967768e-05
( O 0 5.1410042942734435e-06
C676T O 0 7.417336018988863e-05
- O 0 0.0002743246441241354
- O 0 0.00015750175225548446
> O 0 3.371834463905543e-05
Arg226Stop O 0 0.00015987534425221384
) O 0 7.477531198674114e-06
. O 0 1.0545772056502756e-05

Thus O 0 5.4668926168233156e-05
, O 0 3.3669514323264593e-06
a O 0 7.491235464840429e-06
homozygous O 0 0.00013280111306812614
germ O 0 0.0015481211012229323
- O 0 0.0020415051840245724
line O 0 0.00023537897504866123
MLH1 O 0 0.041475579142570496
mutation O 0 5.9822112234542146e-05
and O 0 6.651332114415709e-06
consequent O 1 0.8680903315544128
mismatch O 1 0.9999926090240479
repair O 1 1.0
deficiency O 1 0.9999881982803345
results O 0 1.45855919981841e-05
in O 0 1.8395077177046915e-06
a O 0 5.7367458794033155e-05
mutator O 1 0.9956265687942505
phenotype O 0 0.3326472342014313
characterized O 0 0.00042892928468063474
by O 0 6.870926154078916e-05
leukemia B-Disease 1 0.9999167919158936
and O 0 0.0012130175018683076
/ O 1 0.9998598098754883
or O 1 0.850907027721405
lymphoma B-Disease 1 1.0
associated O 0 0.01025523990392685
with O 0 0.000405707600293681
neurofibromatosis B-Disease 1 0.9999979734420776
type I-Disease 0 0.0015500320587307215
1 I-Disease 0 6.8554609242710285e-06
. O 0 2.754886281763902e-06
. O 0 1.212290044350084e-05

Missense O 0 0.31091371178627014
mutations O 0 0.004066775552928448
in O 0 5.937616151641123e-06
the O 0 1.7917105878950679e-06
most O 0 2.3252270864304592e-07
ancient O 0 5.141295105204335e-07
residues O 0 1.0194301012234064e-06
of O 0 1.336968011855788e-07
the O 0 1.1760017741835327e-06
PAX6 O 0 0.00033357663778588176
paired O 0 1.6803685866761953e-05
domain O 0 5.56136728846468e-06
underlie O 0 1.927030461956747e-05
a O 0 3.2663162983226357e-06
spectrum O 0 3.5766250221058726e-05
of O 0 3.3013625397870783e-06
human O 0 0.05165060609579086
congenital B-Disease 1 1.0
eye I-Disease 1 0.999991774559021
malformations I-Disease 1 0.9999978542327881
. O 0 0.0003989760880358517

Mutations O 0 0.0009159448673017323
of O 0 4.177626124146627e-06
the O 0 4.4671173782262485e-06
human O 0 1.4575191016774625e-05
PAX6 O 0 0.00982167199254036
gene O 0 0.0011249020462855697
underlie O 1 0.8988951444625854
aniridia B-Disease 1 1.0
( O 1 0.7241504788398743
congenital B-Disease 1 0.9999966621398926
absence I-Disease 0 5.62689137950656e-06
of I-Disease 0 1.835179830322886e-07
the I-Disease 0 2.148567773474497e-06
iris I-Disease 0 0.02181771770119667
) O 0 4.6810373532935046e-07
, O 0 9.893720687159657e-08
a O 0 1.0070012876894907e-06
rare O 0 1.588112354511395e-05
dominant O 0 0.14122365415096283
malformation B-Disease 1 0.9407077431678772
of I-Disease 0 6.946597181922698e-07
the I-Disease 0 8.455797797068954e-06
eye I-Disease 0 0.006279720459133387
. O 0 4.468098995857872e-05

The O 0 4.28869498136919e-05
spectrum O 0 8.840949885779992e-05
of O 0 5.6963576753332745e-06
PAX6 O 0 0.13196447491645813
mutations O 0 0.0007310392102226615
in O 0 4.299075226299465e-05
aniridia B-Disease 1 1.0
patients O 0 0.004175967536866665
is O 0 6.208643981153728e-07
highly O 0 8.297314479932538e-07
biased O 0 2.832817699527368e-06
, O 0 7.818743341658774e-08
with O 0 9.109967891163251e-08
92 O 0 1.0183476888414589e-06
% O 0 6.864195256639505e-08
of O 0 3.79678937179051e-08
all O 0 7.238622146132911e-08
reported O 0 2.7569270969252102e-05
mutations O 0 2.6548595997155644e-06
leading O 0 8.151960173563566e-07
to O 0 7.259395147229952e-07
premature O 0 2.396463241893798e-05
truncation O 0 6.984907031437615e-06
of O 0 1.2674914273702598e-07
the O 0 4.6042956114433764e-07
protein O 0 1.503978069195e-06
( O 0 5.194468144509301e-07
nonsense O 0 1.3904498246120056e-06
, O 0 9.87445289979405e-08
splicing O 0 1.5064800891195773e-06
, O 0 1.1831953372620774e-07
insertions O 0 2.0565619252010947e-06
and O 0 2.3315578800975345e-07
deletions O 0 3.1030272111820523e-06
) O 0 1.2950506800279982e-07
and O 0 5.9110345063118075e-08
just O 0 7.219565389959826e-08
2 O 0 1.5633439431894658e-07
% O 0 5.998327168299511e-08
leading O 0 1.1067641025874764e-07
to O 0 8.40327629703097e-08
substitution O 0 2.344955021271744e-07
of O 0 5.3583153913905335e-08
one O 0 9.92922295495191e-08
amino O 0 8.938587825468858e-07
acid O 0 2.090171165036736e-06
by O 0 4.7674211600678973e-07
another O 0 1.4589977581636049e-06
( O 0 5.62759942113189e-06
missense O 0 0.00013582479732576758
) O 0 7.04913600202417e-06
. O 0 1.244439681613585e-05

The O 0 1.5686826372984797e-05
extraordinary O 0 1.465743116568774e-05
conservation O 0 2.9924083264631918e-06
of O 0 2.419108113826951e-07
the O 0 7.187805408648273e-07
PAX6 O 0 0.00011175831605214626
protein O 0 2.241699121441343e-06
at O 0 5.075116291664017e-07
the O 0 2.4831805944813823e-07
amino O 0 9.308301400778873e-07
acid O 0 1.2843357808378641e-06
level O 0 4.058556157815474e-07
amongst O 0 7.83483415034425e-07
vertebrates O 0 4.713910584541736e-06
predicts O 0 2.3421967853209935e-05
that O 0 7.69847133597068e-07
pathological O 0 3.442394154262729e-05
missense O 0 0.0009038971038535237
mutations O 0 6.269908044487238e-05
should O 0 5.422919571174134e-07
in O 0 3.3010243782882753e-07
fact O 0 3.069612830586266e-07
be O 0 1.1949980205372412e-07
common O 0 1.1600900506891776e-07
even O 0 9.73605978060732e-08
though O 0 1.5366616423762025e-07
they O 0 5.974326455771006e-08
are O 0 5.1119556587764237e-08
hardly O 0 5.121226536175527e-07
ever O 0 5.735478794122173e-07
seen O 0 2.063036617983016e-06
in O 0 6.6495754253992345e-06
aniridia B-Disease 1 0.9999991655349731
patients O 0 0.0009954356355592608
. O 0 2.757584661594592e-05

This O 0 1.4503159036394209e-05
indicates O 0 8.71930387802422e-06
that O 0 4.1858149302242964e-07
there O 0 1.2686548700457934e-07
is O 0 7.134012491860631e-08
a O 0 3.5826334965349815e-07
heavy O 0 0.000222485265112482
ascertainment O 0 0.00031433303956873715
bias O 0 1.0322929483663756e-05
in O 0 1.6405562064392143e-07
the O 0 1.8440535143326997e-07
selection O 0 2.819593021285982e-07
of O 0 2.3563410422866582e-07
patients O 0 4.314069883548655e-06
for O 0 9.072917919183965e-07
PAX6 O 0 0.03361308202147484
mutation O 0 2.0574252630467527e-05
analysis O 0 1.1839759963550023e-06
and O 0 3.131941070932953e-07
that O 0 1.3810020504934073e-07
the O 0 8.676441893840092e-07
missing O 0 8.712413546163589e-06
PAX6 O 0 0.015766577795147896
missense O 0 0.009965186938643456
mutations O 0 0.00057219248265028
frequently O 0 0.0001719552674330771
may O 0 0.00036403938429430127
underlie O 0 0.0007037159521132708
phenotypes O 0 0.00022131147852633148
distinct O 0 1.0208738785877358e-05
from O 0 1.3965515790914651e-05
textbook O 0 0.0065890164114534855
aniridia B-Disease 1 0.9999600648880005
. O 0 0.0001334189873887226

Here O 0 2.412066351098474e-05
we O 0 1.5373476571767242e-06
present O 0 1.2766131476382725e-06
four O 0 8.391166375076864e-07
novel O 0 7.100480161170708e-06
PAX6 O 0 0.0013600896345451474
missense O 0 0.0012379891704767942
mutations O 0 4.7096335038077086e-05
, O 0 3.2471081112817046e-07
two O 0 2.555896685407788e-07
in O 0 9.720757816467085e-07
association O 0 2.6816469471668825e-06
with O 0 1.808893216548313e-06
atypical O 0 0.0004157439689151943
phenotypes O 0 0.0007174733327701688
ectopia B-Disease 0 0.008342812769114971
pupillae I-Disease 0 0.003403636161237955
( O 0 2.1946566448605154e-06
displaced B-Disease 0 1.991505769183277e-06
pupils I-Disease 0 1.6029761127356323e-06
) O 0 2.091948090310325e-06
and O 0 0.00030845447327010334
congenital B-Disease 1 0.9999994039535522
nystagmus I-Disease 0 0.07142136245965958
( O 0 1.3505072047337308e-06
searching B-Disease 0 1.4698744053021073e-06
gaze I-Disease 0 1.450165109417867e-05
) O 0 1.94819165244553e-07
, O 0 3.894017908123715e-08
and O 0 3.4092671796770446e-08
two O 0 4.2892573048902705e-08
in O 0 2.384844606240222e-07
association O 0 4.887995146418689e-07
with O 0 1.8945020485716668e-07
more O 0 1.0384259212514735e-06
recognizable O 0 0.00017625707550905645
aniridia B-Disease 1 0.9999912977218628
phenotypes O 0 0.005773497745394707
. O 0 4.1570605390006676e-05

Strikingly O 0 0.0005910973413847387
, O 0 2.944523885162198e-06
all O 0 3.1241816600413586e-07
four O 0 3.926745648641372e-07
mutations O 0 2.3542797862319276e-06
are O 0 5.363028776628198e-08
located O 0 3.4580980923237803e-07
within O 0 2.907094085458084e-07
the O 0 5.133001081958355e-07
PAX6 O 0 7.063886732794344e-05
paired O 0 3.7499191876122495e-06
domain O 0 8.747260835662019e-07
and O 0 1.8559572367848887e-07
affect O 0 5.278282060316997e-07
amino O 0 6.02340094246756e-07
acids O 0 4.4801663534599356e-07
which O 0 1.1516123521460031e-07
are O 0 2.2802199239890797e-08
highly O 0 1.5678590159495798e-07
conserved O 0 4.3861859921889845e-07
in O 0 1.4240599455206393e-07
all O 0 5.9530677276598e-08
known O 0 6.251345325836155e-07
paired O 0 4.421980520419311e-06
domain O 0 4.203017851978075e-06
proteins O 0 9.118144589592703e-06
. O 0 9.096040230360813e-06

Our O 0 1.4835652109468356e-05
results O 0 4.888628154731123e-06
support O 0 7.771921559651673e-07
the O 0 3.505430754557892e-07
hypothesis O 0 8.880740551830968e-07
that O 0 6.242557759605916e-08
the O 0 9.007355572521192e-08
under O 0 2.631143729558971e-07
- O 0 1.768153424563934e-06
representation O 0 2.600351365344977e-07
of O 0 2.4118219243973726e-07
missense O 0 0.00015489518409594893
mutations O 0 2.999139906023629e-05
is O 0 3.9434573295693554e-07
caused O 0 4.097886630916037e-06
by O 0 9.693698075352586e-07
ascertainment O 0 0.00037582567892968655
bias O 0 7.125764386728406e-05
and O 0 7.353131081799802e-07
suggest O 0 8.899647241378261e-07
that O 0 1.1543139777359102e-07
a O 0 3.7445693124027457e-07
substantial O 0 9.241996394848684e-07
burden O 0 2.742325250437716e-06
of O 0 4.2397792299198045e-07
PAX6 B-Disease 0 0.29034462571144104
- I-Disease 1 0.9036484956741333
related I-Disease 0 0.0006032810779288411
disease I-Disease 0 0.0014175287215039134
remains O 0 2.1806074528285535e-06
to O 0 4.1709799347700027e-07
be O 0 5.371520046537626e-07
uncovered O 0 2.4051269065239467e-05
. O 0 2.667716898940853e-06
. O 0 1.4962574823584873e-05

The O 0 3.492942778393626e-05
chromosomal O 0 0.0003701020614244044
order O 0 3.269987928433693e-06
of O 0 4.296606164189143e-07
genes O 0 2.427907929813955e-06
controlling O 0 5.617690476356074e-06
the O 0 1.1453511206127587e-06
major O 0 2.894152885346557e-06
histocompatibility O 0 0.00014497445954475552
complex O 0 5.361594503483502e-06
, O 0 1.067891275852162e-06
properdin O 0 0.000123629899462685
factor O 0 3.5042480703850742e-06
B O 0 6.298257630987791e-06
, O 0 3.241028707634541e-07
and O 0 6.5670938056427985e-06
deficiency B-Disease 0 0.0002831303281709552
of I-Disease 0 4.2717200443576075e-08
the I-Disease 0 1.9504317094742873e-07
second I-Disease 0 6.264582452786271e-07
component I-Disease 0 1.4879511809340329e-06
of I-Disease 0 3.543131015248946e-07
complement I-Disease 0 8.314967999467626e-06
. O 0 1.223416347784223e-05

The O 0 1.6491272617713548e-05
relationship O 0 1.1303081919322722e-05
of O 0 5.014735506847501e-07
the O 0 9.916662975228974e-07
genes O 0 3.3301444091193844e-06
coding O 0 8.251016879512463e-06
for O 0 7.463009410457744e-07
HLA O 0 0.0002664230123627931
to O 0 3.60682264499701e-07
those O 0 1.6383874879011273e-07
coding O 0 2.7828100428450853e-06
for O 0 1.8222343101115257e-07
properdin O 0 2.2275435185292736e-05
Factor O 0 1.324567961091816e-06
B O 0 1.8285444411958451e-06
allotypes O 0 1.4757843018742278e-05
and O 0 5.61740478133288e-07
for O 0 2.6372588308731792e-06
deficiency B-Disease 0 0.0027829729951918125
of I-Disease 0 5.267138902809165e-08
the I-Disease 0 1.7321102063760918e-07
second I-Disease 0 5.60440184926847e-07
component I-Disease 0 4.960369324180647e-07
of I-Disease 0 9.827686398011792e-08
complement I-Disease 0 1.4967022252676543e-06
( O 0 3.3212763810297474e-06
C2 O 0 0.0002229437232017517
) O 0 3.1678743539487186e-07
was O 0 1.5240548236761242e-06
studied O 0 3.8684416381329356e-07
in O 0 2.0457687810448988e-07
families O 0 2.437035675484367e-07
of O 0 1.8802055024025321e-07
patients O 0 2.0626608602469787e-05
with O 0 0.0005046970909461379
connective O 1 0.9999978542327881
tissue O 1 0.9999996423721313
disorders O 1 0.999996542930603
. O 0 0.00017464622214902192

Patients O 0 0.0010317355627194047
were O 0 6.509212198579917e-06
selected O 0 2.0705147107946686e-06
because O 0 4.715124362064671e-07
they O 0 1.9340468782047537e-07
were O 0 3.402868742341525e-07
heterozygous O 0 8.235483619500883e-06
or O 0 3.650689677670016e-06
homozygous O 0 0.0004051182186231017
for O 0 0.0012157484889030457
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 7.648275641258806e-05

12 O 0 6.28173365839757e-05
families O 0 9.72262478171615e-06
with O 0 2.4866549210855737e-06
15 O 0 5.751062872150214e-06
matings O 0 8.708560926606879e-05
informative O 0 5.5351993069052696e-05
for O 0 0.03618869185447693
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.4593267880845815e-05
found O 0 1.4164672393235378e-05
. O 0 2.355531250941567e-05

Of O 0 1.4639520486525726e-05
57 O 0 3.6102079320698977e-05
informative O 0 1.958597385964822e-05
meioses O 0 9.819092520046979e-05
, O 0 3.4089819678229105e-07
two O 0 1.4047724050669785e-07
crossovers O 0 1.6769558897067327e-06
were O 0 1.8377087940280035e-07
noted O 0 3.423097894028615e-07
between O 0 7.156601213864633e-07
the O 0 0.01691289246082306
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
gene O 0 5.830713689647382e-06
and O 0 4.040875580813008e-07
the O 0 2.6060613436129643e-06
HLA O 0 0.2815438210964203
- O 0 0.0009402447612956166
B O 0 5.269960638543125e-06
gene O 0 1.299949872191064e-06
, O 0 6.958738651974272e-08
with O 0 6.532306429107848e-08
a O 0 5.642925202664628e-07
recombinant O 0 5.4596512200077996e-06
fraction O 0 1.9693159174494212e-06
of O 0 1.3484326473189867e-06
0 O 0 2.1204774384386837e-05
. O 0 1.441161111870315e-05

035 O 0 0.13382834196090698
. O 0 0.0014585923636332154

A O 0 0.00046316682710312307
lod O 0 0.0024995035491883755
score O 0 5.113855422678171e-06
of O 0 7.36289223368658e-07
13 O 0 1.85147882802994e-06
was O 0 2.773106189124519e-06
calculated O 0 1.0113360531249782e-06
for O 0 3.6161665661893494e-07
linkage O 0 0.00020646715711336583
between O 0 0.01651989296078682
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.6074391169240698e-05
HLA O 0 0.4729517698287964
- O 0 0.001030206331051886
B O 0 2.102442294926732e-06
at O 0 1.9962661212957755e-07
a O 0 1.7136784435933805e-07
maximum O 0 4.106835831407807e-07
likelihood O 0 3.739922647127969e-07
value O 0 5.0068791779267485e-08
of O 0 3.727644681816855e-08
the O 0 2.482072432030691e-07
recombinant O 0 3.3254884783673333e-06
fraction O 0 1.20545121262694e-06
of O 0 4.024891211429349e-07
0 O 0 7.015924438746879e-06
. O 0 7.744864888081793e-06

04 O 0 0.03304055705666542
. O 0 0.0012959751766175032

18 O 0 7.902870129328221e-05
families O 0 7.56587587602553e-06
with O 0 1.4372659506989294e-06
21 O 0 3.623817747211433e-06
informative O 0 5.089324986329302e-06
matings O 0 1.646273631195072e-05
for O 0 4.5226053657643206e-07
both O 0 6.626378876717354e-07
properdin O 0 8.449266897514462e-05
Factor O 0 2.971784169858438e-06
B O 0 6.157724783406593e-06
allotype O 0 3.419216591282748e-05
and O 0 5.2320374379632995e-06
HLA O 0 0.03252040594816208
- O 0 0.0008538234978914261
B O 0 1.195613276649965e-05
were O 0 1.1760242841774016e-06
found O 0 3.4909726309706457e-06
. O 0 1.2311164937273134e-05

Of O 0 1.4466430911852513e-05
72 O 0 2.8558108169818297e-05
informative O 0 1.996314495045226e-05
meioses O 0 9.77639647317119e-05
, O 0 6.110168442319264e-07
three O 0 3.767009388866427e-07
recombinants O 0 8.193651592591777e-05
were O 0 5.594372964878858e-07
found O 0 2.42556495777535e-07
, O 0 8.126315975687248e-08
giving O 0 1.8234128162930574e-07
a O 0 6.362154749695037e-07
recombinant O 0 4.319281742937164e-06
fraction O 0 8.472688364236092e-07
of O 0 6.950162401153648e-07
0 O 0 1.1158845154568553e-05
. O 0 8.389778486161958e-06

042 O 0 0.03564231097698212
. O 0 0.0015371806221082807

A O 0 0.00032062394893728197
lod O 0 0.002193995751440525
score O 0 4.926787369186059e-06
of O 0 5.841121151206607e-07
16 O 0 2.3340057850873563e-06
between O 0 3.28619694300869e-06
HLA O 0 0.0121206259354949
- O 0 4.946262561134063e-05
B O 0 2.188010739700985e-06
and O 0 1.8560403702849726e-07
Factor O 0 6.933968847988581e-07
B O 0 2.5063634438993176e-06
allotypes O 0 2.5803154130699113e-05
was O 0 3.833763912552968e-06
calculated O 0 5.37137111678021e-07
at O 0 1.9726493860616756e-07
a O 0 1.9258600048033259e-07
maximum O 0 5.253564268059563e-07
likelihood O 0 4.1241955273108033e-07
value O 0 4.2453301318801095e-08
of O 0 3.527620862087133e-08
the O 0 2.8114411065871536e-07
recombinant O 0 3.546978405211121e-06
fraction O 0 1.3605530284621636e-06
of O 0 6.618881798203802e-07
0 O 0 1.1192599231435452e-05
. O 0 9.405016498931218e-06

04 O 0 0.043663013726472855
. O 0 0.0013823325280100107

A O 0 6.489938095910475e-05
crossover O 0 5.1974562666146085e-05
was O 0 2.4069509890978225e-05
shown O 0 1.7504993365946575e-06
to O 0 3.4076816746164695e-07
have O 0 1.0624418678162328e-07
occurred O 0 3.698015405007027e-07
between O 0 1.35197723238889e-07
genes O 0 3.989861454556376e-07
for O 0 1.2498726675858052e-07
Factor O 0 4.203007222258748e-07
B O 0 1.793026740415371e-06
and O 0 1.0221783668384887e-06
HLA O 0 0.0046355645172297955
- O 0 0.0046802363358438015
D O 0 0.001524043851532042
, O 0 1.3821878042108438e-07
in O 0 2.3406720117691293e-07
which O 0 1.4559815326720127e-06
HLA O 0 0.009471006691455841
- O 0 0.0009083563345484436
D O 0 0.0013108523562550545
segregared O 0 3.689552977448329e-05
with O 0 1.7514145156383165e-06
HLA O 0 0.005451091565191746
- O 0 1.9931812857976183e-05
A O 0 4.427191470313119e-06
and O 0 1.7559199250172242e-06
B O 0 3.4580622013891116e-05
. O 0 9.370824955112766e-06

These O 0 1.2147203051426914e-05
studies O 0 5.64902165933745e-06
suggest O 0 2.0162556211289484e-06
that O 0 1.4501570433367306e-07
the O 0 2.563816110523476e-07
genes O 0 8.024748581192398e-07
for O 0 1.7985313149893045e-07
Factor O 0 1.8458373460816802e-06
B O 0 3.570537955965847e-05
and O 0 0.01612190157175064
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
are O 0 1.2444158414837148e-07
located O 0 3.9075965219126374e-07
outside O 0 1.854258897537875e-07
those O 0 6.168229305103523e-08
for O 0 1.5964923250066931e-07
HLA O 0 0.0009081079624593258
, O 0 8.135574347534202e-08
that O 0 2.6542338105173258e-08
the O 0 5.3398487409594964e-08
order O 0 1.0252385607145698e-07
of O 0 7.764781173591473e-08
genese O 0 3.501440369291231e-05
is O 0 6.330694191092334e-07
HLA O 0 8.959915430750698e-05
- O 0 3.5204566302127205e-06
A O 0 7.412301670228771e-07
, O 0 1.93708885376509e-07
- O 0 9.822597348829731e-06
B O 0 1.0854190577447298e-06
, O 0 1.830429141591594e-07
- O 0 4.680084020947106e-05
D O 0 8.051368786254898e-05
, O 0 1.4320077923457575e-07
Factor O 0 6.794687124056509e-07
B O 0 2.9420002647384536e-06
allotype O 0 0.001637067412957549
, O 0 0.14449627697467804
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
, O 0 3.1100614705792395e-07
that O 0 9.033007586367603e-08
the O 0 5.260001216811361e-07
genes O 0 4.159986474405741e-06
coding O 0 4.321629603509791e-05
for O 0 0.00028445202042348683
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 2.4978994588309433e-06
Factor O 0 2.1767739326605806e-06
B O 0 3.030691914318595e-06
allotypes O 0 8.221248208428733e-06
are O 0 8.264652251455118e-08
approximately O 0 1.764683617011542e-07
3 O 0 3.543076729783934e-07
- O 0 3.830350578937214e-06
- O 0 3.4341110222158022e-06
5 O 0 3.346104904267122e-07
centimorgans O 0 6.402334747690475e-06
from O 0 3.1613222972737276e-07
the O 0 7.453620014530316e-07
HLA O 0 0.0001692053920123726
- O 0 4.9835075515147764e-06
A O 0 1.7532092897454277e-06
and O 0 2.6053755846078275e-06
HLA O 0 0.004336403217166662
- O 0 7.023048965493217e-05
B O 0 2.5527617708576145e-06
loci O 0 9.76257410911785e-07
, O 0 4.58279885151569e-08
and O 0 4.3344485334273486e-08
that O 0 3.1869763716940724e-08
the O 0 1.0236362868454307e-07
apparent O 0 1.422552145413647e-06
lack O 0 2.0133336420258274e-07
of O 0 6.93869921519763e-08
recombinants O 0 1.3057760952506214e-05
between O 0 2.0021994373564667e-07
the O 0 3.953537657253037e-07
Factor O 0 1.4658148757007439e-06
B O 0 8.078274731815327e-06
gene O 0 2.467579543008469e-05
and O 0 0.011626476421952248
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 1.5786145013407804e-05
suggests O 0 1.4412107702810317e-06
that O 0 8.647349858392772e-08
these O 0 2.7999719875992923e-08
two O 0 7.576971938760835e-08
genes O 0 6.382093147294654e-07
lie O 0 3.7269978747644927e-07
in O 0 1.5575402301237773e-07
close O 0 6.866937951599539e-07
proximity O 0 1.0589393468762864e-06
to O 0 4.1373490944351943e-07
one O 0 4.39684043840316e-07
another O 0 3.2188645491260104e-06
. O 0 7.424367140629329e-06

Distribution O 0 4.2700496123870835e-05
of O 0 4.112112947041169e-06
emerin O 0 0.00018564796482678503
and O 0 2.8872168513771612e-06
lamins O 0 0.00017069544992409647
in O 0 7.78643254761846e-07
the O 0 1.992525994864991e-06
heart O 0 0.00025499987532384694
and O 0 9.20332411169511e-07
implications O 0 2.341487515877816e-06
for O 0 1.6946275991358561e-06
Emery B-Disease 1 0.9175089597702026
- I-Disease 1 0.9969021081924438
Dreifuss I-Disease 1 0.9997914433479309
muscular I-Disease 1 0.9999948740005493
dystrophy I-Disease 1 0.9999889135360718
. O 0 0.00013637245865538716

Emerin O 0 0.001462632091715932
is O 0 6.660663075308548e-06
a O 0 2.9464815725077642e-06
nuclear O 0 8.346540198544972e-06
membrane O 0 4.977157004759647e-06
protein O 0 9.041967814482632e-07
which O 0 2.2050883785595943e-07
is O 0 1.1171607638971182e-07
missing O 0 4.0198773376687313e-07
or O 0 6.67735037040984e-07
defective O 0 5.5015927500789985e-05
in O 0 4.604862624546513e-06
Emery B-Disease 1 0.8968024849891663
- I-Disease 1 0.9889127016067505
Dreifuss I-Disease 1 0.9992052912712097
muscular I-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9999995231628418
( O 0 0.0006068487418815494
EDMD B-Disease 1 0.9999953508377075
) O 0 3.687288335640915e-05
. O 0 2.3144044462242164e-05

It O 0 5.466163656819845e-06
is O 0 4.877155106441933e-07
one O 0 1.1307800917847999e-07
member O 0 1.4316501051325758e-07
of O 0 4.178491863626732e-08
a O 0 4.602447347679117e-07
family O 0 1.1515336382217356e-06
of O 0 2.3921543856886274e-07
lamina O 0 0.02215619944036007
- O 0 0.0009307571453973651
associated O 0 1.5497481626880472e-06
proteins O 0 4.131296975629084e-07
which O 0 1.3352223504625726e-07
includes O 0 7.219523467938416e-07
LAP1 O 0 4.943112799082883e-05
, O 0 1.209724928230571e-06
LAP2 O 0 0.00014351896243169904
and O 0 6.782025593565777e-06
lamin O 0 0.0016468052053824067
B O 0 0.00020065259013790637
receptor O 0 0.00021834654035046697
( O 0 1.95566717593465e-05
LBR O 0 0.0005199700826779008
) O 0 2.1003377696615644e-05
. O 0 1.8740913219517097e-05

A O 0 5.6396409490844235e-05
panel O 0 4.205410732538439e-05
of O 0 2.0847346604568884e-06
16 O 0 6.665003184025409e-06
monoclonal O 0 6.40324578853324e-05
antibodies O 0 2.1989510059938766e-05
( O 0 2.5845579330052715e-06
mAbs O 0 2.4060398573055863e-05
) O 0 3.669762236313545e-07
has O 0 1.7854272016393224e-07
been O 0 1.9004538387434877e-07
mapped O 0 1.8968065660374123e-06
to O 0 8.228067827076302e-08
six O 0 1.4491588729015348e-07
specific O 0 1.494738057772338e-07
sites O 0 2.3567275775349117e-07
throughout O 0 3.3766900742193684e-07
the O 0 3.8682571812387323e-07
emerin O 0 2.0382107322802767e-05
molecule O 0 2.5167298645101255e-06
using O 0 8.735464689380024e-07
phage O 0 7.861744052206632e-06
- O 0 2.3590173441334628e-06
displayed O 0 1.1618865300988546e-06
peptide O 0 1.247351178790268e-06
libraries O 0 2.805200836064614e-07
and O 0 9.975026671327214e-08
has O 0 1.0189300780893973e-07
been O 0 9.730676708841202e-08
used O 0 2.1327717547592329e-07
to O 0 3.0954822705098195e-07
localize O 0 1.7151303836726584e-05
emerin O 0 4.171150067122653e-05
in O 0 8.973776175480452e-07
human O 0 1.2872013712694752e-06
and O 0 3.000970764333033e-06
rabbit O 0 0.0025783348828554153
heart O 0 0.031880319118499756
. O 0 6.034247053321451e-05

Several O 0 9.282184328185394e-05
mAbs O 0 0.0005701483460143209
against O 0 1.1344312952132896e-05
different O 0 2.108047738147434e-06
emerin O 0 0.0005007163854315877
epitopes O 0 0.0005724161746911705
did O 0 6.849632427474717e-06
not O 0 4.5733816023130203e-07
recognize O 0 1.183576273433573e-06
intercalated O 0 8.981003702501766e-06
discs O 0 1.0403547094028909e-05
in O 0 2.6601995273267676e-07
the O 0 7.518609663748066e-07
heart O 0 0.0003722584806382656
, O 0 1.840608092606999e-07
though O 0 1.106584690546697e-07
they O 0 5.282904780301578e-08
recognized O 0 2.3256106373992225e-07
cardiomyocyte O 0 1.0926299182756338e-05
nuclei O 0 5.470711130328709e-06
strongly O 0 1.3592380128102377e-06
, O 0 5.4673137128702365e-08
both O 0 4.0209005902624995e-08
at O 0 1.0360227520322951e-07
the O 0 1.7854628708846576e-07
rim O 0 2.1049261249572737e-06
and O 0 3.8225454090934363e-07
in O 0 7.723467092546343e-07
intranuclear O 0 0.00010747308260761201
spots O 0 7.035449016257189e-06
or O 0 2.2335345875035273e-06
channels O 0 1.4704923160024919e-05
. O 0 1.2996068107895553e-05

A O 0 0.00039306041435338557
polyclonal O 0 0.0034413582179695368
rabbit O 0 0.0009645945392549038
antiserum O 0 0.00042180140735581517
against O 0 1.358171175525058e-05
emerin O 0 0.0005447327275760472
did O 0 2.6056388833239907e-06
recognize O 0 9.176313255920832e-07
both O 0 3.169427316151996e-07
nuclear O 0 2.4496348487446085e-06
membrane O 0 1.9356480152055155e-06
and O 0 2.2184910619671427e-07
intercalated O 0 6.436747298721457e-06
discs O 0 1.2557869013107847e-05
but O 0 1.6118933388042933e-07
, O 0 7.596884898930512e-08
after O 0 2.874595566026983e-07
affinity O 0 9.820075774769066e-07
purification O 0 1.3415665307547897e-06
against O 0 3.238523049731157e-07
a O 0 4.3447124653539504e-07
pure O 0 1.0061881994261057e-06
- O 0 2.2976271793595515e-05
emerin O 0 1.5028273082862142e-05
band O 0 1.5262817214534152e-06
on O 0 2.2876719185660477e-07
a O 0 3.2873052191462193e-07
western O 0 1.618385681467771e-06
blot O 0 0.0003807797620538622
, O 0 2.581138858204213e-07
it O 0 1.984041233527023e-07
stained O 0 3.1755789677845314e-05
only O 0 1.3787084185423737e-07
the O 0 5.409335130934778e-07
nuclear O 0 3.068610021728091e-05
membrane O 0 5.063863136456348e-05
. O 0 1.52800785144791e-05

These O 0 7.4282056630181614e-06
results O 0 6.3001557464303914e-06
would O 0 6.359649660225841e-07
not O 0 8.3926565253023e-08
be O 0 7.805706303543047e-08
expected O 0 2.7921410605813435e-07
if O 0 9.10777941953711e-08
immunostaining O 0 7.65101685828995e-06
at O 0 4.328005331899476e-07
intercalated O 0 6.747015049768379e-06
discs O 0 3.813487637671642e-05
were O 0 3.380311284217896e-07
due O 0 3.8888893527655455e-07
to O 0 7.196262430397837e-08
a O 0 9.259697719699034e-08
product O 0 6.635693949874621e-08
of O 0 1.907242008769572e-08
the O 0 1.368664328538216e-07
emerin O 0 2.1566442228504457e-05
gene O 0 9.531014484309708e-07
and O 0 1.0344095358050254e-07
, O 0 6.02521623704888e-08
therefore O 0 4.6854943036578334e-08
, O 0 3.130154979658073e-08
cast O 0 9.149147928155799e-08
some O 0 2.670478416177957e-08
doubt O 0 1.2028738183289533e-07
upon O 0 8.34052258369411e-08
the O 0 3.1638404607292614e-07
hypothesis O 0 7.690297934459522e-06
that O 0 3.97933126805583e-06
cardiac B-Disease 1 0.999934196472168
defects I-Disease 1 0.9993958473205566
in O 0 3.166585156577639e-05
EDMD B-Disease 1 0.9999998807907104
are O 0 7.780806186019618e-07
caused O 0 3.924038537661545e-06
by O 0 2.452224237003975e-07
absence O 0 1.1042650385206798e-06
of O 0 5.426106213235471e-07
emerin O 0 0.0023248582147061825
from O 0 7.704275049036369e-06
intercalated O 0 0.00042396390927024186
discs O 0 0.0008905499707907438
. O 0 4.241692295181565e-05

Although O 0 4.6512930566677824e-05
emerin O 0 0.0004365022759884596
was O 0 1.3674024557985831e-05
abundant O 0 1.2597009799719672e-06
in O 0 3.261483811911603e-07
the O 0 3.61908206514272e-07
membranes O 0 3.361785502420389e-06
of O 0 2.322813372757082e-07
cardiomyocyte O 0 4.542489114101045e-05
nuclei O 0 1.136535320256371e-05
, O 0 1.9084652080891829e-07
it O 0 1.2707096175290644e-07
was O 0 2.5187325718434295e-06
absent O 0 8.879537745087873e-07
from O 0 1.275122372135229e-07
many O 0 5.0794444206303524e-08
non O 0 4.015965089365636e-07
- O 0 1.5430499843205325e-05
myocyte O 0 0.00018124518101103604
cells O 0 3.6705534967040876e-06
in O 0 6.172708140184113e-07
the O 0 3.3705173336784355e-06
heart O 0 0.0011805315734818578
. O 0 1.9411292669246905e-05

This O 0 4.021824224764714e-06
distribution O 0 2.569987827882869e-06
of O 0 3.52314316387492e-07
emerin O 0 0.00017431695596314967
was O 0 8.281683221866842e-06
similar O 0 4.765611834045558e-07
to O 0 1.1199534100114761e-07
that O 0 6.204477642768325e-08
of O 0 7.141650826270052e-08
lamin O 0 4.69385959149804e-05
A O 0 2.4287346604978666e-06
, O 0 1.0145550533025016e-07
a O 0 3.420131804432458e-07
candidate O 0 8.866430789566948e-07
gene O 0 9.955931545846397e-07
for O 0 9.239232667823671e-08
an O 0 7.027483093224873e-07
autosomal O 0 0.0003332034684717655
form O 0 2.772540256046341e-06
of O 0 5.830591362609994e-06
EDMD B-Disease 1 0.9999982118606567
. O 0 7.649828330613673e-05

In O 0 3.4422497265040874e-05
contrast O 0 2.4126205971697345e-05
, O 0 4.945537511957809e-06
lamin O 0 0.00906970351934433
B1 O 0 0.4243641197681427
was O 0 1.7909889720613137e-05
absent O 0 4.405547315400327e-06
from O 0 4.6588627355959034e-07
cardiomyocyte O 0 1.552019784867298e-05
nuclei O 0 6.07809715802432e-06
, O 0 2.305066999497285e-07
showing O 0 1.4377567367773736e-06
that O 0 8.46157718115137e-07
lamin O 0 0.0011069519678130746
B1 O 0 0.011373428627848625
is O 0 1.8788664135627187e-07
not O 0 6.703037769284492e-08
essential O 0 7.258516632191458e-08
for O 0 7.138314117582922e-08
localization O 0 1.1190624036316876e-06
of O 0 1.6938474800554104e-07
emerin O 0 3.4043998311972246e-05
to O 0 5.607727189271827e-07
the O 0 2.159689984182478e-06
nuclear O 0 0.00015665653336327523
lamina O 0 0.001524421968497336
. O 0 2.7728263376047835e-05

Lamin O 1 0.9732130765914917
B1 O 1 0.9778956770896912
is O 0 1.2271591913304292e-05
also O 0 1.7704581978250644e-06
almost O 0 1.164161403721664e-06
completely O 0 4.3709296733140945e-06
absent O 0 1.1007806278939825e-05
from O 0 3.822654434770811e-06
skeletal O 0 0.4995405972003937
muscle O 0 0.27187424898147583
nuclei O 0 0.0009536116849631071
. O 0 3.162535358569585e-05

In O 0 0.00010954472236335278
EDMD B-Disease 1 0.998401939868927
, O 0 2.6776986032928107e-06
the O 0 5.457457064039772e-07
additional O 0 3.885486421495443e-07
absence O 0 7.701349886701792e-07
of O 0 5.127472491039953e-07
lamin O 0 0.013244167901575565
B1 O 0 0.23683296144008636
from O 0 2.511811999283964e-06
heart O 0 0.0004006790986750275
and O 0 4.637329311663052e-06
skeletal O 0 0.43451640009880066
muscle O 0 0.007534739561378956
nuclei O 0 3.2429936254629865e-05
which O 0 6.950255055926391e-07
already O 0 8.533775144314859e-07
lack O 0 8.703757430339465e-07
emerin O 0 0.0023827652912586927
may O 0 1.8749013861452113e-06
offer O 0 1.7370365412716637e-07
an O 0 8.732843781444899e-08
alternative O 0 4.7602111408195924e-07
explanation O 0 3.708044857830828e-07
of O 0 6.863121626565771e-08
why O 0 4.121729944017716e-07
these O 0 2.851904241651937e-07
tissues O 0 1.2689100913121365e-05
are O 0 1.9889195357336575e-07
particularly O 0 2.193403133787797e-06
affected O 0 5.50581034985953e-06
. O 0 3.458560513536213e-06
. O 0 1.4944451322662644e-05

Genetic O 0 0.00026699184672906995
mapping O 0 3.4683598642004654e-05
of O 0 1.756844540068414e-06
the O 0 8.644298759463709e-06
copper B-Disease 0 0.0006215150933712721
toxicosis I-Disease 0 0.0017658047145232558
locus O 0 4.528898716671392e-05
in O 0 2.017940687437658e-06
Bedlington O 0 0.00019866987713612616
terriers O 0 0.00022350264771375805
to O 0 4.270655153959524e-06
dog O 0 0.00011352812725817785
chromosome O 0 8.352639270015061e-06
10 O 0 3.846475919999648e-07
, O 0 1.151451982650542e-07
in O 0 1.1239144015462443e-07
a O 0 5.801399538540863e-07
region O 0 1.79390599441831e-06
syntenic O 0 7.081740477588028e-05
to O 0 1.024866605803254e-06
human O 0 2.1866633233003085e-06
chromosome O 0 1.9722314391401596e-05
region O 0 1.1048231499444228e-05
2p13 O 0 0.00023074638738762587
- O 0 0.0004150968452449888
p16 O 0 0.0005344327073544264
. O 0 4.4396630983101204e-05

Abnormal O 1 0.974698007106781
hepatic B-Disease 1 0.9996583461761475
copper I-Disease 1 0.5313959121704102
accumulation I-Disease 0 0.00018993407138623297
is O 0 1.9955248262704117e-06
recognized O 0 1.4462458466368844e-06
as O 0 1.3060100627626525e-06
an O 0 0.00575404753908515
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.5568566595902666e-05
man O 0 4.028966577607207e-05
, O 0 9.371114515488443e-07
mouse O 0 2.1795865905005485e-05
, O 0 1.062706814991543e-06
rat O 0 0.00015860400162637234
and O 0 2.4485723315592622e-06
dog O 0 0.00029552486375905573
. O 0 1.6993571989587508e-05

The O 0 2.6923737095785327e-05
major O 0 1.0153261428058613e-05
cause O 0 1.4590781574952416e-05
of O 0 1.51173321683018e-06
hepatic B-Disease 1 0.5912858843803406
copper I-Disease 0 0.15568412840366364
accumulation I-Disease 0 6.536103319376707e-05
in O 0 3.1743447834742256e-06
man O 0 1.3448378012981266e-05
is O 0 5.360810177990061e-07
a O 0 3.789565425904584e-06
dysfunctional O 0 0.000444862263975665
ATP7B O 0 0.003504360793158412
gene O 0 3.347130405018106e-05
, O 0 3.2626769552734913e-06
causing O 0 0.0010876422747969627
Wilson B-Disease 0 0.4724103510379791
disease I-Disease 1 0.812211275100708
( O 0 4.2183848563581705e-05
WD B-Disease 1 0.7183505296707153
) O 0 2.0904961274936795e-05
. O 0 2.0055902496096678e-05

Mutations O 0 0.0010650571202859282
in O 0 9.298380973632447e-06
the O 0 2.502969209672301e-06
ATP7B O 0 0.00030267544207163155
genes O 0 3.8133730413392186e-06
have O 0 2.9196189643698744e-07
also O 0 3.5220145377934386e-07
been O 0 3.2835109209372604e-07
demonstrated O 0 1.0264413958793739e-06
in O 0 6.881261356284085e-07
mouse O 0 3.9037106034811586e-05
and O 0 7.102322342689149e-06
rat O 0 0.0015515050617977977
. O 0 2.783129457384348e-05

The O 0 2.1922778614680283e-05
ATP7B O 0 0.0005811514565721154
gene O 0 4.483776865527034e-05
has O 0 1.7115416994784027e-06
been O 0 8.665559221299191e-07
excluded O 0 1.0474631153556402e-06
in O 0 1.3477496452196647e-07
the O 0 2.2079146333453536e-07
much O 0 6.218090220500017e-07
rarer O 0 2.3879994841990992e-05
human O 0 6.137890522950329e-06
copper B-Disease 1 0.9843499064445496
overload I-Disease 1 0.9679310321807861
disease O 0 9.36795913730748e-05
non B-Disease 0 2.6537911708146567e-06
- I-Disease 0 5.751415665145032e-05
Indian I-Disease 0 5.533002422453137e-06
childhood I-Disease 0 0.022084712982177734
cirrhosis I-Disease 0 0.3242686986923218
, O 0 4.435275968717178e-06
indicating O 0 0.00013578000653069466
genetic O 0 0.00015619162877555937
heterogeneity O 0 0.0006105669890530407
. O 0 8.397249621339142e-05

By O 0 3.018600182258524e-05
investigating O 0 4.822913615498692e-05
the O 0 1.4142535292194225e-05
common O 0 0.0008011895115487278
autosomal O 1 0.9997751116752625
recessive O 1 0.9999182224273682
copper B-Disease 1 0.9965575933456421
toxicosis I-Disease 1 0.9982025623321533
( O 0 3.519860911183059e-05
CT B-Disease 1 0.7409887313842773
) O 0 1.430641759725404e-06
in O 0 8.002089089131914e-07
Bedlington O 0 7.849706889828667e-05
terriers O 0 0.00010363874753238633
, O 0 4.985894861420093e-07
we O 0 1.0418924034638621e-07
have O 0 9.598746686378945e-08
identified O 0 3.574855611532257e-07
a O 0 3.76202990537422e-07
new O 0 1.394675564370118e-06
locus O 0 1.0774205293273553e-05
involved O 0 2.3754409994580783e-06
in O 0 0.0001072754748747684
progressive O 1 0.9999947547912598
liver B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0001840969198383391

We O 0 4.088470814167522e-05
examined O 0 7.001023914199322e-05
whether O 0 5.5073228395485785e-06
the O 0 2.4498826860508416e-06
WD B-Disease 0 0.0023794975131750107
gene O 0 2.1847683456144296e-05
ATP7B O 0 0.0002974035742226988
was O 0 2.3397118638968095e-05
also O 0 8.60649095102417e-07
causative O 0 3.833292339550098e-06
for O 0 2.82870701084903e-07
CT B-Disease 0 0.07433516532182693
by O 0 7.091258567015757e-07
investigating O 0 3.1306678920373088e-06
the O 0 1.2574001857501571e-06
chromosomal O 0 0.0003262795798946172
co O 0 2.2631782485404983e-05
- O 0 4.384422481962247e-06
localization O 0 2.155145011784043e-06
of O 0 1.92191535575148e-07
ATP7B O 0 4.6937697334215045e-05
and O 0 4.663810386773548e-07
C04107 O 0 6.637176738877315e-06
, O 0 2.3824735251309903e-07
using O 0 5.92213893924054e-07
fluorescence O 0 1.0354165169701446e-05
in O 0 1.4895555295879603e-06
situ O 0 1.930260259541683e-05
hybridization O 0 9.285718078899663e-06
( O 0 2.0461229723878205e-06
FISH O 0 4.7119870032474864e-06
) O 0 4.123524831811665e-06
. O 0 9.723059520183597e-06

C04107 O 0 0.0014284291537478566
is O 0 1.0441107406222727e-05
an O 0 4.025507678306894e-06
anonymous O 0 2.3440579752787016e-05
microsatellite O 0 0.00039780218503437936
marker O 0 8.513662032783031e-05
closely O 0 2.2603657271247357e-05
linked O 0 0.00017747636593412608
to O 0 1.7947058950085193e-05
CT B-Disease 1 0.9935761094093323
. O 0 4.7735695261508226e-05

However O 0 6.932488759048283e-05
, O 0 1.0034581464424264e-05
BAC O 0 0.00021107315842527896
clones O 0 1.5924375475151464e-05
containing O 0 2.5532465315336594e-06
ATP7B O 0 4.2129573557758704e-05
and O 0 7.086505888764805e-07
C04107 O 0 1.6119229258038104e-05
mapped O 0 9.737721484270878e-06
to O 0 5.436465357888665e-07
the O 0 8.195268605959427e-07
canine O 0 3.271949026384391e-05
chromosome O 0 1.9697690731845796e-05
regions O 0 2.8494623620645143e-06
CFA22q11 O 0 2.4755110644036904e-05
and O 0 8.313266448567447e-07
CFA10q26 O 0 3.758838283829391e-05
, O 0 3.647887751867529e-07
respectively O 0 8.739922918721277e-07
, O 0 1.7843768773673219e-07
demonstrating O 0 8.802786055639444e-07
that O 0 8.216774176617037e-07
WD B-Disease 0 0.10777276009321213
cannot O 0 2.042116875600186e-06
be O 0 3.618005166572402e-07
homologous O 0 5.3533785830950364e-06
to O 0 6.867992397019407e-06
CT B-Disease 1 0.985317051410675
. O 0 3.106592703261413e-05

The O 0 2.7167498046765104e-05
copper O 0 0.0001078351415344514
transport O 0 3.204292806913145e-05
genes O 0 9.386101737618446e-06
CTR1 O 0 7.435465522576123e-05
and O 0 1.246032525159535e-06
CTR2 O 0 0.00014610089419875294
were O 0 8.505704158778826e-07
also O 0 4.822357482225925e-07
excluded O 0 6.485243488896231e-07
as O 0 1.1519077958155322e-07
candidate O 0 5.513495011655323e-07
genes O 0 6.456695587075956e-07
for O 0 2.6049528401017596e-07
CT B-Disease 1 0.9694487452507019
since O 0 5.012931978853885e-06
they O 0 2.0066649142336246e-07
both O 0 3.050835459816881e-07
mapped O 0 1.0047805517388042e-05
to O 0 1.7982755480261403e-06
canine O 0 0.00012042000162182376
chromosome O 0 9.104550554184243e-05
region O 0 3.4651860914891586e-05
CFA11q22 O 0 0.001011769287288189
. O 0 4.564169648801908e-05

2 O 0 0.0004606814472936094
- O 0 0.0005036175134591758
22 O 0 7.721498695900664e-05
. O 0 5.661934119416401e-05

5 O 0 0.0012479774886742234
. O 0 0.00035414635203778744

A O 0 6.783181015634909e-05
transcribed O 0 9.951589163392782e-05
sequence O 0 6.728958851454081e-06
identified O 0 2.859897449525306e-06
from O 0 3.193877375906595e-07
the O 0 3.3011440336849773e-07
C04107 O 0 1.250237528438447e-05
- O 0 1.544389124319423e-05
containing O 0 1.9523797618603567e-06
BAC O 0 0.0002659704477991909
was O 0 8.281794180220459e-06
found O 0 1.664156741298939e-07
to O 0 8.799724326991054e-08
be O 0 5.652777090858763e-08
homologous O 0 4.71014459435537e-07
to O 0 6.205459612829145e-08
a O 0 3.522108329434559e-07
gene O 0 1.517292503194767e-06
expressed O 0 4.71590681172529e-07
from O 0 3.190482971149322e-07
human O 0 8.527754857823311e-07
chromosome O 0 7.050487511151005e-06
2p13 O 0 1.835766488511581e-05
- O 0 2.2517338948091492e-05
p16 O 0 1.0795391062856652e-05
, O 0 1.684825292613823e-07
a O 0 4.60007754554681e-07
region O 0 9.458990462007932e-07
devoid O 0 1.3574476724897977e-06
of O 0 1.745803359654019e-07
any O 0 4.1423317043154384e-07
positional O 0 2.600698462629225e-05
candidate O 0 9.544663043925539e-06
genes O 0 2.2147094568936154e-05
. O 0 1.4962232853577007e-05

Molecular O 0 0.0001736878475639969
analysis O 0 1.2406620953697711e-05
of O 0 9.204491675518511e-07
the O 0 1.5019327292975504e-06
APC B-Disease 0 4.26656479248777e-05
gene O 0 4.308511506678769e-06
in O 0 4.256425825133192e-07
205 O 0 2.8111724077461986e-06
families O 0 6.735872375429608e-07
: O 0 4.6831760869281425e-07
extended O 0 1.085080839402508e-05
genotype O 0 0.00019342827727086842
- O 0 0.0019671537447720766
phenotype O 0 0.00016593749751336873
correlations O 0 3.7461768442881294e-06
in O 0 8.389997674385086e-07
FAP B-Disease 0 1.0458985343575478e-05
and O 0 1.4029370731805102e-07
evidence O 0 1.3171018053981243e-07
for O 0 4.526074448563122e-08
the O 0 9.350334551072592e-08
role O 0 2.436893851154309e-07
of O 0 1.608987645340676e-07
APC B-Disease 0 1.8180928236688487e-05
amino O 0 2.1182815999054583e-06
acid O 0 1.3002539162698667e-05
changes O 0 1.4878737601975445e-05
in O 1 0.7496960163116455
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9893507361412048
. O 0 0.00015339732635766268

BACKGROUND O 0 0.0005283275386318564
/ O 0 0.00016423336637672037
AIMS O 0 1.0795452908496372e-05
The O 0 9.916567478285288e-07
development O 0 2.9840869046893204e-06
of O 0 8.099459228105843e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.6365265663771424e-06
a O 0 5.7933666539611295e-06
variable O 0 3.989742253907025e-06
range O 0 7.302703011191625e-07
of O 0 3.55106010374584e-07
extracolonic O 0 0.000634952390100807
manifestations O 0 0.00023468317522201687
in O 0 0.0003003662859555334
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999984502792358
polyposis I-Disease 1 0.9999998807907104
( O 0 0.0003592994762584567
FAP B-Disease 0 0.004183704033493996
) O 0 1.470044026063988e-06
is O 0 1.608983097867167e-07
the O 0 9.59826991220325e-08
result O 0 1.3341723104076664e-07
of O 0 5.9409195785065094e-08
the O 0 5.952454102953197e-07
dominant O 0 3.068206206080504e-05
inheritance O 0 9.315250645158812e-05
of O 0 3.940521492040716e-05
adenomatous B-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9999953508377075
( O 0 0.00021141475008334965
APC B-Disease 0 0.003096219850704074
) O 0 2.076593227684498e-05
gene O 0 0.00012797083763871342
mutations O 0 0.00020817306358367205
. O 0 3.6307817936176434e-05

In O 0 2.0452473108889535e-05
this O 0 1.3882357734473771e-06
study O 0 9.099641715692997e-07
, O 0 1.4572718498584436e-07
direct O 0 4.403617879233934e-07
mutation O 0 1.3718255331696128e-06
analysis O 0 2.0322211469192553e-07
of O 0 6.693736764873393e-08
the O 0 7.521248335251585e-07
APC B-Disease 0 7.34255590941757e-05
gene O 0 4.336621714173816e-06
was O 0 4.810594418813707e-06
performed O 0 8.76352601153485e-07
to O 0 2.856814944607322e-07
determine O 0 1.4275683497544378e-06
genotype O 0 5.629652150673792e-05
- O 0 0.0007642777636647224
phenotype O 0 5.170780423213728e-05
correlations O 0 1.707635419734288e-06
for O 0 1.2255343051492673e-07
nine O 0 5.342426447896287e-07
extracolonic O 0 8.35894825286232e-05
manifestations O 0 5.412640348367859e-06
and O 0 1.5884840820490354e-07
to O 0 1.3445864510686079e-07
investigate O 0 9.255165309696167e-07
the O 0 2.9117776989551203e-07
incidence O 0 6.269510322454153e-06
of O 0 4.856852910961607e-07
APC B-Disease 0 0.0007037718314677477
mutations O 0 2.5696745069581084e-05
in O 0 5.58324609301053e-06
non O 0 0.00023772432177793235
- O 1 0.9999885559082031
FAP O 1 0.9999953508377075
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002690419787541032

METHODS O 0 9.594392031431198e-05
The O 0 1.7843027308117598e-05
APC B-Disease 0 0.0003635502071119845
gene O 0 3.107691736659035e-05
was O 0 1.4999222003098112e-05
analysed O 0 9.27756536839297e-06
in O 0 8.595073381911789e-07
190 O 0 6.146254690975184e-06
unrelated O 0 1.4153302799968515e-05
FAP B-Disease 0 7.141404057620093e-05
and O 0 1.2249025758137577e-06
15 O 0 3.056871719309129e-06
non O 0 4.6897257561795413e-05
- O 1 0.999993085861206
FAP O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.006666217930614948
using O 0 3.757053491426632e-05
denaturing O 0 0.23436464369297028
gradient O 0 0.009088832885026932
gel O 0 0.009580044075846672
electrophoresis O 0 6.836051761638373e-05
, O 0 5.227101951277291e-07
the O 0 6.785821824450977e-07
protein O 0 2.0512420633167494e-06
truncation O 0 1.2307208635320421e-05
test O 0 3.783401325563318e-06
, O 0 3.215662900402094e-07
and O 0 3.4742592447400966e-07
direct O 0 3.977801952714799e-06
sequencing O 0 3.297414878034033e-05
. O 0 1.630915721761994e-05

RESULTS O 0 0.0002440375101286918
Chain O 0 0.00017301672778557986
terminating O 0 6.197225593496114e-05
signals O 0 1.9470993720460683e-05
were O 0 6.676573320874013e-07
only O 0 1.2098132629034808e-07
identified O 0 5.888674650122994e-07
in O 0 5.942080747445289e-07
patients O 0 2.2620708932663547e-06
belonging O 0 2.6291675112588564e-06
to O 0 3.9667332885073847e-07
the O 0 1.2479163160605822e-06
FAP B-Disease 0 6.927744107088074e-05
group O 0 3.431930736041977e-06
( O 0 1.3653233281729626e-06
105 O 0 9.932659850164782e-06
patients O 0 5.224389678915031e-05
) O 0 5.664017862727633e-06
. O 0 1.2127826266805641e-05

Amino O 0 0.00022732302022632211
acid O 0 0.00017363781807944179
changes O 0 9.058643627213314e-06
were O 0 7.6057199294155e-07
identified O 0 7.239421506710642e-07
in O 0 1.7068279589693702e-07
four O 0 4.312661587846378e-07
patients O 0 2.1411101442936342e-06
, O 0 6.049005207842129e-08
three O 0 4.973850664669044e-08
of O 0 7.896662168604962e-08
whom O 0 8.710516681276204e-07
belonged O 0 2.4426763047813438e-06
to O 0 1.5061684166539635e-07
the O 0 3.0319355914798507e-07
non O 0 1.26238285247382e-06
- O 0 3.6070447094971314e-05
FAP O 0 4.775167326442897e-05
group O 0 1.2029134268232156e-05
of O 0 0.0015715057961642742
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8075814843177795
. O 0 0.00016675624647177756

Genotype O 0 0.13278374075889587
- O 1 0.63160240650177
phenotype O 0 0.013926113024353981
correlations O 0 0.0001051654908224009
identified O 0 1.4640190784120932e-05
significant O 0 1.1634887187028653e-06
differences O 0 1.1574450127227465e-06
in O 0 3.609916348068509e-07
the O 0 2.1682160422642482e-07
nature O 0 2.33669311455742e-07
of O 0 5.771463307269187e-08
certain O 0 3.024462102985126e-07
extracolonic O 0 0.00011734008876373991
manifestations O 0 2.509342994017061e-05
in O 0 6.313394351309398e-06
FAP B-Disease 0 0.006385431159287691
patients O 0 1.9112654626951553e-05
belonging O 0 6.053206107026199e-06
to O 0 1.0758029702628846e-06
three O 0 2.7079886422143318e-06
mutation O 0 9.940539894159883e-05
subgroups O 0 5.8688623539637774e-05
. O 0 2.5768722480279393e-05

CONCLUSIONS O 0 0.0006854371167719364
Extended O 0 0.00025130464928224683
genotype O 0 0.002711659064516425
- O 0 0.008664313703775406
phenotype O 0 0.0005312488065101206
correlations O 0 1.04228820418939e-05
made O 0 5.666204856424883e-07
in O 0 3.8609303487646685e-07
this O 0 1.7001087826429284e-07
study O 0 8.138862881423847e-07
may O 0 2.6819743652595207e-06
have O 0 4.0957189639811986e-08
the O 0 6.6961888478545e-08
potential O 0 1.0093321378690234e-07
to O 0 5.4334861943061696e-08
determine O 0 6.707590927135243e-08
the O 0 5.427147087289086e-08
most O 0 4.8677588182499676e-08
appropriate O 0 2.4514574192835425e-07
surveillance O 0 6.293184469541302e-06
and O 0 1.6160676068466273e-06
prophylactic O 0 0.00047676829854026437
treatment O 0 0.0008567867917008698
regimens O 0 6.955268327146769e-05
for O 0 5.190798333387647e-07
those O 0 9.436312211619224e-07
patients O 0 4.874918431596598e-06
with O 0 2.6348150186095154e-06
mutations O 0 9.02602550922893e-05
associated O 0 4.0898603401728906e-06
with O 0 1.0163674915020238e-06
life O 0 1.8886852558352984e-05
threatening O 0 0.009479789063334465
conditions O 0 0.0015502541791647673
. O 0 2.8914470021845773e-05

This O 0 1.365497155347839e-05
study O 0 6.201299129315885e-06
also O 0 8.512431008966814e-07
provided O 0 4.376771869374352e-07
evidence O 0 1.0932858884871166e-07
for O 0 6.028802346236262e-08
the O 0 3.020818155619054e-07
pathological O 0 6.440732704504626e-06
nature O 0 7.501892582695291e-07
of O 0 1.3950558752640063e-07
amino O 0 2.140193373634247e-06
acid O 0 4.760669526149286e-06
changes O 0 1.4938517551854602e-06
in O 0 7.741076615275233e-07
APC O 0 3.7924026401015e-05
associated O 0 9.86071995612292e-07
with O 0 2.118773352322023e-07
both O 0 5.155401368028834e-07
FAP B-Disease 0 2.6077790607814677e-05
and O 0 1.9773706299019977e-06
non O 0 8.469957538181916e-05
- O 1 0.9999990463256836
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8865198493003845
. O 0 2.647687870194204e-05
. O 0 3.4622302337083966e-05

Inherited B-Disease 1 0.9999991655349731
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.999996542930603
and O 1 0.9331663846969604
cancer B-Disease 1 0.9997060894966125
risk O 0 2.5340330466860905e-05
of O 0 1.1939653177250875e-06
the O 0 1.0883641152759083e-05
APC O 0 0.0014787826221436262
I1307K O 0 0.000611863739322871
polymorphism O 0 0.0006797862006351352
. O 0 4.484238525037654e-05

Germ O 0 0.06948500126600266
- O 0 0.004938345868140459
line O 0 3.928533260477707e-05
and O 0 2.573067831690423e-06
somatic O 0 3.374169682501815e-05
truncating O 0 0.00012777575466316193
mutations O 0 1.6706648239050992e-05
of O 0 2.2801596344379504e-07
the O 0 8.132361131174548e-07
APC B-Disease 0 6.28137422609143e-05
gene O 0 4.272732894605724e-06
are O 0 1.1753868989217153e-07
thought O 0 6.079548029447324e-07
to O 0 1.4575680324924178e-06
initiate O 0 0.011026261374354362
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.5174762606620789
formation O 0 0.00041005582897923887
in O 0 0.01586053892970085
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0008051738841459155
sporadic O 1 0.9996230602264404
colorectal O 1 1.0
carcinogenesis O 1 0.9916930794715881
, O 0 3.4967390092788264e-05
respectively O 0 5.87268550589215e-05
. O 0 2.8229957024450414e-05

Recently O 0 0.0005062122945673764
, O 0 1.2835623238061089e-05
an O 0 6.6451375460019335e-06
isoleucine O 0 0.009764401242136955
- O 0 0.0010285719763487577
- O 0 0.000289215735392645
> O 0 4.1353374399477616e-05
lysine O 0 0.00012390805932227522
polymorphism O 0 6.282392860157415e-05
at O 0 6.912900062161498e-06
codon O 0 5.854652408743277e-05
1307 O 0 0.00024387445591855794
( O 0 2.1998700958647532e-06
I1307K O 0 9.241219231626019e-06
) O 0 1.7166372856536327e-07
of O 0 5.946791858946199e-08
the O 0 4.0360382058679534e-07
APC B-Disease 0 1.6458259779028594e-05
gene O 0 2.2332278604153544e-06
has O 0 2.734480233357317e-07
been O 0 2.0042034520884044e-07
identified O 0 2.399202401193179e-07
in O 0 1.514612080200095e-07
6 O 0 4.5987530938873533e-07
% O 0 1.7400606111550587e-07
- O 0 2.1130415461811936e-06
7 O 0 3.777672645810526e-07
% O 0 6.055908841062774e-08
of O 0 3.813860161017146e-08
the O 0 4.5592506126013177e-07
Ashkenazi O 0 3.0425477234530263e-05
Jewish O 0 6.827614470239496e-06
population O 0 3.74572323380562e-06
. O 0 1.1109492334071547e-05

To O 0 3.701077002915554e-05
assess O 0 4.298050407669507e-05
the O 0 2.2252684175327886e-06
risk O 0 2.1878479401493678e-06
of O 0 1.9117368310617167e-07
this O 0 2.6957135901284346e-07
common O 0 2.400990751993959e-06
APC B-Disease 0 7.148346776375547e-05
allelic O 0 0.00012082116882083938
variant O 0 0.01960470713675022
in O 0 0.00129783246666193
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.670120894908905
, O 0 4.092591098014964e-06
we O 0 2.883788567942247e-07
have O 0 1.655971715308624e-07
analyzed O 0 8.086145157903957e-07
a O 0 3.7226357108011143e-07
large O 0 5.797113544758759e-07
cohort O 0 4.714185251941672e-06
of O 0 3.963658912198298e-07
unselected O 0 6.247526471270248e-05
Ashkenazi O 0 3.794204167206772e-05
Jewish O 0 3.170868012603023e-06
subjects O 0 4.133506081416272e-06
with O 0 4.12235294788843e-06
adenomatous B-Disease 1 0.5323326587677002
polyps I-Disease 0 0.008013448677957058
and O 0 4.330983756517526e-06
. O 0 1.3469363693729974e-05
or O 1 0.9969791173934937
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.0982157618855126e-06
for O 0 2.4539718879168504e-07
the O 0 3.4686681829043664e-06
APC O 0 0.00044834657455794513
I1307K O 0 0.0002593164681456983
polymorphism O 0 0.0003903140895999968
. O 0 3.4032476833090186e-05

The O 0 5.654029519064352e-05
APC O 0 0.0003433042438700795
I1307K O 0 0.00014377031766343862
allele O 0 6.336609658319503e-05
was O 0 6.658363872702466e-06
identified O 0 1.4193553852237528e-06
in O 0 3.155385570607905e-07
48 O 0 6.355163009175158e-07
( O 0 2.312906133283832e-07
10 O 0 1.3754566907664412e-07
. O 0 7.248817723848333e-08
1 O 0 1.7682044983757805e-07
% O 0 1.621095151449481e-07
) O 0 1.2284222350444907e-07
of O 0 2.657876905232115e-07
476 O 0 0.00014455206110142171
patients O 0 0.00011731065751519054
. O 0 2.674185270734597e-05

Compared O 0 5.0122740503866225e-05
with O 0 1.396064931213914e-06
the O 0 7.38910216568911e-07
frequency O 0 2.5522360829199897e-06
in O 0 1.462882011082911e-07
two O 0 7.808505131379206e-08
separate O 0 2.597580248675513e-07
population O 0 1.1593302673418293e-07
control O 0 7.681757665523037e-07
groups O 0 1.0463293165230425e-07
, O 0 5.9436736421503156e-08
the O 0 2.6568835664875223e-07
APC O 0 1.1438564797572326e-05
I1307K O 0 9.007876542455051e-06
allele O 0 4.920453193335561e-06
is O 0 9.111741405831708e-08
associated O 0 1.0122221283381805e-07
with O 0 2.8565965592974862e-08
an O 0 1.0801365846191402e-07
estimated O 0 2.729436232584703e-07
relative O 0 1.4620871979786898e-06
risk O 0 9.37732750116993e-07
of O 0 3.247170070608263e-07
1 O 0 6.21247454546392e-06
. O 0 1.4422514141188003e-05

5 O 0 0.0003419539425522089
- O 0 0.00045444932766258717
1 O 0 5.3696789109380916e-05
. O 0 5.210060771787539e-05

7 O 0 0.000607793394010514
for O 0 0.00028843811014667153
colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9984368681907654
( O 0 3.954544081352651e-05
both O 0 1.0712669791246299e-05
P O 0 0.14853036403656006
= O 0 7.86798627814278e-05
. O 0 3.6046808418177534e-06
01 O 0 0.00016318079724442214
) O 0 1.0231117812509183e-05
. O 0 2.1813539206050336e-05

Furthermore O 0 0.00016743497690185905
, O 0 6.3161164689518046e-06
compared O 0 3.979160283051897e-06
with O 0 1.2844068351114402e-06
noncarriers O 0 0.00012618533219210804
, O 0 1.2140775424995809e-06
APC O 0 2.3578753825859167e-05
I1307K O 0 1.5776182408444583e-05
carriers O 0 3.0744133709958987e-06
had O 0 7.433914106513839e-07
increased O 0 8.111757097140071e-07
numbers O 0 3.879784173932421e-07
of O 0 4.5508360813073523e-07
adenomas B-Disease 0 0.005758209619671106
and O 0 0.03979349136352539
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.995309054851532
per O 0 2.4797283913358115e-05
patient O 0 0.003826391650363803
( O 0 9.588272405380849e-06
P O 0 0.006776619236916304
= O 0 5.23684957443038e-06
. O 0 2.3753952405058953e-07
03 O 0 2.6503894332563505e-06
) O 0 1.3789279762477236e-07
, O 0 3.3909014263144854e-08
as O 0 3.333786935399985e-08
well O 0 4.3351182199558025e-08
as O 0 8.927719363782671e-08
a O 0 1.0156174994335743e-06
younger O 0 9.22210620046826e-06
age O 0 5.868491825822275e-06
at O 0 4.70089289592579e-05
diagnosis O 0 0.09511823207139969
. O 0 3.8370166294043884e-05

We O 0 1.8375249055679888e-05
conclude O 0 1.6717325706849806e-05
that O 0 8.679322149873769e-07
the O 0 8.978912546808715e-07
APC O 0 2.4396485969191417e-05
I1307K O 0 1.286147835344309e-05
variant O 0 1.5138630260480568e-05
leads O 0 1.9417955172684742e-06
to O 0 7.816729521437082e-07
increased O 0 9.134349056694191e-06
adenoma B-Disease 1 0.997593343257904
formation O 0 5.776677880930947e-06
and O 0 2.2769782503928582e-07
directly O 0 3.7063338709231175e-07
contributes O 0 4.685061298914661e-07
to O 0 8.974514997817096e-08
3 O 0 2.5257799052269547e-07
% O 0 1.6617491382930893e-07
- O 0 1.534658167656744e-06
4 O 0 2.798555271965597e-07
% O 0 7.125962042664469e-08
of O 0 5.123112245541961e-08
all O 0 4.843032570533978e-07
Ashkenazi O 0 0.20784404873847961
Jewish O 1 0.9993651509284973
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002309592382516712

The O 0 1.8482031009625643e-05
estimated O 0 9.283256076741964e-06
relative O 0 7.981032467796467e-06
risk O 0 3.1229205887939315e-06
for O 0 4.5331199771680986e-07
carriers O 0 1.6706297174096107e-05
may O 0 6.585086794075323e-06
justify O 0 5.607632829196518e-06
specific O 0 7.422431167469767e-07
clinical O 0 3.620674078774755e-06
screening O 0 1.6699800653441343e-06
for O 0 1.1362359231270602e-07
the O 0 2.0815670609408699e-07
360 O 0 1.0966040235871333e-06
, O 0 1.0339262246361614e-07
000 O 0 1.2076380073722248e-07
Americans O 0 4.455793600754987e-08
expected O 0 2.0546102064145089e-07
to O 0 1.406664011938119e-07
harbor O 0 5.070745373814134e-06
this O 0 8.70669865093987e-08
allele O 0 1.869801621978695e-06
, O 0 5.3202079186576157e-08
and O 0 9.247448673477265e-08
genetic O 0 6.092206490393437e-07
testing O 0 4.901494889963942e-07
in O 0 6.107330108306996e-08
the O 0 5.742353792470567e-08
setting O 0 1.5962577037953452e-07
of O 0 5.5149047994973444e-08
long O 0 1.2756930800605915e-06
- O 0 2.4083929019980133e-05
term O 0 1.4298096857601195e-06
- O 0 5.994478215143317e-06
outcome O 0 4.823534709430533e-07
studies O 0 5.438591870188247e-07
may O 0 1.243671249540057e-06
impact O 0 2.1505995846382575e-06
significantly O 0 0.00015454467211384326
on O 1 0.9996647834777832
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.002303170505911112
in O 0 1.4272810631155153e-06
this O 0 1.0910065384450718e-06
population O 0 3.4764109386742348e-06
. O 0 1.0438229764986318e-05

Localization O 0 0.00021431520872283727
of O 0 5.724889433622593e-06
human O 0 4.960244950780179e-06
BRCA1 O 0 6.011583172949031e-05
and O 0 7.506100132559368e-07
its O 0 3.016315304193995e-06
loss O 0 9.032413072418422e-05
in O 0 1.0763293403215357e-06
high O 0 7.695947715546936e-06
- O 0 2.8370157451718114e-05
grade O 0 2.5257322704419494e-06
, O 0 3.267252282057598e-07
non B-Disease 0 5.194925961404806e-06
- I-Disease 1 0.9907950758934021
inherited I-Disease 1 0.9999831914901733
breast I-Disease 1 0.9999266862869263
carcinomas I-Disease 1 0.9999905824661255
. O 0 0.00019217876251786947

Although O 0 1.8637219909578562e-05
the O 0 3.6174296837998554e-06
link O 0 1.794693889678456e-05
between O 0 2.5819047095865244e-06
the O 0 1.2826029887946788e-05
BRCA1 O 0 0.03461610898375511
tumour B-Disease 1 0.999991774559021
- O 0 0.0012746406719088554
suppressor O 0 0.0002150830696336925
gene O 0 1.2343233720457647e-05
and O 0 4.5933534238429274e-06
hereditary B-Disease 1 0.9999686479568481
breast I-Disease 1 0.999993085861206
and I-Disease 1 0.9999054670333862
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.1115425877505913e-06
established O 0 6.595140007448208e-07
, O 0 3.218313082697932e-08
the O 0 4.093103100899498e-08
role O 0 1.269831386707665e-07
, O 0 3.793589442580014e-08
if O 0 1.707721075661084e-08
any O 0 2.6110360096254226e-08
, O 0 3.3565203949592615e-08
of O 0 9.07088733015371e-08
BRCA1 O 0 9.143832357949577e-06
in O 0 7.975233984325314e-07
non B-Disease 0 1.047268870024709e-05
- I-Disease 1 0.9701907634735107
familial I-Disease 1 0.981134295463562
cancers I-Disease 0 0.20240648090839386
is O 0 4.1628636608948e-06
unclear O 0 1.918381531140767e-05
. O 0 1.2840962881455198e-05

BRCA1 O 1 0.9505506157875061
mutations O 0 0.0018478425918146968
are O 0 2.0037803096784046e-06
rare O 0 2.6034133497887524e-06
in O 0 1.699223616924428e-06
sporadic B-Disease 0 0.03436721861362457
cancers I-Disease 0 0.027260109782218933
, O 0 5.380071002036857e-07
but O 0 5.250508365861606e-07
loss O 0 6.349175237119198e-06
of O 0 4.48519386964108e-07
BRCA1 O 0 4.719398566521704e-05
resulting O 0 3.6524900224321755e-06
from O 0 8.932418040785706e-07
reduced O 0 5.023082394473022e-06
expression O 0 1.3709519635085599e-06
or O 0 3.96619611819915e-07
incorrect O 0 1.8253108464705292e-06
subcellular O 0 5.011751454730984e-06
localization O 0 4.29448164140922e-06
is O 0 2.611484717363055e-07
postulated O 0 2.6894967959378846e-06
to O 0 1.406524603453363e-07
be O 0 3.431166817335907e-08
important O 0 4.113749696443847e-08
in O 0 1.3933114928477153e-07
non B-Disease 0 2.8418148758646566e-06
- I-Disease 0 0.059797801077365875
familial I-Disease 1 0.9002924561500549
breast I-Disease 1 0.9999099969863892
and I-Disease 1 0.9988729357719421
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999994039535522
. O 0 0.00017438213399145752

Epigenetic O 0 0.0057714590802788734
loss O 0 0.009450103156268597
, O 0 3.2350919809687184e-06
however O 0 1.1944345033043646e-06
, O 0 1.8365120979524363e-07
has O 0 1.7060224877241126e-07
not O 0 3.8181035222351056e-08
received O 0 1.640360665078333e-07
general O 0 2.767932869573997e-07
acceptance O 0 1.022250557980442e-06
due O 0 2.47973275691038e-06
to O 0 2.8822819331253413e-07
controversy O 0 8.375192805942788e-07
regarding O 0 2.1213855916357716e-07
the O 0 2.0683543766608636e-07
subcellular O 0 5.032921762904152e-06
localization O 0 3.590285587051767e-06
of O 0 2.382555521762697e-07
BRCA1 O 0 1.506914668425452e-05
proteins O 0 5.651542096529738e-07
, O 0 8.474048485140884e-08
reports O 0 1.7731554180500098e-07
of O 0 3.435849293964566e-08
which O 0 1.2543767979877884e-07
have O 0 5.155253646194069e-08
ranged O 0 2.950073394458741e-07
from O 0 6.76481661798789e-08
exclusively O 0 1.8877966567742988e-07
nuclear O 0 1.7192650147990207e-06
, O 0 8.1438500387776e-08
to O 0 1.434773366781883e-07
conditionally O 0 1.1189769793418236e-05
nuclear O 0 2.654563331816462e-06
, O 0 6.653614548213227e-08
to O 0 1.3925688335802988e-07
the O 0 6.682510615974024e-07
ER O 0 0.00039579771691933274
/ O 0 0.00010454457515152171
golgi O 0 0.00011574658856261522
, O 0 4.0286354874297103e-07
to O 0 4.073776551649644e-07
cytoplasmic O 0 7.59428530727746e-06
invaginations O 0 1.850347689469345e-05
into O 0 9.759093018146814e-07
the O 0 3.2670795917510986e-06
nucleus O 0 4.391006223158911e-05
. O 0 2.1181047486606985e-05

In O 0 9.14848169486504e-06
an O 0 8.099883075374237e-07
attempt O 0 2.777266445264104e-06
to O 0 4.4303789081823197e-07
resolve O 0 2.7234557364863576e-06
this O 0 1.9758634550726129e-07
issue O 0 4.353912572696572e-07
, O 0 1.2412488104018848e-07
we O 0 1.4115906310507853e-07
have O 0 2.743528852988675e-07
comprehensively O 0 2.203180338256061e-05
characterized O 0 1.9554190657800063e-05
19 O 0 1.2762085134454537e-05
anti O 0 0.0013891084818169475
- O 0 0.2149345576763153
BRCA1 O 0 0.0014610374346375465
antibodies O 0 0.0001613995264051482
. O 0 2.6811489078681916e-05

These O 0 3.590178312151693e-05
reagents O 0 0.00015764265845064074
detect O 0 6.542438495671377e-05
a O 0 3.350282668179716e-06
220 O 0 5.914247594773769e-06
- O 0 9.740244422573596e-05
kD O 0 6.902026507304981e-05
protein O 0 2.416485131107038e-06
localized O 0 4.606224138115067e-06
in O 0 5.508028948497667e-07
discrete O 0 2.282538389408728e-06
nuclear O 0 7.758912033750676e-06
foci O 0 8.632651770312805e-06
in O 0 2.51719768584735e-07
all O 0 9.011977653017311e-08
epithelial O 0 1.5555227946606465e-05
cell O 0 2.271492121508345e-05
lines O 0 1.4533402463712264e-06
, O 0 5.7275105547205385e-08
including O 0 4.6218708860124025e-08
those O 0 1.0410779083258603e-07
derived O 0 1.5859968698350713e-06
from O 0 9.783510904526338e-06
breast B-Disease 0 0.24938981235027313
malignancies I-Disease 0 0.005485722795128822
. O 0 4.247472679708153e-05

Immunohistochemical O 0 0.015679750591516495
staining O 0 0.0018739694496616721
of O 0 9.519446393824182e-06
human O 0 2.9840481147402897e-05
breast O 0 0.007343458477407694
specimens O 0 1.2852895451942459e-05
also O 0 7.3709052230697125e-06
revealed O 0 0.0001063642484950833
BRCA1 O 0 0.00015667728439439088
nuclear O 0 4.1300016164314e-05
foci O 0 0.00018773582996800542
in O 0 2.62351877609035e-05
benign O 1 0.9963229894638062
breast O 1 0.7767009735107422
, O 0 1.8868220649892464e-05
invasive B-Disease 0 0.36729905009269714
lobular I-Disease 1 0.9999769926071167
cancers I-Disease 0 0.31070220470428467
and O 0 6.572689017048106e-06
low B-Disease 0 0.0005028262967243791
- I-Disease 1 0.5054996609687805
grade I-Disease 0 0.006092656869441271
ductal I-Disease 1 0.9986671209335327
carcinomas I-Disease 1 0.9999979734420776
. O 0 0.0001833885908126831

Conversely O 0 0.0008878561784513295
, O 0 2.2372769308276474e-05
BRCA1 O 0 0.00018236538744531572
expression O 0 9.12726954993559e-06
was O 0 1.9655748474178836e-05
reduced O 0 4.254459781805053e-06
or O 0 1.117487158808217e-06
undetectable O 0 6.0203160501259845e-06
in O 0 1.728578808979364e-07
the O 0 1.516736887197112e-07
majority O 0 1.881983280327404e-07
of O 0 6.525444717908613e-08
high O 0 3.965125415561488e-06
- O 0 6.576309533556923e-05
grade O 0 4.199291652184911e-06
, O 0 3.1784159091330366e-06
ductal B-Disease 1 0.950410783290863
carcinomas I-Disease 1 0.9999805688858032
, O 0 1.1429254982431303e-06
suggesting O 0 1.947912778632599e-06
that O 0 1.6045132156250475e-07
absence O 0 7.222043905130704e-07
of O 0 3.2042811426435946e-07
BRCA1 O 0 0.0002164067846024409
may O 0 2.6048014660773333e-06
contribute O 0 2.3099060797449056e-07
to O 0 9.795927979894259e-08
the O 0 2.661663813796622e-07
pathogenesis O 0 3.3796002298913663e-06
of O 0 4.297109867934523e-08
a O 0 2.261423048821598e-07
significant O 0 3.367878207427566e-07
percentage O 0 3.9976160337573674e-07
of O 0 3.3966696832976595e-07
sporadic B-Disease 1 0.8926389813423157
breast I-Disease 1 0.999976396560669
cancers I-Disease 0 0.10098385065793991
. O 0 4.620778781827539e-06
. O 0 1.9720922864507884e-05

